[
  {
    "id": "US7910698B2",
    "text": "NPC1L1 orthologues AbstractThe present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth. Claims (\n35\n)\n\n\n\n\n \n\n\n1. An isolated polypeptide comprising an amino acid sequence that is at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 8 wherein said polypeptide binds to the compound having the structural formula\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nwith a K\ni \nof 92 nM or lower.\n\n\n\n\n \n \n\n\n2. The isolated polypeptide of \nclaim 1\n comprising the amino acid sequence set forth in SEQ ID NO: 8.\n\n\n\n\n \n \n\n\n3. The polypeptide of \nclaim 1\n which is antigenic.\n\n\n\n\n \n \n\n\n4. An isolated fusion polypeptide comprising the polypeptide of \nclaim 1\n which is radiolabeled or fused to a heterologous polypeptide.\n\n\n\n\n \n \n\n\n5. The fusion polypeptide of \nclaim 4\n wherein:\n\n(a) the heterologous polypeptide is a member selected from the group consisting of: glutathione-S-transferase, a hexahistidine tag, a green fluorescent protein tag, a maltose binding protein tag, a haemagglutinin tag, a cellulose binding protein tag and a myc tag; or\n\n\n(b) the radiolabel is a member selected from the group consisting of \n32\nP, \n35\nS, \n3\nH, \n14\nC, \n123\nI, \n111\nIn, \n68\nGa, \n18\nF, \n125\nI, \n131\nI, \n113m\nIn, \n76\nBr, \n67\nGa and \n99m\nTc.\n\n\n\n\n\n\n \n \n\n\n6. The polypeptide of \nclaim 1\n complexed with a compound selected from the group consisting of structural formula 1, 2, 3, 4, 5, 6, 7, 8, 9, a sterol, and a 5α-stanol.\n\n\n\n\n \n \n\n\n7. The polypeptide of \nclaim 6\n wherein the sterol is cholesterol.\n\n\n\n\n \n \n\n\n8. The polypeptide of \nclaim 6\n wherein said compound represented by structural formula 1, 2, 3, 4, 5, 6, 7, 8 or 9, the sterol or the 5α-stanol is detectably labeled.\n\n\n\n\n \n \n\n\n9. The polypeptide of \nclaim 8\n wherein the label is \n3\nH or \n125\nI.\n\n\n\n\n \n \n\n\n10. An isolated polypeptide comprising an amino acid sequence that is at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 8 wherein said polypeptide binds to the compound having the structural formula\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nwith a K\ni \nof 92 nM or lower; wherein the polypeptide is produced by a method comprising culturing a host cell comprising a polynucleotide encoding said polypeptide, in a vector, under conditions in which the polypeptide is expressed.\n\n\n\n\n \n \n\n\n11. A method for identifying an antagonist of NPC1L1 comprising:\n\n(a) contacting the polypeptide of \nclaim 1\n, in the presence of a known amount of a detectable or detectably labeled substance which is known to bind to said polypeptide, with a sample to be tested for the presence of the antagonist; and\n\n\n(b) measuring the amount of the detectable or detectably labeled substance specifically bound to the polypeptide;\n\n\nwherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced binding of the detectable or detectably labeled substance to the polypeptide, compared to what would be measured in the absence of such an antagonist.\n\n\n\n\n\n\n \n \n\n\n12. A method for identifying an antagonist of NPC1L1 comprising:\n\n(a) placing, in an aqueous suspension, a plurality of support particles, impregnated with a fluorescer, to which the polypeptide of \nclaim 1\n is attached;\n\n\n(b) adding, to the suspension, a radiolabeled substance which is known to bind said polypeptide and a sample to be tested for the presence of the antagonist, wherein the radiolabel emits radiation energy capable of activating the fluorescer upon binding of the substance to the polypeptide to produce light energy, whereas radiolabeled substance that does not bind to the polypeptide is, generally, too far removed from the support particles to enable the radioactive energy to activate the fluorescer; and\n\n\n(c) measuring the light energy emitted by the fluorescer in the suspension;\n\n\nwherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced light energy emission, compared to what would be measured in the absence of such an antagonist.\n\n\n\n\n\n\n \n \n\n\n13. The method of \nclaim 12\n wherein the fluorescer is selected from yttrium silicate, yttrium oxide, diphenyloxazole and polyvinyltoluene.\n\n\n\n\n \n \n\n\n14. A method of \nclaim 11\n wherein the substance is a radiolabeled sterol, a radiolabeled 5α-stanol or a radiolabeled compound represented by a structural formula selected from 1-9.\n\n\n\n\n \n \n\n\n15. A method of \nclaim 12\n wherein the substance is a radiolabeled sterol, a radiolabeled 5α-stanol or a radiolabeled compound represented by a structural formula selected from 1-9.\n\n\n\n\n \n \n\n\n16. A method for identifying an antagonist of NPC1L1 comprising:\n\n(a) contacting a host cell expressing, on its cell surface, the polypeptide of \nclaim 1\n with a detectably labeled sterol or 5α-stanol and with a sample to be tested for the presence of the antagonist; and\n\n\n(b) measuring the amount of detectably labeled sterol or 5α-stanol in the cell;\n\n\n\n\nwherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced detectably labeled sterol or 5α-stanol within the host cell, compared to what would be measured in the absence of such an antagonist.\n\n\n\n\n \n \n\n\n17. The method of \nclaim 16\n wherein the sterol or 5α-stanol is detectably labeled with a radiolabel selected from \n3\nH, \n14\nC and \n125\nI.\n\n\n\n\n \n \n\n\n18. The method of \nclaim 16\n wherein the sterol is cholesterol.\n\n\n\n\n \n \n\n\n19. A method of \nclaim 11\n wherein the polypeptide is on a cell membrane of a host cell or in a membrane fraction thereof.\n\n\n\n\n \n \n\n\n20. A method according to \nclaim 12\n wherein the polypeptide is on a cell membrane of a host cell or in a membrane fraction thereof.\n\n\n\n\n \n \n\n\n21. A method according to \nclaim 16\n wherein the polypeptide is on a cell membrane of a host cell or in a membrane fraction thereof.\n\n\n\n\n \n \n\n\n22. A method for screening a sample for an intestinal sterol or 5α-stanol absorption antagonist comprising:\n\n(a) feeding a sterol or 5α-stanol-containing substance to a first and second animal which is a rhesus monkey comprising a functional NPC1L1 gene that encodes the polypeptide of \nclaim 1\n and to a third, mutant animal which is a rhesus monkey which does not comprise a functional NPC1L1 gene;\n\n\n(b) administering the sample to be tested for the presence of the antagonist to the first animal, and optionally to the third animal, but not the second animal;\n\n\n(c) measuring the amount of sterol or 5α-stanol absorption in the intestine of said first, second and third animals; and\n\n\n(d) comparing the levels of intestinal sterol or 5α-stanol absorption in said first, second and third animals;\n\n\n\n\nwherein the sample is determined to contain the intestinal sterol or 5α-stanol absorption antagonist when the level of intestinal sterol or 5α-stanol absorption in the first animal and the third animal are less than the amount of intestinal sterol or 5α-stanol absorption in the second animal.\n\n\n\n\n \n \n\n\n23. The method of \nclaim 22\n wherein the sterol is cholesterol.\n\n\n\n\n \n \n\n\n24. The method of \nclaim 23\n wherein the cholesterol is radiolabeled.\n\n\n\n\n \n \n\n\n25. The method of \nclaim 22\n wherein the level of sterol or 5α-stanol cholesterol absorption is determined by measuring the level of serum sterol or 5α-stanol in the animal.\n\n\n\n\n \n \n\n\n26. A method for identifying an inhibitor of cholesterol absorption comprising the steps of:\n\nproviding a cell expressing the polypeptide of \nclaim 1\n which cell is capable of binding a fluorescent cholesterol absorption inhibitor; contacting said cell with a candidate inhibitor of cholesterol absorption in the presence of said fluorescent cholesterol absorption inhibitor; and measuring fluorescence of said cell, wherein a relative absence of fluorescent cholesterol absorption inhibitor indicates that said candidate inhibitory agent is an inhibitor of cholesterol absorption which inhibits cholesterol absorption.\n\n\n\n\n\n\n \n \n\n\n27. The method of \nclaim 26\n wherein the inhibitor is an azetidinone.\n\n\n\n\n \n \n\n\n28. The method of \nclaim 26\n wherein the fluorescent cholesterol absorption inhibitor is\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nwherein R comprises a fluorescent moiety.\n\n\n\n\n \n \n\n\n29. The method of \nclaim 28\n, wherein R is a fluorescent moiety linked by an alkynyl-containing tether group.\n\n\n\n\n \n \n\n\n30. The method of \nclaim 29\n, wherein R is selected from the group consisting of:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n \n\n\n31. A method for identifying an inhibitor of intestinal absorption of cholesterol, said method comprising the steps of: (a) combining a fluorescent cholesterol absorption inhibitor, a cell membrane comprising the polypeptide of \nclaim 1\n, and a candidate inhibitor of intestinal cholesterol absorption, under conditions wherein, but for the presence of said inhibitor, said fluorescent cholesterol absorption inhibitor is bound to the NPC1L1 in the membrane; and (b) detecting the relative presence or absence of fluorescent cholesterol absorption inhibitor bound to the membrane, wherein a relative absence of fluorescent cholesterol absorption inhibitor indicates that said candidate inhibitor of intestinal cholesterol absorption is an inhibitor of intestinal cholesterol absorption which inhibits intestinal cholesterol absorption.\n\n\n\n\n \n \n\n\n32. The method of \nclaim 31\n wherein the inhibitor is an azetidinone.\n\n\n\n\n \n \n\n\n33. The method of \nclaim 31\n wherein the fluorescent cholesterol absorption inhibitor is\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nwherein R comprises a fluorescent moiety.\n\n\n\n\n \n \n\n\n34. The method of \nclaim 33\n, wherein R is a fluorescent moiety linked by an alkynyl-containing tether group.\n\n\n\n\n \n \n\n\n35. The method of \nclaim 34\n, wherein R is selected from the group consisting of: Description\n\n\n\n\nThis application claims the benefit of U.S. provisional patent application No. 60/776,394, filed Feb. 24, 2006, which is herein incorporated by reference in its entirety.\n\n\nFIELD OF THE INVENTION\n\n\nThe present invention relates to polynucleotides and polypeptides encoding NPC1L1 from various species and uses thereof.\n\n\nBACKGROUND OF THE INVENTION\n\n\nA factor leading to development of vascular disease, a leading cause of death in industrialized nations, is elevated serum cholesterol. It is estimated that 19% of Americans between the ages of 20 and 74 years of age have high serum cholesterol. The most prevalent form of vascular disease is arteriosclerosis, a condition associated with the thickening and hardening of the arterial wall. Arteriosclerosis of the large vessels is referred to as atherosclerosis. Atherosclerosis is the predominant underlying factor in vascular disorders such as coronary artery disease, aortic aneurysm, arterial disease of the lower extremities and cerebrovascular disease.\n\n\nCholesteryl esters are a major component of atherosclerotic lesions and the major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters is also a step in the intestinal absorption of dietary cholesterol. Thus, inhibition of cholesteryl ester formation and reduction of serum cholesterol can inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.\n\n\nThe regulation of whole-body cholesterol homeostasis in mammals and animals involves the regulation of intestinal cholesterol absorption, cellular cholesterol trafficking, dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis, steroid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. Regulation of intestinal cholesterol absorption has proven to be an effective means by which to regulate serum cholesterol levels. For example, a cholesterol absorption inhibitor, ezetimibe (\n\n\n \n \n \n \n \n \n \n \n \n \n\nhas been shown to be effective in this regard. A pharmaceutical composition containing ezetimibe is commercially available from Merck/Schering-Plough Pharmaceuticals, Inc. under the tradename Zetia®. Identification of a gene target through which ezetimibe acts is important to understanding the process of cholesterol absorption and to the development of other, novel absorption inhibitors.\n\n\n\nThe molecular target through which ezetimibe acts, in humans, rats and mice, has been identified previously to be NPC1L1 (also known as NPC3; published U.S. patent application no. 2004/0161838; Genbank Accession No. AF192522; Davies, et al., (2000) Genomics 65(2):137-45 and Ioannou, (2000) Mol. Genet. Metab. 71(1-2):175-81).\n\n\nThere remains a need in the art for the identification of orthologues of NPC1L1, for example, from non-human animals such as canines, rabbits, hamsters, and monkeys. Identification of such targets would aid in the discovery and development of both human and non-human, veterinary treatments for hyperlipidemia, hypertriglyceridemia and/or hypercholesterolemia which target NPC1L1.\n\n\nSUMMARY OF THE INVENTION\n\n\nThe present invention addressed the need in the art for veterinary and human treatments for cardiovascular disorders therein (e.g., hyperlipidemia, hypertriglyceridemia, or hypercholesterolemia), in part, by providing orthologues of NPC1L1 from rabbit, hamster, canine and monkey species.\n\n\nThe present invention provides, an isolated polypeptide (e.g., an antigenic polypeptide) comprising an amino acid selected from the group consisting of: 527 or more contiguous amino acids from SEQ ID NO: 2; 42 or more contiguous amino acids from SEQ ID NO: 4; 70 or more contiguous amino acids from SEQ ID NO: 6; 84 or more contiguous amino acids from SEQ ID NO: 8; and 104 or more contiguous amino acids from SEQ ID NO: 10. In an embodiment of the invention, the isolated polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 2, 4, 6, 8 and 10. In an embodiment of the invention, the polypeptide is labeled with a member selected from the group consisting of \n32\nP, \n35\nS, \n3\nH, \n99m\nTc, \n123\nI, \n111\nIn, \n68\nGa, \n18\nF, \n125\nI, \n131\nI, \n113m\nIn, \n76\nBr, \n67\nGa, \n99m\nTc, \n123\nI, \n111\nIn and \n68\nGa. The present invention also provides an isolated fusion polypeptide comprising the polypeptide of claim \n1\n fused to a heterologous polypeptide (e.g., glutathione-S-transferase (GST), a hexahistidine (His6) tag, a maltose binding protein (MBP) tag, a haemagglutinin (HA) tag, a cellulose binding protein (CBP) tag and a myc tag). An embodiment of the invention also includes a polypeptide of the invention, complexed with a member selected from the group consisting of compounds 1-9, a sterol (e.g., cholesterol), and a 5α-stanol; or a detectably labeled (e.g., \n3\nH or \n125\nI) version thereof.\n\n\nThe present invention further provides an isolated polynucleotide which hybridizes to a polynucleotide encoding a polypeptide of the invention (e.g., as set forth above) under high stringency hybridization conditions. An embodiment of the invention includes an isolated polynucleotide encoding a polypeptide of the invention. An embodiment of the invention includes an isolated polynucleotide comprising a nucleotide sequence selected from SEQ ID NOs: 1, 3, 5, 7 and 9. The present invention also includes a recombinant vector comprising a polynucleotide of the invention (e.g., as set forth above). The present invention also includes an isolated host cell comprising a vector of the invention.\n\n\nThe present invention further provides an isolated antibody (e.g., monoclonal, polyclonal, a human antibody, a canine antibody, a hamster antibody, a rabbit antibody, a rhesus monkey antibody, a cynomolgus monkey antibody, chimeric, anti-idiotypic, recombinant and/or a humanized antibody) which specifically binds to a polypeptide (e.g., an antigenic polypeptide) of the invention. The present invention also includes a complex comprising an antibody of the invention bound to a polypeptide of the invention (e.g., a complex between an isolated antibody and a polypeptide in the body of a patient, e.g., in the intestinal tract of the patient or an in vitro complex). The present invention further provides a pharmaceutical formulation comprising an antibody of the invention along with a pharmaceutically acceptable carrier.\n\n\nThe present invention further provides an isolated canine, hamster, rabbit, rhesus monkey or cynomolgus monkey cell (e.g., an enterocyte) which lacks a gene which encodes a functional canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 protein (e.g., SEQ ID NO: 2, 4, 6, 8 or 10), respectively. In an embodiment of the invention, the cell is isolated from duodenum, gall bladder, liver, small intestine or stomach tissue.\n\n\nThe present also provides a kit comprising: a substituted azetidinone (e.g., ezetimibe) in a pharmaceutical dosage form; and information indicating that canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 is a target of the substituted azetidinone. In an embodiment of the invention, the dosage form is a tablet comprising 10 mg ezetimibe. In an embodiment of the invention, the kit further comprises simvastatin in a pharmaceutical dosage form (e.g., wherein the pharmaceutical dosage form comprises 5 mg, 10 mg, 20 mg, 40 mg or 80 mg simvastatin). In an embodiment of the invention, the simvastatin in pharmaceutical dosage form and the ezetimibe in pharmaceutical dosage form are associated in a single pill or tablet.\n\n\nThe present invention also provides a mutant transgenic dog, hamster, rabbit, rhesus monkey or cynomolgus monkey comprising a homozygous mutation of endogenous, chromosomal NPC1L1 wherein said dog, hamster, rabbit, rhesus monkey or cynomolgus monkey does not produce any functional NPC1L1 protein. In an embodiment of the invention, the animal exhibits a reduced serum sterol or 5α-stanol level, a reduced liver sterol or 5α-stanol level or a reduced level of intestinal absorption of sterol or 5α-stanol. An offspring or progeny of the dog, hamster, rabbit, rhesus monkey or cynomolgus monkey which has inherited a mutated NPC1L1 allele of said dog, hamster, rabbit, rhesus monkey or cynomolgus monkey is also within the scope of the present invention.\n\n\nThe present invention also includes a method for making a polypeptide comprising culturing a host cell (e.g., bacterial cell, an insect cell or a mammalian cell) of the invention (e.g., comprising a vector comprising a polynucleotide that encodes a polypeptide of the invention) under conditions in which the polynucleotide is expressed. In an embodiment of the invention, the polypeptide is isolated from the culture. The present invention further provides any polypeptide produced by said method.\n\n\nThe present invention further provides a method for identifying (i) an antagonist of NPC1L1 (e.g., human NPC1L1) or (ii) a substance useful for the treatment or prevention of hyperlipidemia, hypertriglyceridemia, hycholesterolemia, atherosclerosis or arteriosclerosis or (iii) an inhibitor of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption comprising: (a) contacting a host cell (e.g., chinese hamster ovary (CHO) cell, a J774 cell, a macrophage cell or a Caco2 cell) expressing an NPC1L1 polypeptide of the invention e.g., polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 2, 4, 6, 8 and 10 or a functional fragment thereof on a cell surface, in the presence of a known amount of detectably labeled substance which is known to bind to said polypeptide (e.g., a radiolabeled (e.g., \n3\nH or \n125\nI) compound represented by \n \n \n \n \n \nstructural formula\n \n \n \n \n \n 1, 2, 3, 4, 5, 6, 7, 8 or 9) with a sample to be tested for the presence of the antagonist; and (b) measuring the amount of the detectably labeled substance specifically bound to the polypeptide; wherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced binding of the detectably labeled substance to the polypeptide, compared to what would be measured in the absence of such an antagonist. The present invention also provides a method for inhibiting NPC1L1 mediated sterol or 5α-stanol uptake, in a subject, by administering, to the subject, a substance identified by such a method.\n\n\nThe present invention further provides a method for identifying (i) an antagonist of NPC1L1 (e.g., human NPC1L1) or (ii) a substance useful for the treatment or prevention of hyperlipidemia, hypertriglyceridemia, hycholesterolemia, atherosclerosis or arteriosclerosis or (iii) an inhibitor of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption comprising: (a) placing, in an aqueous suspension, a plurality of support particles, impregnated with a fluorescer (e.g., yttrium silicate, yttrium oxide, diphenyloxazole or polyvinyltoluene), to which a host cell (e.g., chinese hamster ovary (CHO) cell, a J774 cell, a macrophage cell or a Caco2 cell) expressing a polypeptide of the invention (e.g., comprising an amino acid sequence selected from SEQ ID NOs: 2, 4, 6, 8 and 10 or a functional fragment thereof) on a cell surface is attached; (b) adding, to the suspension, a radiolabeled substance which is known to bind said polypeptide (e.g., a radiolabeled (e.g., \n3\nH or \n125\nI) compound represented by \n \n \n \n \n \nstructural formula\n \n \n \n \n \n 1, 2, 3, 4, 5, 6, 7, 8 or 9) and a sample to be tested for the presence of the antagonist, wherein the radiolabel emits radiation energy capable of activating the fluorescer upon binding of the substance to the polypeptide to produce light energy, whereas radiolabeled substance that does not bind to the polypeptide is, generally, too far removed from the support particles to enable the radioactive energy to activate the fluorescer; and (c) measuring the light energy emitted by the fluorescer in the suspension; wherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced light energy emission, compared to what would be measured in the absence of such an antagonist. The present invention also provides a method for inhibiting NPC1L1 mediated sterol or 5α-stanol uptake, in a subject, by administering, to the subject, a substance identified by such a method.\n\n\nThe present invention also provides a method for identifying (i) an antagonist of NPC1L1 (e.g., human NPC1L1) or (ii) a substance useful for the treatment or prevention of hyperlipidemia, hypertriglyceridemia, hycholesterolemia, atherosclerosis or arteriosclerosis or (iii) an inhibitor of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption comprising: (a) contacting a host cell (e.g., chinese hamster ovary (CHO) cell, a J774 cell, a macrophage cell or a Caco2 cell) expressing an NPC1L1 polypeptide of the invention (e.g., comprising an amino acid sequence selected from SEQ ID NOs: 2, 4, 6, 8 and 10 or a functional fragment thereof) on a cell surface with a detectably labeled (e.g., \n3\nH, \n14\nC and \n125\nI) sterol (e.g., cholesterol) or 5α-stanol and with a sample to be tested for the presence of the antagonist; and (b) measuring the amount of detectably labeled sterol or 5α-stanol in the cell; wherein an NPC1L1 antagonist in the sample is identified by measuring substantially reduced detectably labeled sterol or 5α-stanol within the host cell, compared to what would be measured in the absence of such an antagonist. The present invention also provides a method for inhibiting NPC1L1 mediated sterol or 5α-stanol uptake, in a subject, by administering, to the subject, a substance identified by such a method.\n\n\nThe present invention further provides a method for screening a sample for (i) an antagonist of NPC1L1 (e.g., human NPC1L1) or (ii) a substance useful for the treatment or prevention of hyperlipidemia, hypertriglyceridemia, hycholesterolemia, atherosclerosis or arteriosclerosis or (iii) an inhibitor of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption comprising: (a) feeding a sterol or 5α-stanol-containing substance to a first and second animal which is a canine, hamster, rabbit, rhesus monkey or cynomolgus monkey comprising a functional NPC1L1 gene and to a third, mutant animal which is a canine, hamster, rabbit, rhesus monkey or cynomolgus monkey which does not comprise a functional NPC1L1 gene; (b) administering the sample to be tested for the presence of the antagonist to the first animal but not the second animal; (c) measuring the amount of sterol or 5α-stanol absorption in the intestine of said first, second and third animals; and (d) comparing the levels of intestinal sterol or 5α-stanol absorption in said first, second and third animals; wherein the sample is determined to contain the intestinal sterol or 5α-stanol absorption antagonist when the level of intestinal sterol or 5α-stanol absorption in the first animal and third animal are less than the amount of intestinal sterol or 5α-stanol absorption in the second animal. In an embodiment of the invention, the level of sterol or 5α-stanol cholesterol absorption is determined by measuring the level of serum sterol or 5α-stanol in the canine, hamster, rabbit, rhesus monkey or cynomolgus monkey. The present invention also provides a method for inhibiting NPC1L1 mediated sterol or 5α-stanol uptake, in a subject, by administering, to the subject, a substance identified by such a method.\n\n\nThe present invention also provides a method for decreasing the level of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption in a non-human mammalian subject (e.g., a canine such as a dog, hamster, rabbit, rhesus monkey or cynomolgus monkey) comprising reducing the level of expression of endogenous NPC1L1 in the subject. In an embodiment of the invention, the level of expression of NPC1L1 in the subject is reduced by mutating NPC1L1 in the subject.\n\n\n\n\nBRIEF DESCRIPTION OF THE FIGURES\n\n\n \nFIG. 1\n. Ball model of predicted membrane topology of human NPC1L1 (SEQ ID NO: 25). Residues highlighted (black) identify the predicted sterol sensing domain (Carstea et al., Science; 277:228-231 (1997)). Shaded residues (gray) identify amino acids that are not conserved between human and monkey proteins.\n\n\n \nFIG. 2\n. Progressive multiple amino acid sequence alignment using the Clustal W method (Thompson et al., Nucleic Acid Research 22; 4673-80 (1994)). (A) NPC1L1 amino acid sequence pair distances between species comparing percent identity and percent divergence. (B) Phylogenetic tree representation of amino acid sequence alignment using Treeview (Page, 1996).\n\n\n \nFIG. 3\n. Characterization of NPC1L1 binding in multiple species. HEK 293 cells expressing human (A), monkey (B), rat (C), hamster (D), rabbit (E), or canine (F) NPC1L1 were exposed to the indicated concentration of compound 1 for 4 h. The amount of fluorescence bound to the cells was quantified as total binding (open circles). Addition of 100 \nuM compound\n 4 was used to determine nonspecific binding (open triangles). Specific binding (filled circles) was determined by subtraction of nonspecific from total binding. The Kd values were calculated using Prism software and are the mean of at least three separate experiments. Competition binding of \ncompound\n 3 and \ncompound\n 4 to NPC1L1 is also shown. Binding of compound 1 to HEK 293 cells expressing each species NPC1L1 in the presence of the indicated concentration of compound 3 (open circles) or compound 4 (filled circles) was determined. Ki values were calculated using Prism software and are the mean of at least three separate experiments.\n\n\n \nFIG. 4\n. Comparison of binding characteristics of compound 1 and compound 2. (A) Structure of compound 1 and compound 2. Saturation binding of [\n3\nH]-labeled \ncompound\n 4 to membranes derived from HEK 293 cells expressing human NPC1L1 (B) or mouse NPC1L1 (C). [\n3\nH]\ncompound\n 4 bound was determined in the absence (total, filled circles) or presence (nonspecific, open circles) of 100 μM \nunlabeled compound\n 4. Specific binding (filled triangles) was determined by subtracting nonspecific from total binding. Kd values were determined using Prism software. The Ki of compound 1 and compound 2 at human NPC1L1 (D) and monkey NPC1L1 (E) was determined by competition binding studies using [\n3\nH]-labeled \ncompound\n 4. Studies were performed on membranes from HEK 293 cells expressing human or monkey NPC1L1. Ki values are the mean from at least three separate experiments.\n\n\n \nFIG. 5\n. Correlation of NPC1L1 binding and in vivo efficacy. Data (ED50) from studies assessing in vivo efficacy of \ncompound\n 3 in human, monkey, hamster, canine, rat, rabbit, and mouse species is plotted as a function of the ability of compound 3 (A) or compound 4 (B) to bind to each species NPC1L1 ortholog.\n\n\n \nFIG. 6\n. Comparison of compound 1 and compound 2 binding to human and monkey NPC1L1. Saturation binding of [\n3\nH]-labeled \ncompound\n 4 to human (A) and monkey (B) NPC1L1 was performed to determine Kd values. The Ki values of compound 1 (triangles) and compound 2 (circles) at human (C) and monkey (D) NPC1L1 were then determined. Ki values were calculated using Prism software and are the mean of three separate experiments.\n\n\n \nFIG. 7\n. Comparison of the amino acid sequences of monkey NPC1L1 (SEQ ID NO: 8), canine NPC1L1 (SEQ ID NO: 2), hamster NPC1L1 (SEQ ID NO: 6), rabbit NPC1L1 (SEQ ID NO: 4), human NPC1L1 (SEQ ID NO: 25), rat NPC1L1 (SEQ ID NO: 28), mouse NPC1L1 (SEQ ID NO: 27) (Altmann et al., Science 303:1201-1204 (2004)), chimpanzee NPC1L1 (SEQ ID NO: 26) (Genbank XM\n—\n519072) and cow NPC1L1 (SEQ ID NO: 29) (Genbank XM\n—\n588051).\n\n\n\n\nDETAILED DESCRIPTION OF THE INVENTION\n\n\nThe present invention includes any isolated polynucleotide or isolated polypeptide (or any antigenic and/or active fragment thereof) comprising a nucleotide or amino acid sequence referred to, below, in Table 1.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nPolynucleotides and Polypeptides of the Invention.\n\n\n\n\n\n\n\n\n\n\n \n\n\nPolynucleotide or Polypeptide\n\n\nSequence Identifier\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCanine NPC1L1 polynucleotide\n\n\nSEQ ID NO: 1\n\n\n\n\n\n\n \n\n\nCanine NPC1L1 polypeptide\n\n\nSEQ ID NO: 2\n\n\n\n\n\n\n \n\n\nRabbit NPC1L1 polynucleotide\n\n\nSEQ ID NO: 3\n\n\n\n\n\n\n \n\n\nRabbit NPC1L1 polypeptide\n\n\nSEQ ID NO: 4\n\n\n\n\n\n\n \n\n\nHamster NPC1L1 polynucleotide\n\n\nSEQ ID NO: 5\n\n\n\n\n\n\n \n\n\nHamster NPC1L1 polypeptide\n\n\nSEQ ID NO: 6\n\n\n\n\n\n\n \n\n\nRhesus monkey NPC1L1 polynucleotide\n\n\nSEQ ID NO: 7\n\n\n\n\n\n\n \n\n\nRhesus monkey NPC1L1 polypeptide\n\n\nSEQ ID NO: 8\n\n\n\n\n\n\n \n\n\nCynomolgus monkey NPC1L1\n\n\nSEQ ID NO: 9\n\n\n\n\n\n\n \n\n\npolynucleotide\n\n\n\n\n\n\n \n\n\nCynomolgus monkey NPC1L1\n\n\nSEQ ID NO: 10\n\n\n\n\n\n\n \n\n\npolypeptide\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe term “rhesus monkey” is well known in the art and typically refers to the Rhesus Macaque or the \nMacaca mulatto. \n \n\n\nThe term “cynomolgus monkey” is also well known in the art and typically refers to the \nMacaca fascicularis. \n \n\n\nThe term “canine” includes any animal of the genus \nCanis \nand any species, variety or breed thereof, for example, the domestic dog-\nCanis familiaris \n(e.g., beagle). Structural formulas representing compounds 1-9 are as follows:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nMolecular Biology\n\n\nIn accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, \nMolecular Cloning: A Laboratory Manual\n, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein “Sambrook, et al., 1989”); \nDNA Cloning: A Practical Approach\n, Volumes I and II (D. N. Glover ed. 1985); \nOligonucleotide Synthesis \n(M. J. Gait ed. 1984); \nNucleic Acid Hybridization \n(B. D. Hames & S. J. Higgins eds. (1985)); \nTranscription And Translation \n(B. D. Hames & S. J. Higgins, eds. (1984)); \nAnimal Cell Culture \n(R. I. Freshney, ed. (1986)); \nImmobilized Cells And Enzymes \n(IRL Press, (1986)); B. Perbal, \nA Practical Guide To Molecular Cloning \n(1984); F. M. Ausubel, et al. (eds.), \nCurrent Protocols in Molecular Biology\n, John Wiley & Sons, Inc. (1994).\n\n\nA “polynucleotide”, “nucleic acid” or “nucleic acid molecule” includes the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; “RNA molecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; “DNA molecules”), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in single stranded form, double-stranded form or otherwise.\n\n\nA “polynucleotide sequence”, “nucleic acid sequence” or “nucleotide sequence” is a series of nucleotide bases (also called “nucleotides”) in a nucleic acid, such as DNA or RNA, and means any chain of two or more nucleotides.\n\n\nA “coding sequence” or a sequence “encoding” an expression product, such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in production of the product.\n\n\nThe term “gene” means a DNA sequence that codes for or corresponds to a particular sequence of ribonucleotides or amino acids which comprise all or part of one or more RNA molecules, proteins or enzymes, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine, for example, the conditions under which the gene is expressed. Genes may be transcribed from DNA to RNA which may or may not be translated into an amino acid sequence.\n\n\nThe present invention includes nucleic acid fragments of any of SEQ ID NOs: 1, 3, 5, 7, or 9. For example, the present invention includes any polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 10 as well as any polynucleotide encoding a fragment (e.g., an antigenic fragment) of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 10 for example as set forth herein. In an embodiment of the invention, the polynucleotide comprises at least about 1550, 1560, 1570, 1580, 1590, 1600, 1610, 2000, 2500, 3000, 3400, 3800, 3900 or 3950 contiguous nucleotides of SEQ ID NO: 1. In an embodiment of the invention, the polynucleotide comprises at least about 100, 110, 120, 123, 124, 125, 150, 300, 600, 900, 1000, 1500, 2000, 2300, 2600, 2900, 3300, 3500, 3700, 3900 or 3950 contiguous nucleotides of SEQ ID NO: 3. In an embodiment of the invention, the polynucleotide comprises at least about 230, 235, 240, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 300, 500, 700, 900, 1000, 1300, 1500, 1700, 1900, 2000, 2200, 2400, 2600, 2900, 3000, 3300, 3500, 3700, 3800, 3900 or 3950 contiguous nucleotides of SEQ ID NO: 7. In an embodiment of the invention, the polynucleotide comprises at least about 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 500, 700, 900, 1000, 1300, 1500, 1700, 1900, 2000, 2200, 2400, 2600, 2900, 3000, 3300, 3500, 3700, 3800, 3900 or 3950 contiguous nucleotides of SEQ ID NO: 9.\n\n\nAs used herein, the term “oligonucleotide” refers to a nucleic acid, generally of no more than about 100 nucleotides (e.g., 30, 40, 50, 60, 70, 80, or 90), that may be hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., by incorporation of \n32\nP-nucleotides, \n3\nH-nucleotides, \n14\nC-nucleotides, \n35\nS-nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid. In another embodiment, oligonucleotides (one or both of which may be labeled) can be used as PCR primers, either for cloning full length or a fragment of the gene, or to detect the presence of nucleic acids. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer.\n\n\nA “protein sequence”, “peptide sequence” or “polypeptide sequence” or “amino acid sequence” refers to a series of two or more amino acids in a protein, peptide or polypeptide.\n\n\n“Protein”, “peptide” or “polypeptide” includes a contiguous string of two or more amino acids. Preferred peptides of the invention include those set forth in any of SEQ ID NOs: 2, 4, 6, 8 or 10 as well as variants and fragments thereof. In an embodiment of the invention, the fragment is an antigenic fragment. In an embodiment, the fragment is an active fragment which is capable of binding to an azetidinone such as ezetimibe or a related compounds such as any of those set forth herein (e.g., any of compounds 1-9)-active fragments are useful, e.g., for identification of NPC1L1 antagonists, for example, in an assay as set forth herein. Such fragments (e.g., antigenic fragments) comprise, in an embodiment of the invention, at least about 10 (e.g., 11, 12, 13, 14, 15, 16, 17, 18 or 19), or at least about 20 (e.g., 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40), or at least about 42 (e.g., 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 110, 120 or 130) or more contiguous amino acid residues from any of SEQ ID NOs: 2, 4, 6, 8, or 10. An embodiment of the invention includes any polypeptide comprising at least about 527 contiguous amino acids from SEQ ID NO: 2 (e.g., 500, 505, 510, 515, 520, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300 or 1320 contiguous amino acids). An embodiment of the invention includes any polypeptide comprising at least about 42 contiguous amino acids from SEQ ID NO: 4 (e.g., 35, 37, 40, 41, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300 or 1320 contiguous amino acids). An embodiment of the invention includes any polypeptide comprising at least about 70 or more contiguous amino acids from SEQ ID NO: 6 (e.g., 60, 65, 67, 69, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300 or 1320 contiguous amino acids). An embodiment of the invention includes any polypeptide comprising at least about 84 or more contiguous amino acids from SEQ ID NO: 8 (e.g., 75, 77, 79, 82, 83, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1320 or 1330 contiguous amino acids). An embodiment of the invention includes any polypeptide comprising at least about 104 or more contiguous amino acids from SEQ ID NO: 10 (e.g., 90, 93, 95, 97, 99, 100, 101, 102, 103, 105, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1320 or 1330 contiguous amino acids. Also included within the scope of the present invention is any polynucleotide that encodes such a polypeptide. In an embodiment of the invention, a polypeptide as set forth above is an antigenic polypeptide.\n\n\nIn an embodiment of the invention, a polypeptide of the invention (e.g., SEQ ID NO: 2, 4, 6, 8 or 10 or any fragment thereof, e.g., as set forth herein) exhibits the ability to bind to ezetimibe or any structurally related compound (e.g., any of compounds 1-9 herein). The scope of the invention also includes any polynucleotide encoding such a polypeptide.\n\n\nThe polypeptides of the invention can be produced by proteolytic cleavage of an intact peptide, by chemical synthesis or by the application of recombinant DNA technology and are not limited to polypeptides delineated by proteolytic cleavage sites. The polypeptides, either alone or cross-linked or conjugated to a carrier molecule to render them more immunogenic, are useful as antigens to elicit the production of antibodies and fragments thereof and are within the scope of the present invention. The antibodies can be used, e.g., in immunoassays for immunoaffinity purification or for inhibition of NPC1L1, etc.\n\n\nThe terms “isolated polynucleotide” or “isolated polypeptide” include a polynucleotide (e.g., RNA or DNA molecule, or a mixed polymer) or a polypeptide, respectively, which are partially (to any degree) or fully separated from other components that are normally found in cells or in recombinant DNA expression systems. These components include, but are not limited to, cell membranes, cell walls, ribosomes, polymerases, serum components and extraneous genomic sequences.\n\n\nAn isolated polynucleotide or polypeptide will, in an embodiment of the invention, be an essentially homogeneous composition.\n\n\n“Amplification” of DNA as used herein includes the use of polymerase chain reaction (PCR) to increase the concentration of a particular DNA sequence within a mixture of DNA sequences. For a description of PCR see Saiki, et al., Science (1988) 239:487.\n\n\nA practitioner or ordinary skill in the art could easily isolate and express any of the NPC1L1 genes (e.g., SEQ ID NO: 1, 3, 5, 7 or 9) and proteins (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) set forth herein. For example, a convenient method for obtaining an NPC1L1 gene of the invention is to simply amplify the gene, using standard PCR methods from a cDNA library that was generated from canine, rabbit, hamster, rhesus monkey or cynomolgus monkey tissue or cells. Such a cDNA library can be generated using any of several well known methods in the art. In such a embodiment of the invention, oligonucleotide PCR primers, to be used in PCR amplification of an NPC1L1 of the invention, anneal to the extreme 5′ and 3′ ends of a gene of the invention (e.g., SEQ ID NO: 1, 3, 5, 7, or 9).\n\n\nThe term “host cell” includes any cell of any organism that is selected, modified, transfected, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression or replication, by the cell, of a gene, a DNA or RNA sequence or a protein. Suitable host cells include bacterial cells (e.g., \nE. coli\n) and mammalian cells such as chinese hamster ovary (CHO) cells, murine macrophage J774 cells or any other macrophage cell line and human intestinal epithelial Caco2 cells.\n\n\nThe nucleotide sequence of a nucleic acid may be determined by any method known in the art (e.g., chemical sequencing or enzymatic sequencing). “Chemical sequencing” of DNA includes methods such as that of Maxam and Gilbert (1977) (Proc. Natl. Acad. Sci. USA 74:560), in which DNA is randomly cleaved using individual base-specific reactions. “Enzymatic sequencing” of DNA includes methods such as that of Sanger (Sanger, et al., (1977) Proc. Natl. Acad. Sci. USA 74:5463).\n\n\nThe nucleic acids herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5′- and 3′-non-coding regions, and the like.\n\n\nIn general, a “promoter” or “promoter sequence” is a DNA regulatory region capable of binding an RNA polymerase in a cell (e.g., directly or through other promoter-bound proteins or substances) and initiating transcription of a coding sequence. A promoter sequence is, in general, bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at any level. Within the promoter sequence may be found a transcription initiation site (conveniently defined, for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. The promoter may be operably associated with other expression control sequences, including enhancer and repressor sequences or with a nucleic acid of the invention. Promoters which may be used to control gene expression include, but are not limited to, cytomegalovirus (CMV) promoter (U.S. Pat. Nos. 5,385,839 and 5,168,062), the SV40 early promoter region (Benoist, et al., (1981) Nature 290:304-310), the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamoto, et al., (1980) Cell 22:787-797), the herpes thymidine kinase promoter (Wagner, et al., (1981) Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster, et al., (1982) Nature 296:39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Komaroff, et al., (1978) Proc. Natl. Acad. Sci. USA 75:3727-3731), or the tac promoter (DeBoer, et al., (1983) Proc. Natl. Acad. Sci. USA 80:21-25); see also “Useful proteins from recombinant bacteria” in Scientific American (1980) 242:74-94; and promoter elements from yeast or other fungi such as the \nGal\n 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter or the alkaline phosphatase promoter.\n\n\nThe present invention comprises a nucleotide encoding NPC1L1 or a fragment thereof (e.g., a functional or antigenic fragment) operably associated with a control sequence such as a promoter. A coding sequence is “under the control of”, “functionally associated with” or “operably associated with” transcriptional and translational control sequences in a cell when the sequences direct RNA polymerase mediated transcription of the coding sequence into RNA, preferably mRNA, which then may be RNA spliced (if it contains introns) and, optionally, translated into a protein encoded by the coding sequence.\n\n\nThe terms “express” and “expression” mean allowing or causing the information in a gene, RNA or DNA sequence to become manifest; for example, producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene. A DNA sequence is expressed in or by a cell to form an “expression product” such as an RNA (e.g., mRNA) or a protein. The expression product itself may also be said to be “expressed” by the cell.\n\n\nThe term “transformation” means the introduction of a nucleic acid into a cell. The introduced gene or sequence may be called a “clone”. A host cell that receives the introduced DNA or RNA has been “transformed” and is a “transformant” or a “clone.” The DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or from cells of a different genus or species.\n\n\nThe term “vector” includes a vehicle (e.g., a plasmid) by which a DNA or RNA sequence can be introduced into a host cell, so as to transform the host and, optionally, promote expression and/or replication of the introduced sequence.\n\n\nThe present invention includes any polynucleotide (e.g., comprising a nucleotide sequence of SEQ ID NO: 1, 3, 5, 7 or 9) encoding an NPC1L1 polypeptide (e.g., comprising an amino acid sequence of SEQ ID NO: 2, 4, 6, 8 or 10) in a vector. Vectors that can be used in this invention include plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles that may facilitate introduction of the nucleic acids into the genome of the host. Plasmids are the most commonly used form of vector but all other forms of vectors which serve a similar function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al., \nCloning Vectors: A Laboratory Manual, \n1985 and Supplements, Elsevier, N.Y., and Rodriguez et al. (eds.), \nVectors: A Survey of Molecular Cloning Vectors and Their Uses, \n1988, Buttersworth, Boston, Mass.\n\n\nThe term “expression system” means a host cell and compatible vector which, under suitable conditions, can express a protein or nucleic acid which is carried by the vector and introduced to the host cell. Common expression systems include \nE. coli \nhost cells and plasmid vectors, insect host cells and Baculovirus vectors, and mammalian host cells and vectors.\n\n\nExpression of nucleic acids encoding the NPC1L1 polypeptides of this invention can be carried out by conventional methods in either prokaryotic or eukaryotic cells. Although \nE. coli \nhost cells are employed most frequently in prokaryotic systems, many other bacteria, such as various strains of \nPseudomonas \nand \nBacillus\n, are known in the art and can be used as well. Suitable host cells for expressing nucleic acids encoding the NPC1L1 polypeptides include prokaryotes and higher eukaryotes. Prokaryotes include both gram-negative and gram-positive organisms, e.g., \nE. coli \nand \nB. subtilis\n. Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents. The present invention comprise any host cell comprising an NPC1L1 polynucleotide of the invention and/or expressing an NPC1L1 polypeptide of the invention, for example, on the cell surface.\n\n\nProkaryotic host-vector systems include a wide variety of vectors for many different species. A representative vector for amplifying DNA is pBR322 or many of its derivatives (e.g., pUC18 or 19). Vectors that can be used to express the NPC1L1 polypeptides include, but are not limited to, those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); lpp promoter (the plN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius et al., “Expression Vectors Employing Lambda-, trp-, lac-, and lpp-derived Promoters”, in Rodriguez and Denhardt (eds.) \nVectors: A Survey of Molecular Cloning Vectors and Their Uses, \n1988, Buttersworth, Boston, pp. 205-236. Many polypeptides can be expressed, at high levels, in an \nE. coli\n/T7 expression system as disclosed in U.S. Pat. Nos. 4,952,496, 5,693,489 and 5,869,320 and in Davanloo, P., et al., (1984) Proc. Natl. Acad. Sci. USA 81: 2035-2039; Studier, F. W., et al., (1986) J. Mol. Biol. 189: 113-130; Roseonberg, A. H., et al., (1987) Gene 56: 125-135; and Dunn, J. J., et al., (1988) Gene 68: 259.\n\n\nHigher eukaryotic tissue culture cells may also be used for the recombinant production of the NPC1L1 polypeptides of the invention. Although any higher eukaryotic tissue culture cell line might be used, including insect baculovirus expression systems, mammalian cells are preferred. Transformation or transfection and propagation of such cells have become a routine procedure. Examples of useful cell lines include HeLa cells, chinese hamster ovary (CHO) cell lines, J774 cells, Caco2 cells, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines. Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a transcription termination site. These vectors also, usually, contain a selection gene or amplification gene. Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as adenovirus, SV40, parvoviruses, vaccinia virus, or cytomegalovirus. Examples of expression vectors include pCR®3.1, pCDNA1, pCD (Okayama, et al., (1985) Mol. Cell Biol. 5:1136), pMC1neo Poly-A (Thomas, et al., (1987) Cell 51:503), pREP8, pSVSPORT and derivatives thereof, and baculovirus vectors such as pAC373 or pAC610. One embodiment of the invention includes membrane bound NPC1L1. In this embodiment, NPC1L1 can be expressed in the cell membrane of a eukaryotic cell and the membrane bound protein can be isolated from the cell by conventional methods which are known in the art.\n\n\nThe present invention also includes fusions which include the NPC1L1 polypeptides and NPC1L1 polynucleotides of the present invention and a second, heterologous polypeptide or polynucleotide moiety (different from the NPC1L1 moiety in the fusion), which may be referred to as a “tag”. The fusions of the present invention include any of the polynucleotides or polypeptides set forth in Table 1 or any subsequence or fragment thereof (discussed above). The fused polypeptides of the invention may be conveniently constructed, for example, by insertion of a polynucleotide of the invention or fragment thereof into an expression vector. The fusions of the invention include tags which facilitate purification or detection. Such tags include green fluorescent protein (GFP) or any mutant thereof (e.g., S65T mutant; see Heim et al., Nature 373: 663-664 (1995)), glutathione-S-transferase (GST), hexahistidine (His6) tags, maltose binding protein (MBP) tags, haemagglutinin (HA) tags, cellulose binding protein (CBP) tags and myc tags. Detectable tags such as \n32\nP, \n35\nS, \n3\nH, \n99m\nTc, \n123\nI, \n111\nIn, \n68\nGa, \n18\nF, \n125\nI, \n131\nI, \n113m\nIn, \n76\nBr, \n67\nGa, \n99m\nTc, \n123\nI, \n111\nIn and \n68\nGa may also be used to label the polypeptides and polynucleotides of the invention. Methods for constructing and using such fusions are very conventional and well known in the art.\n\n\nModifications (e.g., post-translational modifications) that occur in a polypeptide often will be a function of how it is made. For polypeptides made by expressing a cloned gene in a host, for instance, the nature and extent of the modifications, in large part, will be determined by the host cell's post-translational modification capacity and the modification signals present in the polypeptide amino acid sequence. For instance, as is well known, glycosylation often does not occur in bacterial hosts such as \nE. coli\n. Accordingly, when glycosylation is desired, a polypeptide can be expressed in a glycosylating host, generally a eukaryotic cell. Insect cells often carry out post-translational glycosylations which are similar to those of mammalian cells. For this reason, insect cell expression systems have been developed to express, efficiently, mammalian proteins having native patterns of glycosylation. An insect cell which may be used in this invention is any cell derived from an organism of the class Insecta. In an embodiment of the invention, the insect is \nSpodoptera fruigiperda \n(Sf9 or Sf21) or \nTrichoplusia ni \n(High 5). Examples of insect expression systems that can be used with the present invention, for example to produce NPC1L1 polypeptide, include Bac-To-Bac (Invitrogen Corporation, Carlsbad, Calif.) or Gateway (Invitrogen Corporation, Carlsbad, Calif.). If desired, deglycosylation enzymes can be used to remove carbohydrates attached during production in eukaryotic expression systems. The present invention includes both glycosylated and un-glycosylated canine, rabbit, hamster, cynomolgus monkey and rhesus monkey NPC1L1.\n\n\nOther modifications may also include addition of aliphatic esters or amides to the polypeptide carboxyl terminus. The present invention also includes analogs of the NPC1L1 polypeptides which contain modifications, such as incorporation of unnatural amino acid residues, or phosphorylated amino acid residues such as phosphotyrosine, phosphoserine or phosphothreonine residues. Other potential modifications include sulfonation, biotinylation, or the addition of other moieties. For example, the NPC1L1 polypeptides of the invention may be appended with a polymer which increases the half-life of the peptide in the body of a subject. Subitable polymers include polyethylene glycol (PEG) (e.g., PEG with a molecular weight of 2 kDa, 5 kDa, 10 kDa, 12 kDa, 20 kDa, 30 kDa and 40 kDa), dextran and monomethoxypolyethylene glycol (mPEG).\n\n\nThe peptides of the invention may also be cyclized. Specifically, the amino- and carboxy-terminal residues of an NPC1L1 polypeptide or two internal residues of an NPC1L1 polypeptide of the invention can be fused to create a cyclized peptide. Methods for cyclizing peptides are conventional and very well known in the art; for example see Gurrath, et al., (1992) Eur. J. Biochem. 210:911-921.\n\n\nThe present invention contemplates any superficial or slight modification to the amino acid or nucleotide sequences which correspond to the NPC1L1 polypeptides of the invention. In particular, the present invention contemplates sequence conservative variants of the nucleic acids which encode the polypeptides of the invention. “Sequence-conservative variants” of a polynucleotide sequence are those in which a change of one or more nucleotides in a given codon results in no alteration in the amino acid encoded at that position. Function-conservative variants of the polypeptides of the invention are also contemplated by the present invention. “Function-conservative variants” are those in which one or more amino acid residues in a protein or enzyme have been changed without altering the overall conformation and function of the polypeptide, including, but, by no means, limited to, replacement of an amino acid with one having similar properties. Amino acids with similar properties are well known in the art. For example, polar/hydrophilic amino acids which may be interchangeable include asparagine, glutamine, serine, cysteine, threonine, lysine, arginine, histidine, aspartic acid and glutamic acid; nonpolar/hydrophobic amino acids which may be interchangeable include glycine, alanine, valine, leucine, isoleucine, proline, tyrosine, phenylalanine, tryptophan and methionine; acidic amino acids which may be interchangeable include aspartic acid and glutamic acid and basic amino acids which may be interchangeable include histidine, lysine and arginine.\n\n\nThe present invention includes polynucleotides encoding canine, hamster, rabbit, rhesus monkey and cynomolgus monkey NPC1L1 and fragments thereof as well as nucleic acids which hybridize to the polynucleotides. Preferably, the nucleic acids hybridize under low stringency conditions, more preferably under moderate stringency conditions and most preferably under high stringency conditions. A nucleic acid molecule is “hybridizable” to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook, et al., supra). The conditions of temperature and ionic strength determine the “stringency” of the hybridization. In an embodiment of the invention, low stringency hybridization conditions are 55° C., 5×SSC, 0.1% SDS, 0.25% milk, and no formamide at 42° C.; or 30% formamide, 5×SSC, 0.5% SDS at 42° C. In an embodiment of the invention, moderate stringency hybridization conditions are similar to the low stringency conditions except the hybridization is carried out in 40% formamide, with 5× or 6×SSC at 42° C. In an embodiment of the invention, high stringency hybridization conditions are similar to low stringency conditions except the hybridization conditions are carried out in 50% formamide, 5× or 6×SSC and, optionally, at a higher temperature (e.g., higher than 42° C.: 57° C., 59° C., 60° C., 62° C., 63° C., 65° C. or 68° C.). In general, SSC is 0.15M NaCl and 0.015M Na-citrate.\n\n\nIn an embodiment of the invention, low stringency hybridization conditions comprise conditions equivalent to binding or hybridization at 42° C. in a solution consisting of 5×SSPE (43.8 g/l NaCl, 6.9 g/l NaH\n2\nPO\n4\nH\n2\nO and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5×Denhardt's reagent (50×Denhardt's contains per 500 ml:05 g Ficoll (\nType\n 400, Pharmacia):05 g BSA (Fraction V; Sigma)) and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 1×SSPE, 0.1% SDS at 42° C. when a probe of about 500 nucleotides in length is employed.\n\n\nIn an embodiment of the invention, medium stringency conditions comprise conditions equivalent to binding or hybridization at 42° C. in a solution consisting of 5×SSPE (43.8 g/l NaCl, 6.9 g/l NaH\n2\nPO\n4\nH\n2\nO and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5×Denhardt's reagent and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5.0×SSPE, 1.0% SDS at 42° C. when a probe of about 500 nucleotides in length is employed.\n\n\nIn an embodiment of the invention, high stringency conditions comprise conditions equivalent to binding or hybridization at 42° C. in a solution consisting of 5×SSPE (43.8 g/l NaCl, 6.9 g/l NaH\n2\nPO\n4\nH\n2\nO and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5×Denhardt's reagent and 100 μg/ml denatured salmon sperm DNA followed by washing in a solution comprising 5-10×SSPE, 1.0% SDS at 42° C. when a probe of about 500 nucleotides in length is employed.\n\n\nHybridization requires that the two nucleic acids contain complementary sequences, although, depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the higher the stringency under which the nucleic acids may hybridize. For hybrids of greater than 100 nucleotides in length, equations for calculating the melting temperature have been derived (see Sambrook, et al., supra, 9.50-9.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook, et al., supra).\n\n\nIn an embodiment of the invention, a polynucleotide of the invention (e.g., SEQ ID NO: 1, 3, 5, 7, or 9 or any polynucleotide that hybridizes thereto under any condition, for example, high stringency conditions e.g., as set forth herein) encodes a polypeptide that exhibits the ability to bind to ezetimibe or any structurally related compound (e.g., any of compounds 1-9 herein). The scope of the invention also includes any such polypeptide.\n\n\nAlso included in the present invention are polynucleotides comprising nucleotide sequences and polypeptides comprising amino acid sequences which are at least about 70% identical, preferably at least about 80% identical, more preferably at least about 90% identical and most preferably at least about 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to the reference canine, hamster, rabbit, rhesus monkey, or cynomolgus monkey NPC1L1 nucleotide (e.g., any of SEQ ID NOs: 1, 3, 5, 7, or 9) or amino acid sequences (e.g., SEQ ID NOs: 2, 4, 6, 8, or 10) when the comparison is performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences. Polypeptides comprising amino acid sequences which are at least about 70% similar or homologous, preferably at least about 80% similar or homologous, more preferably at least about 90% similar or homologous and most preferably at least about 95% similar or homologous (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to the reference canine, hamster, rabbit, rhesus monkey, or cynomolgus monkey NPC1L1 (e.g., SEQ ID NOs: 2, 4, 6, 8 or 10), when the comparison is performed with a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences, are also included in the present invention.\n\n\nSequence identity refers to exact matches between the nucleotides or amino acids of two sequences which are being compared. Sequence similarity or homology refers to both exact matches between the amino acids of two polypeptides which are being compared in addition to matches between nonidentical, biochemically related amino acids. Biochemically related amino acids which share similar properties and may be interchangeable are discussed above.\n\n\nIn an embodiment of the invention, a polypeptide of the invention (e.g., SEQ ID NO: 2, 4, 6, 8 or 10 or any polypeptide bearing similarity or identity thereto e.g., 95% or more, including 97% or 99%) exhibits the ability to bind to ezetimibe or any structurally related compound (e.g., any of compounds 1-9 herein). The scope of the invention also includes any polynucleotide encoding such a polypeptide.\n\n\nThe following references regarding the BLAST algorithm are herein incorporated by reference: BLAST ALGORITHMS: Altschul, S. F., et al., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al., (1993) Nature Genet. 3:266-272; Madden, T. L., et al., (1996) Meth. Enzymol. 266:131-141; Altschul, S. F., et al., (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et al., (1997) Genome Res. 7:649-656; Wootton, J. C., et al., (1993) Comput. Chem. 17:149-163; Hancock, J. M., et al., (1994) Comput. Appl. Biosci. 10:67-70; ALIGNMENT SCORING SYSTEMS: Dayhoff, M. O., et al., “A model of evolutionary change in proteins.” in \nAtlas of Protein Sequence and Structure\n, (1978) vol. 5, suppl. 3. M. O. Dayhoff (ed.), pp. 345-352, Natl. Biomed. Res. Found., Washington, D.C.; Schwartz, R. M., et al., “Matrices for detecting distant relationships.” in \nAtlas of Protein Sequence and Structure\n, (1978) vol. 5, suppl. 3.” M. O. Dayhoff (ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, D.C.; Altschul, S. F., (1991) J. Mol. Biol. 219:555-565; States, D. J., et al., (1991) Methods 3:66-70; Henikoff, S., et al., (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919; Altschul, S. F., et al., (1993) J. Mol. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlin, S., et al., (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S., et al., (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A., et al., (1994) Ann. Prob. 22:2022-2039; and Altschul, S. F. “Evaluating the statistical significance of multiple distinct local alignments.” in \nTheoretical and Computational Methods in Genome Research \n(S. Suhai, ed.), (1997) pp. 1-14, Plenum, New York.\n\n\nProtein Purification\n\n\nThe proteins, polypeptides and antigenic fragments of this invention can be purified by standard methods, including, but not limited to, salt or alcohol precipitation, affinity chromatography (e.g., used in conjunction with a purification tagged NPC1L1 polypeptide as discussed above), preparative disc-gel electrophoresis, isoelectric focusing, high pressure liquid chromatography (HPLC), reversed-phase HPLC, gel filtration, cation and anion exchange and partition chromatography, and countercurrent distribution. Such purification methods are well known in the art and are disclosed, e.g., in “\nGuide to Protein Purification”, Methods in Enzymology\n, Vol. 182, M. Deutscher, Ed., 1990, Academic Press, New York, N.Y.\n\n\nPurification steps can be followed by performance of assays for receptor binding activity as described below. Particularly where an NPC1L1 polypeptide is being isolated from a cellular or tissue source, it is preferable to include one or more inhibitors of proteolytic enzymes in the assay system, such as phenylmethanesulfonyl fluoride (PMSF), Pefabloc SC, pepstatin, leupeptin, chymostatin and EDTA.\n\n\nIn an embodiment of the invention, canine, hamster, rabbit, cynomolgus monkey or rhesus monkey NPC1L1 is purified by isolating a cell membrane comprising the polypeptide from other contents of a host cell. For example, the cell carrying the NPC1L1 polypeptide can be lysed and the membranes from the cell can be pelleted by centrifugation.\n\n\nNPC1L1\n\n\nThe present invention includes canine, hamster, rabbit, cynomolgus monkey or rhesus monkey NPC1L1 polypeptides and polynucleotides as set forth below along with allelic variants and fragments thereof (e.g., antigenic fragments thereof).\n\n\n\n\n\n\n\n\n\n\n\n\nCanine NPC1L1 ORF\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 1)\n\n\n \n\n\n\n\n\n\n\n\n\n\natggcggaca ctggcctgag gggctggctg ctatgggcac tgctcctgca tgtggcccag\n\n\n60\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagtgagctgt acacacccat ccaccagcct ggctactgcg ctttctacga cgagtgtggg\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\naagaacccag agctgtctgg gggactggcg cctctgtcta atgtgtcctg cctgtccaac\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\nacgcccgccc tccgtgtcac tggtgagcac ctgaccctcc tacagcgcat ctgcccccgc\n\n\n240\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctacacgg gcaccaccac ctatgcctgc tgctccccca agcagctgct gtccctggag\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\nacgagcctgg cggtcaccaa ggccctcctc acccgctgcc ccacctgctc cgacaacttt\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgaacctgc actgccaaaa cacctgcagc cccaaccaaa gtctcttcat caacgtgacc\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcgtggctg ggggcggggg tggccggccc caggctgtgg tggcctatga ggccttctac\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggacacct ttgcccagca gacctacgac tcttgcagcc gggtgcgcat ccctgcggct\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccacgctgg ccgtgggcac catgtgtggc gtttatggct ccaccctctg caatgctcag\n\n\n600\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgctggctca atttccaggg ggacacttcg aatggcctgg ctcccctaga catcaccttc\n\n\n660\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacctgatgg agcccggcca ggccctaggg agtgggatgc aggctctgac cggggagatc\n\n\n720\n\n\n\n\n\n\n \n\n\n\n\n\n\naggccctgca acgagtccca gggcaatggc acggtggcct gctcctgcca ggactgtgct\n\n\n780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcgtcctgcc ccaccatccc ccagccccag gcactggact ccaccttcta cctgggcggg\n\n\n840\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggaaggtg ggctggccct tgtcatcatc ctctgctctg cttttgccct gcttaccacc\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcctggtgg gtacccgcct ggcctcctcc tgtggcaagg acaagacgcc agaccccaag\n\n\n960\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcaggcatga gcctgtctga caaactcagc ctctccacca acgtcatcct tagccagtgc\n\n\n1020\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccagaact ggggcacatg ggtggcctca tggccgctga ccatcctgtt ggtgtccatc\n\n\n1080\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccgtggtat tggccttgtc aggaggcctg gcctttgtgg aactgaccac ggacccagtg\n\n\n1140\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagctgtggt cggcccccag cagccaagcc cggagtgaga aggctttcca cgaccagcat\n\n\n1200\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttggcccct tcctccgaac caaccaggtg atcttgacgg ctcccaaccg gcccagctac\n\n\n1260\n\n\n\n\n\n\n \n\n\n\n\n\n\ncactacgact ccctgctcct ggggcccaag aacttcagtg gggtcctggc ctctgacctc\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctggagc tgctggagct acaggagacG ctgcggcacc tccaggtgtg gtcgcccgag\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagcagcgcc acatctcgct gcaggacatc tgcttcgcgc ccctcaaccc tcacaatgcc\n\n\n1440\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcctctccg actgctgcat caacagcctc ctgcagtatt tccagagcaa ccgcacgcac\n\n\n1500\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctgctca cggccaacca gacgctgacg ggccagacct cccaggtgga ctggagggac\n\n\n1560\n\n\n\n\n\n\n \n\n\n\n\n\n\ncactttctct actgtgctaa cgccccactc accttcaagg atggcacagc cctagccctg\n\n\n1620\n\n\n\n\n\n\n \n\n\n\n\n\n\nagctgcatgg ctgactatgg gggccctgtc ttccccttcc ttgccgtggg tggctacaaa\n\n\n1680\n\n\n\n\n\n\n \n\n\n\n\n\n\ngggaaggact actctgaggc ggaggccctg attatgacct tctccctcaa caactatgcc\n\n\n1740\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctggggacc cccggctggc ccaggctaag ctctgggagg cagccttctt ggaggagatg\n\n\n1800\n\n\n\n\n\n\n \n\n\n\n\n\n\naaagccttcc agcggcggac agctggcact ttccaggtca cattcatggc tgagcgctcc\n\n\n1860\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggaggacg agattaaccg cacgacggcg gaggacctcc ccatcttcgg agtcagctac\n\n\n1920\n\n\n\n\n\n\n \n\n\n\n\n\n\natcatcatct tcctgtacat ctccctggcg ctgggcagct actccagctg gcgccgggtg\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\nccggtggact ccaaggtcac gctgggcctg ggcggggtgg cggtggtgct gggagcagtg\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\nacagcggcca tgggcttctt ctcctacctc ggcgtgccgt cctccctggt gatccttcag\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggtgcctt tcctggtgtt ggccgtgggc gctgacaaca tcttcatctt tgttctggag\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccagaggc tgccccggag gccgggagag ccgcgggagg cccacatcgg ccgagcgctg\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nggcagtgtgg cccctagcat gttgctctgc agcctgtctg aggccatctg cttctttcta\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\nggggccctga cccctatgcc cgctgtgaag acctttgccc tgatctcggg ctttgccatc\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcctggact tcttgctgca ggtgtcagcc tttgtggctc tgctttctct ggacagcagg\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\naggcaggagg cctcccgctt ggacgtctgc tgctgcgtga gcgccccgaa gctgcctgca\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccggccaga gcgagggact cctgcttcga gtcttccgca agttctacgt cccagtcctg\n\n\n2520\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgcaccggg tgacacgggc ggtggtgctg ctgctgttca ccggcctctt cggggtgggg\n\n\n2580\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctacttca tgtgccacat ccgcgtggga ttggatcagg agctggccct gcccaaggac\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcatacctgc tggactattt cttcttcctg aaccgctact ttgaggtggg ggctcccgtc\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\ntactttgtca ccacgggagg ctacaacttc tccagcgagg cgggcatgaa tgctgtgtgc\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccagtgccg ggtgcgacag ttactcctta acccagaaga tccagtacgc caccgagttc\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccgaggagt cttacctggc catccctgcc tcctcctggg tggatgactt catcgactgg\n\n\n2880\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgaccccgt cctcctgctg ccgcctttat gcctttggtg ctaataagga caaattctgc\n\n\n2940\n\n\n\n\n\n\n \n\n\n\n\n\n\nccttcgactg tcaactccct agcctgcttg aagaactgcg tgaacttcac actgggccct\n\n\n3000\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtccggccat ccgtggacca gttccacaag taccttccct ggttcctgag tgacccgccc\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\naacatcaagt gtcccaaagg tgggctggca gcgtacaaca cctccgtgca tttgggatct\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\ngatggccagg ttttagcctc ccggttcatg gcctaccaca agccgctgcg gaactcggag\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\ngattacactg aggccctgcg ggtgtcacgg gcgctggcgg ccaacatcac ggcccagctg\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggcaggtgc caggcaccga cccggccttc gaggtcttcc cctacacgat caccaacgtg\n\n\n3300\n\n\n\n\n\n\n \n\n\n\n\n\n\nttctacgagc agtacctgag cgtggtcccc gagggcctct tcatgctcgc catctgcctg\n\n\n3360\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgcccacct tcgtagtctg ctgcctgctg ctgggcatgg acctacgctc cggcctcctc\n\n\n3420\n\n\n\n\n\n\n \n\n\n\n\n\n\naacctgttct ccatcgtcat gatcctcgtg gacaccgtgg gcttcatggc cctgtggggc\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\natcagttaca atgccgtgtc gctcatcaac ctggtcacgg cggtgggcat ctccgtggag\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttgtgtccc acatcacccg ctcctttgca gtcagcaccc ggcccacccg gctggagagg\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccaaggagg ccaccatctc catgggcagc gcggtgtttg ctggcgtggc catgaccaac\n\n\n3660\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgccgggca tcctcgtcct gggcctggcc aaggcacagc tcatccagat cttcttcttc\n\n\n3720\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcctcaacc tcctcatcac cgtgctgggt ctgctgcatg gcctggtctt cctgccagtg\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcctcagct acctcgggcc tgatatcaat gcagctctcg tgctggacca gaagaagaca\n\n\n3840\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaagaggcca tcggggcccc tgcccacctg gtcccaacat ccacggccag cagcacctat\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcaactacg gcttccaaca tcccgccaac ggtgtagtgg gcgacagttc tctgccccgc\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\nagtggaccgg acctctga\n\n\n3978\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 2)\n\n\n \n\n\n\n\n\n\n\n\n\n\n   1 MADTGLRGWL LWALLLHVAQ SELYTPIHQP GYCAFYDECG KNPELSGGLA\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n  51 PLSNVSCLSN TPALRVTGEH LTLLQRICPR LYTGTTTYAC CSPKQLLSLE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 101 TSLAVTKALL TRCPTCSDNF VNLHCQNTCS PNQSLFINVT RVAGGGGGRP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 151 QAVVAYEAFY QDTFAQQTYD SCSRVRIPAA ATLAVGTMCG VYGSTLCNAQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 201 RWLNFQGDTS NGLAPLDITF HLMEPGQALG SGMQALTGEI RPCNESQGNG\n\n\n\n\n\n\n \n\n\n\n\n\n\n 251 TVACSCQDCA ASCPTIPQPQ ALDSTFYLGG LEGGLALVII LCSAFALLTT\n\n\n\n\n\n\n \n\n\n\n\n\n\n 301 FLVGTRLASS CGKDKTPDPK AGMSLSDKLS LSTNVILSQC FQNWGTWVAS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 351 WPLTILLVSI AVVLALSGGL AFVELTTDPV ELWSAPSSQA RSEKAFHDQH\n\n\n\n\n\n\n \n\n\n\n\n\n\n 401 FGPFLRTNQV ILTAPNRPSY HYDSLLLGPK NFSGVLASDL LLELLELQET\n\n\n\n\n\n\n \n\n\n\n\n\n\n 451 LRHLQVWSPE EQRHISLQDI CFAPLNPHNA SLSDCCINSL LQYFQSNRTH\n\n\n\n\n\n\n \n\n\n\n\n\n\n 501 LLLTANQTLT GQTSQVDWRD HFLYCANAPL TFKDGTALAL SCMADYGGPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 551 FPFLAVGGYK GKDYSEAEAL IMTFSLNNYA PGDPRLAQAK LWEAAFLEEM\n\n\n\n\n\n\n \n\n\n\n\n\n\n 601 KAFQRRTAGT FQVTFMAERS LEDEINRTTA EDLPIFGVSY IIIFLYISLA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 651 LGSYSSWRRV PVDSKVTLGL GGVAVVLGAV TAAMGFFSYL GVPSSLVILQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 701 VVPFLVLAVG ADNIFIFVLE YQRLPRRPGE PREAHIGRAL GSVAPSMLLC\n\n\n\n\n\n\n \n\n\n\n\n\n\n 751 SLSEAICFFL GALTPMPAVK TFALISGFAI VLDFLLQVSA FVALLSLDSR\n\n\n\n\n\n\n \n\n\n\n\n\n\n 801 RQEASRLDVC CCVSAPKLPA PGQSEGLLLR VFRKFYVPVL LHRVTRAVVL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 851 LLFTGLFGVG LYFMCHIRVG LDQELALPKD SYLLDYFFFL NRYFEVGAPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 901 YFVTTGGYNF SSEAGMNAVC SSAGCDSYSL TQKIQYATEF PEESYLAIPA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 951 SSWVDDFIDW LTPSSCCRLY AFGANKDKFC PSTVNSLACL KNCVNFTLGP\n\n\n\n\n\n\n \n\n\n\n\n\n\n1001 VRPSVDQFHK YLPWFLSDPP NIKCPKGGLA AYNTSVHLGS DGQVLASRFM\n\n\n\n\n\n\n \n\n\n\n\n\n\n1051 AYHKPLRNSE DYTEALRVSR ALAANITAQL RQVPGTDPAF EVFPYTITNV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1101 FYEQYLSVVP EGLFMLAICL LPTFVVCCLL LGMDLRSGLL NLFSIVMILV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1151 DTVGFMALWG ISYNAVSLIN LVTAVGISVE FVSHITRSFA VSTRPTRLER\n\n\n\n\n\n\n \n\n\n\n\n\n\n1201 AKEATISMGS AVFAGVAMTN LPGILVLGLA KAQLIQIFFF RLNLLITVLG\n\n\n\n\n\n\n \n\n\n\n\n\n\n1251 LLHGLVFLPV VLSYLGPDIN AALVLDQKKT EEAIGAPAHL VPTSTASSTY\n\n\n\n\n\n\n \n\n\n\n\n\n\n1301 VNYGFQHPAN GVVGDSSLPR SGPDL*\n\n\n\n\n\n\n \n\n\n\n\n\n\nRabbit NPC1L1 ORF\n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 3)\n\n\n \n\n\n\n\n\n\n\n\n\n\natggcagggg ctgcgcgggg ctggctgctc tgggccctgc tcctgcacca ggcccaggca\n\n\n60\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngagctgtaca cgcccgtgca ccaggccggc tactgcgcct tctacgagga gtgcgggaag\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\naaccctgagc tgtctggggg cctcacatcg ctgtccaacg tgtcctgcct gtccaacacg\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctgcccgcc atgtcacggg cgaccacctg gccctcctgg agcgcatctg cccccgcctc\n\n\n240\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacaacggcc ccaacaccac ctacgcctgc tgctcgccca ggcagctggt gtcgctggag\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\naccagcatgt ccgtcaccaa ggccctgctc acgcgctgcc ccgcctgctc tgacaacttc\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgagcctgc actgccagaa cacctgcagc ccggaccaga gcctcttcat caacgtgacg\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcgtggtct cccagggcgc tgggcagctc caggccgtcg tggcctacga ggcctactac\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagcgcagct tcgccgagcg ggcctacgag tcctgcagcc gcgtgcgcat ccccgccgcc\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccacgctgg ccgtgggcag catgtgcggc gtgtacggct ctgccctctg caacgcccag\n\n\n600\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgctggctca acttccaggg ggacacgagc aacggcctgg ccccgctgga cattaccttc\n\n\n660\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacctgcggg agcccgggca ggcgccgggc agcgggatgc aactgctgaa cgcggagatc\n\n\n720\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcgccctgca acgagtccca ggacagcgcc gcggcctgct cctgccagga ctgtgccgcg\n\n\n780\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcctgcccgg ccatcacgca gcctgaggcc ctggactcct ccttccgcat tggccgcgtg\n\n\n840\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggggtgggg tggcactcgt cgtcatcctc tgcagcaccc tgggcgtgct cctcctgggc\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcgtgtgcg cccgcaggta ctcggccaag gccaggggca cggcgacggc ccccacggcc\n\n\n960\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgctccaggc tctcccaccg catcagcctg tccatccaca ccttcctcca tcggctcttc\n\n\n1020\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagtgctggg gcacgtgggt ggcctcgtgg cccctgacca tcctggccgt gtccatcgcg\n\n\n1080\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcgtggtgt ccttggcgtg tggcctggcc ttcacggagc tcacaacgga ccccgtggag\n\n\n1140\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgtggtcgg cccccaacag ccaagcccgc agcgagaagg ctttccacga ccagcacttc\n\n\n1200\n\n\n\n\n\n\n \n\n\n\n\n\n\nggccccttct tccgaacgaa ccaggtgatc ctgacggcgc ctacccgctc ccgctacact\n\n\n1260\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacaactccc tgctgctggg gccccggaac ttcagtggga tcctggccat ggacctgctg\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggagctac tggagctgca ggagcggctg cgggccctgc aggtgtggtc gcccgaggcg\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcgcaacg tgagcctgcg ggacgtctgc tacgccccgc tcaacccgca caacgccagc\n\n\n1440\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcaccgact gctgtatcaa cagcctgctg cagtacttcc agaacaaccg cacgctgctg\n\n\n1500\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagctcacgg ccaaccagac gctcctgggc cagactgccc aggtcgactg gagggaccac\n\n\n1560\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttctctact gtgccaatgc ccccctcacc ttccaagacg gcacggccct gtccctgagc\n\n\n1620\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgcatggccg actacggggc gcccgtcttc cctttcctcg ccgttggggg atacgaaggc\n\n\n1680\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggactact cggatgcgga ggccctcatc ttaaccttct ccctcaacaa ctaccctgcg\n\n\n1740\n\n\n\n\n\n\n \n\n\n\n\n\n\nggggaccccc gcctggccca ggtcaagctc tgggaggagg ccttcgtgaa ggagatgcga\n\n\n1800\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccttgcagc ttgggaagtc cagcaaattc caggtcacgt tcatggccga gcgctccctg\n\n\n1860\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggatgaga tcaaccgcac cacggctgag gacctgccca tctttgccat cagctacatc\n\n\n1920\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcaccttcc tgtacatcgc cctggccctg ggccgctact ccagctggcg ccgattgccg\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggactcca agatcacgct gggcctgggc ggggtggtca tggtgctgag cgcggtcatg\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcttccatgg gcttcttctc ctacctgggc atcccgtcgt ccctgatcat cctgcaagtg\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcctttcc tggtgctggc cgtgggggcc gacaacatct tcatcctcgt tctcgagtac\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcggctgc cgcggaggcc tgaggagtcg cgggaggccc acatcggccg agccctgggc\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nagggtggctc ccagcatgct gctgtgcagc ctctccgaga ccatctgctt cttcctgggg\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccctgaccc ccatgccagc cgtgcgtacc tttgccctga cgtctggcct ggcggtgcaa\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcgacttcc tgctgcagat gactgccttc gtggccctgc tgtccctgga cagcaagagg\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggaggctt cccggccaga tgtgtgctgc tgcctggagc cccggaagct gccctcccag\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcagagcg aggggctgct gctgtgtttc ttccgcaaag tctacgcccc gctcctgctg\n\n\n2520\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacaaggtca cccgcgtggt cgtgctgctg ctctttctgt tcctgttcgg atcgagtctc\n\n\n2580\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacttcatgt gccaggtcac cgtggggctg gaccaggage tggccctgcc caaggactcg\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacctgatcg actacttcct gtttctgaac cgctactttg aggtgggggc cccagtgtac\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttgtcacca cctcgggcta caacttctcc agcgaggcgg gcatgaacgc catctgctcc\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcgcaggct gcgacagctt ctccctcacc cagaagatcc aatacgccac cgagttcccc\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagcagtctt acctggccat ccccgcctcc tcctgggtgg acgacttcat cgactggcta\n\n\n2880\n\n\n\n\n\n\n \n\n\n\n\n\n\naccccgtcct cctgctgccg cctttacatc ctcggcccca ataaggacga gttctgcccc\n\n\n2940\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccacagtca actccttgaa ctgcctgagg aattgcatga gcttgacgct gggccctgtg\n\n\n3000\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggccctcgg tggagcagtt ccacaagtac ctgccctggt ttctgaatga cccccccaac\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\natccgatgtc ccaagggtgg cctggcggcg tacagcacct ctgtgaacct gagcgccgat\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\nggccagattg tagccacccg cttcatggcc taccacaagc cgctgaagaa ctcgcaggac\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacaccgagg ccctgcgggc gtcgcgggag ctggcggcca acatcaccgc gagcctgcgg\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggtgccgg gcacggaccc cgccttcgag gtcttcccct acacgatctc caacgtgttc\n\n\n3300\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacgagcagt acctgaccgt gctcccggag gggctcgcca cgctcggcct ctgcctcgtg\n\n\n3360\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccaccttcg tcgtctgctg cctcctgctg ggcctggacc tgcgctccgg cctcctcaac\n\n\n3420\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctgacca tcgtcatgat tctcgtggac accgtgggcc tcatgacgct gtggagcatc\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\nagctacaacg ccgtgtccct catcaatctg gtcacggcgg tgggcatgtc cgtggagttc\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgtcccaca tcacccgctc ctttgccgtc agcaccaagc ccagccggct ggagagagcc\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\naaggaggcca ccatctccat gggcagtgcg gtgtttgcag gggtggccat gaccaacctg\n\n\n3660\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgggcatcc tcatcctggg cctcgccaag gcccagctca tccagatctt cttcttccgc\n\n\n3720\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcaacctcc tcatcaccct gctggggctg ctgcacggcc tggtcttcct gcccgtcatc\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcagctacc ttgggcctga cgtcaacccg gctctggttg ctctggagcg gacgcgagcc\n\n\n3840\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggaggcgg ctgacgctgc ggcgggctcc tgcccaaatc accccgaccc tacctccaac\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\natctacgtca actccggctt tgacgaggca gccagggatg tcggcagctc tgcccccacc\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\nagaaagcaga agttctga\n\n\n3978\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 4)\n\n\n \n\n\n\n\n\n\n\n\n\n\n   1 MAGAARGWLL WALLLHQAQA ELYTPVHQAG YCAFYEECGK NPELSGGLTS\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n  51 LSNVSCLSNT PARHVTGDHL ALLERICPRL YNGPNTTYAC CSPRQLVSLE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 101 TSMSVTKALL TRCPACSDNF VSLHCQNTCS PDQSLFINVT RVVSQGAGQL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 151 QAVVAYEAYY ERSFAERAYE SCSRVRIPAA ATLAVGSMCG VYGSALCNAQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 201 RWLNFQGDTS NGLAPLDITF HLREPGQAPG SGMQLLNAEI APCNESQDSA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 251 AACSCQDCAA SCPAITQPEA LDSSFRIGRV RGGVALVVIL CSTLGVLLLG\n\n\n\n\n\n\n \n\n\n\n\n\n\n 301 LVCARRYSAK ARGTATAPTA CSRLSHRISL SIHTFLHRLF QCWGTWVASW\n\n\n\n\n\n\n \n\n\n\n\n\n\n 351 PLTTLAVSIA VVVSLACGLA FTELTTDPVE LWSAPNSQAR SEKAFHDQHF\n\n\n\n\n\n\n \n\n\n\n\n\n\n 401 GPFFRTNQVI LTAPTRSRYT YNSLLLGPRN FSGILAMDLL LELLELQERL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 451 RALQVWSPEA QRNVSLRDVC YAPLNPHNAS LTDCCINSLL QYFQNNRTLL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 501 QLTANQTLLG QTAQVDWRDH FLYCANAPLT FQDGTALSLS CMADYGAPVF\n\n\n\n\n\n\n \n\n\n\n\n\n\n 551 PFLAVGGYEG EDYSDAEALI LTFSLNNYPA GDPRLAQVKL WEEAFVKEMR\n\n\n\n\n\n\n \n\n\n\n\n\n\n 601 ALQLGKSSKF QVTFMAERSL EDEINRTTAE DLPIFAISYI VTFLYIALAL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 651 GRYSSWRRLP VDSKITLGLG GVVMVLSAVM ASMGFFSYLG IPSSLIILQV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 701 VPFLVLAVGA DNIFILVLEY QRLPRRPEES REAHIGRALG RVAPSMLLCS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 751 LSETICFFLG ALTPMPAVRT FALTSGLAVQ LDFLLQMTAF VALLSLDSKR\n\n\n\n\n\n\n \n\n\n\n\n\n\n 801 QEASRPDVCC CLEPRKLPSQ QQSEGLLLCF FRKVYAPLLL HKVTRVVVLL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 851 LFLFLFGSSL YFMCQVTVGL DQELALPKDS YLIDYFLFLN RYFEVGAPVY\n\n\n\n\n\n\n \n\n\n\n\n\n\n 901 FVTTSGYNFS SEAGMNAICS SAGCDSFSLT QKIQYATEFP EQSYLAIPAS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 951 SWVDDFIDWL TPSSCCRLYI LGPNKDEFCP STVNSLNCLR NCMSLTLGPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1001 RPSVEQFHKY LPWFLNDPPN IRCPKGGLAA YSTSVNLSAD GQIVATRFMA\n\n\n\n\n\n\n \n\n\n\n\n\n\n1051 YHKPLKNSQD YTEALRASRE LAANITASLR QVPGTDPAFE VFPYTISNVF\n\n\n\n\n\n\n \n\n\n\n\n\n\n1101 YEQYLTVLPE GLATLGLCLV PTFVVCCLLL GLDLRSGLLN LLTIVMILVD\n\n\n\n\n\n\n \n\n\n\n\n\n\n1151 TVGLMTLWSI SYNAVSLINL VTAVGMSVEF VSHITRSFAV STKPSRLERA\n\n\n\n\n\n\n \n\n\n\n\n\n\n1201 KEATISMGSA VFAGVAMTNL PGILILGLAK AQLIQIFFFR LNLLITLLGL\n\n\n\n\n\n\n \n\n\n\n\n\n\n1251 LHGLVFLPVI LSYLGPDVNP ALVALERTRA QEAADAAAGS CPNHPDPTSN\n\n\n\n\n\n\n \n\n\n\n\n\n\n1301 IYVNSGFDEA ARDVGSSAPT RKQKF*\n\n\n\n\n\n\n \n\n\n\n\n\n\nHamster NPC1L1 ORF\n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 5)\n\n\n \n\n\n\n\n\n\n\n\n\n\natggcagctg gcctacagag atggctgctc tgggccctac tcctgaatgc ggcccggggt\n\n\n60\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngagatacaca cacccattca taaagctggc gtctgtacct tctatgaaga gtgtgggaag\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\naacccagagc tgtccggagg cctcacgtca ctgtccaatg tatcttgcct gtctaacacc\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\nccagcccgcc gtgtcacagg tgaccacctg accctccttc agcgcatctg cccccgcctg\n\n\n240\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacaatggcc ccaacaatac ctatgcttgt tgctccgccc agcagctagt ggcattagaa\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\naagagcatgt ctatcaccaa ggccctcctc acccgctgcc cagcctgctc tgacaatttt\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgagcttgc actgccacaa cacctgcagc cctgaccaga gcctcttcat caatgtcacc\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtgtggttg agcaggcgga ccctcagcag cctccagctg tggtggccta tgaagccttt\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccagagca gctttgcaga gaaggcctat gagtcctgta gccgggtacg catccccgcg\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngctgcctcac tggctgtggg caccatgtgt ggggtgtatg gctctgccct gtgcaatgcc\n\n\n600\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaacgctggc tcaacttcca gggagacaca gggaacggcc tggctcctct cgacatcacc\n\n\n660\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccacctcg tggagtccgg ccaggccctg ccagatggga tgcagcctct gaatggggag\n\n\n720\n\n\n\n\n\n\n \n\n\n\n\n\n\natcacgccct gcaatcagtc ggagggtgta gagtcggctg cctgttcctg ccaggactgt\n\n\n780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcagcgtctt gccctgtcat tccgcagccc tcagccctgc ccccttcctt ctacatgggt\n\n\n840\n\n\n\n\n\n\n \n\n\n\n\n\n\naaaatgcctg gctggctggc tctcatcatc atcttctgtg cggtcttcgt gctgctcaca\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\ngctgtcctta tatatcttcg agtggtttcc aataggagca ggagcaagaa aacaggcctc\n\n\n960\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggaagccc cgaaccgccc tcctaagcgc agattctcac ctcacatcgt ccttggccgg\n\n\n1020\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttttccaga gctggggcac aagagtggcc tcatggccac tcactgtctt ggcgctgtcc\n\n\n1080\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttatggttg tgatagcctt gtcagtgggc atgacctaca tagaactcac cacagaccct\n\n\n1140\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggaactgt ggtcagcccc caaaagccaa gctcggaaag agaaggcttt ccacgacgag\n\n\n1200\n\n\n\n\n\n\n \n\n\n\n\n\n\ncattttggcc ccttcttccg aaccaaccag gtttttgtga cagctcggaa caggtccagc\n\n\n1260\n\n\n\n\n\n\n \n\n\n\n\n\n\ntatagatatg actccctgct gctagggccc aagaacttca gtgggctcct gtccctggac\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggtgctgg agctgctgga gctccaagag aggcttcgac acctgcaggt gtggtcccct\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggcacagc gcaacatctc cctgcaggac atctgctatg cccccctcaa accgcacaac\n\n\n1440\n\n\n\n\n\n\n \n\n\n\n\n\n\naccagcctct ccgactgctg tgtcaacagt ctccttcagt acttccagaa caaccgcacg\n\n\n1500\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcctgctgc tcacagccaa ccagacgctc aatggccaga cttccctggt ggactggagg\n\n\n1560\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaccacttcc tctactgtgc aaatgcgcct ctcacgttca aagacggcac gtctctggcc\n\n\n1620\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgagctgca tcgcggacta tggggcccct atcttcccct tccttgctgt cggggggtac\n\n\n1680\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaagggacgg actactctga ggcagaggcg ctgatcataa ctttctctct caataactac\n\n\n1740\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctgctgatg atccccgcat ggcccaggcc aagctctggg aggaggcttt tctgaaggaa\n\n\n1800\n\n\n\n\n\n\n \n\n\n\n\n\n\natgcaagcct tccagagcag tgtggctgac aagttccagg ttgcattctc agctgagcgc\n\n\n1860\n\n\n\n\n\n\n \n\n\n\n\n\n\ntctctggagg atgagatcaa ccgcaccacc atccaggacc tgcctgtctt cgccatcagc\n\n\n1920\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacattatcg tcttcctgta catctctctg gccctgggca gctactccaa atggaagcga\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtagcggtgg attccaaggc tactctgggc ctcggtgggg tggctgtcgt gctgggagca\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcgtggctg ccatgggttt ctactcctac ctgggtgttc cctcctcact ggttatcatc\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaagtggtgc ctttcctggt gctggccgtg ggagctgaca acatcttcat ctttgttctt\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagtaccaga ggctgcctag gaggcctggg gageagegag aggcccacat cggccgtacc\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgggcagtg tggcccccag catgctgctg tgcagcctct ctgaggctgt ctgcttcttt\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\nctaggggccc tgacccccat gccagctgtg aggacctttg ccttgaccgc tggcctttcg\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\nattatcctcg acttcctgct ccagatgact gccttcgtgg ccctgctctc cctggatagc\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\naagaggcagg aggcctctcg ccccgacatc ttatgctgtc tttcaccccg gaaactaccc\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\nccacctgaac agcaagaggg gctcttactc cgcttcttca gaaagatata tgctcccttc\n\n\n2520\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctgcaca ggttcatccg ccctgttgtg ctgctgctgt ttctggccct gtttggagca\n\n\n2580\n\n\n\n\n\n\n \n\n\n\n\n\n\naatctctact taatgtgcca catcagcgtg gggttggacc aggagctggc cctgcctaag\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\ngattcctact tgattgacta cttcctcttt ttgaaccgat actttgaggt ggggcctccc\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgtactttg tcaccacctc gggttacaac ttctccagcg aggcaggcat gaatgccatt\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgctctagtg caggctgtga cagcttctcc atgacccaga agatccaata tgccactgaa\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccctgagc agtcttacat agggattgct gcatcctcct gggtagacga cttcatcgac\n\n\n2880\n\n\n\n\n\n\n \n\n\n\n\n\n\ntggctgaccc cgtcctcctg ctgccgcctt tatatctttg gccccaatac gggtgacttc\n\n\n2940\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtccttcaa ctgatacttc cttgagctgt ctaaaaaact gcatgaactt cactctgggc\n\n\n3000\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccgtgaggc ccacagcaga acagtttcac aagtatctgc cctggttcct ggacgatcca\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccaacatca gatgccccaa agggggtctg gcagcatata gaacttccgt gaatttgagc\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcagatggcc agattatago ctcccagttc atggcctacc acaagccgct caggaactca\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggacttca cagaagctct ccggacatcc cgattgctgg cagccaacat cacagctgaa\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\nctacggaaag tgcctggcac agccccagac tttgaggtct tcccctacac gatctccaac\n\n\n3300\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgttctacg agcagtacct gactgtcctc cccgagggca tcttcacact ggctctctgc\n\n\n3360\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcgtgccca ccttcgtcgt ctgctacctc ctgctgggcc tggacatgcg ctcaggcatc\n\n\n3420\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcaacctgc tctccatcat catgatcctt gtggacacca tcgggctcat ggctgtgtgg\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\nggcatcagct acaatgctgt gtccctcatc aaccttgtca cggcagtggg aatgtctgtg\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagttcgtgt cccacctcac ccggtccttt gctgtcagca ccaagcccac ccggctggag\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\nagggccaagg atgccaccgt ctccatgggc agtgcggtgt ttgctggcgt ggccatgacc\n\n\n3660\n\n\n\n\n\n\n \n\n\n\n\n\n\naacttcccag gcatcctcat cctgggcttc gcccaggccc agctaatcca gatcttcttc\n\n\n3720\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccgcctca acctcctgat caccttgctg ggcctgctgc acggcctggt cttcctgccg\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngttgtcctca gctatctggg acccgatgtg aacccagagc tggtgctgga ggagaaacta\n\n\n3840\n\n\n\n\n\n\n \n\n\n\n\n\n\ngctacggagg cagcggtggc cccagagcct tccagcccga agtacccctt ccctgataat\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\ngactatgtta atcacagttt tgaggaagcc acccctggag ctgctgctgc tagtagctcc\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\nttgcctaaaa gcggccaaaa gttttaa\n\n\n3987\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 6)\n\n\n \n\n\n\n\n\n\n\n\n\n\n   1 MAAGLQRWLL WALLLNAARG EIHTPIHKAG VCTFYEECGK NPELSGGLTS\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n  51 LSNVSCLSNT PARRVTGDHL TLLQRICPRL YNGPNNTYAC CSAQQLVALE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 101 KSMSITKALL TRCPACSDNF VSLHCHNTCS PDQSLFINVT RVVEQADPQQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 151 PPAVVAYEAF YQSSFAEKAY ESCSRVRIPA AASLAVGTMC GVYGSALCNA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 201 QRWLNFQGDT GNGLAPLDIT FHLVESGQAL PDGMQPLNGE ITPCNQSEGV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 251 ESAACSCQDC AASCPVIPQP SALPPSFYMG KMPGWLALII IFCAVFVLLT\n\n\n\n\n\n\n \n\n\n\n\n\n\n 301 AVLIYLRVVS NRSRSKKTGL QEAPNRPPKR RFSPHIVLGR FFQSWGTRVA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 351 SWPLTVLALS FMVVIALSVG MTYIELTTDP VELWSAPKSQ ARKEKAFHDE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 401 HFGPFFRTNQ VFVTARNRSS YRYDSLLLGP KNFSGLLSLD LVLELLELQE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 451 RLRHLQVWSP EAQRNISLQD ICYAPLKPHN TSLSDCCVNS LLQYFQNNRT\n\n\n\n\n\n\n \n\n\n\n\n\n\n 501 LLLLTANQTL NGQTSLVDWR DHFLYCANAP LTFKDGTSLA LSCIADYGAP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 551 IFPFLAVGGY QGTDYSEAEA LIITFSLNNY PADDPRMAQA KLWEEAFLKE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 601 MQAFQSSVAD KFQVAFSAER SLEDEINRTT IQDLPVFAIS YIIVFLYISL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 651 ALGSYSKWKR VAVDSKATLG LGGVAVVLGA VVAAMGFYSY LGVPSSLVII\n\n\n\n\n\n\n \n\n\n\n\n\n\n 701 QVVPFLVLAV GADNIFIFVL EYQRLPRRPG EQREAHIGRT LGSVAPSMLL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 751 CSLSEAVCFF LGALTPMPAV RTFALTAGLS IILDFLLQMT AFVALLSLDS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 801 KRQEASRPDI LCCLSPRKLP PPEQQEGLLL RFFRKIYAPF LLHRFIRPVV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 851 LLLFLALFGA NLYLMCHISV GLDQELALPK DSYLIDYFLF LNRYFEVGPP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 901 VYFVTTSGYN FSSEAGMNAI CSSAGCDSFS MTQKIQYATE FPEQSYIGIA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 951 ASSWVDDFID WLTPSSCCRL YIFGPNTGDF CPSTDTSLSC LKNCMNFTLG\n\n\n\n\n\n\n \n\n\n\n\n\n\n1001 PVRPTAEQFH KYLPWFLDDP PNIRCPKGGL AAYRTSVNLS SDGQIIASQF\n\n\n\n\n\n\n \n\n\n\n\n\n\n1051 MAYHKPLRNS QDFTEALRTS RLLAANITAE LRKVPGTAPD FEVFPYTISN\n\n\n\n\n\n\n \n\n\n\n\n\n\n1101 VFYEQYLTVL PEGIFTLALC FVPTFVVCYL LLGLDMRSGI LNLLSIIMIL\n\n\n\n\n\n\n \n\n\n\n\n\n\n1151 VDTIGLMAVW GISYNAVSLI NLVTAVGMSV EFVSHLTRSF AVSTKPTRLE\n\n\n\n\n\n\n \n\n\n\n\n\n\n1201 RAKDATVSMG SAVFAGVAMT NFPGILILGF AQAQLIQIFF FRLNLLITLL\n\n\n\n\n\n\n \n\n\n\n\n\n\n1251 GLLHGLVFLP VVLSYLGPDV NPELVLEEKL ATEAAVAPEP SSPKYPFPDN\n\n\n\n\n\n\n \n\n\n\n\n\n\n1301 DYVNHSFEEA TPGAAAASSS LPKSGQKF*\n\n\n\n\n\n\n \n\n\n\n\n\n\nRhesus Monkey NPC1L1 ORF\n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 7)\n\n\n \n\n\n\n\n\n\n\n\n\n\natggcggagg ccggcctgag gggctggctg ctgtgggccc tgctcctgca cttggcccag\n\n\n60\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagcgagcctt acacacccat ccaccagcct ggctactgcg ccttctatga cgaatgtggg\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\naagaacccag agctgtctgg aggcctcatg acactctcca acgtgtcctg tctgtccaac\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\nacgccagccc gcaacatcac aggtgatcac ctgatcctat tacagaggat ctgcccccgc\n\n\n240\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctacaccg gccccaacac ccaagcctgc tgctccgcca agcagctggt atcattggaa\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcgagtctgt cgatcaccaa ggccctcctc acccgctgcc cagcctgctc tgacaatttc\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgagcctgc actgccacaa cacatgcagc cccaaccaga gcctcttcat caatgtgacc\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcgtggctc agctaggggc tggacaactc ccagctgtgg tggcctatga ggccttctac\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcacagct ttgccgagca gagctatgac tcctgcagcc gtgtgcacat ccctgcggct\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccacgctgg ctgtgggcag catgtgtggc gtgtatggct ctgccctttg caatgcccag\n\n\n600\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgctggctca acttccaggg agacacaggc aatggtctgg ccccactgga catcaccttc\n\n\n660\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacctcttgg agcccggcca ggctgtgggg agtgggattc agcctctgaa tgagggggtt\n\n\n720\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcacgttgca atgagtccca aggtgacgac gcagtggcct gctcctgcca ggactgtgct\n\n\n780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcatcctgtc ctgccatcgc ccatccccag gccctggact ccaccttccg cctgggccgg\n\n\n840\n\n\n\n\n\n\n \n\n\n\n\n\n\natgccgggtg ggctggtcct catcatcatc ctctgttctg tcttcactgt ggtcgccatc\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctcgtgg gactccgtgt ggcccccacc agggacaaaa gcaagacggt ggaccccaag\n\n\n960\n\n\n\n\n\n\n \n\n\n\n\n\n\naagggcacca gcctctctga taagctcagc ttctccaccc acaccctcct tggccagttc\n\n\n1020\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccagggct ggggcacctg ggtggcttcg tggcctctga ccatcctggt gctgtctgtc\n\n\n1080\n\n\n\n\n\n\n \n\n\n\n\n\n\natcccggtgg tggtcttggc agcgggcctg gtctttacag aactcactac ggaccccgtg\n\n\n1140\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagctgtggt cggcccccaa cagccaagcc cggagtgaga aggcttttca tgaccagcat\n\n\n1200\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcggcccct tcttccgaac caaccaggtg atcctgacgg ctcctaaccg gtccagctac\n\n\n1260\n\n\n\n\n\n\n \n\n\n\n\n\n\naggtatgact ccctgctgct ggggcccaag aacttcagcg ggatcctgga cctggacttg\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctggagc tgctggagtt gcaggagagg ctgcggcacc tccaggtgtg gtcgcccgaa\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcacagcgca acatctccct gcagcacatc tgctacgccc ccctcaatcc ggacaatacc\n\n\n1440\n\n\n\n\n\n\n \n\n\n\n\n\n\nagtctttccg attgctgcat caacagcctc ctgcagtatt tccagaacaa ccgcacgctc\n\n\n1500\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgttgctca cggccaacca gacactgatg gggcagacct cccaagtcga ctggagggac\n\n\n1560\n\n\n\n\n\n\n \n\n\n\n\n\n\ncattttctgt actgtgccaa tgccccgctc accttcaagg atggcacagc cctggccctg\n\n\n1620\n\n\n\n\n\n\n \n\n\n\n\n\n\nagctgcatgg ctgactatgg ggcccctgtc ttccccttcc ttgccgttgg ggggtacaaa\n\n\n1680\n\n\n\n\n\n\n \n\n\n\n\n\n\ngggaaggact attctgaggc ggaggccctg atcatgacgt tctccctcaa caattaccct\n\n\n1740\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccggggacc cccggctggc ccaggcccag ctgtgggagg aggccttctt ggaggaaatg\n\n\n1800\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgagccttcc agcgtcggac ggctggcaag ttccaggtca cgttcatggc tgagcgctct\n\n\n1860\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggaagatg agatcaatcg caccacagcc gaagacctgc ccatctttgc caccagctac\n\n\n1920\n\n\n\n\n\n\n \n\n\n\n\n\n\nattgtcatct tcctgtacat ctccctggcc ctgggcagct attccagctg gagccgagtg\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\natggtggact ccaaggccac gctgggcctt ggcggggtgg ccgtggtcct gggagcagtc\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\natggctgcca tgggcttctt ctcctacctg ggtatccgct cctccctgat catcctgcaa\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggtgcctt tcctggtgct gtctgtgggg gctgataaca tcttcatctt tgttctcgag\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccagaggc tgccccggag gcctggggag ccgcgagagg ttcacattgg ccgagccctg\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nggcagggtgg cccccagcat gctgttgtgc agcctctctg aggccatctg cttcttccta\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\nggggccctga cccccatgcc agctgtgcgg acctttgccc tgacctctgg ccttgcagtg\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtccttgact tcctcctgca gatgtctgcc tttgtggccc tgctctccct ggacagcaag\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\naggcaggagg cctcccgatt ggacgtctgc tgctgcgtca agccccggga gctgcccctg\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctggccagg gagaggggtt cctgcttggc ctcttccgaa aggcctatgt ccccttcctg\n\n\n2520\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgcactgga tcactcgagg ggttgtgctg ctgctgtttc tcgccctgtt tggagtgagc\n\n\n2580\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctactaca tgtgccacat cagtgttgga ctggaccagg agctggccct gcccaaggac\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcgtacctgc ttgactattt cctctttctg aaccgctact tcgagacggg ggccccggtg\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\ntactttgtta ctacctcagg ctacaacttc tccagtgagg ctgggatgaa tgccatctgc\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccagtgcag gctgcaacaa cttctccttc acccagaaga tccagtatgc cacagagttc\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctgagcagt cttaccttgc catccctgcc tcctcctggg tggatgactt cattgactgg\n\n\n2880\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgaccccat cctcctgctg ccgcctttat atatctggcc ccaataagga ccagttctgc\n\n\n2940\n\n\n\n\n\n\n \n\n\n\n\n\n\nccctcgactg tcaactccct gaactgccta aagaactgcc tgagcatcac gatgggctct\n\n\n3000\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgaggccct cagtggagca gttctataag tatcttccct ggttcctgaa tgaccggccc\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\naacatcaaat gtcccaaagg cggcctggga gcatacagca cctctgtgaa cttgacttca\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\ngatggccagg ttttagcctc caggttcatg gcctatcaca agcccctgaa aaactcacag\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\ngattacacag aagctctgcg ggcagctcgg gagctggcag ccaacatcac tgctgacctg\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggaaggtgc ctgggacaga cccagctttt gaggtcttcc cctacacggt caccaatgtg\n\n\n3300\n\n\n\n\n\n\n \n\n\n\n\n\n\nttttatgagc agtacctgac cattctccct gaggggctct tcatgctcag cctctgcctg\n\n\n3360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcccacct tcgctgtctg ctgcctcctg ctgggcctgg acctgcgctc cggcctcctc\n\n\n3420\n\n\n\n\n\n\n \n\n\n\n\n\n\naacctgctgt ccatcatcat gatcctcgtg gacaccgttg gcttcatggc cctgtggggc\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\natcagttaca atgctgtgtc cctcatcaac ctggtctcgg cggtgggcat gtctgtggag\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcgtgtccc acattacccg ctcctttgcc atcagcacca agcccacccg gctggagagg\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccaaagagg ccaccatctc tatgggaagt gcggtgtttg caggtgtggc catgaccaac\n\n\n3660\n\n\n\n\n\n\n \n\n\n\n\n\n\nctccctggca tcctggtcct gggccttgcc aaggcccagc tcattcagat cttcttcttc\n\n\n3720\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcctcaacc tcctgattac tctgctgggt ctgctgcatg gcttggtctt cctgcctgtc\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\natcctcagct atgtggggcc tgacatcaac ccagctctgg cactggagca gaagctggct\n\n\n3840\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggaggcag cagcggcagc catagcggcc tcctacccaa atcacccctc ccgagtctcc\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\nacagctgaca acatctatgt caaccacagc tttgaaggtt ctatcaaagg tgctggtgcc\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcagcaact tcttgcccaa caatgggcgg cagttctga\n\n\n3999\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 8)\n\n\n \n\n\n\n\n\n\n\n\n\n\n   1 MAEAGLRGWL LWALLLHLAQ SEPYTPIHQP GYCAFYDECG KNPELSGGLM\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n  51 TLSNVSCLSN TPARNITGDH LILLQRICPR LYTGPNTQAC CSAKQLVSLE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 101 ASLSITKALL TRCPACSDNF VSLNCHNTCS PNQSLFINVT RVAQLGAGQL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 151 PAVVAYEAFY QHSFAEQSYD SCSRVHIPAA ATLAVGSMCG VYGSALCNAQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 201 RWLNFQGDTG NGLAPLDITF HLLEPGQAVG SGIQPLNEGV ARCNESQGDD\n\n\n\n\n\n\n \n\n\n\n\n\n\n 251 AVACSCQDCA ASCPAIAHPQ ALDSTFRLGR MPGGLVLIII LCSVFTVVAI\n\n\n\n\n\n\n \n\n\n\n\n\n\n 301 LLVGLRVAPT RDKSKTVDPK KGTSLSDKLS FSTHTLLGQF FQGWGTWVAS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 351 WPLTILVLSV IPVVVLAAGL VFTELTTDPV ELWSAPNSQA RSEKAFHDQH\n\n\n\n\n\n\n \n\n\n\n\n\n\n 401 FGPFFRTNQV ILTAPNRSSY RYDSLLLGPK NFSGILDLDL LLELLELQER\n\n\n\n\n\n\n \n\n\n\n\n\n\n 451 LRHLQVWSPE AQRNISLQHI CYAPLNPDNT SLSDCCINSL LQYFQNNRTL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 501 LLLTANQTLM GQTSQVDWRD HFLYCANAPL TFKDGTALAL SCMADYGAPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 551 FPFLAVGGYK GKDYSEAEAL IMTFSLNNYP AGDPRLAQAQ LWEEAFLEEM\n\n\n\n\n\n\n \n\n\n\n\n\n\n 601 RAFQRRTAGK FQVTFMAERS LEDEINRTTA EDLPIFATSY IVIFLYISLA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 651 LGSYSSWSRV MVDSKATLGL GGVAVVLGAV MAAMGFFSYL GIRSSLIILQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 701 VVPFLVLSVG ADNIFIFVLE YQRLPRRPGE PREVHIGRAL GRVAPSMLLC\n\n\n\n\n\n\n \n\n\n\n\n\n\n 751 SLSEAICFFL GALTPMPAVR TFALTSGLAV VLDFLLQMSA FVALLSLDSK\n\n\n\n\n\n\n \n\n\n\n\n\n\n 801 RQEASRLDVC CCVKPRELPL PGQGEGFLLG LFRKAYVPFL LHWITRGVVL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 851 LLFLALFGVS LYYMCHISVG LDQELALPKD SYLLDYFLFL NRYFETGAPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 901 YFVTTSGYNF SSEAGMNAIC SSAGCNNFSF TQKIQYATEF PEQSYLAIPA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 951 SSWVDDFIDW LTPSSCCRLY ISGPNKDQFC PSTVNSLNCL KNCLSITMGS\n\n\n\n\n\n\n \n\n\n\n\n\n\n1001 VRPSVEQFYK YLPWFLNDRP NIKCPKGGLG AYSTSVNLTS DGQVLASRFM\n\n\n\n\n\n\n \n\n\n\n\n\n\n1051 AYHKPLKNSQ DYTEALRAAR ELAANITADL RKVPGTDPAF EVFPYTVTNV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1101 FYEQYLTILP EGLFMLSLCL VPTFAVCCLL LGLDLRSGLL NLLSIIMILV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1151 DTVGFMALWG ISYNAVSLIN LVSAVGMSVE FVSHITRSFA ISTKPTRLER\n\n\n\n\n\n\n \n\n\n\n\n\n\n1201 AKEATISMGS AVFAGVAMTN LPGILVLGLA KAQLIQIFFF RLNLLITLLG\n\n\n\n\n\n\n \n\n\n\n\n\n\n1251 LLHGLVFLPV ILSYVGPDIN PALALEQKLA EEAAAAAIAA SYPNHPSRVS\n\n\n\n\n\n\n \n\n\n\n\n\n\n1301 TADNIYVNHS FEGSIKGAGA VSNFLPNNGR QF*\n\n\n\n\n\n\n \n\n\n\n\n\n\nCynomolgus Monkey NPC1L1 ORF\n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 9)\n\n\n \n\n\n\n\n\n\n\n\n\n\natggcggagg ccggcctgag gggctggctg ctgtgggccc tgctcctgca cttggcccag\n\n\n60\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagcgagcctt acacacccat ccaccagcct ggctactgcg ccttctatga cgaatgtggg\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\naagaacccag agctgtctgg aggcctcatg acactctcca acgtgtcctg tctgtccaac\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\nacgccagccc gcaacatcac aggtgatcac ctgatcctat tacagaggat ctgcccccgc\n\n\n240\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctacaccg gccccaacac ccaagcctgc tgctccgcca agcagctggt atcattggaa\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcgagtctgt cgatcaccaa ggccctcctc acccgctgcc cagcctgctc tgacaatttc\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgagcctgc actgccacaa cacatgcagc cccaaccaga gcctcttcat caatgtgacc\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcgtggctc agctaggggc tggacaactc ccagctgtgg tggcctatga ggccttctac\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcacagct ttgccgagca gagctatgac tcctgcagcc gtgtgcacat ccctgcggct\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccacgctgg ctgtgggcag catgtgtggc gtgtatggct ctgccctttg caatgcccag\n\n\n600\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgctggctca acttccaggg agacacaggc aatggtctgg ccccactgga catcaccttc\n\n\n660\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacctcttgg agcccggcca ggctgtgggg agtgggattc agcctctgaa tgagggggtt\n\n\n720\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcacgttgca atgagtccca aggtgacgac gcagtggcct gctcctgcca ggactgtgct\n\n\n780\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcatcctgtc ctgccatcgc ccatccccag gccctggact ccaccttccg cctgggccgg\n\n\n840\n\n\n\n\n\n\n \n\n\n\n\n\n\natgccgggtg ggctggtcct catcatcatc ctctgttctg tcttcactgt ggtcgccatc\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctcgtgg gactccgtgt ggcccccacc agggacaaaa gcaagacggt ggaccccaag\n\n\n960\n\n\n\n\n\n\n \n\n\n\n\n\n\naagggcacca gcctctctga caagctcagc ttctccaccc acaccctcct tggccagttc\n\n\n1020\n\n\n\n\n\n\n \n\n\n\n\n\n\nttccagggct ggggcacctg ggtggcttcg tggcctctga ccatcctggt gctgtctgtc\n\n\n1080\n\n\n\n\n\n\n \n\n\n\n\n\n\natcccggtgg tggtcttggc agcgggcctg gtctttacag aactcactac agaccccgtg\n\n\n1140\n\n\n\n\n\n\n \n\n\n\n\n\n\ngagctgtggt cggcccccaa cagccaagcc cggagtgaga aggcttttca tgaccagcat\n\n\n1200\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcggcccct tcttccgaac caaccaggtg atcctgacgg ctcctaaccg gtccagctac\n\n\n1260\n\n\n\n\n\n\n \n\n\n\n\n\n\naggtatgact ccctgctgct ggggcccaag aacttcagcg ggatcctgga cctggacttg\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgctggagc tgctggagtt gcaggagagg ctgcggcacc tccaggtgtg gtcgcccgaa\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcacagcgca acatctccct gcagcacatc tgctacgccc ccctcaatcc ggacaatacc\n\n\n1440\n\n\n\n\n\n\n \n\n\n\n\n\n\nagtctctccg attgctgcat caacagcctc ctgcagtatt tccagaacaa ccgcacgctc\n\n\n1500\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgttgctca cggccaacca gacactgatg gggcagacct cccaagtcga ctggagggac\n\n\n1560\n\n\n\n\n\n\n \n\n\n\n\n\n\ncattttctgt actgtgccaa tgccccgctc accttcaagg atggcacagc cctggccctg\n\n\n1620\n\n\n\n\n\n\n \n\n\n\n\n\n\nagctgcatgg ctgactatgg ggcccctgtc ttccccttcc ttgccgttgg ggggtacaaa\n\n\n1680\n\n\n\n\n\n\n \n\n\n\n\n\n\ngggaaggact attctgaggc ggaggccctg atcatgacgt tctccctcaa caattaccct\n\n\n1740\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccggggacc cccggctggc ccaggcccag ctgtgggagg aggccttctt ggaggaaatg\n\n\n1800\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgagccttcc agcgtcggac ggctggcaag ttccaggtca cgttcatggc tgagcgctct\n\n\n1860\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggaagatg agatcaatcg caccacagcc gaagacctgc ccatctttgc caccagctac\n\n\n1920\n\n\n\n\n\n\n \n\n\n\n\n\n\nattgtcatct tcctgtacat ctccctggcc ctgggcagct attccagctg gagcagagtg\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\natggtggact ccaaggccac gctgggcctt ggcggggtgg ccgtggtcct gggagcagtc\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\natggctgcca tgggcttctt ctcctacctg ggtatccgct cctccctgat catcctgcaa\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggtgcctt tcctggtgct gtctgtgggg gctgataaca tcttcatctt tgttctcgag\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccagaggc tgccccggag gcctggggag ccgcgagagg ttcacattgg ccgagccctg\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nggcagggtgg cccccagcat gctgttgtgc agcctctctg aggccatctg cttcttccta\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\nggggccctga cccccatgcc agctgtgcgg acctttgccc tgacctctgg ccttgcagtg\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtccttgact tcctcctgca gatgtctgcc tttgtggccc tgctctccct ggacagcaag\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\naggcaggagg cctcccgatt ggacgtctgc tgctgcgtca agccccggga gctgcccctg\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctggccagg gagaggggtt cctgcttggc ctcttccgaa aggcctatgt ccccttcctg\n\n\n2520\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgcactgga tcactcgagg ggttgtgctg ctgctgtttc tcgccctgtt tggagtgagc\n\n\n2580\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctactaca tgtgccacat cagtgttgga ctggaccagg agctggccct gcccaaggac\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcgtacctgc ttgactattt cctctttctg aaccgctact tcgagacggg ggccccggtg\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\ntactttgtta ctacctcagg ctacaacttc tccagtgagg ctgggatgaa tgccatctgc\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccagtgcag gctgcaacaa cttctccttc acccagaaga tccagtatgc cacagagttc\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctgagcagt cttaccttgc catccctgcc tcctcctggg tggatgactt cattgactgg\n\n\n2880\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgaccccat cctcctgctg ccgcctttat atatctggcc ccaataagga ccagttctgc\n\n\n2940\n\n\n\n\n\n\n \n\n\n\n\n\n\nccctcgactg tcaactccct gaactgccta aagaactgcc tgagcatcac gatgggctct\n\n\n3000\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgaggccct cagtggagca gttctataag tatcttccct ggttcctgaa tgaccggccc\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\naacatcaaat gtcccaaagg cggcctggga gcatacagca cctctgtgaa cttgacttca\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\ngatggccagg ttttagcctc caggttcatg gcctatcaca agcccctgaa aaactcacag\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\ngattacacag aagctctgcg ggcagctcgg gagctggcag ccaacatcac tgctgacctg\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggaaggtgc ctgggacaga cccagctttt gaggtcttcc cctacacggt caccaatgtg\n\n\n3300\n\n\n\n\n\n\n \n\n\n\n\n\n\nttttatgagc agtacctgac cattctccct gaggggctct tcatgctcag cctctgcctg\n\n\n3360\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcccacct tcgctgtctg ctgcctcctg ctgggcctgg acctgcgctc cggcctcctc\n\n\n3420\n\n\n\n\n\n\n \n\n\n\n\n\n\naacctgctgt ccatcatcat gatcctcgtg gacaccgttg gcttcatggc cctgtggggc\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\natcagttaca atgctgtgtc cctcatcaac ctggtctcgg cggtgggcat gtctgtggag\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcgtgtccc acattacccg ctcctttgcc atcagcacca agcccacccg gctggagagg\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccaaagagg ccaccatctc tatgggaagt gcggtgtttg caggtgtggc catgaccaac\n\n\n3660\n\n\n\n\n\n\n \n\n\n\n\n\n\nctccctggca tcctggtcct gggccttgcc aaggcccagc tcattcagat cttcttcttc\n\n\n3720\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcctcaacc tcctgattac tctgctgggt ctgctgcatg gcttggtctt cctgcctgtc\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\natcctcagct atgtggggcc tgacatcaac ccagctctgg cactggagca gaagctggct\n\n\n3840\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggaggcag cagcggcagc catagcggcc tcctacccaa atcacccctc ccgagtctcc\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\nacagctgaca acatctatgt caaccacagc tttgaaggtt ctatcaaagg tgctggtgcc\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcagcaact tcttgcccaa caatgggcgg cagttctga\n\n\n3999\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 10)\n\n\n \n\n\n\n\n\n\n\n\n\n\n   1 MAEAGLRGWL LWALLLHLAQ SEPYTPIHQP GYCAFYDECG KNPELSGGLM\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n  51 TLSNVSCLSN TPARNITGDH LILLQRICPR LYTGPNTQAC CSAKQLVSLE\n\n\n\n\n\n\n \n\n\n\n\n\n\n 101 ASLSITKALL TRCPACSDNF VSLHCHNTCS PNQSLFINVT RVAQLGAGQL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 151 PAVVAYEAFY QHSFAEQSYD SCSRVHIPAA ATLAVGSMCG VYGSALCNAQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 201 RWLNFQGDTG NGLAPLDITF HLLEPGQAVG SGIQPLNEGV ARCNESQGDD\n\n\n\n\n\n\n \n\n\n\n\n\n\n 251 AVACSCQDCA ASCPAIAHPQ ALDSTFRLGR MPGGLVLIII LCSVFTVVAI\n\n\n\n\n\n\n \n\n\n\n\n\n\n 301 LLVGLRVAPT RDKSKTVDPK KGTSLSDKLS FSTHTLLGQF FQGWGTWVAS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 351 WPLTILVLSV IPVVVLAAGL VFTELTTDPV ELWSAPNSQA RSEKAFHDQH\n\n\n\n\n\n\n \n\n\n\n\n\n\n 401 FGPFFRTNQV ILTAPNRSSY RYDSLLLGPK NFSGILDLDL LLELLELQER\n\n\n\n\n\n\n \n\n\n\n\n\n\n 451 LRHLQVWSPE AQRNISLQHI CYAPLNPDNT SLSDCCINSL LQYFQNNRTL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 501 LLLTANQTLM GQTSQVDWRD HFLYCANAPL TFKDGTALAL SCMADYGAPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 551 FPFLAVGGYK GKDYSEAEAL IMTFSLNNYP AGDPRLAQAQ LWEEAFLEEM\n\n\n\n\n\n\n \n\n\n\n\n\n\n 601 RAFQRRTAGK FQVTFMAERS LEDEINRTTA EDLPIFATSY IVIFLYISLA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 651 LGSYSSWSRV MVDSKATLGL GGVAVVLGAV MAAMGFFSYL GIRSSLIILQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n 701 VVPFLVLSVG ADNIFIFVLE YQRLPRRPGE PREVHIGRAL GRVAPSMLLC\n\n\n\n\n\n\n \n\n\n\n\n\n\n 751 SLSEAICFFL GALTPMPAVR TFALTSGLAV VLDFLLQMSA FVALLSLDSK\n\n\n\n\n\n\n \n\n\n\n\n\n\n 801 RQEASRLDVC CCVKPRELPL PGQGEGFLLG LFRKAYVPFL LHWITRGVVL\n\n\n\n\n\n\n \n\n\n\n\n\n\n 851 LLFLALFGVS LYYMCHISVG LDQELALPKD SYLLDYFLFL NRYFETGAPV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 901 YFVTTSGYNF SSEAGMNAIC SSAGCNNFSF TQKIQYATEF PEQSYLAIPA\n\n\n\n\n\n\n \n\n\n\n\n\n\n 951 SSWVDDFIDW LTPSSCCRLY ISGPNKDQFC PSTVNSLNCL KNCLSITMGS\n\n\n\n\n\n\n \n\n\n\n\n\n\n1001 VRPSVEQFYK YLPWFLNDRP NIKCPKGGLG AYSTSVNLTS DGQVLASRFM\n\n\n\n\n\n\n \n\n\n\n\n\n\n1051 AYHKPLKNSQ DYTEALRAAR ELAANITADL RKVPGTDPAF EVFPYTVTNV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1101 FYEQYLTILP EGLFMLSLCL VPTFAVCCLL LGLDLRSGLL NLLSIIMILV\n\n\n\n\n\n\n \n\n\n\n\n\n\n1151 DTVGFMALWG ISYNAVSLIN LVSAVGMSVE FVSHITRSFA ISTKPTRLER\n\n\n\n\n\n\n \n\n\n\n\n\n\n1201 AKEATISMGS AVFAGVAMTN LPGILVLGLA KAQLIQIFFF RLNLLITLLG\n\n\n\n\n\n\n \n\n\n\n\n\n\n1251 LLHGLVFLPV ILSYVGPDIN PALALEQKLA EEAAAAAIAA SYPNHPSRVS\n\n\n\n\n\n\n \n\n\n\n\n\n\n1301 TADNIYVNHS FEGSIKGAGA VSNFLPNNGR QF*\n\n\n\n\n\n\n\n\n\n\n\n\nScreening Assays\n\n\nThe invention allows the discovery of selective agonists and antagonists of NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8, or 10) that may be useful in treatment, prevention and management of a variety of medical conditions including elevated serum sterol (e.g., cholesterol) or 5α-stanol. Thus, NPC1L1 of this invention can be employed in screening systems to identify agonists or antagonists. For example, the screening assays of the present invention, comprising use of canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1, can be used to identify an agonist or antagonist of NPC1L1 from the same or a different organism (e.g., an antagonist of human NPC1L1). In an embodiment of the invention, these systems provide methods for bringing together NPC1L1, an appropriate, known ligand or agonist or antagonist (e.g., \n \n \n \n \n \ncompound\n \n \n \n \n \n 1, 2, 3, 4, 5, 6, 7, 8 or 9), including a sterol (e.g., cholesterol, phytosterols (including, but not limited to, sitosterol, campesterol, stigmasterol and avenosterol)), a cholesterol oxidation product, a 5α-stanol (including but not limited to cholestanol, 5α-campestanol and 5α-sitostanol), a substituted azetidinone (e.g., ezetimibe), BODIPY-ezetimibe (Altmann, et al., (2002) Biochim. Biophys. Acta 1580(1):77-93) or 4″, 6″-bis[(2-fluorophenyl)carbamoyl]-beta-D-cellobiosyl derivative of 11-ketotigogenin as described in DeNinno, et al., (1997) (J. Med. Chem. 40(16):2547-54) (Merck; L-166,143) or any substituted azetidinone, and a sample to be tested for the presence of an NPC1L1 agonist or antagonist.\n\n\nA convenient method by which to evaluate whether a sample contains an NPC1L1 agonist or antagonist is to determine whether the sample contains a substance which competes for binding between the known agonist or antagonist (e.g., ezetimibe) and NPC1L1.\n\n\nIn an embodiment of the invention, an antagonist of an NPC1L1 of the invention (e.g., canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8, or 10)) is used to treat, prevent or manage hypercholesterolemia (e.g., primary hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH)), sitosterolemia (e.g., homozygous sitosterolemia), hyperlipidemia, hypertriglyceridemia, arteriosclerosis, atherosclerosis or hypertension. In an embodiment of the invention, an NPC1L1 antagonist is used to treat, prevent or manage any of the foregoing disorders in human or non-human animals (e.g., dogs, cats, rabbits, hamsters, monkeys, rats, mice, cows). For example, a veterinary hyperlipidemic disorder such as primary idiopathic hyperlipidemia can be treated with an NPC1L1 antagonist. Primary idiopathic hyperlipidemia has been reported in a variety of canine breeds including miniature Schnauzers, beagles, mixed breeds, poodles, shelties as well as in cats. Dogs with diabetes mellitus, hypothyroidism, Cushings disease, liver Disease and nephrotic Syndrome have been reported with hyperlipidemia. Hypercholesterolemia (which may also be treated, prevented or managed with an NPC1L1 antagonist) has also been reported in dogs such as Shetland sheepdogs and has been observed in dogs with canine hypothyroidism.\n\n\nThe term “specific” when used to describe binding of, for example, a ligand or antagonist of NPC1L1 in a screening assay is a term of art which refers to the extent by which the ligand or antagonist (e.g., detectably labeled substituted azetidinone, detectably labeled ezetimibe, detectably labeled sterol (e.g., cholesterol) or detectably labeled 5α-stanol, e.g., [\n3\nH]-glucuronidated ezetimibe or BODIPY-labeled ezetimibe) binds preferentially to NPC1L1 over that of other proteins in the assay system. For example, an antagonist or ligand of NPC1L1 binds specifically to NPC1L1 when the signal generated in the assay to indicate such binding exceeds, to any extent, a background signal in a negative control experiment wherein, for example, NPC1L1 or the known antagonist or ligand is absent. Furthermore, “specific binding” includes binding of an antagonist or ligand either directly to NPC1L1 or indirectly, for example via another moiety, in a complex of which NPC1L1 is a part. The moiety to which an NPC1L1 ligand or antagonist binds can be another protein or a post-translational modification of NPC1L1 (e.g., a lipid chain or a carbohydrate chain).\n\n\nNon-limiting examples of suitable azetidinones include those disclosed in U.S. Pat. Nos. RE37,721; 5,631,365; 5,767,115; 5,846,966; 5,688,990; 5,656,624; 5,624,920; 5,698,548 and 5,756,470 and U.S. Patent Application Publication No 2003/0105028, each of which is herein incorporated by reference in its entirety.\n\n\nEzetimibe can be prepared by a variety of methods well know to those skilled in the art, for example such as are disclosed in U.S. Pat. Nos. 5,631,365, 5,767,115, 5,846,966, 6,207,822, U.S. Patent Application Publication No. 2002/0193607 and PCT Patent Application WO 93/02048, each of which is incorporated herein by reference in its entirety.\n\n\n“Sample”, “candidate compound” or “candidate substance” refers to a composition which is evaluated in a test or assay, for example, for the ability to agonize or antagonize NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8, or 10) or a functional fragment thereof. The composition may be a small organic or inorganic molecule, peptide, nucleotide, polynucleotide, subatomic particle (e.g., α particles, β particles) or antibody or fragment thereof.\n\n\nNPC1L1 for use in an assay of the invention (e.g., any set forth below) can be from any suitable source. For example, a nucleic acid encoding an NPC1L1 polypeptide of the invention (e.g., SEQ ID NO: 1, 3, 5, 7, or 9) can be transfected into an appropriate host cell (e.g., HEK293), whereby the receptor will become incorporated into the membrane of the cell. A membrane fraction can then be isolated from the cell and used as a source of the receptor for assay. Alternatively, the whole cell expressing the receptor on the cell surface can be used in an assay. In an embodiment, free NPC1L1 is used or a highly soluble fragment of NPC1L1 is generated and used in an assay of the invention.\n\n\nTwo basic types of screening systems that can be used include, a labeled-ligand binding assay (e.g., direct binding assay or scintillation proximity assay (SPA)) and a “sterol (e.g., cholesterol) or 5α-stanol uptake” assay. A labeled ligand, for use in the binding assay, can be obtained by labeling a sterol (e.g., cholesterol) or a 5α-stanol or a known NPC1L1 agonist or antagonist with a measurable group (e.g., \n125\nI or \n3\nH). Various labeled forms of sterols (e.g., cholesterol) or 5α-stanols are available commercially or can be generated using standard techniques (e.g., Cholesterol-[1,2-\n3\nH(N)], Cholesterol-[1,2,6,7-\n3\nH(N)] or Cholesterol-[7-\n3\nH(N)]; American Radiolabeled Chemicals, Inc; St. Louis, Mo.). In an embodiment of the invention, ezetimibe is fluorescently labeled with a BODIPY group (Altmann, et al., Biochim. Biophys. Acta 1580(1):77-93 (2002)) or labeled with a detectable group such as \n125\nI or \n3\nH.\n\n\nDirect Binding Assay. Typically, a given amount of NPC1L1 of the invention (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) or an active fragment thereof is contacted with increasing amounts of labeled ligand or known antagonist or agonist (discussed above) and the amount of the bound, labeled ligand or known antagonist or agonist is measured after removing unbound, labeled ligand or known antagonist or agonist by washing. As the amount of the labeled ligand or known agonist or antagonist is increased, a point is eventually reached at which all receptor binding sites are occupied or saturated. Specific receptor binding of the labeled ligand or known agonist or antagonist is abolished by a large excess of unlabeled ligand or known agonist or antagonist.\n\n\nIn an embodiment of the invention, an assay system is used in which non-specific binding of the labeled ligand or known antagonist or agonist to the receptor is minimal. Non-specific binding is typically less than 50%, preferably less than 15%, and more preferably less than 10% of the total binding of the labeled ligand or known antagonist or agonist. Preferably, specific binding of the labeled ligand or known antagonist or agonist to an untransfected/untransformed host cell or to a membrane fraction from an untransfected/untransformed host cell will be negligible.\n\n\nIn the basic binding assay, the method for identifying an NPC1L1 agonist or antagonist includes:\n\n \n \n \n \n(a) contacting canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) or a subsequence thereof, in the presence of a known amount of detectably labeled sterol (e.g., cholesterol) or 5α-stanol or known antagonist or agonist (e.g., [\n3\nH]-glucuronidated ezetimibe or BODIPY-labeled ezetimibe) with a sample to be tested for the presence of an NPC1L1 agonist or antagonist; and\n \n(b) measuring the amount of labeled sterol (e.g., cholesterol) or 5α-stanol or known antagonist or agonist bound to NPC1L1.\n \n \n \n\n\nAn NPC1L1 antagonist or agonist in the sample is identified by measuring substantially reduced binding of the labeled sterol (e.g., cholesterol) or 5α-stanol or known antagonist or agonist to NPC1L1, compared to what would be measured in the absence of such an antagonist or agonist. For example, reduced binding between [\n3\nH]-cholesterol and NPC1L1 in the presence of a sample would indicate that the sample contains a substance which is competing against [\n3\nH]-cholesterol for NPC1L1 binding.\n\n\nIn an embodiment of the invention, this assay includes a negative-control experiment lacking any NPC1L1-dependent ligand (e.g., [\n3\nH]-glucuronidated ezetimibe or BODIPY-labeled ezetimibe) binding. In an embodiment of the invention, for example, a whole cell or cell membrane lacking any functional NPC1L1, e.g., untransformed HEK293, is assayed for ligand binding. When screening a sample for the presence of an NPC1L1 antagonist, it is useful to compare the level of binding observed in the presence of a sample being tested with that of a control experiment, as described herein, which completely lacks NPC1L1-dependent binding. Ideally, though by no means necessarily, the level of binding seen in the presence of a sample containing an antagonist will be similar to that of the negative-control experiment. If no significant binding is observed, then this indicates that the assay is operating properly.\n\n\nIn another embodiment of the invention, a positive-control experiment is performed in conjunction with the assay. In this embodiment, for example, NPC1L1 is bound to a detectably labeled substance which is known to bind (e.g. \n3\nH-ezetimibe) and, then, exposed to a blank. If binding is observed (e.g., where the labeled substance is competed off of the NPC1L1 by the unlabeled substance), then this indicates that the assay is working properly.\n\n\nAlternatively, a sample can be tested directly for binding to canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10). In an embodiment of the invention, a basic assay of this type includes the following steps:\n\n\n(a) contacting canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10), a subsequence thereof with a detectable or detectably labeled candidate substance (e.g., small molecule or an antibody); and\n\n\n(b) detecting direct binding between the candidate substance and NPC1L1.\n\n\nAgain, these experiment can be performed along with a negative-control experiment wherein NPC1L1-dependent binding is completely lacking. For example, the assay can be performed using a whole cell or cell membrane lacking any functional NPC1L1 (e.g., untransformed HEK293 cells) and/or lacking any candidate substance. If no binding is observed, then this indicates that the assay is working properly.\n\n\nIn an embodiment of the invention, a positive-control assay is performed. In such an assay, a detectable or detectably labeled substance known to bind to NPC1L1 (e.g., \n3\nH-labeled compound 4) is assayed for binding. If binding is observed, then this indicates that the assay is operating properly.\n\n\nThe scope of the present invention includes a method for assaying candidate inhibitory agents for activity against cholesterol absorption (e.g., intestinal cholesterol absorption, for example, in the intestine of a human) comprising the steps of: providing a cell expressing canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) or a functional fragment or variant thereof which is capable of binding a fluorescent cholesterol absorption inhibitor, e.g., wherein said inhibitor is an azetidinone; contacting said cell with a candidate inhibitory agent in the presence of said fluorescent cholesterol absorption inhibitor; and measuring the inhibition of the fluorescence of said cell, wherein a relative absence of fluorescent cholesterol absorption inhibitor indicates that said candidate inhibitory agent is an inhibitory agent which inhibits cholesterol absorption into the cell (e.g., intestinal cholesterol absorption). In an embodiment of the invention, the fluorescent cholesterol absorption inhibitor is\n\n\n \n \n \n \n \n \n \n \n \n \n\nwherein R comprises a fluorescent moiety, e.g., whereing the fluorescent moiety linked by an alkynyl-containing tether group (e.g., C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10 alkynyl group). In an embodiment of the invention, R is\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe scope of the present invention includes a method for identifying inhibitory agents which inhibit the absorption of cholesterol into or onto a cell membrane or which inhibit cholesterol absorption e.g., in the intestine of a human, said method comprising the steps of: (a) combining a fluorescent cholesterol absorption inhibitor e.g., wherein said inhibitor is an azetidinone, said cell membrane, wherein the cell membrane comprises canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) or a functional fragment or variant thereof on its surface or embedded within the membrane in such a manner that the NPC1L1 is capable of mediating cholesterol transport across the membrane or binding or transport of a cholesterol absorption inhibitor, and a candidate inhibitory agent, under conditions wherein, but for the presence of said inhibitory agent, said fluorescent cholesterol absorption inhibitor is bound to the membrane e.g., by the NPC1L1; and (b) detecting the relative presence or absence of fluorescent cholesterol absorption inhibitor bound to the membrane, wherein a relative absence of fluorescent cholesterol absorption inhibitor indicates that said candidate inhibitory agent is an inhibitory agent which inhibits cholesterol absorption into or onto the membrane or which inhibits cholesterol absorption into the intestine. In an embodiment of the invention, the cell membrane is an intestinal epithelial cell membrane. In an embodiment of the invention, the fluorescent cholesterol absorption inhibitor is\n\n\n \n \n \n \n \n \n \n \n \n \n\nwherein R comprises a fluorescent moiety, e.g., whereing the fluorescent moiety linked by an alkynyl-containing tether group. In an embodiment of the invention, R is\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nThe presence of fluorescent inhibitor in the cell or bound to the membrane in these methods would indicate that the candidate inhibitory agent is not an inhibitor of cholesterol absorption.\n\n\nThe present invention also includes any azetidinone, such as ezetimibe or any fluorescent cholesterol absorption inhibitor (e.g., a fluorescently labeled azetidinone) bound to canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) or a functional fragment or variant thereof (e.g., isolated NPC1L1 e.g., soluble or on the surface of an isolated cell or membrane or non-isolated, in vivo NPC1L1, for example, on the surface of a cell), e.g., wherein the inhibitor is\n\n\n \n \n \n \n \n \n \n \n \n \n\nwherein R comprises a fluorescent moiety, e.g., whereing the fluorescent moiety linked by an alkynyl-containing tether group. In an embodiment of the invention, R is\n\n\n\n \n \n \n \n \n \n \n \n \n \n\nU.S. Pat. Nos. 7,144,696; 6,933,107; 6,632,933; and 6,593,078 are herein incorporated by reference in their entireties as is published international application no. WO 00/63703.\n\n\n\nA candidate compound which is found to bind to NPC1L1 may function as an agonist or antagonist of NPC1L1 (e.g., by inhibition of sterol (e.g., cholesterol) or 5α-stanol uptake). This may be confirmed, subsequently, in an uptake assay as discussed below.\n\n\nSPA Assay. NPC1L1 antagonists or agonists may also be measured using scintillation proximity assays (SPA). SPA assays are conventional and very well known in the art; see, for example, U.S. Pat. No. 4,568,649. In SPA, the target of interest is immobilised to a small microsphere approximately 5 microns in diameter. The microsphere, typically, includes a solid scintillant core which has been coated with a polyhydroxy film, which in turn contains coupling molecules, which allow generic links for assay design. When a radioisotopically labeled molecule binds to the microsphere, the radioisotope is brought into close proximity to the scintillant and effective energy transfer from electrons emitted by the isotope will take place resulting in the emission of light. While the radioisotope remains in free solution, it is too distant from the scintillant and the electron will dissipate the energy into the aqueous medium and therefore remain undetected. Scintillation may be detected with a scintillation counter. In general, \n3\nH and \n125\nI labels are well suited to SPA.\n\n\nFor the assay of receptor-mediated binding events, the lectin wheat germ agglutinin (WGA) may be used as the SPA bead coupling molecule (Amersham Biosciences; Piscataway, N.J.). The WGA coupled bead captures glycosylated, cellular membranes and glycoproteins and has been used for a wide variety of receptor sources and cultured cell membranes. The receptor is immobilized onto the WGA-SPA bead and a signal is generated on binding of an isotopically labeled ligand. Other coupling molecules which may be useful for receptor binding SPA assays include poly-L-lysine and WGA/polyethyleneimine (Amersham Biosciences; Piscataway, N.J.). See, for example, Berry, J. A., et al., (1991) Cardiovascular Pharmacol. 17 (Suppl. 7): S143-S145; Hoffman, R., et al., (1992) Anal. Biochem. 203: 70-75; Kienhus, et al., (1992) J. Receptor Research 12: 389-399; Jing, S., et al., (1992) Neuron 9: 1067-1079.\n\n\nThe scintillant contained in SPA beads may include, for example, yttrium silicate (YSi), yttrium oxide (YOx), diphenyloxazole or polyvinyltoluene (PVT) which acts as a solid solvent for diphenylanthracine (DPA).\n\n\nSPA assays may be used to analyze whether a sample contains an NPC1L1 antagonist or agonist. In these assays, canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 or a host cell which expresses canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) on the cell surface or a membrane fraction thereof is incubated with and captured by SPA beads (e.g., WGA coated YOx beads or WGA coated YSi beads). The beads bearing the NPC1L1 are incubated with labeled, known ligand or agonist or antagonist (e.g., \n3\nH-labeled compound 4). The assay mixture further includes either the sample to be tested or a blank (e.g., water). After an optional incubation, scintillation is measured using a scintillation counter. An NPC1L1 agonist or antagonist may be identified in the sample by measuring substantially reduced fluorescence, compared to what would be measured in the absence of such agonist or antagonist (blank). Measuring substantially reduced fluorescence suggests that the sample contains a substance which competes for NPC1L1 binding with the known ligand, agonist or antagonist.\n\n\nIn an embodiment of the invention, a negative-control assay is performed. In a negative-control assay, for example, the assay is performed as set forth above except that no NPC1L1 is present. If no significant fluorescence is observed, then this indicates that the assay is operating properly.\n\n\nIn an embodiment of the invention, a positive-control assay is performed. In a positive-control assay, the substance known to bind to NPC1L1 (e.g., \n3\nH-labeled compound 4) is incubated along with an un-radiolabeled substance also known to bind to NPC1L1 (e.g., unlabeled compound 4). If reduced binding of the labeled substance is observed (i.e., reduced fluorescence), relative to an assay wherein a blank is used in place on the unlabeled substance known to bind NPC1L1, then this indicates that the assay is operating properly.\n\n\nAlternatively, a sample may be identified as an antagonist or agonist of NPC1L1 by directly detecting binding in a SPA assay. In this assay, a labeled version of a candidate compound to be tested is put in contact with canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 or a host cell expressing NPC1L1 or a membrane fraction thereof which is bound to the SPA bead. Fluorescence may then be assayed to detect the presence of a complex between the labeled candidate compound and the NPC1L1. A candidate compound which binds to NPC1L1 may possess NPC1L1 agonistic or antagonistic activity.\n\n\nSPA Assays can also be performed along with a negative-control experiment lacking any NPC1L1-dependent binding. The control experiment can be performed, for example, with a cell or cell membrane lacking any functional NPC1L1. When the control experiment is performed, the level of binding observed in the presence of sample being tested for the presence of an antagonist can be compared with that observed in the control experiment. If no significant binding is observed, this indicates that the assay is operating properly.\n\n\nFurthermore, a positive-control experiment can be performed wherein a radiolabeled compound known to bind to NPC1L1 (e.g., \n3\nH-labeled compound 4) is assayed. If binding is observed, this indicates that the assay is operating properly.\n\n\nHost cells expressing NPC1L1 may be prepared by transforming or transfecting a nucleic acid encoding an NPC1L1 of the invention into an appropriate host cell, whereby the receptor becomes incorporated into the membrane of the cell. A membrane fraction can then be isolated from the cell and used as a source of the receptor for assay. Alternatively, the whole cell expressing the receptor on the cell surface can be used in an assay. Preferably, specific binding of the labeled ligand or known antagonist or agonist to an untransfected/untransformed host cell or membrane fraction from an untransfected/untransformed host cell will be negligible. Preferred host cells include Chinese Hamster Ovary (CHO) cells, murine macrophage J774 cells or any other macrophage cell line and human intestinal epithelial Caco2 cells.\n\n\nSterol/5α-stanol Uptake Assay. Assays may also be performed to determine if a sample can agonize or antagonize NPC1L1 mediated sterol (e.g., cholesterol) or 5α-stanol uptake. In these assays, a host cell expressing canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8 or 10) on the cell surface (discussed above) is contacted with detectably labeled sterol (e.g., \n3\nH-cholesterol or \n125\nI-cholesterol)) or 5α-stanol along with a sample to be tested for an agonist or antagonist of NPC1L1. After an optional incubation, the cells can be washed to remove unabsorbed sterol or 5α-stanol. Sterol or 5α-stanol uptake can be determined by detecting the presence of labeled sterol or 5α-stanol in the host cells. For example, assayed cells or lysates or fractions thereof (e.g., fractions resolved by thin-layer chromatography) can be contacted with a liquid scintillant and scintillation can be measured using a scintillation counter.\n\n\nIn these assays, an NPC1L1 antagonist in the sample may be identified by measuring substantially reduced uptake of the labeled sterol (e.g., \n3\nH-cholesterol) or 5α-stanol, compared to what would be measured in the absence of such an antagonist and an agonist may be identified by measuring substantially increased uptake of the labeled sterol (e.g., \n3\nH-cholesterol) or 5α-stanol, compared to what would be measured in the absence of such an agonist.\n\n\nUptake assays can optionally be performed along with a negative-control assay lacking any NPC1L1-dependent uptake. The negative-control assay can be performed, for example, with a cell lacking any functional NPC1L1 (e.g., an untransformed host cell) or lacking any labeled sterol or 5α-stanol. A substantial lack of uptake indicates that the assay is operating correctly. A positive-control assay may also be optionally performed along with an assay of the invention. For example, in a control assay, a cell expressing NPC1L1 is exposed to labeled sterol or 5α-stanol in the absence of any antagonist. A high level of uptake in the cell would indicate that the assay is operating correctly.\n\n\nIn Vivo Assay. The present invention comprises a mutant, transgenic canine, rabbit, hamster, rhesus monkey or cynomolgus monkey which lacks any functional NPC1L1. This canine, rabbit, hamster, rhesus monkey or cynomolgus monkey may serve as a convenient control experiment in screening assays for identifying inhibitors of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption, preferably inhibitors of NPC1L1. In an embodiment of the invention, a canine, rabbit, hamster, rhesus monkey or cynomolgus monkey-based assay of the present invention would comprise the following steps:\n\n \n \n \n \n(a) feeding a sterol (e.g., cholesterol) or 5α-stanol-containing substance (e.g., comprising radiolabeled cholesterol, such as \n14\nC-cholesterol or \n3\nH-cholesterol) to a first and second canine, rabbit, hamster, rhesus monkey or cynomolgus monkey comprising a functional NPC1L1 gene and to a third, mutant canine, rabbit, hamster, rhesus monkey or cynomolgus monkey lacking a functional NPC1L1;\n \n \n \n\n\nIn an embodiment of the invention, the sterol (e.g., cholesterol) or 5α-stanol containing substance contains labeled cholesterol, such as a radiolabeled cholesterol, for example, \n3\nH or \n14\nC labeled cholesterol. The sterol (e.g., cholesterol) or 5α-stanol containing substance may also include cold, unlabeled sterol (e.g., cholesterol) or 5α-stanol such as in corn oil.\n\n\nIn these assays, the third npc1l1 mutant canine, rabbit, hamster, rhesus monkey or cynomolgus monkey serves as a (+)-control experiment which exhibits low levels of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption and the second canine, rabbit, hamster, rhesus monkey or cynomolgus monkey serves as a (−)-control experiment which exhibits normal, uninhibited levels of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption. The second canine, rabbit, hamster, rhesus monkey or cynomolgus monkey is not administered the sample to be tested for an NPC1L1 antagonist. The first canine, rabbit, hamster, rhesus monkey or cynomolgus monkey is the experimental.\n\n \n \n \n \n(b) administering the sample to be tested for the presence of the antagonist to the first canine, rabbit, hamster, rhesus monkey or cynomolgus monkey comprising a functional NPC1L1 but not to the second canine, rabbit, hamster, rhesus monkey or cynomolgus monkey;\n \n(c) measuring the amount of sterol (e.g., cholesterol) or 5α-stanol absorption in the intestine of said first, second and third canine, rabbit, hamster, rhesus monkey or cynomolgus monkey;\n \n \n \n\n\nIntestinal sterol (e.g., cholesterol) or 5α-stanol absorption may be measured by any method known in the art. For example, the level intestinal absorption can be assayed by measuring the level of serum sterol (e.g., cholesterol) or 5α-stanol.\n\n \n \n \n \n(d) comparing the levels of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption in each canine, rabbit, hamster, rhesus monkey or cynomolgus monkey;\n\n\nwherein the sample is determined to contain the intestinal sterol (e.g., cholesterol) or 5α-stanol absorption antagonist when the level of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption in the first canine, rabbit, hamster, rhesus monkey or cynomolgus monkey and in the third canine, rabbit, hamster, rhesus monkey or cynomolgus monkey are less than the amount of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption in the second canine, rabbit, hamster, rhesus monkey or cynomolgus monkey.\n\n \n \n \n\n\nPreferably, if the sample contains an intestinal sterol (e.g., cholesterol) or 5α-stanol absorption inhibitor (e.g., an NPC1L1 inhibitor), the level of sterol (e.g., cholesterol) or 5α-stanol absorption in the first canine, rabbit, hamster, rhesus monkey or cynomolgus monkey will be similar to that of the third, npc1l1 mutant canine, rabbit, hamster, rhesus monkey or cynomolgus monkey.\n\n\nAn alternative positive-control experiment which may be used in conjunction with these screening assays is to perform the experiment essentially as set forth above, except that the sample tested is ezetimibe. If inhibition of uptake is observed in this assay, this indicates that the assay is operating properly.\n\n\nAntibodies\n\n\nThe present invention includes any antibody or antigen-binding fragment thereof that binds specifically to canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 or an antigenic fragment thereof. Embodiments of the invention include any anti-canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antibody or antigen-binding fragment thereof which is a monoclonal antibody, polyclonal antibody, bispecific antibody, linear antibody, chimeric antibody, humanized antibody, anti-idiotypic antibody, recombinant antibody, Fab antibody fragment, F(ab)\n2 \nantibody fragment, Fv antibody fragment (e.g., VH or VL), single chain Fv antibody fragment or dsFv antibody fragment.\n\n\nThe present invention also includes any antibody or antigen-binding fragment thereof which binds specifically to canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 or an antigenic fragment thereof which was raised against said NPC1L1 or fragment thereof. For example, an embodiment of the invention includes any anti-canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antibody or antigen-binding fragment thereof produced by immunization of an animal with said NPC1L1 or an antigenic fragment thereof.\n\n\nIn an embodiment of the invention, a polyclonal antibody is raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen (e.g., canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 or an antigenic fragment thereof) and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl\n2\n, or R1N═C═NR, where R and R1 are different alkyl groups. In an embodiment of the invention, animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 μg or 5 μg of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with ⅕ to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. In an embodiment of the invention, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.\n\n\nIn an embodiment of the invention, a monoclonal antibody is made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or by recombinant DNA methods (see e.g., U.S. Pat. No. 4,816,567). In an embodiment of the invention, in the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). In an embodiment of the invention, the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that, in an embodiment of the invention, contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. In an embodiment of the invention, myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, myeloma cell lines are murine myeloma lines. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).\n\n\nIn an embodiment of the invention, culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. In an embodiment of the invention, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). In an embodiment of the invention, after hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. In an embodiment of the invention, the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. In an embodiment of the invention, DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as \nE. coli \ncells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.\n\n\nIn an embodiment of the invention, antibodies or antibody fragments of the invention can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990). Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production of high affinity (nM range) human antibodies by chain shuffling (Marks et al., Bio/Technology, 10:779-783 (1992)), as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids. Res., 21:2265-2266 (1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.\n\n\nIn an embodiment of the invention, single-chain Fv or sFv antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in \nThe Pharmacology of Monoclonal Antibodies\n, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).\n\n\nIn an embodiment of the invention, humanized antibody forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. In general, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (e.g., CDRs) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.\n\n\nA linear antibody is an antibody fragment as described in Zapata et al. Protein Eng. 8(10):1057-1062 (1995). Briefly, these fragments comprise a pair of tandem Fd segments (VH—CH1-VH—CH1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.\n\n\nA species-dependent antibody is one which has a stronger binding affinity for an antigen from a first species than it has for a homologue of that antigen from a second species. In an embodiment of the invention, a species-dependent antibody “binds specifically” to a canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antigen (e.g., has a binding affinity (Kd) value of no more than about 1×10\n−7 \nM) but has a binding affinity for a homologue of the antigen from a second species (e.g., another mammalian species such as human NPC1L1) which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antigen. The present invention comprises species dependent anti-canine, rabbit, hamster, cynomolgus monkey and rhesus monkey NPC1L1 antibodies and antigen-binding fragments thereof.\n\n\nThe present invention also includes an anti-canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antibody or antigen-binding fragment thereof produced by a process including introduction of an expression vector comprising the light and/or heavy chain of said antibody into a suitable host cell, expressing said chain(s) in said cell and, optionally isolating said chain(s). For example, an embodiment of the invention includes expressing an anti-canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antibody or antigen-binding fragment thereof of the invention in the plasmid system set forth in published international application no. WO2005/047512.\n\n\nThe present invention also includes any immunoliposome including any anti-canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1 antibody or antigen-binding fragment thereof of the invention. An immunoliposome is a liposome including said antibody or fragment. Liposomes containing the antibody or fragment can be prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. Other useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab fragments of an antibody of the present invention can be conjugated to the liposomes as described in Martin et al. J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange reaction. In an embodiment, a chemotherapeutic agent (such as ezetimibe) is optionally contained within the liposome.\n\n\nIn an embodiment of the invention, an anti-canine NPC1L1 antibody, an anti-hamster NPC1L1 antibody, an anti-rabbit NPC1L1 antibody, an anti-rhesus monkey NPC1L1 antibody or an anti-cynomolgus monkey NPC1L1 antibody that “specifically binds” to or is “specific for” canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1, respectively, is one that binds to that particular polypeptide or an epitope on the polypeptide without substantially binding to any other polypeptide or epitope.\n\n\nIn an embodiment of the invention, an anti-canine NPC1L1 antibody, an anti-hamster NPC1L1 antibody, an anti-rabbit NPC1L1 antibody, an anti-rhesus monkey NPC1L1 antibody or an anti-cynomolgus monkey NPC1L1 antibody that “specifically binds” to or is “specific for” canine, hamster, rabbit, rhesus monkey or cynomolgus monkey NPC1L1, respectively, is one that binds to that particular polypeptide or an epitope on the polypeptide with an affinity constant of at least 10\n−6 \nM, or at least 10\n−8 \nM.\n\n\nIf necessary, non-specific binding can be reduced without substantially affecting specific binding by varying the binding conditions. The appropriate binding conditions such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (e.g., serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques\n\n\nThe present invention further comprises a complex comprising an antibody (e.g., an isolated antibody) or antigen-binding fragment thereof of the present invention (e.g., an anti-canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 antibody) bound to a polypeptide of the present invention (e.g., canine, rabbit, hamster, rhesus monkey or cynomolgus monkey NPC1L1 (e.g., SEQ ID NO: 2, 4, 6, 8, or 10) or any fragment thereof (e.g., an antigenic fragment)). In an embodiment of the invention, the polypeptide is isolated. The present invention includes complexes existing both in vitro as well as in vivo (e.g., in the body of a subject). For example, the present invention includes a complex comprising an isolated antibody of the invention, that was administered to a subject, existing in a complex with an NPC1L1 polypeptide of the present invention, in the body of said subject. Furthermore, the present invention includes a complex comprising a non-isolated antibody, bound to an isolated NPC1L1 polypeptide of the present invention that was administered to a subject (e.g., for the purpose of generating anti-NPC1L1 antibodies), inside or outside the body of said subject.\n\n\nPharmaceutical Compositions\n\n\nNPC1L1 agonists and antagonists discovered, for example, by the screening methods described above may be used therapeutically (e.g., in a pharmaceutical composition) to stimulate or block the activity of NPC1L1 and, thereby, to treat any medical condition caused or mediated by NPC1L1. In addition, the antibodies and antigen-binding fragments thereof of the invention may also be used therapeutically (e.g., in a pharmaceutical composition) to bind NPC1L1 and, thereby, block the ability of NPC1L1 to bind a sterol (e.g., cholesterol) or 5α-stanol. Blocking the binding of a sterol (e.g., cholesterol) or 5α-stanol to NPC1L1 prevents absorption of the molecule (e.g., by intestinal cells such as enterocytes). Blocking absorption of sterol (e.g., cholesterol) or 5α-stanol is a useful way to lower serum sterol (e.g., cholesterol) or 5α-stanol levels in a subject and, thereby, reduce the incidence of, for example, hyperlipidemia, atherosclerosis, coronary heart disease, stroke or arteriosclerosis.\n\n\nThe term “subject” or “patient” includes any organism, preferably animals, more preferably mammals such as humans, hamsters, rhesus monkeys, cynomolgus monkeys, mice, rats, rabbits, dogs, canines, horses, primates, cats).\n\n\nThe term “pharmaceutical composition” refers to a composition including an active ingredient and a pharmaceutically acceptable carrier and/or adjuvant.\n\n\nAlthough the compositions of this invention could be administered in simple solution, they may be used in combination with other materials such as carriers, preferably pharmaceutically acceptable carriers. Useful, pharmaceutically acceptable carriers can be any compatible, non-toxic substances suitable for delivering the compositions of the invention to a subject. Sterile water, alcohol, fats, waxes, and inert solids may be included in a pharmaceutically acceptable carrier. Buffering agents or dispersing agents may also be incorporated into the pharmaceutical composition.\n\n\nIn an embodiment of the invention, the pharmaceutical compositions of the invention are in the form of a pill or capsule. Methods for formulating pills and capsules are very well known in the art. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral, non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Suitable binders include, for example, starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants that may be used in a pharmaceutical composition are boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like. Sweetening and flavoring agents and preservatives may also be included where appropriate.\n\n\nThe pharmaceutical compositions of the invention may be administered in association with a second pharmaceutical composition or substance. In an embodiment of the invention, the second composition includes a cholesterol-lowering drug (e.g., simvastatin, atorvastatin, lovastatin, pravastatin, rosuvastatin or fluvastatin). The term “in association with” indicates that the components of the combinations of the invention can be formulated into a single composition for simultaneous delivery or formulated separately into two or more compositions (e.g., a kit). Furthermore, each component of a combination of the invention can be administered to a subject at a different time than when the other component is administered; for example, each administration may be given non-simultaneously (e.g., separately or sequentially) at several intervals over a given period of time. Moreover, the separate components may be administered to a subject by the same or by a different route (e.g., orally, intravenously, subcutaneously).\n\n\nThe formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman et al. (eds.) (1990), \nThe Pharmacological Bases of Therapeutics, \n8th Ed., Pergamon Press; and \nRemington's Pharmaceutical Sciences\n, supra, Easton, Pa.; Avis et al. (eds.) (1993) \nPharmaceutical Dosage Forms: Parenteral Medications \nDekker, New York; Lieberman et al. (eds.) (1990) \nPharmaceutical Dosage Forms: Tablets \nDekker, New York; and Lieberman et al. (eds.) (1990), \nPharmaceutical Dosage Forms: Disperse Systems \nDekker, New York.\n\n\nThe dosage regimen involved in a therapeutic application may be determined by a physician, considering various factors which may modify the action of the therapeutic substance, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration, and other clinical factors. Often, treatment dosages are titrated upward from a low level to optimize safety and efficacy. Dosages may be adjusted to account for the smaller molecular sizes and possibly decreased half-lives (clearance times) following administration.\n\n\nAn “effective amount” of an antagonist of the invention may be an amount that will detectably reduce the level of intestinal sterol (e.g., cholesterol) or 5α-stanol absorption or detectably reduce the level of serum sterol (e.g., cholesterol) or 5α-stanol in a subject administered the composition.\n\n\nTypical protocols for the therapeutic administration of such substances are well known in the art. Pharmaceutical composition of the invention may be administered, for example, by any parenteral or non-parenteral route.\n\n\nPills and capsules of the invention can be administered orally. Injectable compositions can be administered with medical devices known in the art; for example, by injection with a hypodermic needle.\n\n\nInjectable pharmaceutical compositions of the invention may also be administered with a needleless hypodermic injection device; such as the devices disclosed in U.S. Pat. Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556.\n\n\nAnti-Sense\n\n\nThe present invention also encompasses anti-sense oligonucleotides capable of specifically hybridizing to mRNA encoding NPC1L1 (e.g., any of SEQ ID NOs: 1, 3, 5, 7, or 9) having an amino acid sequence defined by, for example, SEQ ID NO: 2, 4, 6, 8, or 10 or a subsequence thereof so as to prevent translation of the mRNA. Additionally, this invention contemplates anti-sense oligonucleotides capable of specifically hybridizing to the genomic DNA molecule encoding NPC1L1.\n\n\nThis invention further provides pharmaceutical compositions comprising (a) an amount of an oligonucleotide effective to reduce NPC1L1-mediated sterol (e.g., cholesterol) or 5α-stanol absorption by passing through a cell membrane and binding specifically with mRNA encoding NPC1L1 in the cell so as to prevent its translation and (b) a pharmaceutically acceptable carrier capable of passing through a cell membrane. In an embodiment, the oligonucleotide is coupled to a substance that inactivates mRNA. In another embodiment, the substance that inactivates mRNA is a ribozyme.\n\n\nReducing the level of NPC1L1 expression by introducing anti-sense NPC1L1 RNA into the cells of a patient is a useful method reducing intestinal sterol (e.g., cholesterol) or 5α-stanol absorption and serum cholesterol in the patient.\n\n\nKits\n\n\nKits of the present invention include ezetimibe, e.g., combined with a pharmaceutically acceptable carrier, in a pharmaceutical formulation, e.g., in a pharmaceutical dosage form such as a pill, a powder, an injectable liquid, a tablet, dispersible granules, a capsule, a cachet or a suppository. See for example, Gilman et al. (eds.) (1990), \nThe Pharmacological Bases of Therapeutics, \n8th Ed., Pergamon Press; and \nRemington's Pharmaceutical Sciences\n, supra, Easton, Pa.; Avis et al. (eds.) (1993) \nPharmaceutical Dosage Forms: Parenteral Medications \nDekker, New York; Lieberman et al. (eds.) (1990) \nPharmaceutical Dosage Forms: Tablets \nDekker, New York; and Lieberman et al. (eds.) (1990), \nPharmaceutical Dosage Forms: Disperse Systems \nDekker, New York. In an embodiment of the invention, the dosage form is a Zetia® (ezetimibe) or Vytorin® (ezetimibe/simvastatin) tablet (Merck/Schering-Plough Corp.).\n\n\nThe kits of the present invention also include information, for example in the form of a package insert, indicating that the target of ezetimibe is NPC1L1. The term “target of ezetimibe” indicates that ezetimibe reduces intestinal sterol (e.g., cholesterol) or 5α-stanol absorption, either directly or indirectly, by antagonizing NPC1L1. The form of the insert may take any form, such as paper or on electronic media such as a magnetically recorded medium (e.g., floppy disk) or a CD-ROM.\n\n\nThe package insert may also include other information concerning the pharmaceutical compositions and dosage forms in the kit. Generally, such information aids patients and physicians in using the enclosed pharmaceutical compositions and dosage forms effectively and safely. For example, the following information may be supplied in the insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and usage, contraindications, warnings, precautions, adverse reactions, overdosage, proper dosage and administration, how supplied, proper storage conditions, references and patent information.\n\n\nThe kits of the invention may also include simvastatin (\n\n\n \n \n \n \n \n \n \n \n \n \n\ncombined, in an embodiment of the invention, with a pharmaceutically acceptable carrier, in a pharmaceutical formulation, more preferably in a pharmaceutical dosage form such as a pill, a powder, an injectable liquid, a tablet, dispersible granules, a capsule, a cachet or a suppository. In an embodiment of the invention, the dosage form of simvastatin is a Zocor® tablet (Merck & Co.; Whitehouse Station, N.J.).\n\n\n\nEzetimibe and simvastatin may be supplied, in the kit, as separate compositions or combined into a single composition. For example, ezetimibe and simvastatin may be supplied within a single, common pharmaceutical dosage form (e.g., pill or tablet) or in separate pharmaceutical dosage forms (e.g., two separate pills or tablets).\n\n\nnpc1l1\n−\n Cells\n\n\nThe present invention provides any isolated canine, rabbit, hamster, rhesus monkey or cynomolgus monkey cell which lacks an NPC1L1 gene which encodes or can produce a functional NPC1L1 protein. Included within this embodiment are mutant npc1l1 genes comprising a point mutation, truncation or deletion of the genetic coding region (partly or in its entirety) or of any regulatory element (e.g., a promoter).\n\n\nFor example, the cell can be isolated from a mutant animal comprising a homozygous or heterozygous mutation of endogenous, chromosomal NPC1L1 wherein the animal does not produce any functional NPC1L1 protein. Moreover, the present invention comprises any cell, tissue, organ, fluid, nucleic acid, peptide or other biological substance derived or isolated from such an animal. The isolated cell can be isolated or derived, for example, from the duodenum, gall bladder, liver, small intestine or stomach of the mutant animal. Further, the cell can be an enterocyte.\n\n\nThe npc1l1\n−\n mutant cells are useful, for example, for use in control experiments in screening assays (see e.g., supra) since they lack any NPC1L1-dependent uptake or binding of sterol, 5α-stanol or ezetimibe. The level of inhibition caused by a particular sample, in a screening assay, can be compared to that of an assay performed with the mutant cell. Ideally, though by no means necessarily, in a screening assay, for example, as described herein, the same amount of binding will be observed by a non-mutant cell or cell membrane, in the presence of an antagonist, as is observed in connection with a mutant npc1l1\n−\n cell or cell membrane alone.\n\n\nTransgenic Animals\n\n\nGenetically engineered host cells can be further used to produce non-human transgenic animals such as canines (e.g., dogs), rabbits, hamsters, cynomolgus monkeys and rhesus monkeys. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of NPC1L1 and identifying and evaluating modulators (e.g., inhibitors) thereof. The present invention includes for example, knock-out canines (e.g., dogs), rabbits, hamsters, cynomolgus monkeys and rhesus monkeys which lack any functional NPC1L1 protein in their cells. The present invention also includes any transgenic non-human animal comprising a supra-normal level of an NPC1L1 of the invention in its cells.\n\n\nA transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the NPC1L1 nucleotide sequences of the invention can be introduced as a transgene into the genome of an animal.\n\n\nAny of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of NPC1L1 protein to particular cells.\n\n\nMethods for generating transgenic animals via embryo manipulation and microinjection have become conventional in the art and are described. Any technique known in the art may be used to introduce the transgene (i.e., nucleic acids of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, “Transgenic Animals,” Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety. See also Gordon, “Transgenic Animals,” Intl. Rev. Cytol. 115:171-229 (1989); U.S. Pat. No. 5,464,764 (Capecchi, et al., Positive-Negative Selection Methods and Vectors); U.S. Pat. No. 5,631,153 (Capecchi, et al., Cells and Non-Human Organisms Containing Predetermined Genomic Modifications and Positive-Negative Selection Methods and Vectors for Making Same); U.S. Pat. No. 4,736,866 (Leder, et al., Transgenic Non-Human Animals); and U.S. Pat. No. 4,873,191 (Wagner, et al., Genetic Transformation of Zygotes). As stated, any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).\n\n\nIn one embodiment of the invention, a transgenic canine (e.g., dog), hamster, rabbit, cynomolgus monkey or rhesus monkey is a “knock-out” animal having a heterozygous or homozygous alteration in the sequence of an endogenous NPC1L1 gene that results in a decrease of NPC1L1 function, e.g., such that NPC1L1 expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. A deletion, addition or substitution can be introduced into the transgene to functionally disrupt it. Detailed methodologies for homologous recombination in transgenic animals are available (see Capecchi, Science (1989) 244:1288-1292; Joyner et al., Nature (1989) 338:153-156). Other procedures for the production of transgenic animals are also available (Pursel et al., Science (1989) 244:1281-1288; Simms et al., Bio/Technology (1988) 6:179-183).\n\n\nA transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. For example, once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes.\n\n\nAny cell, tissue, gamete, organ, fluid, nucleic acid, peptide or other biological substance derived or isolated from a transgenic animal of the invention is within the scope of the present invention as is any offspring of such an animal (e.g., any offspring inheriting the transgene).\n\n\nEXAMPLES\n\n\nThe invention is further illustrated by the following non-limiting example.\n\n\nExample 1\n\n\nBinding and Inhibition of NPC1L1 Orthologues by Ezetimibe and Related Compounds\n\n\nThis example demonstrates that the NPC1L1 genes set forth herein bind to ezetimibe and structurally related compounds.\n\n\nMaterials and Methods\n\n\nMaterials. The [\n3\nH]-ezetimibe glucuronide (EZE-gluc) [1-([2, 6-3H]-4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-[3,5-\n3\nH]-4-hydroxyphenyl)-2-azetidinone; 34.5 Ci/mmol (Garcia-Calvo et al., Proc. Natl. Acad. Sci. U.S.A. 102:8132-8137 (2005)) and several 2-azetidinone based compounds.\n\n\ncDNA cloning. Cloning and sequencing of NPC1L1 from human (Genbank AY437865), rat (Genbank AY437867) and mouse (Genbank AY437865) have been reported (Altmann et al., Science 303:1201-1204 (2004) and U.S. published patent application nos. US2004/0093629; US 2004/0137467; US 2004/0132058 and US 2004/0161838). Jejunal enterocytes were isolated as previously described (Altmann et al., Biochim. Biophys. Acta 1580:77-93 (2002)) from freshly isolated tissue samples from rhesus monkey, cynomolgus monkey, hamster, rabbit and beagle dog. Isolated enterocytes were immediately extracted with Tri-reagent and the total RNA isolated following manufacturer's instructions (Molecular Research Center Inc.; Cincinnati, Ohio). Messenger RNA was isolated using FastTrack 2.0 (Invitrogen; Carlsbad, Calif.) and cDNA prepared using superscript Choice System (Life Technologies; Gaithersburg, Md.) following oligo-(dT) primed first strand synthesis. NPC1L1 specific oligo primers corresponding to highly conserved regions in the human, mouse and rat were used in varied combinations to polymerase chain reaction (PCR) amplify each cDNA sample. PCR products were sequenced to determine species specific NPC1L1 sequence. To obtain species-specific gene sequences from the 5′-start codon region and the 3′-stop codon region, 5′- and 3′ RACE PCR were performed using Marathon-Ready cDNA Amplification Kit, or Smart RACE cDNA Amplification Kit according to the manufacturer's instructions (BD Biosciences Clontech; Mountain View, Calif.). The species-specific oligonucleotide primers for 5′ and 3′ RACE PCR were designed according to available species-specific NPC1L1 gene sequences. In some cases, oligo primers based upon consensus gene sequences among species were also used in the 5′ and 3′-RACE PCR reaction. Sequence analysis of RACE PCR products identified coding sequence for the start and stop of the protein open reading frame. Preparation of the final NPC1L1 cDNA was carried out by PCR amplification of the complete ORF using species specific forward and reverse primers encompassing the start and stop codons respectively:\n\n\nRabbit NPC1L1:\n\n\n\n\n \n\n\n\n\n\n\n5′-end sequence was obtained by 5′-RACE PCR with primer set of S1352 (TAGGCCCGCTCGGCGAAGCTGCGCTCG) (SEQ ID NO: 11) and primer #98 (AGCTAGCTTGCCAAACCTACAGGT) (SEQ ID NO: 12).\n\n\n3′-end sequence was obtained by 3′-RACE PCR with primer set of S1299 (CATGTCTGTGGAGTTYGTGTCCCACAT) (SEQ ID NO: 13) and primer #98 (AGCTAGC TTGCCAAACCTACAGGT) (SEQ ID NO: 12).\n\n\nThe complete ORF sequence was obtained by PCR with primer set of S1368 (ATGGCAGGGGCTGCGCGGGGCTGGCTG) (SEQ ID NO: 14) and S1317 (TCAGAACTTC TGCTTTCTGGTGGG) (SEQ ID NO: 15)\n\n\nRhesus Monkey NPC1L1\n\n\n\n5′-end sequence was obtained by 5′-RACE PCR with primer S1320R (TARAAGGCCTCATAGGCCACCAC) (SEQ ID NO: 16).\n\n\n3′-end sequence was obtained by 3′-RACE PCR with primer set of S1299 (CATGTCTGTGGAGTTYGTGTCCCACAT) (SEQ ID NO: 13) and primer #98 (AGCTAGC TTGCCAAACCTACAGGT) (SEQ ID NO: 12).\n\n\nThe complete ORF sequence was obtained by PCR with primer set of \nmonkey\n 5′ primer (ATGGCGGAGGCCGGCCTGAGGGGCTGGCTG) (SEQ ID NO: 17) and \nMonkey\n 3′ primer (TCAGAA CTGCCGCCCATTGTTGGGCAAGAA) (SEQ ID NO: 18)\n\n\nHamster NPC1L1\n\n\n\n5′-end sequence was obtained by 5′-RACE PCR with 5′ hamster GSP2 primer (TGACATTGATGAAGAGGCTCTGGTCAGG) (SEQ ID NO: 19).\n\n\n3′-end sequence was obtained by 3′-RACE PCR with 5′ hamster GSP2 primer (TCAGGCATCCTCAACCTGCTCTCCATCAT) (SEQ ID NO: 20).\n\n\nThe complete ORF sequence was obtained by PCR with primer set of \nhamster\n 5′ primer (ATGGCAGCTGGCCTAACGAGATGGCTG) (SEQ ID NO: 21) and \nhamster\n 3′ primer (TTAAAACTT TTGGCCGCTTTTAGGCAAG) (SEQ ID NO: 22)\n\n\nCanine NPC1L1\n\n\n\nThe complete ORF sequence was obtained by PCR with primer set of S1406 (ATGGCGGACACTGGCCAGGGGCT) (SEQ ID NO: 23) and S1414 (TCAGAGGTCCGGT CCACTGCGGGG) (SEQ ID NO: 24)\n\n\nCynomologus Monkey NPC1L1\n\n\n\nThe complete ORF sequence was obtained by PCR with primer set of \nmonkey\n 5′ primer (ATGGCGGAGGCCGGCCTGAGGGGCTGGCTG) (SEQ ID NO: 17) and \nMonkey\n 3′ primer (TCAGAACTGCCGCCCATTGTTGGGCAAGAA) (SEQ ID NO: 18)\n\n\n\n\n\n\n\n\nSequencing of multiple clones from independent PCR reactions resulted in cDNA sequences free from nucleotide errors introduced by Taq polymerase.\n\n\nCell Culture and Membrane Preparation. Each plasmid pCR3.1 harboring NPC1L1 was prepared using standard molecular biology protocols. Stable cell lines expressing human, rhesus monkey, mouse, rat, hamster, canine or rabbit NPC1L1 were generated using \nLipofectamine\n 2000 transfection reagent in HEK-293 cells according to the manufacturer's protocol. Cells were maintained in DMEM supplemented with 10% FBS, 100 U/ml pen/strep, and 500 μg/ml geneticin at 37° C., 5% CO\n2\n. All cell culture reagents were obtained from Invitrogen Life Technologies, (Carlsbad, Calif.). Cell membranes were prepared by lysing cells in 5 mM HEPES with protease inhibitors (Complete™ Protease Inhibitor Cocktail Tablets; Roche Diagnostics Corp., Indianapolis Ind.) for 15 min at 4° C. A membrane pellet was obtained by centrifuging the cell lysates at 12,000×g for 25 min. The membranes were resuspended in 5 mM HEPES with protease inhibitors and triturated with a 21 G needle.\n\n\nNPC1L1 Binding Assays\n\n\nFluorescence. Cells were plated into 384-well black/clear plates (BD Biosciences, Bedford Mass.) for binding experiments the following day. The media was aspirated. Media (20 μl) containing 250 nM BODIPY-labeled glucuronidated ezetimibe (compound 1; Burnett et al., Bioorganic and Medicinal Chemistry Letters 12:315-318 (2002)) was added to each well. Media (20 μl) containing the indicated concentration of compound was then added to the wells. Unlabeled glucuronidated ezetimibe (\ncompound\n 4; 100 μM) was used to determine nonspecific binding. The binding reaction was allowed to proceed for 4 hours at 37° C. Subsequently the media was aspirated and the cells washed once with PBS. The remaining BODIPY-labeled glucuronidated ezetimibe (compound 1) bound to the cells was quantified using a FlexStation plate reader (Molecular Devices, Sunnyvale Calif.).\n\n\nRadioligand. Binding of [\n3\nH]-glucuronidated ezetimibe (compound 4) to membranes from cells expressing NPC1L1 was measured using filtration (Garcia-Calvo et al., Proc. Natl. Acad. Sci. U.S.A. 102:8132-8137 (2005)). Reactions were performed in binding buffer (5 mM HEPES, 5.5 mM glucose, 117 mM NaCl and 5.4 mM KCl, pH 7.4). Cell membranes (50 μg in 20 μl) were added to each well. Subsequently, [\n3\nH]-glucuronidated ezetimibe (\ncompound\n 4; 20 nM; 20 μl) was added to each well. Compounds (20 μl) were then added to the wells as indicated in the figure legends. Nonspecific binding was determined by including unlabeled glucuronidated ezetimibe (\ncompound\n 4; 100 μM) in the binding reaction. Binding reactions were incubated for 2 hours at 37° C. Samples were transferred to Unifilter-96 GF/C plates (Perkin Elmer, Wellesley Mass.) and filtered using a Brandel harvester (Gaithersburg Md.). The plates were washed several times with cold wash buffer (120 mM NaCl, 0.1% Sodium Cholate, 20 mM MES pH 6.7) and dried. Liquid scintillant (50 μl; Microscint-20, Perkin Elmer, Wellesley Mass.) was added and the bound radioactivity was measured using a microplate scintillation counter.\n\n\nAcute cholesterol absorption assay. \n14\nC-cholesterol absorption was determined acutely in rats using conditions previously described (Van Heek et al., J. Pharmacol. Exp. Ther. 283: 157-163 (1997)). Compounds were dissolved in rat bile and delivered (1.0 ml) intraduodenally by bolus injection via an intestinal catheter, followed by 1.0 ml saline rinse (0.9%). Following a 30 min incubation, a cholesterol emulsion containing 3 mg cholesterol and 2 μCi \n14\nC-cholesterol (3 ml) was delivered to each rat as a bolus via intestinal catheter, followed by 1 ml saline rinse. Animals were sacrificed 90 min later and \n14\nC-cholesterol levels in plasma, liver, intestinal contents, and intestinal wall were determined.\n\n\nResults\n\n\nThe effective dose of ezetimibe that inhibits cholesterol absorption varies among several species that have been studied. Since NPC1L1 has been identified as the direct proximal target of ezetimibe, we cloned NPC1L1 from jejunal enterocytes of rhesus and cynomolgus monkey, canine, hamster, and rabbit (see SEQ ID NOs: 1-10). Comparison of the amino acid sequences of NPC1L1 in those species along with previously published amino acid sequences of human, rat, and mouse NPC1L1 (Altmann et al., Science 303:1201-1204 (2004)) and predicted sequences from chimpanzee (Genbank XM\n—\n519072) and cow (Genbank XM\n—\n588051) are shown in \nFIG. 7\n. At the sequence level, the positions of the Cys residues, of which there are ˜40, are highly conserved across all species and suggestive of a highly constrained structure. Several Cys residues are located within predicted \n \ntransmembrane helices\n \n 1, 6 and 9 with the potential of fixing these transmembrane helices in close proximity. The proposed protein topology defined by the predicted transmembrane helices is consistent with the location of the putative N-linked glycosylation sites which reside in three large extracellular loops exposed to the intestinal lumen. \nFIG. 1\n presents a ball model of the predicted membrane topology of human NPC1L1 (Iyer et al., Biochim. Biophys. Acta 1722:382-392 (2005)). Residues in black constitute the sterol sensing domain (SSD) (Carstea et al., Science 277:228-231 (1997)) and residues shaded gray identify non-conserved positions between human and monkey NPC1L1. NPC1L1 is most highly conserved among the primates with human, chimpanzee and monkey exhibiting >95% amino acid identity (\nFIG. 2A\n). Nucleotide sequences in rhesus and cynomolgus monkey coding regions show only 9 substitutions, none of which result in amino acid differences (data not shown). Human and monkey NPC1L1 amino acid sequences are highly homologous being less than 5% divergent. Of the 53 amino acid substitutions in monkey, 28 reside in the extracellular domain and 17 are located within the cytoplasmic domains. The remaining 8 changes occur in the transmembrane domains, 2 of which are located in the SSD.\n\n\nThe rodent family, consisting of sequences from hamster, rat, and mouse, also exhibit strong homology to each other with close to 90% identity in amino acid sequences. Primates and rodents share only 77-78% amino acid sequence identity with each other. The homology of canine NPC1L1 compared to the other species is relatively low (74-81%) as is cow (75-81%). Rabbit NPC1L1 also exhibits relatively low homology to the other species examined (75-79%) but is most closely associated with rodents. A phylogenetic tree representing the homology of NPC1L1 in the various species is shown in \nFIG. 2B\n. As expected, canine and cow NPC1L1 are more divergent compared to both primate and rodent families.\n\n\nBinding characteristics of ezetimibe (compound 3) and its glucuronidated metabolite (compound 4) to the NPC1L1 orthologs of several species were examined herein. Stable HEK-293 cell lines expressing human, rhesus monkey, canine, rat, mouse, hamster, rabbit, or mouse NPC1L1 cDNA were derived and used in subsequent experiments. The saturation binding curves of a fluorescently-labeled (BODIPY) ezetimibe glucuronide (compound 1) to each species NPC1L1 ortholog (except mouse) are shown in \nFIG. 3\n. The calculated Kd values were: monkey 46 nM; hamster 49 nM, canine 52 nM; rat 58 nM; human 61 nM, rabbit 151 nM. Fluorescently-labeled (BODIPY) ezetimibe glucuronide (compound 1) binding to mouse NPC1L1 could not be detected despite demonstrable expression of mouse NPC1L1 in HEK-293 cells by western blot analysis (data not shown).\n\n\nIn an effort to show binding to mouse NPC1L1, several related ezetimibe analogs were examined as possible alternatives to fluorescently-labeled (BODIPY) ezetimibe glucuronide (compound 1) in the binding assay. Compound 2, which is a fluorescently labeled synthetic precursor for fluorescently-labeled (BODIPY) ezetimibe glucuronide (compound 1; Burnett et al., Bioorganic and Medicinal Chemistry Letters 12:315-318 (2002)), was identified as a viable option for detection of mouse NPC1L1 binding. Compound 2 contains a methyl ester substitution for the carboxylic acid on the glucuronide portion of the molecule (compound structures shown in \nFIG. 4A\n). Saturation binding analysis with compound 2 (\nFIG. 4B\n) demonstrated binding to mouse NPC1L1 with a Kd of 118 nM.\n\n\nBinding affinities at each species NPC1L1 ortholog were determined for both ezetimibe (compound 3) and compound 4 (\nFIGS. 3 and 4C\n). The calculated Ki values are listed in Table 2 (columns 1 and 2) and are compared with in vivo ED50 values derived for each species tested (column 3). Divergence in the affinities of ezetimibe (compound 3) and \ncompound\n 4 for NPC1L1 is consistently observed across species. For all species tested, the affinity of \ncompound\n 4 for NPC1L1 is greater than that of ezetimibe (compound 3) (compare column 1 versus column 2). Against monkey NPC1L1, the difference in affinity of these two compounds is most obvious at nearly 10-fold, whereas the difference in affinity is less than 3-fold against rabbit or mouse NPC1L1. Rank order species affinity for ezetimibe (compound 3) is (monkey, dog, rat)>hamster>(human and rabbit)>>mouse. The rank order species affinity for \ncompound\n 4 is slightly modified with monkey>dog>(rat and hamster)>(human and rabbit)>>mouse. By comparison, the rank order of in vivo potency of ezetimibe among species is monkey>dog>(rat and hamster)>>mouse. It should be noted that following oral administration, 90% of ezetimibe is glucuronidated thereby converting ezetimibe (compound 3) to \ncompound\n 4. Therefore, the predominant form of ezetimibe present at the site of action in vivo (NPC1L1 in the jejunum) is the \nglucuronide compound\n 4. \nFIG. 5\n shows the correlation between \ncompound\n 4 or ezetimibe (compound 3) affinity and in vivo potency across multiple species. The results indicate that stronger binding to NPC1L1 by the compound produces more profound cholesterol lowering activity in vivo.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 2\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nBinding affinities of NPC1L1 orthologues\n\n\n\n\n\n\nfor ezetimibe or \ncompound\n 4.\n\n\n\n\n\n\n\n\n\n\n \n\n\nezetimibe\n\n\ncpd. 4\n\n\nezetimibe\n\n\n\n\n\n\n \n\n\nKi (nM)\n\n\nKi (nM)\n\n\nED50 (ug/kg)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nHuman\n\n\n2240\n\n\n660\n\n\nND\n\n\n\n\n\n\n \n\n\nMonkey\n\n\n900\n\n\n92\n\n\n0.5\n\n\n\n\n\n\n \n\n\nHamster\n\n\n1530\n\n\n370\n\n\n40\n\n\n\n\n\n\n \n\n\nCanine\n\n\n770\n\n\n192\n\n\n7\n\n\n\n\n\n\n \n\n\nRat\n\n\n970\n\n\n352\n\n\n30\n\n\n\n\n\n\n \n\n\nRabbit\n\n\n2125\n\n\n830\n\n\nND\n\n\n\n\n\n\n \n\n\nMouse\n\n\n5400\n\n\n9000\n\n\n700\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExpanding the study to several other ezetimibe analogs confirms the observation that NPC1L1 binding correlates with in vivo cholesterol lowering activity. Ezetimibe analogs exhibiting in vivo cholesterol lowering activity (\ncompound\n 5, \ncompound\n 6 and compound 7) as well as analogs displaying no in vivo cholesterol lowering activity (\ncompound\n 8 and compound 9) were evaluated for binding to NPC1L1 orthologs of multiple species. The compound structures and the Ki values at each species NPC1L1 are listed in Table 3. The in vivo data measuring inhibition of cholesterol absorption in rat (ED\n50\n) and percent cholesterol lowering in plasma and liver in hamster are also provided for comparison in Table 3. The three active compounds exhibit variable affinity when evaluated against each species of NPC1L1 with the rank order of affinity among species similar to that of ezetimibe (compound 3) and \ncompound\n 4. Higher affinity is observed at monkey, dog, and rat NPC1L1 and lower affinity at human and rabbit NPC1L1 with affinity for hamster NPC1L1 somewhat intermediate. In comparison, the affinities of the compounds are markedly lower at mouse NPC1L1. Compounds that lack in vivo efficacy exhibit no detectable binding to NPC1L1 orthologs from any of the species tested. These data demonstrate that compound binding to NPC1L1 translates into in vivo activity. Prediction of the extent of in vivo potency is confounded by metabolic parameters following oral administration. Glucuronidation of ezetimibe (compound 3) produces a metabolite (compound 4) with higher affinity for NPC1L1. Similar metabolism may affect related compounds. The ability to generate metabolites with high affinity for NPC1L1 will affect overall in vivo responsiveness. A determinant of in vivo efficacy is the ability of the predominant compound metabolite to bind to NPC1L1. Minor changes in compound structure or NPC1L1 amino acid sequence can affect binding affinity and consequently in vivo efficacy.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 3\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nInhibition of NPC1L1 orthologues with ezetimibe and related compounds.\n\n\n\n\n\n\n\n\n\n\nCompound\n\n\nHuman\n\n\nMonkey\n\n\nMouse\n\n\nHamster\n\n\nRat\n\n\nDog\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n2.24\n\n\n0.9\n\n\n9\n\n\n1.53\n\n\n0.97\n\n\n0.77\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n0.66\n\n\n0.092\n\n\n5.4\n\n\n0.371\n\n\n0.352\n\n\n0.19\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n2.15\n\n\n0.37\n\n\n7.7\n\n\n1.2\n\n\n0.542\n\n\n1.28\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n4.59\n\n\n1.6\n\n\n16.4\n\n\n2.34\n\n\n1.46\n\n\n1.43\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n3.23\n\n\n3.23\n\n\n21.6\n\n\n4.28\n\n\n2.1\n\n\n2.3\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nrat\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCompound\n\n\nRabbit\n\n\nED50\n\n\nLiver\n\n\nPlasma\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n2.1\n\n\n1.6\n\n\n96\n\n\n26\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n0.83\n\n\n1.9\n\n\n92\n\n\n48\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n1.9\n\n\nND\n\n\n86\n\n\n36\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n5\n\n\nND\n\n\n63\n\n\n22\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n5.6\n\n\n36\n\n\n96\n\n\n47\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nInactive\n\n\nInactive\n\n\nND\n\n\nND\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\nInactive\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\nND = experiment not done\n\n\n\n\n\n\n\n\n\n\n\n\nAn example of the effects of small modifications on the binding affinity of related compounds for NPC1L1 is provided by comparison of the binding characteristics of compound 2 and compound 1 (fluorescently labeled (BODIPY) ezetimibe). The Kd of [\n3\nH]-labeled \ncompound\n 4 was determined for both human and monkey NPC1L1 in saturation binding assays (\nFIGS. 6A & 6B\n). A Kd of 206 nM for human and 102 nM for monkey are consistent with previously reported values of 220 nM and 41 nM respectively (Garcia-Calvo et al., Proc. Natl. Acad. Sci. U.S.A. 102:8132-8137 (2005)). Competition binding studies using [\n3\nH]-labeled \ncompound\n 4 were performed to derive Ki values for compound 1 (fluorescently labeled (BODIPY) ezetimibe) and compound 2 at both human NPC1L1 (\nFIG. 6C\n) and monkey NPC1L1 (\nFIG. 6D\n). The Ki of compound 1 (fluorescently labeled (BODIPY) ezetimibe) at human NPC1L1 is calculated to be 2.5 μM and 210 nM at monkey NPC1L1. By comparison, the Ki of compound 2 is calculated to be 120 nM and 70 nM at human and monkey NPC1L1 respectively. The results demonstrate that the small modification of substituting the methyl ester for the carboxylic acid on the glucuronide dramatically increases the affinity for human NPC1L1 (over 20-fold). In comparison, the compound modification increased affinity for monkey NPC1L1 by 3-fold. This illustrates that small variations in ezetimibe related compounds can result in markedly diverse binding interactions. Likewise, diversity in NPC1L1 may also affect the binding interaction. Although human and monkey NPC1L1 share 95% homology, the binding affinity of specific compounds varies markedly between the two species orthologs. Given the data demonstrating the correlation between NPC1L1 binding affinity and in vivo efficacy, the diversity in NPC1L1 among species may be a determinant regulating in vivo responsiveness.\n\n\nDiscussion\n\n\nRecently, NPC1L1, an intestinally expressed protein critical to the absorption of sterols was identified as the molecular target of ezetimibe (Altmann et al., Science 303:1201-1204 (2004); Davis et al., J. Biol. Chem., 279:33586-33592 (2004), Garcia-Calvo et al., Proc. Natl. Acad. Sci. U.S.A. 102:8132-8137 (2005)). Discovery of the drug target enabled in vitro analysis of drug binding and experimental opportunities to explore the inter-species variability in ezetimibe potency and efficacy. Herein, we describe the cloning and expression of NPC1L1 in multiple species for studies comparing target interaction of ezetimibe (compound 3) and the active in vivo glucuronidated metabolite, \ncompound\n 4. A novel fluorescent compound binding assay is utilized to assess the binding properties of several ezetimibe related compounds at the NPC1L1 orthologs of multiple species enabling structure activity relationships to be developed and the interaction of ezetimibe and NPC1L1 to be better understood.\n\n\nIntraduodenal delivery of ezetimibe (compound 3) leads to significant levels of the compound detected in portal plasma of which >95% is the \nglucuronide compound\n 4 following first pass metabolism in the intestine. Traveling from portal plasma to the liver and back to the intestine via bile, \ncompound\n 4 is redelivered to the site of action where it accumulates in the intestinal lumen (van Heek et al., Br. J. Pharmacol. 129:1748-1754 (2000)). Although both ezetimibe (compound 3) and \ncompound\n 4 bind to NPC1L1, the binding affinity of \ncompound\n 4 is greater than that of ezetimibe (compound 3) in all species examined consistent with the stronger potency of \ncompound\n 4 observed in in vivo efficacy studies (van Heek et al., Br. J. Pharmacol. 129:1748-1754 (2000)). The compounds differ in affinity by as much as 10-fold in monkey and as little as 2-fold in mouse (Table 2), but the rank order of potency is similar for both compounds, (monkey, rat, dog, and hamster>human and rabbit>mouse) and correlates well with animal efficacy studies (Table 2). This indicates that compound potency is affected by the binding affinity of the compound for NPC1L1 of a particular species. However, the rate and efficiency of glucuronidation in each species also likely contribute to the diversity in species responsiveness to oral administration of ezetimibe given the binding differential between ezetimibe and \ncompound\n 4. Indeed, compound metabolism may be a factor in determination of ezetimibe potency in species that exhibit the highest degree of separation between ezetimibe (compound 3) and \ncompound\n 4 binding affinities and that are particularly responsive to ezetimibe therapy in vivo (e.g., monkey). Recently, the UDP-glucuronosyltransferase enzyme(s) responsible for glucuronidating ezetimibe (compound 3) in humans was identified (Ghosal et al., Drug. Metab. Dispos. 32: 314-320 (2004)), however little comparative information is available for this enzyme or related enzymes across multiple species.\n\n\nChanges in compound structure affect NPC1L1 binding ability (Table 3). Glucuronidation of ezetimibe (compound 3) following oral administration (forming compound 4) enhances NPC1L1 binding and improves in vivo potency. By contrast, addition of a protective aromatic group to the glucuronide moiety (compound 5) causes the Ki value to revert to that observed for the nonglucuronidated form. It has previously been reported that hydroxylation of the 3-phenylpropyl side chain improves in vivo potency of this class of compounds (Burnett et al., Curr. Medicinal Chem. 11:1873-1887 (2004); Clader et al., J. Med Chem. 39:3684-3693 (1996)). Consistent with that conclusion, compounds that lack the hydroxyl group at the 3-phenylpropyl side chain exhibit decreased (compound 7) or total loss (\ncompound\n 8, compound 9) of NPC1L1 binding activity.\n\n\nDiversity in compounds or NPC1L1 can affect NPC1L1 binding. In \nFIG. 6\n, binding of compound 1 and compound 2 to human and monkey NPC1L1 are compared. Compound 1 is BODIPY-labeled \ncompound\n 4 and differs from compound 2 only by a substitution of a methyl ester for the carboxylic acid on the glucuronide moiety (\nFIG. 4A\n) (Burnett et al., Curr. Medicinal Chem. 11:1873-1887 (2004)). Consistent with other ezetimibe analogs, both compound 1 and compound 2 exhibit stronger affinity for monkey NPC1L1 compared to human NPC1L1. The substitution of the methyl ester on the glucuronide in compound 2 confers much higher affinity to both human and monkey NPC1L1. The methyl ester conveys a 20-fold increase in binding to human NPC1L1 and a 3-fold increase at monkey NPC1L1.\n\n\nThe present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.\n\n\nPatents, patent applications, publications, product descriptions, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes."
  },
  {
    "id": "US7910102B2",
    "text": "Methods of using conjugated toxin peptide therapeutic agents AbstractDisclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. Claims (\n12\n)\n\n\n\n\n \n\n\n1. A method of mitigating a relapse of a symptom of multiple sclerosis, comprising administering to a patient, who has been diagnosed with multiple sclerosis, an effective amount of a composition of matter of the formula\n\n \n(X\n1\n)\na\n—(F\n1\n)\nd\n—(X\n2\n)\nb\n—(F\n2\n)\ne\n—(X\n3\n)\nc \n\n\n\n\n\n\nand multimers thereof, wherein:\n\nF\n1 \nand F\n2 \nare half-life extending moieties, wherein F\n1 \nor F\n2\n, or both is a polyethylene glycol, a copolymer of ethylene glycol, a polypropylene glycol, a copolymer of propylene glycol, a carboxymethylcellulose, a polyvinyl pyrrolidone, a poly-1,3-dioxolane, a poly-1,3,6-trioxane, an ethylene/maleic anhydride copolymer, a polyaminoacid, a dextran n-vinyl pyrrolidone, a poly n-vinyl pyrrolidone, a propylene glycol homopolymer, a propylene oxide polymer, an ethylene oxide polymer, a polyoxyethylated polyol, a polyvinyl alcohol, a linear or branched glycosylated chain, a polyacetal, a long chain fatty acid, a long chain hydrophobic aliphatic group, an immunonlobulin light chain and heavy chain an immunoglobulin F\nc \ndomain or portion thereof a CH2 domain of F\nc\n, an F\nc \ndomain loop, an albumin, an albumin-binding protein, a transthyretin, a thyroxine-binding globulin, or a ligand that has an affinity for a long half-life serum protein, said ligand being selected from the group consisting of peptide ligands and small molecule ligands; and d and e are each independently 0 or 1, provided that at least one of d and e is 1;\n\n\nX\n1\n, X\n2\n, and X\n3 \nare each independently -(L)\nf\n-P-(L)\ng\n-, and f and g are each independently 0 or 1;\n\n\nP is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds, and at least one P is an OSK1 peptide analog comprising the amino acid sequence of SEQ ID NO: 4916;\n\n\nL is a linker; and\n\n\na, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1, such that the symptom of multiple sclerosis is mitigated.\n\n\n\n\n\n\n \n \n\n\n2. A method of treating an autoimmune disorder, comprising administering to a patient who has been diagnosed with an autoimmune disorder selected from multiple sclerosis, type \n1\n diabetes, psoriasis, inflammatory bowel disease (IBD), contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus, a therapeutically effective amount of a composition of matter of the formula\n\n \n(X\n1\n)\na\n—(F\n1\n)\nd\n—(X\n2\n)\nb\n—(F\n2\n)\ne\n—(X\n3\n)\nc \n\n\n\n\n\n\nand multimers thereof, wherein:\n\nF\n1 \nand F\n2 \nare half-life extending moieties, wherein F\n1 \nor F\n2\n, or both is a polyethylene glycol, a copolymer of ethylene glycol, a polypropylene glycol, a copolymer of propylene glycol, a carboxymethylcellulose, a polyvinyl pyrrolidone, a poly-1,3-dioxolane, a poly-1,3,6-trioxane, an ethylene/maleic anhydride copolymer, a polyaminoacid, a dextran n-vinyl pyrrolidone, a poly n-vinyl pyrrolidone, a propylene glycol homopolymer, a propylene oxide polymer, an ethylene oxide polymer, a polyoxyethylated polyol, a polyvinyl alcohol, a linear or branched glycosylated chain, a polyacetal, a long chain fatty acid, a long chain hydrophobic aliphatic group, an immunoglobulin light chain and heavy chain an immunoglobulin F\nc \ndomain or portion thereof a CH2 domain of F\nc \nan F\nc \ndomain loop an albumin an albumin-binding protein, a transthyretin, a thyroxine-binding globulin, or a ligand that has an affinity for a long half-life serum protein, said ligand being selected from the group consisting of peptide ligands and small molecule ligands; and d and e are each independently 0 or 1, provided that at least one of d and e is 1;\n\n\nX\n1\n, X\n2\n, and X\n3 \nare each independently -(L)\nf\n-P-(L)\ng\n-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds, and at least one P is an OSK1 peptide analog comprising the amino acid sequence of SEQ ID NO: 4916;\n\n\nL is a linker; and\n\n\na, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1, whereby at least one symptom of the disorder is alleviated in the patient.\n\n\n\n\n\n\n \n \n\n\n3. The method of \nclaim 1\n or \nclaim 2\n, wherein F\n1 \nor F\n2\n, or both, of the composition of matter comprises a human IgG Fc domain or a portion thereof.\n\n\n\n\n \n \n\n\n4. The method of \nclaim 1\n or \nclaim 2\n, wherein F\n1 \nand F\n2 \nof the composition of matter are different half-life extending moieties.\n\n\n\n\n \n \n\n\n5. The method of \nclaim 1\n or \nclaim 2\n, wherein F\n1 \nor F\n2\n, or both, of the composition of matter comprises a sequence selected from SEQ ID NOS: 2, 4, 70, 71, 72, 74, 75, 76, 1340 through 1342, and 1359 through 1363 as set forth in \nFIGS. 3\n, \n4\n, \n11\nA-C, \n12\nA-C, and \n12\nE-F.\n\n\n\n\n \n \n\n\n6. The method of \nclaim 1\n or \nclaim 2\n, wherein F\n1 \nor F\n2\n, or both, the composition of matter comprises a biologically suitable polymer or copolymer.\n\n\n\n\n \n \n\n\n7. The method of \nclaim 1\n or \nclaim 2\n, in which the toxin peptide of the composition of matter is inserted into a human IgG1 Fc domain loop.\n\n\n\n\n \n \n\n\n8. The method of \nclaim 1\n or \nclaim 2\n, wherein the C-terminal carboxylic acid moiety of the OSK1 peptide analog of the composition of matter is replaced with a moiety selected from\n\n(A) —COOR, where R is independently (C\n1\n-C\n8\n)alkyl, haloalkyl, aryl or heteroaryl;\n\n\n(B) —C(═O)NRR, where R is independently hydrogen, (C\n1\n-C\n8\n)alkyl, haloalkyl, aryl or heteroaryl; and\n\n\n(C) —CH\n2\nOR where R is hydrogen, (C\n1\n-C\n8\n) alkyl, aryl or heteroaryl.\n\n\n\n\n\n\n \n \n\n\n9. The method of \nclaim 1\n or \nclaim 2\n, wherein the OSK1 peptide analog of the composition of matter is conjugated to an acyl, aryl, fatty acid, or polyethylene glycol (PEG) via:\n\n(a) 1, 2, 3 or 4 amino functionalized sites in the OSK1 peptide analog;\n\n\n(b) 1, 2, 3 or 4 thiol functionalized sites in the OSK1 peptide analog;\n\n\n(c) 1 or 2 ketone functionalized sites in the OSK1 peptide analog;\n\n\n(d) 1 or 2 azido functionalized sites in the OSK1 peptide analog;\n\n\n(e) 1 or 2 carboxyl functionalized sites in the OSK1 peptide analog;\n\n\n(f) 1 or 2 aminooxy functionalized sites in the OSK1 peptide analog; or\n\n\n(g) 1 or 2 seleno functionalized sites in the OSK1 peptide analog.\n\n\n\n\n\n\n \n \n\n\n10. The method of \nclaim 1\n or \nclaim 2\n, wherein the OSK1 peptide analog of the composition of matter is conjugated to a polyethylene glycol (PEG) via:\n\n(a) 1, 2, 3 or 4 amino functionalized sites of the PEG;\n\n\n(b) 1, 2, 3 or 4 thiol functionalized sites of the PEG;\n\n\n(c) 1, 2, 3 or 4 maleimido functionalized sites of the PEG;\n\n\n(d) 1, 2, 3 or 4 N-succinimidyl functionalized sites of the PEG;\n\n\n(e) 1, 2, 3 or 4 carboxyl functionalized sites of the PEG; or\n\n\n(f) 1, 2, 3 or 4 p-nitrophenyloxycarbonyl functionalized sites of the PEG.\n\n\n\n\n\n\n \n \n\n\n11. The method of \nclaim 1\n or \nclaim 2\n, wherein the OSK1 peptide analog of the composition of matter is covalently linked at its N-terminal to a moiety selected from acyl, aryl, fatty acid, or polyethylene glycol.\n\n\n\n\n \n \n\n\n12. The method of \nclaim 1\n or \nclaim 2\n, wherein the OSK1 peptide analog of the composition of matter is covalently linked at its N-terminal to a polyethylene glycol. Description\n\n\n\n\nThis application claims priority from U.S. Provisional Application No. 60/854,674, filed Oct. 25, 2006, and U.S. Application No. 60/995,370, filed Sep. 25, 2007, both of which are hereby incorporated by reference.\n\n\nThis application is related to U.S. Non-provisional Application Ser. No. 11/584,177, filed Oct. 19, 2006, which claims priority from U.S. Provisional Application No. 60/729,083, filed Oct. 21, 2005, both of which applications are hereby incorporated by reference.\n\n\nThe instant application contains an ASCII “txt” compliant sequence listing submitted via EFS-WEB on May 18, 2010, which serves as both the computer readable form (CRF) and the paper copy required by 37 C.F.R. Section 1.821(c) and 1.821(e), and is hereby incorporated by reference in its entirety. The name of the “txt” file created on Sep. 11, 2009, is: A-1186-US-NP4-RevSeqList091109-Submitted 102909.txt, and is 2,607 kB in size.\n\n\nThroughout this application various publications are referenced within parentheses or brackets. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.\n\n\nBACKGROUND OF THE INVENTION\n\n\n1. Field of the Invention\n\n\nThe present invention is related to the biochemical arts, in particular to therapeutic peptides and conjugates.\n\n\n2. Discussion of the Related Art\n\n\nIon channels are a diverse group of molecules that permit the exchange of small inorganic ions across membranes. All cells require ion channels for function, but this is especially so for excitable cells such as those present in the nervous system and the heart. The electrical signals orchestrated by ion channels control the thinking brain, the beating heart and the contracting muscle. Ion channels play a role in regulating cell volume, and they control a wide variety of signaling processes.\n\n\nThe ion channel family includes Na\n+\n, K\n+\n, and Ca\n2+\n cation and Cl\n−\n anion channels. Collectively, ion channels are distinguished as either ligand-gated or voltage-gated. Ligand-gated channels include both extracellular and intracellular ligand-gated channels. The extracellular ligand-gated channels include the nicotinic acetylcholine receptor (nAChR), the serotonin (5-hdroxytryptamine, 5-HT) receptors, the glycine and γ-butyric acid receptors (GABA) and the glutamate-activated channels including kanate, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-methyl-D-aspartate receptors (NMDA) receptors. (Harte and Ouzounis (2002), \nFEBS Lett. \n514: 129-34). Intracellular ligand gated channels include those activated by cyclic nucleotides (e.g. cAMP, cGMP), Ca\n2+\n and G-proteins. (Harte and Ouzounis (2002), \nFEBS Lett. \n514: 129-34). The voltage-gated ion channels are categorized by their selectivity for inorganic ion species, including sodium, potassium, calcium and chloride ion channels. (Harte and Ouzounis (2002), \nFEBS Lett. \n514: 129-34).\n\n\nA unified nomenclature for classification of voltage-gated channels was recently presented. (Catterall et al. (2000), \nPharmacol. Rev. \n55: 573-4; Gutman et al. (2000), \nPharmacol. Rev. \n55, 583-6; Catterall et al. (2000) \nPharmacol. Rev. \n55: 579-81; Catterall et al. (2000), \nPharmacol. Rev. \n55: 575-8; Hofmann et al. (2000), \nPharmacol. Rev. \n55: 587-9; Clapham et al. (2000), \nPharmacol Rev. \n55: 591-6; Chandy (1991), \nNature \n352: 26; Goldin et al. (2000), \nNeuron \n28: 365-8; Ertel et al. (2000), \nNeuron \n25: 533-5).\n\n\nThe K\n+\n channels constitute the largest and best characterized family of ion channels described to date. Potassium channels are subdivided into three general groups: the 6 transmembrane (6™) K\n+\n channels, the 2™-2™/leak K\n+\n channels and the 2™/K\n+\n inward rectifying channels. (Tang et al. (2004), \nAnn. Rev. Physiol. \n66, 131-159). These three groups are further subdivided into families based on sequence similarity. The voltage-gated K\n+\n channels, including (Kv1-6, Kv8-9), EAG, KQT, and Slo (BKCa), are family members of the 6™ group. The 2™-2™ group comprises TWIK, TREK, TASK, TRAAK, and THIK, whereas the 2™/Kir group consists of Kir1-7. Two additional classes of ion channels include the inward rectifier potassium (IRK) and ATP-gated purinergic (P2X) channels. (Harte and Ouzounis (2002), \nFEBS Lett. \n514: 129-34).\n\n\nToxin peptides produced by a variety of organisms have evolved to target ion channels. Snakes, scorpions, spiders, bees, snails and sea anemone are a few examples of organisms that produce venom that can serve as a rich source of small bioactive toxin peptides or “toxins” that potently and selectively target ion channels and receptors. In most cases, these toxin peptides have evolved as potent antagonists or inhibitors of ion channels, by binding to the channel pore and physically blocking the ion conduction pathway. In some other cases, as with some of the tarantula toxin peptides, the peptide is found to antagonize channel function by binding to a region outside the pore (e.g., the voltage sensor domain).\n\n\nThe toxin peptides are usually between about 20 and about 80 amino acids in length, contain 2-5 disulfide linkages and form a very compact structure (see, e.g., \nFIG. 10\n). Toxin peptides (e.g., from the venom of scorpions, sea anemones and cone snails) have been isolated and characterized for their impact on ion channels. Such peptides appear to have evolved from a relatively small number of structural frameworks that are particularly well suited to addressing the critical issues of potency and stability. The majority of scorpion and Conus toxin peptides, for example, contain 10-40 amino acids and up to five disulfide bonds, forming extremely compact and constrained structure (microproteins) often resistant to proteolysis. The conotoxin and scorpion toxin peptides can be divided into a number of superfamilies based on their disulfide connections and peptide folds. The solution structure of many of these has been determined by NMR spectroscopy, illustrating their compact structure and verifying conservation of their family fold. (E.g., Tudor et al., Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin, Eur. J. Biochem. 251(1-2):133-41 (1998); Pennington et al., Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin, Biochem. 38(44): 14549-58 (1999); Jaravine et al., Three-dimensional structure of toxin OSK1 from \nOrthochirus scrobiculosus \nscorpion venom, Biochem. 36(6):1223-32 (1997); del Rio-Portillo et al.; NMR solution structure of Cn12, a novel peptide from the Mexican scorpion \nCentruroides noxius \nwith a typical beta-toxin sequence but with alpha-like physiological activity, Eur. J. Biochem. 271(12): 2504-16 (2004); Prochnicka-Chalufour et al., Solution structure of discrepin, a new K\n+\n-channel blocking peptide from the alpha-KTx15 subfamily, Biochem. 45(6):1795-1804 (2006)).\n\n\nConserved disulfide structures can also reflect the individual pharmacological activity of the toxin family. (Nicke et al. (2004), \nEur. J. Biochem. \n271: 2305-19, Table 1; Adams (1999), \nDrug Develop. Res. \n46: 219-34). For example, α-conotoxins have well-defined four cysteine/two disulfide loop structures (Loughnan, 2004) and inhibit nicotinic acetylcholine receptors. In contrast, ω-conotoxins have six cysteine/three disulfide loop consensus structures (Nielsen, 2000) and block calcium channels. Structural subsets of toxins have evolved to inhibit either voltage-gated or calcium-activated potassium channels. \nFIG. 9\n shows that a limited number of conserved disulfide architectures shared by a variety of venomous animals from bee to snail and scorpion to snake target ion channels. \nFIG. 7A-7B\n shows alignment of alpha-scorpion toxin family and illustrates that a conserved structural framework is used to derive toxins targeting a vast array of potassium channels.\n\n\nDue to their potent and selective blockade of specific ion channels, toxin peptides have been used for many years as tools to investigate the pharmacology of ion channels. Other than excitable cells and tissues such as those present in heart, muscle and brain, ion channels are also important to non-excitable cells such as immune cells. Accordingly, the potential therapeutic utility of toxin peptides has been considered for treating various immune disorders, in particular by inhibition of potassium channels such as Kv1.3 and IKCa1 since these channels indirectly control calcium signaling pathway in lymphocytes. [e.g., Kem et al., ShK toxin compositions and methods of use, U.S. Pat. No. 6,077,680; Lebrun et al., Neuropeptides originating in scorpion, U.S. Pat. No. 6,689,749; Beeton et al., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4):1369-81 (2005); Mouhat et al., K\n+\n channel types targeted by synthetic OSK1, a toxin from \nOrthochirus scrobiculosus \nscorpion venom, Biochem. J. 385:95-104 (2005); Mouhat et al., Pharmacological profiling of \n \nOrthochirus scrobiculosus \n \n \ntoxin\n 1 analogs with a trimmed N-terminal domain, \nMolec. Pharmacol. \n69:354-62 (2006); Mouhat et al., OsK1 derivatives, WO 2006/002850 A2; B. S. Jensen et al. The Ca\n2+\n-activated K+ Channel of Intermediate Conductance: A Molecular Target for Novel Treatments?, Current Drug Targets 2:401-422 (2001); Rauer et al., Structure-guided Transformation of Charybdotoxin Yields an Analog That Selectively Targets Ca\n2+\n-activated over Voltage-gated K\n+\n Channels, J. Biol. Chem. 275: 1201-1208 (2000); Castle et al., Maurotoxin: A Potent Inhibitor of Intermediate Conductance Ca\n2+\n-Activated Potassium Channels, Molecular Pharmacol. 63: 409-418 (2003); Chandy et al., K\n+\n channels as targets for specific Immunomodulation, Trends in Pharmacol. Sciences 25: 280-289 (2004); Lewis & Garcia, Therapeutic Potential of Venom Peptides, Nat. Rev. Drug Discov. 2: 790-802 (2003)].\n\n\nSmall molecules inhibitors of Kv1.3 and IKCa1 potassium channels and the major calcium entry channel in T cells, CRAC, have also been developed to treat immune disorders [A. Schmitz et al. (2005) Molecul. Pharmacol. 68, 1254; K. G. Chandy et al. (2004) \n \nTIPS\n \n 25, 280; H. Wulff et al. (2001) J. Biol. Chem. 276, 32040; C. Zitt et al. (2004) J. Biol. Chem. 279, 12427], but obtaining small molecules with selectivity toward some of these targets has been difficult.\n\n\nCalcium mobilization in lymphocytes is known to be a critical pathway in activation of inflammatory responses [M. W. Winslow et al. (2003) Current Opinion Immunol. 15, 299]. Compared to other cells, T cells show a unique sensitivity to increased levels of intracellular calcium and ion channels both directly and indirectly control this process. Inositol triphosphate (IP3) is the natural second messenger which activates the calcium signaling pathway. IP3 is produced following ligand-induced activation of the T cell receptor (TCR) and upon binding to its intracellular receptor (a channel) causes unloading of intracellular calcium stores. The endoplasmic reticulum provides one key calcium store. Thapsigargin, an inhibitor of the sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA), also causes unloading of intracellular stores and activation of the calcium signaling pathway in lymphocytes. Therefore, thapsigargin can be used as a specific stimulus of the calcium signaling pathway in T cells. The unloading of intracellular calcium stores in T cells is known to cause activation of a calcium channel on the cell surface which allows for influx of calcium from outside the cell. This store operated calcium channel (SOCC) on T cells is referred to as “CRAC” (calcium release activated channel) and sustained influx of calcium through this channel is known to be critical for full T cell activation [S. Feske et al. (2005) J. Exp. Med. 202, 651 and N. Venkatesh et al. (2004) \nPNAS\n 101, 8969]. For many years it has been appreciated that in order to maintain continued calcium influx into T cells, the cell membrane must remain in a hyperpolarized condition through efflux of potassium ions. In T cells, potassium efflux is accomplished by the voltage-gated potassium channel Kv1.3 and the calcium-activated potassium channel IKCa1 [K. G. Chandy et al. (2004) \nTIPS\n 25, 280]. These potassium channels therefore indirectly control the calcium signaling pathway, by allowing for the necessary potassium efflux that allows for a sustained influx of calcium through CRAC.\n\n\nSustained increases in intracellular calcium activate a variety of pathways in T cells, including those leading to activation of NFAT, NF-kB and AP-1 [Quintana-A (2005) Pflugers Arch.—Eur. J. Physiol. 450, 1]. These events lead to various T cell responses including alteration of cell size and membrane organization, activation of cell surface effector molecules, cytokine production and proliferation. Several calcium sensing molecules transmit the calcium signal and orchestrate the cellular response. Calmodulin is one molecule that binds calcium, but many others have been identified (M. J. Berridge et al. (2003) Nat. Rev. Mol. Cell. Biol. 4, 517). The calcium-calmodulin dependent phosphatase calcineurin is activated upon sustained increases in intracellular calcium and dephosphorylates cytosolic NFAT. Dephosphorylated NFAT quickly translocates to the nucleus and is widely accepted as a critical transcription factor for T cell activation (F. Macian (2005) Nat. Rev. Immunol. 5, 472 and N. Venkatesh et al. (2004) \nPNAS\n 101, 8969). Inhibitors of calcineurin, such as cyclosporin A (Neoral, Sand immune) and FK506 (Tacrolimus) are a main stay for treatment of severe immune disorders such as those resulting in rejection following solid organ transplant (I. M. Gonzalez-Pinto et al. (2005) Transplant. Proc. 37, 1713 and D. R. J. Kuypers (2005) \nTransplant International\n 18, 140). Neoral has been approved for the treatment of transplant rejection, severe rheumatoid arthritis (D. E. Yocum et al. (2000) Rheumatol. 39, 156) and severe psoriasis (J. Koo (1998) British J. Dermatol. 139, 88). Preclinical and clinical data has also been provided suggesting calcineurin inhibitors may have utility in treatment of inflammatory bowel disease (IBD; Baumgart D C (2006) Am. J. Gastroenterol. March 30; Epub ahead of print), multiple sclerosis (Ann. Neurol. (1990) 27, 591) and asthma (S. Rohatagi et al. (2000) J. Clin. Pharmacol. 40, 1211). Lupus represents another disorder that may benefit from agents blocking activation of helper T cells. Despite the importance of calcineurin in regulating NFAT in T cells, calcineurin is also expressed in other tissues (e.g. kidney) and cyclosporine A & FK506 have a narrow safety margin due to mechanism based toxicity. Renal toxicity and hypertension are common side effects that have limited the promise of cyclosporine & FK506. Due to concerns regarding toxicity, calcineurin inhibitors are used mostly to treat only severe immune disease (Bissonnette-R et al. (2006) J. Am. Acad. Dermatol. 54, 472). Kv1.3 inhibitors offer a safer alternative to calcineurin inhibitors for the treatment of immune disorders. This is because Kv1.3 also operates to control the calcium signaling pathway in T cells, but does so through a distinct mechanism to that of calcineurin inhibitors, and evidence on Kv1.3 expression and function show that Kv1.3 has a more restricted role in T cell biology relative to calcineurin, which functions also in a variety of non-lymphoid cells and tissues.\n\n\nCalcium mobilization in immune cells also activates production of the cytokines interleukin 2 (IL-2) and interferon gamma (IFNg) which are critical mediators of inflammation. IL-2 induces a variety of biological responses ranging from expansion and differentiation of CD4\n+\n and CD8\n+\n T cells, to enhancement of proliferation and antibody secretion by B cells, to activation of NK cells [S. L. Gaffen & K. D. Liu (2004) \nCytokine\n 28, 109]. Secretion of IL-2 occurs quickly following T cell activation and T cells represent the predominant source of this cytokine. Shortly following activation, the high affinity IL-2 receptor (IL2-R) is upregulated on T cells endowing them with an ability to proliferate in response to IL-2. T cells, NK cells, B cells and professional antigen presenting cells (APCs) can all secrete IFNg upon activation. T cells represent the principle source of IFNg production in mediating adaptive immune responses, whereas natural killer (NK) cells & APCs are likely an important source during host defense against infection [K. Schroder et al. (2004) J. Leukoc. Biol. 75, 163]. IFNg, originally called macrophage-activating factor, upregulates antigen processing and presentation by monocytes, macrophages and dendritic cells. IFNg mediates a diverse array of biological activities in many cell types [U. Boehm et al. (1997) Annu. Rev. Immunol. 15, 749] including growth & differentiation, enhancement of NK cell activity and regulation of B cell immunoglobulin production and class switching.\n\n\nCD40L is another cytokine expressed on activated T cells following calcium mobilization and upon binding to its receptor on B cells provides critical help allowing for B cell germinal center formation, B cell differentiation and antibody isotype switching. CD40L-mediated activation of CD40 on B cells can induce profound differentiation and clonal expansion of immunoglobulin (Ig) producing B cells [S. Quezada et al. (2004) Annu. Rev. Immunol. 22, 307]. The CD40 receptor can also be found on dendritic cells and CD40L signaling can mediate dendritic cell activation and differentiation as well. The antigen presenting capacity of B cells and dendritic cells is promoted by CD40L binding, further illustrating the broad role of this cytokine in adaptive immunity. Given the essential role of CD40 signaling to B cell biology, neutralizing antibodies to CD40L have been examined in preclinical and clinical studies for utility in treatment of systemic lupus erythematosis (SLE),—a disorder characterized by deposition of antibody complexes in tissues, inflammation and organ damage [J. Yazdany and J Davis (2004) Lupus 13, 377].\n\n\nProduction of toxin peptides is a complex process in venomous organisms, and is an even more complex process synthetically. Due to their conserved disulfide structures and need for efficient oxidative refolding, toxin peptides present challenges to synthesis. Although toxin peptides have been used for years as highly selective pharmacological inhibitors of ion channels, the high cost of synthesis and refolding of the toxin peptides and their short half-life in vivo have impeded the pursuit of these peptides as a therapeutic modality. Far more effort has been expended to identify small molecule inhibitors as therapeutic antagonists of ion channels, than has been given the toxin peptides themselves. One exception is the recent approval of the small ω-conotoxin MVIIA peptide (Ziconotide™) for treatment of intractable pain. The synthetic and refolding production process for Ziconotide™, however, is costly and only results in a small peptide product with a very short half-life in vivo (about 4 hours).\n\n\nA cost-effective process for producing therapeutics, such as but not limited to, inhibitors of ion channels, is a desideratum provided by the present invention, which involves toxin peptides fused, or otherwise covalently conjugated to a vehicle.\n\n\nSUMMARY OF THE INVENTION\n\n\nThe present invention relates to a composition of matter of the formula:\n\n\n(X\n1\n)\na\n—(F\n1\n)\nd\n—(X\n2\n)\nb\n—(F\n2\n)\ne\n—(X\n3\n)\nc\n  (I)\n\n\nand multimers thereof, wherein:\n\n\n\nF\n1 \nand F\n2 \nare half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1;\n\n\nX\n1\n, X\n2\n, and X\n3 \nare each independently -(L)\nf\n-P-(L)\ng\n-, and f and g are each independently 0 or 1;\n\n\nP is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds, and at least one P is an OSK1 peptide analog;\n\n\nL is an optional linker (present when f=1 and/or g=1); and\n\n\na, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1.\n\n\nThe present invention thus concerns molecules having variations on Formula I, such as the formulae:\n\n\nP-(L)\ng\n-F\n1 \n(i.e., b, c, and e equal to 0);  (II)\n\n\nF\n1\n-(L)\ng\n-P (i.e., a, c, and e equal to 0);  (III)\n\n\nP-(L)\ng\n-F\n1\n-(L)\nf\n-P or (X\n1\n)\na\n—F\n1\n—(X\n2\n)\nb \n(i.e., c and e equal to 0);  (IV)\n\n\nF\n1\n-(L)\nf\n-P-(L)\ng\n-F\n2 \n(i.e., a and c equal to 0);  (V)\n\n\nF\n1\n-(L)\nf\n-P-(L)\ng\n-F\n2\n-(L)\nf\n-P (i.e., a equal to 0);  (VI)\n\n\nF\n1\n—F\n2\n-(L)\nf\n-P (i.e., a and b equal to 0);  (VII)\n\n\nP-(L)\ng\n-F\n1\n—F\n2 \n(i.e., b and c equal to 0);  (VIII)\n\n\nP-(L)\ng\n-F\n1\n—F\n2\n-(L)\nf\n-P (i.e., b equal to 0);  (IX)\n\n\nand any multimers of any of these, when stated conventionally with the N-terminus of the peptide(s) on the left. All of such molecules of Formulae II-IX are within the meaning of Structural Formula I. Within the meaning of Formula I, the toxin peptide (P), if more than one is present, can be independently the same or different from the OSK1 peptide analog, or any other toxin peptide(s) also present in the inventive composition, and the linker moiety ((L)\nf \nand/or (L)\ng\n), if present, can be independently the same or different from any other linker, or linkers, that may be present in the inventive composition. Conjugation of the toxin peptide(s) to the half-life extending moiety, or moieties, can be via the N-terminal and/or C-terminal of the toxin peptide, or can be intercalary as to its primary amino acid sequence, F\n1 \nbeing linked closer to the toxin peptide's N-terminus than is linked F\n2\n. Examples of useful half-life extending moieties (F\n1 \nor F\n2\n) include immunoglobulin Fc domain (e.g., a human immunoglobulin Fc domain, including Fc of IgG1, IgG2, IgG3 or IgG4) or a portion thereof, human serum albumin (HSA), or poly(ethylene glycol) (PEG). These and other half-life extending moieties described herein are useful, either individually or in combination. A monovalent dimeric Fc-toxin peptide fusion (as represented schematically in \nFIG. 2B\n), for example, an Fc-OSK1 peptide analog fusion or Fc-ShK peptide analog fusion, is an example of the inventive composition of matter encompassed by Formula VII above.\n\n\n\nThe present invention also relates to a composition of matter, which includes, conjugated or unconjugated, a toxin peptide analog of ShK, OSK1, ChTx, or Maurotoxin modified from the native sequences at one or more amino acid residues, having greater Kv1.3 or IKCa1 antagonist activity, and/or target selectivity, compared to a ShK, OSK1, or Maurotoxin (MTX) peptides having a native sequence. The toxin peptide analogs comprise an amino acid sequence selected from any of the following:\n\n\nSEQ ID NOS: 88, 89, 92, 148 through 200, 548 through 561, 884 through 949, or 1295 through 1300 as set forth in Table 2; or\n\n\nSEQ ID NOS: 980 through 1274, 1303, or 1308 as set forth in Table 7; or any of SEQ ID NOS: 1391 through 4912, 4916, 4920 through 5006, 5009, 5010, and 5012 through 5015 as set forth in Table 7A, Table 7B, Table 7C, Table 7D, Table 7E, Table 7F, Table 7G, Table 7H, Table 7I or Table 7J.\n\n\nSEQ ID NOS: 330 through 337, 341, 1301, 1302, 1304 through 1307, 1309, 1311, 1312, and 1315 through 1336 as set forth in Table 13; or\n\n\nSEQ ID NOS: 36, 59, 344-346, or 1369 through 1390 as set forth in Table 14.\n\n\nThe present invention also relates to other toxin peptide analogs that comprise an amino acid sequence selected from, or comprise the amino acid primary sequence of, any of the following:\n\n\nSEQ ID NOS: 201 through 225 as set forth in Table 3; or\n\n\nSEQ ID NOS: 242 through 248 or 250 through 260 as set forth in Table 4; or\n\n\nSEQ ID NOS: 261 through 275 as set forth in Table 5; or\n\n\nSEQ ID NOS: 276 through 293 as set forth in Table 6; or\n\n\nSEQ ID NOS: 299 through 315 as set forth in Table 8; or\n\n\nSEQ ID NOS: 316 through 318 as set forth in Table 9; or\n\n\nSEQ ID NO: 319 as set forth in Table 10; or\n\n\nSEQ ID NO: 327 or 328 as set forth in Table 11; or\n\n\nSEQ ID NOS: 330 through 337, 341, 1301, 1302, 1304 through 1307, 1309, 1311, 1312, or 1315 through 1336 as set forth in Table 13;\n\n\nSEQ ID NOS: 1369 through 1390 as set forth in Table 14; or\n\n\nSEQ ID NOS: 348 through 353 as set forth in Table 16; or\n\n\nSEQ ID NOS: 357 through 362, 364 through 368, 370, 372 through 385, or 387 through 398 as set forth in Table 19; or\n\n\nSEQ ID NOS: 399 through 408 as set forth in Table 20; or\n\n\nSEQ ID NOS: 410 through 421 as set forth in Table 22; or\n\n\nSEQ ID NOS: 422, 424, 426, or 428 as set forth in Table 23; or\n\n\nSEQ ID NOS: 430 through 437 as set forth in Table 24; or\n\n\nSEQ ID NOS: 438 through 445 as set forth in Table 25; or\n\n\nSEQ ID NOS: 447, 449, 451, 453, 455, or 457 as set forth in Table 26; or\n\n\nSEQ ID NOS: 470 through 482 or 484 through 493 as set forth in Table 28; or\n\n\nSEQ ID NOS: 495 through 506 as set forth in Table 29; or\n\n\nSEQ ID NOS: 507 through 518 as set forth in Table 30.\n\n\nThe present invention is also directed to a pharmaceutical composition that includes the inventive composition of matter and a pharmaceutically acceptable carrier.\n\n\nThe compositions of this invention can be prepared by conventional synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins well known in the art. Compositions of this invention that have non-peptide portions can be synthesized by conventional organic chemistry reactions, in addition to conventional peptide chemistry reactions when applicable. Thus the present invention also relates to DNAs encoding the inventive compositions and expression vectors and host cells for recombinant expression.\n\n\nThe primary use contemplated is as therapeutic and/or prophylactic agents. The inventive compositions incorporating the toxin peptide can have activity and/or ion channel target selectivity comparable to—or even greater than—the unconjugated peptide.\n\n\nAccordingly, the present invention includes a method of treating an autoimmune disorder, which involves administering to a patient who has been diagnosed with an autoimmune disorder, such as multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease (IBD, including Crohn's Disease and ulcerative colitis), contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, or lupus, a therapeutically effective amount of the inventive composition of matter (preferably comprising a Kv1.3 antagonist peptide or IKCa1 antagonist peptide), whereby at least one symptom of the disorder is alleviated in the patient. In addition, the present invention also relates to the use of one or more of the inventive compositions of matter in the manufacture of a medicament for the treatment or prevention of an autoimmune disorder, such as, but not limited to, any of the above-listed autoimmune disorders, e.g. multiple sclerosis, \ntype\n 1 diabetes or IBD.\n\n\nThe present invention is further directed to a method of preventing or mitigating a relapse of a symptom of multiple sclerosis, which method involves administering to a patient, who has previously experienced at least one symptom of multiple sclerosis, a prophylactically effective amount of the inventive composition of matter (preferably comprising a Kv1.3 antagonist peptide or IKCa1 antagonist peptide), such that the at least one symptom of multiple sclerosis is prevented from recurring or is mitigated.\n\n\nAlthough mostly contemplated as therapeutic agents, compositions of this invention can also be useful in screening for therapeutic or diagnostic agents. For example, one can use an Fc-peptide in an assay employing anti-Fc coated plates. The half-life extending moiety, such as Fc, can make insoluble peptides soluble and thus useful in a number of assays.\n\n\nNumerous additional aspects and advantages of the present invention will become apparent upon consideration of the figures and detailed description of the invention.\n\n\nU.S. Nonprovisional patent application Ser. No. 11/406,454, filed Apr. 17, 2006, is hereby incorporated by reference in its entirety.\n\n\n\n\nBRIEF DESCRIPTION OF THE FIGURES\n\n\n \nFIG. 1\n shows schematic structures of some exemplary Fc dimers that can be derived from an IgG1 antibody. “Fc” in the figure represents any of the Fc variants within the meaning of “Fc domain” herein. “X1” and “X2” represent peptides or linker-peptide combinations as defined hereinafter. The specific dimers are as follows:\n\n\n \nFIG. 1A\n and \nFIG. 1D\n: Single disulfide-bonded dimers;\n\n\n \nFIG. 1B\n and \nFIG. 1E\n: Doubly disulfide-bonded dimers;\n\n\n \nFIG. 1C\n and \nFIG. 1F\n: Noncovalent dimers.\n\n\n \nFIG. 2A-C\n show schematic structures of some embodiments of the composition of the invention that shows a single unit of the pharmacologically active toxin peptide. \nFIG. 2A\n shows a single chain molecule and can also represent the DNA construct for the molecule. \nFIG. 2B\n shows a dimer in which the linker-peptide portion is present on only one chain of the dimer (i.e., a “monovalent” dimer). \nFIG. 2C\n shows a dimer having the peptide portion on both chains. The dimer of \nFIG. 2C\n will form spontaneously in certain host cells upon expression of a DNA construct encoding the single chain shown in \nFIG. 2A\n. In other host cells, the cells could be placed in conditions favoring formation of dimers or the dimers can be formed in vitro.\n\n\n \nFIG. 3A-3B\n shows exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of human IgG1 Fc that is optimized for mammalian expression and can be used in this invention.\n\n\n \nFIG. 4A-4B\n shows exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 3 and 4, respectively) of human IgG1 Fc that is optimized for bacterial expression and can be used in this invention.\n\n\n \nFIG. 5A\n shows the amino acid sequence of the mature ShK peptide (SEQ ID NO: 5), which can be encoded for by a nucleic acid sequence containing codons optimized for expression in mammalian cell, bacteria or yeast.\n\n\n \nFIG. 5B\n shows the three disulfide bonds (—S—S—) formed by the six cysteines within the ShK peptide (SEQ ID NO: 10).\n\n\n \nFIG. 6\n shows an alignment of the voltage-gated potassium channel inhibitor \nStichodactyla helianthus \n(ShK) with other closely related members of the sea anemone toxin family. The sequence of the 35 amino acid mature ShK toxin (Accession #P29187) isolated from the venom of \nStichodactyla helianthus \nis shown aligned to other closely related members of the sea anemone family. The consensus sequence and predicted disulfide linkages are shown, with highly conserved residues being shaded. The HmK peptide toxin sequence shown (Swiss-Protein Accession #097436) is of the immature precursor from the Magnificent sea anemone (\nRadianthus magnifica; Heteractis maqnifica\n) and the putative signal peptide is underlined. The mature HmK peptide toxin would be predicted to be 35 amino acids in length and \nspan residues\n 40 through 74. AeK is the mature peptide toxin, isolated from the venom of the sea anemone \nActinia equine \n(Accession #P81897). The sequence of the mature peptide toxin AsKS (Accession #Q9TWG1) and BgK (Accession #P29186) isolated from the venom of the sea anemone \nAnemonia sulcata \nand \nBunodosoma granulifera\n, respectively, are also shown. \nFIG. 6A\n shows the amino acid alignment (SEQ ID NO: 10) of ShK to other members of the sea anemone family of toxins, HmK (SEQ ID NO: 6 (Mature Peptide), (SEQ ID NO: 542, Signal and Mature Peptide portions)), AeK (SEQ ID NO: 7), AsKs (SEQ ID NO: 8), and BgK (SEQ ID NO: 9). The predicted disulfide linkages are shown and conserved residues are highlighted. (HmK, SEQ ID NO: 543; ShK, SEQ ID NO: 10; AeK, SEQ ID NO: 544; AsKS, SEQ ID NO: 545). \nFIG. 6B\n shows a disulfide linkage map for this family having 3 disulfide linkages (C1-C6, C2-C4, C3-C5).\n\n\n \nFIG. 7A-7B\n shows an amino acid alignment of the alpha-scorpion toxin family of potassium channel inhibitors. (BmKK1, SEQ ID NO: 11; BmKK4, SEQ ID NO: 12; PBTx1, SEQ ID NO: 14; Tc32, SEQ ID NO: 13; BmKK6, SEQ ID NO: 15; P01, SEQ ID NO: 16; Pi2, SEQ ID NO: 17; Pi3, SEQ ID NO: 18; Pi4, SEQ ID NO: 19; MTX, SEQ ID NO: 20; Pi1, SEQ ID NO: 21; HsTx1, SEQ ID NO: 61; AgTx2, SEQ ID NO: 23; KTX1, SEQ ID NO: 24; OSK1, SEQ ID NO: 25; BmKTX, SEQ ID NO: 22; HgTX1, SEQ ID NO: 27; MgTx, SEQ ID NO: 28; C11Tx1, SEQ ID NO: 29; NTX, SEQ ID NO: 30; Tc30, SEQ ID NO: 31; TsTX-Ka, SEQ ID NO: 32; PBTx3, SEQ ID NO: 33; Lqh 15-1, SEQ ID NO: 34; MartenTx, SEQ ID NO: 37; ChTx, SEQ ID NO:36; ChTx-Lq2, SEQ ID NO: 42; IbTx, SEQ ID NO: 38; SloTx, SEQ ID NO: 39; BmTx1; SEQ ID NO: 43; BuTx, SEQ ID NO: 41; AmmTx3, SEQ ID NO: 44; AaTX1, SEQ ID NO: 45; BmTX3, SEQ ID NO: 46; Tc1, SEQ ID NO: 48; OSK2, SEQ ID NO: 49; TsK, SEQ ID NO: 54; CoTx1, SEQ ID NO:55; CoTx2, SEQ ID NO: 871; BmPo5, SEQ ID NO: 60; ScyTx, SEQ ID NO: 51; P05, SEQ ID NO: 52; Tamapin, SEQ ID NO: 53; and TmTx, SEQ ID NO: 691. Highly conserved residues are shaded and a consensus sequence is listed. Subfamilies of the α-KTx are listed and are from Rodriguez de la Vega, R. C. et al. (2003) \nTIPS \n24: 222-227. A list of some ion channels reported to antagonized is listed (IK=IKCa, BK=BKCa, SK=SKCa, Kv=voltage-gated K+ channels). Although most family members in this alignment represent the mature peptide product, several represent immature or modified forms of the peptide and these include: BmKK1, BmKK4, BmKK6, BmKTX, MartenTx, ChTx, ChTx-Lq2, BmTx1, AaTx1, BmTX3, TsK, CoTx1, BmP05.\n\n\n \nFIG. 8\n shows an alignment of toxin peptides converted to peptibodies in this invention (Apamin, SEQ ID NO: 68; HaTx1, SEQ ID NO: 494; ProTx1, SEQ ID NO: 56; PaTx2, SEQ ID NO: 57; ShK[2-35], SEQ ID NO: 92; ShK[1-35], SEQ ID NO: 5; HmK, SEQ ID NO: 6; ChTx (K32E), SEQ ID NO: 59; ChTx, SEQ ID NO: 36; IbTx, SEQ ID NO: 38; OSK1 (E16K, K20D), SEQ ID NO: 296; OSK1, SEQ ID NO: 25; AgTx2, SEQ ID NO: 23; KTX1, SEQ ID NO: 24; MgTx, SEQ ID NO: 28; NTX, SEQ ID NO: 30; MTX, SEQ ID NO: 20; Pi2, SEQ ID NO: 17; HsTx1, SEQ ID NO: 61; Anuroctoxin [AnTx], SEQ ID NO: 62; BeKm1, SEQ ID NO: 63; ScyTx, SEQ ID NO: 51; ωGVIA, SEQ ID NO: 64; ωMVIIa, SEQ ID NO: 65; Ptu1, SEQ ID NO: 66; and CTX, SEQ ID NO: 67). The original sources of the toxins is indicated, as well as, the number of cysteines in each. Key ion channels targeted are listed. The alignment shows clustering of toxin peptides based on their source and ion channel target impact.\n\n\n \nFIG. 9\n shows disulfide arrangements within the toxin family. The number of disulfides and the disulfide bonding order for each subfamily is indicated. A partial list of toxins that fall within each disulfide linkage category is presented.\n\n\n \nFIG. 10\n illustrates that solution structures of toxins reveal a compact structure. Solution structures of native toxins from sea anemone (ShK), scorpion (MgTx, MTX, HsTx1), marine cone snail (wGVIA) and tarantula (HaTx1) indicate the 28 to 39 amino acid peptides all form a compact structure. The toxins shown have 3 or 4 disulfide linkages and fall within 4 of the 6 subfamilies shown in \nFIG. 9\n. The solution structures of native toxins from sea anemone (ShK), scorpion (MgTx, MTX, HsTx1), marine cone snail (wGVIA) and tarantula (HaTx1) were derived from Protein Data Bank (PDB) accession numbers 1ROO (mmdbld:5247), 1MTX (mmdbld:4064), 1TXM (mmdbld:6201), 1QUZ (mmdbld:36904), 1OMZ (mmdbld:1816) and 1D1H (mmdbld:14344) using the MMDB Entrez 3D-structure database [J. Chen et al. (2003) Nucleic Acids Res. 31, 474] and viewer.\n\n\n \nFIG. 11A-C\n shows the nucleic acid (SEQ ID NO: 69 and SEQ ID NO: 1358) and encoded amino acid (SEQ ID NO:70, SEQ ID NO:1359 and SEQ ID NO: 1360) sequences of residues 5131-6660 of pAMG21ampR-Fc-pep. The sequences of the Fc domain (SEQ ID NOS: 71 and 72) exclude the five C-terminal glycine residues. This vector enables production of peptibodies in which the peptide-linker portion is at the C-terminus of the Fc domain.\n\n\n \nFIG. 11D\n shows a circle diagram of a peptibody bacterial expression vector pAMG21ampR-Fc-pep having a chloramphenicol acetyltransferase gene (cat; “CmR” site) that is replaced with the peptide-linker sequence.\n\n\n \nFIG. 12A-C\n shows the nucleic acid (SEQ ID NO: 73 and SEQ ID NO: 1361) and encoded amino acid (SEQ ID NO:74, SEQ ID NO: 1362 and SEQ ID NO: 1363) sequences of residues 5131-6319 of pAMG21ampR-Pep-Fc. The sequences of the Fc domain (SEQ ID NOS: 75 and 76) exclude the five N-terminal glycine residues. This vector enables production of peptibodies in which the peptide-linker portion is at the N-terminus of the Fc domain.\n\n\n \nFIG. 12D\n shows a circle diagram of a peptibody bacterial expression vector having a zeocin resistance (ble; “ZeoR”) site that is replaced with the peptide-linker sequence.\n\n\n \nFIG. 12E-G\n shows the nucleic acid (SEQ ID NO:1339) and encoded amino acid sequences of pAMG21ampR-Pep-Fc (SEQ ID NO:1340, SEQ ID NO:1341, and SEQ ID NO:1342). The sequences of the Fc domain (SEQ ID NOS: 75 and 76) exclude the five N-terminal glycine residues. This vector enables production of peptibodies in which the peptide-linker portion is at the N-terminus of the Fc domain.\n\n\n \nFIG. 13A\n is a circle diagram of mammalian expression vector pCDNA3.1(+) CMVi.\n\n\n \nFIG. 13B\n is a circle diagram of mammalian expression vector pCDNA3.1 (+) CMVi-Fc-2×G4S-Activin RIIb that contains a Fc region from human IgG1, a 10 amino acid linker and the activin RIIb gene.\n\n\n \nFIG. 13C\n is a circle diagram of the CHO expression vector pDSRa22 containing the Fc-L10-ShK[2-35] coding sequence.\n\n\n \nFIG. 14A-14B\n shows the nucleotide and encoded amino acid sequences (SEQ. ID. NOS: 77 and 78, respectively) of the molecule identified as “Fc-L10-ShK[1-35]” in Example 1 hereinafter. The L10 linker amino acid sequence (SEQ ID NO: 79) is underlined.\n\n\n \nFIG. 15A-15B\n shows the nucleotide and encoded amino acid sequences (SEQ. ID. NOS: 80 and 81, respectively) of the molecule identified as “Fc-L10-ShK[2-35]” in Example 2 hereinafter. The same L10 linker amino acid sequence (SEQ ID NO: 79) as used in Fc-L10-ShK[1-35] (\nFIG. 14A-14B\n) is underlined.\n\n\n \nFIG. 16A-16B\n shows the nucleotide and encoded amino acid sequences (SEQ. ID. NOS: 82 and 83, respectively) of the molecule identified as “Fc-L25-ShK[2-35]” in Example 2 hereinafter. The L25 linker amino acid sequence (SEQ ID NO: 84) is underlined.\n\n\n \nFIG. 17\n shows a scheme for N-terminal PEGylation of ShK peptide (SEQ ID NO: 5 and SEQ ID NO:10) by reductive amination, which is also described in Example 32 hereinafter.\n\n\n \nFIG. 18\n shows a scheme for N-terminal PEGylation of ShK peptide (SEQ ID NO: 5 and SEQ ID NO:10) via amide formation, which is also described in Example 34 hereinafter.\n\n\n \nFIG. 19\n shows a scheme for N-terminal PEGylation of ShK peptide (SEQ ID NO: 5 and SEQ ID NO:10) by chemoselective oxime formation, which is also described in Example 33 hereinafter.\n\n\n \nFIG. 20A\n shows a reversed-phase HPLC analysis at 214 nm and \nFIG. 20B\n shows electrospray mass analysis of folded ShK[2-35], also described as folded-“Des-Arg1-ShK” (Peptide 2).\n\n\n \nFIG. 21\n shows reversed phase HPLC analysis at 214 nm of N-terminally PEGylated ShK[2-35], also referred to as N-Terminally PEGylated-“Des-Arg1-ShK”.\n\n\n \nFIG. 22A\n shows a reversed-phase HPLC analysis at 214 nm of folded ShK[1-35], also referred to as “ShK”.\n\n\n \nFIG. 22B\n shows electrospray mass analysis of folded ShK[1-35], also referred to as “ShK”.\n\n\n \nFIG. 23\n illustrates a scheme for N-terminal PEGylation of ShK[2-35] (SEQ ID NO: 92 and SEQ ID NO: 58, also referred to as “Des-Arg1-ShK” or “ShK d1”) by reductive amination, which is also described in Example 31 hereinafter.\n\n\n \nFIG. 24A\n shows a western blot of conditioned medium from \nHEK\n 293 cells transiently transfected with Fc-L10-ShK[1-35]. Lane 1: molecular weight markers; Lane 2: 15 μl Fc-L10-ShK; Lane 3: 10 μl Fc-L10-ShK; Lane 4: 5 μl Fc-L10-ShK; \nLane\n 5; molecular weight markers; Lane 6: blank; Lane 7: 15 μl No DNA control; Lane 8: 10 μl No DNA control; Lane 9: 5 μl No DNA control; \nLane\n 10; molecular weight markers.\n\n\n \nFIG. 24B\n shows a western blot of with 15 μl of conditioned medium from clones of Chinese Hamster Ovary (CHO) cells stably transfected with Fc-L-ShK[1-35]. Lanes 1-15 were loaded as follows: blank, BB6, molecular weight markers, BB5, BB4, BB3, BB2, BB1, blank, BD6, BD5, molecular weight markers, BD4, BD3, BD2.\n\n\n \nFIG. 25A\n shows a western blot of a non-reducing SDS-PAGE gel containing conditioned medium from 293T cells transiently transfected with Fc-L-SmIIIA.\n\n\n \nFIG. 25B\n shows a western blot of a reducing SDS-PAGE gel containing conditioned medium from 293T cells transiently transfected with Fc-L-SmIIIA.\n\n\n \nFIG. 26A\n shows a Spectral scan of 10 μl purified bivalent dimeric Fc-L10-ShK[1-35] product from stably transfected CHO cells diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1-cm path length quartz cuvette.\n\n\n \nFIG. 26B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final bivalent dimeric Fc-L10-ShK[1-35] product. Lanes 1-12 were loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 26C\n shows size exclusion chromatography on 20 μg of the final bivalent dimeric Fc-L10-ShK[1-35] product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, and pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 26D\n shows a MALDI mass spectral analysis of the final sample of bivalent dimeric Fc-L10-ShK[1-35] analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 26E\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final monovalent dimeric Fc-L10-ShK[1-35] product. Lanes 1-12 were loaded as follows: Novex Mark12 wide range protein standards (10 μL), 0.5 μg product non-reduced (1.3 μL), blank, 2.0 μg product non-reduced (5 μL), blank, 10 μg product non-reduced (25 μL), Novex Mark12 wide range protein standards (10 μL), 0.5 μg product reduced (1.3 μL), blank, 2.0 μg product reduced (5 μL), blank, and 10 μg product reduced (25 μL).\n\n\n \nFIG. 26F\n shows size exclusion chromatography on 20 μg of the final monovalent dimeric Fc-L10-ShK[1-35] product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, and pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 27A\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final purified bivalent dimeric Fc-L10-ShK[2-35] product from stably transfected CHO cells. Lane 1-12 were loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 27B\n shows size exclusion chromatography on 50 μg of the purified bivalent dimeric Fc-L10-ShK[2-35] injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, and pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 27C\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of bivalent dimeric Fc-L5-ShK[2-35] purified from stably transfected CHO cells. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 27D\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of bivalent dimeric Fc-L25-ShK[2-35] purified from stably transfected CHO cells. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 27E\n shows a spectral scan of 10 μl of the bivalent dimeric Fc-L10-ShK[2-35] product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 27F\n shows a MALDI mass spectral analysis of the final sample of bivalent dimeric Fc-L110-ShK[2-35] analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from about 200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 27G\n shows a spectral scan of 10 μl of the bivalent dimeric Fc-L5-ShK[2-35] product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 27H\n shows the size exclusion chromatography on 50 mg of the final bivalent dimeric Fc-L5-ShK[2-35] product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH2PO4, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 27I\n shows a MALDI mass spectral analysis of the final sample of bivalent dimeric Fc-L5-ShK[2-35] analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 27J\n shows a Spectral scan of 20 μl of the product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 27K\n shows the size exclusion chromatography on 50 μg of the final bivalent dimeric Fc-L25-ShK[2-35] product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 27L\n shows a MALDI mass spectral analysis of the final sample of bivalent dimeric Fc-L25-ShK[2-35] analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from about 200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 28A\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of Fc-L10-KTX1 purified and refolded from bacterial cells. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 28B\n shows size exclusion chromatography on 45 μg of purified Fc-L10-KTX1 injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 28C\n shows a Spectral scan of 20 μl of the Fc-L10-KTX1 product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 28D\n shows a MALDI mass spectral analysis of the final sample of Fc-L10-KTX1 analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 29A\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of Fc-L-AgTx2 purified and refolded from bacterial cells. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 29B\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of Fc-L10-HaTx1 purified and refolded from bacterial cells. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced, spectral scan of the purified material.\n\n\n \nFIG. 29C\n shows a Spectral scan of 20 μl of the Fc-L110-AgTx2 product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 29D\n shows the Size exclusion chromatography on 20 μg of the final Fc-L10-AgTx2 product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 29E\n shows a MALDI mass spectral analysis of the final sample of Fc-L10-AgTx2 analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from about 200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 29F\n shows a Spectral scan of 20 μl of the Fc-L10-HaTx1 product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 29G\n shows the size exclusion chromatography on 20 μg of the final Fc-L10-HaTx1 product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 29H\n shows a MALDI mass spectral analysis of the final sample of Fc-L10-HaTx1 analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 30A\n shows Fc-L10-ShK[1-35] purified from CHO cells produces a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing the human Kv1.3 channel.\n\n\n \nFIG. 30B\n shows the time course of potassium current block by Fc-L10-ShK[1-35] at various concentrations. The IC\n50 \nwas estimated to be 15±2 pM (n=4 cells).\n\n\n \nFIG. 30C\n shows synthetic ShK[1-35] (also referred to as “ShK” alone) produces a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel.\n\n\n \nFIG. 30D\n shows the time course of ShK[1-35] block at various concentrations. The IC\n50 \nfor ShK was estimated to be 12±1 pM (n=4 cells).\n\n\n \nFIG. 31A\n shows synthetic peptide analog ShK[2-35] producing a concentration dependent block of the outward potassium current as recorded from HEK293 cells stably expressing human Kv1.3 channel with an IC50 of 49±5 pM (n=3 cells).\n\n\n \nFIG. 31B\n shows the CHO-derived Fc-L10-ShK[2-35] peptibody producing a concentration dependent block of the outward potassium current as recorded from HEK293 cell stably expressing human Kv1.3 channel with an IC50 of 115±18 pM (n=3 cells).\n\n\n \nFIG. 31C\n shows the Fc-L5-ShK[2-35] peptibody produces a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel with an IC50 of 100 pM (n=3 cells).\n\n\n \nFIG. 32A\n shows Fc-L-KTX1 peptibody purified from bacterial cells producing a concentration dependent block of the outward potassium current as recorded from HEK293 cell stably expressing human Kv1.3 channel.\n\n\n \nFIG. 32B\n shows the time course of potassium current block by Fc-L10-KTX1 at various concentrations.\n\n\n \nFIG. 33\n shows by immunohistochemistry that CHO-derived Fc-L10-ShK[1-35] peptibody stains \nHEK\n 293 cells stably transfected with human Kv1.3 (\nFIG. 33A\n), whereas \nuntransfected HEK\n 293 cells are not stained with the peptibody (\nFIG. 33B\n).\n\n\n \nFIG. 34\n shows results of an enzyme-immunoassay using fixed \nHEK\n 293 cells stably transfected with human Kv1.3. \nFIG. 34A\n shows the CHO-derived Fc-L10-ShK[1-35] (referred to here simply as “Fc-L10-ShK”) peptibody shows a dose-dependent increase in response, whereas the CHO-Fc control (“Fc control”) does not. \nFIG. 34B\n shows the Fc-L10-ShK[1-35] peptibody (referred to here as “Fc-ShK”) does not elicit a response from \nuntransfected HEK\n 293 cells using similar conditions and also shows other negative controls.\n\n\n \nFIG. 35\n shows the CHO-derived Fc-L10-ShK[1-35] peptibody shows a dose-dependent inhibition of IL-2 (\nFIG. 35A\n) and IFNγ (\nFIG. 35B\n) production from PMA and αCD3 antibody stimulated human PBMCs. The peptibody shows a novel pharmacology exhibiting a complete inhibition of the response, whereas the synthetic ShK[1-35] peptide alone shows only a partial inhibition.\n\n\n \nFIG. 36\n shows the mammalian-derived Fc-L10-ShK[1-35] peptibody inhibits T cell proliferation (3H-thymidine incorporation) in human PBMCs from two normal donors stimulated with antibodies to CD3 and CD28. \nFIG. 36A\n shows the response of \ndonor\n 1 and \nFIG. 36B\n the response of \ndonor\n 2. Pre-incubation with the anti-CD32 (FcgRII) blocking antibody did not alter the sensitivity toward the peptibody.\n\n\n \nFIG. 37\n shows the purified CHO-derived Fc-L10-ShK[1-35] peptibody causes a dose-dependent inhibition of IL-2 (\nFIG. 37A\n) and IFNγ (\nFIG. 37B\n) production from αCD3 and αCD28 antibody stimulated human PBMCs.\n\n\n \nFIG. 38A\n shows the PEGylated ShK[2-35] synthetic peptide produces a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel and the time course of potassium current block at various concentrations is shown in \nFIG. 38B\n.\n\n\n \nFIG. 39A\n shows a spectral scan of 50 μl of the Fc-L10-ShK(1-35) product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 39B\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-ShK(1-35) product. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 39C\n shows the Size exclusion chromatography on 50 μg of the final Fc-L10-ShK(1-35) product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 40A\n shows a Spectral scan of 20 μl of the Fc-L10-ShK(2-35) product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 40B\n shows a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-ShK(2-35) product. Lanes 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 40C\n shows the size exclusion chromatography on 50 μg of the final Fc-L10-ShK(2-35) product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 40D\n shows a MALDI mass spectral analysis of the final sample of Fc-L10-ShK(2-35) analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 41A\n shows spectral scan of 50 μl of the Fc-L10-OSK1 product diluted in 700 μl Formulation Buffer using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 41B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-OSK1 product. Lanes 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 41C\n shows size exclusion chromatography on 123 μg of the final Fc-L10-OSK1 product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 41D\n shows liquid chromatography—mass spectral analysis of approximately 4 μg of the final Fc-L110-OSK1 sample using a Vydac C\n4 \ncolumn with part of the effluent directed into a LCQ ion trap mass spectrometer. The mass spectrum was deconvoluted using the Bioworks software provided by the mass spectrometer manufacturer.\n\n\n \nFIG. 42A-B\n shows nucleotide and amino acid sequences (SEQ ID NO: 1040 and SEQ ID NO: 1041, respectively) of Fc-L10-OSK1.\n\n\n \nFIG. 43A-B\n shows nucleotide and amino acid sequences (SEQ ID NO: 1042 and SEQ ID NO: 1043, respectively) of Fc-L10-OSK1[K7S].\n\n\n \nFIG. 44A-B\n shows nucleotide and amino acid sequences (SEQ ID NO: 1044 and SEQ ID NO: 1045, respectively) of Fc-L10-OSK1[E16K,K20D].\n\n\n \nFIG. 45A-B\n shows nucleotide and amino acid sequences (SEQ ID NO: 1046 and SEQ ID NO: 1047, respectively) of Fc-L10-OSK1[K7S,E16K,K20D].\n\n\n \nFIG. 46\n shows a Western blot (from tris-glycine 4-20% SDS-PAGE) with anti-human Fc antibodies. Lanes 1-6 were loaded as follows: 15 μl of Fc-L10-OSK1[K7S,E16K,K20D]; 15 μl of Fc-L10-OSK1[E16K,K20D]; 15 μl of Fc-L10-OSK1[K7S]; 15 μl of Fc-L10-OSK1; 15 μl of “No DNA” control; molecular weight markers.\n\n\n \nFIG. 47\n shows a Western blot (from tris-glycine 4-20% SDS-PAGE) with anti-human Fc antibodies. Lanes 1-5 were loaded as follows: 21 of Fc-L10-OSK1; 5 μl of Fc-L10-OSK1; 10 μl of Fc-L10-OSK1; 20 ng Human IgG standard; molecular weight markers.\n\n\n \nFIG. 48\n shows a Western blot (from tris-glycine 4-20% SDS-PAGE) with anti-human Fc antibodies. Lanes 1-13 were loaded as follows: 20 ng Human IgG standard; D1; C3; C2; B6; B5; B2; B1; A6; A5; A4; A3; A2 (5 μl of clone-conditioned medium loaded in lanes 2-13).\n\n\n \nFIG. 49A\n shows a spectral scan of 50 μl of the Fc-L10-OSK1 product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 49B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-OSK1 product. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 49C\n shows Size exclusion chromatography on 149 μg of the final Fc-L10-OSK1 product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 49D\n shows MALDI mass spectral analysis of the final sample of Fc-L10-OsK1 analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 50A\n shows a spectral scan of 50 μl of the Fc-L10-OsK1(K7S) product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 50B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-OsK1(K7S) product. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 50C\n shows size exclusion chromatography on 50 μg of the final Fc-L10-OsK1(K7S) product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 50D\n shows MALDI mass spectral analysis of a sample of the final product Fc-L10-OsK1 (K7S) analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 51A\n shows a spectral scan of 50 μl of the Fc-L10-OsK1(E16K, K20D) product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 51B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-OsK1(E16K, K20D) product. Lane 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 51C\n shows size exclusion chromatography on 50 μg of the final Fc-L10-OsK1(E16K, K20D) product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 51D\n shows MALDI mass spectral analysis of a sample of the final product Fc-L10-OsK1 (E16K, K20D) analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 52A\n shows a spectral scan of 50 μl of the Fc-L110-OsK1 (K7S, E16K, K20D) product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 52B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final Fc-L10-OsK1(K7S, E16K, K20D) product. Lanes 1-12 are loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 52C\n shows size exclusion chromatography on 50 μg of the final Fc-L10-OsK1(K7S, E16K, K20D) product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 52D\n shows MALDI mass spectral analysis of a sample of the final product Fc-L10-OsK1(K7S, E16K, K20D) analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 53\n shows inhibition of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel by synthetic Osk1, a 38-residue toxin peptide of the Asian scorpion \nOrthochirus scrobiculosus \nvenom. \nFIG. 53A\n shows a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel by the synthetic Osk1 toxin peptide. \nFIG. 53B\n shows the time course of the synthetic Osk1 toxin peptide block at various concentrations. The IC50 for the synthetic Osk1 toxin peptide was estimated to be 39±12 pM (n=4 cells).\n\n\n \nFIG. 54\n shows that modification of the synthetic OSK1 toxin peptide by fusion to the Fc-fragment of an antibody (OSK1-peptibody) retained the inhibitory activity against the human Kv1.3 channel. \nFIG. 54A\n shows a concentration dependent block of the outward potassium current recorded from HEK293 cells stably expressing human Kv1.3 channel by OSK1 linked to a human IgG1 Fc-fragment with a linker chain length of 10 amino acid residues (Fc-L10-OSK1). The fusion construct was stably expressed in Chinese Hamster Ovarian (CHO) cells. \nFIG. 54B\n shows the time course of the Fc-L10-OSK1 block at various concentrations. The IC50 for Fc-L10-OSK1 was estimated to be 198±35 pM (n=6 cells), approximately 5-fold less potent than the synthetic OSK1 toxin peptide.\n\n\n \nFIG. 55\n shows that a single amino-acid residue substitution of the OSK1-peptibody retained the inhibitory activity against the human Kv1.3 channel. \nFIG. 55A\n shows a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel by OSK1-peptibody with a single amino acid substitution (lysine to serine at the 7\nth \nposition from N-terminal, [K7S]) and linked to a human IgG1 Fc-fragment with a linker chain length of 10 amino acid residues (Fc-L10-OSK1[K7S]). The fusion construct was stably expressed in Chinese Hamster Ovarian (CHO) cells. \nFIG. 55B\n shows the time course of potassium current block by Fc-L10-OSK1[K7S] at various concentrations. The IC50 was estimated to be 372±71 pM (n=4 cells), approximately 10-fold less potent than the synthetic OSK1 toxin peptide.\n\n\n \nFIG. 56\n shows that a two amino-acid residue substitution of the OSK1-peptibody retained the inhibitory activity against the human Kv1.3 channel. \nFIG. 56A\n shows a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel by OSK1-peptibody with two amino acid substitutions (glutamic acid to lysine and lysine to aspartic acid at the 16\nth \nand 20\nth \nposition from N-terminal respectively, [E16KK20D]) and linked to a human IgG1 Fc-fragment with a linker chain length of 10 amino acid residues (Fc-L10-OSK1[E16KK20D]). The fusion construct was stably expressed in Chinese Hamster Ovarian (CHO) cells. \nFIG. 56B\n shows the time course of potassium current block by Fc-L10-OSK1[E16KK20D] at various concentrations. The IC50 was estimated to be 248±63 pM (n=3 cells), approximately 6-fold less potent than the synthetic OSK1 toxin peptide.\n\n\n \nFIG. 57\n shows that a triple amino-acid residue substitution of the OSK1-peptibody retained the inhibitory activity against the human Kv1.3 channel, but the potency of inhibition was significantly reduced when compared to the synthetic OSK1 toxin peptide. \nFIG. 57A\n shows a concentration dependent block of the outward potassium current recorded from HEK293 cell stably expressing human Kv1.3 channel by OSK1-peptibody with triple amino acid substitutions (lysine to serine, glutamic acid to lysine and lysine to aspartic acid at the 7\nth\n, 16\nth \nand 20\nth \nposition from N-terminal respectively, [K7SE16KK20D]) and linked to a human IgG1 Fc-fragment with a linker chain length of 10 amino acid residues (Fc-L10-OSK1[K7SE16KK20D]). The fusion construct was stably expressed in Chinese Hamster Ovarian (CHO) cells. \nFIG. 57B\n shows the time course of potassium current block by Fc-L10-OSK1[K7SE16KK20D] at various concentrations. The IC50 was estimated to be 812±84 pM (n=3 cells), approximately 21-fold less potent than the synthetic OSK1 toxin peptide.\n\n\n \nFIG. 58\n shows Standard curves for ShK (\nFIG. 58A\n) and 20K PEG-ShK[1-35] (\nFIG. 58B\n) containing linear regression equations for each Standard at a given percentage of serum.\n\n\n \nFIG. 59\n shows the pharmacokinetic profile in rats of 20K PEG ShK[1-35] molecule after IV injection.\n\n\n \nFIG. 60\n shows Kv1.3 inhibitory activity in serum samples (5%) of rats receiving a single equal molar IV injection of Kv1.3 inhibitors ShK versus 20K PEG-ShK[1-35].\n\n\n \nFIG. 61\n illustrates an Adoptive Transfer EAE model experimental design (n=5 rats per treatment group). Dosing values in microgram per kilogram (mg/kg) are based on peptide content.\n\n\n \nFIG. 62\n shows that treatment with PEG-ShK ameliorated disease in rats in the adoptive transfer EAE model. Clinical scoring: 0=No signs, 0.5=distal limp tail, 1.0=limp tail, 2.0=mild paraparesis, ataxia, 3.0=moderate paraparesis, 3.5=one hind leg paralysis, 4.0=complete hind leg paralysis, 5.0=complete hind leg paralysis and incontinence, 5.5=tetraplegia, 6.0=moribund state or death. Rats reaching a score of 5.5 to 6 died or were euthanized. Mean±sem values are shown. (n=5 rats per treatment group.)\n\n\n \nFIG. 63\n shows that treatment with PEG-ShK prevented loss of body weight in the adoptive transfer EAE model. Rats were weighed on days −1, 4, 6, and 8 (for surviving rats). Mean±sem values are shown.\n\n\n \nFIG. 64\n shows that thapsigargin-induced IL-2 production in human whole blood was suppressed by the Kv1.3 channel inhibitors ShK[1-35] and Fc-L10-ShK[2-35]. The calcineurin inhibitor cyclosporine A also blocked the response. The BKCa channel inhibitor iberiotoxin (IbTx) showed no significant activity. The response of whole blood from two separate donors is shown in \nFIG. 64A\n and \nFIG. 64B\n.\n\n\n \nFIG. 65\n shows that thapsigargin-induced IFN-g production in human whole blood was suppressed by the Kv1.3 channel inhibitors ShK[1-35] and Fc-L10-ShK[2-35]. The calcineurin inhibitor cyclosporine A also blocked the response. The BKCa channel inhibitor iberiotoxin (IbTx) showed no significant activity. The response of whole blood from two separate donors is shown in \nFIG. 65A\n and \nFIG. 65B\n.\n\n\n \nFIG. 66\n shows that thapsigargin-induced upregulation of CD40L on T cells in human whole blood was suppressed by the Kv1.3 channel inhibitors ShK[1-35] and Fc-L10-ShK[1-35] (Fc-ShK). The calcineurin inhibitor cyclosporine A (CsA) also blocked the response. \nFIG. 66A\n shows results of an experiment looking at the response of total CD4+ T cells. \nFIG. 66B\n shows results of an experiment that looked at total CD4+ T cells, as well as CD4+CD45+ and CD4+CD45-T cells. In \nFIG. 66B\n, the BKCa channel inhibitor iberiotoxin (IbTx) and the Kv1.1 channel inhibitor dendrotoxin-K (DTX-K) showed no significant activity.\n\n\n \nFIG. 67\n shows that thapsigargin-induced upregulation of the IL-2R on T cells in human whole blood was suppressed by the Kv1.3 channel inhibitors ShK[1-35] and Fc-L10-ShK[1-35] (Fc-ShK). The calcineurin inhibitor cyclosporine A (CsA) also blocked the response. \nFIG. 67A\n shows results of an experiment looking at the response of total CD4+ T cells. \nFIG. 67B\n shows results of an experiment that looked at total CD4+ T cells, as well as CD4+CD45+ and CD4+CD45-T cells. In \nFIG. 67B\n, the BKCa channel inhibitor iberiotoxin (IbTx) and the Kv1.1 channel inhibitor dendrotoxin-K (DTX-K) showed no significant activity.\n\n\n \nFIG. 68\n shows cation exchange chromatograms of PEG-peptide purification on SP Sepharose HP columns for PEG-Shk purification (\nFIG. 68A\n) and PEG-OSK-1 purification (\nFIG. 68B\n).\n\n\n \nFIG. 69\n shows RP-HPLC chromatograms on final PEG-peptide pools to demonstrate purity of PEG-Shk purity >99% (\nFIG. 69A\n) and PEG-Osk1 purity >97% (\nFIG. 69B\n).\n\n\n \nFIG. 70\n shows the amino acid sequence (SEQ ID NO: 976) of an exemplary FcLoop-L2-OsK1-L2 having three linked domains: Fc N-terminal domain (amino acid residues 1-139); OsK1 (underlined amino acid residues 142-179); and Fc C-terminal domain (amino acid residues 182-270).\n\n\n \nFIG. 71\n shows the amino acid sequence (SEQ ID NO: 977) of an exemplary FcLoop-L2-ShK-L2 having three linked domains: Fc N-terminal domain (amino acid residues 1-139); ShK (underlined amino acid residues 142-176); and Fc C-terminal domain (amino acid residues 179-267).\n\n\n \nFIG. 72\n shows the amino acid sequence (SEQ ID NO: 978) of an exemplary FcLoop-L2-ShK-L4 having three linked domains: Fc N-terminal domain (amino acid residues 1-139); ShK (underlined amino acid residues 142-176); and Fc C-terminal domain (amino acid residues 181-269).\n\n\n \nFIG. 73\n shows the amino acid sequence (SEQ ID NO: 979) of an exemplary FcLoop-L4-OsK1-L2 having three linked domains: Fc N-terminal domain (amino acid residues 1-139); OsK1(underlined amino acid residues 144-181); and Fc C-terminal domain (amino acid residues 184-272).\n\n\n \nFIG. 74\n shows that the 20K PEGylated ShK[1-35] provided potent blockade of human Kv1.3 as determined by whole cell patch clamp electrophysiology on HEK293/Kv1.3 cells. The data represents blockade of peak current.\n\n\n \nFIG. 75\n shows schematic structures of some other exemplary embodiments of the composition of matter of the invention. “X\n2\n” and “X\n3\n” represent toxin peptides or linker-toxin peptide combinations (i.e., -(L)\nf\n-P-(L)\ng\n-) as defined herein. As described herein but not shown in \nFIG. 75\n, an additional X\n1 \ndomain and one or more additional PEG moieties are also encompassed in other embodiments. The specific embodiments shown here are as follows:\n\n\n \nFIG. 75C\n, \nFIG. 75D\n, \nFIG. 75G\n and \nFIG. 75H\n: show a single chain molecule and can also represent the DNA construct for the molecule.\n\n\n \nFIG. 75A\n, \nFIG. 75B\n, \nFIG. 75E\n and \nFIG. 75F\n: show doubly disulfide-bonded Fc dimers (in position F\n2\n); \nFIG. 75A\n and \nFIG. 75B\n show a dimer having the toxin peptide portion on both chains in position X\n3\n; \nFIG. 75E\n and \nFIG. 75F\n show a dimer having the toxin peptide portion on both chains In position X\n2\n.\n\n\n \nFIG. 76A\n shows a spectral scan of 50 μl of the ShK[2-35]-Fc product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 76B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final ShK[2-35]-Fc product. Lanes 1-12 were loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 76C\n shows size exclusion chromatography on 70 μg of the final ShK[2-35]-Fc product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 76D\n shows LC-MS analysis of the final ShK[2-35]-Fc sample using an Agilent 1100 HPCL running reverse phase chromatography, with the column effluent directly coupled to an electrospray source of a Thermo Finnigan LCQ ion trap mass spectrometer. Relevant spectra were summed and deconvoluted to mass data with the Bioworks software package.\n\n\n \nFIG. 77A\n shows a spectral scan of 20 μl of the met-ShK[1-35]-Fc product diluted in 700 μl PBS (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 77B\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final met-ShK[1-35]-Fc product. Lanes 1-12 were loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, Novex Mark12 wide range protein standards, 0.5 μg product reduced, blank, 2.0 μg product reduced, blank, and 10 μg product reduced.\n\n\n \nFIG. 77C\n shows size exclusion chromatography on 93 μg of the final met-ShK[1-35]-Fc product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 77D\n shows MALDI mass spectral analysis of the final met-ShK[1-35]-Fc sample analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\n \nFIG. 78\n shows a spectral scan of 10 μl of the CH2-OSK1 fusion protein product diluted in 150 μl water (blanking buffer) using a Hewlett Packard 8453 spectrophotometer and a 1 cm path length quartz cuvette.\n\n\n \nFIG. 79\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final CH2-OSK1 fusion protein product. Lane 1-7 were loaded as follows: Novex Mark12 wide range protein standards, 0.5 μg product non-reduced, blank, 2.0 μg product non-reduced, blank, 10 μg product non-reduced, and Novex Mark12 wide range protein standards.\n\n\n \nFIG. 80\n shows size exclusion chromatography on 50 μg of the final CH2-OSK1 fusion protein product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm.\n\n\n \nFIG. 81\n shows liquid chromatography—mass spectral analysis of the CH2-OSK1 fusion protein sample using a Vydac C\n4 \ncolumn with part of the effluent directed into a LCQ ion trap mass spectrometer. The mass spectrum was deconvoluted using the Bioworks software provided by the mass spectrometer manufacturer.\n\n\n \nFIG. 82\n shows cation exchange chromatogram of PEG-CH2-OSK1 reaction mixture. Vertical lines delineate fractions pooled to obtain mono-PEGylated CH2-OSK1.\n\n\n \nFIG. 83\n shows Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE of the final PEGylated CH2-OSK1 pool. Lane 1-2 were loaded as follows: Novex Mark12 wide range protein standards, 2.0 μg product non-reduced.\n\n\n \nFIG. 84\n shows whole cell patch clamp (WCPC) and PatchXpress (PX) electrophysiology comparing the activity of OSK1[Ala-12] (SEQ ID No:1410) on human Kv1.3 and human Kv1.1 heterologously overexpressed on CHO and HEK293 cells, respectively. The table summarizes the calculated IC\n50 \nvalues and the plots show the individual traces of the impact of various concentrations of analog on the relative Kv1.3 or Kv1.1 current (percent of control, POC).\n\n\n \nFIG. 85\n shows whole cell patch clamp electrophysiology comparing the activity of OSK1[Ala-29] (SEQ ID No:1424) on human Kv1.3 and human Kv1.1 heterologously overexpressed on CHO and HEK293 cells, respectively. Concentration response curves of OSK1[Ala-29] on CHO/Kv1.3 (circle, square and diamond, IC\n50\n=0.033 nM, n=3) and on HEK/Kv1.1 (filled triangle, IC\n50\n=2.7 nM, n=1).\n\n\n \nFIG. 86\n shows a dose-response curve for OSK1[Ala-29] (SEQ ID No:1424) against human Kv1.3 (CHO) (panel A) and human Kv1.1 (HEK293) (panel B) as determined by high-throughput 384-well planar patch clamp electrophysiology using the IonWorks Quattro system.\n\n\n \nFIG. 87A-B\n show Western blots of Tris-glycine 4-20% SDS-PAGE (\nFIG. 87A\n with longer exposure time and \nFIG. 87B\n with shorter exposure time) of a monovalent dimeric Fc-L-ShK(2-35) molecule product expressed by and released into the conditioned media from mammalian cells transiently transfected with pTT5-Fc-Fc-L10-Shk(2-35), which was sampled after the indicated number of days. Lanes 3-8 were loaded with 20 μL of conditioned medium per lane. The immunoblot was probed with anti-human IgG-Fc-HRP (Pierce). The lanes were loaded as follows: 1) MW Markers; 2) purified Fc-L10-ShK(2-35), 10 ng; 3) 293-6E-HD (5-day); 4) 293-6E-HD (6-day); 5) 293-6E-PEI (5-day); 6) 293-6E-PEI (6-day); 7) CHO-S (5-day); 8) CHO-S (6-day). Four bands were expected in the reduced gel: Linker-Fc-Shk(2-35) (one cut at 3′ furin site; predicted MW: 33.4 kDa); Fc-ShK(2-35) (both furin sites cut; predicted MW: 30.4 kDa); Fc-linker (one cut at 5′ furin site; predicted MW: 29.1 kDa); Fc (both furin sites cut; predicted MW: 25.8 kDa). Further mass spec or amino acid sequence analysis of the individual bands is needed to identify these bands and their relative ratios.\n\n\n \nFIG. 88\n shows a western blot of serum samples from a pharmacokinetic study on monovalent dimeric Fc-ShK(1-35) in SD rats. Various times (0.083-168 hours) after a single 1 mg/kg intravenous injection of monovalent dimeric Fc-L10-ShK(1-35) (see, Example 2), blood was drawn, and serum was collected. A Costar EIA/\nRIA\n 96 well plate was coated with 2 μg/ml polyclonal goat anti-human Fc antibody overnight at 4° C. Capture antibody was removed and the plate was washed with PBST and then blocked with Blotto. After the plate was washed, serum samples diluted in PBST/0.1% BSA were added. Binding was allowed to occur at room temperature for several hours, and then the plate was again washed. Samples were eluted from the plate with reducing Laemmle buffer, heated, then run on SDS-Page gels. Run in an adjacent lane (“5 ng Control”) of the gel as a standard was 5 ng of the purified monovalent dimeric Fc-L10-ShK(1-35) fusion protein used in the pharmacokinetic study. Proteins were transferred to PVDF membranes by western blot. Membranes were blocked with Blotto followed by incubation with goat anti-Human Fc-HRP conjugated antibody. After the membranes were washed, signal was detected via chemiluminescence using a CCD camera.\n\n\n \nFIG. 89\n shows the NMR solution structure of OSK1 and sites identified by analoging to be important for Kv1.3 activity and selectivity. Space filling structures are shown in \nFIGS. 89A\n, \n89\nB and \n89\nD. The color rendering in \nFIG. 89A\n depicts amino acid charge. In \nFIG. 89B\n, several key OSK1 amino acid residues found to be important for Kv1.3 activity (Tables 37-40) are lightly shaded and labeled Phe25, Gly26, Lys27, Met29 and Asn30. In \nFIG. 89D\n residues Ser11, Met29 and His34 are labeled. Some analogues of these residues were found to result in improved Kv1.3 selectivity over Kv1.1 (Tables 41). \nFIG. 89C\n shows the three beta strands and single alpha helix of OSK1. The amino acid sequence of native OSK1 (SEQ ID No: 25) is shown in \nFIG. 89E\n, with residues forming the molecules beta strands (β1, β2, β3) and alpha helix (al) underlined. The OSK1 structures shown were derived from PDB:1SCO, and were rendered using Cn3D vers4.1.\n\n\n \nFIG. 90A-D\n illustrates that toxin peptide inhibitors of Kv1.3 provide potent blockade of the whole blood inflammatory response. The activity of the calcineurin inhibitor cyclosporin A (\nFIG. 90A\n) and Kv1.3 peptide inhibitors ShK-Ala22 (\nFIG. 90B\n; SEQ ID No: 123), OSK1-Ala29 (\nFIG. 90C\n; SEQ ID No: 1424) and OSK1-Ala12 (\nFIG. 90D\n; SEQ ID No: 1410) were compared in the whole blood assay of inflammation (Example 46) using the same donor blood sample. The potency (IC50) of each molecule is shown, where for each panel the left curve is the impact on IL-2 production and the right curve is the impact on IFNγ production.\n\n\n \nFIG. 91A-B\n shows an immunoblot analysis of expression of monovalent dimeric IgG1-Fc-L-ShK(2-35) from non-reduced SDS-PAGE. \nFIG. 91A\n shows detection of human Fc expression with goat anti-human IgG (H+L)-HRP. \nFIG. 91B\n shows detection of ShK(2-35) expression with a goat anti-mouse IgG (H+L)-HRP that cross reacts with human IgG. Lane 1: purified Fc-L10-Shk(2-35); Lane 2: conditioned medium from 293EBNA cells transiently transfected with pTT5-huIgG1+pTT5-hKappa+pCMVi-Fc-L10-ShK(2-35); Lane 3: conditioned media from 293EBNA cells transiently transfected with pTT5-huIgG2+pTT5-hKappa+pCMVi-Fc-L10-Shk(2-35); Lane 4: conditioned media from 293EBNA cells transiently transfected with pTT14 vector alone. The two arrows point to the full length huIgG (mol. wt.˜150 kDa) and monovalent dimeric huIgG-FcShK(2-35) (mol. wt.˜100 kDa); the abundant 60-kDa band is the bivalent dimeric Fc-ShK(2-35).\n\n\n \nFIG. 92A-C\n shows schematic representations of an embodiment of a monovalent “hemibody”-toxin peptide fusion protein construct; the single toxin peptide is represented by an oval. \nFIG. 92A\n, which can also represent the DNA construct for the fusion protein, represents an immunoglobulin light chain (LC, open rectangle), an immunoglobulin heavy chain (HC, longer cross-hatched rectangle), and an immunoglobulin Fc domain (Fc, shorter cross-hatched rectangle), each separated by an intervening peptidyl linker sequence (thick lines) comprising at least one protease cleavage site (arrows), e.g., a furin cleavage site. \nFIG. 92\n illustrates the association of the recombinantly expressed LC, HC, and Fc-toxin peptide components connected by the peptidyl linker sequences (thick lines) and, in \nFIG. 92C\n, the final monovalent chimeric immunoglobulin (LC+HC)-Fc (i.e., “hemibody”)-toxin peptide fusion protein after cleavage (intracellularly or extracellularly) at the protease cleavage sites, to release the linkers, and formation of disulfide bridges between the light and heavy chains and between the heavy chain and the Fc components (shown as thin horizontal lines between the LC, HC, and Fc components in \nFIG. 92C\n).\n\n\n\n\nDETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION\n\n\nDefinition of Terms\n\n\nThe terms used throughout this specification are defined as follows, unless otherwise limited in specific instances. As used in the specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.\n\n\n“Polypeptide” and “protein” are used interchangeably herein and include a molecular chain of two or more amino acids linked through peptide bonds. The terms do not refer to a specific length of the product. Thus, “peptides,” and “oligopeptides,” are included within the definition of polypeptide. The terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. In addition, protein fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide. The terms also include molecules in which one or more amino acid analogs or non-canonical or unnatural amino acids are included as can be synthesized, or expressed recombinantly using known protein engineering techniques. In addition, inventive fusion proteins can be derivatized as described herein by well-known organic chemistry techniques.\n\n\nThe term “fusion protein” indicates that the protein includes polypeptide components derived from more than one parental protein or polypeptide. Typically, a fusion protein is expressed from a fusion gene in which a nucleotide sequence encoding a polypeptide sequence from one protein is appended in frame with, and optionally separated by a linker from, a nucleotide sequence encoding a polypeptide sequence from a different protein. The fusion gene can then be expressed by a recombinant host cell as a single protein.\n\n\nA “domain” of a protein is any portion of the entire protein, up to and including the complete protein, but typically comprising less than the complete protein. A domain can, but need not, fold independently of the rest of the protein chain and/or be correlated with a particular biological, biochemical, or structural function or location (e.g., a ligand binding domain, or a cytosolic, transmembrane or extracellular domain).\n\n\nA “secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a secretory signal peptide sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a “mature” protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.\n\n\nThe term “signal peptide” refers to a relatively short (3-60 amino acid residues long) peptide chain that directs the post-translational transport of a protein, e.g., its export to the extracellular space. Thus, secretory signal peptides are encompassed by “signal peptide”. Signal peptides may also be called targeting signals, signal sequences, transit peptides, or localization signals.\n\n\nThe term “recombinant” indicates that the material (e.g., a nucleic acid or a polypeptide) has been artificially or synthetically (i.e., non-naturally) altered by human intervention. The alteration can be performed on the material within, or removed from, its natural environment or state. For example, a “recombinant nucleic acid” is one that is made by recombining nucleic acids, e.g., during cloning, DNA shuffling or other well known molecular biological procedures. A “recombinant DNA molecule,” is comprised of segments of DNA joined together by means of such molecular biological techniques. The term “recombinant protein” or “recombinant polypeptide” as used herein refers to a protein molecule which is expressed using a recombinant DNA molecule. A “recombinant host cell” is a cell that contains and/or expresses a recombinant nucleic acid.\n\n\nA “polynucleotide sequence” or “nucleotide sequence” or “nucleic acid sequence,” as used interchangeably herein, is a polymer of nucleotides, including an oligonucleotide, a DNA, and RNA, a nucleic acid, or a character string representing a nucleotide polymer, depending on context. From any specified polynucleotide sequence, either the given nucleic acid or the complementary polynucleotide sequence can be determined. Included are DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.\n\n\nAs used herein, the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of ribonucleotides along the mRNA chain, and also determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the RNA sequence and for the amino acid sequence.\n\n\n“Expression of a gene” or “expression of a nucleic acid” means transcription of DNA into RNA (optionally including modification of the RNA, e.g., splicing), translation of RNA into a polypeptide (possibly including subsequent post-translational modification of the polypeptide), or both transcription and translation, as indicated by the context.\n\n\nThe term “gene” is used broadly to refer to any nucleic acid associated with a biological function. Genes typically include coding sequences and/or the regulatory sequences required for expression of such coding sequences. The term “gene” applies to a specific genomic or recombinant sequence, as well as to a cDNA or mRNA encoded by that sequence. A “fusion gene” contains a coding region that encodes a fusion protein. Genes also include non-expressed nucleic acid segments that, for example, form recognition sequences for other proteins. Non-expressed regulatory sequences including transcriptional control elements to which regulatory proteins, such as transcription factors, bind, resulting in transcription of adjacent or nearby sequences.\n\n\nAs used herein the term “coding region” when used in reference to a structural gene refers to the nucleotide sequences which encode the amino acids found in the nascent polypeptide as a result of translation of an mRNA molecule. The coding region is bounded, in eukaryotes, on the 5′ side by the nucleotide triplet “ATG” which encodes the initiator methionine and on the 3′ side by one of the three triplets which specify stop codons (i.e., TAA, TAG, TGA).\n\n\nTranscriptional control signals in eukaryotes comprise “promoter” and “enhancer” elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription (Maniatis, et al., Science 236:1237 (1987)). Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in prokaryotes). The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types (for review see Voss, et al., Trends Biochem. Sci., 11:287 (1986) and Maniatis, et al., Science 236:1237 (1987)).\n\n\nThe term “expression vector” as used herein refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host cell. Nucleic acid sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals. A secretory signal peptide sequence can also, optionally, be encoded by the expression vector, operably linked to the coding sequence for the inventive recombinant fusion protein, so that the expressed fusion protein can be secreted by the recombinant host cell, for more facile isolation of the fusion protein from the cell, if desired. Such techniques are well known in the art. (E.g., Goodey, Andrew R.; et al., Peptide and DNA sequences, U.S. Pat. No. 5,302,697; Weiner et al., Compositions and methods for protein secretion, U.S. Pat. No. 6,022,952 and U.S. Pat. No. 6,335,178; Uemura et al., Protein expression vector and utilization thereof, U.S. Pat. No. 7,029,909; Ruben et al., 27 human secreted proteins, US 2003/0104400 A1).\n\n\nThe terms “in operable combination”, “in operable order” and “operably linked” as used herein refer to the linkage of nucleic acid sequences in such a manner or orientation that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced and/or transported.\n\n\nRecombinant DNA- and/or RNA-mediated protein expression techniques, or any other methods of preparing peptides or, are applicable to the making of the inventive recombinant fusion proteins. For example, the peptides can be made in transformed host cells. Briefly, a recombinant DNA molecule, or construct, coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences encoding the peptides can be excised from DNA using suitable restriction enzymes. Any of a large number of available and well-known host cells may be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial host cells in culture include bacteria (such as \nEscherichia coli \nsp.), yeast (such as \nSaccharomyces \nsp.) and other fungal cells, insect cells, plant cells, mammalian (including human) cells, e.g., CHO cells and HEK293 cells. Modifications can be made at the DNA level, as well. The peptide-encoding DNA sequence may be changed to codons more compatible with the chosen host cell. For \nE. coli\n, optimized codons are known in the art. Codons can be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell. Next, the transformed host is cultured and purified. Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art.\n\n\nThe term “half-life extending moiety” (i.e., F\n1 \nor F\n2 \nin Formula I) refers to a pharmaceutically acceptable moiety, domain, or “vehicle” covalently linked (“conjugated”) to the toxin peptide directly or via a linker, that prevents or mitigates in vivo proteolytic degradation or other activity-diminishing chemical modification of the toxin peptide, increases half-life or other pharmacokinetic properties such as but not limited to increasing the rate of absorption, reduces toxicity, improves solubility, increases biological activity and/or target selectivity of the toxin peptide with respect to a target ion channel of interest, increases manufacturability, and/or reduces immunogenicity of the toxin peptide, compared to an unconjugated form of the toxin peptide.\n\n\nBy “PEGylated peptide” is meant a peptide or protein having a polyethylene glycol (PEG) moiety covalently bound to an amino acid residue of the peptide itself or to a peptidyl or non-peptidyl linker (including but not limited to aromatic or aryl linkers) that is covalently bound to a residue of the peptide.\n\n\nBy “polyethylene glycol” or “PEG” is meant a polyalkylene glycol compound or a derivative thereof, with or without coupling agents or derivatization with coupling or activating moieties (e.g., with aldehyde, hydroxysuccinimidyl, hydrazide, thiol, triflate, tresylate, azirdine, oxirane, orthopyridyl disulphide, vinylsulfone, iodoacetamide or a maleimide moiety). In accordance with the present invention, useful PEG includes substantially linear, straight chain PEG, branched PEG, or dendritic PEG. (See, e.g., Merrill, U.S. Pat. No. 5,171,264; Harris et al., Multiarmed, monofunctional, polymer for coupling to molecules and surfaces, U.S. Pat. No. 5,932,462; Shen, N-maleimidyl polymer derivatives, U.S. Pat. No. 6,602,498).\n\n\nThe term “peptibody” refers to molecules of Formula I in which F\n1 \nand/or F\n2 \nis an immunoglobulin Fc domain or a portion thereof, such as a CH2 domain of an Fc, or in which the toxin peptide is inserted into a human IgG1 Fc domain loop, such that F\n1 \nand F\n2 \nare each a portion of an Fc domain with a toxin peptide inserted between them (See, e.g., \nFIGS. 70-73\n and Example 49 herein). Peptibodies of the present invention can also be PEGylated as described further herein, at either an Fc domain or portion thereof, or at the toxin peptide(s) portion of the inventive composition, or both.\n\n\nThe term “native Fc” refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgG1 or IgG2 are preferred. Native Fc's are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgGA2). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG (see Ellison et al. (1982), \nNucleic Acids Res. \n10: 4071-9). The term “native Fc” as used herein is generic to the monomeric, dimeric, and multimeric forms.\n\n\nThe term “Fc variant” refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn. Several published patent documents describe exemplary Fc variants, as well as interaction with the salvage receptor. See International Applications WO 97/34 631 (published 25 Sep. 1997; WO 96/32 478, corresponding to U.S. Pat. No. 6,096,891, issued Aug. 1, 2000, hereby incorporated by reference in its entirety; and WO 04/110 472. Thus, the term “Fc variant” includes a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises sites that can be removed because they provide structural features or biological activity that are not required for the fusion molecules of the present invention. Thus, the term “Fc variant” includes a molecule or sequence that lacks one or more native Fc sites or residues that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC). Fc variants are described in further detail hereinafter.\n\n\nThe term “Fc domain” encompasses native Fc and Fc variant molecules and sequences as defined above. As with Fc variants and native Fc's, the term “Fc domain” includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means.\n\n\nThe term “multimer” as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more polypeptide chains associated covalently, noncovalently, or by both covalent and non-covalent interactions. IgG molecules typically form dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dimers, trimers, or tetramers. One skilled in the art can form multimers by exploiting the sequence and resulting activity of the native Ig source of the Fc or by derivatizing (as defined below) such a native Fc.\n\n\nThe term “dimer” as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently. Thus, exemplary dimers within the scope of this invention are as shown in \nFIG. 2\n. A “monovalent dimeric” Fc-toxin peptide fusion, or “monovalent dimer”, is a Fc-toxin peptide fusion that includes a toxin peptide conjugated with only one of the dimerized Fc domains (e.g., as represented schematically in \nFIG. 2B\n). A “bivalent dimeric” Fc-toxin peptide fusion, or “bivalent dimer”, is a Fc-toxin peptide fusion having both of the dimerized Fc domains each conjugated separately with a toxin peptide (e.g., as represented schematically in \nFIG. 2C\n).\n\n\nThe terms “derivatizing” and “derivative” or “derivatized” comprise processes and resulting compounds respectively in which (1) the compound has a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl residue and thus forms cross-linked dimers in culture or in vivo; (3) one or more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N-terminus is replaced by —NRR\n1\n, NRC(O)R\n1\n, —NRC(O)OR\n1\n, —NRS(O)\n2\nR\n1\n, —NHC(O)NHR, a succinimide group, or substituted or unsubstituted benzyloxycarbonyl-NH—, wherein R and R\n1 \nand the ring substituents are as defined hereinafter; (5) the C-terminus is replaced by —C(O)R\n2 \nor —NR\n3\nR\n4 \nwherein R\n2\n, R\n3 \nand R\n4 \nare as defined hereinafter; and (6) compounds in which individual amino acid moieties are modified through treatment with agents capable of reacting with selected side chains or terminal residues. Derivatives are further described hereinafter.\n\n\nThe term “peptide” refers to molecules of 2 to about 80 amino acid residues, with molecules of about 10 to about 60 amino acid residues preferred and those of about 30 to about 50 amino acid residues most preferred. Exemplary peptides can be randomly generated by any known method, carried in a peptide library (e.g., a phage display library), or derived by digestion of proteins. In any peptide portion of the inventive compositions, for example a toxin peptide or a peptide linker moiety described herein, additional amino acids can be included on either or both of the N- or C-termini of the given sequence. Of course, these additional amino acid residues should not significantly interfere with the functional activity of the composition.\n\n\n“Toxin peptides” include peptides having the same amino acid sequence of a naturally occurring pharmacologically active peptide that can be isolated from a venom, and also include modified peptide analogs (spelling used interchangeably with “analogues”) of such naturally occurring molecules.\n\n\nThe term “peptide analog” refers to a peptide having a sequence that differs from a peptide sequence existing in nature by at least one amino acid residue substitution, internal addition, or internal deletion of at least one amino acid, and/or amino- or carboxy-terminal end truncations, or additions). An “internal deletion” refers to absence of an amino acid from a sequence existing in nature at a position other than the N- or C-terminus. Likewise, an “internal addition” refers to presence of an amino acid in a sequence existing in nature at a position other than the N- or C-terminus. “Toxin peptide analogs”, such as, but not limited to, an OSK1 peptide analog, ShK peptide analog, or ChTx peptide analog, contain modifications of a native toxin peptide sequence of interest (e.g., amino acid residue substitutions, internal additions or insertions, internal deletions, and/or amino- or carboxy-terminal end truncations, or additions as previously described above) relative to a native toxin peptide sequence of interest, which is in the case of OSK1: GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK (SEQ ID NO:25).\n\n\nExamples of toxin peptides useful in practicing the present invention are listed in Tables 1-32. The toxin peptide (“P”, or equivalently shown as “P\n1\n” in \nFIG. 2\n) comprises at least two intrapeptide disulfide bonds, as shown, for example, in \nFIG. 9\n. Accordingly, this invention concerns molecules comprising:\n\n \n \n \n \na) C\n1\n-C\n3 \nand C\n2\n-C\n4 \ndisulfide bonding in which C\n1\n, C\n2\n, C\n3\n, and C\n4 \nrepresent the order in which cysteine residues appear in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide on the left, with the first and third cysteines in the amino acid sequence forming a disulfide bond, and the second and fourth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n3\n, C\n2\n-C\n4 \ndisulfide bonding pattern include, but are not limited to, apamin peptides, α-conopeptides, PnIA peptides, PnIB peptides, and MII peptides, and analogs of any of the foregoing.\n \nb) C\n1\n-C\n6\n, C\n2\n-C\n4 \nand C\n3\n-C\n5 \ndisulfide bonding in which, as described above, C\n1\n, C\n2\n, C\n3\n, C\n4\n, C\n5 \nand C\n6 \nrepresent the order of cysteine residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and sixth cysteines in the amino acid sequence forming a disulfide bond, the second and fourth cysteines forming a disulfide bond, and the third and fifth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n6\n, C\n2\n-C\n4\n, C\n3\n-C\n5 \ndisulfide bonding pattern include, but are not limited to, ShK, BgK, HmK, AeKS, AsK, and DTX1, and analogs of any of the foregoing.\n \nc) C\n1\n-C\n4\n, C\n2\n-C\n5 \nand C\n3\n-C\n6 \ndisulfide bonding in which, as described above, C\n1\n, C\n2\n, C\n3\n, C\n4\n, C\n5 \nand C\n6 \nrepresent the order of cysteine residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and fourth cysteines in the amino acid sequence forming a disulfide bond, the second and fifth cysteines forming a disulfide bond, and the third and sixth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n4\n, C\n2\n-C\n5\n, C\n3\n-C\n6 \ndisulfide bonding pattern include, but are not limited to, ChTx, MgTx, OSK1, KTX1, AgTx2, Pi2, Pi3, NTX, HgTx1, BeKM1, BmKTX, P01, BmKK6, Tc32, Tc1, BmTx1, BmTX3, IbTx, P05, ScyTx, TsK, HaTx1, ProTX1, PaTX2, Ptu1, ωGVIA, ωMVIIA, and SmIIIa, and analogs of any of the foregoing.\n \nd) C\n1\n-C\n5\n, C\n2\n-C\n6\n, C\n3\n-C\n7\n, and C\n4\n-C\n8 \ndisulfide bonding in which C\n1\n, C\n2\n, C\n3\n, C\n4\n, C\n5\n, C\n6\n, C\n7 \nand C\n8 \nrepresent the order of cysteine residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and fifth cysteines in the amino acid sequence forming a disulfide bond, the second and sixth cysteines forming a disulfide bond, the third and seventh cysteines forming a disulfide bond, and the fourth and eighth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n5\n, C\n2\n-C\n6\n, C\n3\n-C\n7\n, C\n4\n-C\n8 \ndisulfide bonding pattern include, but are not limited to, Anuoroctoxin (AnTx), Pi1, HsTx1, MTX (P12A, P20A), and Pi4 peptides, and analogs of any of the foregoing.\n \ne) C\n1\n-C\n4\n, C\n2\n-C\n6\n, C\n3\n-C\n7\n, and C\n5\n-C\n8 \ndisulfide bonding in which C\n7\n, C\n2\n, C\n3\n, C\n4\n, C\n5\n, C\n6\n, C\n7 \nand C\n8 \nrepresent the order of cysteine residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and fourth cysteines in the amino acid sequence forming a disulfide bond, the second and sixth cysteines forming a disulfide bond, the third and seventh cysteines forming a disulfide bond, and the fifth and eighth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n4\n, C\n2\n-C\n6\n, C\n3\n-C\n7\n, C\n5\n-C\n8 \ndisulfide bonding pattern include, but are not limited to, Chlorotoxin, Bm-12b, and, and analogs of either.\n \nf) C\n1\n-C\n5\n, C\n2\n-C\n6\n, C\n3\n-C\n4\n, and C\n7\n-C\n8 \ndisulfide bonding in which C\n1\n, C\n2\n, C\n3\n, C\n4\n, C\n5\n, C\n6\n, C\n7 \nand C\n8 \nrepresent the order of cysteine residues appearing in the primary sequence of the toxin peptide stated conventionally with the N-terminus of the peptide(s) on the left, with the first and fifth cysteines in the amino acid sequence forming a disulfide bond, the second and sixth cysteines forming a disulfide bond, the third and fourth cysteines forming a disulfide bond, and the seventh and eighth cysteines forming a disulfide bond. Examples of toxin peptides with such a C\n1\n-C\n5\n, C\n2\n-C\n6\n, C\n3\n-C\n4\n, C\n7\n-C\n8 \ndisulfide bonding pattern include, but are not limited to, Maurotoxin peptides and analogs thereof.\n \n \n \n\n\nThe term “randomized” as used to refer to peptide sequences refers to fully random sequences (e.g., selected by phage display methods) and sequences in which one or more residues of a naturally occurring molecule is replaced by an amino acid residue not appearing in that position in the naturally occurring molecule. Exemplary methods for identifying peptide sequences include phage display, \nE. coli \ndisplay, ribosome display, yeast-based screening, RNA-peptide screening, chemical screening, rational design, protein structural analysis, and the like.\n\n\nThe term “pharmacologically active” means that a substance so described is determined to have activity that affects a medical parameter (e.g., blood pressure, blood cell count, cholesterol level) or disease state (e.g., cancer, autoimmune disorders). Thus, pharmacologically active peptides comprise agonistic or mimetic and antagonistic peptides as defined below.\n\n\nThe terms “-mimetic peptide” and “-agonist peptide” refer to a peptide having biological activity comparable to a naturally occurring toxin peptide molecule, e.g., naturally occurring ShK toxin peptide. These terms further include peptides that indirectly mimic the activity of a naturally occurring toxin peptide molecule, such as by potentiating the effects of the naturally occurring molecule.\n\n\nThe term “antagonist peptide” or “inhibitor peptide” refers to a peptide that blocks or in some way interferes with the biological activity of a receptor of interest, or has biological activity comparable to a known antagonist or inhibitor of a receptor of interest (such as, but not limited to, an ion channel).\n\n\nThe term “acidic residue” refers to amino acid residues in D- or L-form having sidechains comprising acidic groups. Exemplary acidic residues include D and E.\n\n\nThe term “amide residue” refers to amino acids in D- or L-form having sidechains comprising amide derivatives of acidic groups. Exemplary residues include N and Q.\n\n\nThe term “aromatic residue” refers to amino acid residues in D- or L-form having sidechains comprising aromatic groups. Exemplary aromatic residues include F, Y, and W.\n\n\nThe term “basic residue” refers to amino acid residues in D- or L-form having sidechains comprising basic groups. Exemplary basic residues include H, K, R, N-methyl-arginine, ω-aminoarginine, ω-methyl-arginine, 1-methyl-histidine, 3-methyl-histidine, and homoarginine (hR) residues.\n\n\nThe term “hydrophilic residue” refers to amino acid residues in D- or L-form having sidechains comprising polar groups. Exemplary hydrophilic residues include C, S, T, N, Q, D, E, K, and citrulline (Cit) residues.\n\n\nThe term “nonfunctional residue” refers to amino acid residues in D- or L-form having sidechains that lack acidic, basic, or aromatic groups. Exemplary nonfunctional amino acid residues include M, G, A, V, I, L and norleucine (Nle).\n\n\nThe term “neutral polar residue” refers to amino acid residues in D- or L-form having sidechains that lack basic, acidic, or polar groups. Exemplary neutral polar amino acid residues include A, V, L, I, P, W, M, and F.\n\n\nThe term “polar hydrophobic residue” refers to amino acid residues in D- or L-form having sidechains comprising polar groups. Exemplary polar hydrophobic amino acid residues include T, G, S, Y, C, Q, and N.\n\n\nThe term “hydrophobic residue” refers to amino acid residues in D- or L-form having sidechains that lack basic or acidic groups. Exemplary hydrophobic amino acid residues include A, V, L, I, P, W, M, F, T, G, S, Y, C, Q, and N.\n\n\nIn some useful embodiments of the compositions of the invention, the amino acid sequence of the toxin peptide is modified in one or more ways relative to a native toxin peptide sequence of interest, such as, but not limited to, a native ShK or OSK1 sequence, their peptide analogs, or any other toxin peptides having amino acid sequences as set for in any of Tables 1-32. The one or more useful modifications can include amino acid additions or insertions, amino acid deletions, peptide truncations, amino acid substitutions, and/or chemical derivatization of amino acid residues, accomplished by known chemical techniques. Such modifications can be, for example, for the purpose of enhanced potency, selectivity, and/or proteolytic stability, or the like. Those skilled in the art are aware of techniques for designing peptide analogs with such enhanced properties, such as alanine scanning, rational design based on alignment mediated mutagenesis using known toxin peptide sequences and/or molecular modeling. For example, ShK analogs can be designed to remove protease cleavage sites (e.g., trypsin cleavage sites at K or R residues and/or chymotrypsin cleavage sites at F, Y, or W residues) in a ShK peptide- or ShK analog-containing composition of the invention, based partially on alignment mediated mutagenesis using HmK (see, e.g., \nFIG. 6\n) and molecular modeling. (See, e.g., Kalman et al., ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide, J. Biol. Chem. 273(49):32697-707 (1998); Kem et al., U.S. Pat. No. 6,077,680; Mouhat et al., OsK1 derivatives, WO 2006/002850 A2)).\n\n\nThe term “protease” is synonymous with “peptidase”. Proteases comprise two groups of enzymes: the endopeptidases which cleave peptide bonds at points within the protein, and the exopeptidases, which remove one or more amino acids from either N- or C-terminus respectively. The term “proteinase” is also used as a synonym for endopeptidase. The four mechanistic classes of proteinases are: serine proteinases, cysteine proteinases, aspartic proteinases, and metallo-proteinases. In addition to these four mechanistic classes, there is a section of the enzyme nomenclature which is allocated for proteases of unidentified catalytic mechanism. This indicates that the catalytic mechanism has not been identified.\n\n\nCleavage subsite nomenclature is commonly adopted from a scheme created by Schechter and Berger (Schechter I. & Berger A., On the size of the active site in proteases. I. Papain, Biochemical and Biophysical Research Communication, 27:157 (1967); Schechter I. & Berger A., On the active site of proteases. 3. Mapping the active site of papain; specific inhibitor peptides of papain, Biochemical and Biophysical Research Communication, 32:898 (1968)). According to this model, amino acid residues in a substrate undergoing cleavage are designated P1, P2, P3, P4 etc. in the N-terminal direction from the cleaved bond. Likewise, the residues in the C-terminal direction are designated P1′, P2′, P3′, P4′. etc.\n\n\nThe skilled artisan is aware of a variety of tools for identifying protease binding or protease cleavage sites of interest. For example, the PeptideCutter software tool is available through the ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of Bioinformatics (SIB; expasy.org/tools/peptidecutter). PeptideCutter searches a protein sequence from the SWISS-PROT and/or TrEMBL databases or a user-entered protein sequence for protease cleavage sites. Single proteases and chemicals, a selection or the whole list of proteases and chemicals can be used. Different forms of output of the results are available: tables of cleavage sites either grouped alphabetically according to enzyme names or sequentially according to the amino acid number. A third option for output is a map of cleavage sites. The sequence and the cleavage sites mapped onto it are grouped in blocks, the size of which can be chosen by the user. Other tools are also known for determining protease cleavage sites. (E.g., Turk, B. et al., Determination of protease cleavage site motifs using mixture-based oriented peptide libraries, Nature Biotechnology, 19:661-667 (2001); Barrett A. et al., Handbook of proteolytic enzymes, Academic Press (1998)).\n\n\nThe serine proteinases include the chymotrypsin family, which includes mammalian protease enzymes such as chymotrypsin, trypsin or elastase or kallikrein. The serine proteinases exhibit different substrate specificities, which are related to amino acid substitutions in the various enzyme subsites interacting with the substrate residues. Some enzymes have an extended interaction site with the substrate whereas others have a specificity restricted to the P1 substrate residue.\n\n\nTrypsin preferentially cleaves at R or K in position P1. A statistical study carried out by Keil (1992) described the negative influences of residues surrounding the Arg- and Lys-bonds (i.e. the positions P2 and P1′, respectively) during trypsin cleavage. (Keil, B., Specificity of proteolysis, Springer-Verlag Berlin-Heidelberg-New York, 335 (1992)). A proline residue in position P1′ normally exerts a strong negative influence on trypsin cleavage. Similarly, the positioning of R and K in P1′ results in an inhibition, as well as negatively charged residues in positions P2 and P1′.\n\n\nChymotrypsin preferentially cleaves at a W, Y or F in position P1 (high specificity) and to a lesser extent at L, M or H residue in position P1. (Keil, 1992). Exceptions to these rules are the following: When W is found in position P1, the cleavage is blocked when M or P are found in position P1′ at the same time. Furthermore, a proline residue in position P1′ nearly fully blocks the cleavage independent of the amino acids found in position P1. When an M residue is found in position P1, the cleavage is blocked by the presence of a Y residue in position P1′. Finally, when H is located in position P1, the presence of a D, M or W residue also blocks the cleavage.\n\n\nMembrane metallo-endopeptidase (NEP; neutral endopeptidase, kidney-brush-border neutral proteinase, enkephalinase, EC 3.4.24.11) cleaves peptides at the amino side of hydrophobic amino acid residues. (Connelly, J C et al., Neutral Endopeptidase 24.11 in Human Neutrophils: Cleavage of Chemotactic Peptide, PNAS, 82(24):8737-8741 (1985)).\n\n\nThrombin preferentially cleaves at an R residue in position P1. (Keil, 1992). The natural substrate of thrombin is fibrinogen. Optimum cleavage sites are when an R residue is in position P1 and Gly is in position P2 and position P1′. Likewise, when hydrophobic amino acid residues are found in position P4 and position P3, a proline residue in position P2, an R residue in position P1, and non-acidic amino acid residues in position P1′ and position P2′. A very important residue for its natural substrate fibrinogen is a D residue in P10.\n\n\nCaspases are a family of cysteine proteases bearing an active site with a conserved amino acid sequence and which cleave peptides specifically following D residues. (Eamshaw W C et al., Mammalian caspases: Structure, activation, substrates, and functions during apoptosis, Annual Review of Biochemistry, 68:383-424 (1999)).\n\n\nThe Arg-C proteinase preferentially cleaves at an R residue in position P1. The cleavage behavior seems to be only moderately affected by residues in position P1′. (Keil, 1992). The Asp-N endopeptidase cleaves specifically bonds with a D residue in position P1′. (Keil, 1992).\n\n\nFurin is a ubiquitous subtilisin-like proprotein convertase. It is the major processing enzyme of the secretory pathway and intracellularly is localized in the trans-golgi network (van den Ouweland, A. M. W. et al. (1990) Nucl. Acids Res., 18, 664; Steiner, D. F. (1998) Curr. Opin. Chem. Biol., 2, 31-39). The minimal furin cleavage site is Arg-X-X-Arg′. However, the enzyme prefers the site Arg-X-(Lys/Arg)-Arg′. An additional arginine at the P6 position appears to enhance cleavage (Krysan, D. J. et al. (1999) J. Biol. Chem., 274, 23229-23234).\n\n\nThe foregoing is merely exemplary and by no means an exhaustive treatment of knowledge available to the skilled artisan concerning protease binding and/or cleavage sites that the skilled artisan may be interested in eliminating in practicing the invention.\n\n\nAdditional useful embodiments of the toxin peptide, e.g., the OSK1 peptide analog, can result from conservative modifications of the amino acid sequences of the peptides disclosed herein. Conservative modifications will produce peptides having functional, physical, and chemical characteristics similar to those of the parent peptide from which such modifications are made. Such conservatively modified forms of the peptides disclosed herein are also contemplated as being an embodiment of the present invention.\n\n\nIn contrast, substantial modifications in the functional and/or chemical characteristics of the toxin peptides may be accomplished by selecting substitutions in the amino acid sequence that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the region of the substitution, for example, as an α-helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the size of the molecule.\n\n\nFor example, a “conservative amino acid substitution” may involve a substitution of a native amino acid residue with a normative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for “alanine scanning mutagenesis” (see, for example, MacLennan et al., Acta Physiol. Scand. Suppl., 643:55-67 (1998); Sasaki et al., 1998, Adv. Biophys. 35:1-24 (1998), which discuss alanine scanning mutagenesis).\n\n\nDesired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important residues of the peptide sequence, or to increase or decrease the affinity of the peptide or vehicle-conjugated peptide molecules described herein.\n\n\nNaturally occurring residues may be divided into classes based on common side chain properties:\n\n\n1) hydrophobic: norleucine (Nor), Met, Ala, Val, Leu, Ile;\n\n\n2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;\n\n\n3) acidic: Asp, Glu;\n\n\n4) basic: His, Lys, Arg;\n\n\n5) residues that influence chain orientation: Gly, Pro; and\n\n\n6) aromatic: Trp, Tyr, Phe.\n\n\nConservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class. Conservative amino acid substitutions may encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.\n\n\nNon-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class. Such substituted residues may be introduced into regions of the human antibody that are homologous with non-human antibodies, or into the non-homologous regions of the molecule.\n\n\nIn making such changes, according to certain embodiments, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).\n\n\nThe importance of the hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art (see, for example, Kyte et al., 1982, J. Mol Biol. 157:105-131). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, in certain embodiments, the substitution of amino acids whose hydropathic indices are within ±2 is included. In certain embodiments, those that are within ±1 are included, and in certain embodiments, those within ±0.5 are included.\n\n\nIt is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as disclosed herein. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.\n\n\nThe following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5) and tryptophan (−3.4). In making changes based upon similar hydrophilicity values, in certain embodiments, the substitution of amino acids whose hydrophilicity values are within ±2 is included, in certain embodiments, those that are within ±1 are included, and in certain embodiments, those within ±0.5 are included. One may also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as “epitopic core regions.”\n\n\nExamples of conservative substitutions include the substitution of one non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine norleucine, alanine, or methionine for another, the substitution of one polar (hydrophilic) amino acid residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic amino acid residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. The phrase “conservative amino acid substitution” also includes the use of a chemically derivatized residue in place of a non-derivatized residue, provided that such polypeptide displays the requisite biological activity. Other exemplary amino acid substitutions that can be useful in accordance with the present invention are set forth in Table 1A.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1A\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nSome Useful Amino Acid Substitutions\n\n\n\n\n\n\n\n\n\n\n \n\n\nOriginal\n\n\nExemplary\n\n\n\n\n\n\n \n\n\nResidues\n\n\nSubstitutions\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nAla\n\n\nVal, Leu, Ile\n\n\n\n\n\n\n \n\n\nArg\n\n\nLys, Gln, Asn\n\n\n\n\n\n\n \n\n\nAsn\n\n\nGln\n\n\n\n\n\n\n \n\n\nAsp\n\n\nGlu\n\n\n\n\n\n\n \n\n\nCys\n\n\nSer, Ala\n\n\n\n\n\n\n \n\n\nGln\n\n\nAsn\n\n\n\n\n\n\n \n\n\nGlu\n\n\nAsp\n\n\n\n\n\n\n \n\n\nGly\n\n\nPro, Ala\n\n\n\n\n\n\n \n\n\nHis\n\n\nAsn, Gln, Lys, Arg\n\n\n\n\n\n\n \n\n\nIle\n\n\nLeu, Val, Met, Ala, Phe,\n\n\n\n\n\n\n \n\n\n \n\n\nNorleucine\n\n\n\n\n\n\n \n\n\nLeu\n\n\nNorleucine, Ile, Val,\n\n\n\n\n\n\n \n\n\n \n\n\nMet, Ala, Phe\n\n\n\n\n\n\n \n\n\nLys\n\n\nArg, 1,4-Diamino-\n\n\n\n\n\n\n \n\n\n \n\n\nbutyric Acid, Gln, Asn\n\n\n\n\n\n\n \n\n\nMet\n\n\nLeu, Phe, Ile\n\n\n\n\n\n\n \n\n\nPhe\n\n\nLeu, Val, Ile, Ala, Tyr\n\n\n\n\n\n\n \n\n\nPro\n\n\nAla\n\n\n\n\n\n\n \n\n\nSer\n\n\nThr, Ala, Cys\n\n\n\n\n\n\n \n\n\nThr\n\n\nSer\n\n\n\n\n\n\n \n\n\nTrp\n\n\nTyr, Phe\n\n\n\n\n\n\n \n\n\nTyr\n\n\nTrp, Phe, Thr, Ser\n\n\n\n\n\n\n \n\n\nVal\n\n\nIle, Met, Leu, Phe, Ala,\n\n\n\n\n\n\n \n\n\n \n\n\nNorleucine\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nIn other examples, a toxin peptide amino acid sequence, e.g., an OSK1 peptide analog sequence, modified from a naturally occurring toxin peptide amino acid sequence includes at least one amino acid residue inserted or substituted therein, relative to the amino acid sequence of the native toxin peptide sequence of interest, in which the inserted or substituted amino acid residue has a side chain comprising a nucleophilic or electrophilic reactive functional group by which the peptide is conjugated to a linker or half-life extending moiety. In accordance with the invention, useful examples of such a nucleophilic or electrophilic reactive functional group include, but are not limited to, a thiol, a primary amine, a seleno, a hydrazide, an aldehyde, a carboxylic acid, a ketone, an aminooxy, a masked (protected) aldehyde, or a masked (protected) keto functional group. Examples of amino acid residues having a side chain comprising a nucleophilic reactive functional group include, but are not limited to, a lysine residue, an α,β-diaminopropionic acid residue, an α,γ-diaminobutyric acid residue, an ornithine residue, a cysteine, a homocysteine, a glutamic acid residue, an aspartic acid residue, or a selenocysteine residue. In some embodiments, the toxin peptide amino acid sequence (or “primary sequence”) is modified at one, two, three, four, five or more amino acid residue positions, by having a residue substituted therein different from the native primary sequence (e.g., OSK1 SEQ ID NO:25) or omitted (e.g., an OSK1 peptide analog optionally lacking a residue at \n \npositions\n \n 36, 37, 36-38, 37-38, or 38).\n\n\nIn further describing toxin peptides herein, a one-letter abbreviation system is frequently applied to designate the identities of the twenty “canonical” amino acid residues generally incorporated into naturally occurring peptides and proteins (Table 1B). Such one-letter abbreviations are entirely interchangeable in meaning with three-letter abbreviations, or non-abbreviated amino acid names. Within the one-letter abbreviation system used herein, an uppercase letter indicates a L-amino acid, and a lower case letter indicates a D-amino acid, unless otherwise noted herein. For example, the abbreviation “R” designates L-arginine and the abbreviation “r” designates D-arginine.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1B\n\n\n\n\n\n\n \n\n\n\n\n\n\nOne-letter abbreviations for the canonical amino acids\n\n\n\n\n\n\nThree-letter abbreviations are in parentheses\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nAlanine (Ala)\n\n\nA\n\n\n\n\n\n\n \n\n\nGlutamine (Gln)\n\n\nQ\n\n\n\n\n\n\n \n\n\nLeucine (Leu)\n\n\nL\n\n\n\n\n\n\n \n\n\nSerine (Ser)\n\n\nS\n\n\n\n\n\n\n \n\n\nArginine (Arg)\n\n\nR\n\n\n\n\n\n\n \n\n\nGlutamic Acid (Glu)\n\n\nE\n\n\n\n\n\n\n \n\n\nLysine (Lys)\n\n\nK\n\n\n\n\n\n\n \n\n\nThreonine (Thr)\n\n\nT\n\n\n\n\n\n\n \n\n\nAsparagine (Asn)\n\n\nN\n\n\n\n\n\n\n \n\n\nGlycine (Gly)\n\n\nG\n\n\n\n\n\n\n \n\n\nMethionine (Met)\n\n\nM\n\n\n\n\n\n\n \n\n\nTryptophan (Trp)\n\n\nW\n\n\n\n\n\n\n \n\n\nAspartic Acid (Asp)\n\n\nD\n\n\n\n\n\n\n \n\n\nHistidine (His)\n\n\nH\n\n\n\n\n\n\n \n\n\nPhenylalanine (Phe)\n\n\nF\n\n\n\n\n\n\n \n\n\nTyrosine (Tyr)\n\n\nY\n\n\n\n\n\n\n \n\n\nCysteine (Cys)\n\n\nC\n\n\n\n\n\n\n \n\n\nIsoleucine (Ile)\n\n\nI\n\n\n\n\n\n\n \n\n\nProline (Pro)\n\n\nP\n\n\n\n\n\n\n \n\n\nValine (Val)\n\n\nV\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nAn amino acid substitution in an amino acid sequence is typically designated herein with a one-letter abbreviation for the amino acid residue in a particular position, followed by the numerical amino acid position relative to the native toxin peptide sequence of interest, which is then followed by the one-letter symbol for the amino acid residue substituted in. For example, “T30D” symbolizes a substitution of a threonine residue by an aspartate residue at \namino acid position\n 30, relative to a hypothetical native toxin peptide sequence. By way of further example, “R18hR” or “R18Cit” indicates a substitution of an arginine residue by a homoarginine or a citrulline residue, respectively, at \namino acid position\n 18, relative to the hypothetical native toxin peptide. An amino acid position within the amino acid sequence of any particular toxin peptide (or peptide analog) described herein may differ from its position relative to the native sequence, i.e., as determined in an alignment of the N-terminal or C-terminal end of the peptide's amino acid sequence with the N-terminal or C-terminal end, as appropriate, of the native toxin peptide sequence. For example, \namino acid position\n 1 of the sequence SCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC ShK(2-35); SEQ ID NO:92), a N-terminal truncation of the native ShK sequence, thus aligned with the C-terminal of native ShK(1-35) (SEQ ID NO:5), corresponds to \namino acid position\n 2 relative to the native sequence, and \namino acid position\n 34 of SEQ ID NO:92 corresponds to \namino acid position\n 35 relative to the native sequence (SEQ ID NO:5).\n\n\nIn certain embodiments of the present invention, amino acid substitutions encompass, non-canonical amino acid residues, which include naturally rare (in peptides or proteins) amino acid residues or unnatural amino acid residues. Non-canonical amino acid residues can be incorporated into the peptide by chemical peptide synthesis rather than by synthesis in biological systems, such as recombinantly expressing cells, or alternatively the skilled artisan can employ known techniques of protein engineering that use recombinantly expressing cells. (See, e.g., Link et al., Non-canonical amino acids in protein engineering, Current Opinion in Biotechnology, 14(6):603-609 (2003)). The term “non-canonical amino acid residue” refers to amino acid residues in D- or L-form that are not among the 20 canonical amino acids generally incorporated into naturally occurring proteins, for example, β-amino acids, homoamino acids, cyclic amino acids and amino acids with derivatized side chains. Examples include (in the L-form or D-form; abbreviated as in parentheses): citrulline (Cit), homocitrulline (hCit), N\nα\n-methylcitrulline (NMeCit), N\nα\n-methylhomocitrulline (N\nα\n-MeHoCit), ornithine (Orn), N\nα\n-Methylornithine (N\nα\n-MeOrn or NMeOrn), sarcosine (Sar), homolysine (hLys or hK), homoarginine (hArg or hR), homoglutamine (hQ), N\nα\n-methylarginine (NMeR), N\nα\n-methylleucine (N\nα\n-MeL or NMeL), N-methylhomolysine (NMeHoK), N\nα\n-methylglutamine (NMeQ), norleucine (Nle), norvaline (Nva), 1,2,3,4-tetrahydroisoquinoline (Tic), Octahydroindole-2-carboxylic acid (Oic), 3-(1-naphthyl)alanine (1-Nal), 3-(2-naphthyl)alanine (2-Nal), 1,2,3,4-tetrahydroisoquinoline (Tic), 2-indanylglycine (Igl), para-iodophenylalanine (pI-Phe), para-aminophenylalanine (4AmP or 4-Amino-Phe), 4-guanidino phenylalanine (Guf), glycyllysine (abbreviated herein “K(N\nε\n-glycyl)” or “K(glycyl)” or “K(gly)”), nitrophenylalanine (nitrophe), aminophenylalanine (aminophe or Amino-Phe), benzylphenylalanine (benzylphe), γ-carboxyglutamic acid (γ-carboxyglu), hydroxyproline (hydroxypro), p-carboxyl-phenylalanine (Cpa), α-aminoadipic acid (Aad), Nα-methyl valine (NMeVal), N-α-methyl leucine (NMeLeu), Nα-methylnorleucine (NMeNle), cyclopentylglycine (Cpg), cyclohexylglycine (Chg), acetylarginine (acetylarg), α,β-diaminopropionoic acid (Dpr), α,γ-diaminobutyric acid (Dab), diaminopropionic acid (Dap), cyclohexylalanine (Cha), 4-methyl-phenylalanine (MePhe), β,β-diphenyl-alanine (BiPhA), aminobutyric acid (Abu), 4-phenyl-phenylalanine (or biphenylalanine; 4Bip), α-amino-isobutyric acid (Aib), beta-alanine, beta-aminopropionic acid, piperidinic acid, aminocaproic acid, aminoheptanoic acid, aminopimelic acid, desmosine, diaminopimelic acid, N-ethylglycine, N-ethylaspargine, hydroxylysine, allo-hydroxylysine, isodesmosine, allo-isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, 4-hydroxyproline (Hyp), γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω-methylarginine, 4-Amino-O-Phthalic Acid (4APA), and other similar amino acids, and derivatized forms of any of these as described herein. Table 1B contains some exemplary non-canonical amino acid residues that are useful in accordance with the present invention and associated abbreviations as typically used herein, although the skilled practitioner will understand that different abbreviations and nomenclatures may be applicable to the same substance and my appear interchangeably herein.\n\n\nTable 1B. Useful non-canonical amino acids for amino acid addition, insertion, or substitution into toxin peptide sequences, including OSK1 peptide analog sequences, in accordance with the present invention. In the event an abbreviation listed in Table 1B differs from another abbreviation for the same substance disclosed elsewhere herein, both abbreviations are understood to be applicable.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAbbreviation\n\n\nAmino Acid\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nSar\n\n\nSarcosine\n\n\n\n\n\n\nNle\n\n\nnorleucine\n\n\n\n\n\n\nIle\n\n\nisoleucine\n\n\n\n\n\n\n1-Nal\n\n\n3-(1-naphthyl)alanine\n\n\n\n\n\n\n2-Nal\n\n\n3-(2-naphthyl)alanine\n\n\n\n\n\n\nBip\n\n\n4,4′-biphenyl alanine\n\n\n\n\n\n\nDip\n\n\n3,3-diphenylalanine\n\n\n\n\n\n\nNvl\n\n\nnorvaline\n\n\n\n\n\n\nNMe-Val\n\n\nNα-methyl valine\n\n\n\n\n\n\nNMe-Leu\n\n\nNα-methyl leucine\n\n\n\n\n\n\nNMe-Nle\n\n\nNα-methyl norleucine\n\n\n\n\n\n\nCpg\n\n\ncyclopentyl glycine\n\n\n\n\n\n\nChg\n\n\ncyclohexyl glycine\n\n\n\n\n\n\nHyp\n\n\nhydroxy proline\n\n\n\n\n\n\nOic\n\n\nOctahydroindole-2-Carboxylic Acid\n\n\n\n\n\n\nIgl\n\n\nIndanyl glycine\n\n\n\n\n\n\nAib\n\n\naminoisobutyric acid\n\n\n\n\n\n\nAic\n\n\n2-aminoindane-2-carboxylic acid\n\n\n\n\n\n\nPip\n\n\npipecolic acid\n\n\n\n\n\n\nBhTic\n\n\nβ-homo Tic\n\n\n\n\n\n\nBhPro\n\n\nβ-homo proline\n\n\n\n\n\n\nSar\n\n\nSarcosine\n\n\n\n\n\n\nCpg\n\n\ncyclopentyl glycine\n\n\n\n\n\n\nTiq\n\n\n1,2,3,4-L-Tetrahydroisoquinoline-1-Carboxylic\n\n\n\n\n\n\n \n\n\nacid\n\n\n\n\n\n\nNip\n\n\nNipecotic Acid\n\n\n\n\n\n\nThz\n\n\nThiazolidine-4-carboxylic acid\n\n\n\n\n\n\nThi\n\n\n3-thienyl alanine\n\n\n\n\n\n\n4GuaPr\n\n\n4-guanidino proline\n\n\n\n\n\n\n4Pip\n\n\n4-Amino-1-piperidine-4-carboxylic acid\n\n\n\n\n\n\nIdc\n\n\nindoline-2-carboxylic acid\n\n\n\n\n\n\nHydroxyl-Tic\n\n\n1,2,3,4-Tetrahydroisoquinoline-7-hydroxy-3-\n\n\n\n\n\n\n \n\n\ncarboxylic acid\n\n\n\n\n\n\nBip\n\n\n4,4′-biphenyl alanine\n\n\n\n\n\n\nOme-Tyr\n\n\nO-methyl tyrosine\n\n\n\n\n\n\nI-Tyr\n\n\nIodotyrosine\n\n\n\n\n\n\nTic\n\n\n1,2,3,4-L-Tetrahydroisoquinoline-3-Carboxylic\n\n\n\n\n\n\n \n\n\nacid\n\n\n\n\n\n\nIgl\n\n\nIndanyl glycine\n\n\n\n\n\n\nBhTic\n\n\nβ-homo Tic\n\n\n\n\n\n\nBhPhe\n\n\nβ-homo phenylalanine\n\n\n\n\n\n\nAMeF\n\n\nα-methyl Phenyalanine\n\n\n\n\n\n\nBPhe\n\n\nβ-phenylalanine\n\n\n\n\n\n\nPhg\n\n\nphenylglycine\n\n\n\n\n\n\nAnc\n\n\n3-amino-2-naphthoic acid\n\n\n\n\n\n\nAtc\n\n\n2-aminotetraline-2-carboxylic acid\n\n\n\n\n\n\nNMe-Phe\n\n\nNα-methyl phenylalanine\n\n\n\n\n\n\nNMe-Lys\n\n\nNα-methyl lysine\n\n\n\n\n\n\nTpi\n\n\n1,2,3,4-Tetrahydronorharman-3-Carboxylic acid\n\n\n\n\n\n\nCpg\n\n\ncyclopentyl glycine\n\n\n\n\n\n\nDip\n\n\n3,3-diphenylalanine\n\n\n\n\n\n\n4Pal\n\n\n4-pyridinylalanine\n\n\n\n\n\n\n3Pal\n\n\n3-pyridinylalanine\n\n\n\n\n\n\n2Pal\n\n\n2-pyridinylalanine\n\n\n\n\n\n\n4Pip\n\n\n4-Amino-1-piperidine-4-carboxylic acid\n\n\n\n\n\n\n4AmP\n\n\n4-amino-phenylalanine\n\n\n\n\n\n\nIdc\n\n\nindoline-2-carboxylic acid\n\n\n\n\n\n\nChg\n\n\ncyclohexyl glycine\n\n\n\n\n\n\nhPhe\n\n\nhomophenylalanine\n\n\n\n\n\n\nBhTrp\n\n\nβ-homotryptophan\n\n\n\n\n\n\npI-Phe\n\n\n4-iodophenylalanine\n\n\n\n\n\n\nAic\n\n\n2-aminoindane-2-carboxylic acid\n\n\n\n\n\n\nNMe-Lys\n\n\nNα-methyl lysine\n\n\n\n\n\n\nOrn\n\n\nornithine\n\n\n\n\n\n\nDpr\n\n\n2,3-Diaminopropionic acid\n\n\n\n\n\n\nDbu\n\n\n2,4-Diaminobutyric acid\n\n\n\n\n\n\nhomoLys\n\n\nhomolysine\n\n\n\n\n\n\nN-eMe-K\n\n\nNε-methyl-lysine\n\n\n\n\n\n\nN-eEt-K\n\n\nNε-ethyl-lysine\n\n\n\n\n\n\nN-eIPr-K\n\n\nNε-isopropyl-lysine\n\n\n\n\n\n\nbhomoK\n\n\nβ-homolysine\n\n\n\n\n\n\nrLys\n\n\nLys ψ(CH\n2\nNH)-reduced amide bond\n\n\n\n\n\n\nrOrn\n\n\nOrn ψ(CH\n2\nNH)-reduced amide bond\n\n\n\n\n\n\nAcm\n\n\nacetamidomethyl\n\n\n\n\n\n\nAhx\n\n\n6-aminohexanoic acid\n\n\n\n\n\n\nεAhx\n\n\n6-aminohexanoic acid\n\n\n\n\n\n\nK(NPeg11)\n\n\nNε-(O-(aminoethyl)-O′-(2-propanoyl)-\n\n\n\n\n\n\n \n\n\nundecaethyleneglycol)-Lysine\n\n\n\n\n\n\nK(NPeg27)\n\n\nNε-(O-(aminoethyl)-O′-(2-propanoyl)-\n\n\n\n\n\n\n \n\n\n(ethyleneglycol)27-Lysine\n\n\n\n\n\n\nCit\n\n\nCitrulline\n\n\n\n\n\n\nhArg\n\n\nhomoarginine\n\n\n\n\n\n\nhCit\n\n\nhomocitrulline\n\n\n\n\n\n\nNMe-Arg\n\n\nNα-methyl arginine (NMeR)\n\n\n\n\n\n\nGuf\n\n\n4-guanidinyl phenylalanine\n\n\n\n\n\n\nbhArg\n\n\nβ-homoarginine\n\n\n\n\n\n\n3G-Dpr\n\n\n2-amino-3-guanidinopropanoic acid\n\n\n\n\n\n\n4AmP\n\n\n4-amino-phenylalanine\n\n\n\n\n\n\n4AmPhe\n\n\n4-amidino-phenylalanine\n\n\n\n\n\n\n4AmPig\n\n\n2-amino-2-(1-carbamimidoylpiperidin-4-\n\n\n\n\n\n\n \n\n\nyl) acetic acid\n\n\n\n\n\n\n4GuaPr\n\n\n4-guanidino proline\n\n\n\n\n\n\nN-Arg\n\n\nNα-[(CH\n2\n)\n3\nNHCH(NH)NH\n2\n] substituted glycine\n\n\n\n\n\n\nrArg\n\n\nArg ψ(CH\n2\nNH) -reduced amide bond\n\n\n\n\n\n\n4PipA\n\n\n4-Piperidinyl alanine\n\n\n\n\n\n\nNMe-Arg\n\n\nNα-methyl arginine (or NMeR)\n\n\n\n\n\n\nNMe-Thr\n\n\nNα-methyl threonine(or NMeThr)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nNomenclature and Symbolism for Amino Acids and Peptides by the UPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) have been published in the following documents: Biochem. J., 1984, 219, 345-373; Eur. J. Biochem., 1984, 138, 9-37; 1985, 152, 1; 1993, 213, 2; Internat. J. Pept. Prot. Res., 1984, 24, following p 84; J. Biol. Chem., 1985, 260, 14-42; Pure Appl. Chem., 1984, 56, 595-624; Amino Acids and Peptides, 1985, 16, 387-410; Biochemical Nomenclature and Related Documents, 2nd edition, Portland Press, 1992, pages 39-69].\n\n\nAs stated herein, in accordance with the present invention, peptide portions of the inventive compositions, such as the toxin peptide or a peptide linker, can also be chemically derivatized at one or more amino acid residues. Peptides that contain derivatized amino acid residues can be synthesized by known organic chemistry techniques. “Chemical derivative” or “chemically derivatized” in the context of a peptide refers to a subject peptide having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty canonical amino acids, whether in L- or D-form. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine maybe substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.\n\n\nUseful derivatizations include, in some embodiments, those in which the amino terminal of the toxin peptide, such as but not limited to the OSK1 peptide analog, is chemically blocked so that conjugation with the vehicle will be prevented from taking place at an N-terminal free amino group. There may also be other beneficial effects of such a modification, for example a reduction in the toxin peptide's susceptibility to enzymatic proteolysis. The N-terminus of the toxin peptide, e.g., the OSK1 peptide analog, can be acylated or modified to a substituted amine, or derivatized with another functional group, such as an aromatic or aryl moiety (e.g., an indole acid, benzyl (Bzl or Bn), dibenzyl (DiBzl or Bn\n2\n), benzoyl, or benzyloxycarbonyl (Cbz or Z)), N,N-dimethylglycine or creatine. For example, in some embodiments, an acyl moiety, such as, but not limited to, a formyl, acetyl (Ac), propanoyl, butanyl, heptanyl, hexanoyl, octanoyl, or nonanoyl, can be covalently linked to the N-terminal end of the peptide, e.g., the OSK1 peptide analog, which can prevent undesired side reactions during conjugation of the vehicle to the peptide. Alternatively, a fatty acid (e.g. butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic or the like) or polyethylene glycol moiety can be covalently linked to the N-terminal end of the peptide, e.g., the OSK1 peptide analog. Other exemplary N-terminal derivative groups include —NRR\n1 \n(other than —NH\n2\n), —NRC(O)R\n1\n, —NRC(O)OR\n1\n, —NRS(O)\n2\nR\n1\n, —NHC(O)NHR\n1\n, succinimide, or benzyloxycarbonyl-NH-(Cbz-NH—), wherein R and R\n1 \nare each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from C\n1\n-C\n4 \nalkyl, C\n1\n-C\n4 \nalkoxy, chloro, and bromo.\n\n\nIn some embodiments of the present invention, basic residues (e.g., lysine) of the toxin peptide of interest can be replaced with other residues (nonfunctional residues preferred). Such molecules will be less basic than the molecules from which they are derived and otherwise retain the activity of the molecules from which they are derived, which can result in advantages in stability and immunogenicity; the present invention should not, however, be limited by this theory.\n\n\nAdditionally, physiologically acceptable salts of the inventive compositions are also encompassed, including when the inventive compositions are referred to herein as “molecules” or “compounds.”. By “physiologically acceptable salts” is meant any salts that are known or later discovered to be pharmaceutically acceptable. Some non-limiting examples of pharmaceutically acceptable salts are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; maleate; tartrate; glycolate; gluconate; succinate; mesylate; besylate; salts of gallic acid esters (gallic acid is also known as 3, 4, 5 trihydroxybenzoic acid) such as PentaGalloylGlucose (PGG) and epigallocatechin gallate (EGCG), salts of cholesteryl sulfate, pamoate, tannate and oxalate salts.\n\n\nStructure of Compounds:\n\n\nIn general. Recombinant proteins have been developed as therapeutic agents through, among other means, covalent attachment to half-life extending moieties. Such moieties include the “Fc” domain of an antibody, as is used in Enbrel® (etanercept), as well as biologically suitable polymers (e.g., polyethylene glycol, or “PEG”), as is used in Neulasta® (pegfilgrastim). Feige et al. described the use of such half-life extenders with peptides in U.S. Pat. No. 6,660,843, issued Dec. 9, 2003 (hereby incorporated by reference in its entirety).\n\n\nThe present inventors have determined that molecules of this invention—peptides of about 80 amino acids or less with at least two intrapeptide disulfide bonds—possess therapeutic advantages when covalently attached to half-life extending moieties. Molecules of the present invention can further comprise an additional pharmacologically active, covalently bound peptide, which can be bound to the half-life extending moiety (F\n1 \nand/or F\n2\n) or to the peptide portion (P). Embodiments of the inventive compositions containing more than one half-life extending moiety (F\n1 \nand F\n2\n) include those in which F\n1 \nand F\n2 \nare the same or different half-life extending moieties. Examples (with or without a linker between each domain) include structures as illustrated in \nFIG. 75\n as well as the following embodiments (and others described herein and in the working Examples):\n\n\n20KPEG—toxin peptide—Fc domain, consistent with the formula [(F\n1\n)\n1\n—(X\n2\n)\n1\n—(F\n2\n)\n1\n];\n\n\n20KPEG—toxin peptide—Fc CH2 domain, consistent with the formula [(F\n1\n)\n1\n—(X\n2\n)\n1\n—(F\n2\n)\n1\n];\n\n\n20KPEG—toxin peptide—HSA, consistent with the formula [(F\n1\n)\n1\n(X\n2\n)\n1\n—(F\n2\n)\n1\n];\n\n\n20KPEG—Fc domain—toxin peptide, consistent with the formula [(F\n1\n)\n1\n—(F\n2\n)\n1\n—(X\n3\n)\n1\n];\n\n\n20KPEG—Fc CH2 domain—toxin peptide, consistent with the formula [(F\n1\n)\n1\n—(F\n2\n)\n1\n—(X\n3\n)\n1\n]; and\n\n\n20KPEG—HSA—toxin peptide, consistent with the formula [(F\n1\n)\n1\n—(F\n2\n)\n1\n—(X\n3\n)\n1\n].\n\n\nToxin peptides. Any number of toxin peptides (i.e., “P”, or equivalently shown as “P\n1\n” in \nFIG. 2\n) can be used in conjunction with the present invention. Of particular interest are the toxin peptides ShK, HmK, MgTx, AgTx2, Agatoxins, and HsTx1, as well as modified analogs of these, in particular OsK1 (also referred to as “OSK1”) peptide analogs of the present invention, and other peptides that mimic the activity of such toxin peptides. As stated herein above, if more than one toxin peptide “P” is present in the inventive composition, “P” can be independently the same or different from any other toxin peptide(s) also present in the inventive composition. For example, in a composition having the formula P-(L)\ng\n-F\n1\n-(L)\nf\n-P, both of the toxin peptides, “P”, can be the same peptide analog of ShK, different peptide analogs of ShK, or one can be a peptide analog of ShK and the other a peptide analog of OSK1. In a preferred embodiment, at least one P is a an OSK1 peptide analog as further described herein.\n\n\nIn some embodiments of the invention, other peptides of interest are especially useful in molecules having additional features over the molecules of structural Formula I. In such molecules, the molecule of Formula I further comprises an additional pharmacologically active, covalently bound peptide, which is an agonistic peptide, an antagonistic peptide, or a targeting peptide; this peptide can be conjugated to F\n1 \nor F\n2 \nor P. Such agonistic peptides have activity agonistic to the toxin peptide but are not required to exert such activity by the same mechanism as the toxin peptide. Peptide antagonists are also useful in embodiments of the invention, with a preference for those with activity that can be complementary to the activity of the toxin peptide. Targeting peptides are also of interest, such as peptides that direct the molecule to particular cell types, organs, and the like. These classes of peptides can be discovered by methods described in the references cited in this specification and other references. Phage display, in particular, is useful in generating toxin peptides for use in the present invention. Affinity selection from libraries of random peptides can be used to identify peptide ligands for any site of any gene product. Dedman et al. (1993), \nJ. Biol. Chem. \n268: 23025-30. Phage display is particularly well suited for identifying peptides that bind to such proteins of interest as cell surface receptors or any proteins having linear epitopes. Wilson et al. (1998), \nCan. J. Microbiol. \n44: 313-29; Kay et al. (1998), \nDrug Disc. Today \n3: 370-8. Such proteins are extensively reviewed in Herz et al. (1997), \nJ. Receptor and Signal Transduction Res. \n17(5): 671-776, which is hereby incorporated by reference in its entirety. Such proteins of interest are preferred for use in this invention.\n\n\nParticularly preferred peptides appear in the following tables. These peptides can be prepared by methods disclosed in the art or as described hereinafter. Single letter amino acid abbreviations are used. Unless otherwise specified, each X is independently a nonfunctional residue.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nKv1.3 inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nLVKCRGTSDCGRPCQQQTGCPNSKCIN\n\n\nPi1\n\n\n21\n\n\n\n\n\n\nRMCKCYGC\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNR\n\n\nPi2\n\n\n17\n\n\n\n\n\n\n \nKCKCFGR\n \n \n \n\n\n \n\n\n\n\n\n\nTISCTNEKQCYPHCKKETGYPNAKCMNR\n\n\nPi3\n \n \n \n \n\n\n18\n\n\n\n\n\n\n \nKCKCFGR\n \n \n \n\n\n \n\n\n\n\n\n\nIEAIRCGGSRDCYRPCQKRTGCPNAKCIN\n\n\nPi4\n \n \n \n \n\n\n19\n\n\n\n\n\n\n \nKTCKCYGCS\n \n \n \n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNR\n\n\nHsTx1\n \n \n \n \n\n\n61\n\n\n\n\n\n\n \nKCKCNRC\n \n \n \n\n\n \n\n\n\n\n\n\nGVPINVSCTGSPQCIKPCKDAGMRFGKC\n\n\nAgTx2\n \n \n \n \n\n\n23\n\n\n\n\n\n\n \nMNRKCHCTPK\n \n \n \n\n\n \n\n\n\n\n\n\nGVPINVKCTGSPQCLKPCKDAGMRFGKC\n\n\nAgTx1\n \n \n \n \n\n\n85\n\n\n\n\n\n\n \nINGKCHCTPK\n \n \n \n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN\n\n\nOSK1\n \n \n \n \n\n\n25\n\n\n\n\n\n\n \nGKCHCTPK\n \n \n \n\n\n \n\n\n\n\n\n\nZKECTGPQHCTNFCRKNKCTHGKCMNRK\n\n\nAnuroctoxin\n \n \n \n \n\n\n62\n\n\n\n\n\n\n \nCKCFNCK\n \n \n \n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCSKPCKELYGSSAGAKC\n\n\nNTX\n \n \n \n \n\n\n30\n\n\n\n\n\n\nMNGKCKCYNN\n\n\n\n\n\n\n \n\n\n\n\n\n\nTVIDVKCTSPKQCLPPCKAQFGIRAGAKC\n\n\nHgTx1\n\n\n27\n\n\n\n\n\n\n \nMNGKCKCYPH\n \n \n \n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKC\n\n\nChTx\n \n \n \n \n\n\n36\n\n\n\n\n\n\nMNKKCRCYS\n\n\n\n\n\n\n \n\n\n\n\n\n\nVFINAKCRGSPECLPKCKEAIGKAAGKCM\n\n\nTitystoxin-Ka\n\n\n86\n\n\n\n\n\n\n \nNGKCKCYP\n \n \n \n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRA\n\n\nBgK\n \n \n \n \n\n\n9\n\n\n\n\n\n\n \nNCAKTCELC\n \n \n \n\n\n \n\n\n\n\n\n\nVGINVKCKHSGQCLKPCKDAGMRFGKCIN\n\n\nBmKTX\n \n \n \n \n\n\n26\n\n\n\n\n\n\n \nGKCDCTPKG\n \n \n \n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKC\n\n\nBmTx1\n \n \n \n \n\n\n40\n\n\n\n\n\n\nMNGKCRCYS\n\n\n\n\n\n\n \n\n\n\n\n\n\nVFINVKCRGSKECLPACKAAVGKAAGKCM\n\n\nTc30\n\n\n87\n\n\n\n\n\n\nNGKCKCYP\n\n\n\n\n\n\n \n\n\n\n\n\n\nTGPQTTCQAAMCEAGCKGLGKSMESCQG\n\n\nTc32\n\n\n13\n\n\n\n\n\n\nDTCKCKA\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 2\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nShK peptide and ShK peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ\n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK\n\n\n5\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQSKHSMKYRLSFCRKTSGTC\n\n\nShK-S17/S32\n\n\n88\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSSIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTS\n\n\nShK-S3/S35\n\n\n89\n\n\n\n\n\n\n \n\n\n\n\n\n\nSSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-S1\n\n\n90\n\n\n\n\n\n\n \n\n\n\n\n\n\n(N-acetylarg)\n\n\nShK-N-acetylarg1\n\n\n91\n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-d1\n\n\n92\n\n\n\n\n\n\n \n\n\n\n\n\n\nCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-d2\n\n\n93\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A1\n\n\n94\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCADTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A4\n\n\n95\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCADTIPKSRCTAAQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A4/A15\n\n\n96\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCADTIPKSRCTAAQCKHSMKYRASFCRKTCGTC\n\n\nShK-A4/A15/A25\n\n\n97\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDAIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A6\n\n\n98\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTAPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A7\n\n\n99\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIAKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A8\n\n\n100\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9\n\n\n101\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPESRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-E9\n\n\n102\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPQSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Q9\n\n\n103\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKARCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A10\n\n\n104\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A11\n\n\n105\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-E11\n\n\n106\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSQCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Q11\n\n\n107\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCAAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A13\n\n\n108\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAAQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A15\n\n\n109\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAWQCKHSMKYRLSFCRKTCGTC\n\n\nShK-W15\n\n\n110\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAX\ns15\nQCKHSMKYRLSFCRKTCGTC\n\n\nShK-X15\n\n\n111\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAAQCKHSMKYRASFCRKTCGTC\n\n\nShK-A15/A25\n\n\n112\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFACKHSMKYRLSFCRKTCGTC\n\n\nShK-A16\n\n\n113\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFECKHSMKYRLSFCRKTCGTC\n\n\nShK-E16\n\n\n114\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCAHSMKYRLSFCRKTCGTC\n\n\nShK-A18\n\n\n115\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCEHSMKYRLSFCRKTCGTC\n\n\nShK-E18\n\n\n116\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKASMKYRLSFCRKTCGTC\n\n\nShK-A19\n\n\n117\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKKSMKYRLSFCRKTCGTC\n\n\nShK-K19\n\n\n118\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHAMKYRLSFCRKTCGTC\n\n\nShK-A20\n\n\n119\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSAKYRLSFCRKTCGTC\n\n\nShK-A21\n\n\n120\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSX\ns21\nKYRLSFCRKTCGTC\n\n\nShK-X21\n\n\n121\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHS(norleu)KYRLSFCRKTCGTC\n\n\nShK-Nle21\n\n\n122\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A22\n\n\n123\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMEYRLSFCRKTCGTC\n\n\nShK-E22\n\n\n124\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMRYRLSFCRKTCGTC\n\n\nShK-R22\n\n\n125\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMX\ns22\nYRLSFCRKTCGTC\n\n\nShK-X22\n\n\n126\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSM(norleu)YRLSFCRKTCGTC\n\n\nShK-Nle22\n\n\n127\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSM(orn)YRLSFCRKTCGTC\n\n\nShK-Orn22\n\n\n128\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSM(homocit)YRLSFCRKTCGTC\n\n\nShK-Homocit22\n\n\n129\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSM(diaminopropionic)YRLS\n\n\nShK-Diamino-\n\n\n130\n\n\n\n\n\n\nFCRKTCGTC\n\n\npropionic22\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKARLSFCRKTCGTC\n\n\nShK-A23\n\n\n131\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKSRLSFCRKTCGTC\n\n\nShK-S23\n\n\n132\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKFRLSFCRKTCGTC\n\n\nShK-F23\n\n\n133\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKX\ns23\nRLSFCRKTCGTC\n\n\nShK-X23\n\n\n134\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMK(nitrophe)RLSFCRKTCGTC\n\n\nShK-Nitrophe23\n\n\n135\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMK(aminophe)RLSFCRKTCGTC\n\n\nShK-Aminophe23\n\n\n136\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMK(benzylphe)RLSFCRKTCG\n\n\nShK-Benzylphe23\n\n\n137\n\n\n\n\n\n\nTC\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYALSFCRKTCGTC\n\n\nShK-A24\n\n\n138\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYELSFCRKTCGTC\n\n\nShK-E24\n\n\n139\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRASFCRKTCGTC\n\n\nShK-A25\n\n\n140\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLAFCRKTCGTC\n\n\nShK-A26\n\n\n141\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSACRKTCGTC\n\n\nShK-A27\n\n\n142\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSX\ns27\nCRKTCGTC\n\n\nShK-X27\n\n\n143\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSFCAKTCGTC\n\n\nShK-A29\n\n\n144\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRATCGTC\n\n\nShK-A30\n\n\n145\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKACGTC\n\n\nShK-A31\n\n\n146\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGAC\n\n\nShK-A34\n\n\n147\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCADTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A4d1\n\n\n148\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCADTIPKSRCTAAQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A4/A15d1\n\n\n149\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCADTIPKSRCTAAQCKHSMKYRASFCRKTCGTC\n\n\nShK-A4/A15/A25\n\n\n150\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDAIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A6 d1\n\n\n151\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTAPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A7 d1\n\n\n152\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIAKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A8 d1\n\n\n153\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9 d1\n\n\n154\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPESRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-E9 d1\n\n\n155\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPQSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Q9 d1\n\n\n156\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKARCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A10 d1\n\n\n157\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A11 d1\n\n\n158\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-E11 d1\n\n\n159\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSQCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Q11 d1\n\n\n160\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCAAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A13 d1\n\n\n161\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAAQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A15 d1\n\n\n162\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAWQCKHSMKYRLSFCRKTCGTC\n\n\nShK-W15 d1\n\n\n163\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAX\ns15\nQCKHSMKYRLSFCRKTCGTC\n\n\nShK-X15 d1\n\n\n164\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAAQCKHSMKYRASFCRKTCGTC\n\n\nShK-A15/A25 d1\n\n\n165\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFACKHSMKYRLSFCRKTCGTC\n\n\nShK-A16 d1\n\n\n166\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFECKHSMKYRLSFCRKTCGTC\n\n\nShK-E16 d1\n\n\n167\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCAHSMKYRLSFCRKTCGTC\n\n\nShK-A18 d1\n\n\n168\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCEHSMKYRLSFCRKTCGTC\n\n\nShK-E18 d1\n\n\n169\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKASMKYRLSFCRKTCGTC\n\n\nShK-A19 d1\n\n\n170\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKKSMKYRLSFCRKTCGTC\n\n\nShK-K19 d1\n\n\n171\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHAMKYRLSFCRKTCGTC\n\n\nShK-A20 d1\n\n\n172\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSAKYRLSFCRKTCGTC\n\n\nShK-A21 d1\n\n\n173\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSX\ns21\nKYRLSFCRKTCGTC\n\n\nShK-X21 d1\n\n\n174\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHS(norleu)KYRLSFCRKTCGTC\n\n\nShK-Nle21 d1\n\n\n175\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A22 d1\n\n\n176\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMEYRLSFCRKTCGTC\n\n\nShK-E22 d1\n\n\n177\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMRYRLSFCRKTCGTC\n\n\nShK-R22 d1\n\n\n178\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMX\ns22\nYRLSFCRKTCGTC\n\n\nShK-X22 d1\n\n\n179\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSM(norleu)YRLSFCRKTCGTC\n\n\nShK-Nle22 d1\n\n\n180\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSM(orn)YRLSFCRKTCGTC\n\n\nShK-Orn22 d1\n\n\n181\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSM(homocit)YRLSFCRKTCGTC\n\n\nShK-Homocit22\n\n\n182\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSM(diaminopropionic)YRLSF\n\n\nShK-Diamino-\n\n\n183\n\n\n\n\n\n\nCRKTCGTC\n\n\npropionic22 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKARLSFCRKTCGTC\n\n\nShK-A23 d1\n\n\n184\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKSRLSFCRKTCGTC\n\n\nShK-S23 d1\n\n\n185\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKFRLSFCRKTCGTC\n\n\nShK-F23 d1\n\n\n186\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKX\ns23\nRLSFCRKTCGTC\n\n\nShK-X23 d1\n\n\n187\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMK(nitrophe)RLSFCRKTCGTC\n\n\nShK-Nitrophe23\n\n\n188\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMK(aminophe)RLSFCRKTCGTC\n\n\nShK-Aminophe23\n\n\n189\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMK(benzylphe)RLSFCRKTCGTC\n\n\nShK-Benzylphe23\n\n\n190\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYALSFCRKTCGTC\n\n\nShK-A24 d1\n\n\n191\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYELSFCRKTCGTC\n\n\nShK-E24 d1\n\n\n192\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRASFCRKTCGTC\n\n\nShK-A25 d1\n\n\n193\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLAFCRKTCGTC\n\n\nShK-A26 d1\n\n\n194\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSACRKTCGTC\n\n\nShK-A27 d1\n\n\n195\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSX\ns27\nCRKTCGTC\n\n\nShK-X27 d1\n\n\n196\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCAKTCGTC\n\n\nShK-A29 d1\n\n\n197\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRATCGTC\n\n\nShK-A30 d1\n\n\n198\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKACGTC\n\n\nShK-A31 d1\n\n\n199\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGAC\n\n\nShK-A34 d1\n\n\n200\n\n\n\n\n\n\n \n\n\n\n\n\n\nYSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Y1\n\n\n548\n\n\n\n\n\n\n \n\n\n\n\n\n\nKSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-K1\n\n\n549\n\n\n\n\n\n\n \n\n\n\n\n\n\nHSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-H1\n\n\n550\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-Q1\n\n\n551\n\n\n\n\n\n\n \n\n\n\n\n\n\nPPRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nPP-ShK\n\n\n552\n\n\n\n\n\n\n \n\n\n\n\n\n\nMRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nM-ShK\n\n\n553\n\n\n\n\n\n\n \n\n\n\n\n\n\nGRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nG-ShK\n\n\n554\n\n\n\n\n\n\n \n\n\n\n\n\n\nYSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-Y1/A22\n\n\n555\n\n\n\n\n\n\n \n\n\n\n\n\n\nKSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-K1/A22\n\n\n556\n\n\n\n\n\n\n \n\n\n\n\n\n\nHSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-H1/A22\n\n\n557\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-Q1/A22\n\n\n558\n\n\n\n\n\n\n \n\n\n\n\n\n\nPPRSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nPP-ShK-A22\n\n\n559\n\n\n\n\n\n\n \n\n\n\n\n\n\nMRSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nM-ShK-A22\n\n\n560\n\n\n\n\n\n\n \n\n\n\n\n\n\nGRSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nG-ShK-A22\n\n\n561\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/A22\n\n\n884\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/A22 d1\n\n\n885\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9\n\n\n886\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/A22\n\n\n887\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9 d1\n\n\n888\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/A22 d1\n\n\n889\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPESRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-E9/A22\n\n\n890\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPESRCTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-E9/A22 d1\n\n\n891\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A11/A22\n\n\n892\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A11/22 d1\n\n\n893\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-E11/A22\n\n\n894\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-E11/A22 d1\n\n\n895\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTDFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-D14\n\n\n896\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTDFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-D14/A22\n\n\n897\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTDFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-D14 d1\n\n\n898\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTDFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-D14/A22 d1\n\n\n899\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAAQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A15A/22\n\n\n900\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAAQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A15/A22 d1\n\n\n901\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAIQCKHSMKYRLSFCRKTCGTC\n\n\nShK-I15\n\n\n902\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAIQCKHSMAYRLSFCRKTCGTC\n\n\nShK-I15/A22\n\n\n903\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAIQCKHSMKYRLSFCRKTCGTC\n\n\nShK-I15 d1\n\n\n904\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAIQCKHSMAYRLSFCRKTCGTC\n\n\nShK-I15/A22 d1\n\n\n905\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAVQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V15\n\n\n906\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAVQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V15/A22\n\n\n907\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAVQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V15 d1\n\n\n908\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAVQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V15/A22 d1\n\n\n909\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFRCKHSMKYRLSFCRKTCGTC\n\n\nShK-R16\n\n\n910\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFRCKHSMAYRLSFCRKTCGTC\n\n\nShK-R16/A22\n\n\n911\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFRCKHSMKYRLSFCRKTCGTC\n\n\nShK-R16 d1\n\n\n912\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFRCKHSMAYRLSFCRKTCGTC\n\n\nShK-R16/A22 d1\n\n\n913\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFKCKHSMKYRLSFCRKTCGTC\n\n\nShK-K16\n\n\n914\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSRCTAFKCKHSMAYRLSFCRKTCGTC\n\n\nShK-K16/A22\n\n\n915\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFKCKHSMKYRLSFCRKTCGTC\n\n\nShK-K16 d1\n\n\n916\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSRCTAFKCKHSMAYRLSFCRKTCGTC\n\n\nShK-K16/A22 d1\n\n\n917\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9/E11\n\n\n918\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/E11/A22\n\n\n919\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9/E11 d1\n\n\n920\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/E11/A22\n\n\n921\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9/E11\n\n\n922\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/E11/A22\n\n\n923\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9/E11 d1\n\n\n924\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/E11/A22\n\n\n925\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9/A11\n\n\n926\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/A11/A22\n\n\n927\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-V9/A11 d1\n\n\n928\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-V9/A11/A22\n\n\n929\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9/A11\n\n\n930\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPASACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/A11/A22\n\n\n931\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASACTAFQCKHSMKYRLSFCRKTCGTC\n\n\nShK-A9/A11 d1\n\n\n932\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPASACTAFQCKHSMAYRLSFCRKTCGTC\n\n\nShK-A9/A11/A22\n\n\n933\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n934\n\n\n\n\n\n\n \n\n\nE11/D14/I15/R16\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPKSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n935\n\n\n\n\n\n\n \n\n\nE11/D14/I15/R16/\n\n\n\n\n\n\n \n\n\nA22\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n936\n\n\n\n\n\n\n \n\n\nE11/D14/I15/R16\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPKSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n937\n\n\n\n\n\n\n \n\n\nE11/D14/I15//R16\n\n\n\n\n\n\n \n\n\nA22 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n938\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/\n\n\n\n\n\n\n \n\n\nR16\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n939\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/\n\n\n\n\n\n\n \n\n\nR16/A22\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n940\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/\n\n\n\n\n\n\n \n\n\nR16 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n941\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/\n\n\n\n\n\n\n \n\n\nR16/A22 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTDIQCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n942\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15\n\n\n\n\n\n\n \n\n\n\n\n\n\nRSCIDTIPVSECTDIQCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n943\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/A22\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTDIQCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n944\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDTIPVSECTDIQCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n945\n\n\n\n\n\n\n \n\n\nV9/E11/D14/I15/A22\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTCKDLIPVSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n946\n\n\n\n\n\n\n \n\n\nT2/K4/L6/V9/E11/\n\n\n\n\n\n\n \n\n\nD14/I15/R16\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTCKDLIPVSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n947\n\n\n\n\n\n\n \n\n\nT2/K4/L6/V9/E11/\n\n\n\n\n\n\n \n\n\nD14/I15/R16/A22\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCKHSMKYRLSFCRKTCGTC\n\n\nShK-\n\n\n948\n\n\n\n\n\n\n \n\n\nT2/K4/L6/V9/E11/\n\n\n\n\n\n\n \n\n\nD14/I15/R16 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCKHSMAYRLSFCRKTCGTC\n\n\nShK-\n\n\n949\n\n\n\n\n\n\n \n\n\nT2/K4/L6/V9/E11/\n\n\n\n\n\n\n \n\n\nD14/I15/R16/A22\n\n\n\n\n\n\n \n\n\nd1\n\n\n\n\n\n\n \n\n\n\n\n\n\n(L-Phosphotyrosine)-\n\n\nShK(L5)\n\n\n950\n\n\n\n\n\n\nAEEARSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSMKYRLSFCRKTCGTC\n\n\nShK Q1/A4/A15\n\n\n1295\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSMAYRLSFCRKTCGTC\n\n\nShK\n\n\n1296\n\n\n\n\n\n\n \n\n\nQ1/A4/A15/A22\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSM(Dap)YRLSFCRKTCGTC\n\n\nShK\n\n\n1297\n\n\n\n\n\n\n \n\n\nQ1/A4/A15/Dap22\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSMKYRASFCRKTCGTC\n\n\nShK\n\n\n1298\n\n\n\n\n\n\n \n\n\nQ1/A4/A15/A25\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSMAYRASFCRKTCGTC\n\n\nShK\n\n\n1299\n\n\n\n\n\n\n \n\n\nQ1/A4/A15/A22/A25\n\n\n\n\n\n\n \n\n\n\n\n\n\nQSCADTIPKSRCTAAQCKHSM(Dap)YRASFCRKTCGTC\n\n\nShK\n\n\n1300\n\n\n\n\n\n\n \n\n\nQ1/A4/A15/Dap22/\n\n\n\n\n\n\n \n\n\nA25\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nMany peptides as described in Table 2 can be prepared as described in U.S. Pat. No. 6,077,680 issued Jun. 20, 2000 to Kem et al., which is hereby incorporated by reference in its entirety. Other peptides of Table 2 can be prepared by techniques known in the art. For example, ShK(L5) (SEQ ID NO: 950) can be prepared as described in Beeton et al., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4): 1369-81 (2005), which is hereby incorporated by reference in its entirety. In Table 2 and throughout the specification, X\ns15\n, X\ns21\n, X\ns22\n, X\ns23 \nand X\ns27 \neach independently refer to nonfunctional amino acid residues.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 3\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nHmK, BgK, AeK and AsKS\n\n\n\n\n\n\npeptide and peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nRTCKDLIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK\n\n\n6\n\n\n\n\n\n\n \n\n\n\n\n\n\nATCKDLIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-A1\n\n\n201\n\n\n\n\n\n\n \n\n\n\n\n\n\nSTCKDLIPVSECTDIRCRTSMKYRLNLCRK\n\n\nHmK-S1\n\n\n202\n\n\n\n\n\n\nTCGSC\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-d1\n\n\n203\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCKDLIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-d1/S2\n\n\n204\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCIDLIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-d1/I4\n\n\n205\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDTIPVSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-d1/T6\n\n\n206\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPKSECTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-d1/K9\n\n\n207\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSRCTDIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n208\n\n\n\n\n\n\n \n\n\nd1/R11\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTAIRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n209\n\n\n\n\n\n\n \n\n\nd1/A14\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDFRCRTSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n210\n\n\n\n\n\n\n \n\n\nd1/F15\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIQCRTSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n211\n\n\n\n\n\n\n \n\n\nd1/Q16\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCKTSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n212\n\n\n\n\n\n\n \n\n\nd1/K18\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCRHSMKYRLNLCRKTCGSC\n\n\nHmK-\n\n\n213\n\n\n\n\n\n\n \n\n\nd1/H19\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCRTSMKYRLSLCRKTCGSC\n\n\nHmK-\n\n\n214\n\n\n\n\n\n\n \n\n\nd1/S26\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCRTSMKYRLNFCRKTCGSC\n\n\nHmK-\n\n\n215\n\n\n\n\n\n\n \n\n\nd1/F27\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSECTDIRCRTSMKYRLNLCRKTCGTC\n\n\nHmK-\n\n\n216\n\n\n\n\n\n\n \n\n\nd1/T34\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCKDLIPVSRCTDIRCRTSMKYRLNFCRKTCGSC\n\n\nHmK-\n\n\n217\n\n\n\n\n\n\n \n\n\nd1/R11/F27\n\n\n\n\n\n\n \n\n\n\n\n\n\nATCKDLIPVSRCTDIRCRTSMKYRLNFCRKT\n\n\nHmK-\n\n\n218\n\n\n\n\n\n\nCGSC\n\n\nA1/R11/F27\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGSC\n\n\nHmK-d1/Z1\n\n\n219\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCIDTIPKSRCTAFQCRTSMKYRLNFCRKTCGSC\n\n\nHmK-d1/Z2\n\n\n220\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCADLIPASRCTAIACRTSMKYRLNFCRKTCGSC\n\n\nHmK-d1/Z3\n\n\n221\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCADLIPASRCTAIACKHSMKYRLNFCRKTCGSC\n\n\nHmK-d1/Z4\n\n\n222\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCADLIPASRCTAIACAHSMKYRLNFCRKTCGSC\n\n\nHmK-d1/Z5\n\n\n223\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTCKDLIPVSECTDIRCRTSMX\nh22\n \n\n\nHmK-X22\n\n\n224\n\n\n\n\n\n\nYRLNLCRKTCGSC\n\n\n\n\n\n\n \n\n\n\n\n\n\nATCKDLX\nh6\nPVSRCTDIRCRTSMKX\nh22\nRLNX\nh26\n \n\n\nHmK-X6,\n\n\n225\n\n\n\n\n\n\nCRKTCGSC\n\n\n22, 26\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK\n\n\n9\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nACRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A1\n\n\n226\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCADWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A3\n\n\n227\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDAFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A5\n\n\n228\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKATACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A8\n\n\n229\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKEAACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A9\n\n\n230\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACAHAKSLGNCRTSQKYRANCA\n\n\nBgK-A12\n\n\n231\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAASLGNCRTSQKYRANCA\n\n\nBgK-A15\n\n\n232\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKALGNCRTSQKYRANCA\n\n\nBgK-A16\n\n\n233\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSAGNCRTSQKYRANCA\n\n\nBgK-A17\n\n\n234\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCATSQKYRANCA\n\n\nBgK-A21\n\n\n235\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRASQKYRANCA\n\n\nBgK-A22\n\n\n236\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYAANCA\n\n\nBgK-A27\n\n\n237\n\n\n\n\n\n\nKTCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A32\n\n\n238\n\n\n\n\n\n\nATCELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A33\n\n\n239\n\n\n\n\n\n\nKACELC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A35\n\n\n240\n\n\n\n\n\n\nKTCALC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCRDWFKETACRHAKSLGNCRTSQKYRANCA\n\n\nBgK-A37\n\n\n241\n\n\n\n\n\n\nKTCEAC\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCKDNFSANTCKHVKANNNCGSQKYATNCA\n\n\nAeK\n\n\n7\n\n\n\n\n\n\nKTCGKC\n\n\n\n\n\n\n \n\n\n\n\n\n\nACKDNFAAATCKHVKENKNCGSQKYATNCA\n\n\nAsKS\n\n\n8\n\n\n\n\n\n\nKTCGKC\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nIn Table 3 and throughout the specification, X\nh6\n, X\nh22\n, X\nh26 \nare each independently nonfunctional residues.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 4\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nMgTx peptide and MgTx peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nTIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGK\n \n \nMgTx\n \n \n\n\n28\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVACTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-A6\n\n\n242\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVSCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-S6\n\n\n243\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPAQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-A11\n\n\n244\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCAAQFGQSAGAKCMNGK\n\n\nMgTx-A18\n\n\n245\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCKAQFGQSAGAACMNGK\n\n\nMgTx-A28\n\n\n246\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGA\n\n\nMgTx-A33\n\n\n247\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-A35\n\n\n248\n\n\n\n\n\n\nCACYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-H39N\n\n\n249\n\n\n\n\n\n\nCKCYPN\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVACTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-\n\n\n250\n\n\n\n\n\n\nCKCYPN\n\n\nA6/H39N\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVSCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-\n\n\n251\n\n\n\n\n\n\nCKCYS\n\n\nS6/38/d39\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIITISCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-T4/I5/S6\n\n\n252\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-\n\n\n253\n\n\n\n\n\n\nCKCYPH\n\n\nd3/T4/I5/S6\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-Pi2\n\n\n254\n\n\n\n\n\n\nCKCFGR\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVACTSPKQCLPPCKAQFGQSAGAKCMNG\n\n\nMgTx-d3/A6\n\n\n255\n\n\n\n\n\n\nKCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-ChTx\n\n\n256\n\n\n\n\n\n\nCKCYS\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCTSPKQCLPPCKAQFGQSAGAKCM\n\n\nMgTx-IbTx\n\n\n257\n\n\n\n\n\n\nNGKCKCYQ\n\n\n\n\n\n\n \n\n\n\n\n\n\nIINVSCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-Z1\n\n\n258\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nIITISCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-Z2\n\n\n259\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCTSPKQCLPPCKAQFGQSAGAKCMNGK\n\n\nMgTx-\nZ3\n \n\n\n260\n\n\n\n\n\n\nCKCYPH\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nMany peptides as described in Table 4 can be prepared as described in WO 95/03065, published Feb. 2, 1995, for which the applicant is Merck & Co., Inc. That application corresponds to U.S. Ser. No. 07/096,942, filed 22 Jul. 1993, which is hereby incorporated by reference in its entirety.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 5\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAgTx2 peptide and AgTx2 peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\n \n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nGVPINVSCTGSPQCIKPCKDAGMR\n \n \nAgTx2\n \n \n\n\n23\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIAVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A5\n\n\n261\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIAPCKDAGMR\n\n\nAgTx2-A16\n\n\n262\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCADAGMR\n\n\nAgTx2-A19\n\n\n263\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMA\n\n\nAgTx2-A24\n\n\n264\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A27\n\n\n265\n\n\n\n\n\n\n \n\n\nFGACMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A31\n\n\n266\n\n\n\n\n\n\n \n\n\nFGKCMNAKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A32\n\n\n267\n\n\n\n\n\n\n \n\n\nFGKCMNRACHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A38\n\n\n268\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPA\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIAVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-A5/A38\n\n\n269\n\n\n\n\n\n\n \n\n\nFGKCMNRKCHCTPA\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPINVSCTGSPQCIKPCKDAGMR\n\n\nAgTx2-\nG31\n \n\n\n270\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIIVSCKGSRQCIKPCKDAGMR\n\n\nAgTx2-\n\n\n271\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\nOSK_z1\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIIVSCKISRQCIKPCKDAGMR\n\n\nAgTx2-\n\n\n272\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\nOSK_z2\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIIVKCKGSRQCIKPCKDAGMR\n\n\nAgTx2-\n\n\n273\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\nOSK_z3\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIIVKCKISRQCIKPCKDAGMR\n\n\nAgTx2-\n\n\n274\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\nOSK_z4\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGVPIIVKCKISRQCIKPCKDAGMR\n\n\nAgTx2-\n\n\n275\n\n\n\n\n\n\n \n\n\nFGKCMNGKCHCTPK\n\n\nOSK_z5\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 6\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nHeteromitrus spinnifer \n(HsTx1)\n\n\n\n\n\n\npeptide and HsTx1 peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nASCRTPKDCADPCRKETGCPYGKCMNRKCKCNRC\n \n \nHsTx1\n \n \n\n\n61\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCXTPKDCADPCRKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-X4\n\n\n276\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCATPKDCADPCRKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-A4\n\n\n277\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPXDCADPCRKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-X7\n\n\n278\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPADCADPCRKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-A7\n\n\n279\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCXKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-\nX14\n \n\n\n280\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCAKETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-A14\n\n\n281\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRXETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-X15\n\n\n282\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRAETGCPYGKCMNRKCKCNRC\n\n\nHsTx1-A15\n\n\n283\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGXCMNRKCKCNRC\n\n\nHsTx1-X23\n\n\n284\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGACMNRKCKCNRC\n\n\nHsTx1-A23\n\n\n285\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNXKCKCNRC\n\n\nHsTx1-X27\n\n\n286\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNAKCKCNRC\n\n\nHsTx1-A27\n\n\n287\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRXCKCNRC\n\n\nHsTx1-X28\n\n\n288\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRACKCNRC\n\n\nHsTx1-A28\n\n\n289\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRKCXCNRC\n\n\nHsTx1-\nX30\n \n\n\n290\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRKCACNRC\n\n\nHsTx1-A30\n\n\n291\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRKCKCNXC\n\n\nHsTx1-X33\n\n\n292\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCRTPKDCADPCRKETGCPYGKCMNRKCKCNAC\n\n\nHsTx1-\nA33\n \n\n\n293\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPeptides as described in Table 5 can be prepared as described in U.S. Pat. No. 6,689,749, issued Feb. 10, 2004 to Lebrun et al., which is hereby incorporated by reference in its entirety.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nOrthochirus scrobiculosus \n(OSK1)\n\n\n \n\n\n\n\n\n\npeptide and OSK1 peptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n \n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nOSK1\n\n\n25\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nOSK1-S7\n\n\n1303\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCMNGKCHCTPK\n\n\nOSK1-K16\n\n\n294\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-D20\n\n\n295\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-K16, D20\n\n\n296\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-S7, K16, D20\n\n\n1308\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-P12, K16, D20\n\n\n297\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-K16, D20, Y36\n\n\n298\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-P12,\n\n\n562\n\n\n\n\n\n\n \n\n\nK16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-P12, K16,\n\n\n563\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-P12,\n\n\n564\n\n\n\n\n\n\n \n\n\nK16, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYPK-NH\n2\n \n\n\nOSK1-K16, D20,\n\n\n565\n\n\n\n\n\n\n \n\n\nY36-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYPK\n\n\nAc-OSK1-K16,\n\n\n566\n\n\n\n\n\n\n \n\n\nD20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYPK-NH\n2\n \n\n\nAc-OSK1-K16, D20,\n\n\n567\n\n\n\n\n\n\n \n\n\nY36-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K16-NH\n2\n \n\n\n568\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-K16\n\n\n569\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K16-NH\n2\n \n\n\n570\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-D20\n\n\n571\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-D20-NH\n2\n \n\n\n572\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-D20-NH\n2\n \n\n\n573\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-NH\n2\n \n\n\n574\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1\n\n\n575\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-NH\n2\n \n\n\n576\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K16, D20-NH\n2\n \n\n\n577\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-K16,\n\n\n578\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K16, D20-\n\n\n579\n\n\n\n\n\n\n \n\n\nNH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nΔ1-OSK1\n\n\n580\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nAc-Δ1-OSK1\n\n\n581\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nΔ1-OSK1-NH\n2\n \n\n\n582\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-Δ1-OSK1-NH\n2\n \n\n\n583\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\nOSK1-A34\n\n\n584\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\nAc-OSK1-A34\n\n\n585\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nOSK1-A34-NH\n2\n \n\n\n586\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nAc-OSK1-A34-NH\n2\n \n\n\n587\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nΔ1-OSK1-K16, D20\n\n\n588\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-Δ1-OSK1-K16,\n\n\n589\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nΔ1-OSK1-K16, D20-\n\n\n590\n\n\n\n\n\n\n \n\n\nNH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-Δ1-OSK1-K16,\n\n\n591\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n(Δ1-4)-OSK1-K16,\n\n\n592\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-(Δ1-4)-OSK1-\n\n\n593\n\n\n\n\n\n\n \n\n\nK16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\n(Δ1-4)-OSK1-K16,\n\n\n594\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-(Δ1-4)-OSK1-\n\n\n595\n\n\n\n\n\n\n \n\n\nK16, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n(Δ1-6)-OSK1-K16,\n\n\n596\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-(Δ1-6)-OSK1-\n\n\n597\n\n\n\n\n\n\n \n\n\nK16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\n(Δ1-6)-OSK1-K16,\n\n\n598\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-(Δ1-6)-OSK1-\n\n\n599\n\n\n\n\n\n\n \n\n\nK16, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n(Δ1-7)-OSK1-K16,\n\n\n600\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-(Δ1-7)-OSK1-\n\n\n601\n\n\n\n\n\n\n \n\n\nK16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\n(Δ1-7)-OSK1-K16,\n\n\n602\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-(Δ1-7)-OSK1-\n\n\n603\n\n\n\n\n\n\n \n\n\nK16, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCMNGKCHCTPK\n\n\nOSK1-K16, D20,\n\n\n604\n\n\n\n\n\n\n \n\n\nN25\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K16, D20,\n\n\n605\n\n\n\n\n\n\n \n\n\nN25-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCMNGKCHCTPK\n\n\nAc-OSK1-K16,\n\n\n606\n\n\n\n\n\n\n \n\n\nD20, N25\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K16, D20,\n\n\n607\n\n\n\n\n\n\n \n\n\nN25-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\nOSK1-K16, D20,\n\n\n608\n\n\n\n\n\n\n \n\n\nR31\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-NH\n2\n \n\n\nOSK1-K16, D20,\n\n\n609\n\n\n\n\n\n\n \n\n\nR31-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\nAc-OSK1-K16,\n\n\n610\n\n\n\n\n\n\n \n\n\nD20, R31\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K16, D20,\n\n\n611\n\n\n\n\n\n\n \n\n\nR31-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-K12, K16,\n\n\n612\n\n\n\n\n\n\n \n\n\nR19, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-K12, K16,\n\n\n613\n\n\n\n\n\n\n \n\n\nR19, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K12, K16,\n\n\n614\n\n\n\n\n\n\n \n\n\nR19, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K12, K16,\n\n\n615\n\n\n\n\n\n\n \n\n\nR19, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nΔ1-OSK1-T2, K16,\n\n\n616\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-Δ1-OSK1-T2,\n\n\n617\n\n\n\n\n\n\n \n\n\nK16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nΔ1-OSK1-T2, K16,\n\n\n618\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-Δ1-OSK1-T2,\n\n\n619\n\n\n\n\n\n\n \n\n\nK16, D20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nOSK1-K3\n\n\n620\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-K3\n\n\n621\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K3-NH\n2\n \n\n\n622\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K3-NH\n2\n \n\n\n623\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\nOSK1-K3, A34\n\n\n624\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-K3, K16, D20\n\n\n625\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-K3, K16, D20,\n\n\n626\n\n\n\n\n\n\n \n\n\nA34\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\nAc-OSK1-K3, A34\n\n\n627\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nOSK1-K3, A34-NH\n2\n \n\n\n628\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nAc-OSK1-K3, A34-\n\n\n629\n\n\n\n\n\n\n \n\n\nNH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCACTPK\n\n\nAc-OSK1-K3, K16,\n\n\n630\n\n\n\n\n\n\n \n\n\nD20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nOSK1-K3, K16, D20,\n\n\n631\n\n\n\n\n\n\n \n\n\nA34-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCACTPK-NH\n2\n \n\n\nAc-OSK1-K3, K16,\n\n\n632\n\n\n\n\n\n\n \n\n\nD20, A34-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\nAc-OSK1-K3, K16,\n\n\n633\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nOSK1-K3, K16, D20-\n\n\n634\n\n\n\n\n\n\n \n\n\nNH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK-NH\n2\n \n\n\nAc-OSK1-K3, K16,\n\n\n635\n\n\n\n\n\n\n \n\n\nD20-NH\n2\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCT\n\n\nΔ36-38-OSK1-K16,\n\n\n636\n\n\n\n\n\n\n \n\n\nD20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-O16, D20\n\n\n980\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hLys\n\n\n981\n\n\n\n\n\n\n \n\n\n16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hArg\n\n\n982\n\n\n\n\n\n\n \n\n\n16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Cit 16, D20\n\n\n983\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hCit\n\n\n984\n\n\n\n\n\n\n \n\n\n16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Dpr 16, D20\n\n\n985\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Dab 16, D20\n\n\n986\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-O16, D20, Y36\n\n\n987\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hLys\n\n\n988\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hArg\n\n\n989\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Cit\n\n\n990\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hCit\n\n\n991\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Dpr\n\n\n992\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Dab\n\n\n993\n\n\n\n\n\n\n \n\n\n16, D20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYPK\n\n\nOSK1-\n\n\n994\n\n\n\n\n\n\n \n\n\nK16, D20, A34, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCGCYPK\n\n\nOSK1-\n\n\n995\n\n\n\n\n\n\n \n\n\nK16, D20, G34, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACFPK\n\n\nOSK1-\n\n\n996\n\n\n\n\n\n\n \n\n\nK16, D20, A34, F36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACWPK\n\n\nOSK1-\n\n\n997\n\n\n\n\n\n\n \n\n\nK16, D20, A34, W36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACYPK\n\n\nOSK1-\n\n\n998\n\n\n\n\n\n\n \n\n\nK16, E20, A34, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-O16, D20, A34\n\n\n999\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-hLys\n\n\n1000\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-hArg\n\n\n1001\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-Cit\n\n\n1002\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hCit\n\n\n1003\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-Dpr\n\n\n1004\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACTPK\n\n\nOSK1-Dab\n\n\n1005\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1006\n\n\n\n\n\n\n \n\n\nO16, D20,\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1007\n\n\n\n\n\n\n \n\n\nhLys 16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1008\n\n\n\n\n\n\n \n\n\nhArg 16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-Cit\n\n\n1009\n\n\n\n\n\n\n \n\n\n16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1010\n\n\n\n\n\n\n \n\n\nhCit 16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-Dpr\n\n\n1011\n\n\n\n\n\n\n \n\n\n16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1012\n\n\n\n\n\n\n \n\n\nDab16, D20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1013\n\n\n\n\n\n\n \n\n\nO16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1014\n\n\n\n\n\n\n \n\n\nhLys 16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1015\n\n\n\n\n\n\n \n\n\nhArg 16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Cit\n\n\n1016\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1017\n\n\n\n\n\n\n \n\n\nhCit 16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Dpr\n\n\n1018\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Dab\n\n\n1019\n\n\n\n\n\n\n \n\n\n16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCGCYGG\n\n\nOSK1-\n\n\n1020\n\n\n\n\n\n\n \n\n\nK16, D20, G34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-\n\n\n1021\n\n\n\n\n\n\n \n\n\nO16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hLys\n\n\n1022\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hArg\n\n\n1023\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-Cit\n\n\n1024\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hCit\n\n\n1025\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-Dpr\n\n\n1026\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-\n\n\n1027\n\n\n\n\n\n\n \n\n\nK16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-\n\n\n1028\n\n\n\n\n\n\n \n\n\nO16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-hLys\n\n\n1029\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-hArg\n\n\n1030\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-Cit\n\n\n1031\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hCit\n\n\n1032\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y3, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-Dpr\n\n\n1033\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-Dab\n\n\n1034\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYG\n\n\nΔ38, OSK1-\n\n\n1035\n\n\n\n\n\n\n \n\n\nK16, D20, A34, Y36, G37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-\n\n\n1036\n\n\n\n\n\n\n \n\n\nO16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hLys\n\n\n1037\n\n\n\n\n\n\n \n\n\n16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hArg\n\n\n1038\n\n\n\n\n\n\n \n\n\n16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-Cit\n\n\n1039\n\n\n\n\n\n\n \n\n\n16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hCit\n\n\n1040\n\n\n\n\n\n\n \n\n\n16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-Dpr\n\n\n1041\n\n\n\n\n\n\n \n\n\n16, D20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACFGG\n\n\nOSK1-\n\n\n1042\n\n\n\n\n\n\n \n\n\nK16, D20, A34, F36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-\n\n\n1043\n\n\n\n\n\n\n \n\n\nO16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-hLys\n\n\n1044\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-hArg\n\n\n1045\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-Cit\n\n\n1046\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-hCit\n\n\n1047\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-Dpr\n\n\n1048\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACGGG\n\n\nOSK1-Dab\n\n\n1049\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACGG\n\n\nΔ38, OSK1-\n\n\n1050\n\n\n\n\n\n\n \n\n\nK16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYG\n\n\nΔ38, OSK1-\n\n\n1051\n\n\n\n\n\n\n \n\n\nK16, D20, A35, Y36, G37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACGG\n\n\nΔ38, OSK1-\n\n\n1052\n\n\n\n\n\n\n \n\n\nO16, D20, A35, Y36,\n\n\n\n\n\n\n \n\n\nG37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hLys\n\n\n1053\n\n\n\n\n\n\n \n\n\n16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hArg\n\n\n1054\n\n\n\n\n\n\n \n\n\n16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Cit 16, E20\n\n\n1055\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hCit\n\n\n1056\n\n\n\n\n\n\n \n\n\n16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Dpr 16, E20\n\n\n1057\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-Dab 16, E20\n\n\n1058\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-O16, E20, Y36\n\n\n1059\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hLys\n\n\n1060\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hArg\n\n\n1061\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Cit\n\n\n1062\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-hCit\n\n\n1063\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Dpr\n\n\n1064\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCYPK\n\n\nOSK1-Dab\n\n\n1065\n\n\n\n\n\n\n \n\n\n16, E20, Y36\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-O16, E20, A34\n\n\n1066\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-hLys\n\n\n1067\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-hArg\n\n\n1068\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-Cit\n\n\n1069\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK\n\n\nOSK1-hCit\n\n\n1070\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-Dpr\n\n\n1071\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACTPK\n\n\nOSK1-Dab\n\n\n1072\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1073\n\n\n\n\n\n\n \n\n\nO16, E20,\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1074\n\n\n\n\n\n\n \n\n\nhLys 16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1075\n\n\n\n\n\n\n \n\n\nhArg 16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-Cit\n\n\n1076\n\n\n\n\n\n\n \n\n\n16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1077\n\n\n\n\n\n\n \n\n\nhCit16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-Dpr\n\n\n1078\n\n\n\n\n\n\n \n\n\n16, E20\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1079\n\n\n\n\n\n\n \n\n\nO16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1080\n\n\n\n\n\n\n \n\n\nhLys 16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-\n\n\n1081\n\n\n\n\n\n\n \n\n\nhArg 16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Cit\n\n\n1082\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHC\n\n\nΔ36-38, OSK1-\n\n\n1083\n\n\n\n\n\n\n \n\n\nhCit 16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Dpr\n\n\n1084\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCAC\n\n\nΔ36-38, OSK1-Dab\n\n\n1085\n\n\n\n\n\n\n \n\n\n16, E20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-\n\n\n1086\n\n\n\n\n\n\n \n\n\nK16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-\n\n\n1087\n\n\n\n\n\n\n \n\n\nO16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCHCYG\n\n\nΔ38 OSK1-\n\n\n1088\n\n\n\n\n\n\n \n\n\nK16, E20, Y36, G37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACYG\n\n\nΔ38 OSK1-\n\n\n1089\n\n\n\n\n\n\n \n\n\nK16, E20, A34,\n\n\n\n\n\n\n \n\n\nY36, G37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hLys\n\n\n1090\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hArg\n\n\n1091\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-Cit\n\n\n1092\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG\n\n\nΔ37-38, OSK1-\n\n\n1093\n\n\n\n\n\n\n \n\n\nhCit\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-Dpr\n\n\n1094\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-Dab\n\n\n1095\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACYG\n\n\nΔ38, OSK1-\n\n\n1096\n\n\n\n\n\n\n \n\n\nK16, E20, A34, Y36, G37\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-\n\n\n1097\n\n\n\n\n\n\n \n\n\nO16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-hLys\n\n\n1098\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-hArg\n\n\n1099\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-Cit\n\n\n1100\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG\n\n\nOSK1-hCit\n\n\n1101\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y3, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-Dpr\n\n\n1102\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACYGG\n\n\nOSK1-Dab\n\n\n1103\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACFGG\n\n\nOSK1-\n\n\n1104\n\n\n\n\n\n\n \n\n\nK16, D20, A34, F36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-\n\n\n1105\n\n\n\n\n\n\n \n\n\nO16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hLys\n\n\n1106\n\n\n\n\n\n\n \n\n\n16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hArg\n\n\n1107\n\n\n\n\n\n\n \n\n\n16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-Cit\n\n\n1108\n\n\n\n\n\n\n \n\n\n16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-hCit\n\n\n1109\n\n\n\n\n\n\n \n\n\n16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCGGG\n\n\nOSK1-Dpr\n\n\n1110\n\n\n\n\n\n\n \n\n\n16, E20, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACGGG\n\n\nOSK1-\n\n\n1111\n\n\n\n\n\n\n \n\n\nO16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACGGG\n\n\nOSK1-hLys\n\n\n1112\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACGGG\n\n\nOSK1-hArg\n\n\n1113\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACGGG\n\n\nOSK1-Cit\n\n\n1114\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCACTP\n\n\nOSK1-hCit\n\n\n1115\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACTP\n\n\nOSK1-Dpr\n\n\n1116\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACTP\n\n\nOSK1-Dab\n\n\n1117\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-O16, D20-\n\n\n1118\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-hLys\n\n\n1119\n\n\n\n\n\n\nNH2\n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-hArg\n\n\n1120\n\n\n\n\n\n\nNH2\n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Cit\n\n\n1121\n\n\n\n\n\n\n \n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-hCit\n\n\n1122\n\n\n\n\n\n\nNH2\n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Dpr\n\n\n1123\n\n\n\n\n\n\n \n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Dab 16, D20\n\n\n1124\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-\n\n\n1125\n\n\n\n\n\n\n \n\n\nO16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-hLys\n\n\n1126\n\n\n\n\n\n\nNH2\n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-hArg\n\n\n1127\n\n\n\n\n\n\nNH2\n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Cit\n\n\n1128\n\n\n\n\n\n\n \n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-hCit\n\n\n1129\n\n\n\n\n\n\nNH2\n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Dpr\n\n\n1130\n\n\n\n\n\n\n \n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Dab\n\n\n1131\n\n\n\n\n\n\n \n\n\n16, D20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-\n\n\n1132\n\n\n\n\n\n\n \n\n\nO16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACTPK-\n\n\nOSK1-hLys\n\n\n1133\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACTPK-\n\n\nOSK1-hArg\n\n\n1134\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Cit\n\n\n1135\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCACTPK-\n\n\nOSK1-hCit\n\n\n1136\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Dpr\n\n\n1137\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Dab\n\n\n1138\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1139\n\n\n\n\n\n\n \n\n\nO16, D20, -\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1140\n\n\n\n\n\n\n \n\n\nhLys 16, D20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1141\n\n\n\n\n\n\n \n\n\nhArg 16, D20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-Cit\n\n\n1142\n\n\n\n\n\n\n \n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1143\n\n\n\n\n\n\n \n\n\nhCit16, D20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-Dpr\n\n\n1144\n\n\n\n\n\n\n \n\n\n16, D20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1145\n\n\n\n\n\n\n \n\n\nO16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1146\n\n\n\n\n\n\n \n\n\nhLys 16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1147\n\n\n\n\n\n\n \n\n\nhArg 16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Cit\n\n\n1148\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1149\n\n\n\n\n\n\n \n\n\nhCit16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Dpr\n\n\n1150\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Dab\n\n\n1151\n\n\n\n\n\n\n \n\n\n16, D20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-\n\n\n1152\n\n\n\n\n\n\n \n\n\nO16, D20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-\n\n\n1153\n\n\n\n\n\n\n \n\n\nO16, D20, Y36, G37, G38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hLys\n\n\n1154\n\n\n\n\n\n\nNH2\n\n\n16, D20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hArg\n\n\n1155\n\n\n\n\n\n\nNH2\n\n\n16, D20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-Cit\n\n\n1156\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-\n\n\n1157\n\n\n\n\n\n\nNH2\n\n\nhCit16, D20, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-Dpr\n\n\n1158\n\n\n\n\n\n\n \n\n\n16, D20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCFGG-NH2\n\n\nOSK1-\n\n\n1159\n\n\n\n\n\n\n \n\n\nK16, D20, F36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCYG-NH2\n\n\nΔ38-OSK1-\n\n\n1160\n\n\n\n\n\n\n \n\n\nK16, D20, Y36, G37-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYG-NH2\n\n\nΔ38-OSK1-\n\n\n1161\n\n\n\n\n\n\n \n\n\nK16, D20, A34,\n\n\n\n\n\n\n \n\n\nY36, G37-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-\n\n\n1162\n\n\n\n\n\n\n \n\n\nO16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACYGG-\n\n\nOSK1-hLys\n\n\n1163\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACYGG-\n\n\nOSK1-hArg\n\n\n1164\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Cit\n\n\n1165\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCACYGG-\n\n\nOSK1-\n\n\n1166\n\n\n\n\n\n\nNH2\n\n\nhCit16, D20, A34, Y3,\n\n\n\n\n\n\n \n\n\nG37, G38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Dpr\n\n\n1167\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Dab\n\n\n1168\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-\n\n\n1169\n\n\n\n\n\n\n \n\n\nK16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-\n\n\n1170\n\n\n\n\n\n\n \n\n\nO16, D20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-hLys\n\n\n1171\n\n\n\n\n\n\nNH2\n\n\n16, D20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-hArg\n\n\n1172\n\n\n\n\n\n\nNH2\n\n\n16, D20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-Cit\n\n\n1173\n\n\n\n\n\n\n \n\n\n16, D20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-\n\n\n1174\n\n\n\n\n\n\nNH2\n\n\nhCit16, D20, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-Dpr\n\n\n1175\n\n\n\n\n\n\n \n\n\n16, D20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-\n\n\n1176\n\n\n\n\n\n\n \n\n\nK16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACFGG-NH2\n\n\nOSK1-\n\n\n1177\n\n\n\n\n\n\n \n\n\nO16, D20, A34, F36,\n\n\n\n\n\n\n \n\n\nG37-38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-\n\n\n1178\n\n\n\n\n\n\n \n\n\nO16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMNGKCACGGG-\n\n\nOSK1-hLys\n\n\n1179\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMNGKCACGGG-\n\n\nOSK1-hArg\n\n\n1180\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Cit\n\n\n1181\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMNGKCACGGG-\n\n\nOSK1-\n\n\n1182\n\n\n\n\n\n\nNH2\n\n\nhCit16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Dpr\n\n\n1183\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Dab\n\n\n1184\n\n\n\n\n\n\n \n\n\n16, D20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-O16, E20-\n\n\n1185\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-hLys\n\n\n1186\n\n\n\n\n\n\nNH2\n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-hArg\n\n\n1187\n\n\n\n\n\n\nNH2\n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Cit\n\n\n1188\n\n\n\n\n\n\n \n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK-\n\n\nOSK1-\n\n\n1189\n\n\n\n\n\n\nNH2\n\n\nhCit16, E20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Dpr\n\n\n1190\n\n\n\n\n\n\n \n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCTPK-NH2\n\n\nOSK1-Dab\n\n\n1191\n\n\n\n\n\n\n \n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-\n\n\n1192\n\n\n\n\n\n\n \n\n\nO16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-hLys\n\n\n1193\n\n\n\n\n\n\nNH2\n\n\n16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-hArg\n\n\n1194\n\n\n\n\n\n\nNH2\n\n\n16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Cit\n\n\n1195\n\n\n\n\n\n\n \n\n\n16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYPK-\n\n\nOSK1-\n\n\n1196\n\n\n\n\n\n\nNH2\n\n\nhCit16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Dpr\n\n\n1197\n\n\n\n\n\n\n \n\n\n16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCYPK-NH2\n\n\nOSK1-Dab\n\n\n1198\n\n\n\n\n\n\n \n\n\n16, E20, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-\n\n\n1199\n\n\n\n\n\n\n \n\n\nO16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACTPK-\n\n\nOSK1-hLys\n\n\n1200\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACTPK-\n\n\nOSK1-hArg\n\n\n1201\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Cit\n\n\n1202\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCACTPK-\n\n\nOSK1-\n\n\n1203\n\n\n\n\n\n\nNH2\n\n\nhCit16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Dpr\n\n\n1204\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACTPK-NH2\n\n\nOSK1-Dab\n\n\n1205\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1206\n\n\n\n\n\n\n \n\n\nO16, E20, -\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1207\n\n\n\n\n\n\n \n\n\nhLys 16, E20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1208\n\n\n\n\n\n\n \n\n\nhArg 16, E20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-Cit\n\n\n1209\n\n\n\n\n\n\n \n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1210\n\n\n\n\n\n\n \n\n\nhCit16, E20-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-Dpr\n\n\n1211\n\n\n\n\n\n\n \n\n\n16, E20-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1212\n\n\n\n\n\n\n \n\n\nO16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1213\n\n\n\n\n\n\n \n\n\nhLys16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1214\n\n\n\n\n\n\n \n\n\nhArg16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Cit\n\n\n1215\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHC-NH2\n\n\nΔ36-38, OSK1-\n\n\n1216\n\n\n\n\n\n\n \n\n\nhCit16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Dpr\n\n\n1217\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCAC-NH2\n\n\nΔ36-38, OSK1-Dab\n\n\n1218\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCHCWGG-NH2\n\n\nOSK1-\n\n\n1219\n\n\n\n\n\n\n \n\n\nO16, E20, W36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-\n\n\n1220\n\n\n\n\n\n\n \n\n\nO16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hLys\n\n\n1221\n\n\n\n\n\n\nNH2\n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hArg\n\n\n1222\n\n\n\n\n\n\nNH2\n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-Cit\n\n\n1223\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hCit\n\n\n1224\n\n\n\n\n\n\nNH2\n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-Dpr\n\n\n1225\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-Dpr\n\n\n1226\n\n\n\n\n\n\n \n\n\n16, E20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-\n\n\n1227\n\n\n\n\n\n\n \n\n\nK16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-\n\n\n1228\n\n\n\n\n\n\n \n\n\nO16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACYGG-\n\n\nOSK1-hLys\n\n\n1229\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACYGG-\n\n\nOSK1-hArg\n\n\n1230\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Cit\n\n\n1231\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG-\n\n\nOSK1-hCit\n\n\n1232\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34, Y3, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Dpr\n\n\n1233\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-Dab\n\n\n1234\n\n\n\n\n\n\n \n\n\n16, E20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-\n\n\n1235\n\n\n\n\n\n\n \n\n\nO16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-hLys\n\n\n1236\n\n\n\n\n\n\nNH2\n\n\n16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-hArg\n\n\n1237\n\n\n\n\n\n\nNH2\n\n\n16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-Cit\n\n\n1238\n\n\n\n\n\n\n \n\n\n16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCHCGGG-\n\n\nOSK1-hCit\n\n\n1239\n\n\n\n\n\n\nNH2\n\n\n16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCHCGGG-NH2\n\n\nOSK1-Dpr\n\n\n1240\n\n\n\n\n\n\n \n\n\n16, E20, G36-38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-\n\n\n1241\n\n\n\n\n\n\n \n\n\nO16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMNGKCACGGG-\n\n\nOSK1-hLys\n\n\n1242\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMNGKCACGGG-\n\n\nOSK1-hArg\n\n\n1243\n\n\n\n\n\n\nNH2\n\n\n16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Cit\n\n\n1244\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMNGKCACTP-NH2\n\n\nΔ38 OSK1-hCit\n\n\n1245\n\n\n\n\n\n\n \n\n\n16, E20, A34-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Dpr\n\n\n1246\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-Dab\n\n\n1247\n\n\n\n\n\n\n \n\n\n16, E20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-K\n\n\n1248\n\n\n\n\n\n\n \n\n\n16, CPA20, A34, Y36,\n\n\n\n\n\n\n \n\n\nG37, G38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMNGKCACGGG-NH2\n\n\nOSK1-K\n\n\n1249\n\n\n\n\n\n\n \n\n\n16, CPA20, A34, G36-\n\n\n\n\n\n\n \n\n\n38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMNGKCACY-NH2\n\n\nΔ37-38OSK1-K\n\n\n1250\n\n\n\n\n\n\n \n\n\n16, CPA20, A34, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nAcetyl-OSK1-K\n\n\n1251\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-K 16,\n\n\n1252\n\n\n\n\n\n\n \n\n\nAad20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-K 16,\n\n\n1253\n\n\n\n\n\n\n \n\n\nAad20, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMNGKCACYGG\n\n\nOSK1-K 16,\n\n\n1254\n\n\n\n\n\n\n \n\n\nAad20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCACYGG-NH2\n\n\nOSK1-H\n\n\n1255\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCACYGG\n\n\nOSK1-H\n\n\n1256\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCACY-NH2\n\n\nΔ37-38-OSK1-H\n\n\n1257\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCHCYGG-NH2\n\n\nOSK1-H\n\n\n1258\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCHCYGG\n\n\nOSK1-H\n\n\n1259\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36, G37,\n\n\n\n\n\n\n \n\n\nG38\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCHCYPK\n\n\nOSK1-H\n\n\n1260\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36,\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCAC\n\n\nΔ36-38 OSK1-H\n\n\n1261\n\n\n\n\n\n\n \n\n\n16, D20, A34, Y36,\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[1Nal]GG-\n\n\nOSK1-K\n\n\n1262\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, 1Nal36,\n\n\n\n\n\n\n \n\n\nG37, G38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[1Nal]PK-\n\n\nOSK1-K\n\n\n1263\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, 1Nal36-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[2Nal]GG-\n\n\nOSK1-K\n\n\n1264\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, 2Nal36,\n\n\n\n\n\n\n \n\n\nG37, G38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[Cha]GG-NH2\n\n\nOSK1-K\n\n\n1265\n\n\n\n\n\n\n \n\n\n16, D20, A34, Cha36,\n\n\n\n\n\n\n \n\n\nG37, G38-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[MePhe]GG-\n\n\nOSK1-K\n\n\n1266\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34,\n\n\n\n\n\n\n \n\n\nMePhe36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[BiPhA]GG-\n\n\nOSK1-K\n\n\n1267\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34,\n\n\n\n\n\n\n \n\n\nBiPhA36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKC[Aib]CYGG-NH2\n\n\nOSK1-K 16, D20,\n\n\n1268\n\n\n\n\n\n\n \n\n\nAib34, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKC[Abu]CYGG-NH2\n\n\nOSK1-K 16, D20,\n\n\n1269\n\n\n\n\n\n\n \n\n\nAbu34, Y36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[1Nal]\n\n\nΔ37-38 OSK1-H\n\n\n1270\n\n\n\n\n\n\n \n\n\n16, D20, A34, 1Nal36, -\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCAC[1Nal]GG-\n\n\nOSK1-H\n\n\n1271\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34,\n\n\n\n\n\n\n \n\n\n1Nal36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC[4Bip]-NH2\n\n\nΔ37-38 OSK1-H\n\n\n1272\n\n\n\n\n\n\n \n\n\n16, D20, A34, 4Bip\n\n\n\n\n\n\n \n\n\n36, -amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMNGKCAC[4Bip]GG-\n\n\nOSK1-H\n\n\n1273\n\n\n\n\n\n\nNH2\n\n\n16, D20, A34, 4Bip\n\n\n\n\n\n\n \n\n\n36, G37, G38-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCGGG\n\n\nOSK1-K16, E20, G36-\n\n\n1274\n\n\n\n\n\n\n \n\n\n38\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7A\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analog sequences\n\n\n\n\n\n\n\n\n\n\nSEQ\n\n\n \n\n\n\n\n\n\nID\n\n\n\n\n\n\nNO\n\n\nSequence\n\n\n\n\n\n\n \n\n\n\n\n\n\n1391\n\n\n\n\nGVIINVKCKISAQCLKPCRDAGMRFGKCMNGKCACTPK\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1392\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1393\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGIRFGKCINGKCACTPK\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1394\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMNGKCACTPK\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1395\n\n\n\n\nGGGGSGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1396\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHC\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1397\n\n\n\n\nGVIINVKCKISPQCLOPCKEAGMRFGKCMNGKCHCTY[Nle]\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1398\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTY[Nle]\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1399\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCHCGGG\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n1400\n\n\n \nA\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1401\n\n\nG\nA\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1402\n\n\nGV\nA\nINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1403\n\n\nGVI\nA\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1404\n\n\nGVII\nA\nVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1405\n\n\nGVIIN\nA\nKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1406\n\n\nGVIINV\nA\nCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1407\n\n\nGVIINVKC\nA\nISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1408\n\n\nGVIINVKCK\nA\nSRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1409\n\n\nGVIINVKCKI\nA\nRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1410\n\n\nGVIINVKCKIS\nA\nQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1411\n\n\nGVIINVKCKISR\nA\nCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1412\n\n\nGVIINVKCKISRQC\nA\nEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1413\n\n\nGVIINVKCKISRQCL\nA\nPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1414\n\n\nGVIINVKCKISRQCLE\nA\nCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1415\n\n\nGVIINVKCKISRQCLEPC\nA\nKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1416\n\n\nGVIINVKCKISRQCLEPCK\nA\nAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1417\n\n\nGVIINVKCKISRQCLEPCKK\nA\nGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1418\n\n\nGVIINVKCKISRQCLEPCKKA\nA\nMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1419\n\n\nGVIINVKCKISRQCLEPCKKAG\nA\nRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1420\n\n\nGVIINVKCKISRQCLEPCKKAGM\nA\nFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1421\n\n\nGVIINVKCKISRQCLEPCKKAGMR\nA\nGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1422\n\n\nGVIINVKCKISRQCLEPCKKAGMRF\nA\nKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1423\n\n\nGVIINVKCKISRQCLEPCKKAGMRFG\nA\nCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1424\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC\nA\nNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1425\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCM\nA\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1426\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN\nA\nKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1427\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG\nA\nCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1428\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1429\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\nA\nPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1430\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nA\nK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1431\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\nA\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1432\n\n\n \nR\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1433\n\n\nG\nR\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1434\n\n\nGV\nR\nINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1435\n\n\nGVI\nR\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1436\n\n\nGVII\nR\nVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1437\n\n\nGVIIN\nR\nKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1438\n\n\nGVIINV\nR\nCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1439\n\n\nGVIINVKC\nR\nISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1440\n\n\nGVIINVKCK\nR\nSRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1441\n\n\nGVIINVKCKI\nR\nRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1442\n\n\nGVIINVKCKISR\nR\nCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1443\n\n\nGVIINVKCKISRQC\nR\nEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1444\n\n\nGVIINVKCKISRQCL\nR\nPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1445\n\n\nGVIINVKCKISRQCLE\nR\nCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1446\n\n\nGVIINVKCKISRQCLEPC\nR\nKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1447\n\n\nGVIINVKCKISRQCLEPCK\nR\nAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1448\n\n\nGVIINVKCKISRQCLEPCKK\nR\nGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1449\n\n\nGVIINVKCKISRQCLEPCKKA\nR\nMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1450\n\n\nGVIINVKCKISRQCLEPCKKAG\nR\nRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1451\n\n\nGVIINVKCKISRQCLEPCKKAGMR\nR\nGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1452\n\n\nGVIINVKCKISRQCLEPCKKAGMRF\nR\nKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1453\n\n\nGVIINVKCKISRQCLEPCKKAGMRFG\nR\nCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1454\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC\nR\nNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1455\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCM\nR\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1456\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN\nR\nKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1457\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG\nR\nCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1458\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nR\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1459\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\nR\nPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1460\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nR\nK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1461\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\nR\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1462\n\n\n \nE\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1463\n\n\nG\nE\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1464\n\n\nGV\nE\nINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1465\n\n\nGVI\nE\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1466\n\n\nGVII\nE\nVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1467\n\n\nGVIIN\nE\nKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1468\n\n\nGVIINV\nE\nCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1469\n\n\nGVIINVKC\nE\nISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1470\n\n\nGVIINVKCK\nE\nSRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1471\n\n\nGVIINVKCKI\nE\nRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1472\n\n\nGVIINVKCKIS\nE\nQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1473\n\n\nGVIINVKCKISR\nE\nCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1474\n\n\nGVIINVKCKISRQC\nE\nEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1475\n\n\nGVIINVKCKISRQCLE\nE\nCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1476\n\n\nGVIINVKCKISRQCLEPC\nE\nKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1477\n\n\nGVIINVKCKISRQCLEPCK\nE\nAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1478\n\n\nGVIINVKCKISRQCLEPCKK\nE\nGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1479\n\n\nGVIINVKCKISRQCLEPCKKA\nE\nMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1480\n\n\nGVIINVKCKISRQCLEPCKKAG\nE\nRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1481\n\n\nGVIINVKCKISRQCLEPCKKAGM\nE\nFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1482\n\n\nGVIINVKCKISRQCLEPCKKAGMR\nE\nGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1483\n\n\nGVIINVKCKISRQCLEPCKKAGMRF\nE\nKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1484\n\n\nGVIINVKCKISRQCLEPCKKAGMRFG\nE\nCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1485\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC\nE\nNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1486\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCM\nE\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1487\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN\nE\nKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1488\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG\nE\nCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1489\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nE\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1490\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\nE\nPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1491\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nE\nK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1492\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\nE\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1493\n\n\n \n[1-Nal]\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1494\n\n\nG\n[1-Nal]\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1495\n\n\nGV\n[1-Nal]\nINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1496\n\n\nGVI\n[1-Nal]\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1497\n\n\nGVII\n[1-Nal]\nVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1498\n\n\nGVIIN\n[1-Nal]\nKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1499\n\n\nGVIINV\n[1-Nal]\nCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1500\n\n\nGVIINVKC\n[1-Nal]\nISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1501\n\n\nGVIINVKCK\n[1-Nal]\nSRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1502\n\n\nGVIINVKCKI\n[1-Nal]\nRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1503\n\n\nGVIINVKCKIS\n[1-Nal]\nQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1504\n\n\nGVIINVKCKISR\n[1-Nal]\nCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1505\n\n\nGVIINVKCKISRQC\n[1-Nal]\nEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1506\n\n\nGVIINVKCKISRQCL\n[1-Nal]\nPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1507\n\n\nGVIINVKCKISRQCLE\n[1-Nal]\nCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1508\n\n\nGVIINVKCKISRQCLEPC\n[1-Nal]\nKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1509\n\n\nGVIINVKCKISRQCLEPCK\n[1-Nal]\nAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1510\n\n\nGVIINVKCKISRQCLEPCKK\n[1-Nal]\nGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1511\n\n\nGVIINVKCKISRQCLEPCKKA\n[1-Nal]\nMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1512\n\n\nGVIINVKCKISRQCLEPCKKAG\n[1-Nal]\nRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1513\n\n\nGVIINVKCKISRQCLEPCKKAGM\n[1-Nal]\nFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1514\n\n\nGVIINVKCKISRQCLEPCKKAGMR\n[1-Nal]\nGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1515\n\n\nGVIINVKCKISRQCLEPCKKAGMRF\n[1-Nal]\nKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1516\n\n\nGVIINVKCKISRQCLEPCKKAGMRFG\n[1-Nal]\nCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1517\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC\n[1-Nal]\nNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1518\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCM\n[1-Nal]\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1519\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN\n[1-Nal]\nKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1520\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG\n[1-Nal]\nCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1521\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n[1-Nal]\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1522\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n[1-Nal]\nPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1523\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\n[1-Nal]\nK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1524\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\n[1-Nal]\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1525\n\n\nAc-AVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1526\n\n\nAc-GAIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1527\n\n\nAc-GVAINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1528\n\n\nAc-GVIANVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1529\n\n\nAc-GVIIAVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1530\n\n\nAc-GVIINAKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1531\n\n\nAc-GVIINVACKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1532\n\n\nAc-GVIINVKCAISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1533\n\n\nAc-GVIINVKCKASRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1534\n\n\nAc-GVIINVKCKIARQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1535\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1536\n\n\nAc-GVIINVKCKISRACLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1537\n\n\nAc-GVIINVKCKISRQCAEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1538\n\n\nAc-GVIINVKCKISRQCLAPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1539\n\n\nAc-GVIINVKCKISRQCLEACKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1540\n\n\nAc-GVIINVKCKISRQCLEPCAKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1541\n\n\nAc-GVIINVKCKISRQCLEPCKAAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1542\n\n\nAc-GVIINVKCKISRQCLEPCKKAAMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1543\n\n\nAc-GVIINVKCKISRQCLEPCKKAGARFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1544\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMAFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1545\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRAGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1546\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFAKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1547\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1548\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1549\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1550\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNAKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1551\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGACHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1552\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1553\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCAPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1554\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTAK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1555\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPA\n\n\n\n\n\n\n \n\n\n\n\n\n\n1556\n\n\nAc-RVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1557\n\n\nAc-GRIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1558\n\n\nAc-GVRINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1559\n\n\nAc-GVIRNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1560\n\n\nAc-GVIIRVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1561\n\n\nAc-GVIINRKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1562\n\n\nAc-GVIINVRCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1563\n\n\nAc-GVIINVKCRISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1564\n\n\nAc-GVIINVKCKRSRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1565\n\n\nAc-GVIINVKCKIRRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1566\n\n\nAc-GVIINVKCKISRRCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1567\n\n\nAc-GVIINVKCKISRQCREPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1568\n\n\nAc-GVIINVKCKISRQCLRPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1569\n\n\nAc-GVIINVKCKISRQCLERCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1570\n\n\nAc-GVIINVKCKISRQCLEPCRKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1571\n\n\nAc-GVIINVKCKISRQCLEPCKRAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1572\n\n\nAc-GVIINVKCKISRQCLEPCKKRGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1573\n\n\nAc-GVIINVKCKISRQCLEPCKKARMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1574\n\n\nAc-GVIINVKCKISRQCLEPCKKAGRRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1575\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRRGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1576\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFRKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1577\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGRCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1578\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCRNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1579\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMRGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1580\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNRKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1581\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGRCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1582\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCRCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1583\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCRPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1584\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTRK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1585\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPR\n\n\n\n\n\n\n \n\n\n\n\n\n\n1586\n\n\nAc-EVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1587\n\n\nAc-GEIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1588\n\n\nAc-GVEINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1589\n\n\nAc-GVIENVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1590\n\n\nAc-GVIIEVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1591\n\n\nAc-GVIINEKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1592\n\n\nAc-GVIINVECKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1593\n\n\nAc-GVIINVKCEISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1594\n\n\nAc-GVIINVKCKESRQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1595\n\n\nAc-GVIINVKCKIERQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1596\n\n\nAc-GVIINVKCKISEQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1597\n\n\nAc-GVIINVKCKISRECLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1598\n\n\nAc-GVIINVKCKISRQCEEPCKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1599\n\n\nAc-GVIINVKCKISRQCLEECKKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1600\n\n\nAc-GVIINVKCKISRQCLEPCEKAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1601\n\n\nAc-GVIINVKCKISRQCLEPCKEAGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1602\n\n\nAc-GVIINVKCKISRQCLEPCKKEGMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1603\n\n\nAc-GVIINVKCKISRQCLEPCKKAEMRFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1604\n\n\nAc-GVIINVKCKISRQCLEPCKKAGERFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1605\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMEFGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1606\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMREGKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1607\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFEKCMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1608\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGECMNGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1609\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCENGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1610\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMEGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1611\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNEKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1612\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGECHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1613\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCECTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1614\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCEPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1615\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTEK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1616\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPE\n\n\n\n\n\n\n \n\n\n\n\n\n\n1617\n\n\nAc-[1-Nal]VIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1618\n\n\nAc-G[1-Nal]IINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1619\n\n\nAc-GV[1-Nal]INVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1620\n\n\nAc-GVI[1-Nal]NVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1621\n\n\nAc-GVII[1-Nal]VKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1622\n\n\nAc-GVIIN[1-Nal]KCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1623\n\n\nAc-GVIINV[1-Nal]CKISRQCLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1624\n\n\nAc-GVIINVKC[1-Nal]ISRQCLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1625\n\n\nAc-GVIINVKCK[1-Nal]SRQCLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1626\n\n\nAc-GVIINVKCKI[1-Nal]RQCLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1627\n\n\nAc-GVIINVKCKIS[1-Nal]QCLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1628\n\n\nAc-GVIINVKCKISR[1-Nal]CLEPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1629\n\n\nAc-GVIINVKCKISRQC[1-Nal]EPCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1630\n\n\nAc-GVIINVKCKISRQCL[1-Nal]PCKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1631\n\n\nAc-GVIINVKCKISRQCLE[1-Nal]CKKAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1632\n\n\nAc-GVIINVKCKISRQCLEPC[1-Nal]KAGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1633\n\n\nAc-GVIINVKCKISRQCLEPCK[1-Nal]AGMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1634\n\n\nAc-GVIINVKCKISRQCLEPCKK[1-Nal]GMRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1635\n\n\nAc-GVIINVKCKISRQCLEPCKKA[1-Nal]MRFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1636\n\n\nAc-GVIINVKCKISRQCLEPCKKAG[1-Nal]RFGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1637\n\n\nAc-GVIINVKCKISRQCLEPCKKAGM[1-Nal]FGKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1638\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMR[1-Nal]GKCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1639\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRF[1-Nal]KCMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1640\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFG[1-Nal]CMNGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1641\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKC[1-Nal]NGKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1642\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCM[1-Nal]GKCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1643\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMN[1-Nal]KCH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1644\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNG[1-Nal]CH\n\n\n\n\n\n\n \n\n\nCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1645\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\n[1-Nal]CTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1646\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n\n\n\n\n \n\n\n[1-Nal]PK\n\n\n\n\n\n\n \n\n\n\n\n\n\n1647\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\n\n\n\n\n\n\n \n\n\n[1-Nal]K\n\n\n\n\n\n\n \n\n\n\n\n\n\n1648\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\n\n\n\n\n\n\n \n\n\n[1-Nal]\n\n\n\n\n\n\n \n\n\n\n\n\n\n1649\n\n\nAVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1650\n\n\nGAIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1651\n\n\nGVAINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1652\n\n\nGVIANVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1653\n\n\nGVIIAVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1654\n\n\nGVIINAKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1655\n\n\nGVIINVACKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1656\n\n\nGVIINVKCAISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1657\n\n\nGVIINVKCKASRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1658\n\n\nGVIINVKCKIARQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1659\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1660\n\n\nGVIINVKCKISRACLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1661\n\n\nGVIINVKCKISRQCAEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1662\n\n\nGVIINVKCKISRQCLAPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1663\n\n\nGVIINVKCKISRQCLEACKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1664\n\n\nGVIINVKCKISRQCLEPCAKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1665\n\n\nGVIINVKCKISRQCLEPCKAAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1666\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1667\n\n\nGVIINVKCKISRQCLEPCKKAAMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1668\n\n\nGVIINVKCKISRQCLEPCKKAGARFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1669\n\n\nGVIINVKCKISRQCLEPCKKAGMAFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1670\n\n\nGVIINVKCKISRQCLEPCKKAGMRAGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1671\n\n\nGVIINVKCKISRQCLEPCKKAGMRFAKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1672\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1673\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1674\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1675\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNAKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1676\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGACHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1677\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1678\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCAPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1679\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTAK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1680\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPA-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1681\n\n\nRVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1682\n\n\nGRIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1683\n\n\nGVRINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1684\n\n\nGVIRNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1685\n\n\nGVIIRVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1686\n\n\nGVIINRKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1687\n\n\nGVIINVRCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1688\n\n\nGVIINVKCRISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1689\n\n\nGVIINVKCKRSRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1690\n\n\nGVIINVKCKIRRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1691\n\n\nGVIINVKCKISRRCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1692\n\n\nGVIINVKCKISRQCREPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1693\n\n\nGVIINVKCKISRQCLRPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1694\n\n\nGVIINVKCKISRQCLERCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1695\n\n\nGVIINVKCKISRQCLEPCRKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1696\n\n\nGVIINVKCKISRQCLEPCKRAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1697\n\n\nGVIINVKCKISRQCLEPCKKRGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1698\n\n\nGVIINVKCKISRQCLEPCKKARMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1699\n\n\nGVIINVKCKISRQCLEPCKKAGRRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1700\n\n\nGVIINVKCKISRQCLEPCKKAGMRRGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1701\n\n\nGVIINVKCKISRQCLEPCKKAGMRFRKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1702\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGRCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1703\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCRNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1704\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMRGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1705\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNRKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1706\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGRCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1707\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCRCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1708\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCRPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1709\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTRK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1710\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPR-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1711\n\n\nEVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1712\n\n\nGEIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1713\n\n\nGVEINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1714\n\n\nGVIENVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1715\n\n\nGVIIEVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1716\n\n\nGVIINEKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1717\n\n\nGVIINVECKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1718\n\n\nGVIINVKCEISRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1719\n\n\nGVIINVKCKESRQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1720\n\n\nGVIINVKCKIERQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1721\n\n\nGVIINVKCKISEQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1722\n\n\nGVIINVKCKISRECLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1723\n\n\nGVIINVKCKISRQCEEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1724\n\n\nGVIINVKCKISRQCLEECKKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1725\n\n\nGVIINVKCKISRQCLEPCEKAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1726\n\n\nGVIINVKCKISRQCLEPCKEAGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1727\n\n\nGVIINVKCKISRQCLEPCKKEGMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1728\n\n\nGVIINVKCKISRQCLEPCKKAEMRFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1729\n\n\nGVIINVKCKISRQCLEPCKKAGERFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1730\n\n\nGVIINVKCKISRQCLEPCKKAGMEFGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1731\n\n\nGVIINVKCKISRQCLEPCKKAGMREGKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1732\n\n\nGVIINVKCKISRQCLEPCKKAGMRFEKCMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1733\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGECMNGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1734\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCENGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1735\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMEGKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1736\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNEKCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1737\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGECHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1738\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCECTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1739\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCEPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1740\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTEK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1741\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPE-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1742\n\n\n[1-Nal]VIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1743\n\n\nG[1-Nal]IINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1744\n\n\nGV[1-Nal]INVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1745\n\n\nGVI[1-Nal]NVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1746\n\n\nGVII[1-Nal]VKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1747\n\n\nGVIIN[1-Nal]KCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1748\n\n\nGVIINV[1-Nal]CKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1749\n\n\nGVIINVKC[1-Nal]ISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1750\n\n\nGVIINVKCK[1-Nal]SRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1751\n\n\nGVIINVKCKI[1-Nal]RQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1752\n\n\nGVIINVKCKIS[1-Nal]QCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1753\n\n\nGVIINVKCKISR[1-Nal]CLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1754\n\n\nGVIINVKCKISRQC[1-Nal]EPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1755\n\n\nGVIINVKCKISRQCL[1-Nal]PCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1756\n\n\nGVIINVKCKISRQCLE[1-Nal]CKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1757\n\n\nGVIINVKCKISRQCLEPC[1-Nal]KAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1758\n\n\nGVIINVKCKISRQCLEPCK[1-Nal]AGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1759\n\n\nGVIINVKCKISRQCLEPCKK[1-Nal]GMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1760\n\n\nGVIINVKCKISRQCLEPCKKA[1-Nal]MRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1761\n\n\nGVIINVKCKISRQCLEPCKKAG[1-Nal]RFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1762\n\n\nGVIINVKCKISRQCLEPCKKAGM[1-Nal]FGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1763\n\n\nGVIINVKCKISRQCLEPCKKAGMR[1-Nal]GKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1764\n\n\nGVIINVKCKISRQCLEPCKKAGMRF[1-Nal]KCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1765\n\n\nGVIINVKCKISRQCLEPCKKAGMRFG[1-Nal]CMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1766\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC[1-Nal]NGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1767\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCM[1-Nal]GKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1768\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMN[1-Nal]KCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1769\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG[1-Nal]CHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1770\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC[1-Nal]CTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1771\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC[1-Nal]PK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1772\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT[1-Nal]K-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1773\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP[1-Nal]-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1774\n\n\nAc-AVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1775\n\n\nAc-GAIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1776\n\n\nAc-GVAINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1777\n\n\nAc-GVIANVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1778\n\n\nAc-GVIIAVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1779\n\n\nAc-GVIINAKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1780\n\n\nAc-GVIINVACKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1781\n\n\nAc-GVIINVKCAISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1782\n\n\nAc-GVIINVKCKASRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1783\n\n\nAc-GVIINVKCKIARQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1784\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1785\n\n\nAc-GVIINVKCKISRACLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1786\n\n\nAc-GVIINVKCKISRQCAEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1787\n\n\nAc-GVIINVKCKISRQCLAPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1788\n\n\nAc-GVIINVKCKISRQCLEACKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1789\n\n\nAc-GVIINVKCKISRQCLEPCAKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1790\n\n\nAc-GVIINVKCKISRQCLEPCKAAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1791\n\n\nAc-GVIINVKCKISRQCLEPCKKAAMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1792\n\n\nAc-GVIINVKCKISRQCLEPCKKAGARFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1793\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMAFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1794\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRAGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1795\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFAKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1796\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1797\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1798\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1799\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNAKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1800\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGACHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1801\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCACTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1802\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCAPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1803\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTAK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1804\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPA-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1805\n\n\nAc-RVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1806\n\n\nAc-GRIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1807\n\n\nAc-GVRINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1808\n\n\nAc-GVIRNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1809\n\n\nAc-GVIIRVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1810\n\n\nAc-GVIINRKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1811\n\n\nAc-GVIINVRCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1812\n\n\nAc-GVIINVKCRISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1813\n\n\nAc-GVIINVKCKRSRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1814\n\n\nAc-GVIINVKCKIRRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1815\n\n\nAc-GVIINVKCKISRRCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1816\n\n\nAc-GVIINVKCKISRQCREPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1817\n\n\nAc-GVIINVKCKISRQCLRPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1818\n\n\nAc-GVIINVKCKISRQCLERCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1819\n\n\nAc-GVIINVKCKISRQCLEPCRKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1820\n\n\nAc-GVIINVKCKISRQCLEPCKRAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1821\n\n\nAc-GVIINVKCKISRQCLEPCKKRGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1822\n\n\nAc-GVIINVKCKISRQCLEPCKKARMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1823\n\n\nAc-GVIINVKCKISRQCLEPCKKAGRRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1824\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRRGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1825\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFRKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1826\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGRCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1827\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCRNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1828\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMRGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1829\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNRKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1830\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGRCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1831\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCRCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1832\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCRPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1833\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTRK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1834\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPR-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1835\n\n\nAc-EVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1836\n\n\nAc-GEIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1837\n\n\nAc-GVEINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1838\n\n\nAc-GVIENVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1839\n\n\nAc-GVIIEVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1840\n\n\nAc-GVIINEKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1841\n\n\nAc-GVIINVECKISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1842\n\n\nAc-GVIINVKCEISRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1843\n\n\nAc-GVIINVKCKESRQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1844\n\n\nAc-GVIINVKCKIERQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1845\n\n\nAc-GVIINVKCKISEQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1846\n\n\nAc-GVIINVKCKISRECLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1847\n\n\nAc-GVIINVKCKISRQCEEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1848\n\n\nAc-GVIINVKCKISRQCLEECKKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1849\n\n\nAc-GVIINVKCKISRQCLEPCEKAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\n \namide\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n1850\n\n\nAc-GVIINVKCKISRQCLEPCKEAGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1851\n\n\nAc-GVIINVKCKISRQCLEPCKKEGMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1852\n\n\nAc-GVIINVKCKISRQCLEPCKKAEMRFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1853\n\n\nAc-GVIINVKCKISRQCLEPCKKAGERFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1854\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMEFGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1855\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMREGKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1856\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFEKCMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1857\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGECMNGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1858\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCENGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1859\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMEGKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1860\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNEKCHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1861\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGECHCTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1862\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCECTPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1863\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCEPK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1864\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTEK-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1865\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPE-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1866\n\n\nAc-[1-Nal]VIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n1867\n\n\nAc-G[1-Nal]IINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1868\n\n\nAc-GV[1-Nal]INVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1869\n\n\nAc-GVI[1-Nal]NVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1870\n\n\nAc-GVII[1-Nal]VKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1871\n\n\nAc-GVIIN[1-Nal]KCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1872\n\n\nAc-GVIINV[1-Nal]CKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1873\n\n\nAc-GVIINVKC[1-Nal]ISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1874\n\n\nAc-GVIINVKCK[1-Nal]SRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1875\n\n\nAc-GVIINVKCKI[1-Nal]RQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1876\n\n\nAc-GVIINVKCKIS[1-Nal]QCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1877\n\n\nAc-GVIINVKCKISR[1-Nal]CLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1878\n\n\nAc-GVIINVKCKISRQC[1-Nal]EPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1879\n\n\nAc-GVIINVKCKISRQCL[1-Nal]PCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1880\n\n\nAc-GVIINVKCKISRQCLE[1-Nal]CKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1881\n\n\nAc-GVIINVKCKISRQCLEPC[1-Nal]KAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1882\n\n\nAc-GVIINVKCKISRQCLEPCK[1-Nal]AGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1883\n\n\nAc-GVIINVKCKISRQCLEPCKK[1-Nal]GMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1884\n\n\nAc-GVIINVKCKISRQCLEPCKKA[1-Nal]MRFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1885\n\n\nAc-GVIINVKCKISRQCLEPCKKAG[1-Nal]RFGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1886\n\n\nAc-GVIINVKCKISRQCLEPCKKAGM[1-Nal]FGKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1887\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMR[1-Nal]GKCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1888\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRF[1-Nal]KCMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1889\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFG[1-Nal]CMNGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1890\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKC[1-Nal]NGKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1891\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCM[1-Nal]GKC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1892\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMN[1-Nal]KC\n\n\n\n\n\n\n \n\n\nHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1893\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNG[1-Nal]\n\n\n\n\n\n\n \n\n\nCHCTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1894\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\n\n\n\n\n\n\n \n\n\n[1-Nal]CTPK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1895\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n\n\n\n\n \n\n\n[1-Nal]PK-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1896\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\n\n\n\n\n\n\n \n\n\n[1-Nal]K-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n1897\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTP\n\n\n\n\n\n\n \n\n\n[1-Nal]-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7B\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analog\n\n\n\n\n\n\nsequences: Ala-12 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1898\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1899\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCMNGKCHCTPK\n\n\n1900\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCMNGKCHCTPK\n\n\n1901\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1902\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1903\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1904\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYPK\n\n\n1905\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1906\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1907\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1908\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYPK-\namide\n \n\n\n1909\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYPK\n\n\n1910\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYPK-\n\n\n1911\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n1912\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCMNGKCHCTPK\n\n\n1913\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCMNGKCHCTPK-\n\n\n1914\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCMNGKCHCTPK\n\n\n1915\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCMNCKCHCTPK-amide\n\n\n1916\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1917\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n1918\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1919\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n1920\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1921\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1922\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1923\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1924\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1925\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n1926\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n1927\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\n1928\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\n1929\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK-amide\n\n\n1930\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK-\n\n\n1931\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1932\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1933\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1934\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1935\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1936\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1937\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1938\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1939\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1940\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1941\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1942\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1943\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1944\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1945\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1946\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1947\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCMNGKCHCTPK\n\n\n1948\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCMNGKCHCTPK-amide\n\n\n1949\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCMNGKCHCTPK\n\n\n1950\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCMNGKCHCTPK-\n\n\n1951\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n1952\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n1953\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n1954\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n1955\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK\n\n\n1956\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK\n\n\n1957\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK-amide\n\n\n1958\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMNGKCHCTPK-\n\n\n1959\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1960\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1961\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1962\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1963\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1964\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK\n\n\n1965\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-amide\n\n\n1966\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCHCTPK-\n\n\n1967\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\n1968\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1969\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCACTPK\n\n\n1970\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK\n\n\n1971\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK-amide\n\n\n1972\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMNGKCACTPK-\n\n\n1973\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCACTPK\n\n\n1974\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCACTPK-amide\n\n\n1975\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCACTPK-\n\n\n1976\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK\n\n\n1977\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n1978\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCTPK-\n\n\n1979\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCT\n\n\n1980\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCTPK\n\n\n1981\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1982\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1983\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1984\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1985\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1986\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCHCTPK\n\n\n1987\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCYPK\n\n\n1988\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1989\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1990\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1991\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1992\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1993\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCHCYPK\n\n\n1994\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYPK\n\n\n1995\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCGCYPK\n\n\n1996\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACFPK\n\n\n1997\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACWPK\n\n\n1998\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCACYPK\n\n\n1999\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACTPK\n\n\n2000\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACTPK\n\n\n2001\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACTPK\n\n\n2002\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACTPK\n\n\n2003\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK\n\n\n2004\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACTPK\n\n\n2005\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACTPK\n\n\n2006\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHC\n\n\n2007\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHC\n\n\n2008\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHC\n\n\n2009\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHC\n\n\n2010\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHC\n\n\n2011\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHC\n\n\n2012\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCHC\n\n\n2013\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCAC\n\n\n2014\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCAC\n\n\n2015\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCAC\n\n\n2016\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCAC\n\n\n2017\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHC\n\n\n2018\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCAC\n\n\n2019\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCAC\n\n\n2020\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCGCYGG\n\n\n2021\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCYGG\n\n\n2022\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2023\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2024\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2025\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2026\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2027\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYGG\n\n\n2028\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACYGG\n\n\n2029\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACYGG\n\n\n2030\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACYGG\n\n\n2031\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACYGG\n\n\n2032\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG\n\n\n2033\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACYGG\n\n\n2034\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACYGG\n\n\n2035\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYG\n\n\n2036\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCGGG\n\n\n2037\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCGGG\n\n\n2038\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCGGG\n\n\n2039\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCGGG\n\n\n2040\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCGGG\n\n\n2041\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCGGG\n\n\n2042\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACFGG\n\n\n2043\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACGGG\n\n\n2044\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACGGG\n\n\n2045\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACGGG\n\n\n2046\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACGGG\n\n\n2047\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCACGGG\n\n\n2048\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACGGG\n\n\n2049\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACGGG\n\n\n2050\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACGG\n\n\n2051\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYG\n\n\n2052\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACGG\n\n\n2053\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2054\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2055\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2056\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2057\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2058\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2059\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCYPK\n\n\n2060\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2061\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2062\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2063\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2064\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2065\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCYPK\n\n\n2066\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACTPK\n\n\n2067\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACTPK\n\n\n2068\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACTPK\n\n\n2069\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACTPK\n\n\n2070\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK\n\n\n2071\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACTPK\n\n\n2072\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACTPK\n\n\n2073\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHC\n\n\n2074\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHC\n\n\n2075\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHC\n\n\n2076\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHC\n\n\n2077\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHC\n\n\n2078\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHC\n\n\n2079\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCAC\n\n\n2080\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCAC\n\n\n2081\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCAC\n\n\n2082\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCAC\n\n\n2083\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHC\n\n\n2084\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCAC\n\n\n2085\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCAC\n\n\n2086\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCHCYGG\n\n\n2087\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCYGG\n\n\n2088\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCHCYG\n\n\n2089\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCACYG\n\n\n2090\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2091\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2092\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2093\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2094\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2095\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2096\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCACYG\n\n\n2097\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACYGG\n\n\n2098\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACYGG\n\n\n2099\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACYGG\n\n\n2100\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACYGG\n\n\n2101\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG\n\n\n2102\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACYGG\n\n\n2103\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACYGG\n\n\n2104\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCACFGG\n\n\n2105\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCGGG\n\n\n2106\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCGGG\n\n\n2107\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCGGG\n\n\n2108\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCGGG\n\n\n2109\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCGGG\n\n\n2110\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCGGG\n\n\n2111\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACGGG\n\n\n2112\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACGGG\n\n\n2113\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACGGG\n\n\n2114\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACGGG\n\n\n2115\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCACTP\n\n\n2116\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACTP\n\n\n2117\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACTP\n\n\n2118\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCTPK-amide\n\n\n2119\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2120\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2121\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2122\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2123\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2124\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCHCTPK-\n\n\n2125\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCYPK-amide\n\n\n2126\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2127\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2128\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2129\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2130\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2131\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCHCYPK-\n\n\n2132\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACTPK-amide\n\n\n2133\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2134\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2135\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2136\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2137\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2138\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACTPK-\n\n\n2139\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHC-amide\n\n\n2140\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHC-\n\n\n2141\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHC-\n\n\n2142\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHC-amide\n\n\n2143\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHC-\n\n\n2144\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHC-amide\n\n\n2145\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCAC-amide\n\n\n2146\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCAC-\n\n\n2147\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCAC-\n\n\n2148\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCAC-\namide\n \n\n\n2149\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHC-\n\n\n2150\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCAC-amide\n\n\n2151\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCAC-amide\n\n\n2152\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYGG-amide\n\n\n2153\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCYGG-amide\n\n\n2154\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCYGG-\n\n\n2155\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCYGG-\n\n\n2156\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCYGG-\n\n\n2157\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCYGG-\n\n\n2158\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCYGG-\n\n\n2159\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCFGG-amide\n\n\n2160\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCYG-amide\n\n\n2161\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYG-amide\n\n\n2162\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACYGG-amide\n\n\n2163\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2164\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2165\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2166\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2167\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2168\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACYGG-\n\n\n2169\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYGG-amide\n\n\n2170\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCHCGGG-amide\n\n\n2171\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCHCGGG-\n\n\n2172\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCHCGGG-\n\n\n2173\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCHCGGG-\n\n\n2174\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCHCGGG-\n\n\n2175\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCHCGGG-\n\n\n2176\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACGGG-amide\n\n\n2177\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACFGG-amide\n\n\n2178\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMNGKCACGGG-amide\n\n\n2179\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2180\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2181\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2182\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2183\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2184\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMNGKCACGGG-\n\n\n2185\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCTPK-amide\n\n\n2186\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2187\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2188\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2189\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2190\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2191\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCTPK-\n\n\n2192\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCYPK-amide\n\n\n2193\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2194\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2195\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2196\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2197\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2198\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCYPK-\n\n\n2199\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACTPK-amide\n\n\n2200\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2201\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2202\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2203\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2204\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2205\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACTPK-\n\n\n2206\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHC-amide\n\n\n2207\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHC-\n\n\n2208\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHC-\n\n\n2209\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHC-\namide\n \n\n\n2210\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHC-\n\n\n2211\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHC-amide\n\n\n2212\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCAC-amide\n\n\n2213\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCAC-\n\n\n2214\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCAC-\n\n\n2215\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCAC-amide\n\n\n2216\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHC-\n\n\n2217\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCAC-amide\n\n\n2218\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCAC-amide\n\n\n2219\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCHCWGG-amide\n\n\n2220\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCYGG-amide\n\n\n2221\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2222\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2223\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2224\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2225\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2226\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2227\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMNGKCACYGG-amide\n\n\n2228\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACYGG-amide\n\n\n2229\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACYGG-\n\n\n2230\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACYGG-\n\n\n2231\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACYGG-\n\n\n2232\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCYGG-\n\n\n2233\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACYGG-\n\n\n2234\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACYGG-\n\n\n2235\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCHCGGG-amide\n\n\n2236\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCHCGGG-\n\n\n2237\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCHCGGG-\n\n\n2238\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCHCGGG-\n\n\n2239\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCHCGGG-\n\n\n2240\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCHCGGG-\n\n\n2241\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMNGKCACGGG-amide\n\n\n2242\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMNGKCACGGG-\n\n\n2243\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMNGKCACGGG-\n\n\n2244\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMNGKCACGGG-\n\n\n2245\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMNGKCACTP-\n\n\n2246\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMNGKCACGGG-\n\n\n2247\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMNGKCACGGG-\n\n\n2248\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMNGKCACYGG-\n\n\n2249\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMNGKCACGGG-\n\n\n2250\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMNGKCACY-\n\n\n2251\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCACYGG-\n\n\n2252\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMNGKCACYGG-\n\n\n2253\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMNGKCHCYGG-\n\n\n2254\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMNGKCACYGG\n\n\n2255\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCACYGG-amide\n\n\n2256\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCACYGG\n\n\n2257\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCACY-amide\n\n\n2258\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCHCYGG-amide\n\n\n2259\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCHCYGG\n\n\n2260\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCHCYPK\n\n\n2261\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCAC\n\n\n2262\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[1Nal]GG-\n\n\n2263\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[1Nal]PK-\n\n\n2264\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[2Nal]GG-\n\n\n2265\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[Cha]GG-\n\n\n2266\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[MePhe]GG-\n\n\n2267\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[BiPhA]GG-\n\n\n2268\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKC[Aib]CYGG-\n\n\n2269\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKC[Abu]CYGG-\n\n\n2270\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[1Nal]\n\n\n2271\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCAC[1Nal]GG-\n\n\n2272\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC[4Bip]-\n\n\n2273\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMNGKCAC[4Bip]GG-\n\n\n2274\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCHCGGG\n\n\n2275\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7C\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analog sequences:\n\n\n\n\n\n\nAla-12 & Ala27 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2276\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2277\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGACMNGKCHCTPK\n\n\n2278\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGACMNGKCHCTPK\n\n\n2279\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2280\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2281\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2282\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYPK\n\n\n2283\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2284\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2285\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n2286\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYPK-amide\n\n\n2287\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYPK\n\n\n2288\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYPK-\n\n\n2289\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n2290\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGACMNGKCHCTPK\n\n\n2291\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGACMNGKCHCTPK-\n\n\n2292\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGACMNGKCHCTPK\n\n\n2293\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2294\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGACMNGKCHCTPK-\n\n\n2295\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n2296\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2297\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n2298\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2299\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2300\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n2301\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2302\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2303\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n2304\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n2305\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n2306\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n2307\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK-amide\n\n\n2308\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK-\n\n\n2309\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2310\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2311\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2312\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n2313\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2314\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2315\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2316\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2317\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2318\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2319\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2320\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2321\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2322\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2323\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2324\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2325\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGACMNGKCHCTPK\n\n\n2326\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGACMNGKCHCTPK-amide\n\n\n2327\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGACMNGKCHCTPK\n\n\n2328\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGACMNGKCHCTPK-\n\n\n2329\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n2330\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n2331\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n2332\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n2333\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK\n\n\n2334\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK\n\n\n2335\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCGDAGMRFGACMNGKCHCTPK-amide\n\n\n2336\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK-\n\n\n2337\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2338\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2339\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2340\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n2341\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2342\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n2343\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n2344\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n2345\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n2346\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2347\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGACMNGKCACTPK\n\n\n2348\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n2349\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK-amide\n\n\n2350\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGACMNGKCACTPK-\n\n\n2351\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGACMNGKCACTPK\n\n\n2352\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGACMNGKCACTPK-amide\n\n\n2353\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGACMNGKCACTPK-\n\n\n2354\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n2355\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2356\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n2357\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCT\n\n\n2358\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCTPK\n\n\n2359\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCTPK\n\n\n2360\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCTPK\n\n\n2361\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCTPK\n\n\n2362\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCTPK\n\n\n2363\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCTPK\n\n\n2364\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCHCTPK\n\n\n2365\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCYPK\n\n\n2366\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCYPK\n\n\n2367\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCYPK\n\n\n2368\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCYPK\n\n\n2369\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCYPK\n\n\n2370\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCYPK\n\n\n2371\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCHCYPK\n\n\n2372\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYPK\n\n\n2373\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCGCYPK\n\n\n2374\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACFPK\n\n\n2375\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACWPK\n\n\n2376\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCACYPK\n\n\n2377\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACTPK\n\n\n2378\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACTPK\n\n\n2379\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACTPK\n\n\n2380\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACTPK\n\n\n2381\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCTPK\n\n\n2382\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACTPK\n\n\n2383\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACTPK\n\n\n2384\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHC\n\n\n2385\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHC\n\n\n2386\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHC\n\n\n2387\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHC\n\n\n2388\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHC\n\n\n2389\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHC\n\n\n2390\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCHC\n\n\n2391\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCAC\n\n\n2392\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCAC\n\n\n2393\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCAC\n\n\n2394\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCAC\n\n\n2395\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHC\n\n\n2396\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCAC\n\n\n2397\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCAC\n\n\n2398\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCGCYGG\n\n\n2399\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCYGG\n\n\n2400\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCYGG\n\n\n2401\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCYGG\n\n\n2402\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCYGG\n\n\n2403\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCYGG\n\n\n2404\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCYGG\n\n\n2405\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYGG\n\n\n2406\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACYGG\n\n\n2407\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACYGG\n\n\n2408\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACYGG\n\n\n2409\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACYGG\n\n\n2410\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCYGG\n\n\n2411\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACYGG\n\n\n2412\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACYGG\n\n\n2413\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYG\n\n\n2415\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCGGG\n\n\n2416\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCGGG\n\n\n2417\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCGGG\n\n\n2418\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCGGG\n\n\n2419\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCGGG\n\n\n2420\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCGGG\n\n\n2421\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACFGG\n\n\n2422\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACGGG\n\n\n2423\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACGGG\n\n\n2424\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACGGG\n\n\n2425\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACGGG\n\n\n2426\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCACGGG\n\n\n2427\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACGGG\n\n\n2428\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACGGG\n\n\n2429\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACGG\n\n\n2430\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYG\n\n\n2431\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACGG\n\n\n2432\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCTPK\n\n\n2433\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCTPK\n\n\n2434\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCTPK\n\n\n2435\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCTPK\n\n\n2436\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCTPK\n\n\n2437\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCTPK\n\n\n2438\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCYPK\n\n\n2439\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCYPK\n\n\n2440\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCYPK\n\n\n2441\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCYPK\n\n\n2442\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYPK\n\n\n2443\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCYPK\n\n\n2444\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCYPK\n\n\n2445\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACTPK\n\n\n2446\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACTPK\n\n\n2447\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACTPK\n\n\n2448\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACTPK\n\n\n2449\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCTPK\n\n\n2450\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACTPK\n\n\n2451\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACTPK\n\n\n2452\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHC\n\n\n2453\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHC\n\n\n2454\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHC\n\n\n2455\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHC\n\n\n2456\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHC\n\n\n2457\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHC\n\n\n2458\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCAC\n\n\n2459\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCAC\n\n\n2460\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCAC\n\n\n2461\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCAC\n\n\n2462\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHC\n\n\n2463\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCAC\n\n\n2464\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCAC\n\n\n2465\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCHCYGG\n\n\n2466\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCYGG\n\n\n2467\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCHCYG\n\n\n2468\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCACYG\n\n\n2469\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCYGG\n\n\n2470\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCYGG\n\n\n2471\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCYGG\n\n\n2472\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYGG\n\n\n2473\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCYGG\n\n\n2474\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCYGG\n\n\n2475\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCACYG\n\n\n2476\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACYGG\n\n\n2477\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACYGG\n\n\n2478\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACYGG\n\n\n2479\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACYGG\n\n\n2480\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYGG\n\n\n2481\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACYGG\n\n\n2482\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACYGG\n\n\n2483\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCACFGG\n\n\n2484\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCGGG\n\n\n2485\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCGGG\n\n\n2486\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCGGG\n\n\n2487\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCGGG\n\n\n2488\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCGGG\n\n\n2489\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCGGG\n\n\n2490\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACGGG\n\n\n2491\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACGGG\n\n\n2492\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACGGG\n\n\n2493\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACGGG\n\n\n2494\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCACTP\n\n\n2495\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACTP\n\n\n2496\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACTP\n\n\n2497\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n2498\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2499\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2500\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2501\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2502\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2503\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCHCTPK-\n\n\n2504\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCYPK-amide\n\n\n2505\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2506\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2507\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2508\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2509\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2510\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCHCYPK-\n\n\n2511\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACTPK-amide\n\n\n2512\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACTPK-\n\n\n2513\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACTPK-\n\n\n2514\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACTPK-\n\n\n2515\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCACTPK-\n\n\n2516\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACTPK-\n\n\n2517\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACTPK-\n\n\n2518\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHC-amide\n\n\n2519\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHC-\n\n\n2520\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHC-\n\n\n2521\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHC-\n\n\n2522\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHC-\n\n\n2523\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHC-amide\n\n\n2524\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCAC-amide\n\n\n2525\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCAC-\n\n\n2526\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCAC-\n\n\n2527\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCAC-amide\n\n\n2528\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHC-\n\n\n2529\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCAC-amide\n\n\n2530\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCAC-amide\n\n\n2531\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n2532\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n2533\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCYGG-\n\n\n2534\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCYGG-\n\n\n2535\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCYGG-\n\n\n2536\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCYGG-\n\n\n2537\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCYGG-\n\n\n2538\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCFGG-amide\n\n\n2539\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCYG-amide\n\n\n2540\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYG-amide\n\n\n2541\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACYGG-amide\n\n\n2542\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACYGG-\n\n\n2543\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACYGG-\n\n\n2544\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACYGG-\n\n\n2545\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCACYGG-\n\n\n2546\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACYGG-\n\n\n2547\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACYGG-\n\n\n2548\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYGG-amide\n\n\n2549\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCHCGGG-amide\n\n\n2550\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCHCGGG-\n\n\n2551\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCHCGGG-\n\n\n2552\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCHCGGG-\n\n\n2553\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCHCGGG-\n\n\n2554\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCHCGGG-\n\n\n2555\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACGGG-amide\n\n\n2556\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACFGG-amide\n\n\n2557\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGACMNGKCACGGG-amide\n\n\n2558\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGACMNGKCACGGG-\n\n\n2559\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGACMNGKCACGGG-\n\n\n2560\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGACMNGKCACGGG-\n\n\n2561\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGACMNGKCACGGG-\n\n\n2562\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGACMNGKCACGGG-\n\n\n2563\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGACMNGKCACGGG-\n\n\n2564\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCTPK-amide\n\n\n2565\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2566\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2567\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2568\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2569\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2570\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCTPK-\n\n\n2571\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCYPK-amide\n\n\n2572\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2573\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2574\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2575\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2576\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2577\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCYPK-\n\n\n2578\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACTPK-amide\n\n\n2579\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACTPK-\n\n\n2580\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACTPK-\n\n\n2581\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACTPK-\n\n\n2582\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCACTPK-\n\n\n2583\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACTPK-\n\n\n2584\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACTPK-\n\n\n2585\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHC-amide\n\n\n2586\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHC-\n\n\n2587\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHC-\n\n\n2588\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHC-amide\n\n\n2589\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHC-\n\n\n2590\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHC-amide\n\n\n2591\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCAC-amide\n\n\n2592\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCAC-\n\n\n2593\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCAC-\n\n\n2594\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCAC-amide\n\n\n2595\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHC-\n\n\n2596\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCAC-amide\n\n\n2597\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCAC-amide\n\n\n2598\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCHCWGG-amide\n\n\n2599\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCYGG-amide\n\n\n2600\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2601\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2602\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2603\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2604\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2605\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2606\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGACMNGKCACYGG-amide\n\n\n2607\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACYGG-amide\n\n\n2608\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACYGG-\n\n\n2609\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACYGG-\n\n\n2610\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACYGG-\n\n\n2611\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n2612\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACYGG-\n\n\n2613\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACYGG-\n\n\n2614\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCHCGGG-amide\n\n\n2615\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCHCGGG-\n\n\n2616\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCHCGGG-\n\n\n2617\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCHCGGG-\n\n\n2618\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCHCGGG-\n\n\n2619\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCHCGGG-\n\n\n2620\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGACMNGKCACGGG-amide\n\n\n2621\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGACMNGKCACGGG-\n\n\n2622\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGACMNGKCACGGG-\n\n\n2623\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGACMNGKCACGGG-\n\n\n2624\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGACMNGKCACTP-\n\n\n2625\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGACMNGKCACGGG-\n\n\n2626\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGACMNGKCACGGG-\n\n\n2627\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGACMNGKCACYGG-\n\n\n2628\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGACMNGKCACGGG-\n\n\n2629\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGACMNGKCACY-\n\n\n2630\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGACMNGKCACYGG-\n\n\n2631\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGACMNGKCACYGG-\n\n\n2632\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGACMNGKCHCYGG-\n\n\n2633\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGACMNGKCACYGG\n\n\n2634\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCACYGG-amide\n\n\n2635\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCACYGG\n\n\n2636\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCACY-amide\n\n\n2637\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n2638\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCHCYGG\n\n\n2639\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCHCYPK\n\n\n2640\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCAC\n\n\n2641\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[1Nal]GG-\n\n\n2642\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[1Nal]PK-\n\n\n2643\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[2Nal]GG-\n\n\n2644\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[Cha]GG-\n\n\n2645\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[MePhe]GG-\n\n\n2646\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[BiPhA]GG-\n\n\n2647\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKC[Aib]CYGG-\n\n\n2648\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKC[Abu]CYGG-\n\n\n2649\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[1Nal]\n\n\n2650\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCAC[1Nal]GG-\n\n\n2651\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCAC[4Bip]-\n\n\n2652\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGACMNGKCAC[4Bip]GG-\n\n\n2653\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGACMNGKCHCGGG\n\n\n2654\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7D\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analog sequences:\n\n\n\n\n\n\nAla-12 & Ala29 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2655\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2656\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCANGKCHCTPK\n\n\n2657\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCANGKCHCTPK\n\n\n2658\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2659\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2660\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2661\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYPK\n\n\n2662\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2663\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2664\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n2665\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYPK-amide\n\n\n2666\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYPK\n\n\n2667\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYPK-\n\n\n2668\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n2669\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCANGKCHCTPK\n\n\n2670\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCANGKCHCTPK-\n\n\n2671\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCANGKCHCTPK\n\n\n2672\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2673\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCANGKCHCTPK-\n\n\n2674\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n2675\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2676\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n2677\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2678\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2679\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n2680\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2681\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2682\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n2683\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n2684\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n2685\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n2686\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK-amide\n\n\n2687\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK-\n\n\n2688\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2689\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2690\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2691\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n2692\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2693\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2694\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2695\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2696\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2697\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2698\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2699\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2700\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2701\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2702\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2703\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2704\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCANGKCHCTPK\n\n\n2705\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCANGKCHCTPK-amide\n\n\n2706\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCANGKCHCTPK\n\n\n2707\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCANGKCHCTPK-\n\n\n2708\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n2709\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n2710\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n2711\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n2712\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK\n\n\n2713\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK\n\n\n2714\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK-amide\n\n\n2715\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK-\n\n\n2716\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2717\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2718\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2719\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n2720\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2721\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n2722\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n2723\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n2724\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n2725\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2726\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCANGKCACTPK\n\n\n2727\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n2728\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK-amide\n\n\n2729\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCANGKCACTPK-\n\n\n2730\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCANGKCACTPK\n\n\n2731\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCANGKCACTPK-amide\n\n\n2732\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCANGKCACTPK-\n\n\n2733\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n2734\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2735\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n2736\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCT\n\n\n2737\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCTPK\n\n\n2738\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCTPK\n\n\n2739\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCTPK\n\n\n2740\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCTPK\n\n\n2741\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCTPK\n\n\n2742\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCTPK\n\n\n2743\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCHCTPK\n\n\n2744\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCYPK\n\n\n2745\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCYPK\n\n\n2746\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCYPK\n\n\n2747\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCYPK\n\n\n2748\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCYPK\n\n\n2749\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCYPK\n\n\n2750\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCHCYPK\n\n\n2751\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYPK\n\n\n2752\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCGCYPK\n\n\n2753\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACFPK\n\n\n2754\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACWPK\n\n\n2755\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCACYPK\n\n\n2756\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACTPK\n\n\n2757\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACTPK\n\n\n2758\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACTPK\n\n\n2759\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACTPK\n\n\n2760\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCTPK\n\n\n2761\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACTPK\n\n\n2762\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACTPK\n\n\n2763\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHC\n\n\n2764\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHC\n\n\n2765\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHC\n\n\n2766\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHC\n\n\n2767\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHC\n\n\n2768\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHC\n\n\n2769\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCHC\n\n\n2770\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCAC\n\n\n2771\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCAC\n\n\n2772\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCAC\n\n\n2773\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCAC\n\n\n2774\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHC\n\n\n2775\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCAC\n\n\n2776\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCAC\n\n\n2777\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCGCYGG\n\n\n2778\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCYGG\n\n\n2779\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCYGG\n\n\n2780\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCYGG\n\n\n2781\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCYGG\n\n\n2782\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCYGG\n\n\n2783\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCYGG\n\n\n2784\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYGG\n\n\n2785\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACYGG\n\n\n2786\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACYGG\n\n\n2787\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACYGG\n\n\n2788\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACYGG\n\n\n2789\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCYGG\n\n\n2790\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACYGG\n\n\n2791\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACYGG\n\n\n2792\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYG\n\n\n2793\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCGGG\n\n\n2794\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCGGG\n\n\n2795\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCGGG\n\n\n2796\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCGGG\n\n\n2797\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCGGG\n\n\n2798\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCGGG\n\n\n2799\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACFGG\n\n\n2800\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACGGG\n\n\n2801\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACGGG\n\n\n2802\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACGGG\n\n\n2803\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACGGG\n\n\n2804\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCACGGG\n\n\n2805\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACGGG\n\n\n2806\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACGGG\n\n\n2807\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACGG\n\n\n2808\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYG\n\n\n2809\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACGG\n\n\n2810\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCTPK\n\n\n2811\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCTPK\n\n\n2812\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCTPK\n\n\n2813\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCTPK\n\n\n2814\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCTPK\n\n\n2815\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCTPK\n\n\n2816\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCYPK\n\n\n2817\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCYPK\n\n\n2818\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCYPK\n\n\n2819\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCYPK\n\n\n2820\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYPK\n\n\n2821\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCYPK\n\n\n2822\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCYPK\n\n\n2823\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACTPK\n\n\n2824\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACTPK\n\n\n2825\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACTPK\n\n\n2826\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACTPK\n\n\n2827\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCTPK\n\n\n2828\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACTPK\n\n\n2829\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACTPK\n\n\n2830\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHC\n\n\n2831\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHC\n\n\n2832\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHC\n\n\n2833\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHC\n\n\n2834\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHC\n\n\n2835\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHC\n\n\n2836\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCAC\n\n\n2837\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCAC\n\n\n2838\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCAC\n\n\n2839\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCAC\n\n\n2840\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHC\n\n\n2841\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCAC\n\n\n2842\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCAC\n\n\n2843\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCHCYGG\n\n\n2844\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCYGG\n\n\n2845\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCHCYG\n\n\n2846\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCACYG\n\n\n2847\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCYGG\n\n\n2848\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCYGG\n\n\n2849\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCYGG\n\n\n2850\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYGG\n\n\n2851\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCYGG\n\n\n2852\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCYGG\n\n\n2853\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCACYG\n\n\n2854\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACYGG\n\n\n2855\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACYGG\n\n\n2856\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACYGG\n\n\n2857\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACYGG\n\n\n2858\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYGG\n\n\n2859\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACYGG\n\n\n2860\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACYGG\n\n\n2861\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCACFGG\n\n\n2862\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCGGG\n\n\n2863\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCGGG\n\n\n2864\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCGGG\n\n\n2865\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCGGG\n\n\n2866\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCGGG\n\n\n2867\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCGGG\n\n\n2868\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACGGG\n\n\n2869\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACGGG\n\n\n2870\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACGGG\n\n\n2871\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACGGG\n\n\n2872\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCACTP\n\n\n2873\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACTP\n\n\n2874\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACTP\n\n\n2875\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n2876\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2877\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2878\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2879\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2880\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2881\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCHCTPK-\n\n\n2882\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCYPK-amide\n\n\n2883\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2884\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2885\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2886\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2887\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2888\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCHCYPK-\n\n\n2889\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACTPK-amide\n\n\n2890\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACTPK-\n\n\n2891\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACTPK-\n\n\n2892\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACTPK-\n\n\n2893\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCACTPK-\n\n\n2894\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACTPK-\n\n\n2895\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACTPK-\n\n\n2896\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHC-amide\n\n\n2897\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHC-\n\n\n2898\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHC-\n\n\n2899\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHC-amide\n\n\n2900\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHC-\n\n\n2901\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHC-amide\n\n\n2902\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCAC-amide\n\n\n2903\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCAC-\n\n\n2904\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCAC-\n\n\n2905\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCAC-amide\n\n\n2906\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHC-\n\n\n2907\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCAC-amide\n\n\n2908\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCAC-amide\n\n\n2909\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n2910\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n2911\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCYGG-\n\n\n2912\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCYGG-\n\n\n2913\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCYGG-\n\n\n2914\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCYGG-\n\n\n2915\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCYGG-\n\n\n2916\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCFGG-amide\n\n\n2917\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCYG-amide\n\n\n2918\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYG-amide\n\n\n2919\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACYGG-amide\n\n\n2920\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACYGG-\n\n\n2921\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACYGG-\n\n\n2922\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACYGG-\n\n\n2923\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCACYGG-\n\n\n2924\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACYGG-\n\n\n2925\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACYGG-\n\n\n2926\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYGG-amide\n\n\n2927\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCHCGGG-amide\n\n\n2928\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCHCGGG-\n\n\n2929\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCHCGGG-\n\n\n2930\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCHCGGG-\n\n\n2931\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCHCGGG-\n\n\n2932\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCHCGGG-\n\n\n2933\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACGGG-amide\n\n\n2934\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACFGG-amide\n\n\n2935\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCANGKCACGGG-amide\n\n\n2936\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCANGKCACGGG-\n\n\n2937\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCANGKCACGGG-\n\n\n2938\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCANGKCACGGG-\n\n\n2939\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCANGKCACGGG-\n\n\n2940\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCANGKCACGGG-\n\n\n2941\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCANGKCACGGG-\n\n\n2942\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCTPK-amide\n\n\n2943\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2944\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2945\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2946\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2947\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2948\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCTPK-\n\n\n2949\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCYPK-amide\n\n\n2950\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2951\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2952\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2953\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2954\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2955\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCYPK-\n\n\n2956\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACTPK-amide\n\n\n2957\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACTPK-\n\n\n2958\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACTPK-\n\n\n2959\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACTPK-\n\n\n2960\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCACTPK-\n\n\n2961\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACTPK-\n\n\n2962\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACTPK-\n\n\n2963\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHC-amide\n\n\n2964\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHC-\n\n\n2965\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHC-\n\n\n2966\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHC-amide\n\n\n2967\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHC-\n\n\n2968\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHC-amide\n\n\n2969\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCAC-amide\n\n\n2970\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCAC-\n\n\n2971\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCAC-\n\n\n2972\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCAC-amide\n\n\n2973\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHC-\n\n\n2974\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCAC-amide\n\n\n2975\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCAC-amide\n\n\n2976\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCHCWGG-amide\n\n\n2977\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCYGG-amide\n\n\n2978\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2979\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2980\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2981\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2982\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2983\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2984\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCANGKCACYGG-amide\n\n\n2985\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACYGG-amide\n\n\n2986\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACYGG-\n\n\n2987\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACYGG-\n\n\n2988\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACYGG-\n\n\n2989\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n2990\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACYGG-\n\n\n2991\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACYGG-\n\n\n2992\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCHCGGG-amide\n\n\n2993\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCHCGGG-\n\n\n2994\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCHCGGG-\n\n\n2995\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCHCGGG-\n\n\n2996\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCHCGGG-\n\n\n2997\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCHCGGG-\n\n\n2998\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCANGKCACGGG-amide\n\n\n2999\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCANGKCACGGG-\n\n\n3000\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCANGKCACGGG-\n\n\n3001\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCANGKCACGGG-\n\n\n3002\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCANGKCACTP-\n\n\n3003\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCANGKCACGGG-\n\n\n3004\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCANGKCACGGG-\n\n\n3005\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCANGKCACYGG-\n\n\n3006\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCANGKCACGGG-\n\n\n3007\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCANGKCACY-\n\n\n3008\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCANGKCACYGG-\n\n\n3009\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCANGKCACYGG-\n\n\n3010\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCANGKCHCYGG-\n\n\n3011\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCANGKCACYGG\n\n\n3012\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCACYGG-amide\n\n\n3013\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCACYGG\n\n\n3014\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCACY-amide\n\n\n3015\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n3016\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCHCYGG\n\n\n3017\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCHCYPK\n\n\n3018\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCAC\n\n\n3019\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[1Nal]GG-\n\n\n3020\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[1Nal]PK-\n\n\n3021\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[2Nal]GG-\n\n\n3022\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[Cha]GG-\n\n\n3023\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[MePhe]GG-\n\n\n3024\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[BiPhA]GG-\n\n\n3025\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKC[Aib]CYGG-\n\n\n3026\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKC[Abu]CYGG-\n\n\n3027\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[1Nal]\n\n\n3028\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCAC[1Nal]GG-\n\n\n3029\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC[4Bip]-\n\n\n3030\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCANGKCAC[4Bip]GG-\n\n\n3031\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCHCGGG\n\n\n3032\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7E\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analogs:\n\n\n\n\n\n\nAla-12 & Ala30 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3033\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3034\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCMAGKCHCTPK\n\n\n3035\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCMAGKCHCTPK\n\n\n3036\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3037\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3038\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3039\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYPK\n\n\n3040\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3041\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3042\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3043\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYPK-amide\n\n\n3044\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYPK\n\n\n3045\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYPK-\n\n\n3046\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n3047\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCMAGKCHCTPK\n\n\n3048\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKKAGMRFGKCMAGKCHCTPK-\n\n\n3049\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCMAGKCHCTPK\n\n\n3050\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3051\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3052\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n3053\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3054\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n3055\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3056\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3057\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3058\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3059\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3060\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n3061\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n3062\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n3063\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n3064\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK-amide\n\n\n3065\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK-\n\n\n3066\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3067\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3068\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3069\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3070\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3071\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3072\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3073\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3074\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3075\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3076\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3077\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3078\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3079\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3080\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3081\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3082\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCMAGKCHCTPK\n\n\n3083\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRNGKCMAGKCHCTPK-amide\n\n\n3084\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCMAGKCHCTPK\n\n\n3085\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRNGKCMAGKCHCTPK-\n\n\n3086\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3087\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n3088\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3089\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n3090\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK\n\n\n3091\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK\n\n\n3092\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK-amide\n\n\n3093\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK-\n\n\n3094\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3095\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3096\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3097\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3098\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3099\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n3100\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n3101\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n3102\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n3103\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3104\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCACTPK\n\n\n3105\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n3106\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK-amide\n\n\n3107\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLEPCKKAGMRFGKCMAGKCACTPK-\n\n\n3108\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCACTPK\n\n\n3109\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCACTPK-amide\n\n\n3110\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCACTPK-\n\n\n3111\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n3112\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3113\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n3114\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCT\n\n\n3115\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCTPK\n\n\n3116\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3117\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3118\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3119\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3120\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3121\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCHCTPK\n\n\n3122\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCYPK\n\n\n3123\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3124\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3125\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3126\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3127\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3128\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCHCYPK\n\n\n3129\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYPK\n\n\n3130\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCGCYPK\n\n\n3131\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACFPK\n\n\n3132\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACWPK\n\n\n4920\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCACYPK\n\n\n4921\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACTPK\n\n\n4922\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACTPK\n\n\n4923\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACTPK\n\n\n4924\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACTPK\n\n\n4925\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4926\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACTPK\n\n\n4927\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACTPK\n\n\n4928\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHC\n\n\n4929\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHC\n\n\n3133\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHC\n\n\n3134\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHC\n\n\n3135\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHC\n\n\n3136\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHC\n\n\n3137\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCHC\n\n\n3138\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCAC\n\n\n3139\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCAC\n\n\n3140\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCAC\n\n\n3141\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCAC\n\n\n3142\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHC\n\n\n3143\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCAC\n\n\n3144\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCAC\n\n\n3145\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCGCYGG\n\n\n3146\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCYGG\n\n\n3147\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3148\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3149\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3150\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3151\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3152\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYGG\n\n\n3153\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACYGG\n\n\n3154\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACYGG\n\n\n3155\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACYGG\n\n\n3156\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACYGG\n\n\n3157\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n3158\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACYGG\n\n\n3159\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACYGG\n\n\n3160\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYG\n\n\n3161\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCGGG\n\n\n3162\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCGGG\n\n\n3163\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCGGG\n\n\n3164\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCGGG\n\n\n3165\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCGGG\n\n\n3166\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCGGG\n\n\n3167\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACFGG\n\n\n3168\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACGGG\n\n\n3169\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACGGG\n\n\n3170\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACGGG\n\n\n3171\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACGGG\n\n\n3172\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCACGGG\n\n\n3173\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACGGG\n\n\n3174\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACGGG\n\n\n3175\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACGG\n\n\n3176\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYG\n\n\n3177\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACGG\n\n\n3178\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3179\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3180\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3181\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3182\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3183\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3184\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCYPK\n\n\n3185\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3186\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3187\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3188\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3189\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3190\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCYPK\n\n\n3191\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACTPK\n\n\n3192\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACTPK\n\n\n3193\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACTPK\n\n\n3194\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACTPK\n\n\n3195\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n3196\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACTPK\n\n\n3197\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACTPK\n\n\n3198\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHC\n\n\n3199\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHC\n\n\n3200\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHC\n\n\n3201\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHC\n\n\n3202\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHC\n\n\n3203\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHC\n\n\n3204\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCAC\n\n\n3205\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCAC\n\n\n3206\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCAC\n\n\n3207\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCAC\n\n\n3208\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHC\n\n\n3209\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCAC\n\n\n3210\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCAC\n\n\n3211\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCHCYGG\n\n\n3212\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCYGG\n\n\n3213\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCHCYG\n\n\n3214\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCACYG\n\n\n3215\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3216\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3217\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3218\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3219\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3220\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3221\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCACYG\n\n\n3222\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACYGG\n\n\n3223\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACYGG\n\n\n3224\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACYGG\n\n\n3225\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACYGG\n\n\n3226\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n3227\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACYGG\n\n\n3228\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACYGG\n\n\n3229\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCACFGG\n\n\n3230\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCGGG\n\n\n3231\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCGGG\n\n\n3232\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCGGG\n\n\n3233\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCGGG\n\n\n3234\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCGGG\n\n\n3235\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCGGG\n\n\n3236\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACGGG\n\n\n3237\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACGGG\n\n\n3238\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACGGG\n\n\n3239\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACGGG\n\n\n3240\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCACTP\n\n\n3241\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACTP\n\n\n3242\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACTP\n\n\n3243\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n3244\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3245\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3246\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3247\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3248\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3249\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n3250\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCYPK-amide\n\n\n3251\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3252\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3253\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3254\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3255\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3256\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n3257\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACTPK-amide\n\n\n3258\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3259\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3260\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3261\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3262\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3263\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACTPK-\n\n\n3264\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHC-amide\n\n\n3265\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHC-\n\n\n3266\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHC-\n\n\n3267\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHC-amide\n\n\n3268\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHC-\n\n\n3269\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHC-amide\n\n\n3270\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCAC-amide\n\n\n3271\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCAC-\n\n\n3272\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCAC-\n\n\n3273\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCAC-amide\n\n\n3274\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHC-\n\n\n3275\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCAC-amide\n\n\n3276\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCAC-amide\n\n\n3277\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n3278\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n3279\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n3280\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n3281\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n3282\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n3283\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n3284\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCFGG-amide\n\n\n3285\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCYG-amide\n\n\n3286\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYG-amide\n\n\n3287\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n3288\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3289\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3290\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3291\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3292\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3293\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACYGG-\n\n\n3294\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n3295\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCHCGGG-amide\n\n\n3296\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n3297\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n3298\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n3299\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n3300\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n3301\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACGGG-amide\n\n\n3302\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACFGG-amide\n\n\n3303\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKDAGMRFGKCMAGKCACGGG-amide\n\n\n3304\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3305\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3306\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3307\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3308\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3309\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKDAGMRFGKCMAGKCACGGG-\n\n\n3310\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCTPK-amide\n\n\n3311\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3312\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3313\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3314\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3315\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3316\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n3317\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCYPK-amide\n\n\n3318\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3319\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3320\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3321\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3322\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3323\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n3324\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACTPK-amide\n\n\n3325\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3326\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3327\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3328\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3329\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3330\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACTPK-\n\n\n3331\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHC-amide\n\n\n3332\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHC-\n\n\n3333\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHC-\n\n\n3334\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHC-amide\n\n\n3335\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHC-\n\n\n3336\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHC-amide\n\n\n3337\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCAC-amide\n\n\n3338\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCAC-\n\n\n3339\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCAC-\n\n\n3340\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCAC-amide\n\n\n3341\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHC-\n\n\n3342\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCAC-amide\n\n\n3343\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCAC-amide\n\n\n3344\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCHCWGG-amide\n\n\n3345\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCYGG-amide\n\n\n3346\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3347\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3348\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3349\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3350\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3351\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3352\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKEAGMRFGKCMAGKCACYGG-amide\n\n\n3353\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACYGG-amide\n\n\n3354\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACYGG-\n\n\n3355\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACYGG-\n\n\n3356\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACYGG-\n\n\n3357\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n3358\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACYGG-\n\n\n3359\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACYGG-\n\n\n3360\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCHCGGG-amide\n\n\n3361\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n3362\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n3363\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n3364\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n3365\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n3366\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLOPCKEAGMRFGKCMAGKCACGGG-amide\n\n\n3367\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hLys]PCKEAGMRFGKCMAGKCACGGG-\n\n\n3368\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hArg]PCKEAGMRFGKCMAGKCACGGG-\n\n\n3369\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Cit]PCKEAGMRFGKCMAGKCACGGG-\n\n\n3370\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[hCit]PCKEAGMRFGKCMAGKCACTP-\n\n\n3371\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dpr]PCKEAGMRFGKCMAGKCACGGG-\n\n\n3372\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCL[Dab]PCKEAGMRFGKCMAGKCACGGG-\n\n\n3373\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMAGKCACYGG-\n\n\n3374\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMAGKCACGGG-\n\n\n3375\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Cpa]AGMRFGKCMAGKCACY-\n\n\n3376\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCACYGG-\n\n\n3377\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMAGKCACYGG-\n\n\n3378\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMAGKCHCYGG-\n\n\n3379\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCK[Aad]AGMRFGKCMAGKCACYGG\n\n\n3380\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n3381\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCACYGG\n\n\n3382\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCACY-amide\n\n\n3383\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n3384\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCHCYGG\n\n\n3385\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCHCYPK\n\n\n3386\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCAC\n\n\n3387\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[1Nal]GG-\n\n\n3388\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[1Nal]PK-\n\n\n3389\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[2Nal]GG-\n\n\n3390\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[Cha]GG-\n\n\n3391\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[MePhe]GG-\n\n\n3392\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[BiPhA]GG-\n\n\n3393\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKC[Aib]CYGG-\n\n\n3394\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKC[Abu]CYGG-\n\n\n3395\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[1Nal]\n\n\n3396\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCAC[1Nal]GG-\n\n\n3397\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCAC[4Bip]-\n\n\n3398\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLHPCKDAGMRFGKCMAGKCAC[4Bip]GG-\n\n\n3399\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMAGKCHCGGG\n\n\n3400\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7F\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAddit6ional useful OSK1 peptide\n\n\n\n\n\n\nanalogs: Ala27Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3401\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3402\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGACMNGKCHCTPK\n\n\n3403\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGACMNGKCHCTPK\n\n\n3404\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3405\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3406\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3407\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYPK\n\n\n3408\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3409\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3410\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n3411\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYPK-amide\n\n\n3412\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYPK\n\n\n3413\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYPK-\n\n\n3414\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n3415\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGACMNGKCHCTPK\n\n\n3416\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGACMNGKCHCTPK-\n\n\n3417\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGACMNGKCHCTPK\n\n\n3418\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3419\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGACMNGKCHCTPK-\n\n\n3420\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n3421\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3422\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n3423\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3424\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3425\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n3426\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3427\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3428\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n3429\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n3430\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n3431\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n3432\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK-amide\n\n\n3433\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK-\n\n\n3434\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3435\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3436\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3437\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n3438\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3439\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3440\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3441\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3442\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3443\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3444\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3445\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3446\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3447\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3448\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3449\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3450\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGACMNGKCHCTPK\n\n\n3451\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGACMNGKCHCTPK-amide\n\n\n3452\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGACMNGKCHCTPK\n\n\n3453\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGACMNGKCHCTPK-\n\n\n3454\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3455\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n3456\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3457\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n3458\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK\n\n\n3459\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK\n\n\n3460\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK-amide\n\n\n3461\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACMNGKCHCTPK-\n\n\n3462\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3463\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3464\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3465\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n3466\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3467\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK\n\n\n3468\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-amide\n\n\n3469\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGACMNGKCHCTPK-\n\n\n3470\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n3471\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3472\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGACMNGKCACTPK\n\n\n3473\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK\n\n\n3474\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK-amide\n\n\n3475\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGACMNGKCACTPK-\n\n\n3476\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGACMNGKCACTPK\n\n\n3477\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGACMNGKCACTPK-amide\n\n\n3478\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGACMNGKCACTPK-\n\n\n3479\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK\n\n\n3480\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3481\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGACMNGKCHCTPK-\n\n\n3482\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCT\n\n\n3483\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCTPK\n\n\n3484\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCTPK\n\n\n3485\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCTPK\n\n\n3486\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCTPK\n\n\n3487\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCTPK\n\n\n3488\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCTPK\n\n\n3489\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCHCTPK\n\n\n3490\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCYPK\n\n\n3491\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCYPK\n\n\n3492\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCYPK\n\n\n3493\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCYPK\n\n\n3494\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCYPK\n\n\n3495\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCYPK\n\n\n3496\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCHCYPK\n\n\n3497\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYPK\n\n\n3498\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCGCYPK\n\n\n3499\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACFPK\n\n\n3500\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACWPK\n\n\n3501\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCACYPK\n\n\n3502\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACTPK\n\n\n3503\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACTPK\n\n\n3504\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACTPK\n\n\n3505\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACTPK\n\n\n3506\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCTPK\n\n\n3507\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACTPK\n\n\n3508\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACTPK\n\n\n3509\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHC\n\n\n3510\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHC\n\n\n3511\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHC\n\n\n3512\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHC\n\n\n3513\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHC\n\n\n3514\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHC\n\n\n3515\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCHC\n\n\n3516\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCAC\n\n\n3517\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCAC\n\n\n3518\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCAC\n\n\n3519\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCAC\n\n\n3520\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHC\n\n\n3521\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCAC\n\n\n3522\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCAC\n\n\n3523\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCGCYGG\n\n\n3524\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCYGG\n\n\n3525\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCYGG\n\n\n3526\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCYGG\n\n\n3527\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCYGG\n\n\n3528\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCYGG\n\n\n3529\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCYGG\n\n\n3530\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYGG\n\n\n3531\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACYGG\n\n\n3532\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACYGG\n\n\n3533\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACYGG\n\n\n3534\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACYGG\n\n\n3535\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCYGG\n\n\n3536\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACYGG\n\n\n3537\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACYGG\n\n\n3538\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYG\n\n\n3539\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCGGG\n\n\n3540\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCGGG\n\n\n3541\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCGGG\n\n\n3542\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCGGG\n\n\n3543\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCGGG\n\n\n3544\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCGGG\n\n\n3545\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACFGG\n\n\n3546\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACGGG\n\n\n3547\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACGGG\n\n\n3548\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACGGG\n\n\n3549\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACGGG\n\n\n3550\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCACGGG\n\n\n3551\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACGGG\n\n\n3552\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACGGG\n\n\n3553\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACGG\n\n\n3554\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYG\n\n\n3555\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACGG\n\n\n3556\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCTPK\n\n\n3557\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCTPK\n\n\n3558\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCTPK\n\n\n3559\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCTPK\n\n\n3560\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCTPK\n\n\n3561\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCTPK\n\n\n3562\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCYPK\n\n\n3563\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCYPK\n\n\n3564\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCYPK\n\n\n3565\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCYPK\n\n\n3566\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYPK\n\n\n3567\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCYPK\n\n\n3568\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCYPK\n\n\n3569\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACTPK\n\n\n3570\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACTPK\n\n\n3571\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACTPK\n\n\n3572\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACTPK\n\n\n3573\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCTPK\n\n\n3574\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACTPK\n\n\n3575\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACTPK\n\n\n3576\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHC\n\n\n3577\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHC\n\n\n3578\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHC\n\n\n3579\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHC\n\n\n3580\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHC\n\n\n3581\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHC\n\n\n3582\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCAC\n\n\n3583\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCAC\n\n\n3584\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCAC\n\n\n3585\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCAC\n\n\n3586\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHC\n\n\n3587\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCAC\n\n\n3588\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCAC\n\n\n3589\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCHCYGG\n\n\n3590\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCYGG\n\n\n3591\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCHCYG\n\n\n3592\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCACYG\n\n\n3593\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCYGG\n\n\n3594\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCYGG\n\n\n3595\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCYGG\n\n\n3596\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYGG\n\n\n3597\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCYGG\n\n\n3598\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCYGG\n\n\n3599\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCACYG\n\n\n3600\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACYGG\n\n\n3601\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACYGG\n\n\n3602\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACYGG\n\n\n3603\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACYGG\n\n\n3604\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYGG\n\n\n3605\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACYGG\n\n\n3606\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACYGG\n\n\n3607\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCACFGG\n\n\n3608\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCGGG\n\n\n3609\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCGGG\n\n\n3610\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCGGG\n\n\n3611\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCGGG\n\n\n3612\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCGGG\n\n\n3613\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCGGG\n\n\n3614\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACGGG\n\n\n3615\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACGGG\n\n\n3616\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACGGG\n\n\n3617\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACGGG\n\n\n3618\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCACTP\n\n\n3619\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACTP\n\n\n3620\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACTP\n\n\n3621\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCTPK-amide\n\n\n3622\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3623\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3624\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3625\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3626\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3627\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCHCTPK-\n\n\n3628\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCYPK-amide\n\n\n3629\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3630\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3631\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3632\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3633\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3634\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCHCYPK-\n\n\n3635\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACTPK-amide\n\n\n3636\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACTPK-\n\n\n3637\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACTPK-\n\n\n3638\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACTPK-\n\n\n3639\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCACTPK-\n\n\n3640\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACTPK-\n\n\n3641\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACTPK-\n\n\n3642\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHC-amide\n\n\n3643\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHC-\n\n\n3644\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHC-\n\n\n3645\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHC-amide\n\n\n3646\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHC-\n\n\n3647\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHC-amide\n\n\n3648\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCAC-amide\n\n\n3649\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCAC-\n\n\n3650\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCAC-\n\n\n3651\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCAC-amide\n\n\n3652\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHC-\n\n\n3653\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCAC-amide\n\n\n3654\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCAC-amide\n\n\n3655\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n3656\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n3657\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCYGG-\n\n\n3658\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCYGG-\n\n\n3659\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCYGG-\n\n\n3660\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCYGG-\n\n\n3661\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCYGG-\n\n\n3662\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCFGG-amide\n\n\n3663\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCYG-amide\n\n\n3664\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYG-amide\n\n\n3665\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACYGG-amide\n\n\n3666\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACYGG-\n\n\n3667\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACYGG-\n\n\n3668\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACYGG-\n\n\n3669\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCACYGG-\n\n\n3670\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACYGG-\n\n\n3671\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACYGG-\n\n\n3672\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYGG-amide\n\n\n3673\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCHCGGG-amide\n\n\n3674\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCHCGGG-\n\n\n3675\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCHCGGG-\n\n\n3676\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCHCGGG-\n\n\n3677\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCHCGGG-\n\n\n3678\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCHCGGG-\n\n\n3679\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACGGG-amide\n\n\n3680\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACFGG-amide\n\n\n3681\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGACMNGKCACGGG-amide\n\n\n3682\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGACMNGKCACGGG-\n\n\n3683\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGACMNGKCACGGG-\n\n\n3684\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGACMNGKCACGGG-\n\n\n3685\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGACMNGKCACGGG-\n\n\n3686\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGACMNGKCACGGG-\n\n\n3687\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGACMNGKCACGGG-\n\n\n3688\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCTPK-amide\n\n\n3689\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3690\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3691\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3692\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3693\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3694\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCTPK-\n\n\n3695\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCYPK-amide\n\n\n3696\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3697\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3698\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3699\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3700\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3701\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCYPK-\n\n\n3702\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACTPK-amide\n\n\n3703\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACTPK-\n\n\n3704\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACTPK-\n\n\n3705\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACTPK-\n\n\n3706\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCACTPK-\n\n\n3707\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACTPK-\n\n\n3708\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACTPK-\n\n\n3709\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHC-amide\n\n\n3710\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHC-\n\n\n3711\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHC-\n\n\n3712\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHC-amide\n\n\n3713\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHC-\n\n\n3714\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHC-amide\n\n\n3715\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCAC-amide\n\n\n3716\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCAC-\n\n\n3717\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCAC-\n\n\n3718\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCAC-amide\n\n\n3719\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHC-\n\n\n3720\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCAC-amide\n\n\n3721\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCAC-amide\n\n\n3722\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCHCWGG-amide\n\n\n3723\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCYGG-amide\n\n\n3724\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3725\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3726\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3727\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3728\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3729\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3730\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGACMNGKCACYGG-amide\n\n\n3731\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACYGG-amide\n\n\n3732\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACYGG-\n\n\n3733\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACYGG-\n\n\n3734\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACYGG-\n\n\n3735\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCYGG-\n\n\n3736\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACYGG-\n\n\n3737\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACYGG-\n\n\n3738\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCHCGGG-amide\n\n\n3739\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCHCGGG-\n\n\n3740\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCHCGGG-\n\n\n3741\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCHCGGG-\n\n\n3742\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCHCGGG-\n\n\n3743\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCHCGGG-\n\n\n3744\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGACMNGKCACGGG-amide\n\n\n3745\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGACMNGKCACGGG-\n\n\n3746\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGACMNGKCACGGG-\n\n\n3747\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGACMNGKCACGGG-\n\n\n3748\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGACMNGKCACTP-\n\n\n3749\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGACMNGKCACGGG-\n\n\n3750\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGACMNGKCACGGG-\n\n\n3751\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGACMNGKCACYGG-\n\n\n3752\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGACMNGKCACGGG-\n\n\n3753\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGACMNGKCACY-\n\n\n3754\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGACMNGKCACYGG-\n\n\n3755\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGACMNGKCACYGG-\n\n\n3756\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGACMNGKCHCYGG-\n\n\n3757\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGACMNGKCACYGG\n\n\n3758\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCACYGG-amide\n\n\n3759\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCACYGG\n\n\n3760\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCACY-amide\n\n\n3761\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCHCYGG-amide\n\n\n3762\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCHCYGG\n\n\n3763\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCHCYPK\n\n\n3764\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCAC\n\n\n3765\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[1Nal]GG-\n\n\n3766\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[1Nal]PK-\n\n\n3767\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[2Nal]GG-\n\n\n3768\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[Cha]GG-\n\n\n3769\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[MePhe]GG-\n\n\n3770\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[BiPhA]GG-\n\n\n3771\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKC[Aib]CYGG-\n\n\n3772\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKC[Abu]CYGG-\n\n\n3773\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[1Nal]\n\n\n3774\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCAC[1Nal]GG-\n\n\n3775\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCAC[4Bip]-\n\n\n3776\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGACMNGKCAC[4Bip]GG-\n\n\n3777\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGACMNGKCHCGGG\n\n\n3778\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7G\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide\n\n\n\n\n\n\nanalogs: Ala 29 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3779\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3780\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCANGKCHCTPK\n\n\n3781\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCANGKCHCTPK\n\n\n3782\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3783\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3784\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3785\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYPK\n\n\n3786\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3787\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3788\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n3789\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYPK-amide\n\n\n3790\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYPK\n\n\n3791\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYPK-\n\n\n3792\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n3793\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCANGKCHCTPK\n\n\n3794\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCANGKCHCTPK-\n\n\n3795\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCANGKCHCTPK\n\n\n3796\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3797\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCANGKCHCTPK-\n\n\n3798\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n3799\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3800\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n3801\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3802\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3803\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n3804\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3805\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3806\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n3807\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n3808\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n3809\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n3810\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK-amide\n\n\n3811\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK-\n\n\n3812\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3813\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3814\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3815\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n3816\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3817\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3818\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3819\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3820\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3821\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3822\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3823\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3824\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3825\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3826\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3827\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3828\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCANGKCHCTPK\n\n\n3829\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCANGKCHCTPK-amide\n\n\n3830\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCANGKCHCTPK\n\n\n3831\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCANGKCHCTPK-\n\n\n3832\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3833\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n3834\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n3835\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n3836\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK\n\n\n3837\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK\n\n\n3838\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK-amide\n\n\n3839\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCANGKCHCTPK-\n\n\n3840\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3841\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3842\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3843\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n3844\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3845\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK\n\n\n3846\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-amide\n\n\n3847\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCANGKCHCTPK-\n\n\n3848\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n3849\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3850\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCANGKCACTPK\n\n\n3851\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK\n\n\n3852\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK-amide\n\n\n3853\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK-\n\n\n3854\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCANGKCACTPK\n\n\n3855\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCANGKCACTPK-amide\n\n\n3856\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCANGKCACTPK-\n\n\n3857\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK\n\n\n3858\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-amide\n\n\n3859\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCANGKCHCTPK-\n\n\n3860\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCT\n\n\n3861\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCTPK\n\n\n3862\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCTPK\n\n\n3863\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCTPK\n\n\n3864\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCTPK\n\n\n3865\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCTPK\n\n\n3866\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCTPK\n\n\n3867\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCHCTPK\n\n\n3868\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCYPK\n\n\n3869\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCYPK\n\n\n3870\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCYPK\n\n\n3871\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCYPK\n\n\n3872\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCYPK\n\n\n3873\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCYPK\n\n\n3874\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCHCYPK\n\n\n3875\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYPK\n\n\n3876\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCGCYPK\n\n\n3877\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACFPK\n\n\n3878\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACWPK\n\n\n3879\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCACYPK\n\n\n3880\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACTPK\n\n\n3881\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACTPK\n\n\n3882\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACTPK\n\n\n3883\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACTPK\n\n\n3884\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCTPK\n\n\n3885\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACTPK\n\n\n3886\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACTPK\n\n\n3887\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHC\n\n\n3888\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHC\n\n\n3889\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHC\n\n\n3890\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHC\n\n\n3891\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHC\n\n\n3892\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHC\n\n\n3893\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCHC\n\n\n3894\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCAC\n\n\n3895\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCAC\n\n\n3896\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCAC\n\n\n3897\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCAC\n\n\n3898\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHC\n\n\n3899\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCAC\n\n\n3900\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCAC\n\n\n3901\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCGCYGG\n\n\n3902\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCYGG\n\n\n3903\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCYGG\n\n\n3904\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCYGG\n\n\n3905\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCYGG\n\n\n3906\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCYGG\n\n\n3907\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCYGG\n\n\n3908\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYGG\n\n\n3909\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACYGG\n\n\n3910\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACYGG\n\n\n3911\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACYGG\n\n\n3912\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACYGG\n\n\n3913\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCYGG\n\n\n3914\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACYGG\n\n\n3915\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACYGG\n\n\n3916\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYG\n\n\n3917\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCGGG\n\n\n3918\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCGGG\n\n\n3919\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCGGG\n\n\n3920\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCGGG\n\n\n3921\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCGGG\n\n\n3922\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCGGG\n\n\n3923\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACFGG\n\n\n3924\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACGGG\n\n\n3925\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACGGG\n\n\n3926\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACGGG\n\n\n3927\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACGGG\n\n\n3928\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCACGGG\n\n\n3929\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACGGG\n\n\n3930\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACGGG\n\n\n3931\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACGG\n\n\n3932\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYG\n\n\n3933\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACGG\n\n\n3934\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCTPK\n\n\n3935\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCTPK\n\n\n3936\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCTPK\n\n\n3937\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCTPK\n\n\n3938\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCTPK\n\n\n3939\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCTPK\n\n\n3940\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCYPK\n\n\n3941\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCYPK\n\n\n3942\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCYPK\n\n\n3943\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCYPK\n\n\n3944\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYPK\n\n\n3945\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCYPK\n\n\n3946\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCYPK\n\n\n3947\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACTPK\n\n\n3948\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACTPK\n\n\n3949\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACTPK\n\n\n3950\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACTPK\n\n\n3951\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCTPK\n\n\n3952\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACTPK\n\n\n3953\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACTPK\n\n\n3954\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHC\n\n\n3955\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHC\n\n\n3956\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHC\n\n\n3957\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHC\n\n\n3958\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHC\n\n\n3959\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHC\n\n\n3960\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCAC\n\n\n3961\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCAC\n\n\n3962\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCAC\n\n\n3963\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCAC\n\n\n3964\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHC\n\n\n3965\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCAC\n\n\n3966\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCAC\n\n\n3967\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCHCYGG\n\n\n3968\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCYGG\n\n\n3969\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCHCYG\n\n\n3970\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCACYG\n\n\n3971\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCYGG\n\n\n3972\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCYGG\n\n\n3973\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCYGG\n\n\n3974\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYGG\n\n\n3975\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCYGG\n\n\n3976\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCYGG\n\n\n3977\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCACYG\n\n\n3978\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACYGG\n\n\n3979\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACYGG\n\n\n3980\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACYGG\n\n\n3981\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACYGG\n\n\n3982\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYGG\n\n\n3983\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACYGG\n\n\n3984\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACYGG\n\n\n3985\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCACFGG\n\n\n3986\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCGGG\n\n\n3987\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCGGG\n\n\n3988\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCGGG\n\n\n3989\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCGGG\n\n\n3990\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCGGG\n\n\n3991\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCGGG\n\n\n3992\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACGGG\n\n\n3993\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACGGG\n\n\n3994\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACGGG\n\n\n3995\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACGGG\n\n\n3996\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCACTP\n\n\n3997\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACTP\n\n\n3998\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACTP\n\n\n3999\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCTPK-\namide\n \n\n\n4000\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4001\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4002\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4003\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4004\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4005\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCHCTPK-\n\n\n4006\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCYPK-amide\n\n\n4007\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4008\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4009\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4010\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4011\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4012\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCHCYPK-\n\n\n4013\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACTPK-amide\n\n\n4014\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACTPK-\n\n\n4015\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACTPK-\n\n\n4016\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACTPK-\n\n\n4017\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCACTPK-\n\n\n4018\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACTPK-\n\n\n4019\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACTPK-\n\n\n4020\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHC-amide\n\n\n4021\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHC-\n\n\n4022\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHC-\n\n\n4023\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHC-amide\n\n\n4024\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHC-\n\n\n4025\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHC-amide\n\n\n4026\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCAC-amide\n\n\n4027\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCAC-\n\n\n4028\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCAC-\n\n\n4029\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCAC-amide\n\n\n4030\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHC-\n\n\n4031\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCAC-amide\n\n\n4032\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCAC-amide\n\n\n4033\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n4034\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n4035\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCYGG-\n\n\n4036\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCYGG-\n\n\n4037\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCYGG-\n\n\n4038\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCYGG-\n\n\n4039\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCYGG-\n\n\n4040\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCFGG-amide\n\n\n4041\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCYG-amide\n\n\n4042\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYG-amide\n\n\n4043\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACYGG-amide\n\n\n4044\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACYGG-\n\n\n4045\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACYGG-\n\n\n4046\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACYGG-\n\n\n4047\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCACYGG-\n\n\n4048\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACYGG-\n\n\n4049\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACYGG-\n\n\n4050\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYGG-amide\n\n\n4051\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCHCGGG-amide\n\n\n4052\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCHCGGG-\n\n\n4053\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCHCGGG-\n\n\n4054\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCHCGGG-\n\n\n4055\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCHCGGG-\n\n\n4056\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCHCGGG-\n\n\n4057\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACGGG-amide\n\n\n4058\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACFGG-amide\n\n\n4059\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCANGKCACGGG-amide\n\n\n4060\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCANGKCACGGG-\n\n\n4061\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCANGKCACGGG-\n\n\n4062\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCANGKCACGGG-\n\n\n4063\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCANGKCACGGG-\n\n\n4064\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCANGKCACGGG-\n\n\n4065\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCANGKCACGGG-\n\n\n4066\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCTPK-amide\n\n\n4067\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4068\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4069\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4070\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4071\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4072\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCTPK-\n\n\n4073\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCYPK-amide\n\n\n4074\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4075\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4076\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4077\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4078\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4079\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCYPK-\n\n\n4080\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACTPK-amide\n\n\n4081\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACTPK-\n\n\n4082\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACTPK-\n\n\n4083\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACTPK-\n\n\n4084\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCACTPK-\n\n\n4085\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACTPK-\n\n\n4086\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACTPK-\n\n\n4087\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHC-amide\n\n\n4088\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHC-\n\n\n4089\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHC-\n\n\n4090\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHC-amide\n\n\n4091\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHC-\n\n\n4092\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHC-amide\n\n\n4093\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCAC-amide\n\n\n4094\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCAC-\n\n\n4095\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCAC-\n\n\n4096\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCAC-amide\n\n\n4097\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHC-\n\n\n4098\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCAC-amide\n\n\n4099\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCAC-amide\n\n\n4100\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCHCWGG-amide\n\n\n4101\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCYGG-amide\n\n\n4102\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4103\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4104\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4105\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4106\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4107\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4108\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCANGKCACYGG-amide\n\n\n4109\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACYGG-amide\n\n\n4110\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACYGG-\n\n\n4111\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACYGG-\n\n\n4112\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACYGG-\n\n\n4113\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCYGG-\n\n\n4114\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACYGG-\n\n\n4115\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACYGG-\n\n\n4116\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCHCGGG-amide\n\n\n4117\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCHCGGG-\n\n\n4118\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCHCGGG-\n\n\n4119\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCHCGGG-\n\n\n4120\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCHCGGG-\n\n\n4121\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCHCGGG-\n\n\n4122\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCANGKCACGGG-amide\n\n\n4123\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCANGKCACGGG-\n\n\n4124\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCANGKCACGGG-\n\n\n4125\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCANGKCACGGG-\n\n\n4126\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCANGKCACTP-\n\n\n4127\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCANGKCACGGG-\n\n\n4128\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCANGKCACGGG-\n\n\n4129\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCANGKCACYGG-\n\n\n4130\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCANGKCACGGG-\n\n\n4131\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCANGKCACY-\n\n\n4132\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCANGKCACYGG-\n\n\n4133\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCANGKCACYGG-\n\n\n4134\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCANGKCHCYGG-\n\n\n4135\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCANGKCACYGG\n\n\n4136\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCACYGG-amide\n\n\n4137\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCACYGG\n\n\n4138\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCACY-amide\n\n\n4139\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCHCYGG-amide\n\n\n4140\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCHCYGG\n\n\n4141\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCHCYPK\n\n\n4142\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCAC\n\n\n4143\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[1Nal]GG-\n\n\n4144\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[1Nal]PK-\n\n\n4145\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[2Nal]GG-\n\n\n4146\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[Cha]GG-\n\n\n4147\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[MePhe]GG-\n\n\n4148\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[BiPhA]GG-\n\n\n4149\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKC[Aib]CYGG-\n\n\n4150\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKC[Abu]CYGG-\n\n\n4151\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[1Nal]\n\n\n4152\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCAC[1Nal]GG-\n\n\n4153\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCAC[4Bip]-\n\n\n4154\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCANGKCAC[4Bip]GG-\n\n\n4155\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCANGKCHCGGG\n\n\n4156\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7H\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide\n\n\n\n\n\n\nanalogs: Ala 30 Substituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4157\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4158\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCMAGKCHCTPK\n\n\n4159\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCMAGKCHCTPK\n\n\n4160\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4161\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4162\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4163\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYPK\n\n\n4164\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4165\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4166\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4167\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYPK-amide\n\n\n4168\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYPK\n\n\n4169\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYPK-\n\n\n4170\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n4171\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCMAGKCHCTPK\n\n\n4172\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKKAGMRFGKCMAGKCHCTPK-\n\n\n4173\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCMAGKCHCTPK\n\n\n4174\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4175\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4176\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n4177\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4178\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n4179\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4180\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4181\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4182\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4183\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4184\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n4185\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n4186\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n4187\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n4188\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK-amide\n\n\n4189\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK-\n\n\n4190\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4191\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4192\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4193\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4194\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4195\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4196\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4197\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4198\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4199\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4200\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4201\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4202\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4203\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4204\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4205\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4206\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCMAGKCHCTPK\n\n\n4207\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRNGKCMAGKCHCTPK-amide\n\n\n4208\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCMAGKCHCTPK\n\n\n4209\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRNGKCMAGKCHCTPK-\n\n\n4210\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n4211\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n4212\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n4213\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n4214\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK\n\n\n4215\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK\n\n\n4216\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK-amide\n\n\n4217\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGKCMAGKCHCTPK-\n\n\n4218\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4219\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4220\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4221\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4222\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4223\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK\n\n\n4224\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-amide\n\n\n4225\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCHCTPK-\n\n\n4226\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n4227\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4228\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCACTPK\n\n\n4229\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK\n\n\n4230\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK-amide\n\n\n4231\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLEPCKKAGMRFGKCMAGKCACTPK-\n\n\n4232\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCACTPK\n\n\n4233\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCACTPK-amide\n\n\n4234\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCACTPK-\n\n\n4235\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK\n\n\n4236\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4237\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCTPK-\n\n\n4238\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCT\n\n\n4239\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCTPK\n\n\n4240\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4241\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4242\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4243\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4244\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4245\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4246\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCYPK\n\n\n4247\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4248\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4249\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4250\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4251\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4252\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCHCYPK\n\n\n4253\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYPK\n\n\n4254\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCGCYPK\n\n\n4255\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACFPK\n\n\n4256\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACWPK\n\n\n4257\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCACYPK\n\n\n4258\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACTPK\n\n\n4259\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACTPK\n\n\n4260\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACTPK\n\n\n4261\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACTPK\n\n\n4262\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK\n\n\n4263\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACTPK\n\n\n4264\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACTPK\n\n\n4265\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHC\n\n\n4266\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHC\n\n\n4267\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHC\n\n\n4268\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHC\n\n\n4269\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHC\n\n\n4270\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHC\n\n\n4271\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCHC\n\n\n4272\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCAC\n\n\n4273\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCAC\n\n\n4274\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCAC\n\n\n4275\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCAC\n\n\n4276\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHC\n\n\n4277\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCAC\n\n\n4278\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCAC\n\n\n4279\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCGCYGG\n\n\n4280\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCYGG\n\n\n4281\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4282\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4283\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4284\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4285\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4286\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYGG\n\n\n4287\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACYGG\n\n\n4288\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACYGG\n\n\n4289\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACYGG\n\n\n4290\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACYGG\n\n\n4291\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG\n\n\n4292\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACYGG\n\n\n4293\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACYGG\n\n\n4294\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYG\n\n\n4295\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCGGG\n\n\n4296\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCGGG\n\n\n4297\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCGGG\n\n\n4298\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCGGG\n\n\n4299\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCGGG\n\n\n4300\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCGGG\n\n\n4301\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACFGG\n\n\n4302\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACGGG\n\n\n4303\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACGGG\n\n\n4304\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACGGG\n\n\n4305\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACGGG\n\n\n4306\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCACGGG\n\n\n4307\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACGGG\n\n\n4308\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACGGG\n\n\n4309\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACGG\n\n\n4310\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYG\n\n\n4311\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACGG\n\n\n4312\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4313\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4314\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4315\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4316\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4317\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4318\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCYPK\n\n\n4319\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4320\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4321\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4322\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4323\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4324\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCYPK\n\n\n4325\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACTPK\n\n\n4326\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACTPK\n\n\n4327\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACTPK\n\n\n4328\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACTPK\n\n\n4329\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK\n\n\n4330\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACTPK\n\n\n4331\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACTPK\n\n\n4332\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHC\n\n\n4333\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHC\n\n\n4334\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHC\n\n\n4335\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHC\n\n\n4336\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHC\n\n\n4337\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHC\n\n\n4338\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCAC\n\n\n4339\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCAC\n\n\n4340\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCAC\n\n\n4341\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCAC\n\n\n4342\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHC\n\n\n4343\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCAC\n\n\n4344\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCAC\n\n\n4345\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCHCYGG\n\n\n4346\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCYGG\n\n\n4347\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCHCYG\n\n\n4348\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCACYG\n\n\n4349\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4350\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4351\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4352\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4353\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4354\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4355\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCACYG\n\n\n4356\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACYGG\n\n\n4357\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACYGG\n\n\n4358\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACYGG\n\n\n4359\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACYGG\n\n\n4360\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG\n\n\n4361\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACYGG\n\n\n4362\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACYGG\n\n\n4363\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCACFGG\n\n\n4364\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCGGG\n\n\n4365\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCGGG\n\n\n4366\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCGGG\n\n\n4367\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCGGG\n\n\n4368\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCGGG\n\n\n4369\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCGGG\n\n\n4370\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACGGG\n\n\n4371\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACGGG\n\n\n4372\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACGGG\n\n\n4373\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACGGG\n\n\n4374\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCACTP\n\n\n4375\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACTP\n\n\n4376\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACTP\n\n\n4377\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCTPK-amide\n\n\n4378\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4379\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4380\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4381\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4382\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4383\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCHCTPK-\n\n\n4384\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCYPK-amide\n\n\n4385\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4386\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4387\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4388\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4389\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4390\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCHCYPK-\n\n\n4391\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACTPK-amide\n\n\n4392\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4393\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4394\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4395\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4396\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4397\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACTPK-\n\n\n4398\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHC-amide\n\n\n4399\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHC-\n\n\n4400\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHC-\n\n\n4401\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHC-amide\n\n\n4402\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHC-\n\n\n4403\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHC-amide\n\n\n4404\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCAC-amide\n\n\n4405\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCAC-\n\n\n4406\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCAC-\n\n\n4407\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCAC-amide\n\n\n4408\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHC-\n\n\n4409\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCAC-amide\n\n\n4410\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCAC-amide\n\n\n4411\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n4412\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n4413\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n4414\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n4415\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n4416\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n4417\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCYGG-\n\n\n4418\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCFGG-amide\n\n\n4419\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCYG-amide\n\n\n4420\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYG-amide\n\n\n4421\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n4422\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4423\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4424\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4425\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4426\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4427\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACYGG-\n\n\n4428\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n4429\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCHCGGG-amide\n\n\n4430\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n4431\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n4432\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n4433\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n4434\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCHCGGG-\n\n\n4435\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACGGG-amide\n\n\n4436\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACFGG-amide\n\n\n4437\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKDAGMRFGKCMAGKCACGGG-amide\n\n\n4438\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4439\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4440\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4441\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4442\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4443\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKDAGMRFGKCMAGKCACGGG-\n\n\n4444\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCTPK-amide\n\n\n4445\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4446\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4447\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4448\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4449\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4450\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCTPK-\n\n\n4451\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCYPK-amide\n\n\n4452\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4453\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4454\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4455\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4456\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4457\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCYPK-\n\n\n4458\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACTPK-amide\n\n\n4459\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4460\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4461\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4462\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4463\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4464\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACTPK-\n\n\n4465\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHC-amide\n\n\n4466\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHC-\n\n\n4467\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHC-\n\n\n4468\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHC-amide\n\n\n4469\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHC-\n\n\n4470\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHC-amide\n\n\n4471\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCAC-amide\n\n\n4472\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCAC-\n\n\n4473\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCAC-\n\n\n4474\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCAC-amide\n\n\n4475\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHC-\n\n\n4476\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCAC-amide\n\n\n4477\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCAC-amide\n\n\n4478\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCHCWGG-amide\n\n\n4479\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCYGG-amide\n\n\n4480\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4481\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4482\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4483\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4484\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4485\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4486\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKEAGMRFGKCMAGKCACYGG-amide\n\n\n4487\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACYGG-amide\n\n\n4488\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACYGG-\n\n\n4489\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACYGG-\n\n\n4490\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACYGG-\n\n\n4491\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCYGG-\n\n\n4492\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACYGG-\n\n\n4493\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACYGG-\n\n\n4494\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCHCGGG-amide\n\n\n4495\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n4496\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n4497\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n4498\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n4499\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCHCGGG-\n\n\n4500\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLOPCKEAGMRFGKCMAGKCACGGG-amide\n\n\n4501\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hLys]PCKEAGMRFGKCMAGKCACGGG-\n\n\n4502\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hArg]PCKEAGMRFGKCMAGKCACGGG-\n\n\n4503\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Cit]PCKEAGMRFGKCMAGKCACGGG-\n\n\n4504\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[hCit]PCKEAGMRFGKCMAGKCACTP-\n\n\n4505\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dpr]PCKEAGMRFGKCMAGKCACGGG-\n\n\n4506\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCL[Dab]PCKEAGMRFGKCMAGKCACGGG-\n\n\n4507\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMAGKCACYGG-\n\n\n4508\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMAGKCACGGG-\n\n\n4509\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Cpa]AGMRFGKCMAGKCACY-\n\n\n4510\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCACYGG-\n\n\n4511\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMAGKCACYGG-\n\n\n4512\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMAGKCHCYGG-\n\n\n4513\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCK[Aad]AGMRFGKCMAGKCACYGG\n\n\n4514\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCACYGG-amide\n\n\n4515\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCACYGG\n\n\n4516\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCACY-amide\n\n\n4517\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCHCYGG-amide\n\n\n4518\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCHCYGG\n\n\n4519\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCHCYPK\n\n\n4520\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCAC\n\n\n4521\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[1Nal]GG-\n\n\n4522\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[1Nal]PK-\n\n\n4523\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[2Nal]GG-\n\n\n4524\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[Cha]GG-\n\n\n4525\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[MePhe]GG-\n\n\n4526\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[BiPhA]GG-\n\n\n4527\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKC[Aib]CYGG-\n\n\n4528\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKC[Abu]CYGG-\n\n\n4529\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[1Nal]\n\n\n4530\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCAC[1Nal]GG-\n\n\n4531\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCAC[4Bip]-\n\n\n4532\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLHPCKDAGMRFGKCMAGKCAC[4Bip]GG-\n\n\n4533\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMAGKCHCGGG\n\n\n4534\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7I\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analogs:\n\n\n\n\n\n\nCombined Ala-11, 12, 27, 29, 30\n\n\n\n\n\n\nSubstituted Series\n\n\n\n\n\n\n\n\n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4535\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4536\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKKAGMRFGACAAGKCHCTPK\n\n\n4537\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKDAGMRFGACAAGKCHCTPK\n\n\n4538\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4539\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVSCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4540\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4541\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYPK\n\n\n4542\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4543\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4544\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISPQCLKPCKDAGMRFGACAAGKCHCTPK-\n\n\n4545\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYPK-amide\n\n\n4546\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYPK\n\n\n4547\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYPK-\n\n\n4548\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKKAGMRFGACAAGKCHCTPK-amide\n\n\n4549\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKKAGMRFGACAAGKCHCTPK\n\n\n4550\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKKAGMRFGACAAGKCHCTPK-\n\n\n4551\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKDAGMRFGACAAGKCHCTPK\n\n\n4552\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4553\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKDAGMRFGACAAGKCHCTPK-\n\n\n4554\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-amide\n\n\n4555\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4556\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-\n\n\n4557\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4558\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4559\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-\n\n\n4560\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4561\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4562\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-amide\n\n\n4563\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-\n\n\n4564\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK\n\n\n4565\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK\n\n\n4566\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK-amide\n\n\n4567\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK-\n\n\n4568\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4569\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4570\n\n\n\n\n\n\n \n\n\n\n\n\n\nVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4571\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-VIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-\n\n\n4572\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4573\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4574\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4575\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-NVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4576\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4577\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4578\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4579\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-KCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4580\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4581\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4582\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4583\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-CKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4584\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRNGACAAGKCHCTPK\n\n\n4585\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRNGACAAGKCHCTPK-amide\n\n\n4586\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRNGACAAGKCHCTPK\n\n\n4587\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRNGACAAGKCHCTPK-\n\n\n4588\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n4589\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGKCMNRKCHCTPK-amide\n\n\n4590\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n4591\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGKCMNRKCHCTPK-\n\n\n4592\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGACAAGKCHCTPK\n\n\n4593\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACAAGKCHCTPK\n\n\n4594\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISKQCLKPCRDAGMRFGACAAGKCHCTPK-amide\n\n\n4595\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKISKQCLKPCRDAGMRFGACAAGKCHCTPK-\n\n\n4596\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4597\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4598\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4599\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-TIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-\n\n\n4600\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4601\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK\n\n\n4602\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-amide\n\n\n4603\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCHCTPK-\n\n\n4604\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK\n\n\n4605\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4606\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCACTPK\n\n\n4607\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK\n\n\n4608\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK-amide\n\n\n4609\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLEPCKKAGMRFGACAAGKCACTPK-\n\n\n4610\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCACTPK\n\n\n4611\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCACTPK-amide\n\n\n4612\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCACTPK-\n\n\n4613\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK\n\n\n4614\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4615\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVKINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCTPK-\n\n\n4616\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCT\n\n\n4617\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCTPK\n\n\n4618\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCTPK\n\n\n4619\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCTPK\n\n\n4620\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCTPK\n\n\n4621\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCTPK\n\n\n4622\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCTPK\n\n\n4623\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCHCTPK\n\n\n4624\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCYPK\n\n\n4625\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCYPK\n\n\n4626\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCYPK\n\n\n4627\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCYPK\n\n\n4628\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCYPK\n\n\n4629\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCYPK\n\n\n4630\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCHCYPK\n\n\n4631\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYPK\n\n\n4632\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCGCYPK\n\n\n4633\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACFPK\n\n\n4634\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACWPK\n\n\n4635\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCACYPK\n\n\n4636\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACTPK\n\n\n4637\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACTPK\n\n\n4638\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACTPK\n\n\n4639\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACTPK\n\n\n4640\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCTPK\n\n\n4641\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACTPK\n\n\n4642\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACTPK\n\n\n4643\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHC\n\n\n4644\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHC\n\n\n4645\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHC\n\n\n4646\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHC\n\n\n4647\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHC\n\n\n4648\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHC\n\n\n4649\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCHC\n\n\n4650\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCAC\n\n\n4651\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCAC\n\n\n4652\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCAC\n\n\n4653\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCAC\n\n\n4654\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHC\n\n\n4655\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCAC\n\n\n4656\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCAC\n\n\n4657\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCGCYGG\n\n\n4658\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCYGG\n\n\n4659\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCYGG\n\n\n4660\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCYGG\n\n\n4661\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCYGG\n\n\n4662\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCYGG\n\n\n4663\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCYGG\n\n\n4664\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYGG\n\n\n4665\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACYGG\n\n\n4666\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACYGG\n\n\n4667\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACYGG\n\n\n4668\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACYGG\n\n\n4669\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCYGG\n\n\n4670\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACYGG\n\n\n4671\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACYGG\n\n\n4672\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYG\n\n\n4673\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCGGG\n\n\n4674\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCGGG\n\n\n4675\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCGGG\n\n\n4676\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCGGG\n\n\n4677\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCGGG\n\n\n4678\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCGGG\n\n\n4679\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACFGG\n\n\n4680\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACGGG\n\n\n4681\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACGGG\n\n\n4682\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACGGG\n\n\n4683\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACGGG\n\n\n4684\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCACGGG\n\n\n4685\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACGGG\n\n\n4686\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACGGG\n\n\n4687\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACGG\n\n\n4688\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYG\n\n\n4689\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACGG\n\n\n4690\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCTPK\n\n\n4691\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCTPK\n\n\n4692\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCTPK\n\n\n4693\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCTPK\n\n\n4694\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCTPK\n\n\n4695\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCTPK\n\n\n4696\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCYPK\n\n\n4697\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCYPK\n\n\n4698\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCYPK\n\n\n4699\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCYPK\n\n\n4700\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYPK\n\n\n4701\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCYPK\n\n\n4702\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCYPK\n\n\n4703\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACTPK\n\n\n4704\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACTPK\n\n\n4705\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACTPK\n\n\n4706\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACTPK\n\n\n4707\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCTPK\n\n\n4708\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACTPK\n\n\n4709\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACTPK\n\n\n4710\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHC\n\n\n4711\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHC\n\n\n4712\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHC\n\n\n4713\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHC\n\n\n4714\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHC\n\n\n4715\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHC\n\n\n4716\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCAC\n\n\n4717\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCAC\n\n\n4718\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCAC\n\n\n4719\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCAC\n\n\n4720\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHC\n\n\n4721\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCAC\n\n\n4722\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCAC\n\n\n4723\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCHCYGG\n\n\n4724\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCYGG\n\n\n4725\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCHCYG\n\n\n4726\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCACYG\n\n\n4727\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCYGG\n\n\n4728\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCYGG\n\n\n4729\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCYGG\n\n\n4730\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYGG\n\n\n4731\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCYGG\n\n\n4732\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCYGG\n\n\n4733\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCACYG\n\n\n4734\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACYGG\n\n\n4735\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACYGG\n\n\n4736\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACYGG\n\n\n4737\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACYGG\n\n\n4738\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYGG\n\n\n4739\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACYGG\n\n\n4740\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACYGG\n\n\n4741\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCACFGG\n\n\n4742\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCGGG\n\n\n4743\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCGGG\n\n\n4744\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCGGG\n\n\n4745\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCGGG\n\n\n4746\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCGGG\n\n\n4747\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCGGG\n\n\n4748\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACGGG\n\n\n4749\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACGGG\n\n\n4750\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACGGG\n\n\n4751\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACGGG\n\n\n4752\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCACTP\n\n\n4753\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACTP\n\n\n4754\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACTP\n\n\n4755\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCTPK-amide\n\n\n4756\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4757\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4758\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4759\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4760\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4761\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCHCTPK-\n\n\n4762\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCYPK-amide\n\n\n4763\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4764\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4765\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4766\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4767\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4768\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCHCYPK-\n\n\n4769\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACTPK-amide\n\n\n4770\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACTPK-\n\n\n4771\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACTPK-\n\n\n4772\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACTPK-\n\n\n4773\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCACTPK-\n\n\n4774\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACTPK-\n\n\n4775\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACTPK-\n\n\n4776\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHC-amide\n\n\n4777\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHC-\n\n\n4778\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHC-\n\n\n4779\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHC-amide\n\n\n4780\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHC-\n\n\n4781\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHC-amide\n\n\n4782\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCAC-amide\n\n\n4783\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCAC-\n\n\n4784\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCAC-\n\n\n4785\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCAC-amide\n\n\n4786\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHC-\n\n\n4787\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCAC-amide\n\n\n4788\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCAC-amide\n\n\n4789\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYGG-amide\n\n\n4790\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCYGG-amide\n\n\n4791\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCYGG-\n\n\n4792\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCYGG-\n\n\n4793\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCYGG-\n\n\n4794\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCYGG-\n\n\n4795\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCYGG-\n\n\n4796\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCFGG-amide\n\n\n4797\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCYG-amide\n\n\n4798\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYG-amide\n\n\n4799\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACYGG-amide\n\n\n4800\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACYGG-\n\n\n4801\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACYGG-\n\n\n4802\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACYGG-\n\n\n4803\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCACYGG-\n\n\n4804\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACYGG-\n\n\n4805\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACYGG-\n\n\n4806\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYGG-amide\n\n\n4807\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCHCGGG-amide\n\n\n4808\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCHCGGG-\n\n\n4809\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCHCGGG-\n\n\n4810\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCHCGGG-\n\n\n4811\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCHCGGG-\n\n\n4812\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCHCGGG-\n\n\n4813\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACGGG-amide\n\n\n4814\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACFGG-amide\n\n\n4815\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKDAGMRFGACAAGKCACGGG-amide\n\n\n4816\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKDAGMRFGACAAGKCACGGG-\n\n\n4817\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKDAGMRFGACAAGKCACGGG-\n\n\n4818\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKDAGMRFGACAAGKCACGGG-\n\n\n4819\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKDAGMRFGACAAGKCACGGG-\n\n\n4820\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKDAGMRFGACAAGKCACGGG-\n\n\n4821\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKDAGMRFGACAAGKCACGGG-\n\n\n4822\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCTPK-amide\n\n\n4823\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4824\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4825\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4826\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4827\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4828\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCTPK-\n\n\n4829\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCYPK-amide\n\n\n4830\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4831\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4832\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4833\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4834\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4835\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCYPK-\n\n\n4836\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACTPK-amide\n\n\n4837\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACTPK-\n\n\n4838\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACTPK-\n\n\n4839\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACTPK-\n\n\n4840\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCACTPK-\n\n\n4841\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACTPK-\n\n\n4842\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACTPK-\n\n\n4843\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHC-amide\n\n\n4844\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHC-\n\n\n4845\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHC-\n\n\n4846\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHC-amide\n\n\n4847\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHC-\n\n\n4848\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHC-amide\n\n\n4849\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCAC-amide\n\n\n4850\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCAC-\n\n\n4851\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCAC-\n\n\n4852\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCAC-amide\n\n\n4853\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHC-\n\n\n4854\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCAC-amide\n\n\n4855\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCAC-amide\n\n\n4856\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCHCWGG-amide\n\n\n4857\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCYGG-amide\n\n\n4858\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4859\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4860\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4861\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4862\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4863\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4864\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKEAGMRFGACAAGKCACYGG-amide\n\n\n4865\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACYGG-amide\n\n\n4866\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACYGG-\n\n\n4867\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACYGG-\n\n\n4868\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACYGG-\n\n\n4869\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCYGG-\n\n\n4870\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACYGG-\n\n\n4871\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACYGG-\n\n\n4872\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCHCGGG-amide\n\n\n4873\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCHCGGG-\n\n\n4874\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCHCGGG-\n\n\n4875\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCHCGGG-\n\n\n4876\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCHCGGG-\n\n\n4877\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCHCGGG-\n\n\n4878\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLOPCKEAGMRFGACAAGKCACGGG-amide\n\n\n4879\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hLys]PCKEAGMRFGACAAGKCACGGG-\n\n\n4880\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hArg]PCKEAGMRFGACAAGKCACGGG-\n\n\n4881\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Cit]PCKEAGMRFGACAAGKCACGGG-\n\n\n4882\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[hCit]PCKEAGMRFGACAAGKCACTP-\n\n\n4883\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dpr]PCKEAGMRFGACAAGKCACGGG-\n\n\n4884\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCL[Dab]PCKEAGMRFGACAAGKCACGGG-\n\n\n4885\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Cpa]AGMRFGACAAGKCACYGG-\n\n\n4886\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Cpa]AGMRFGACAAGKCACGGG-\n\n\n4887\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Cpa]AGMRFGACAAGKCACY-\n\n\n4888\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-GVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCACYGG-\n\n\n4889\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Aad]AGMRFGACAAGKCACYGG-\n\n\n4890\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Aad]AGMRFGACAAGKCHCYGG-\n\n\n4891\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCK[Aad]AGMRFGACAAGKCACYGG\n\n\n4892\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCACYGG-amide\n\n\n4893\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCACYGG\n\n\n4894\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCACY-amide\n\n\n4895\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCHCYGG-amide\n\n\n4896\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCHCYGG\n\n\n4897\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCHCYPK\n\n\n4898\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCAC\n\n\n4899\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[1Nal]GG-\n\n\n4900\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[1Nal]PK-\n\n\n4901\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[2Nal]GG-\n\n\n4902\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[Cha]GG-\n\n\n4903\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[MePhe]GG-\n\n\n4904\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[BiPhA]GG-\n\n\n4905\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKC[Aib]CYGG-\n\n\n4906\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKC[Abu]CYGG-\n\n\n4907\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[1Nal]\n\n\n4908\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCAC[1Nal]GG-\n\n\n4909\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCAC[4Bip]-\n\n\n4910\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLHPCKDAGMRFGACAAGKCAC[4Bip]GG-\n\n\n4911\n\n\n\n\n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIAAQCLKPCKDAGMRFGACAAGKCHCGGG\n\n\n4912\n\n\n\n\n\n\n \n\n\n\n\n\n\nGIINVKCKISAQCLKPCRDAGMRFGKCMNGKCACTPK\n\n\n4916\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7J\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAdditional useful OSK1 peptide analogs\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n \n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/Structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nG\nC\n\n\n[Gly34]OSK1\n\n\n4930\n\n\n \n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nS\nC\n\n\n[Ser34]OSK1\n\n\n4931\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nT\nC\n\n\n[Thr34]OSK1\n\n\n4932\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nN\nC\n\n\n[Asn34]OSK1\n\n\n4933\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nV\nC\n\n\n[Val34]OSK1\n\n\n4934\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nL\nC\n\n\n[Leu34]OSK1\n\n\n4935\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nI\nC\n\n\n[Ile34]OSK1\n\n\n4936\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nP\nC\n\n\n[Pro34]OSK1\n\n\n4937\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nM\nC\n\n\n[Met34]OSK1\n\n\n4938\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nQ\nC\n\n\n[Gln34]OSK1\n\n\n4939\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nK\nC\n\n\n[Lys34]OSK1\n\n\n4940\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nD\nC\n\n\n[Asp34]OSK1\n\n\n4941\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nW\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n[Trp1]OSK1\n\n\n4942\n\n\n\n\n\n\nWPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGV\nW\nINVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n[Trp3]OSK1\n\n\n4943\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVII\nW\nVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n[Trp5]OSK1\n\n\n4944\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n[1Nal]\nVIINVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal1]OSK1\n\n\n4945\n\n\n\n\n\n\nGKCHCWPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGV\n[1Nal]\nINVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal3]OSK1\n\n\n4946\n\n\n\n\n\n\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVII\n[1Nal]\nVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal5]OSK1\n\n\n4947\n\n\n\n\n\n\nGKCHCTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVI\nK\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHC\n\n\n[Lys4]OSK1\n\n\n4948\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVI\nK\nNVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Lys4, Ala34]OSK1\n\n\n4949\n\n\n\n\n\n\nTPK\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n[1Nal]\nVIINVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal1;\n\n\n4950\n\n\n\n\n\n\nGKC\nA\nCWPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGV\n[1Nal]\nINVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal3;\n\n\n4951\n\n\n\n\n\n\nGKC\nA\nCTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVII\n[1Nal]\nVKCKISRQCLEPCKKAGMRFGKCMN\n\n\n[1Nal5;\n\n\n4952\n\n\n\n\n\n\nGKC\nA\nCTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nW\nVIINVKCKISRQCLEPCKKAGMRFCKCMNGKC\nA\nC\n\n\n[Trp1;\n\n\n4953\n\n\n\n\n\n\nWPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGV\nW\nINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Trp3;\n\n\n4954\n\n\n\n\n\n\nTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVII\nW\nVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Trp5;\n\n\n4955\n\n\n\n\n\n\nTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nW\nV\nW\nI\nW\nVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Trp1, 3, 5;\n\n\n4956\n\n\n\n\n\n\nTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n[1Nal]\nV\n[1Nal]\nI\n[1Nal]\nVKCKISRQCLEPCKK\n\n\n[1Nal1, 3, 5;\n\n\n4957\n\n\n\n\n\n\nAGMRFGKCMNGKC\nA\nCTPK\n\n\nAla34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nCTPK\n\n\nΔ1-7,\n\n\n4958\n\n\n\n\n\n\n \n\n\n[Ala34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nCTPK\n\n\nΔ1-6,\n\n\n4959\n\n\n\n\n\n\n \n\n\n[Ala34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\n[1Nal]\nRQCLEPCKKAGMRFGKC\nA\nN\n\n\n[1Nal11; Ala29,\n\n\n4960\n\n\n\n\n\n\nGKC\nA\nCWPK\n\n\n34]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nR\nRQCLEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Ala29,\n\n\n4961\n\n\n\n\n\n\nWPK\n\n\n34]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Glu15; Ala29,\n\n\n4962\n\n\n\n\n\n\nWPK\n\n\n34]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nR\nRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Arg11;\n\n\n4963\n\n\n\n\n\n\nWPK\n\n\nAla34]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQC\nE\nEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Glu15;\n\n\n4964\n\n\n\n\n\n\nWPK\n\n\nAla34]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKI\nR\nRQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nCTPK\n\n\nΔ1-7, [Arg11;\n\n\n4965\n\n\n\n\n\n\n \n\n\nGlu15; Ala29, 34]\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nR\nRQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Glu15;\n\n\n4966\n\n\n\n\n\n\nTPK\n\n\nAla29, 34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nCVIINVKCKI\nR\nRQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Cys1, 37; Arg11;\n\n\n4967\n\n\n\n\n\n\nTCK\n\n\nGlu15;\n\n\n\n\n\n\n \n\n\nAla29, 34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nRA\nQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Ala12,\n\n\n4968\n\n\n\n\n\n\nTPK\n\n\n29, 34; Glu15]\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nRA\nQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Glu15;\n\n\n4969\n\n\n\n\n\n\nTPK-NH2\n\n\nAla12, 29, 34]OSK1-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nAc-\n\n\nAc-[Arg11;\n\n\n4970\n\n\n\n\n\n\nGVIINVKCKI\nRA\nQC\nE\nEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\nGlu15; Ala12,\n\n\n\n\n\n\nTPK-NH2\n\n\n29, 34]OSK1-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\n[1Nal]A\nQC\nE\nEPCKKAGMRFGKC\nA\nN\n\n\n[1Nal11;\n\n\n4971\n\n\n\n\n\n\nGKC\nA\nCTPK\n\n\nGlu15;\n\n\n\n\n\n\n \n\n\nAla12, 29, 34]OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKC\nA\nNGKC\n[1Nal]\n \n\n\n[Ala29; 1Nal34]\n\n\n4972\n\n\n\n\n\n\nCWPK\n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIS\nA\nQCL\nK\nPCK\nD\nAGMRFGKCMNGKCHC\n\n\n[Ala12; Lys16;\n\n\n4973\n\n\n\n\n\n\nTPK\n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIS\nA\nQCL\nK\nPCK\nD\nAGMRFGKCMNGKC\nA\nC\n\n\n[Ala12, 34; Lys16;\n\n\n4974\n\n\n\n\n\n\nTPK\n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIS\nA\nQCL\nK\nPCK\nD\nAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Ala12, 29, 34; Lys16;\n\n\n4975\n\n\n\n\n\n\nTPK\n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nRA\nQCL\nK\nPCK\nD\nAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Ala12,\n\n\n4976\n\n\n\n\n\n\nTPK\n\n\n29, 34; Lys16; Asp20]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIS\nA\nQC\nEK\nPCK\nD\nAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Ala12, 29, 34;\n\n\n4977\n\n\n\n\n\n\nTPK\n\n\nGlu15, Lys16;\n\n\n\n\n\n\n \n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\n[1Nal]A\nQCL\nK\nPCK\nD\nAGMRFGKC\nA\nN\n\n\n[1Nal11; Ala12,\n\n\n4978\n\n\n\n\n\n\nGKC\nA\nCTPK\n\n\n29, 34; Lys16;\n\n\n\n\n\n\n \n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nRA\nQC\nEK\nPCK\nD\nAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Ala12,\n\n\n4979\n\n\n\n\n\n\nTPK\n\n\n29, 34; Glu15; Lys16;\n\n\n\n\n\n\n \n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI\nRA\nQC\nEK\nPCKDAGMRFGKCMNGKC\nA\nC\n\n\n[Arg11; Ala12,\n\n\n4980\n\n\n\n\n\n\nTPK\n\n\n34; Glu15; Lys16;\n\n\n\n\n\n\n \n\n\nAsp20]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKC[1Nal]\n\n\n[A12, K16,\n\n\n4981\n\n\n\n\n\n\nCTPK\n\n\nD20, Nal34]-\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCMNGKCAC\n\n\n[A12, K16,\n\n\n4982\n\n\n\n\n\n\nTPK\n\n\nD20, A34]-\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKC[1Nal]\n\n\n[A12, K16,\n\n\n4983\n\n\n\n\n\n\nCTPK\n\n\nD20, A29,\n\n\n\n\n\n\n \n\n\nNal34]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISAQCLKPCKDAGMRFGKCANGKCAC\n\n\n[A12, K16,\n\n\n4984\n\n\n\n\n\n\nTPK\n\n\nD20, A29,\n\n\n\n\n\n\n \n\n\nA34]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n{Acetyl}GVIINVKCKISRQCLEPCK(Glycyl)\n\n\nAc-\n\n\n4985\n\n\n\n\n\n\nKAGMRFGKCMNGKCACTPK\n\n\n[K(Gly)19, Ala34]-\n\n\n\n\n\n\n \n\n\nOsk1\n\n\n\n\n\n\n \n\n\n\n\n\n\n{Acetyl}GVIK(Glycyl)NVKCKISRQCLEPCK\n\n\nAc-\n\n\n4986\n\n\n\n\n\n\nKAGMRFGKCMNGKCACTPK\n\n\n[K(Gly)4, Ala34]-\n\n\n\n\n\n\n \n\n\nOsk1\n\n\n\n\n\n\n \n\n\n\n\n\n\n{Acetyl}GVIINVKCKISRQCLEPCKKAGMRFGK\n\n\nAc-\n\n\n4987\n\n\n\n\n\n\nCMNGKCACTPK(Glycyl)\n\n\n[Ala34, K(Gly)\n\n\n\n\n\n\n \n\n\n38]-Osk1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCANGKC[1Nal]\n\n\n[A29, Nal34]-\n\n\n4988\n\n\n\n\n\n\nCTPK\n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLKPCKDAGMRFGKCMNGKCHC{Amide}\n\n\nOSK1[des1-\n\n\n4989\n\n\n\n\n\n\n \n\n\n7, E16K,\n\n\n\n\n\n\n \n\n\nK20D, des36-\n\n\n\n\n\n\n \n\n\n38]-amide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISRQCLKPCKDAGMRFGKCMNGKCAC\n\n\nOSK1-\n\n\n4990\n\n\n\n\n\n\nTPK\n\n\nK16, D20, A34\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI[1Nal]AQCLEPCKKAGMRFGKCAN\n\n\nOsk-\n\n\n4991\n\n\n\n\n\n\nGKC[1Nal]CTPK\n\n\n1[1Nal11, A12,\n\n\n\n\n\n\n \n\n\nA29, 1-Nal34]\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI[1Nal]AQCLEPCKKAGMRFGKCAN\n\n\n[1Nal11, A12, A29,\n\n\n4992\n\n\n\n\n\n\nGKC[1Nal]CTEK\n\n\n1Nal34, E37]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI[1Nal]AQCEEPCKKAGMRFGKCAN\n\n\nOsk-1[1-\n\n\n4993\n\n\n\n\n\n\nGKC[1Nal]CEEK\n\n\nNal11, A12, E15,\n\n\n\n\n\n\n \n\n\nA29, 1Nal34,\n\n\n\n\n\n\n \n\n\nE36, E37]\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI[1Nal]AQCLEPCKKAGFRFGKCAN\n\n\n[1Nal11, A12, F23,\n\n\n4994\n\n\n\n\n\n\nGKC[1Nal]CTPK\n\n\nA29, 1Nal34]\n\n\n\n\n\n\n \n\n\nOsk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKI[1Nal]AQCLEPCKKAG[Nle]RFG\n\n\n[1Nal11, A12,\n\n\n4995\n\n\n\n\n\n\nKCANGKC[1Nal]CTEK\n\n\nNle23, A29, 1Nal34,\n\n\n\n\n\n\n \n\n\nE37]Osk-1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLKPCKDAGMRFGKCMNGKCAC\n\n\n[Pro12, Lys16,\n\n\n4996\n\n\n\n\n\n\nTY[Nle]\n\n\nAsp20,\n\n\n\n\n\n\n \n\n\nAla34, Tyr37, Nle38]\n\n\n\n\n\n\n \n\n\nOsk-1-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKISPQCLOPCKEAGMRFGKCMNGKCAC\n\n\n[P12, Orn16, E20,\n\n\n4997\n\n\n\n\n\n\nTY[Nle]\n\n\nA34, Y37, Nle38]\n\n\n\n\n\n\n \n\n\nOsk-1-\n\n\n\n\n\n\n \n\n\namide\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLEPCKKAGMRFGKCANGKC[1Nal]\n\n\ndes1-4, [A29,\n\n\n4998\n\n\n\n\n\n\nCTPK\n\n\nNal34]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nNVKCKISRQCLEPCKKAGMRFGKCANGKCACTPK\n\n\ndes1-4, [A29,\n\n\n4999\n\n\n\n\n\n\n \n\n\nA34]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIRRQCLEPCKKAGMRFGKCANGKCAC\n\n\n[R11, A29,\n\n\n5000\n\n\n\n\n\n\nTPK\n\n\nA34]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVIINVKCKIRAQCLEPCKKAGMRFGKCANGKCAC\n\n\n[R11, A12,\n\n\n5001\n\n\n\n\n\n\nTPK\n\n\nA29, A34]-\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nCTPK\n\n\n[Ala34]OSK1\n\n\n5002\n\n\n\n\n\n\n \n\n\n(8-35)\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Ala34]OSK1\n\n\n5003\n\n\n\n\n\n\n \n\n\n(8-35)\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKI\nR\nRQCLEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Arg11; Ala29,\n\n\n5004\n\n\n\n\n\n\n \n\n\n34]\n\n\n\n\n\n\n \n\n\nOsk-1(8-35)\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKIS\nA\nQCLEPCKKAGMRFGKC\nA\nNGKC\nA\nC\n\n\n[Ala12; Ala29,\n\n\n5005\n\n\n\n\n\n\n \n\n\n34]\n\n\n\n\n\n\n \n\n\nOsk-1(8-35)\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKIS\nA\nQCLEPCKKAGMRFGKCMNGKC\nA\nC\n\n\n[Ala12; Ala34]\n\n\n5006\n\n\n\n\n\n\n \n\n\nOsk-1(8-35)\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVI\n[Dpr(AOA)]\nNVKCKISRQCLEPCKKAGMRFGKCM\n\n\n[Dpr\n(AOA)\n4]\n\n\n5009\n\n\n\n\n\n\nNGKCHCTPK\n\n\nOsk1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVI\n[Dpr\n \n(AOA-PEG)\n \n]\nNVKCKISRQCLEPCKKAGMRF\n\n\n[Dpr\n(AOA)-PEG)\n \n\n\n5010\n\n\n\n\n\n\nGKCMNGKCHCTPK\n\n\n4]Osk1\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nC\nK\n\n\n[C2, C37]-\n\n\n5012\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nSC\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nC\nK\n\n\n[S1, C2, C37]-\n\n\n5013\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nSC\nIINVKCKISRQCLEPCKKAGMRFGKCMNGKC\nA\nCT\nC\nK\n\n\n[S1, C2, A34,\n\n\n5014\n\n\n\n\n\n\n \n\n\nC37]-OSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nSC\nVIINVKCKISRQCLEPCKKAGMRFGKCMNGKCHCT\nC\nK\n\n\nSer-[C1, C37]-\n\n\n5015\n\n\n\n\n\n\n \n\n\nOSK1\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nAny OSK1 peptide analog that comprises an amino acid sequence selected from SEQ ID NOS: 1391 through 4912, 4916, 4920 through 5006, 5009, 5010, and 5012 through 5015 as set forth in Tables 7, 7A, 7B, 7C, 7D, 7E, 7F, 7G, 7H or 7I, is useful in accordance with the present invention. Any of these can also be derivatized at either its N-terminal or C-terminal, e.g., with a fatty acid having from 4 to 10 carbon atoms and from 0 to 2 carbon-carbon double bonds, or a derivative thereof such as an ω-amino-fatty acid. (E.g., Mouhat et al., WO 2006/002850 A2, which is incorporated by reference in its entirety). Examples of such fatty acids include valeric acid or (for the C-terminal) ω-amino-valeric acid.\n\n\nAmong useful OSK1 peptide analog sequences of the present invention are analog sequences that introduce amino acid residues that can form an intramolecular covalent bridge (e.g., a disulfide bridge) or non-covalent interactions (e.g. hydrophobic, ionic, stacking) between the first and last beta strand, which may enhance the stability of the structure of the unconjugated or conjugated (e.g., PEGylated) OSK1 peptide analog molecule. Examples of such sequences include SEQ ID NOS: 4985-4987 and 5012-5015.\n\n\nIn some embodiments of the composition of matter, the C-terminal carboxylic acid moiety of the OSK1 peptide analog is replaced with a moiety selected from:\n\n\n(A) —COOR, where R is independently (C\n1\n-C\n8\n)alkyl, haloalkyl, aryl or heteroaryl;\n\n\n(B) —C(═O)NRR, where R is independently hydrogen, (C\n1\n-C\n8\n)alkyl, haloalkyl, aryl or heteroaryl; and\n\n\n(C) —CH\n2\nOR where R is hydrogen, (C\n1\n-C\n8\n) alkyl, aryl or heteroaryl.\n\n\n“Aryl” is phenyl or phenyl vicinally-fused with a saturated, partially-saturated, or unsaturated 3-, 4-, or 5 membered carbon bridge, the phenyl or bridge being substituted by 0, 1, 2 or 3 substituents selected from C\n18 \nalkyl, C\n14 \nhaloalkyl or halo.\n\n\n“Heteroaryl” is an unsaturated 5, 6 or 7 membered monocyclic or partially-saturated or unsaturated 6-, 7-, 8-, 9-, 10- or 11 membered bicyclic ring, wherein at least one ring is unsaturated, the monocyclic and the bicyclic rings containing 1, 2, 3 or 4 atoms selected from N, O and S, wherein the ring is substituted by 0, 1, 2 or 3 substituents selected from C\n18 \nalkyl, C\n14 \nhaloalkyl and halo.\n\n\nIn other embodiments of the composition of matter comprising a half-life extending moiety, the OSK1 peptide analog comprises an amino acid sequence of the formula:\n\n\n\n\n\n\n\n\n\n\n\n\nG\n1\nV\n2\nI\n3\nI\n4\nN\n5\nV\n6\nK\n7\nC\n8\nK\n9\nI\n10\nX\naa\n \n11\nX\naa\n \n12\n \n\n\nSEQ ID NO: 5011\n\n\n\n\n\n\nQ\n13\nC\n14\nX\naa\n \n15\nX\naa\n \n16\nP\n17\nC\n18\nX\naa\n \n19\nX\naa\n \n20\n \n\n\n\n\n\n\nA\n21\nG\n22\nM\n23\nR\n24\nF\n25\nG\n26\nX\naa\n \n27\nC\n28\nX\naa\n \n29\n \n\n\n\n\n\n\nX\naa\n \n30\nG\n31\nX\naa\n \n32\nC\n33\nX\naa\n \n34\nC\n35\nX\naa\n \n36\n \n\n\n\n\n\n\nX\naa\n \n37\nX\naa\n \n38\n \n\n\n\n\n\n\n\n\n\n\n\n\nwherein:\n\n\n \namino acid residues\n 1 through 7 are optional (Thus, the OSK1 peptide analog optionally includes residues 1-7 as indicated above in SEQ ID NO:5011, or a N-terminal truncation leaving present residues 2-7, 3-7, 4-7, 5-7, 6-7, or 7, or alternatively, a N-terminal truncation wherein all of residues 1-7 are entirely absent.);\n\n \n \n \n \nX\naa\n \n11 \nis a neutral, basic, or acidic amino acid residue (e.g., Ser, Thr, Ala, Gly, Leu, Ile, Val, Met, Cit, Homocitrulline, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Guf, and 4-Amino-Phe, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Lys, His, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n12 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n15 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n16 \nis a neutral or basic amino acid residue (e.g., Lys, His, Arg, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Cit, N\nα\n-Methyl-Cit, Homocitrulline, His, Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Ser, Thr, Guf, and 4-Amino-Phe);\n \nX\naa\n \n19 \nis a neutral or basic amino acid residue (e.g., Lys, His, Arg, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Cit, N\nα\n-Methyl-Cit, Homocitrulline, His, Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Ser, Thr, Guf, and 4-Amino-Phe);\n \nX\naa\n \n20 \nis a neutral or basic amino acid residue (e.g., Lys, His, Arg, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Cit, N\nα\n-Methyl-Cit, Homocitruiline, His, Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Ser, Thr, Guf, and 4-Amino-Phe);\n \nX\naa\n \n27 \nis a neutral, basic, or acidic amino acid residue (e.g., Ser, Thr, Ala, Gly, Leu, Ile, Val, Met, Cit, Homocitrulline, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Guf, and 4-Amino-Phe, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Lys, His, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n29 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n30 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n32 \nis a neutral, basic, or acidic amino acid residue (e.g., Ser, Thr, Ala, Gly, Leu, Ile, Val, Met, Cit, Homocitrulline, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Guf, and 4-Amino-Phe, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Lys, His, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n34 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n36 \nis optional, and if present, is a neutral amino acid residue (e.g., Pro, Ala, Gly, Leu, Ile, Val, Met, Oic, Hyp, Tic, D-Tic, D-Pro, Thz, N\nα\n-Methyl-Cit, Homocitrulline, Aib, Sar, Pip, Tyr, Thr, Ser, Phe, Trp, 1-Nal, 2-Nal, and Bip;\n \nX\naa\n \n37 \nis optional, and if present, is a neutral amino acid residue (e.g., Pro, Ala, Gly, Leu, Ile, Val, Met, Oic, Hyp, Tic, D-Tic, D-Pro, Thz, N\nα\n-Methyl-Cit, Homocitrulline, Aib, Sar, Pip, Tyr, Thr, Ser, Phe, Trp, 1-Nal, 2-Nal, and Bip); and\n \nX\naa\n \n38 \nis optional, and if present, is a basic amino acid residue (e.g., Lys, His, Orn, D-Orn, Arg, N\nα\n Methyl-Arg; homoarginine, Cit, N\nα\n-Methyl-Cit, Homocitrulline, Guf, and 4-Amino-Phe).\n \n \n \n\n\nIn some other embodiments of the composition of matter comprising a half-life extending moiety, the OSK1 peptide analog comprises an amino acid sequence of the formula:\n\n\n\n\n\n\n\n\n\n\n\n\nG\n1\nV\n2\nI\n3\nI\n4\nN\n5\nV\n6\nK\n7\nC\n8\nK\n9\nI\n10\nX\naa\n \n11\nX\naa\n \n12\n \n\n\nSEQ ID NO: 4913\n\n\n\n\n\n\nQ\n13\nC\n14\nL\n15\nX\naa\n \n16\nP\n17\nC\n18\nK\n19\nX\naa\n \n20\nA\n21\n \n\n\n\n\n\n\nG\n22\nM\n23\nR\n24\nF\n25\nG\n26\nX\naa\n \n27\nC\n28\nX\naa\n \n29\nX\naa\n \n30\n \n\n\n\n\n\n\nG\n31\nK\n32\nC\n33\nX\naa\n \n34\nC\n35\nX\naa\n \n36\nX\naa\n \n37\nX\naa\n \n38\n \n\n\n\n\n\n\n\n\n\n\n\n\nwherein:\n\n \n \n \n \n \namino acid residues\n 1 to 7 are optional (Thus, the OSK1 peptide analog optionally includes residues 1-7 as indicated above in SEQ ID NO:4913, or a N-terminal truncation leaving present residues 2-7, 3-7, 4-7, 5-7, 6-7, or 7, or alternatively, a N-terminal truncation wherein all of residues 1-7 are entirely absent.);\n \nX\naa\n \n11 \nis a neutral, basic or acidic amino acid residue (e.g., Ser, Thr, Ala, Gly, Leu, Ile, Val, Met, Cit, Homocitrulline, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Guf, and 4-Amino-Phe, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Lys, His, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n12 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n16 \nis a neutral or basic amino acid residue (e.g., Lys, His, Arg, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Cit, N\nα\n-Methyl-Cit, Homocitrulline, His, Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Ser, Thr, Guf, and 4-Amino-Phe);\n \nX\naa\n \n20 \nis a neutral or basic amino acid residue (e.g., Lys, His, Arg, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Cit, N\nα\n-Methyl-Cit, Homocitrulline, His, Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Ser, Thr, Guf, and 4-Amino-Phe);\n \nX\naa\n \n27 \nis a neutral, basic, or acidic amino acid residue (e.g., Ser, Thr, Ala, Gly, Leu, Ile, Val, Met, Cit, Homocitrulline, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Guf, and 4-Amino-Phe, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Lys, His, Trp, Arg, N\nα\n Methyl-Arg; homoarginine, 1-Nal, 2-Nal, Orn, D-Orn, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n29 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n30 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n35 \nis a neutral or acidic amino acid residue (e.g., Ala, Gly, Leu, Ile, Val, Met, Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, Pip, Bip, Phe, Tyr, Ser, Thr, Asn, Gln, Glu, Asp, α-aminoadipic acid, and para-carboxyl-phenylalanine);\n \nX\naa\n \n36 \nis optional, and if present, is a neutral amino acid residue (e.g., Pro, Ala, Gly, Leu, Ile, Val, Met, Oic, Hyp, Tic, D-Tic, D-Pro, Thz, N\nα\n-Methyl-Cit, Homocitrulline, Aib, Sar, Pip, Tyr, Thr, Ser, Phe, Trp, 1-Nal, 2-Nal, and Bip;\n \nX\naa\n \n37 \nis optional, and if present, is a neutral amino acid residue (e.g., Pro, Ala, Gly, Leu, Ile, Val, Met, Oic, Hyp, Tic, D-Tic, D-Pro, Thz, N\nα\n-Methyl-Cit, Homocitrulline, Aib, Sar, Pip, Tyr, Thr, Ser, Phe, Trp, 1-Nal, 2-Nal, and Bip); and\n \nX\naa\n \n38 \nis optional, and if present, is a basic amino acid residue (e.g., Lys, His, Orn, D-Orn, Arg, N\nα\n Methyl-Arg; homoarginine, Cit, N\nα\n-Methyl-Cit, Homocitruiline, Guf, and 4-Amino-Phe).\n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 8\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nPi2 peptide and PiP2 s peptide analog equences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-\n\n\n \n\n\n\n\n\n\n \n\n\nhand\n\n\n \n\n\n\n\n\n\n \n\n\ndesig-\n\n\nSEQ ID\n\n\n\n\n\n\nSequence/structure\n\n\nnation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCKCFGR\n\n\nPi2\n\n\n17\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPXQCYPHCKKETGYPNAKCMNRKCKCFGR\n\n\nPi2-X8\n\n\n299\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPAQCYPHCKKETGYPNAKCMNRKCKCFGR\n\n\nPi2-A8\n\n\n300\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCXKETGYPNAKCMNRKCKCFGR\n\n\nPi2-X15\n\n\n301\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCAKETGYPNAKCMNRKCKCFGR\n\n\nPi2-A15\n\n\n302\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKXETGYPNAKCMNRKCKCFGR\n\n\nPi2-X16\n\n\n303\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKAETGYPNAKCMNRKCKCFGR\n\n\nPi2-A16\n\n\n304\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAXCMNRKCKCFGR\n\n\nPi2-X24\n\n\n305\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAACMNRKCKCFGR\n\n\nPi2-A24\n\n\n306\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNXKCKCFGR\n\n\nPi2-X28\n\n\n307\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNAKCKCFGR\n\n\nPi2-A28\n\n\n308\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRXCKCFGR\n\n\nPi2-X29\n\n\n309\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRACKCFGR\n\n\nPi2-A29\n\n\n310\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCXCFGR\n\n\nPi2-X31\n\n\n311\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCACFGR\n\n\nPi2-A31\n\n\n312\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCKCFGX\n\n\nPi2-X35\n\n\n313\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCKCFGA\n\n\nPi2-A35\n\n\n314\n\n\n\n\n\n\n \n\n\n\n\n\n\nTISCTNPKQCYPHCKKETGYPNAKCMNRKCKCFG\n\n\nPi2-d35\n\n\n315\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 9\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAnuroctoxin (AnTx) peptide and peptide\n\n\n\n\n\n\nanalog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nZKECTGPQHCTNFCRKNKCTHGKCMNRKCKCF\n\n\nAnuroctoxin\n\n\n62\n\n\n\n\n\n\nNCK\n\n\n(AnTx)\n\n\n\n\n\n\n \n\n\n\n\n\n\nKECTGPQHCTNFCRKNKCTHGKCMNRKCKCFNCK\n\n\nAnTx-d1\n\n\n316\n\n\n\n\n\n\n \n\n\n\n\n\n\nXECTGPQHCTNFCRKNKCTHGKCMNRKCKCFNCK\n\n\nAnTx-d1, X2\n\n\n317\n\n\n\n\n\n\n \n\n\n\n\n\n\nAECTGPQHCTNFCRKNKCTHGKCMNRKCKCFNCK\n\n\nAnTx-d1, A2\n\n\n318\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 10\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nNoxiustoxin (NTX) peptide and NTX peptide\n\n\n\n\n\n\nanalog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-\n\n\n \n\n\n\n\n\n\n \n\n\nhand\n\n\nSEQ\n\n\n\n\n\n\n \n\n\ndesig-\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nnation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nTIINVKCTSPKQCSKPCKELYGSSAGAKCMNGKCKCYNN\n\n\n \nNTX\n \n\n\n30\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVACTSPKQCSKPCKELYGSSAGAKCMNGKCKCYNN\n\n\nNTX-A6\n\n\n319\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCSKPCKELYGSSRGAKCMNGKCKCYNN\n\n\nNTX-\n\n\n320\n\n\n\n\n\n\n \n\n\nR25\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSSKQCSKPCKELYGSSAGAKCMNGKCKCYNN\n\n\nNTX-\n\n\n321\n\n\n\n\n\n\n \n\n\nS10\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCWKPCKELYGSSAGAKCMNGKCKCYNN\n\n\nNTX-\n\n\n322\n\n\n\n\n\n\n \n\n\nW14\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCSKPCKELYGSSGAKCMNGKCKCYNN\n\n\nNTX-\n\n\n323\n\n\n\n\n\n\n \n\n\nA25d\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCSKPCKELFGVDRGKCMNGKCKCYNN\n\n\nNTX-\n\n\n324\n\n\n\n\n\n\n \n\n\nIbTx1\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCWKPCKELFGVDRGKCMNGKCKCYN\n\n\nNTX-\n\n\n325\n\n\n\n\n\n\n \n\n\nIBTX2\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 11\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nKaliotoxin1 (KTX1) peptide and KTX1 peptide\n\n\n\n\n\n\nanalog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-\n\n\n \n\n\n\n\n\n\n \n\n\nhand\n\n\nSEQ\n\n\n\n\n\n\n \n\n\ndesig-\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nnation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nGVEINVKCSGSPQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\n \nKTX1\n \n\n\n24\n\n\n\n\n\n\n \n\n\n\n\n\n\nVRIPVSCKHSGQCLKPCKDAGMRFGKCMNGKCDCTPK\n\n\nKTX2\n\n\n326\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVEINVSCSGSPQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\nKTX1-\n\n\n327\n\n\n\n\n\n\n \n\n\nS7\n\n\n\n\n\n\n \n\n\n\n\n\n\nGVEINVACSGSPQCLKPCKDAGMRFGKCMNRKCHCTPK\n\n\nKTX1-\n\n\n328\n\n\n\n\n\n\n \n\n\nA7\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 12\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nIKCa1 inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-\n\n\n \n\n\n\n\n\n\n \n\n\nhand\n\n\nSEQ\n\n\n\n\n\n\n \n\n\ndesig-\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nnation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\n \nMTX\n \n\n\n20\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\n \nChTx\n \n\n\n36\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTQESCTASNQCWSICKRLHNTNRGKCMNKKCRCYS\n\n\nChTx-Lq2\n\n\n329\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 13\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nMaurotoxin (MTx) peptide amd MTx peptide\n\n\n\n\n\n\nanalog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-\n\n\n \n\n\n\n\n\n\n \n\n\nhand\n\n\nSEQ\n\n\n\n\n\n\n \n\n\ndesig-\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\nnation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX\n\n\n20\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCAGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A4\n\n\n330\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGAKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A6\n\n\n331\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSADCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A7\n\n\n332\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCAAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A10\n\n\n333\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCQKQTGCPNAKCINKSCKCYGC\n\n\nMTX-Q14\n\n\n334\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRQQTGCPNAKCINKSCKCYGC\n\n\nMTX-Q15\n\n\n335\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCQQQTGCPNAKCINKSCKCYGC\n\n\nMTX-\n\n\n336\n\n\n\n\n\n\n \n\n\nQ14, 15\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYAC\n\n\nMTX-A33\n\n\n337\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPYGKCMNRKCKCNRC\n\n\nMTX-\n\n\n338\n\n\n\n\n\n\n \n\n\nHsTx1\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAACRKQTGCANAKCINKSCKCYGC\n\n\nMTX-\n\n\n339\n\n\n\n\n\n\n \n\n\nA12, 20\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGX\nM19\n \n\n\nMTX-\n\n\n340\n\n\n\n\n\n\nPNAKCINKSCKCYGX\nM34\n \n\n\nX19, 34\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGSPNAKCINKSCKCYGS\n\n\nMTX-\n\n\n341\n\n\n\n\n\n\n \n\n\nS19, 34\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSADCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A7\n\n\n342\n\n\n\n\n\n\n \n\n\n\n\n\n\nVVIGQRCTGSKDCYAPCRKQTGCPNAKCINK\n\n\nTsK-MTX\n\n\n343\n\n\n\n\n\n\nSCKCYGC\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCRGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-R4\n\n\n1301\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCGGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-G4\n\n\n1302\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTTSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-T5\n\n\n1304\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTASKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A5\n\n\n1305\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGTKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-T6\n\n\n1306\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGPKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-P6\n\n\n1307\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCGAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-G10\n\n\n1309\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYRPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-R11\n\n\n1311\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYDPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-D11\n\n\n1312\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKRTGCPNAKCINKSCKCYGC\n\n\nMTX-R16\n\n\n1315\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKETGCPNAKCINKSCKCYGC\n\n\nMTX-E16\n\n\n1316\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPYAKCINKSCKCYGC\n\n\nMTX-Y21\n\n\n1317\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNSKCINKSCKCYGC\n\n\nMTX-S22\n\n\n1318\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNGKCINKSCKCYGC\n\n\nMTX-G22\n\n\n1319\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINRSCKCYGC\n\n\nMTX-R27\n\n\n1320\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKTCKCYGC\n\n\nMTX-T28\n\n\n1321\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKMCKCYGC\n\n\nMTX-M28\n\n\n1322\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKKCKCYGC\n\n\nMTX-K28\n\n\n1323\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCNGC\n\n\nMTX-N32\n\n\n1324\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYRC\n\n\nMTX-R33\n\n\n1325\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGCS\n\n\nMTX-S35\n\n\n1326\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-d1\n\n\n1327\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGCS\n\n\nMTX-\n\n\n1328\n\n\n\n\n\n\n \n\n\nS35 d1\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCAKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A14\n\n\n1329\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRAQTGCPNAKCINKSCKCYGC\n\n\nMTX-A15\n\n\n1330\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAACINKSCKCYGC\n\n\nMTX-A23\n\n\n1331\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINASCKCYGC\n\n\nMTX-A27\n\n\n1332\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCACYGC\n\n\nMTX-A30\n\n\n1333\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCTGSKDCYAPCRKQTGCPNAKCINKSCKCAGC\n\n\nMTX-A32\n\n\n1334\n\n\n\n\n\n\n \n\n\n\n\n\n\nASCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-A1\n\n\n1335\n\n\n\n\n\n\n \n\n\n\n\n\n\nMSCTGSKDCYAPCRKQTGCPNAKCINKSCKCYGC\n\n\nMTX-M1\n\n\n1336\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nIn Table 13 and throughout this specification, X\nm19 \nand X\nm34 \nare each independently nonfunctional residues.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 14\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCharybdotoxin(ChTx) peptide and ChTx peptide\n\n\n \n\n\n\n\n\n\nanalog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\n \nChTx\n \n\n\n36\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKCMNKECRCYS\n\n\nChTx-\nE32\n \n\n\n59\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKCMNKDCRCYS\n\n\nChTx-D32\n\n\n344\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-d1-d6\n\n\n345\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLFGVDRGKCMGKKCRCYQ\n\n\nChTx-IbTx\n\n\n346\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSRGKCMNGKCRCYS\n\n\nChTx-G31\n\n\n1369\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECLSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-L14\n\n\n1370\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECASVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A14\n\n\n1371\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWAVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A15\n\n\n1372\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWPVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-P15\n\n\n1373\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSACQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A16\n\n\n1374\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSPCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-P16\n\n\n1375\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKECWSVCQRLHNTSAGKCMNKKCRCYS\n\n\nChTx-A25\n\n\n1376\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVACTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A6\n\n\n1377\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVKCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-K6\n\n\n1378\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTAKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A10\n\n\n1379\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTPKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-P10\n\n\n1380\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKACWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A12\n\n\n1381\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTNVSCTTSKQCWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-Q12\n\n\n1382\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A1\n\n\n1383\n\n\n\n\n\n\n \n\n\n\n\n\n\nTFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-T1\n\n\n1384\n\n\n\n\n\n\n \n\n\n\n\n\n\nQATNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A2\n\n\n1385\n\n\n\n\n\n\n \n\n\n\n\n\n\nQITNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-I2\n\n\n1386\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFANVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-A3\n\n\n1387\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFINVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS\n\n\nChTx-I3\n\n\n1388\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVKCTSPKQCLPPCKAQFGTSRGKCMNKKCRCYSP\n\n\nChTx-MgTx\n\n\n1389\n\n\n\n\n\n\n \n\n\n\n\n\n\nTIINVSCTSPKQCLPPCKAQFGTSRGKCMNKKCRCYSP\n\n\nChTx-MgTx-b\n\n\n1390\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 15\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nSKCa inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nCNCKAPETALCARRCQQHG\n\n\nApamin\n\n\n68\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFCNLRMCQLSCRSLGLLGKCIGDKCECVKH\n\n\nScyTx\n\n\n51\n\n\n\n\n\n\n \n\n\n\n\n\n\nAVCNLKRCQLSCRSLGLLGKCIGDKCECVKHG\n\n\n \nBmP05\n \n\n\n50\n\n\n\n\n\n\n \n\n\n\n\n\n\nTVCNLRRCQLSCRSLGLLGKCIGVKCECVKH\n\n\nP05\n\n\n52\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFCNLRRCELSCRSLGLLGKCIGEECKCVPY\n\n\nTamapin\n\n\n53\n\n\n\n\n\n\n \n\n\n\n\n\n\nVSCEDCPEHCSTQKAQAKCDNDKCVCEPI\n\n\n \nP01\n \n\n\n16\n\n\n\n\n\n\n \n\n\n\n\n\n\nVVIGQRCYRSPDCYSACKKLVGKATGKCTNGRCDC\n\n\n \nTsK\n \n\n\n47\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 16\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nApamin peptide and peptide analog\n\n\n\n\n\n\ninhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nShort-hand\n\n\n \n\n\n\n\n\n\n \n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nCNCKAPETALCARRCQQHG\n\n\nApamin (Ap)\n\n\n68\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCXAPETALCARRCQQHG\n\n\nAp-X4\n\n\n348\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCAAPETALCARRCQQHG\n\n\nAp-A4\n\n\n349\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCKAPETALCAXRCQQHG\n\n\nAp-X13\n\n\n350\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCKAPETALCAARCQQHG\n\n\nAp-A13\n\n\n351\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCKAPETALCARXCQQHG\n\n\nAp-X14\n\n\n352\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCNCKAPETALCARACQQHG\n\n\nAp-A14\n\n\n353\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 17\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nScyllatoxin (ScyTx), BmP05, P05,\n\n\n\n\n\n\nTamapin, P01 peptide\n\n\n\n\n\n\nand peptide analog inhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAFCNLRMCQLSCRSLGLLGKCIGDKCECVKH\n\n\nScyTx\n\n\n51\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFCNLRRCQLSCRSLGLLGKCIGDKCECVKH\n\n\nScyTx-R7\n\n\n354\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFCNLRMCQLSCRSLGLLGKCMGKKCRCVKH\n\n\nScyTx-IbTx\n\n\n355\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFSNLRMCQLSCRSLGLLGKSIGDKCECVKH\n\n\nScyTx-C/S\n\n\n356\n\n\n\n\n\n\n \n\n\n\n\n\n\nAFCNLRRCELSCRSLGLLGKCIGEECKCVPY\n\n\nTamapin\n\n\n53\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 18\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nBKCa inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKD\n\n\nIbTx\n\n\n38\n\n\n\n\n\n\nLFGVDRGKCMGKKCRCYQ\n\n\n\n\n\n\n \n\n\n\n\n\n\nTFIDVDCTVSKECWAPCKAA\n\n\nSlotoxin\n\n\n39\n\n\n\n\n\n\nFGVDRGKCMGKKCKCYV\n\n\n(SloTx)\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nQFTDVKCTGSKQCWPVCK\n \n \nBmTx1\n \n \n\n\n40\n\n\n\n\n\n\nQMFGKPNGKCMNGKCRCYS\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAF\n\n\nBuTx\n\n\n41\n\n\n\n\n\n\nGRAHGKCMNKCRCYTN\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKV\n\n\nMartenTx\n\n\n35\n\n\n\n\n\n\nTGSGQGKCQNNQCRCY\n\n\n\n\n\n\n \n\n\n\n\n\n\nITINVKCTSPQQCLRPCKDRFGQ\n\n\n \nCIITx1\n \n\n\n29\n\n\n\n\n\n\nHAGGKCINGKCKCYP\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 19\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nIbTx, Slotoxin, BmTx1, & BuTX (Slotoxin family) peptide\n\n\n \n\n\n\n\n\n\nand peptide analog inhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGKKCRCYQ\n\n\n \nIbTx\n \n\n\n38\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSXECWSVCKDLFGVDRGKCMGKKCRCYQ\n\n\nIbTx-X11\n\n\n357\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSAECWSVCKDLFGVDRGKCMGKKCRCYQ\n\n\nIbTx-A11\n\n\n358\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCXDLFGVDRGKCMGKKCRCYQ\n\n\nIbTx-X18\n\n\n359\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCADLFGVDRGKCMGKKCRCYQ\n\n\nIbTx-A18\n\n\n360\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDXGKCMGKKCRCYQ\n\n\nIbTx-\nX25\n \n\n\n361\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDAGKCMGKKCRCYQ\n\n\nIbTx-A25\n\n\n362\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGXCMGKKCRCYQ\n\n\nIbTx-X27\n\n\n363\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGACMGKKCRCYQ\n\n\nIbTx-A27\n\n\n364\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGXKCRCYQ\n\n\nIbTx-X31\n\n\n365\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGAKCRCYQ\n\n\nIbTx-A31\n\n\n366\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGKXCRCYQ\n\n\nIbTx-X32\n\n\n367\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGKACRCYQ\n\n\nIbTx-A32\n\n\n368\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGKKCXCYQ\n\n\nIbTx-X34\n\n\n369\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVDCSVSKECWSVCKDLFGVDRGKCMGKKCACYQ\n\n\nIbTx-A34\n\n\n370\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1\n\n\n371\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVXCTGSKQCWPVCKQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-X6\n\n\n372\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVACTGSKQCWPVCKQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-A6\n\n\n373\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSXQCWPVCKQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-X11\n\n\n374\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSAQCWPVCKQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-A11\n\n\n375\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCXQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-X18\n\n\n376\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCAQMFGKPNGKCMNGKCRCYS\n\n\nBmTx1-A18\n\n\n377\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGXPNGKCMNGKCRCYS\n\n\nBmTx1-X23\n\n\n378\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGAPNGKCMNGKCRCYS\n\n\nBmTx1-A23\n\n\n379\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGXCMNGKCRCYS\n\n\nBmTx1-X27\n\n\n380\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGACMNGKCRCYS\n\n\nBmTx1-A27\n\n\n381\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKCMNGXCRCYS\n\n\nBmTx1-X32\n\n\n382\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKCMNGARCYS\n\n\nBmTx1-A32\n\n\n383\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKCMNGKCXYS\n\n\nBmTx1-X34\n\n\n384\n\n\n\n\n\n\n \n\n\n\n\n\n\nQFTDVKCTGSKQCWPVCKQMFGKPNGKCMNGKCAYS\n\n\nBmTx1-A34\n\n\n385\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGKCMNNKCRCYTN\n\n\nBuTx\n\n\n386\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASXCYDPCFKAFGRAHGKCMNNKCRCYTN\n\n\nBuTx-X14\n\n\n387\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASACYDPCFKAFGRAHGKCMNNKCRCYTN\n\n\nBuTx-A14\n\n\n388\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFXFGRAHGKCMNNKCRCYTN\n\n\nBuTx-X22\n\n\n389\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFAGRAHGKCMNNKCRCYTN\n\n\nBuTx-A22\n\n\n390\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGXHGKCMNNKCRCYTN\n\n\nBuTx-X26\n\n\n391\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGAHGKCMNNKCRCYTN\n\n\nBuTx-A26\n\n\n392\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGXMNNKCRCYTN\n\n\nBuTx-X30\n\n\n393\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGAMNNKCRCYTN\n\n\nBuTx-A30\n\n\n394\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGKCMNNXRCYTN\n\n\nBuTx-X35\n\n\n395\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGKCMNNARCYTN\n\n\nBuTx-A35\n\n\n396\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGKCMNNKCXYTN\n\n\nBuTx-X37\n\n\n397\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCSTCLDLACGASRECYDPCFKAFGRAHGKCMNNKCAYTN\n\n\nBuTx-A37\n\n\n398\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 20\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nMartentoxin peptide and peptide analog inhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKVTGSGQGKCQNNQCRCY\n\n\nMartenTx\n\n\n35\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVXCFASSECWTACKKVTGSGQGKCQNNQCRCY\n\n\nMartenTx-X7\n\n\n399\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVACFASSECWTACKKVTGSGQGKCQNNQCRCY\n\n\nMartenTx-A7\n\n\n400\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACXKVTGSGQGKCQNNQCRCY\n\n\nMartenTx-X19\n\n\n401\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACAKVTGSGQGKCQNNQCRCY\n\n\nMartenTx-A19\n\n\n402\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKXVTGSGQGKCQNNQCRCY\n\n\nMartenTx-X20\n\n\n403\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKAVTGSGQGKCQNNQCRCY\n\n\nMartenTx-A20\n\n\n404\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKVTGSGQGXCQNNQCRCY\n\n\nMartenTx-X28\n\n\n405\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKVTGSGQGACQNNQCRCY\n\n\nMartenTx-A28\n\n\n406\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKVTGSGQGKCQNNQCXCY\n\n\nMartenTx-X35\n\n\n407\n\n\n\n\n\n\n \n\n\n\n\n\n\nFGLIDVKCFASSECWTACKKVTGSGQGKCQNNQCACY\n\n\nMartenTx-A35\n\n\n408\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 21\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nN type Ca\n2+ \nchannel inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA\n\n\n65\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTKRCY\n\n\nGVIA\n\n\n64\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSKGAKCSKLMYDCCTGSCSGTVGRC\n\n\nCVIA\n\n\n409\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKLKGQSCRKTSYDCCSGSCGRSGKC\n\n\nSVIB\n\n\n347\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPRAWCSSYANKCL\n\n\nPtu1\n\n\n66\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGASCRKTMYDCCRGSCRSGRC\n\n\nCVIB\n\n\n1364\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGQSCSKLMYDCCTGSCSRRGKC\n\n\nCVIC\n\n\n1365\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSKGAKCSKLMYDCCSGSCSGTVGRC\n\n\nCVID\n\n\n1366\n\n\n\n\n\n\n \n\n\n\n\n\n\nCLSXGSSCSXTSYNCCRSCNXYSRKCY\n\n\nTVIA\n\n\n1367\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 22\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nωMVIIA peptide and peptide analog\n\n\n\n\n\n\ninhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA\n\n\n65\n\n\n\n\n\n\n \n\n\n\n\n\n\nCXGKGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA-\nX2\n \n\n\n410\n\n\n\n\n\n\n \n\n\n\n\n\n\nCAGKGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA-A2\n\n\n411\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGXGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA-X4\n\n\n412\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGAGAKCSRLMYDCCTGSCRSGKC\n\n\nMVIIA-A4\n\n\n413\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAXCSRLMYDCCTGSCRSGKC\n\n\nMVIIA-X7\n\n\n414\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAACSRLMYDCCTGSCRSGKC\n\n\nMVIIA-A7\n\n\n415\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSXLMYDCCTGSCRSGKC\n\n\nMVIIA-X10\n\n\n416\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSALMYDCCTGSCRSGKC\n\n\nMVIIA-A10\n\n\n417\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCXSGKC\n\n\nMVIIA-X21\n\n\n418\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCASGKC\n\n\nMVIIA-A21\n\n\n419\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCRSGXC\n\n\nMVIIA-X24\n\n\n420\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAKCSRLMYDCCTGSCRSGAC\n\n\nMVIIA-\nA24\n \n\n\n421\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 23\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n□GVIA peptide and peptide analog\n\n\n\n\n\n\ninhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTKRCY\n\n\nGVIA\n\n\n64\n\n\n\n\n\n\n \n\n\n\n\n\n\nCXSPGSSCSPTSYNCCRSCNPYTKRCY\n\n\nGVIA-X2\n\n\n422\n\n\n\n\n\n\n \n\n\n\n\n\n\nCASPGSSCSPTSYNCCRSCNPYTKRCY\n\n\nGVIA-A2\n\n\n423\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCXSCNPYTKRCY\n\n\nGVIA-X17\n\n\n424\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCASCNPYTKRCY\n\n\nGVIA-A17\n\n\n425\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTXRCY\n\n\nGVIA-X24\n\n\n426\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTARCY\n\n\nGVIA-A24\n\n\n427\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTKXCY\n\n\nGVIA-X25\n\n\n428\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKSPGSSCSPTSYNCCRSCNPYTKACY\n\n\nGVIA-A25\n\n\n429\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 24\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nPtu1 peptide and peptide analog\n\n\n\n\n\n\ninhibitor sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPRAWCSSYANKCL\n\n\nPtu1\n\n\n66\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEXDCIAPGAPCFGTDKPCCNPRAWCSSYANKCL\n\n\nPtu1-X3\n\n\n430\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEADCIAPGAPCFGTDKPCCNPRAWCSSYANKCL\n\n\nPtu1-A3\n\n\n431\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDXPCCNPRAWCSSYANKCL\n\n\nPtu1-X17\n\n\n432\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDAPCCNPRAWCSSYANKCL\n\n\nPtu1-A17\n\n\n433\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPXAWCSSYANKCL\n\n\nPtu1-X23\n\n\n434\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPAAWCSSYANKCL\n\n\nPtu1-A23\n\n\n435\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPRAWCSSYANXCL\n\n\nPtu1-X32\n\n\n436\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEKDCIAPGAPCFGTDKPCCNPRAWCSSYANACL\n\n\nPtu1-A32\n\n\n437\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 25\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nThrixopelma pruriens (ProTx1) and ProTx1\n\n\n\n\n\n\npeptide analogs and other T type\n\n\n\n\n\n\nCa\n2+ \nchannel inhibitor\n\n\n\n\n\n\npeptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nECRYWLGGCSAGQTCCKHLVCSRRHGWC\n\n\n \nProTx1\n \n\n\n56\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECXYWLGGCSAGQTCCKHLVCSRRHGWC\n\n\nProTx1-X3\n\n\n438\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECAYWLGGCSAGQTCCKHLVCSRRHGWC\n\n\nProTx1-A3\n\n\n439\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCXHLVCSRRHGWC\n\n\nProTx1-X17\n\n\n440\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCAHLVCSRRHGWC\n\n\nProTx1-A17\n\n\n441\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCKHLVCSXRHGWC\n\n\nProTx1-X23\n\n\n442\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCKHLVCSARHGWC\n\n\nProTx1-A23\n\n\n443\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCKHLVCSRXHGWC\n\n\nProTx1-X24\n\n\n444\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYWLGGCSAGQTCCKHLVCSRAHGWC\n\n\nProTx1-A24\n\n\n445\n\n\n\n\n\n\nVWDGTFS\n\n\n\n\n\n\n \n\n\n\n\n\n\nKIDGYPVDYW NCKRICWYNN KYCNDLCKGL\n\n\nKurtoxin\n\n\n1276\n\n\n\n\n\n\nKADSGYCWGW TLSCYCQGLP DNARIKRSGR\n\n\n\n\n\n\nCRA\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 26\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nBeKM1 M current inhibitor peptide and BeKM1\n\n\n\n\n\n\npeptide analog sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1\n\n\n63\n\n\n\n\n\n\n \n\n\n\n\n\n\nPTDIKCSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-d1\n\n\n446\n\n\n\n\n\n\n \n\n\n\n\n\n\nXPTDIKCSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-X1\n\n\n447\n\n\n\n\n\n\n \n\n\n\n\n\n\nAPTDIKCSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-A1\n\n\n448\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIXCSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-X6\n\n\n449\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIACSESYQCFPVCKSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-A6\n\n\n450\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCXSRFGKTNGRCVNGFCDCF\n\n\nBeKM1-X18\n\n\n451\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCASRFGKTNGRCVNGFCDCF\n\n\nBeKM1-A18\n\n\n452\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSXFGKTNGRCVNGFCDCF\n\n\nBeKM1-X20\n\n\n453\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSAFGKTNGRCVNGFCDCF\n\n\nBeKM1-A20\n\n\n454\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSRFGXTNGRCVNGFCDCF\n\n\nBeKM1-X23\n\n\n455\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSRFGATNGRCVNGFCDCF\n\n\nBeKM1-A23\n\n\n456\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSRFGKTNGXCVNGFCDCF\n\n\nBeKM1-X27\n\n\n457\n\n\n\n\n\n\n \n\n\n\n\n\n\nRPTDIKCSESYQCFPVCKSRFGKTNGACVNGFCDCF\n\n\nBeKM1-A27\n\n\n458\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 27\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nNa\n+ \nchannel inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ ID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nQRCCNGRRGCSSRWCRDHSRCC\n\n\nSmIIIa\n\n\n459\n\n\n\n\n\n\n \n\n\n\n\n\n\nRDCCTOOKKCKDRQCKOQRCCA\n\n\nμ-GIIIA\n\n\n460\n\n\n\n\n\n\n \n\n\n\n\n\n\nRDCCTOORKCKDRRCKOMRCCA\n\n\nμ-GIIIB\n\n\n461\n\n\n\n\n\n\n \n\n\n\n\n\n\nZRLCCGFOKSCRSRQCKOHRCC\n\n\nμ-PIIIA\n\n\n462\n\n\n\n\n\n\n \n\n\n\n\n\n\nZRCCNGRRGCSSRWCRDHSRCC\n\n\nμ-SmIIIA\n\n\n463\n\n\n\n\n\n\n \n\n\n\n\n\n\nACRKKWEYCIVPIIGFIYCCPGLICGPFVCV\n\n\nμO-MrVIA\n\n\n464\n\n\n\n\n\n\n \n\n\n\n\n\n\nACSKKWEYCIVPIIGFIYCCPGLICGPFVCV\n\n\nμO-MrVIB\n\n\n465\n\n\n\n\n\n\n \n\n\n\n\n\n\nEACYAOGTFCGIKOGLCCSEFCLPGVCFG\n\n\nδ-PVIA\n\n\n466\n\n\n\n\n\n\n \n\n\n\n\n\n\nDGCSSGGTFCGIHOGLCCSEFCFLWCITFID\n\n\nδ-SVIE\n\n\n467\n\n\n\n\n\n\n \n\n\n\n\n\n\nWCKQSGEMCNLLDQNCCDGYCIVLVCT\n\n\nδ-TxVIA\n\n\n468\n\n\n\n\n\n\n \n\n\n\n\n\n\nVKPCRKEGQLCDPIFQNCCRGWNCVLFCV\n\n\nδ-GmVIA\n\n\n469\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 28\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCl\n− \nchannel inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\n \n\n\n \n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nSEQ ID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR\n\n\nCTX\n\n\n67\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMAXKCDDCCGGKGRGKCYGPQCLCR\n\n\nCTX-X14\n\n\n470\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMAAKCDDCCGGKGRGKCYGPQCLCR\n\n\nCTX-A14\n\n\n471\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARXCDDCCGGKGRGKCYGPQCLCR\n\n\nCTX-X15\n\n\n472\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARACDDCCGGKGRGKCYGPQCLCR\n\n\nCTX-A15\n\n\n473\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGXGRGKCYGPQCLCR\n\n\nCTX-X23\n\n\n474\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGAGRGKCYGPQCLCR\n\n\nCTX-A23\n\n\n475\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGXGKCYGPQCLCR\n\n\nCTX-X25\n\n\n476\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGAGKCYGPQCLCR\n\n\nCTX-A25\n\n\n477\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGXCYGPQCLCR\n\n\nCTX-X27\n\n\n478\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGACYGPQCLCR\n\n\nCTX-A27\n\n\n479\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCX\n\n\nCTX-X36\n\n\n480\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCA\n\n\nCTX-A36\n\n\n481\n\n\n\n\n\n\n \n\n\n\n\n\n\nMCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLC\n\n\nCTX-d36\n\n\n482\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCRECCGGNGKCFGPQCLCNRE\n\n\nBm-12b\n\n\n483\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMAXKCRECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-X17\n\n\n484\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMAAKCRECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-A17\n\n\n485\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARXCRECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-X18\n\n\n486\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARACRECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-A18\n\n\n487\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCXECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-X20\n\n\n488\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCAECCGGNGKCFGPQCLCNRE\n\n\nBm-12b-A20\n\n\n489\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCRECCGGNGXCFGPQCLCNRE\n\n\nBm-12b-X28\n\n\n490\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCRECCGGNGACFGPQCLCNRE\n\n\nBm-12b-A28\n\n\n491\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCRECCGGNGKCFGPQCLCNXE\n\n\nBm-12b-X38\n\n\n492\n\n\n\n\n\n\n \n\n\n\n\n\n\nQTDGCGPCFTTDANMARKCRECCGGNGKCFGPQCLCNAE\n\n\nBm-12b-A38\n\n\n493\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 29\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nKv2.1 inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCKFRDKYCAWDFTFS\n\n\nHaTx1\n\n\n494\n\n\n\n\n\n\n \n\n\n\n\n\n\nECXYLFGGCKTTSDCCKHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-X3\n\n\n495\n\n\n\n\n\n\n \n\n\n\n\n\n\nECAYLFGGCKTTSDCCKHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-A3\n\n\n496\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCXTTSDCCKHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-X10\n\n\n497\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCATTSDCCKHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-A10\n\n\n498\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCXHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-X17\n\n\n499\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCAHLGCKFRDKYCAWDFTFS\n\n\nHaTx1-A17\n\n\n500\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCXFRDKYCAWDFTFS\n\n\nHaTx1-X22\n\n\n501\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCAFRDKYCAWDFTFS\n\n\nHaTx1-A22\n\n\n502\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCKFXDKYCAWDFTFS\n\n\nHaTx1-X24\n\n\n503\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCKFADKYCAWDFTFS\n\n\nHaTx1-A24\n\n\n504\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCKFRDXYCAWDFTFS\n\n\nHaTx1-X26\n\n\n505\n\n\n\n\n\n\n \n\n\n\n\n\n\nECRYLFGGCKTTSDCCKHLGCKFRDAYCAWDFTFS\n\n\nHaTx1-A26\n\n\n506\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 30\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nKv4.3 & Kv4.2 inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nSEQ\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nID NO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCRLWCKRIINM\n\n\n \nPaTx2\n \n\n\n57\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQXWMWTCDEERKCCEGLVCRLWCKRIINM\n\n\nPaTx2-X4\n\n\n507\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQAWMWTCDEERKCCEGLVCRLWCKRIINM\n\n\nPaTx2-A4\n\n\n508\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEEXKCCEGLVCRLWCKRIINM\n\n\nPaTx2-X13\n\n\n509\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEEAKCCEGLVCRLWCKRIINM\n\n\nPaTx2-A13\n\n\n510\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERXCCEGLVCRLWCKRIINM\n\n\nPaTx2-X14\n\n\n511\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERACCEGLVCRLWCKRIINM\n\n\nPaTx2-A14\n\n\n512\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCXLWCKRIINM\n\n\nPaTx2-X22\n\n\n513\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCALWCKRIINM\n\n\nPaTx2-A22\n\n\n514\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCRLWCXRIINM\n\n\nPaTx2-X26\n\n\n515\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCRLWCARIINM\n\n\nPaTx2-A26\n\n\n516\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCRLWCKXIINM\n\n\nPaTx2-X27\n\n\n517\n\n\n\n\n\n\n \n\n\n\n\n\n\nYCQKWMWTCDEERKCCEGLVCRLWCKAIINM\n\n\nPaTx2-A27\n\n\n518\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 31\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nnACHR channel inhibitor peptide sequences\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCAANNPDYC\n\n\nPnIA\n\n\n519\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCALNNPDYC\n\n\nPnIA-L10\n\n\n520\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCAASNPDYC\n\n\nPnIA-S11\n\n\n521\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCALSNPDYC\n\n\nPnIB\n\n\n522\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCAASNPDYC\n\n\nPnIB-A10\n\n\n523\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSLPPCALNNPDYC\n\n\nPnIB-N11\n\n\n524\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSNPVCHLEHSNLC\n\n\nMII\n\n\n525\n\n\n\n\n\n\n \n\n\n\n\n\n\nGRCCHPACGKNYSC\n\n\nα-MI\n\n\n526\n\n\n\n\n\n\n \n\n\n\n\n\n\nRD(hydroxypro)CCYHPTCNMSNPQIC\n\n\nα-EI\n\n\n527\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSYPPCFATNPDC\n\n\nα-AuIB\n\n\n528\n\n\n\n\n\n\n \n\n\n\n\n\n\nRDPCCSNPVCTVHNPQIC\n\n\nα-PIA\n\n\n529\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSDPRCAWRC\n\n\nα-ImI\n\n\n530\n\n\n\n\n\n\n \n\n\n\n\n\n\nACCSDRRCRWRC\n\n\nα-ImII\n\n\n531\n\n\n\n\n\n\n \n\n\n\n\n\n\nECCNPACGRHYSC\n\n\nα-GI\n\n\n532\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCGSY(hydroxypro)NAACH(hydroxypro)\n\n\nαA-PIVA\n\n\n533\n\n\n\n\n\n\nCSCKDR (hydroxypro)SYCGQ\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCPY(hydroxypro)NAACH(hydroxypro)\n\n\nαA-EIVA\n\n\n534\n\n\n\n\n\n\nCGCKVGR(hydroxypro)(hydroxypro)YCDR\n\n\n\n\n\n\n(hydroxypro)S\n\n\n\n\n\n\nGG\n\n\n\n\n\n\n \n\n\n\n\n\n\nH(hydroxypro)(hydroxypro)CCLYGKCRRY\n\n\nψ-PIIIE\n\n\n535\n\n\n\n\n\n\n(hydroxypro)GCSSASCCQR\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSDPRCNMNNPDYC\n\n\nEpI\n\n\n536\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSHPACAGNNQHIC\n\n\nGIC\n\n\n537\n\n\n\n\n\n\n \n\n\n\n\n\n\nIRD(γ-carboxyglu) CCSNPACRVNN\n\n\nGID\n\n\n538\n\n\n\n\n\n\n(hydroxypro)HVC\n\n\n\n\n\n\n \n\n\n\n\n\n\nGGCCSHPACAANNQDYC\n\n\nAnIB\n\n\n539\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSYPPCFATNSDYC\n\n\nAuIA\n\n\n540\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCCSYPPCFATNSGYC\n\n\nAuIC\n\n\n541\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 32\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAgelenopsis aperta (Agatoxin) toxin peptides\n\n\n\n\n\n\nand peptide analogs and other Ca\n2+\n channel\n\n\n\n\n\n\ninhibiter peptides\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\nSEQ\n\n\n\n\n\n\n \n\n\nShort-hand\n\n\nID\n\n\n\n\n\n\nSequence/structure\n\n\ndesignation\n\n\nNO:\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nKKKCIAKDYG RCKWGGTPCC RGRGCICSIM\n\n\nω-Aga-IVA\n\n\n959\n\n\n\n\n\n\nGTNCECKPRL IMEGLGLA\n\n\n\n\n\n\n \n\n\n\n\n\n\nEDNCIAEDYG KCTWGGTKCC RGRPCRCSMI\n\n\nω-Aga-IVB\n\n\n960\n\n\n\n\n\n\nGTNCECTPRL IMEGLSFA\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDIGGDCD GEKDDCQCCR RNGYCSCYSL\n\n\nω-Aga-IIIA\n\n\n961\n\n\n\n\n\n\nFGYLKSGCKC VVGTSAEFQG ICRRKARQCY\n\n\n\n\n\n\nNSDPDKCESH NKPKRR\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDIGGDCD GEKDDCQCCR RNGYCSCYSL\n\n\nω-Aga-IIIA-\n\n\n962\n\n\n\n\n\n\nFGYLKSGCKC VVGTSAEFQG ICRRKARTCY\n\n\nT58\n\n\n\n\n\n\nNSDPDKCESH NKPKRR\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDFGGDCD GEKDDCQCCR SNGYCSCYSL\n\n\nω-Aga-IIIB\n\n\n963\n\n\n\n\n\n\nFGYLKSGCKC EVGTSAEFRR ICRRKAKQCY\n\n\n\n\n\n\nNSDPDKCVSV YKPKRR\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDFGGDCD GEKDDCQCCR SNGYCSCYNL\n\n\nω-Aga-IIIB-\n\n\n964\n\n\n\n\n\n\nFGYLKSGCKC EVGTSAEFRR\n\n\nN29\n\n\n\n\n\n\nICRRKAKQCYNSDPDKCVSV YKPKRR\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIDFGGDCD GEKDDCQCCR SNGYCSCYNL\n\n\nω-Aga-IIIB-\n\n\n965\n\n\n\n\n\n\nFGYLRSGCKC EVGTSAEFRR ICRRKAKQCY\n\n\nN29/R35\n\n\n\n\n\n\nNSDPDKCVSV YKPKRR\n\n\n\n\n\n\n \n\n\n\n\n\n\nNCIDFGGDCD GEKDDCQCCX RNGYCSCYNL\n\n\nω-Aga-IIIC\n\n\n966\n\n\n\n\n\n\nFGYLKRGCKX EVG\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCIKIGEDCD GDKDDCQCCR TNGYCSXYXL\n\n\nω-Aga-IIID\n\n\n967\n\n\n\n\n\n\nFGYLKSG\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCIEIGGDCD GYQEKSYCQC CRNNGFCS\n\n\nω-Aga-IIA\n\n\n968\n\n\n\n\n\n\n \n\n\n\n\n\n\nAKAL PPGSVCDGNE SDCKCYGKWH\n\n\nω-Aga-IA\n\n\n969\n\n\n\n\n\n\nKCRCPWKWHF TGEGPCTCEK GMKHTCITKL\n\n\n(major\n\n\n\n\n\n\nHCPNKAEWGL DW\n\n\nchain)\n\n\n\n\n\n\n \n\n\n\n\n\n\nECVPENGHCR DWYDECCEGF YCSCRQPPKC\n\n\nμ-Aga\n\n\n970\n\n\n\n\n\n\nICRNNNX\n\n\n\n\n\n\n \n\n\n\n\n\n\nDCVGESQQCA DWAGPHCCDG YYCTCRYFPK\n\n\nμ-Aga-6\n\n\n971\n\n\n\n\n\n\nCICVNNN\n\n\n\n\n\n\n \n\n\n\n\n\n\nACVGENKQCA DWAGPHCCDG YYCTCRYFPK\n\n\nμ-Aga-5\n\n\n972\n\n\n\n\n\n\nCICRNNN\n\n\n\n\n\n\n \n\n\n\n\n\n\nACVGENQQCA DWAGPHCCDG YYCTCRYFPK\n\n\nμ-Aga-4\n\n\n973\n\n\n\n\n\n\nCICRNNN\n\n\n\n\n\n\n \n\n\n\n\n\n\nADCVGDGQRC ADWAGPYCCS GYYCSCRSMP\n\n\nμ-Aga-3\n\n\n1275\n\n\n\n\n\n\nYCRCRSDS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECATKNKRCA DWAGPWCCDG LYCSCRSYPG\n\n\nμ-Aga-2\n\n\n974\n\n\n\n\n\n\nCMCRPSS\n\n\n\n\n\n\n \n\n\n\n\n\n\nECVPENGHCR DWYDECCEGF YCSCRQPPKC\n\n\nμ-Aga-1\n\n\n975\n\n\n\n\n\n\nICRNNN\n\n\n\n\n\n\n \n\n\n\n\n\n\nAELTSCFPVGHECDGDASNCNCCGDDVYCGC\n\n\nTx-1\n\n\n1277\n\n\n\n\n\n\nGWGRWNCKCKVADQSYAYGICKDKVNCPNRHL\n\n\n\n\n\n\nWPAKVCKKPCRREC\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCANAYKSCNGPHTCCWGYNGYKKACICSGX\n\n\nTx3-3\n\n\n1278\n\n\n\n\n\n\nNWK\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCINVGDFCDGKKDCCQCDRDNAFCSCSVIFG\n\n\nTx3-4\n\n\n1279\n\n\n\n\n\n\nYKTNCRCE\n\n\n\n\n\n\n \n\n\n\n\n\n\nSCINVGDFCDGKKDDCQCCRDNAFCSCSVI\n\n\nω-PtXIIA\n\n\n1280\n\n\n\n\n\n\nFGYKTNCRCEVGTTATSYGICMAKHKCGRQT\n\n\n\n\n\n\nTCTKPCLSKRCKKNH\n\n\n\n\n\n\n \n\n\n\n\n\n\nAECLMIGDTSCVPRLGRRCCYGAWCYCDQQL\n\n\nDw13.3\n\n\n1281\n\n\n\n\n\n\nSCRRVGRKRECGWVEVNCKCGWSWSQRID\n\n\n\n\n\n\nDWRADYSCKCPEDQ\n\n\n\n\n\n\n \n\n\n\n\n\n\nGGCLPHNRFCNALSGPRCCSGLKCKELSIW\n\n\nAgelenin\n\n\n1282\n\n\n\n\n\n\nDSRCL\n\n\n\n\n\n\n \n\n\n\n\n\n\nDCVRFWGKCSQTSDCCPHLACKSKWP\n\n\nω-GTx-SIA\n\n\n1283\n\n\n\n\n\n\nRNICVWDGSV\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCLEVDYFCG IPFANNGLCC SGNCVF\n\n\nω-conotoxin\n\n\n1284\n\n\n\n\n\n\nVCTP Q\n\n\nPnVIA\n\n\n\n\n\n\n \n\n\n\n\n\n\nDDDCEPPGNF CGMIKIGPPC CSGWCFFACA\n\n\nω-conotoxin\n\n\n1285\n\n\n\n\n\n\n \n\n\nPnVIB\n\n\n\n\n\n\n \n\n\n\n\n\n\nVCCGYKLCHP C\n\n\nLambda-\n\n\n1286\n\n\n\n\n\n\n \n\n\nconotoxin\n\n\n\n\n\n\n \n\n\nCMrVIA\n\n\n\n\n\n\n \n\n\n\n\n\n\nMRCLPVLIIL LLLTASAPGV VVLPKTEDDV\n\n\nLambda-\n\n\n1287\n\n\n\n\n\n\nPMSSVYGNGK SILRGILRNG\n\n\nconotoxin\n\n\n\n\n\n\nVCCGYKLCHP C\n\n\nCMrVIB\n\n\n\n\n\n\n \n\n\n\n\n\n\nKIDGYPVDYW NCKRICWYNN KYCNDLCKGL\n\n\nKurtoxin\n\n\n1276\n\n\n\n\n\n\nKADSGYCWGW TLSCYCQGLP DNARIKRSGR\n\n\n\n\n\n\nCRA\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKGKGAPCRKTMYDCCSGSCGRRGKC\n\n\nMVIIC\n\n\n1368\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nIn accordance with this invention are molecules in which at least one of the toxin peptide (P) portions of the molecule comprises a Kv1.3 antagonist peptide. Amino acid sequences selected from ShK, HmK, MgTx, AgTx1, AgTx2, Heterometrus spinnifer (HsTx1), OSK1, Anuroctoxin (AnTx), Noxiustoxin (NTX), KTX1, Hongotoxin, ChTx, Titystoxin, BgK, BmKTX, BmTx, AeK, AsKS Tc30, Tc32, Pi1, Pi2, and/or Pi3 toxin peptides and peptide analogs of any of these are preferred. Examples of useful Kv1.3 antagonist peptide sequences include those having any amino acid sequence set forth in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, and/or Table 11 herein above;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is an IKCa1 antagonist peptide. Useful IKCa1 antagonist peptides include Maurotoxin (MTx), ChTx, peptides and peptide analogs of either of these, examples of which include those having any amino acid sequence set forth in Table 12, Table 13, and/or Table 14;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a SKCa inhibitor peptide. Useful SKCa inhibitor peptides include, Apamin, ScyTx, BmP05, P01, P05, Tamapin, TsK, and peptide analogs of any of these, examples of which include those having any amino acid sequence set forth in Table 15;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is an apamin peptide, and peptide analogs of apamin, examples of which include those having any amino acid sequence set forth in Table 16;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Scyllotoxin family peptide, and peptide analogs of any of these, examples of which include those having any amino acid sequence set forth in Table 17;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a BKCa inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 18;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Slotoxin family peptide, and peptide analogs of any of these, examples of which include those having any amino acid sequence set forth in Table 19;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Martentoxin peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 20;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a N-type Ca\n2+\n channel inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 21;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a ωMVIIA peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 22;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a ωGVIA peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 23;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Ptu1 peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 24;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a ProTx1 peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 25;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a BeKM1 peptide, and peptide analogs thereof, examples of which include those having any amino acid sequence set forth in Table 26;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Na\n+\n channel inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 27;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Cl\n−\n channel inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 28;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Kv2.1 inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 29;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a Kv4.2/Kv4.3 inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 30;\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is a nACHR inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 31; and\n\n\nOther embodiments of the inventive composition include at least one toxin peptide (P) that is an Agatoxin peptide, a peptide analog thereof or other calcium channel inhibitor peptide, examples of which include those having any amino acid sequence set forth in Table 32.\n\n\nHalf-life extending moieties. This invention involves the presence of at least one half-life extending moiety (F\n1 \nand/or F\n2 \nin Formula I) attached to a peptide through the N-terminus, C-terminus or a sidechain of one of the intracalary amino acid residues. Multiple half-life extending moieties can also be used; e.g., Fc's at each terminus or an Fc at a terminus and a PEG group at the other terminus or at a sidechain. In other embodiments the Fc domain can be PEGylated (e.g., in accordance with the formulae F\n1\n—F\n2\n-(L)\nf\n-P; P-(L)\ng\n-F\n1\n—F\n2\n; or P-(L)\n9\n-F\n1\n—F\n2\n-(L)\nf\n-P).\n\n\nThe half-life extending moiety can be selected such that the inventive composition achieves a sufficient hydrodynamic size to prevent clearance by renal filtration in vivo. For example, a half-life extending moiety can be selected that is a polymeric macromolecule, which is substantially straight chain, branched-chain, or dendritic in form. Alternatively, a half-life extending moiety can be selected such that, in vivo, the inventive composition of matter will bind to a serum protein to form a complex, such that the complex thus formed avoids substantial renal clearance. The half-life extending moiety can be, for example, a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor.\n\n\nExemplary half-life extending moieties that can be used, in accordance with the present invention, include an immunoglobulin Fc domain, or a portion thereof, or a biologically suitable polymer or copolymer, for example, a polyalkylene glycol compound, such as a polyethylene glycol or a polypropylene glycol. Other appropriate polyalkylene glycol compounds include, but are not limited to, charged or neutral polymers of the following types: dextran, polylysine, colominic acids or other carbohydrate based polymers, polymers of amino acids, and biotin derivatives. In some monomeric fusion protein embodiments an immunoglobulin (including light and heavy chains) or a portion thereof, can be used as a half-life-extending moiety, preferably an immunoglobulin of human origin, and including any of the immunoglobulins, such as, but not limited to, IgG1, IgG2, IgG3 or IgG4.\n\n\nOther examples of the half-life extending moiety, in accordance with the invention, include a copolymer of ethylene glycol, a copolymer of propylene glycol, a carboxymethylcellulose, a polyvinyl pyrrolidone, a poly-1,3-dioxolane, a poly-1,3,6-trioxane, an ethylene/maleic anhydride copolymer, a polyaminoacid (e.g., polylysine), a dextran n-vinyl pyrrolidone, a poly n-vinyl pyrrolidone, a propylene glycol homopolymer, a propylene oxide polymer, an ethylene oxide polymer, a polyoxyethylated polyol, a polyvinyl alcohol, a linear or branched glycosylated chain, a polyacetal, a long chain fatty acid, a long chain hydrophobic aliphatic group, an immunoglobulin light chain and heavy chain, an immunoglobulin Fc domain or a portion thereof (see, e.g., Feige et al., Modified peptides as therapeutic agents, U.S. Pat. No. 6,660,843), a CH2 domain of Fc, an albumin (e.g., human serum albumin (HSA)); see, e.g., Rosen et al., Albumin fusion proteins, U.S. Pat. No. 6,926,898 and US 2005/0054051; Bridon et al., Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components, U.S. Pat. No. 6,887,470), a transthyretin (TTR; see, e.g., Walker et al., Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins, US 2003/0195154 A1; 2003/0191056 A1), or a thyroxine-binding globulin (TBG). Thus, exemplary embodiments of the inventive compositions also include HSA fusion constructs such as but not limited to: HSA fusions with ShK, OSK1, or modified analogs of those toxin peptides. Examples include HSA-L10-ShK(2-35); HSA-L10-OsK1(1-38); HSA-L10-ShK(2-35); and HSA-L10-OsK1(1-38).\n\n\nOther embodiments of the half-life extending moiety, in accordance with the invention, include peptide ligands or small (organic) molecule ligands that have binding affinity for a long half-life serum protein under physiological conditions of temperature, pH, and ionic strength. Examples include an albumin-binding peptide or small molecule ligand, a transthyretin-binding peptide or small molecule ligand, a thyroxine-binding globulin-binding peptide or small molecule ligand, an antibody-binding peptide or small molecule ligand, or another peptide or small molecule that has an affinity for a long half-life serum protein. (See, e.g., Blaney et al., Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands, U.S. Pat. No. 5,714,142; Sato et al., Serum albumin binding moieties, US 2003/0069395 A1; Jones et al., Pharmaceutical active conjugates, U.S. Pat. No. 6,342,225). A “long half-life serum protein” is one of the hundreds of different proteins dissolved in mammalian blood plasma, including so-called “carrier proteins” (such as albumin, transferrin and haptoglobin), fibrinogen and other blood coagulation factors, complement components, immunoglobulins, enzyme inhibitors, precursors of substances such as angiotensin and bradykinin and many other types of proteins. The invention encompasses the use of any single species of pharmaceutically acceptable half-life extending moiety, such as, but not limited to, those described herein, or the use of a combination of two or more different half-life extending moieties, such as PEG and immunoglobulin Fc domain or a CH2 domain of Fc, albumin (e.g., HSA), an albumin-binding protein, transthyretin or TBG, or a combination such as immunoglobulin (light chain+heavy chain) and Fc domain (the combination so-called “hemibody”).\n\n\nIn some embodiments of the invention an Fc domain or portion thereof, such as a CH2 domain of Fc, is used as a half-life extending moiety. The Fc domain can be fused to the N-terminal (e.g., in accordance with the formula F\n1\n-(L)\nf\n-P) or C-terminal (e.g., in accordance with the formula P-(L)\ng\n-F\n1\n) of the toxin peptides or at both the N and C termini (e.g., in accordance with the formulae F\n1\n-(L)\nf\n-P-(L)\ng\n-F\n2 \nor P-(L)\ng\n-F\n1\n-(L)\nf\n-P). A peptide linker sequence can be optionally included between the Fc domain and the toxin peptide, as described herein. Examples of the formula F\n1\n-(L)\nf\n-P include: Fc-L10-ShK(K22A)[2-35]; Fc-L10-ShK(R1K/K22A)[1-35]; Fc-L10-ShK(R1H/K22A)[1-35]; Fc-L10-ShK(R1Q/K22A)[1-35]; Fc-L10-ShK(R1Y/K22A)[1-35]; Fc-L10-PP-ShK(K22A) [1-35]; and any other working examples described herein. Examples of the formula P-(L)\ng\n-F\n1 \ninclude: ShK(1-35)-L10-Fc; OsK1(1-38)-L10-Fc; Met-ShK(1-35)-L10-Fc; ShK(2-35)-L10-Fc; Gly-ShK(1-35)-L10-Fc; Osk1(1-38)-L10-Fc; and any other working examples described herein.\n\n\nFc variants are suitable half-life extending moieties within the scope of this invention. A native Fc can be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631, WO 96/32478, and WO 04/110 472. In such Fc variants, one can remove one or more sites of a native Fc that provide structural features or functional activity not required by the fusion molecules of this invention. One can remove these sites by, for example, substituting or deleting residues, inserting residues into the site, or truncating portions containing the site. The inserted or substituted residues can also be altered amino acids, such as peptidomimetics or D-amino acids. Fc variants can be desirable for a number of reasons, several of which are described below. Exemplary Fc variants include molecules and sequences in which:\n\n \n \n \n \n1. Sites involved in disulfide bond formation are removed. Such removal can avoid reaction with other cysteine-containing proteins present in the host cell used to produce the molecules of the invention. For this purpose, the cysteine-containing segment at the N-terminus can be truncated or cysteine residues can be deleted or substituted with other amino acids (e.g., alanyl, seryl). In particular, one can truncate the N-terminal 20-amino acid segment of SEQ ID NO: 2 or delete or substitute the cysteine residues at \n \npositions\n \n 7 and 10 of SEQ ID NO: 2. Even when cysteine residues are removed, the single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently.\n \n2. A native Fc is modified to make it more compatible with a selected host cell. For example, one can remove the PA sequence near the N-terminus of a typical native Fc, which can be recognized by a digestive enzyme in \nE. coli \nsuch as proline iminopeptidase. One can also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as \nE. coli\n. The Fc domain of SEQ ID NO: 2 (\nFIG. 4A-4B\n) is one such Fc variant.\n \n3. A portion of the N-terminus of a native Fc is removed to prevent N-terminal heterogeneity when expressed in a selected host cell. For this purpose, one can delete any of the first 20 amino acid residues at the N-terminus, particularly those at \n \n \n \n \npositions\n \n \n \n \n 1, 2, 3, 4 and 5.\n \n4. One or more glycosylation sites are removed. Residues that are typically glycosylated (e.g., asparagine) can confer cytolytic response. Such residues can be deleted or substituted with unglycosylated residues (e.g., alanine).\n \n5. Sites involved in interaction with complement, such as the C1q binding site, are removed. For example, one can delete or substitute the EKK sequence of human IgG1. Complement recruitment may not be advantageous for the molecules of this invention and so can be avoided with such an Fc variant.\n \n6. Sites are removed that affect binding to Fc receptors other than a salvage receptor. A native Fc can have sites for interaction with certain white blood cells that are not required for the fusion molecules of the present invention and so can be removed.\n \n7. The ADCC site is removed. ADCC sites are known in the art; see, for example, \nMolec. Immunol. \n29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. These sites, as well, are not required for the fusion molecules of the present invention and so can be removed.\n \n8. When the native Fc is derived from a non-human antibody, the native Fc can be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.\n \n \n \n\n\nPreferred Fc variants include the following. In SEQ ID NO: 2, the leucine at \nposition\n 15 can be substituted with glutamate; the glutamate at position 99, with alanine; and the lysines at \npositions\n 101 and 103, with alanines. In addition, phenyalanine residues can replace one or more tyrosine residues.\n\n\nAn alternative half-life extending moiety would be a protein, polypeptide, peptide, antibody, antibody fragment, or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor. For example, one could use as a half-life extending moiety a polypeptide as described in U.S. Pat. No. 5,739,277, issued Apr. 14, 1998 to Presta et al. Peptides could also be selected by phage display for binding to the FcRn salvage receptor. Such salvage receptor-binding compounds are also included within the meaning of “half-life extending moiety” and are within the scope of this invention. Such half-life extending moieties should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immunogenic sequences, as discovered in antibody humanization).\n\n\nAs noted above, polymer half-life extending moieties can also be used for F\n1 \nand F\n2\n. Various means for attaching chemical moieties useful as half-life extending moieties are currently available, see, e.g., Patent Cooperation Treaty (“PCT”) International Publication No. WO 96/11953, entitled “N-Terminally Chemically Modified Protein Compositions and Methods,” herein incorporated by reference in its entirety. This PCT publication discloses, among other things, the selective attachment of water-soluble polymers to the N-terminus of proteins.\n\n\nIn some embodiments of the inventive compositions, the polymer half-life extending moiety is polyethylene glycol (PEG), as F\n1 \nand/or F\n2\n, but it should be understood that the inventive composition of matter, beyond positions F\n1 \nand/or F\n2\n, can also include one or more PEGs conjugated at other sites in the molecule, such as at one or more sites on the toxin peptide. Accordingly, some embodiments of the inventive composition of matter further include one or more PEG moieties conjugated to a non-PEG half-life extending moiety, which is F\n1 \nand/or F\n2\n, or to the toxin peptide(s) (P), or to any combination of any of these. For example, an Fc domain or portion thereof (as F1 and/or F2) in the inventive composition can be made mono-PEGylated, di-PEGylated, or otherwise multi-PEGylated, by the process of reductive alkylation.\n\n\nCovalent conjugation of proteins and peptides with poly(ethylene glycol) (PEG) has been widely recognized as an approach to significantly extend the in vivo circulating half-lives of therapeutic proteins. PEGylation achieves this effect predominately by retarding renal clearance, since the PEG moiety adds considerable hydrodynamic radius to the protein. (Zalipsky, S., et al., Use of functionalized poly(ethylene glycol)s for modification of polypeptides., in poly(ethylene glycol) chemistry: Biotechnical and biomedical applications., J. M. Harris, Ed., Plenum Press: New York., 347-370 (1992)). Additional benefits often conferred by PEGylation of proteins and peptides include increased solubility, resistance to proteolytic degradation, and reduced immunogenicity of the therapeutic polypeptide. The merits of protein PEGylation are evidenced by the commercialization of several PEGylated proteins including PEG-Adenosine deaminase (Adagen™/Enzon Corp.), PEG-L-asparaginase (Oncaspar™/Enzon Corp.), PEG-Interferon α-2b (PEG-Intron™/Schering/Enzon), PEG-Interferon α-2a (PEGASYS™/Roche) and PEG-G-CSF (Neulasta™/Amgen) as well as many others in clinical trials.\n\n\nBriefly, the PEG groups are generally attached to the peptide portion of the composition of the invention via acylation or reductive alkylation (or reductive amination) through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group).\n\n\nA useful strategy for the PEGylation of synthetic peptides consists of combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other. The peptides can be easily prepared with conventional solid phase synthesis (see, for example, \nFIGS. 5 and 6\n and the accompanying text herein). The peptides are “preactivated” with an appropriate functional group at a specific site. The precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC. The PEGylated peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.\n\n\nPEG is a well-known, water soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, Polymer Synthesis, Academic Press, New York, Vol. 3, pages 138-161). In the present application, the term “PEG” is used broadly to encompass any polyethylene glycol molecule, in mono-, bi-, or poly-functional form, without regard to size or to modification at an end of the PEG, and can be represented by the formula:\n\n\nX—O(CH\n2\nCH\n2\nO)\nn-1\nCH\n2\nCH\n2\nOH,  (X)\n\n\n\nwhere n is 20 to 2300 and X is H or a terminal modification, e.g., a C\n1-4 \nalkyl.\n\n\nIn some useful embodiments, a PEG used in the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CH\n3 \n(“methoxy PEG”). It is noted that the other end of the PEG, which is shown in formula (II) terminating in OH, covalently attaches to an activating moiety via an ether oxygen bond, an amine linkage, or amide linkage. When used in a chemical structure, the term “PEG” includes the formula (II) above without the hydrogen of the hydroxyl group shown, leaving the oxygen available to react with a free carbon atom of a linker to form an ether bond. More specifically, in order to conjugate PEG to a peptide, the peptide must be reacted with PEG in an “activated” form. Activated PEG can be represented by the formula:\n\n\n(PEG)-(A)  (XI)\n\n\nwhere PEG (defined supra) covalently attaches to a carbon atom of the activation moiety (A) to form an ether bond, an amine linkage, or amide linkage, and (A) contains a reactive group which can react with an amino, azido, alkyne, imino, maleimido, N-succinimidyl, carboxyl, aminooxy, seleno, or thiol group on an amino acid residue of a peptide or a linker moiety covalently attached to the peptide, e.g., the OSK1 peptide analog. Residues baring chemoselective reactive groups can be introduced into the toxin peptide, e.g., an OSK1 peptide analog during assembly of the peptide sequence solid-phase synthesis as protected derivatives. Alternatively, chemoselective reactive groups can be introduced in the toxin peptide after assembly of the peptide sequence by solid-phase synthesis via the use of orthogonal protecting groups at specific sites. Examples of amino acid residues useful for chemoselective reactions include, but are not limited to, (amino-oxyacetyl)-L-diaminopropionic acid, p-azido-phenylalanine, azidohomolalanine, para-propargyloxy-phenylalanine, selenocysteine, para-acetylphenylalanine, (N\nε\n-levulinyl)-Lysine, (N\nε\n-pyruvyl)-Lysine, selenocysteine, and orthogonally protected cysteine and homocysteine.\n\n\n\nAccordingly, in some embodiments of the composition of matter, the toxin peptide, e.g., the OSK1 peptide analog, is conjugated to a polyethylene glycol (PEG) at:\n\n\n(a) 1, 2, 3 or 4 amino functionalized sites in the toxin peptide;\n\n\n(b) 1, 2, 3 or 4 thiol functionalized sites in the toxin peptide; (c) 1 or 2 ketone functionalized sites in the toxin peptide; (d) 1 or 2 azido functionalized sites of the toxin peptide; (e) 1 or 2 carboxyl functionalized sites in the toxin peptide; (f) 1 or 2 aminooxy functionalized sites in the toxin peptide; or (g) 1 or 2 seleno functionalized sites in the toxin peptide.\n\n\nIn other embodiments of the composition of matter, the toxin peptide, e.g., the OSK1 peptide analog, is conjugated to a polyethylene glycol (PEG) at:\n\n\n(a) 1, 2, 3 or 4 amino functionalized sites of the PEG;\n\n\n(b) 1, 2, 3 or 4 thiol functionalized sites of the PEG;\n\n\n(c) 1, 2, 3 or 4 maleimido functionalized sites of the PEG;\n\n\n(d) 1, 2, 3 or 4 N-succinimidyl functionalized sites of the PEG;\n\n\n(e) 1, 2, 3 or 4 carboxyl functionalized sites of the PEG; or\n\n\n(f) 1, 2, 3 or 4 p-nitrophenyloxycarbonyl functionalized sites of the PEG.\n\n\nTechniques for the preparation of activated PEG and its conjugation to biologically active peptides are well known in the art. (E.g., see U.S. Pat. Nos. 5,643,575, 5,919,455, 5,932,462, and 5,990,237; Thompson et al., PEGylation of polypeptides, EP 0575545 B1; Petit, Site specific protein modification, U.S. Pat. Nos. 6,451,986, and 6,548,644; S. Herman et al., Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins, J. Bioactive Compatible Polymers, 10:145-187 (1995); Y. Lu et al., Pegylated peptides III: Solid-phase synthesis with PEGylating reagents of varying molecular weight: synthesis of multiply PEGylated peptides, Reactive Polymers, 22:221-229 (1994); A. M. Felix et al., PEGylated Peptides IV: Enhanced biological activity of site-directed PEGylated GRF analogs, Int. J. Peptide Protein Res., 46:253-264 (1995); A. M. Felix, Site-specific poly(ethylene glycol)ylation of peptides, ACS Symposium Series 680(poly(ethylene glycol)): 218-238 (1997); Y. Ikeda et al., Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides, EP 0473084 B1; G. E. Means et al., Selected techniques for the modification of protein side chains, in: Chemical modification of proteins, Holden Day, Inc., 219 (1971)).\n\n\nActivated PEG, such as PEG-aldehydes or PEG-aldehyde hydrates, can be chemically synthesized by known means or obtained from commercial sources, e.g., Shearwater Polymers, (Huntsville, Ala.) or Enzon, Inc. (Piscataway, N.J.).\n\n\nAn example of a useful activated PEG for purposes of the present invention is a PEG-aldehyde compound (e.g., a methoxy PEG-aldehyde), such as PEG-propionaldehyde, which is commercially available from Shearwater Polymers (Huntsville, Ala.). PEG-propionaldehyde is represented by the formula PEG-CH\n2\nCH\n2\nCHO. (See, e.g., U.S. Pat. No. 5,252,714). Other examples of useful activated PEG are PEG acetaldehyde hydrate and PEG bis aldehyde hydrate, which latter yields a bifunctionally activated structure. (See., e.g., Bentley et al., Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines, U.S. Pat. No. 5,990,237).\n\n\nAnother useful activated PEG for generating the PEG-conjugated peptides of the present invention is a PEG-maleimide compound, such as, but not limited to, a methoxy PEG-maleimide, such as maleimido monomethoxy PEG, are particularly useful for generating the PEG-conjugated peptides of the invention. (E.g., Shen, N-maleimidyl polymer derivatives, U.S. Pat. No. 6,602,498; C. Delgado et al., The uses and properties of PEG-linked proteins., Crit. Rev. Therap. Drug Carrier Systems, 9:249-304 (1992); S. Zalipsky et al., Use of functionalized poly(ethylene glycol)s for modification of polypeptides, in: Poly(ethylene glycol) chemistry: Biotechnical and biomedical applications (J. M. Harris, Editor, Plenum Press: New York, 347-370 (1992); S. Herman et al., Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins, J. Bioactive Compatible Polymers, 10:145-187 (1995); P. J. Shadle et al., Conjugation of polymer to colony stimulating factor-1, U.S. Pat. No. 4,847,325; G. Shaw et al., Cysteine added variants IL-3 and chemical modifications thereof, U.S. Pat. No. 5,166,322 and EP 0469074 B1; G. Shaw et al., Cysteine added variants of EPO and chemical modifications thereof, EP 0668353 A1; G. Shaw et al., Cysteine added variants G-CSF and chemical modifications thereof, EP 0668354 A1; N. V. Katre et al., Interleukin-2 muteins and polymer conjugation thereof, U.S. Pat. No. 5,206,344; R. J. Goodson and N. V. Katre, Site-directed pegylation of recombinant interleukin-2 at its glycosylation site, Biotechnology, 8:343-346 (1990)).\n\n\nA poly(ethylene glycol) vinyl sulfone is another useful activated PEG for generating the PEG-conjugated peptides of the present invention by conjugation at thiolated amino acid residues, e.g., at C residues. (E.g., M. Morpurgo et al., Preparation and characterization of poly(ethylene glycol) vinyl sulfone, Bioconj. Chem., 7:363-368 (1996); see also Harris, Functionalization of polyethylene glycol for formation of active sulfone-terminated PEG derivatives for binding to proteins and biologically compatible materials, U.S. Pat. Nos. 5,446,090; 5,739,208; 5,900,461; 6,610,281 and 6,894,025; and Harris, Water soluble active sulfones of poly(ethylene glycol), WO 95/13312 A1).\n\n\nAnother activated form of PEG that is useful in accordance with the present invention, is a PEG-N-hydroxysuccinimide ester compound, for example, methoxy PEG-N-hydroxysuccinimidyl (NHS) ester.\n\n\nHeterobifunctionally activated forms of PEG are also useful. (See, e.g., Thompson et al., PEGylation reagents and biologically active compounds formed therewith, U.S. Pat. No. 6,552,170).\n\n\nTypically, a toxin peptide or, a fusion protein comprising the toxin peptide, is reacted by known chemical techniques with an activated PEG compound, such as but not limited to, a thiol-activated PEG compound, a diol-activated PEG compound, a PEG-hydrazide compound, a PEG-oxyamine compound, or a PEG-bromoacetyl compound. (See, e.g., S. Herman, Poly(ethylene glycol) with Reactive Endgroups: I. Modification of Proteins, J. Bioactive and Compatible Polymers, 10:145-187 (1995); S. Zalipsky, Chemistry of Polyethylene Glycol Conjugates with Biologically Active Molecules, Advanced Drug Delivery Reviews, 16:157-182 (1995); R. Greenwald et al., Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review, Critical Reviews in Therapeutic Drug Carrier Systems, 17:101-161 (2000)).\n\n\nMethods for N-terminal PEGylation are exemplified herein in Examples 31-34, 45 and 47-48, but these are in no way limiting of the PEGylation methods that can be employed by one skilled in the art.\n\n\nAny molecular mass for a PEG can be used as practically desired, e.g., from about 1,000 or 2,000 Daltons (Da) to about 100,000 Da (n is 20 to 2300). Preferably, the combined or total molecular mass of PEG used in a PEG-conjugated peptide of the present invention is from about 3,000 Da or 5,000 Da, to about 50,000 Da or 60,000 Da (total n is from 70 to 1,400), more preferably from about 10,000 Da to about 40,000 Da (total n is about 230 to about 910). The most preferred combined mass for PEG is from about 20,000 Da to about 30,000 Da (total n is about 450 to about 680). The number of repeating units “n” in the PEG is approximated for the molecular mass described in Daltons. It is preferred that the combined molecular mass of PEG on an activated linker is suitable for pharmaceutical use. Thus, the combined molecular mass of the PEG molecule should not exceed about 100,000 Da.\n\n\nPolysaccharide polymers are another type of water-soluble polymer that can be used for protein modification. Dextrans are polysaccharide polymers comprised of individual subunits of glucose predominantly linked by α1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kDa to about 70 kDa. Dextran is a suitable water-soluble polymer for use in the present invention as a half-life extending moiety by itself or in combination with another half-life extending moiety (e.g., Fc). See, for example, WO 96/11953 and WO 96/05309. The use of dextran conjugated to therapeutic or diagnostic immunoglobulins has been reported; see, for example, European Patent Publication No. 0 315 456, which is hereby incorporated by reference in its entirety. Dextran of about 1 kDa to about 20 kDa is preferred when dextran is used as a half-life extending moiety in accordance with the present invention.\n\n\nLinkers. Any “linker” group or moiety (i.e., “-(L)\ng\n-” or “-(L)\ng\n-” in Formulae I-IX) is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer. As stated herein above, the linker moiety (-(L)\nf\n- and/or -(L)\ng\n-), if present, can be independently the same or different from any other linker, or linkers, that may be present in the inventive composition. For example, an “(L)\nf\n” can represent the same moiety as, or a different moiety from, any other “(L)\nf\n” or any “(L)\ng\n” in accordance with the invention. The linker is preferably made up of amino acids linked together by peptide bonds. Some of these amino acids can be glycosylated, as is well understood by those in the art. For example, a useful linker sequence constituting a sialylation site is X\n1\nX\n2\nNX\n4\nX\n5\nG (SEQ ID NO: 637), wherein X\n1\n, X\n2\n, X\n4 \nand X\n5 \nare each independently any amino acid residue.\n\n\nAs stated above, in some embodiments, a peptidyl linker is present (i.e., made up of amino acids linked together by peptide bonds) that is made in length, preferably, of from 1 up to about 40 amino acid residues, more preferably, of from 1 up to about 20 amino acid residues, and most preferably of from 1 to about 10 amino acid residues. Preferably, but not necessarily, the amino acid residues in the linker are from among the twenty canonical amino acids, more preferably, cysteine, glycine, alanine, proline, asparagine, glutamine, and/or serine. Even more preferably, a peptidyl linker is made up of a majority of amino acids that are sterically unhindered, such as glycine, serine, and alanine linked by a peptide bond. It is also desirable that, if present, a peptidyl linker be selected that avoids rapid proteolytic turnover in circulation in vivo. Thus, preferred linkers include polyglycines (particularly (Gly)\n4 \n(SEQ ID NO: 4918), (Gly)\n5\n) (SEQ ID NO: 4919), poly(Gly-Ala), and polyalanines. Other preferred linkers are those identified herein as “L5” (GGGGS; SEQ ID NO: 638), “L10” (GGGGSGGGGS; SEQ ID NO:79), “L25” GGGGSGGGGSGGGGSGGGGSGGGGS; SEQ ID NO:84) and any linkers used in the working examples hereinafter. The linkers described herein, however, are exemplary; linkers within the scope of this invention can be much longer and can include other residues.\n\n\nIn some embodiments of the compositions of this invention, which comprise a peptide linker moiety (L), acidic residues, for example, glutamate or aspartate residues, are placed in the amino acid sequence of the linker moiety (L). Examples include the following peptide linker sequences:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nGGEGGG;\n\n\n(SEQ ID NO: 639)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGGEEEGGG;\n\n\n(SEQ ID NO: 640)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGEEEG;\n\n\n(SEQ ID NO: 641)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGEEE;\n\n\n(SEQ ID NO: 642)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGGDGGG;\n\n\n(SEQ ID NO: 643)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGGDDDGG;\n\n\n(SEQ ID NO: 644)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGDDDG;\n\n\n(SEQ ID NO: 645)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGDDD;\n\n\n(SEQ ID NO: 646)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGGGGSDDSDEGSDGEDGGGGS;\n\n\n(SEQ ID NO: 647)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nWEWEW;\n\n\n(SEQ ID NO: 648)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nFEFEF;\n\n\n(SEQ ID NO: 649)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nEEEWWW;\n\n\n(SEQ ID NO: 650)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nEEEFFF;\n\n\n(SEQ ID NO: 651)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nWWEEEWW;\n\n\n(SEQ ID NO: 652)\n\n\n\n\n\n\n \n\n\nor\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nFFEEEFF.\n\n\n(SEQ ID NO: 653)\n\n\n\n\n\n\n\n\n\n\n\n\nIn other embodiments, the linker constitutes a phosphorylation site, e.g., X\n1\nX\n2\nYX\n3\nX\n4\nG (SEQ ID NO: 654), wherein X\n1\n, X\n2\n, X\n3 \nand X\n4 \nare each independently any amino acid residue; X\n1\nX\n2\nSX\n3\nX\n4\nG (SEQ ID NO: 655), wherein X\n1\n, X\n2\n, X\n3 \nand X\n4 \nare each independently any amino acid residue; or X\n1\nX\n2\nTX\n3\nX\n4\nG (SEQ ID NO: 656), wherein X\n1\n, X\n2\n, X\n3 \nand X\n4 \nare each independently any amino acid residue.\n\n\nNon-peptide linkers are also possible. For example, alkyl linkers such as —NH—(CH\n2\n)\ns\n—C(O)—, wherein s=2-20 could be used. These alkyl linkers can further be substituted by any non-sterically hindering group such as lower alkyl (e.g., C\n1\n-C\n6\n) lower acyl, halogen (e.g., Cl, Br), CN, NH\n2\n, phenyl, etc. An exemplary non-peptide linker is a PEG linker,\n\n\n \n \n \n \n \n \n \n \n \n \n\nwherein n is such that the linker has a molecular weight of 100 to 5000 kDa, preferably 100 to 500 kDa. The peptide linkers can be altered to form derivatives in the same manner as described above.\n\n\n\nUseful linker embodiments also include aminoethyloxyethyloxy-acetyl linkers as disclosed by Chandy et al. (Chandy et al., WO 2006/042151 A2, incorporated herein by reference in its entirety).\n\n\nDerivatives. The inventors also contemplate derivatizing the peptide and/or half-life extending moiety portion of the compounds. Such derivatives can improve the solubility, absorption, biological half-life, and the like of the compounds. The moieties can alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like. Exemplary derivatives include compounds in which:\n\n \n \n1. The compound or some portion thereof is cyclic. For example, the peptide portion can be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation.\n \n2. The compound is cross-linked or is rendered capable of cross-linking between molecules. For example, the peptide portion can be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a like molecule. The compound can also be cross-linked through its C-terminus, as in the molecule shown below.\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n3. Non-peptidyl linkages (bonds) replace one or more peptidyl [—C(O)NR—] linkages. Exemplary non-peptidyl linkages are —CH\n2\n-carbamate [—CH\n2\n—OC(O)NR—], phosphonate, —CH\n2\n-sulfonamide [—CH\n2\n—S(O)\n2\nNR—], urea [—NHC(O)NH—], —CH\n2\n-secondary amine, and alkylated peptide [—C(O)NR\n6\n— wherein R\n6 \nis lower alkyl].\n\n\n4. The N-terminus is chemically derivatized. Typically, the N-terminus can be acylated or modified to a substituted amine. Exemplary N-terminal derivative groups include —NRR\n1 \n(other than —NH\n2\n), —NRC(O)R\n1\n,\n\n\n —NRC(O)OR\n1\n, —NRS(O)\n2\nR\n1\n, —NHC(O)NHR\n1\n, succinimide, or benzyloxycarbonyl-NH— (CBZ-NH—), wherein R and R\n1 \nare each independently hydrogen or lower alkyl and wherein the phenyl ring can be substituted with 1 to 3 substituents selected from the group consisting of C\n1\n-C\n4 \nalkyl, C\n1\n-C\n4 \nalkoxy, chloro, and bromo.\n\n\n5. The free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated. For example, one can use methods described in the art to add (NH—CH\n2\n—CH\n2\n—NH\n2\n)\n2 \nto compounds of this invention having any of SEQ ID NOS: 504 to 508 at the C-terminus. Likewise, one can use methods described in the art to add —NH\n2 \nto compounds of this invention having any of SEQ ID NOS: 924 to 955, 963 to 972, 1005 to 1013, or 1018 to 1023 at the C-terminus. Exemplary C-terminal derivative groups include, for example, —C(O)R\n2 \nwherein R\n2 \nis lower alkoxy or —NR\n3\nR\n4 \nwherein R\n3 \nand R\n4 \nare independently hydrogen or C\n1\n-C\n8 \nalkyl (preferably C\n1\n-C\n4 \nalkyl).\n\n\n6. A disulfide bond is replaced with another, preferably more stable, cross-linking moiety (e.g., an alkylene). See, e.g., Bhatnagar et al. (1996), \nJ. Med. Chem. \n39: 3814-9; Alberts et al. (1993) \nThirteenth Am. Pep. Symp., \n357-9.\n\n\n7. One or more individual amino acid residues are modified. Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.\n\n\n\n\nLysinyl residues and amino terminal residues can be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.\n\n\nArginyl residues can be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents can react with the groups of lysine as well as the arginine epsilon-amino group.\n\n\nSpecific modification of tyrosyl residues has been studied extensively, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.\n\n\nCarboxyl sidechain groups (aspartyl or glutamyl) can be selectively modified by reaction with carbodiimides (R′—N═C═N—R′) such as 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.\n\n\nGlutaminyl and asparaginyl residues can be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.\n\n\nCysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross-linking. See, e.g., Bhatnagar et al. (1996), \nJ. Med. Chem. \n39: 3814-9.\n\n\nDerivatization with bifunctional agents is useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular half-life extending moieties. Commonly used cross-linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.\n\n\nCarbohydrate (oligosaccharide) groups can conveniently be attached to sites that are known to be glycosylation sites in proteins. Generally, O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. X is preferably one of the 19 naturally occurring amino acids other than proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, can confer acidic properties to the glycosylated compound. Such site(s) can be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites can further be glycosylated by synthetic or semi-synthetic procedures known in the art.\n\n\nOther possible modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, oxidation of the sulfur atom in Cys, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains. Creighton, \nProteins: Structure and Molecule Properties \n(W. H. Freeman and Co., San Francisco), pp. 79-86 (1983).\n\n\nCompounds of the present invention can be changed at the DNA level, as well. The DNA sequence of any portion of the compound can be changed to codons more compatible with the chosen host cell. For \nE. coli\n, which is the preferred host cell, optimized codons are known in the art. Codons can be substituted to eliminate restriction sites or to include silent restriction sites, which can aid in processing of the DNA in the selected host cell. The half-life extending moiety, linker and peptide DNA sequences can be modified to include any of the foregoing sequence changes.\n\n\nA process for preparing conjugation derivatives is also contemplated. Tumor cells, for example, exhibit epitopes not found on their normal counterparts. Such epitopes include, for example, different post-translational modifications resulting from their rapid proliferation. Thus, one aspect of this invention is a process comprising:\n\n \n \n \n \na) selecting at least one randomized peptide that specifically binds to a target epitope; and\n \nb) preparing a pharmacologic agent comprising (i) at least one half-life extending moiety (Fc domain preferred), (ii) at least one amino acid sequence of the selected peptide or peptides, and (iii) an effector molecule.\n\n\nThe target epitope is preferably a tumor-specific epitope or an epitope specific to a pathogenic organism. The effector molecule can be any of the above-noted conjugation partners and is preferably a radioisotope.\n\n \n \n \n\n\nMethods of Making\n\n\nThe present invention also relates to nucleic acids, expression vectors and host cells useful in producing the polypeptides of the present invention. Host cells can be eukaryotic cells, with mammalian cells preferred and CHO cells most preferred. Host cells can also be prokaryotic cells, with \nE. coli \ncells most preferred.\n\n\nThe compounds of this invention largely can be made in transformed host cells using recombinant DNA techniques. To do so, a recombinant DNA molecule coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques could be used.\n\n\nThe invention also includes a vector capable of expressing the peptides in an appropriate host. The vector comprises the DNA molecule that codes for the peptides operatively linked to appropriate expression control sequences. Methods of effecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known. Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.\n\n\nThe resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation can be performed using methods well known in the art.\n\n\nAny of a large number of available and well-known host cells can be used in the practice of this invention. The selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts can be equally effective for the expression of a particular DNA sequence. Within these general guidelines, useful microbial hosts include bacteria (such as \nE. coli \nsp.), yeast (such as \nSaccharomyces \nsp.) and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.\n\n\nNext, the transformed host is cultured and purified. Host cells can be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art. Finally, the peptides are purified from culture by methods well known in the art.\n\n\nIn some embodiments of the inventive DNA, the DNA encodes a recombinant fusion protein composition of the invention, preferably, but not necessarily, monovalent with respect to the toxin peptide, for expression in a mammalian cell, such as, but not limited to, CHO or HEK293. The encoded fusion protein includes (a)-(c) immediately below, in the N-terminal to C-terminal direction:\n\n\n(a) an immunoglobulin, which includes the constant and variable regions of the immunoglobulin light and heavy chains, or a portion of an immunoglobulin (e.g., an Fc domain, or the variable regions of the light and heavy chains); if both immunoglobulin light chain and heavy chain components are to be included in the construct, then a peptidyl linker, as further described in (b) immediately below, is also included to separate the immunoglobulin components (See, e.g., \nFIG. 92A-C\n); useful coding sequences for immunoglobulin light and heavy chains are well known in the art;\n\n\n(b) a peptidyl linker, which is at least 4 (or 5) amino acid residues long and comprises at least one protease cleavage site (e.g., a furin cleavage site, which is particularly useful for intracellular cleavage of the expressed fusion protein); typically, the peptidyl linker sequence can be up to about 35 to 45 amino acid residues long (e.g., a 7× L5 linker modified to include the desired protease cleavage site(s)), but linkers up to about 100 to about 300 amino acid residues long are also useful; and\n\n\n(c) an immunoglobulin Fc domain or a portion thereof. The Fc domain of (c) can be from the same type of immunoglobulin in (a), or different. In such embodiments, the DNA encodes a toxin peptide covalently linked to the N-terminal or C-terminal end of (a) or (c) above, either directly or indirectly via a peptidyl linker (a linker minus a protease cleavage site). Any toxin peptide or peptide analog thereof as described herein can be encoded by the DNA (e.g., but not limited to, ShK, HmK, MgTx, AgTx1, AgTx2, HsTx1, OSK1, Anuroctoxin, Noxiustoxin, Hongotoxin, HsTx1, ChTx, MTx, Titystoxin, BgK, BmKTX, BmTx, Tc30, Tc32, Pi1, Pi2, Pi3 toxin peptide, or a peptide analog of any of these). For example, an OSK1 peptide analog comprising an amino acid sequence selected from SEQ ID NOS: 25, 294 through 298, 562 through 636, 980 through 1274, 1303, 1308, 1391 through 4912, 4916, 4920 through 5006, 5009, 5010, and 5012 through 5015, as set forth in Tables 7 and Tables 7A-J, can be employed. Alternatively, an ShK peptide analog comprising an amino acid sequence selected from SEQ ID NOS: 5, 88 through 200, 548 through 561, 884 through 950, and 1295 through 1300 as set forth in Table 2, can be employed. Any other toxin peptide sequence described herein that can alternatively be expressed recombinantly using recombinant and protein engineering techniques known in the art can also be used. The immunoglobulin of (a) and (c) above can be in each instance independently selected from any desired type, such as but not limited to, IgG1, IgG2, IgG3, and IgG4. The variable regions can be non-functional in vivo (e.g., CDRs specifically binding KLH), or alternatively, if targeting enhancement function is also desired, the variable regions can be chosen to specifically bind (non-competitively) the ion channel target of the toxin peptide (e.g., Kv1.3) or specifically bind another antigen typically found associated with, or in the vicinity of, the target ion channel. In addition, the inventive DNA optionally further encodes, 5′ to the coding region of (a) above, a signal peptide sequence (e.g., a secretory signal peptide) operably linked to the expressed fusion protein. An example of the inventive DNA encoding a recombinant fusion protein for expression in a mammalian cell, described immediately above, is a DNA that encodes a fusion protein comprising, in the N-terminal to C-terminal direction:\n\n\n(a) an immunoglobulin light chain;\n\n\n(b) a first peptidyl linker at least 4 amino acid residues long comprising at least one protease cleavage site, as described above;\n\n\n(c) an immunoglobulin heavy chain;\n\n\n(d) a second peptidyl linker at least 4 amino acid residues long comprising at least one protease cleavage site, as described above; and\n\n\n(e) an immunoglobulin Fc domain or a portion thereof. Here, the Fc domain of (e) can be from the same type of immunoglobulin as the heavy chain in (c), or different. The DNA encodes a toxin peptide covalently linked to the N-terminal or C-terminal end of (a), (c), or (e) of the expressed fusion protein, either directly or indirectly via a peptidyl linker (a linker minus a protease cleavage site). \nFIG. 92A-C\n illustrates schematically an embodiment, in which the toxin peptide (e.g., an OSK1, ShK, or a peptide analog of either of these) is covalently linked to the C-terminal end of the Fc domain of (e). In \nFIG. 92A-C\n, a linker is shown covalently linking the toxin peptide to the rest of the molecule, but as previously described, this linker is optional.\n\n\nIn some embodiments particularly suited for the recombinant expression of monovalent dimeric Fc-toxin peptide fusions or “peptibodies” (see, \nFIG. 2B\n and Example 56) by mammalian cells, such as, but not limited to, CHO or HEK293, the inventive DNA encodes a recombinant expressed fusion protein that comprises, in the N-terminal to C-terminal direction:\n\n \n \n \n \n(a) a first immunoglobulin Fc domain or portion thereof;\n \n(b) a peptidyl linker at least 4 (or 5) amino acid residues long comprising at least one protease cleavage site (e.g., a furin cleavage site, which is particularly useful for intracellular cleavage of the expressed fusion protein); typically, the peptidyl linker sequence can be up to about 35 to 45 amino acid residues long (e.g., a 7×L5 linker modified to include the desired protease cleavage site(s)), but linkers up to about 100 to about 300 amino acid residues long are also useful; and\n \n(c) a second immunoglobulin Fc domain or portion thereof (which may be the same or different from the first Fc domain, but should be expressed in the same orientation as the first Fc domain).\n\n\nFor such embodiments, the DNA encodes a toxin peptide covalently linked to the N-terminal or C-terminal end of (a) or (c) of the expressed fusion protein, either directly or indirectly via a peptidyl linker (a linker minus a protease cleavage site); Example 56 describes an embodiment in which the toxin peptide is conjugated to the C-terminal end of the second immunoglobulin Fc domain (c). Any toxin peptide or peptide analog thereof as described herein can be encoded by the DNA (e.g., but not limited to, ShK, HmK, MgTx, AgTx1, AgTx2, HsTx1, OSK1, Anuroctoxin, Noxiustoxin, Hongotoxin, HsTx1, ChTx, MTx, Titystoxin, BgK, BmKTX, BmTx, Tc30, Tc32, Pi1, Pi2, Pi3 toxin peptide, or a peptide analog of any of these). For example, an OSK1 peptide analog comprising an amino acid sequence selected from SEQ ID NOS: 25, 294 through 298, 562 through 636, 980 through 1274, 1303, 1308, 1391 through 4912, 4916, 4920 through 5006, 5009, 5010, and 5012 through 5015, as set forth in Tables 7 and Tables 7A-J, can be employed. Alternatively, an ShK peptide analog comprising an amino acid sequence selected from SEQ ID NOS: 5, 88 through 200, 548 through 561, 884 through 950, and 1295 through 1300 as set forth in Table 2, can be employed. Any other toxin peptide sequence described herein that can alternatively be expressed using recombinant and protein engineering techniques known in the art can also be used. In addition, the inventive DNA optionally further encodes, 5′ to the coding region of (a) above, a signal peptide sequence (e.g., a secretory signal peptide) operably linked to the expressed fusion protein.\n\n \n \n \n\n\nDNA constructs similar to those described above are also useful for recombinant expression by mammalian cells of other dimeric Fc fusion proteins (“peptibodies”) or chimeric immunoglobulin (light chain+heavy chain)-Fc heterotrimers (“hemibodies”), conjugated to pharmacologically active peptides (e.g., agonist or antagonist peptides) other than toxin peptides.\n\n\nPeptide compositions of the present invention can also be made by synthetic methods. Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides. For example, well known solid phase synthesis techniques include the use of protecting groups, linkers, and solid phase supports, as well as specific protection and deprotection reaction conditions, linker cleavage conditions, use of scavengers, and other aspects of solid phase peptide synthesis. Suitable techniques are well known in the art. (E.g., Merrifield (1973), \nChem. Polypeptides\n, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), \nJ. Am. Chem. Soc. \n85: 2149; Davis et al. (1985), \nBiochem. Intl. \n10: 394-414; Stewart and Young (1969), \nSolid Phase Peptide Synthesis\n; U.S. Pat. No. 3,941,763; Finn et al. (1976), \nThe Proteins \n(3rd ed.) 2: 105-253; and Erickson et al. (1976), \nThe Proteins \n(3rd ed.) 2: 257-527; “Protecting Groups in Organic Synthesis,” 3rd Edition, T. W. Greene and P. G. M. Wuts, Eds., John Wiley & Sons, Inc., 1999; NovaBiochem Catalog, 2000; “Synthetic Peptides, A User's Guide,” G. A. Grant, Ed., W.H. Freeman & Company, New York, N.Y., 1992; “Advanced Chemtech Handbook of Combinatorial & Solid Phase Organic Chemistry,” W. D. Bennet, J. W. Christensen, L. K. Hamaker, M. L. Peterson, M. R. Rhodes, and H. H. Saneii, Eds., Advanced Chemtech, 1998; “Principles of Peptide Synthesis, 2nd ed.,” M. Bodanszky, Ed., Springer-Verlag, 1993; “The Practice of Peptide Synthesis, 2nd ed.,” M. Bodanszky and A. Bodanszky, Eds., Springer-Verlag, 1994; “Protecting Groups,” P. J. Kocienski, Ed., Georg Thieme Verlag, Stuttgart, Germany, 1994; “Fmoc Solid Phase Peptide Synthesis, A Practical Approach,” W. C. Chan and P. D. White, Eds., Oxford Press, 2000, G. B. Fields et al., Synthetic Peptides: A User's Guide, 1990, 77-183).\n\n\nWhether the compositions of the present invention are prepared by synthetic or recombinant techniques, suitable protein purification techniques can also be involved, when applicable. In some embodiments of the compositions of the invention, the toxin peptide portion and/or the half-life extending portion, or any other portion, can be prepared to include a suitable isotopic label (e.g., \n125\nI, \n14\nC, \n13\nC, \n35\nS, \n3\nH, \n2\nH, \n13\nN, \n15\nN, \n18\nO, \n17\nO, etc.), for ease of quantification or detection.\n\n\nCompounds that contain derivatized peptides or which contain non-peptide groups can be synthesized by well-known organic chemistry techniques.\n\n\nUses of the Compounds\n\n\nIn general. The compounds of this invention have pharmacologic activity resulting from their ability to bind to proteins of interest as agonists, mimetics or antagonists of the native ligands of such proteins of interest. Heritable diseases that have a known linkage to ion channels (“channelopathies”) cover various fields of medicine, some of which include neurology, nephrology, myology and cardiology. A list of inherited disorders attributed to ion channels includes:\n\n \n \n \n \ncystic fibrosis (Cl\n−\n channel; CFTR),\n \nDent's disease (proteinuria and hypercalciuria; Cl\n−\n channel; CLCN5),\n \nosteopetrosis (Cl\n−\n channel; CLCN7),\n \nfamilial hyperinsulinemia (SUR1; KCNJ11; K channel),\n \ndiabetes (KATP/SUR channel),\n \nAndersen syndrome (KCNJ2, Kir2.1 K channel),\n \nBartter syndrome (KCNJ1; Kir1.1/ROMK; K channel),\n \nhereditary hearing loss (KCNQ4; K channel),\n \nhereditary hypertension (Liddle's syndrome; SCNN1; epithelial Na channel),\n \ndilated cardiomyopathy (SUR2, K channel),\n \nlong-QT syndrome or cardiac arrhythmias (cardiac potassium and sodium channels),\n \nThymothy syndrome (CACNA1C, Cav1.2),\n \nmyasthenic syndromes (CHRNA, CHRNB, CNRNE; nAChR), and a variety of other myopathies,\n \nhyperkalemic periodic paralysis (Na and K channels),\n \nepilepsy (Na\n+\n and K\n+\n channels),\n \nhemiplegic migraine (CACNA1A, Cav2.1 Ca\n2+\n channel and ATP1A2),\n \ncentral core disease (RYR1, RYR1; Ca\n2+\n channel), and\n \nparamyotonia and myotonia (Na\n+\n, Cl\n−\n channels)\n\n\nSee L. J. Ptacek and Y-H Fu (2004), \nArch. Neurol. \n61: 166-8; B. A. Niemeyer et al. (2001), \nEMBO reports \n21: 568-73; F. Lehmann-Horn and K. Jurkat-Rott (1999), \nPhysiol. Rev. \n79: 1317-72. Although the foregoing list concerned disorders of inherited origin, molecules targeting the channels cited in these disorders can also be useful in treating related disorders of other, or indeterminate, origin.\n\n \n \n \n\n\nIn addition to the aforementioned disorders, evidence has also been provided supporting ion channels as targets for treatment of:\n\n \n \n \n \nsickle cell anemia (IKCa1)—in sickle cell anemia, water loss from erythrocytes leads to hemoglobin polymerization and subsequent hemolysis and vascular obstruction. The water loss is consequent to potassium efflux through the so-called Gardos channel i.e., IKCa1. Therefore, block of IKCa1 is a potential therapeutic treatment for sickle cell anemia.\n \nglaucoma (BKCa),—in glaucoma the intraocular pressure is too high leading to optic nerve damage, abnormal eye function and possibly blindness. Block of BKCa potassium channels can reduce intraocular fluid secretion and increase smooth muscle contraction, possibly leading to lower intraocular pressure and neuroprotection in the eye.\n \nmultiple sclerosis (Kv, KCa),\n \npsoriasis (Kv, KCa),\n \narthritis (Kv, KCa),\n \nasthma (KCa, Kv),\n \nallergy (KCa, Kv),\n \nCOPD (KCa, Kv, Ca),\n \nallergic rhinitis (KCa, Kv),\n \npulmonary fibrosis,\n \nlupus (IKCa1, Kv),\n \ntransplantation, GvHD (KCa, Kv),\n \ninflammatory bone resorption (KCa, Kv),\n \nperiodontal disease (KCa, Kv),\n \ndiabetes, type I (Kv),—type I diabetes is an autoimmune disease that is characterized by abnormal glucose, protein and lipid metabolism and is associated with insulin deficiency or resistance. In this disease, Kv1.3-expressing T-lymphocytes attack and destroy pancreatic islets leading to loss of beta-cells. Block of Kv1.3 decreases inflammatory cytokines. In addition block of Kv1.3 facilitates the translocation of GLUT4 to the plasma membrane, thereby increasing insulin sensitivity.\n \nobesity (Kv),—Kv1.3 appears to play a critical role in controlling energy homeostasis and in protecting against diet-induced obesity. Consequently, Kv1.3 blockers could increase metabolic rate, leading to greater energy utilization and decreased body weight.\n \nrestenosis (KCa, Ca\n2+\n),—proliferation and migration of vascular smooth muscle cells can lead to neointimal thickening and vascular restenosis. Excessive neointimal vascular smooth muscle cell proliferation is associated with elevated expression of IKCa1. Therefore, block of IKCa1 could represent a therapeutic strategy to prevent restenosis after angioplasty.\n \nischaemia (KCa, Ca\n2+\n),—in neuronal or cardiac ischemia, depolarization of cell membranes leads to opening of voltage-gated sodium and calcium channels. In turn this can lead to calcium overload, which is cytotoxic. Block of voltage-gated sodium and/or calcium channels can reduce calcium overload and provide cytoprotective effects. In addition, due to their critical role in controlling and stabilizing cell membrane potential, modulators of voltage- and calcium-activated potassium channels can also act to reduce calcium overload and protect cells.\n \nrenal incontinence (KCa), renal incontinence is associated with overactive bladder smooth muscle cells. Calcium-activated potassium channels are expressed in bladder smooth muscle cells, where they control the membrane potential and indirectly control the force and frequency of cell contraction. Openers of calcium-activated potassium channels therefore provide a mechanism to dampen electrical and contractile activity in bladder, leading to reduced urge to urinate.\n \nosteoporosis (Kv),\n \npain, including migraine (Na\nv\n, TRP [transient receptor potential channels], P2X, Ca\n2+\n), N-type voltage-gated calcium channels are key regulators of nociceptive neurotransmission in the spinal cord. Ziconotide, a peptide blocker of N-type calcium channels reduces nociceptive neurotransmission and is approved worldwide for the symptomatic alleviation of severe chronic pain in humans. Novel blockers of nociceptor-specific N-type calcium channels would be improved analgesics with reduced side-effect profiles.\n \nhypertension (Ca\n2+\n),—L-type and T-type voltage-gated calcium channels are expressed in vascular smooth muscle cells where they control excitation-contraction coupling and cellular proliferation. In particular, T-type calcium channel activity has been linked to neointima formation during hypertension. Blockers of L-type and T-type calcium channels are useful for the clinical treatment of hypertension because they reduce calcium influx and inhibit smooth muscle cell contraction.\n \nwound healing, cell migration serves a key role in wound healing. Intracellular calcium gradients have been implicated as important regulators of cellular migration machinery in keratinocytes and fibroblasts. In addition, ion flux across cell membranes is associated with cell volume changes. By controlling cell volume, ion channels contribute to the intracellular environment that is required for operation of the cellular migration machinery. In particular, IKCa1 appears to be required universally for cell migration. In addition, Kv1.3, Kv3.1, NMDA receptors and N-type calcium channels are associated with the migration of lymphocytes and neurons.\n \nstroke,\n \nAlzheimer's,\n \nParkenson's Disease (nACHR, Nav)\n \nBipolar Disorder (Nav, Cav)\n \ncancer, many potassium channel genes are amplified and protein subunits are upregulated in many cancerous condition. Consistent with a pathophysiological role for potassium channel upregulation, potassium channel blockers have been shown to suppress proliferation of uterine cancer cells and hepatocarcinoma cells, presumably through inhibition of calcium influx and effects on calcium-dependent gene expression.\n \na variety of neurological, cardiovascular, metabolic and autoimmune diseases.\n \n \n \n\n\nBoth agonists and antagonists of ion channels can achieve therapeutic benefit. Therapeutic benefits can result, for example, from antagonizing Kv1.3, IKCa1, SKCa, BKCa, N-type or T-type Ca\n2+\n channels and the like. Small molecule and peptide antagonists of these channels have been shown to possess utility in vitro and in vivo. Limitations in production efficiency and pharmacokinetics, however, have largely prevented clinical investigation of inhibitor peptides of ion channels.\n\n\nCompositions of this invention incorporating peptide antagonists of the voltage-gated potassium channel Kv1.3, in particular OSK1 peptide analogs, whether or not conjugated to a half-life extending moiety, are useful as immunosuppressive agents with therapeutic value for autoimmune diseases. For example, such molecules are useful in treating multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, and rheumatoid arthritis. (See, e.g., H. Wulff et al. (2003) J. Clin. Invest. 111, 1703-1713 and H. Rus et al. (2005) PNAS 102, 11094-11099; Beeton et al., Targeting effector memory T cells with a selective inhibitor peptide of Kv1.3 channels for therapy of autoimmune diseases, Molec. Pharmacol. 67(4):1369-81 (2005);1 Beeton et al. (2006), Kv1.3: therapeutic target for cell-mediated autoimmune disease, electronic preprint at //webfiles.uci.edu/xythoswfs/webui/2670029.1). Inhibitors of the voltage-gated potassium channel Kv1.3 have been examined in a variety of preclinical animal models of inflammation. Small molecule and peptide inhibitors of Kv1.3 have been shown to block delayed type hypersensitivity responses to ovalbumin [C. Beeton et al. (2005) Mol. Pharmacol. 67, 1369] and tetanus toxoid [G. C. Koo et al. (1999) Clin. Immunol. 197, 99]. In addition to suppressing inflammation in the skin, inhibitors also reduced antibody production [G. C. Koo et al. (1997) J. Immunol. 158, 5120]. Kv1.3 antagonists have shown efficacy in a rat adoptive-transfer experimental autoimmune encephalomyelitis (AT-EAE) model of multiple sclerosis (MS). The Kv1.3 channel is overexpressed on myelin-specific T cells from MS patients, lending further support to the utility Kv1.3 inhibitors may provide in treating MS. Inflammatory bone resorption was also suppressed by Kv1.3 inhibitors in a preclinical adoptive-transfer model of periodontal disease [P. Valverde et al. (2004) J. Bone Mineral Res. 19, 155]. In this study, inhibitors additionally blocked antibody production to a bacterial outer membrane protein,—one component of the bacteria used to induce gingival inflammation. Recently in preclinical rat models, efficacy of Kv1.3 inhibitors was shown in treating pristane-induced arthritis and diabetes [C. Beeton et al. (2006) preprint available at //webfiles.uci.edu/xythoswfs/webui/_xy-2670029\n—\n1.]. The Kv1.3 channel is expressed on all subsets of T cells and B cells, but effector memory T cells and class-switched memory B cells are particularly dependent on Kv1.3 [H. Wulff et al. (2004) J. Immunol. 173, 776]. Gad5/insulin-specific T cells from patients with \nnew onset type\n 1 diabetes, myelin-specific T cells from MS patients and T cells from the synovium of rheumatoid arthritis patients all overexpress Kv1.3 [C. Beeton et al. (2006) preprint at //webfiles.uci.edu/xythoswfs/webui/_xy-2670029\n—\n1.]. Because mice deficient in Kv1.3 gained less weight when placed on a high fat diet [J. Xu et al. (2003) Human Mol. Genet. 12, 551] and showed altered glucose utilization [J. Xu et al. (2004) Proc. Natl. Acad. Sci. 101, 3112], Kv1.3 is also being investigated for the treatment of obesity and diabetes. Breast cancer specimens [M. Abdul et al. (2003) Anticancer Res. 23, 3347] and prostate cancer cell lines [S. P. Fraser et al. (2003) Pflugers Arch. 446, 559] have also been shown to express Kv1.3, and Kv1.3 blockade may be of utility for treatment of cancer. Disorders that can be treated in accordance with the inventive method of treating an autoimmune disorder, involving Kv1.3 inhibitor toxin peptide(s), include multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and systemic lupus erythematosus (SLE) and other forms of lupus.\n\n\nSome of the cells that express the calcium-activated potassium of intermediate conductance IKCa1 include T cells, B cells, mast cells and red blood cells (RBCs). T cells and RBCs from mice deficient in IKCa1 show defects in volume regulation [T. Begenisich et al. (2004) J. Biol. Chem. 279, 47681]. Preclinical and clinical studies have demonstrated IKCa1 inhibitors utility in treating sickle cell anemia [J. W. Stocker et al. (2003) \nBlood\n 101, 2412]. Blockers of the IKCa1 channel have also been shown to block EAE, indicating they may possess utility in treatment of MS [E. P. Reich et al. (2005) Eur. J. Immunol. 35, 1027]. IgE-mediated histamine production from mast cells is also blocked by IKCa1 inhibitors [S. Mark Duffy et al. (2004) J. Allergy Clin. Immunol. 114, 66], therefore they may also be of benefit in treating asthma. The IKCa1 channel is overexpressed on activated T and B lymphocytes [H. Wulff et al. (2004) J. Immunol. 173, 776] and thus may show utility in treatment of a wide variety of immune disorders. Outside of the immune system, IKCa1 inhibitors have also shown efficacy in a rat model of vascular restinosis and thus might represent a new therapeutic strategy to prevent restenosis after angioplasty [R. Kohler et al. (2003) Circulation 108, 1119]. It is also thought that IKCa1 antagonists are of utility in treatment of tumor angiogenesis since inhibitors suppressed endothelial cell proliferation and angionenesis in vivo [I. Grgic et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25, 704]. The IKCa1 channel is upregulated in pancreatic tumors and inhibitors blocked proliferation of pancreatic tumor cell lines [H. Jager et al. (2004) Mol Pharmacol. 65, 630]. IKCa1 antagonists may also represent an approach to attenuate acute brain damage caused by traumatic brain injury [F. Mauler (2004) Eur. J. Neurosci. 20, 1761]. Disorders that can be treated with IKCa1 inhibitors include multiple sclerosis, asthma, psoriasis, contact-mediated dermatitis, rheumatoid & psoriatic arthritis, inflammatory bowel disease, transplant rejection, graft-versus-host disease, Lupus, restinosis, pancreatic cancer, tumor angiogenesis and traumatic brain injury.\n\n\nAccordingly, molecules of this invention incorporating peptide antagonists of the calcium-activated potassium channel of intermediate conductance, IKCa can be used to treat immune dysfunction, multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus.\n\n\nAccordingly, the present invention includes a method of treating an autoimmune disorder, which involves administering to a patient who has been diagnosed with an autoimmune disorder, such as multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, or lupus, a therapeutically effective amount of the inventive composition of matter, whereby at least one symptom of the disorder is alleviated in the patient. “Alleviated” means to be lessened, lightened, diminished, softened, mitigated (i.e., made more mild or gentle), quieted, assuaged, abated, relieved, nullified, or allayed, regardless of whether the symptom of interest is entirely erased, eradicated, eliminated, or prevented in a particular patient.\n\n\nThe present invention is further directed to a method of preventing or mitigating a relapse of a symptom of multiple sclerosis, which method involves administering to a patient, who has previously experienced at least one symptom of multiple sclerosis, a prophylactically effective amount of the inventive composition of matter, such that the at least one symptom of multiple sclerosis is prevented from recurring or is mitigated.\n\n\nThe inventive compositions of matter preferred for use in practicing the inventive method of treating an autoimmune disorder, e.g., inflammatory bowel disease (IBD, including Crohn's Disease and ulcerative colitis), and the method of preventing or mitigating a relapse of a symptom of multiple sclerosis include as P (conjugated as in Formula I), a Kv1.3 or IKCa1 antagonist peptide, such as a ShK peptide, an OSK1 peptide or an OSK1 peptide analog, a ChTx peptide and/or a Maurotoxin (MTx) peptide, or peptide analogs of any of these.\n\n\nFor example, the conjugated ShK peptide or ShK peptide analog can comprise an amino acid sequence selected from the following:\n\n \n \n \n \nSEQ ID NOS: 5, 88 through 200, 548 through 561, 884 through 950, or 1295 through 1300 as set forth in Table 2.\n \n \n \n\n\nThe conjugated OSK1 peptide, or conjugated or unconjugated OSK1 peptide analog, can comprise an amino acid sequence selected from the following:\n\n \n \n \n \nSEQ ID NOS: 25, 294 through 298, 562 through 636, 980 through 1274, GVIINVSCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK (OSK1-S7) (SEQ ID NO: 1303), or GVIINVSCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK (OSK1-S7,K16,D20) (SEQ ID NO: 1308) as set forth in Table 7, or any of SEQ ID NOS: 1391 through 4912, 4916, 4920 through 5006, 5009, 5010, and 5012 through 5015 as set forth in Table 7A, Table 7B, Table 7C, Table 7D, Table 7E, Table 7F, Table 7G, Table 7H, Table 7I, or Table 7J.\n \n \n \n\n\nAlso by way of example, a the conjugated MTX peptide, MTX peptide analog, ChTx peptide or ChTx peptide analog can comprise an amino acid sequence selected from:\n\n \n \n \n \nSEQ ID NOS: 20, 330 through 343, 1301, 1302, 1304 through 1307, 1309, 1311, 1312, or 1315 through 1336 as set forth in Table 13; or SEQ ID NOS: 36, 59, 344 through 346, or 1369 through 1390 as set forth in Table 14.\n \n \n \n\n\nAlso useful in these methods conjugated, or unconjugated, are a Kv1.3 or IKCa1 inhibitor toxin peptide analog that comprises an amino acid sequence selected from:\n\n \n \n \n \nSEQ ID NOS: 88, 89, 92, 148 through 200, 548 through 561, 884 through 949, or 1295 through 1300 as set forth in Table 2; or\n \nSEQ ID NOS: 980 through 1274, GVIINVSCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK (OSK1-S7) (SEQ ID NO: 1303), or GVIINVSCKISRQCLKPCKDAGMRFGKCMNGKCHCTPK (OSK1-S7,K16,D20) (SEQ ID NO: 1308) as set forth in Table 7; or\n \nSEQ ID NOS: 330 through 337, 341, 1301, 1302, 1304 through 1307, 1309, 1311, 1312, and 1315 through 1336 as set forth in Table 13.\n \n \n \n\n\nIn accordance with these inventive methods, a patient who has been diagnosed with an autoimmune disorder, such as, but not limited to multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoratic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, or lupus, or a patient who has previously experienced at least one symptom of multiple sclerosis, are well-recognizable and/or diagnosed by the skilled practitioner, such as a physician, familiar with autoimmune disorders and their symptoms.\n\n\nFor example, symptoms of multiple sclerosis can include the following:\n\n \n \n \n \nvisual symptoms, such as, optic neuritis (blurred vision, eye pain, loss of color vision, blindness); diplopia (double vision); nystagmus (jerky eye movements); ocular dysmetria (constant under- or overshooting eye movements); internuclear opthalmoplegia (lack of coordination between the two eyes, nystagmus, diplopia); movement and sound phosphenes (flashing lights when moving eyes or in response to a sudden noise); afferent pupillary defect (abnormal pupil responses);\n \nmotor symptoms, such as, paresis, monoparesis, paraparesis, hemiparesis, quadraparesis (muscle weakness—partial or mild paralysis); plegia, paraplegia, hemiplegia, tetraplegia, quadraplegia (paralysis—total or near total loss of muscle strength); spasticity (loss of muscle tone causing stiffness, pain and restricting free movement of affected limbs); dysarthria (slurred speech and related speech problems); muscle atrophy (wasting of muscles due to lack of use); spasms, cramps (involuntary contraction of muscles); hypotonia, clonus (problems with posture); myoclonus, myokymia (jerking and twitching muscles, tics); restless leg syndrome (involuntary leg movements, especially bothersome at night); footdrop (foot drags along floor during walking); dysfunctional reflexes (MSRs, Babinski's, Hoffman's, Chaddock's);\n \nsensory symptoms, such as, paraesthesia (partial numbness, tingling, buzzing and vibration sensations); anaesthesia (complete numbness/loss of sensation); neuralgia, neuropathic and neurogenic pain (pain without apparent cause, burning, itching and electrical shock sensations); L'Hermitte's (electric shocks and buzzing sensations when moving head); proprioceptive dysfunction (loss of awareness of location of body parts); trigeminal neuralgia (facial pain);\n \ncoordination and balance symptoms, such as, ataxia (loss of coordination); intention tremor (shaking when performing fine movements); dysmetria (constant under- or overshooting limb movements); vestibular ataxia (abnormal balance function in the inner ear); vertigo (nausea/vomitting/sensitivity to travel sickness from vestibular ataxia); speech ataxia (problems coordinating speech, stuttering); dystonia (slow limb position feedback); dysdiadochokinesia (loss of ability to produce rapidly alternating movements, for example to move to a rhythm);\n \nbowel, bladder and sexual symptoms, such as, frequent micturation, bladder spasticity (urinary urgency and incontinence); flaccid bladder, detrusor-sphincter dyssynergia (urinary hesitancy and retention); erectile dysfunction (male and female impotence); anorgasmy (inability to achieve orgasm); retrograde ejaculation (ejaculating into the bladder); frigidity (inability to become sexually aroused); constipation (infrequent or irregular bowel movements); fecal urgency (bowel urgency); fecal incontinence (bowel incontinence);\n \ncognitive symptoms, such as, depression; cognitive dysfunction (short-term and long-term memory problems, forgetfulness, slow word recall); dementia; mood swings, emotional lability, euphoria; bipolar syndrome; anxiety; aphasia, dysphasia (impairments to speech comprehension and production); and\n \nother symptoms, such as, fatigue; Uhthoff's Symptom (increase in severity of symptoms with heat); gastroesophageal reflux (acid reflux); impaired sense of taste and smell; epileptic seizures; swallowing problems, respiratory problems; and sleeping disorders.\n \n \n \n\n\nBy way of further example, symptoms of inflammatory bowel disease can include the following symptoms of Crohn's Disease or ulcerative colitis:\n\n\nA. Symptoms of Crohn's disease can include:\n\n \n \n \n \nAbdominal pain. The pain often is described as cramping and intermittent, and the abdomen may be sore when touched. Abdominal pain may turn to a dull, constant ache as the condition progresses.\n \nDiarrhea. Some patients may have \ndiarrhea\n 10 to 20 times per day. They may wake up at night and need to go to the bathroom. Crohn's disease may cause blood in stools, but not always.\n \nLoss of appetite.\n \nFever. In severe cases, fever or other symptoms that affect the entire body may develop. A high fever may indicate a complication involving infection, such as an abscess.\n \nWeight loss. Ongoing symptoms, such as diarrhea, can lead to weight loss. Too few red blood cells (anemia). Some patients with Crohn's disease develop anemia because of low iron levels caused by bloody stools or the intestinal inflammation itself.\n \n \n \n\n\nB. The symptoms of ulcerative colitis may include:\n\n \n \n \n \nDiarrhea or rectal urgency. Some patients may have \ndiarrhea\n 10 to 20 times per day. The urge to defecate may wake patients at night.\n \nRectal bleeding. Ulcerative colitis usually causes bloody diarrhea and mucus. Patients also may have rectal pain and an urgent need to empty the bowels.\n \nAbdominal pain, often described as cramping. The patient's abdomen may be sore when touched.\n \nConstipation. This symptom may develop depending on what part of the colon is affected.\n \nLoss of appetite.\n \nFever. In severe cases, fever or other symptoms that affect the entire body may develop.\n \nWeight loss. Ongoing (chronic) symptoms, such as diarrhea, can lead to weight loss.\n \nToo few red blood cells (anemia). Some patients develop anemia because of low iron levels caused by bloody stools or intestinal inflammation.\n \n \n \n\n\nThe symptoms of multiple sclerosis and inflammatory bowel disease (including Crohn's Disease and ulcerative colitis) enumerated above, are merely illustrative and are not intended to be an exhaustive description of all possible symptoms experienced by a single patient or by several sufferers in composite, and to which the present invention is directed. Those skilled in the art are aware of various clinical symptoms and constellations of symptoms of autoimmune disorders suffered by individual patients, and to those symptoms are also directed the present inventive methods of treating an autoimmune disorder or of preventing or mitigating a relapse of a symptom of multiple sclerosis.\n\n\nThe therapeutically effective amount, prophylactically effective amount, and dosage regimen involved in the inventive methods of treating an autoimmune disorder or of preventing or mitigating a relapse of a symptom of multiple sclerosis, will be determined by the attending physician, considering various factors which modify the action of therapeutic agents, such as the age, condition, body weight, sex and diet of the patient, the severity of the condition being treated, time of administration, and other clinical factors. Generally, the daily amount or regimen should be in the range of about 1 to about 10,000 micrograms (μg) of the vehicle-conjugated peptide per kilogram (kg) of body mass, preferably about 1 to about 5000 μg per kilogram of body mass, and most preferably about 1 to about 1000 μg per kilogram of body mass.\n\n\nMolecules of this invention incorporating peptide antagonists of the voltage-gated potassium channel Kv2.1 can be used to treat type II diabetes.\n\n\nMolecules of this invention incorporating peptide antagonists of the M current (e.g., BeKm-1) can be used to treat Alzheimer's disease and enhance cognition.\n\n\nMolecules of this invention incorporating peptide antagonists of the voltage-gated potassium channel Kv4.3 can be used to treat Alzheimer's disease.\n\n\nMolecules of this invention incorporating peptide antagonists of the calcium-activated potassium channel of small conductance, SKCa can be used to treat epilepsy, memory, learning, neuropsychiatric, neurological, neuromuscular, and immunological disorders, schizophrenia, bipolar disorder, sleep apnea, neurodegeneration, and smooth muscle disorders.\n\n\nMolecules of this invention incorporating N-type calcium channel antagonist peptides are useful in alleviating pain. Peptides with such activity (e.g., Ziconotide™, ω-conotoxin-MVIIA) have been clinically validated.\n\n\nMolecules of this invention incorporating T-type calcium channel antagonist peptides are useful in alleviating pain. Several lines of evidence have converged to indicate that inhibition of Cav3.2 in dorsal root ganglia may bring relief from chronic pain. T-type calcium channels are found at extremely high levels in the cell bodies of a subset of neurons in the DRG; these are likely mechanoreceptors adapted to detect slowly-moving stimuli (Shin et al., Nature Neuroscience 6:724-730, 2003), and T-type channel activity is likely responsible for burst spiking (Nelson et al., J Neurosci 25:8766-8775, 2005). Inhibition of T-type channels by either mibefradil or ethosuximide reverses mechanical allodynia in animals induced by nerve injury (Dogrul et al., Pain 105:159-168, 2003) or by chemotherapy (Flatters and Bennett, Pain 109:150-161, 2004). Antisense to Cav3.2, but not Cav3.1 or Cav3.3, increases pain thresholds in animals and also reduces expression of Cav3.2 protein in the DRG (Bourinet et al., EMBO J 24:315-324, 2005). Similarly, locally injected reducing agents produce pain and increase Cav3.2 currents, oxidizing agents reduce pain and inhibit Cav3.2 currents, and peripherally administered neurosteroids are analgesic and inhibit T-type currents from DRG (Todorovic et al., Pain 109:328-339, 2004; Pathirathna et al., Pain 114:429-443, 2005). Accordingly, it is thought that inhibition of Cav3.2 in the cell bodies of DRG neurons can inhibit the repetitive spiking of these neurons associated with chronic pain states.\n\n\nMolecules of this invention incorporating L-type calcium channel antagonist peptides are useful in treating hypertension. Small molecules with such activity (e.g., DHP) have been clinically validated.\n\n\nMolecules of this invention incorporating peptide antagonists of the Na\nV\n1 (TTX\nS\n-type) channel can be used to alleviate pain. Local anesthetics and tricyclic antidepressants with such activity have been clinically validated. Such molecules of this invention can in particular be useful as muscle relaxants.\n\n\nMolecules of this invention incorporating peptide antagonists of the Na\nV\n1 (TTX\nR\n-type) channel can be used to alleviate pain arising from nerve and or tissue injury.\n\n\nMolecules of this invention incorporating peptide antagonists of glial & epithelial cell Ca\n2+\n-activated chloride channel can be used to treat cancer and diabetes.\n\n\nMolecules of this invention incorporating peptide antagonists of NMDA receptors can be used to treat pain, epilepsy, brain and spinal cord injury.\n\n\nMolecules of this invention incorporating peptide antagonists of nicotinic receptors can be used as muscle relaxants. Such molecules can be used to treat pain, gastric motility disorders, urinary incontinence, nicotine addiction, and mood disorders.\n\n\nMolecules of this invention incorporating peptide antagonists of 5HT3 receptor can be used to treat Nausea, pain, and anxiety.\n\n\nMolecules of this invention incorporating peptide antagonists of the norepinephrine transporter can be used to treat pain, anti-depressant, learning, memory, and urinary incontinence.\n\n\nMolecules of this invention incorporating peptide antagonists of the Neurotensin receptor can be used to treat pain.\n\n\nIn addition to therapeutic uses, the compounds of the present invention can be useful in diagnosing diseases characterized by dysfunction of their associated protein of interest. In one embodiment, a method of detecting in a biological sample a protein of interest (e.g., a receptor) that is capable of being activated comprising the steps of: (a) contacting the sample with a compound of this invention; and (b) detecting activation of the protein of interest by the compound. The biological samples include tissue specimens, intact cells, or extracts thereof. The compounds of this invention can be used as part of a diagnostic kit to detect the presence of their associated proteins of interest in a biological sample. Such kits employ the compounds of the invention having an attached label to allow for detection. The compounds are useful for identifying normal or abnormal proteins of interest.\n\n\nThe therapeutic methods, compositions and compounds of the present invention can also be employed, alone or in combination with other molecules in the treatment of disease.\n\n\nPharmaceutical Compositions\n\n\nIn General. The present invention also provides pharmaceutical compositions comprising the inventive composition of matter and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be configured for administration to a patient by a wide variety of delivery routes, e.g., an intravascular delivery route such as by injection or infusion, subcutaneous, intramuscular, intraperitoneal, epidural, or intrathecal delivery routes, or for oral, enteral, pulmonary (e.g., inhalant), intranasal, transmucosal (e.g., sublingual administration), transdermal or other delivery routes and/or forms of administration known in the art. The inventive pharmaceutical compositions may be prepared in liquid form, or may be in dried powder form, such as lyophilized form. For oral or enteral use, the pharmaceutical compositions can be configured, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups, elixirs or enteral formulas.\n\n\nIn the practice of this invention the “pharmaceutically acceptable carrier” is any physiologically tolerated substance known to those of ordinary skill in the art useful in formulating pharmaceutical compositions, including, any pharmaceutically acceptable diluents, excipients, dispersants, binders, fillers, glidants, anti-frictional agents, compression aids, tablet-disintegrating agents (disintegrants), suspending agents, lubricants, flavorants, odorants, sweeteners, permeation or penetration enhancers, preservatives, surfactants, solubilizers, emulsifiers, thickeners, adjuvants, dyes, coatings, encapsulating material(s), and/or other additives singly or in combination. Such pharmaceutical compositions can include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., \nTween®\n 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol®, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., \nRemington's Pharmaceutical Sciences, \n18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, which are herein incorporated by reference in their entirety. The compositions can be prepared in liquid form, or can be in dried powder, such as lyophilized form. Implantable sustained release formulations are also useful, as are transdermal or transmucosal formulations. Additionally (or alternatively), the present invention provides compositions for use in any of the various slow or sustained release formulations or microparticle formulations known to the skilled artisan, for example, sustained release microparticle formulations, which can be administered via pulmonary, intranasal, or subcutaneous delivery routes.\n\n\nOne can dilute the inventive compositions or increase the volume of the pharmaceutical compositions of the invention with an inert material. Such diluents can include carbohydrates, especially, mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may also be used as fillers, including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-\nRx\n 1500, Emcompress and Avicell.\n\n\nA variety of conventional thickeners are useful in creams, ointments, suppository and gel configurations of the pharmaceutical composition, such as, but not limited to, alginate, xanthan gum, or petrolatum, may also be employed in such configurations of the pharmaceutical composition of the present invention. A permeation or penetration enhancer, such as polyethylene glycol monolaurate, dimethyl sulfoxide, N-vinyl-2-pyrrolidone, N-(2-hydroxyethyl)-pyrrolidone, or 3-hydroxy-N-methyl-2-pyrrolidone can also be employed. Useful techniques for producing hydrogel matrices are known. (E.g., Feijen, Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents, U.S. Pat. No. 4,925,677; Shah et al., Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents, WO 00/38651 A1). Such biodegradable gel matrices can be formed, for example, by crosslinking a proteinaceous component and a polysaccharide or mucopolysaccharide component, then loading with the inventive composition of matter to be delivered.\n\n\nLiquid pharmaceutical compositions of the present invention that are sterile solutions or suspensions can be administered to a patient by injection, for example, intramuscularly, intrathecally, epidurally, intravascularly (e.g., intravenously or intraarterially), intraperitoneally or subcutaneously. (See, e.g., Goldenberg et al., Suspensions for the sustained release of proteins, U.S. Pat. No. 6,245,740 and WO 00/38652 A1). Sterile solutions can also be administered by intravenous infusion. The inventive composition can be included in a sterile solid pharmaceutical composition, such as a lyophilized powder, which can be dissolved or suspended at a convenient time before administration to a patient using sterile water, saline, buffered saline or other appropriate sterile injectable medium.\n\n\nImplantable sustained release formulations are also useful embodiments of the inventive pharmaceutical compositions. For example, the pharmaceutically acceptable carrier, being a biodegradable matrix implanted within the body or under the skin of a human or non-human vertebrate, can be a hydrogel similar to those described above. Alternatively, it may be formed from a poly-alpha-amino acid component. (Sidman, Biodegradable, implantable drug delivery device, and process for preparing and using same, U.S. Pat. No. 4,351,337). Other techniques for making implants for delivery of drugs are also known and useful in accordance with the present invention.\n\n\nIn powder forms, the pharmaceutically acceptable carrier is a finely divided solid, which is in admixture with finely divided active ingredient(s), including the inventive composition. For example, in some embodiments, a powder form is useful when the pharmaceutical composition is configured as an inhalant. (See, e.g., Zeng et al., Method of preparing dry powder inhalation compositions, WO 2004/017918; Trunk et al., Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them, U.S. Pat. No. 6,900,317).\n\n\nOne can dilute or increase the volume of the compound of the invention with an inert material. These diluents could include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts can also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo™, Emdex™, STA-\nRx™\n 1500, Emcompress™ and Avicell™.\n\n\nDisintegrants can be included in the formulation of the pharmaceutical composition into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab™. Sodium starch glycolate, Amberlite™, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite can all be used. Insoluble cationic exchange resin is another form of disintegrant. Powdered gums can be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.\n\n\nBinders can be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.\n\n\nAn antifrictional agent can be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants can be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants can also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, \n \nCarbowax\n \n 4000 and 6000.\n\n\nGlidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants can include starch, talc, pyrogenic silica and hydrated silicoaluminate.\n\n\nTo aid dissolution of the compound of this invention into the aqueous environment a surfactant might be added as a wetting agent. Surfactants can include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated \n \n \ncastor oil\n \n \n 10, 50 and 60, glycerol monostearate, \n \n \n \npolysorbate\n \n \n \n 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.\n\n\nOral dosage forms. Also useful are oral dosage forms of the inventive compositions. If necessary, the composition can be chemically modified so that oral delivery is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the compound and increase in circulation time in the body. Moieties useful as covalently attached half-life extending moieties in this invention can also be used for this purpose. Examples of such moieties include: PEG, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. See, for example, Abuchowski and Davis (1981), \nSoluble Polymer\n-\nEnzyme Adducts, Enzymes as Drugs \n(Hocenberg and Roberts, eds.), Wiley-Interscience, New York, N.Y., pp 367-83; Newmark, et al. (1982), \nJ. Appl. Biochem. \n4:185-9. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are PEG moieties.\n\n\nFor oral delivery dosage forms, it is also possible to use a salt of a modified aliphatic amino acid, such as sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), as a carrier to enhance absorption of the therapeutic compounds of this invention. The clinical efficacy of a heparin formulation using SNAC has been demonstrated in a Phase II trial conducted by Emisphere Technologies. See U.S. Pat. No. 5,792,451, “Oral drug delivery composition and methods.”\n\n\nIn one embodiment, the pharmaceutically acceptable carrier can be a liquid and the pharmaceutical composition is prepared in the form of a solution, suspension, emulsion, syrup, elixir or pressurized composition. The active ingredient(s) (e.g., the inventive composition of matter) can be dissolved, diluted or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both, or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as detergents and/or solubilizers (e.g., \nTween\n 80, Polysorbate 80), emulsifiers, buffers at appropriate pH (e.g., Tris-HCl, acetate, phosphate), adjuvants, anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol), sweeteners, flavoring agents, suspending agents, thickening agents, bulking substances (e.g., lactose, mannitol), colors, viscosity regulators, stabilizers, electrolytes, osmolutes or osmo-regulators. Additives can also be included in the formulation to enhance uptake of the inventive composition. Additives potentially having this property are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.\n\n\nUseful are oral solid dosage forms, which are described generally in \nRemington's Pharmaceutical Sciences \n(1990), supra, in Chapter 89, which is hereby incorporated by reference in its entirety. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation can be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation can be used and the liposomes can be derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given in Marshall, K., \nModern Pharmaceutics \n(1979), edited by G. S. Banker and C. T. Rhodes, in \nChapter\n 10, which is hereby incorporated by reference in its entirety. In general, the formulation will include the inventive compound, and inert ingredients that allow for protection against the stomach environment, and release of the biologically active material in the intestine.\n\n\nThe composition of this invention can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.\n\n\nColorants and flavoring agents can all be included. For example, the protein (or derivative) can be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.\n\n\nIn tablet form, the active ingredient(s) are mixed with a pharmaceutically acceptable carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.\n\n\nThe powders and tablets preferably contain up to 99% of the active ingredient(s). Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.\n\n\nControlled release formulation can be desirable. The composition of this invention could be incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms e.g., gums. Slowly degenerating matrices can also be incorporated into the formulation, e.g., alginates, polysaccharides. Another form of a controlled release of the compositions of this invention is by a method based on the Oros™ therapeutic system (Alza Corp.), i.e., the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.\n\n\nOther coatings can be used for the formulation. These include a variety of sugars that could be applied in a coating pan. The therapeutic agent could also be given in a film-coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methylcellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxymethyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.\n\n\nA mix of materials might be used to provide the optimum film coating. Film coating can be carried out in a pan coater or in a fluidized bed or by compression coating.\n\n\nPulmonarv delivery forms. Pulmonary delivery of the inventive compositions is also useful. The protein (or derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei et al., \nPharma. Res\n. (1990) 7: 565-9; Adjei et al. (1990), \nInternatl. J. Pharmaceutics \n63: 135-44 (leuprolide acetate); Braquet et al. (1989), \nJ. Cardiovasc. Pharmacol. \n13 (suppl.5): s.143-146 (endothelin-1); Hubbard et al. (1989), \nAnnals Int. Med. \n3: 206-12 (α1-antitrypsin); Smith et al. (1989), \nJ. Clin. Invest. \n84: 1145-6 (α1-proteinase); Oswein et al. (March 1990), “Aerosolization of Proteins,” \nProc. Symp. Resp. Drug Delivery II\n, Keystone, Colo. (recombinant human growth hormone); Debs et al. (1988), \nJ. Immunol. \n140: 3482-8 (interferon-γ and tumor necrosis factor α) and Platz et al., U.S. Pat. No. 5,284,656 (granulocyte colony stimulating factor).\n\n\nUseful in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, N.C.; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Mass. (See, e.g., Helgesson et al., Inhalation device, U.S. Pat. No. 6,892,728; McDerment et al., Dry powder inhaler, WO 02/11801 A1; Ohki et al., Inhalant medicator, U.S. Pat. No. 6,273,086).\n\n\nAll such devices require the use of formulations suitable for the dispensing of the inventive compound. Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.\n\n\nThe inventive compound should most advantageously be prepared in particulate form with an average particle size of less than 10 μm (or microns), most preferably 0.5 to 5 μm, for most effective delivery to the distal lung.\n\n\nPharmaceutically acceptable carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations can include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants can be used. PEG can be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, can be used. Bile salts and other related enhancers can be used. Cellulose and cellulose derivatives can be used. Amino acids can be used, such as use in a buffer formulation.\n\n\nAlso, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.\n\n\nFormulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the inventive compound dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.\n\n\nFormulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant. The propellant can be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid can also be useful as a surfactant. (See, e.g., Bäckström et al., Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides, U.S. Pat. No. 6,932,962).\n\n\nFormulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and can also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.\n\n\nNasal delivery forms. In accordance with the present invention, intranasal delivery of the inventive composition of matter and/or pharmaceutical compositions is also useful, which allows passage thereof to the blood stream directly after administration to the inside of the nose, without the necessity for deposition of the product in the lung. Formulations suitable for intransal administration include those with dextran or cyclodextran, and intranasal delivery devices are known. (See, e.g, Freezer, Inhaler, U.S. Pat. No. 4,083,368).\n\n\nTransdermal and transmucosal (e.g., buccal) delivery forms). In some embodiments, the inventive composition is configured as a part of a pharmaceutically acceptable transdermal or transmucosal patch or a troche. Transdermal patch drug delivery systems, for example, matrix type transdermal patches, are known and useful for practicing some embodiments of the present pharmaceutical compositions. (E.g., Chien et al., Transdermal estrogen/progestin dosage unit, system and process, U.S. Pat. Nos. 4,906,169 and 5,023,084; Cleary et al., Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same, U.S. Pat. No. 4,911,916; Teillaud et al., EVA-based transdermal matrix system for the administration of an estrogen and/or a progestogen, U.S. Pat. No. 5,605,702; Venkateshwaran et al., Transdermal drug delivery matrix for coadministering estradiol and another steroid, U.S. Pat. No. 5,783,208; Ebert et al., Methods for providing testosterone and optionally estrogen replacement therapy to women, U.S. Pat. No. 5,460,820). A variety of pharmaceutically acceptable systems for transmucosal delivery of therapeutic agents are also known in the art and are compatible with the practice of the present invention. (E.g., Heiber et al., Transmucosal delivery of macromolecular drugs, U.S. Pat. Nos. 5,346,701 and 5,516,523; Longenecker et al., Transmembrane formulations for drug administration, U.S. Pat. No. 4,994,439).\n\n\nBuccal delivery of the inventive compositions is also useful. Buccal delivery formulations are known in the art for use with peptides. For example, known tablet or patch systems configured for drug delivery through the oral mucosa (e.g., sublingual mucosa), include some embodiments that comprise an inner layer containing the drug, a permeation enhancer, such as a bile salt or fusidate, and a hydrophilic polymer, such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, dextran, pectin, polyvinyl pyrrolidone, starch, gelatin, or any number of other polymers known to be useful for this purpose. This inner layer can have one surface adapted to contact and adhere to the moist mucosal tissue of the oral cavity and can have an opposing surface adhering to an overlying non-adhesive inert layer. Optionally, such a transmucosal delivery system can be in the form of a bilayer tablet, in which the inner layer also contains additional binding agents, flavoring agents, or fillers. Some useful systems employ a non-ionic detergent along with a permeation enhancer. Transmucosal delivery devices may be in free form, such as a cream, gel, or ointment, or may comprise a determinate form such as a tablet, patch or troche. For example, delivery of the inventive composition can be via a transmucosal delivery system comprising a laminated composite of, for example, an adhesive layer, a backing layer, a permeable membrane defining a reservoir containing the inventive composition, a peel seal disc underlying the membrane, one or more heat seals, and a removable release liner. (E.g., Ebert et al., Transdermal delivery system with adhesive overlay and peel seal disc, U.S. Pat. No. 5,662,925; Chang et al., Device for administering an active agent to the skin or mucosa, U.S. Pat. Nos. 4,849,224 and 4,983,395). These examples are merely illustrative of available transmucosal drug delivery technology and are not limiting of the present invention.\n\n\nDosages. The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.\n\n\nWORKING EXAMPLES\n\n\nThe compositions described above can be prepared as described below. These examples are not to be construed in any way as limiting the scope of the present invention.\n\n\nExample 1\n\n\nFc-L10-ShK[1-35] Mammalian Expression\n\n\nFc-L10-ShK[1-35], also referred to as “Fc-2xL-ShK[1-35]”, an inhibitor of Kv1.3. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a linker sequence and a monomer of the Kv1.3 inhibitor peptide ShK[1-35] was constructed as described below. Methods for expressing and purifying the peptibody from mammalian cells (\nHEK\n 293 and Chinese Hamster Ovary cells) are disclosed herein.\n\n\nThe expression vector pcDNA3.1(+) CMVi (\nFIG. 13A\n) was constructed by replacing the CMV promoter between MluI and HindIII in pcDNA3.1(+) with the CMV promoter plus intron (Invitrogen). The expression vector pcDNA3.1 (+) CMVi-hFc-ActivinRIIB (\nFIG. 13B\n) was generated by cloning a HindIII-NotI digested PCR product containing a 5′ Kozak sequence, a signal peptide and the human Fc-linker-ActivinRIIB fusion protein with the large fragment of HindIII-NotI digested pcDNA3.1(+) CMVi. The nucleotide and amino acid sequence of the human IgG1 Fc region in pcDNA3.1(+) CMVi-hFc-ActivinRIIB is shown in \nFIG. 3A-3B\n. This vector also has a GGGGSGGGGS (“L10”; SEQ ID NO:79) linker split by a BamHI site thus enabling with the oligo below formation of the 10 amino acid linker between Fc and the ShK[1-35] peptide (see \nFIG. 14A-14B\n) for the final Fc-L10-ShK[1-35] nucleotide and amino acid sequence (\nFIG. 14A-14B\n and SEQ ID NO: 77 and SEQ ID NO:78).\n\n\nThe Fc-L10-ShK[1-35] expression vector was constructing using PCR stategies to generate the full length ShK gene linked to a four glycine and one serine amino acid linker (lower case letters here indicate linker sequence of L-form amino acid residues) with two stop codons and flanked by BamHI and NotI restriction sites as shown below.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nBamHI\n\n\n \n\n\n\n\n\n\n \n\n\nGGATCCGGAGGAGGAGGAAGCCGCAGC\n\n\nSEQ ID NO: 657\n\n\n\n\n\n\n \n\n\n      g  g  g  g  s  R  S\n\n\nSEQ ID NO: 658\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTGCATCGACACCATCCCCAAGAGCCGC\n\n\n\n\n\n\n \n\n\nC  I  D  T  I  P  K  S  R\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTGCACCGCCTTCCAG\n\n\n\n\n\n\n \n\n\nC  T  A  F  Q\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTGCAAGCACAGCATGAAGTACCGCCTG\n\n\n\n\n\n\n \n\n\nC  K  H  S  M  K  Y  R  L\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nAGCTTCTGCCGCAAGACCTGCGGCACC\n\n\n\n\n\n\n \n\n\nS  F  C  R  K  T  C  G  T\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTGCTAATGAGCGGCCGC//\n\n\n\n\n\n\n \n\n\nC        NotI//\n\n\n\n\n\n\n\n\n\n\n\n\nTwo oligos with the sequence as depicted below were used in a PCR reaction with Herculase™ polymerase (Stratagene) at 94° C.-30 sec, 50° C.-30 sec, and 72° C.-1 min for 30 cycles.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\ncat gga tcc gga gga gga gga\n\n\nSEQ ID NO: 659\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nagc cgc agc tgc atc gac acc\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\natc ccc aag agc cgc tgc acc\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ngcc ttc cag tgc aag cac//\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ncat gcg gcc gct cat tag cag gtg\n\n\nSEQ ID NO: 660\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nccg cag gtc ttg cgg cag aag ctc\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nagg cgg tac ttc atg ctg tgc ttg\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ncac tgg aag g//\n\n\n\n\n\n\n\n\n\n\n\n\nThe resulting PCR products were resolved as the 150 bp bands on a one percent agarose gel. The 150 bp PCR product was digested with BamHI and NotI (Roche) restriction enzymes and agarose gel purified by Gel Purification Kit (Qiagen). At the same time, the pcDNA3.1 (+) CMVi-hFc-ActivinRIIB vector (\nFIG. 13B\n) was digested with BamHI and NotI restriction enzymes and the large fragment was purified by Gel Purification Kit. The gel purified PCR fragment was ligated to the purified large fragment and transformed into XL-1 blue bacteria (Stratagene). DNAs from transformed bacterial colonies were isolated and digested with BamHI and NotI restriction enzyme digestion and resolved on a one percent agarose gel. DNAs resulting in an expected pattern were submitted for sequencing. Although, analysis of several sequences of clones yielded a 100% percent match with the above sequence, only one clone was selected for large scaled plasmid purification. The DNA from Fc-2xL-ShK in pcDNA3.1(+) CMVi clone was resequenced to confirm the Fc and linker regions and the sequence was 100% identical to the predicted coding sequence, which is shown in \nFIG. 14A-14B\n.\n\n\nHEK-293 cells used in transient transfection expression of Fc-2xL-ShK[1-35] in pcDNA3.1(+) CMVi protein were cultured in growth medium containing DMEM High Glucose (Gibco), 10% fetal bovine serum (FBS from Gibco) and 1× non-essential amino acid (NEAA from Gibco). 5.6 ug of Fc-2xL-ShK[1-35] in pcDNA3.1(+) CMVi plasmid that had been phenol/chloroform extracted was transfected into HEK-293 cells using Fugene 6 (Roche). The cells recovered for 24 hours, and then placed in DMEM High Glucose and 1×NEAA medium for 48 hours. The conditioned medium was concentrated 50× by running 30 ml through Centriprep YM-10 filter (Amicon) and further concentrated by a Centricon YM-10 (Amicon) filter. Various amounts of concentrated medium were mixed with an in-\nhouse\n 4× Loading Buffer (without B-mercaptoethanol) and electrophoresed on a Novex 4-20% tris-glycine gel using a Novex Xcell II apparatus at 101V/46 mA for 2 hours in a 5× Tank buffer solution (0.123 Tris Base, 0.96M Glycine) along with 10 ul of BenchMark Pre-Stained Protein ladder (Invitrogen). The gel was then soaked in Electroblot buffer (35 mM Tris base, 20% methanol, 192 mM glycine) for 30 minutes. A PVDF membrane from Novex (Cat. No. LC2002, 0.2 um pores size) was soaked in methanol for 30 seconds to activate the PVDF, rinsed with deionized water, and soaked in Electroblot buffer. The pre-soaked gel was blotted to the PVDF membrane using the XCell II Blot module according to the manufacturer instructions (Novex) at 40 mA for 2 hours. Then, the blot was first soaked in a 5% milk (Carnation) in Tris buffered saline solution pH7.5 (TBS) for 1 hour at room temperature and incubated with 1:500 dilution in TBS with 0.1% Tween-20 (TBST Sigma) and 1% milk buffer of the HRP-conjugated murine anti-human Fc antibody (Zymed Laboratores Cat. no. 05-3320) for two hours shaking at room temperature. The blot was then washed three times in TBST for 15 minutes per wash at room temperature. The primary antibody was detected using Amersham Pharmacia Biotech's ECL western blotting detection reagents according to manufacturer's instructions. Upon ECL detection, the western blot analysis displayed the expected size of 66 kDa under non-reducing gel conditions (\nFIG. 24A\n).\n\n\nAM1 CHOd- (Amgen Proprietary) cells used in the stable expression of Fc-L10-ShK[1-35] protein were cultured in AM1 CHOd- growth medium containing DMEM High Glucose, 10% fetal bovine serum, 1× hypoxantine/thymidine (HT from Gibco) and 1×NEAA. 6.5 ug of pcDNA3.1(+) CMVi-Fc-ShK plasmid was also transfected into AM1 CHOd- \ncells using Fugene\n 6. The following day, the transfected cells were plated into twenty 15 cm dishes and selected using DMEM high glucose, 10% FBS, 1×HT, 1×NEAA and Geneticin (800 μg/ml G418 from Gibco) for thirteen days. Forty-eight surviving colonies were picked into two 24-well plates. The plates were allowed to grow up for a week and then replicated for freezing. One set of each plate was transferred to AM1 CHOd- growth medium without 10% FBS for 48 hours and the conditioned media were harvested. Western Blot analysis similar to the transient Western blot analysis with detection by the same anti-human Fc antibody was used to screen 15 ul of conditioned medium for expressing stable CHO clones. Of the 48 stable clones, more than 50% gave ShK expression at the expected size of 66 kDa. The BB6, BD5 and BD6 clones were selected with BD5 and BD6 as a backup to the primary clone BB6 (\nFIG. 24B\n).\n\n\nThe BB6 clone was scaled up into ten roller bottles (Corning) using AM1 CHOd- growth medium and grown to confluency as judged under the microscope. Then, the medium was exchanged with a serum-free medium containing to 50% DMEM high glucose and 50% Ham's F12 (Gibco) with 1×HT and 1×NEAA and let incubate for one week. The conditioned medium was harvested at the one-week incubation time, filtered through 0.45 μm filter (Corning) and frozen. Fresh serum-free medium was added and incubated for an additional week. The conditioned serum-free medium was harvested like the first time and frozen.\n\n\nPurification of monovalent and bivalent dimeric Fc-L10-ShK(1-35). Approximately 4 L of conditioned medium was thawed in a water bath at room temperature. The medium was concentrated to about 450 ml using a \nSatorius Sartocon Polysulfon\n 10 tangential flow ultra-filtration cassette (0.1 m\n2\n) at room temperature. The retentate was then filtered through a 0.22 μm cellulose acetate filter with a pre-filter. The retentate was then loaded on to a 5 ml Amersham HiTrap Protein A column at 5 ml/\nmin\n 7° C., and the column was washed with several column volumes of Dulbecco's phosphate buffered saline without divalent cations (PBS) and sample was eluted with a step to 100 mM glycine pH 3.0. The protein A elution pool (approximately 9 ml) was diluted to 50 ml with water and loaded on to a 5 ml Amersham HiTrap SP-HP column in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 5 ml/min and 7° C. The column was then washed with several column volumes S-Buffer A, and then developed using a linear gradient from 25% to 75% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) at 5 ml/min followed by a step to 100% S-Buffer B at 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pooled material was then concentrated to about 3.4 ml using a Pall Life Sciences Macrosep 10K Omega centrifugal ultra-filtration device and then filtered though a Costar 0.22 μm cellulose acetate syringe filter.\n\n\nA spectral scan was then conducted on 10 μl of the filtered material diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 26A\n). The concentration of the filtered material was determined to be 5.4 mg/ml using a calculated molecular mass of 32,420 g/mol and extinction coefficient of 47,900 M\n−1\ncm\n−1\n.\n\n\nThe purity of the filtered bivalent dimeric Fc-L10-ShK(1-35) product was assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 26B\n). The monvalent dimeric Fc-L10-ShK(1-35) product was analyzed using reducing and non-reducing sample buffers by SDS-PAGE on a 1.0 mm TRIS-glycine 4-20% gel developed at 220 V and stained with Boston Biologicals QuickBlue (\nFIG. 26E\n). The endotoxin levels were then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 108-fold dilution of the sample in PBS yielding a result of <1 EU/mg protein. The macromolecular state of the products was then determined using size exclusion chromatography on 20 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 26C\n, bivalent dimeric Fc-L10-ShK(1-35); \nFIG. 26F\n, monovalent dimeric Fc-L10-SHK(1-35)). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 26D\n) and confirmed (within experimental error) the integrity of the purified peptibody. The product was then stored at −80° C.\n\n\nPurified bivalent dimeric Fc-L10-ShK[1-35] potently blocked human Kv1.3 (\nFIG. 30A\n and \nFIG. 30B\n) as determined by electrophysiology (see Example 36). The purified bivalent dimeric Fc-L10-ShK[1-35] molecule also blocked T cell proliferation (\nFIG. 36A\n and \nFIG. 36B\n) and production of the cytokines IL-2 (\nFIG. 35A\n and \nFIG. 37A\n) and IFN-g (\nFIG. 35B\n and \nFIG. 37B\n).\n\n\nExample 2\n\n\nFc-L-ShK[2-35] Mammalian Expression\n\n\nA DNA sequence coding for the Fc region of human IgG1 fused in-frame to a monomer of the Kv1.3 inhibitor peptide ShK[2-35] was constructed using standard PCR technology. The ShK[2-35] and the 5, 10, or 25 amino acid linker portion of the molecule were generated in a PCR reaction using the original Fc-2xL-ShK[1-35] in pcDNA3.1(+) CMVi as a template (Example 1, \nFIG. 14A-14B\n). All ShK constructs should have the following amino acid sequence of\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC  (SEQ ID NO: 92)\n\n\nwith the first amino acid of the wild-type sequence deleted.\n\n\n\nThe sequences of the primers used to generate Fc-L5-ShK[2-35], also referred to as “Fc-1×L-ShK[2-35]”, are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\ncat gga tcc agc tgc atc gac\n\n\nSEQ ID NO: 661\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nacc atc//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ncat gcg gcc gct cat tag c//;\n\n\nSEQ ID NO: 662\n\n\n\n\n\n\n\n\n\n\n\n\nThe sequences of the primers used to generate Fc-L10-ShK[2-35], also referred to as “Fc-2×L-ShK[2-35]” are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\ncat gga tcc gga gga gga gga\n\n\nSEQ ID NO: 663\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nagc agc tgc a//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ncat gcg gcc gct cat tag cag\n\n\nSEQ ID NO: 664\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ngtg c//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe sequences of the primers used to generate Fc-L25-ShK[2-35], also referred to as “Fc-5×L-ShK[2-35]”, are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\ncat gga tcc ggg ggt ggg ggt\n\n\nSEQ ID NO: 665\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ntct ggg ggt ggg ggt tct gga\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ngga gga gga agc gga gga\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ngga gga agc agc tgc a//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ncat gcg gcc gct cat tag cag\n\n\nSEQ ID NO: 666\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\ngtg c//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe PCR products were digested with BamHI and NotI (Roche) restriction enzymes and agarose gel purified by Gel Purification Kit. At the same time, the pcDNA3.1(+) CMVi-hFc-ActivinRIIB vector was digested with BamHI and NotI restriction enzymes and the large fragment was purified by Gel Purification Kit. Each purified PCR product was ligated to the large fragment and transformed into XL-1 blue bacteria. DNAs from transformed bacterial colonies were isolated and subjected to BamHI and NotI restriction enzyme digestions and resolved on a one percent agarose gel. DNAs resulting in an expected pattern were submitted for sequencing. Although, analysis of several sequences of clones yielded a 100% percent match with the above sequence, only one clone was selected for large scaled plasmid purification. The DNA from this clone was resequenced to confirm the Fc and linker regions and the sequence was 100% identical to the expected sequence.\n\n\nPlasmids containing the Fc-1xL-Shk[2-35], Fc-2xL-Shk[2-35] and Fc-5xL-Shk[2-35] inserts in pcDNA3.1 (+) CMVi vector were digested with Xba1 and Xho1 (Roche) restriction enzymes and gel purified. The inserts were individually ligated into Not1 and SalI (Roche) digested pDSRα-22 (Amgen Proprietary) expression vector. Integrity of the resulting constructs were confirmed by DNA sequencing. The final plasmid DNA expression vector constructs were pDSRα-22-Fc-1xL-Shk[2-35], pDSRα-22-Fc-2xL-Shk[2-35] (\nFIG. 13C\n and \nFIG. 15A-15B\n) and pDSRα-22-Fc-5xL-Shk[2-35] (\nFIG. 16A-16B\n) and contained 5, 10 and 25 amino acid linkers, respectively.\n\n\nTwenty-four hours prior to transfection, 1.2e7 AM-1/D CHOd- (Amgen Proprietary) cells were plated into a T-175 cm sterile tissue culture flask, to allow 70-80% confluency on the day of transfection. The cells had been maintained in the AM-1/D CHOd- culture medium containing DMEM High Glucose, 5% FBS, 1× Glutamine Pen/Strep (Gibco), 1×HT, 1×NEAA's and 1× sodium pyruvate (Gibco). The following day, eighteen micrograms of each of the linearized pDSRα22:Fc-1xL-ShK[2-35], pDSRα22:Fc-2xL-ShK[2-35] and pDSRα22:Fc-5xL-ShK[2-35] (RDS's #20050037685, 20050053709, 20050073295) plasmids were mixed with 72 μg of linearized Selexis MAR plasmid and pPAGO1 (RDS 20042009896) and diluted into 6 ml of OptiMEM in a 50 ml conical tube and incubate for five minutes. LF2000 (210 μl) was added to 6 ml of OptiMEM and incubated for five minutes. The diluted DNA and LF2000 were mixed together and incubated for 20 minutes at room temperature. In the meantime, the cells were washed one time with PBS and then 30 ml OptiMEM without antibiotics were added to the cells. The OptiMEM was aspirated off, and the cells were incubated with 12 ml of DNA/LF2000 mixture for 6 hours or overnight in the 37° C. incubator with shaking. Twenty-four hours post transfection, the cells were split 1:5 into AM-1/D CHOd- culture medium and at differing dilutions for colony selection. Seventy-two hours post transfection, the cell medium was replaced with DHFR selection medium containing 10% Dialyzed FBS (Gibco) in DMEM High Glucose, plus 1× Glutamine Pen/Strep, 1×NEAA's and 1× Na Pyr to allow expression and secretion of protein into the cell medium. The selection medium was changed two times a week until the colonies are big enough to pick. The pDSRa22 expression vector contains a DHFR expression cassette, which allows transfected cells to grow in the absence of hypoxanthine and thymidine. The five T-175 pools of the resulting colonies were scaled up into roller bottles and cultured under serum free conditions. The conditioned media were harvested and replaced at one-week intervals. The resulting 3 liters of conditioned medium was filtered through a 0.45 μm cellulose acetate filter (Corning, Acton, Mass.) and transferred to Protein Chemistry for purification. As a backup, twelve colonies were selected from the 10 cm plates after 10-14 days on DHFR selection medium and expression levels evaluated by western blot using HRP conjugated anti human IgGFc as a probe. The three best clones expressing the highest level of each of the different linker length Fc-L-ShK[2-35] fusion proteins were expanded and frozen for future use.\n\n\nPurification of Fc-L10-ShK(2-35). Approximately 1 L of conditioned medium was thawed in a water bath at room temperature. The medium was loaded on to a 5 ml Amersham HiTrap Protein A column at 5 ml/\nmin\n 7° C., and the column was washed with several column volumes of Dulbecco's phosphate buffered saline without divalent cations (PBS) and sample was eluted with a step to 100 mM glycine pH 3.0. The protein A elution pool (approximately 8.5 ml) combined with 71 μl 3 M sodium acetate and then diluted to 50 ml with water. The diluted material was then loaded on to a 5 ml Amersham HiTrap SP-HP column in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 5 ml/\nmin\n 7° C. The column was then washed with several column volumes S-Buffer A, and then developed using a linear gradient from 0% to 75% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) at 5 ml/min followed by a step to 100% S-Buffer B at 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pooled material was then filtered through a 0.22 μm cellulose acetate filter and concentrated to about 3.9 ml using a Pall Life Sciences Macrosep 10K Omega centrifugal ultra-filtration device. The concentrated material was then filtered though a Pall Life Sciences Acrodisc with a 0.22 μm, 25 mm Mustang E membrane at 2 ml/min room temperature. A spectral scan was then conducted on 10 μl of the filtered material diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 27E\n). The concentration of the filtered material was determined to be 2.76 mg/ml using a calculated molecular mass of 30,008 g/mol and extinction coefficient of 36,900 M\n−1\ncm\n−1\n. Since material was found in the permeate, repeated concentration step on the permeate using a new Macrosep cartridge. The new batch of concentrated material was then filtered though a Pall Life Sciences Acrodisc with a 0.22 μm, 25 mm Mustang E membrane at 2 ml/min room temperature. Both lots of concentrated material were combined into one pool.\n\n\nA spectral scan was then conducted on 10 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer. The concentration of the filtered material was determined to be 3.33 mg/ml using a calculated molecular mass of 30,008 g/mol and extinction coefficient of 36,900 M\n−1\ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 27A\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 67-fold dilution of the sample in PBS yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 27B\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 27F\n) and the experiment confirmed the integrity of the peptibody, within experimental error. The product was then stored at −80° C.\n\n\n \nFIG. 31B\n shows that purified Fc-L10-ShK[2-35] potently blocks human Kv1.3 current (electrophysiology was done as described in Example 36). The purified Fc-L10-ShK[2-35] molecule also blocked IL-2 (\nFIG. 64A\n and \nFIG. 64B\n) and IFN-g (\nFIG. 65A\n and \nFIG. 65B\n) production in human whole blood, as well as, upregulation of CD40L (\nFIG. 66A\n and \nFIG. 66B\n) and IL-2R (\nFIG. 67A\n and \nFIG. 67B\n) on T cells.\n\n\nPurification of Fc-L5-ShK(2-35). Approximately 1 L of conditioned medium was loaded on to a 5 ml Amersham HiTrap Protein A column at 5 ml/\nmin\n 7° C., and the column was washed with several column volumes of Dulbecco's phosphate buffered saline without divalent cations (PBS) and sample was eluted with a step to 100 mM glycine pH 3.0. The protein A elution pool (approximately 9 ml) combined with 450 μl 1 M tris HCl pH 8.5 followed by 230 μl 2 M acetic acid and then diluted to 50 ml with water. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 5 ml Amersham HiTrap SP-HP column in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 5 ml/\nmin\n 7° C. The column was then washed with several column volumes S-Buffer A, and then developed using a linear gradient from 0% to 75% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) at 5 ml/min followed by a step to 100% S-Buffer B at 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pooled material was then concentrated to about 5.5 ml using a Pall Life Sciences Macrosep 10K Omega centrifugal ultra-filtration device. The concentrated material was then filtered though a Pall Life Sciences Acrodisc with a 0.22 μm, 25 mm Mustang E membrane at 2 ml/min room temperature.\n\n\nA spectral scan was then conducted on 10 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 27G\n). The concentration of the filtered material was determined to be 4.59 mg/ml using a calculated molecular mass of 29,750 g/mol and extinction coefficient of 36,900 M\n−1\ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 27C\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 92-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 27H\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 27I\n) and confirmed the integrity of the peptibody, within experimental error. The product was then stored at −80° C.\n\n\n \nFIG. 31C\n shows that purified Fc-L5-ShK[2-35] is highly active and blocks human Kv1.3 as determined by whole cell patch clamp electrophysiology (see Example 36).\n\n\nPurification of Fc-L25-ShK(2-35). Approximately 1 L of conditioned medium was loaded on to a 5 ml Amersham HiTrap Protein A column at 5 ml/\nmin\n 7° C., and the column was washed with several column volumes of Dulbecco's phosphate buffered saline without divalent cations (PBS) and sample was eluted with a step to 100 mM glycine pH 3.0. The protein A elution pool (approximately 9.5 ml) combined with 119 μl 3 M sodium acetate and then diluted to 50 ml with water. The pH adjusted material was then loaded on to a 5 ml Amersham HiTrap SP-HP column in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 5 ml/\nmin\n 7° C. The column was then washed with several column volumes S-Buffer A, and then developed using a linear gradient from 0% to 75% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) at 5 ml/min followed by a step to 100% S-Buffer B at 7° C. Fractions containing the main peak from the chromatogram were pooled and filtered through a 0.22 μm cellulose acetate filter.\n\n\nA spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer \nFIG. 27J\n. The concentration of the filtered material was determined to be 1.40 mg/ml using a calculated molecular mass of 31,011 g/mol and extinction coefficient of 36,900 M\n−1 \ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 27D\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 28-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 27K\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 27L\n) and this confirmed the integrity of the peptibody, within experimental error. The product was then stored at −80° C.\n\n\nPurified Fc-L25-ShK[2-35] inhibited human Kv1.3 with an IC\n50 \nof ˜150 pM by whole cell patch clamp electrophysiology on HEK293/Kv1.3 cells (Example 36).\n\n\nExample 3\n\n\nFc-L-ShK[1-35] Bacterial Expression\n\n\nDescription of bacterial peptibody expression vectors and procedures for cloning and expression of peptibodies. The cloning vector used for bacterial expression (Examples 3-30) is based on pAMG21 (originally described in U.S. Patent 2004/0044188). It has been modified in that the kanamycin resistance component has been replaced with ampicillin resistance by excising the DNA between the unique BstBI and NsiI sites of the vector and replacing with an appropriately digested PCR fragment bearing the beta-lactamase gene using PCR primers CCA ACA CAC TTC GAA AGA CGT TGA TCG GCA C (SEQ ID NO: 667) and CAC CCA ACA ATG CAT CCT TAA AAA AAT TAC GCC C (SEQ ID NO: 668) with pUC19 DNA as the template source of the beta-lactamase gene conferring resistance to ampicillin. The new version is called pAMG21ampR.\n\n\nDescription of cloning vector pAMG21ampR-Fc-Pep used in examples 3 to 30, excluding 15 and 16. \nFIG. 11A-C\n and \nFIG. 11D\n (schematic diagram) show the ds-DNA that has been added to the basic vector pAMG21ampR to permit the cloning of peptide fusions to the C-terminus of the Fc gene. The DNA has been introduced between the unique NdeI and BamHI sites in the pAMG21ampR vector. This entire region of DNA is shown in \nFIG. 11A-C\n. The coding region for Fc extends from nt 5134 to 5817 and the protein sequence appears below the DNA sequence. This is followed in frame by a glyX5 linker (nt's 5818-5832). A BsmBI site (GAGACG) spansnucleotides 5834-5839. DNA cleavage occurs between nucleotides 5828 and 5829 on the upper DNA strand and between nucleotides 5832 and 5833 on the lower DNA strand. Digestion creates 4 bp cohesive termini as shown here. The BsmBI site is underlined.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nAGGTGG\n\n\nTGGTT\nGAGACG\n SEQ ID NO: 683\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTCCACCACCA\n\n\n    A\nCTCTGC\n \n\n\n\n\n\n\n \n\n\nSEQ ID NO: 684\n\n\n\n\n\n\n\n\n\n\n\n\nA second BsmBI site occurs at nucleotides 6643 through 6648; viz., CGTCTC. DNA cleavage occurs between nucleotides 6650 and 6651 on the upper strand and between 6654 and 6655 on the lower strand.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nCGTCTC\nT\n\n\nTAAGGATCCG SEQ ID NO: 685\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n \nGCAGAG\nAATTC\n\n\n    CTAGGC\n\n\n\n\n\n\n \n\n\nSEQ ID NO: 686\n\n\n\n\n\n\n\n\n\n\n\n\nBetween the two BsmBI sites is a dispensable chloramphenicol resistance cassette constitutively expressing chloramphenicol acetyltransferase (cat gene). The cat protein sequence:\n\n\n \n \n \n \n \n \n \n \n \n \n \n1\n \nMEKKITGYTT VDISQWHRKE HFEAFQS\n \nSEQ ID NO: 1337\n \n \n \n \n \n \nVAQCTYNQTVQLD ITAFLKTVKK\n \n \n \n \n \n \n \n \n51\n \nNKHKFYPAFI HILARLMNAH \nPEFRMAM\n \n \n \n \n \n \nKDGELVIWDSVHP CYTVFHEQTE\n \n \n \n \n \n \n \n \n \n \n \n101\n \nTFSSLWSEYH DDFRQFLHIY \nSQDVACY\n \n \n \n \n \n \nGENLAYFPKGFIE NMFFVSANPW\n \n \n \n \n \n \n \n \n \n \n \n151\n \nVSFTSFDLNV ANMDNFFAPV \nFTMGKYY\n \n \n \n \n \n \nTQGDKVLMPLAIQ VHHAVCDGFH\n \n \n \n \n \n \n \n \n \n \n \n201\n \nVGRMLNELQQ YCDEWQGGA//\n \n \n \n \n \n\nis shown in \nFIG. 11A-C\n and extends from nucleotides 5954 to 6610. The peptide encoding duplexes in each example (except Examples 15 and 16) bear cohesive ends complementary to those presented by the vector.\n\n\n\nDescription of the cloning vector pAMG21ampR-Pep-Fc used in examples 15 and 16. \nFIG. 12A-C\n, and the schematic diagram in \nFIG. 12D\n, shows the ds-DNA sequence that has been added to the basic vector pAMG21ampR to permit the cloning of peptide fusions to the N-terminus of the Fc gene. The DNA has been introduced between the unique NdeI and BamHI sites in the pAMG21ampR vector. The coding region for Fc extends from nt 5640 to 6309 and the protein sequence appears below the DNA sequence. This is preceded in frame by a glyX5 linker (nt's 5614-5628). A BsmBI site spans nucleotides 5138 to 5143; viz., GAGACG. The cutting occurs between nucleotides 5132 and 5133 on the upper DNA strand and between 5136 and 5137 on the lower DNA strand.\n\n\nDigestion creates 4 bp cohesive termini as shown. The BsmBI site is underlined.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nAATAACA\n\n\nTATGC\nGAGACG\n SEQ ID NO: 687\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTTATTGTATAC\n\n\n    G\nCTCTGC\n \n\n\n\n\n\n\n \n\n\nSEQ ID NO: 688\n\n\n\n\n\n\n\n\n\n\n\n\nA second BsmBI site occurs at nucleotides 5607 through 5612; viz., CGTCTC. Cutting occurs between nucleotides 5613 and 5614 on the upper strand and between 5617 and 5618 on the lower strand.\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nCGTCTC\nA\n\n\nGGTGGTGGT\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\n \nGCAGAG\nTCCAC\n\n\n    CACCA\n\n\n\n\n\n\n \n\n\nSEQ ID NO: 689\n\n\n\n\n\n\n\n\n\n\n\n\nBetween the BsmBI sites is a dispensable zeocin resistance cassette constitutively expressing the \nShigella \nble protein. The ble protein sequence:\n\n\n \n \n \n \n \n \n \n \n \n1\n \nMAKLTSAVPV LTARDVAGAV\n \nSEQ ID NO: 1338\n \n \n \n \n \n \nEFWTDRLGFS RDFVEDDFAG\n \n \n \n \n \n \nVVRDDVTLFI\n \n \n \n \n \n \n \n \n \n \n \n51\n \nSAVQDQVVPD NTLAWVWVRG\n \n \n \n \n \n \nLDELYAEWSE VVSTNFRDAS\n \n \n \n \n \n \nGPAMTEIGEQ\n \n \n \n \n \n \n \n \n \n \n \n101\n \nPWGREFALRD PAGNCVHFVA EEQD//\n \n \n \n \n \n\nis shown extending from nucleotides 5217 to 5588 in \nFIG. 12A-C\n. The peptide encoding duplexes in Examples 15 and 16 bear cohesive ends complementary to those presented by the vector.\n\n\n\nDescription of the cloning vector DAMG21ampR-Pep-Fc used in Examples 52 and 53. \nFIG. 12E-G\n shows the ds-DNA sequence that has been added to the basic vector pAMG21ampR to permit the cloning of peptide fusions to the N-terminus of the Fc gene in which the first two codons of the peptide are to be met-gly. The DNA has been introduced between the unique NdeI and BamHI sites in the pAMG21ampR vector. The coding region for Fc extends from nt 5632 to 6312 and the protein sequence appears below the DNA sequence. This is preceded in frame by a glyX5 linker (nt's 5617-5631). A BsmBI site spans nucleotides 5141 to 5146; viz., GAGACG. The cutting occurs between nucleotides 5135 and 5136 on the upper DNA strand and between 5139 and 5140 on the lower DNA strand.\n\n\nDigestion creates 4 bp cohesive termini as shown. The BsmBI site is underlined.\n\n\n \n \n \n \n \n \n \nAATAACATAT\n \nGGGTC\nGAGACG\n SEQ ID NO: 1344\n \n \n \n \n \nSEQ ID NO: 1343\n \n \n \n \n \n \n \n \n \n \n \nTTATTGTATACCCA\n \n    G\nCTCTGC\n \n \n \n \n \n \nSEQ ID NO: 1345\n \n \n \n \n \n\nA second BsmBI site occurs at nucleotides 5607 through 5612; viz., CGTCTC. Cutting occurs between nucleotides 5613 and 5614 on the upper strand and between 5617 and 5618 on the lower strand.\n\n\n\n \n \n \n \n \n \n \n \nCGTCTC\nA\n \nGGTGGTGGT\n \n \n \n \n \n \n \n \n \n \n \n \nGCAGAG\nTCCAC\n \n    CACCA\n \n \n \n \n \nSEQ ID NO: 1346\n \n \n \n \n \n\nBetween the BsmBI sites is a dispensable zeocin resistance cassette constitutively expressing the \nShigella \nble protein. The ble protein sequence, as described above, is shown extending from nucleotide positions 5220 to 5591. The peptide encoding duplexes in Examples 52 and 53 herein below bear cohesive ends complementary to those presented by the vector.\n\n\n\nFor Examples 3 to 30 for which all are for bacterial expression, cloned peptide sequences are all derived from the annealing of oligonucleotides to create a DNA duplex that is directly ligated into the appropriate vector. Two oligos suffice for Example 20, four are required for all other examples. When the duplex is to be inserted at the N-terminus of Fc (see, Examples 15, 16, 52, and 53 herein) the design is as follows with the ordinal numbers matching the listing of oligos in each example:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nWhen the duplex is to be inserted at the C-terminus of Fc (Examples 3, 4, 5, 10, 11, 12, 13, and 30) the design is as follows:\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nAll remaining examples have the duplex inserted at the C-terminus of Fc and utilize the following design.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nNo kinasing step is required for the phosphorylation of any of the oligos. A successful insertion of a duplex results in the replacement of the dispensable antibiotic resistance cassette (Zeocin resistance for pAMG21ampR-Pep-Fc and chloramphenicol resistance for pAMG21ampR-Fc-Pep). The resulting change in phenotype is useful for discriminating recombinant from nonrecombinant clones.\n\n\nThe following description gives the uniform method for carrying out the cloning of all 30 bacterially expressed recombinant proteins exemplified herein. Only the set of oligonucleotides and the vector are varied. These specifications are given below in each example.\n\n\nAn oligonucleotide duplex containing the coding region for a given peptide was formed by annealing the oligonucleotides listed in each example. Ten picomoles of each oligo was mixed in a final volume of 10 μl containing 1× ligation buffer along with 0.3 μg of appropriate vector that had been previously digested with restriction endonuclease BsmBI. The mix was heated to 80° C. and allowed to cool at 0.1 degree/sec to room temperature. To this was added 10 μl of 1× ligase buffer plus 400 units of T4 DNA ligase. The sample was incubated at 14 C for 20 min. Ligase was inactivated by heating at 65° C. for 10 minutes. Next, 10 units of restriction endonucleases BsmBI were added followed by incubation at 55 C for one hour to cleave any reformed parental vector molecules. Fifty ul of chemically competent \nE. coli \ncells were added and held at 2 C for 20 minutes followed by heat shock at 42 C for 5 second. The entire volume was spread onto Luria Agar plates supplemented with carbenicillin at 200 μg/ml and incubated overnight at 37 C. Colonies were tested for the loss of resistance to the replaceable antibiotic resistance marker. A standard PCR test can be used to confirm the expected size of the duplex insert. Plasmid preparations were obtained and the recombinant insert was verified by DNA sequencing. Half liter cultures of a sequence confirmed construct were grown in Terrific Broth, expression of the peptibody was induced by addition of N-(3-oxo-hexanoyl)-homoserine lactone at 50 ng/ml and after 4-6 hours of shaking at 37 C the cells were centrifuged and the cell paste stored at −20 C.\n\n\nThe following gives for each example the cloning vector and the set of oligonucleotides used for constructing each fusion protein. Also shown is a DNA/protein map.\n\n\nBacterial expression of Fc-L-ShK[1-35] inhibitor of Kv1.3. The methods to clone and express the peptibody in bacteria are described above. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ShK[1-35].\n\n\nOligos used to form the duplex:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCGTTCCTG\n\n\nSEQ ID NO: 669\n\n\n\n\n\n\nCATCGACACCAT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCCGAAATCCCGTTGCACCGCTTTCCAGTGCAAACA\n\n\nSEQ ID NO: 670\n\n\n\n\n\n\nCTCCATGAAATACCGTCTGTCCTTCTGCCGTAAAAC\n\n\n\n\n\n\nCTGCGGTACCTGC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGCAGGTACCGCAGGTTTTACGGCAGAAGGACA\n\n\nSEQ ID NO: 671\n\n\n\n\n\n\nGACGGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nATTTCATGGAGTGTTTGCACTGGAAAGCGGTGCAAC\n\n\nSEQ ID NO: 672\n\n\n\n\n\n\nGGGATTTCGGGATGGTGTCGATGCAGGAACGGGAAC\n\n\n\n\n\n\nCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligo duplex is shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCGTTCCTGCATCGACACCATCCCGAAATCCCGTTGCAC\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGGCAAGGACGTAGCTGTGGTAGGGCTTTAGGGCAACGTG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  R  S  C  I  D  T  I  P  K  S  R  C  T\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGCTTTCCAGTGCAAACACTCCATGAAATACCGTCTGTCCTTCTGCCGTAAAACCTGCGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGCGAAAGGTCACGTTTGTGAGGTACTTTATGGCAGACAGGAAGACCGCATTTTGGACCCC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n A  F  Q  C  K  H  S  M  K  Y  R  L  S  F  C  R  K  T  C  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTACCTGC\n\n\n \n\n\n//SEQ ID NO: 673\n\n\n\n\n\n\n121\n\n\n-------\n\n\n\n\n\n\n \n\n\nATGGACGATTC\n\n\n \n\n\n//SEQ ID NO: 675\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n T  C\n\n\n—\n\n\n//SEQ ID NO: 674\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen. Purification of bacterially expressed Fc-L10-ShK(1-35) is further described in Example 38 herein below.\n\n\nExample 4\n\n\nFc-L-ShK[2-35] Bacterial Expression\n\n\nBacterial expression of Fc-L-ShK[2-35]. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ShK[2-35].\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCTGCATCGACACCAT\n\n\nSEQ ID NO: 676\n\n\n\n\n\n\nCCCGAAATCCCGTTGCACCGCTTTCCAGTGCAAACA\n\n\n\n\n\n\nCTCCATGAAAT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nACCGTCTGTCCTTCTGCCGTAAAACCTGCGGTACCT\n\n\nSEQ ID NO: 677\n\n\n\n\n\n\nGC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGCAGGTACCGCAGGTTTTACGGCAGAAGGACA\n\n\nSEQ ID NO: 678\n\n\n\n\n\n\nGACGGTATTTCATGGAGTGTTTGCACTGGAAAGCGG\n\n\n\n\n\n\nTGCAACGGGA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTTCGGGATGGTGTCGATGCAGGAACCACCACCACC\n\n\nSEQ ID NO: 679\n\n\n\n\n\n\nGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligo duplex formed is shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCTGCATCGACACCATCCCGAAATCCCGTTGCACCGCTTT\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGACGTAGCTGTGGTAGGGCTTTAGGGCAACGTCGCGAAA\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  C  I  D  T  I  P  K  S  R  C  T  A F\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n \nCCAGTGCAAACACTCCATGAAATACCGTCTGTCCTTCTGCCGTAAAACCTGCGGTACCTG\n \n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGGTCACGTTTGTGAGGTACTTTATGGCAGACAGGAAGACGGCATTTTGGACGCCATGGAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n Q  C  K  H  S  M  K  Y  R  L  S  F  C  R  K  T  C  G  T  C\n\n\n—\n\n\n//SEQ ID NO: 681\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nC\n\n\n \n\n\n//SEQ ID NO: 680\n\n\n\n\n\n\n121\n\n\n \n\n\n—\n\n\n\n\n\n\n \n\n\nGATTC\n\n\n \n\n\n//SEQ ID NO: 682\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen. Purification of bacterially expressed Fc-L10-ShK(2-35) is further described in Example 39 herein below.\n\n\nExample 5\n\n\nFc-L-HmK Bacterial Expression\n\n\nBacterial expression of Fc-L-HmK. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-HmK.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCGTACCTGCAAAGA\n\n\nSEQ ID NO: 690\n\n\n\n\n\n\nCCTGAT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCCGGTTTCCGAATGCACCGACATCCGTTGCCGTAC\n\n\nSEQ ID NO: 692\n\n\n\n\n\n\nCTCCATGAAATACCGTCTGAACCTGTGCCGTAAAAC\n\n\n\n\n\n\nCTGCGGTTCCTGC;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGCAGGAACCGCAGGTTTTACGGCACAGGTTCA\n\n\nSEQ ID NO: 693\n\n\n\n\n\n\nGACGGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nATTTCATGGAGGTACGGCAACGGATGTCGGTGCATT\n\n\nSEQ ID NO: 694\n\n\n\n\n\n\nCGGAAACCGGGATCAGGTCTTTGCAGGTACGGGAA\n\n\n\n\n\n\nCCACCACCACCGGA//\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligo duplex formed is shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCGTACCTGCAAAGACCTGATCCCGGTTTCCGAATGCAC\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGGCATGGACGTTTCTGGACTAGCGCCAAAGGCTTACGTG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  R  T  C  K  D  L  I  P  V  S  E  C  T\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGACATCCGTTGCCGTACCTCCATGAAATACCGTCTCAACCTGTGCCCTAAAACCTGCCG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGCTGTAGGCAACGGCATGGAGGTACTTTATGGCAGACTTGGACACGGCATTTTGGACGCC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n D  I  R  C  R  T  S  M  K  Y  R  L  N  L  C  R  K  T  C  G\n\n\n—\n\n\n//SEQ ID NO: 696\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTCCTGC\n\n\n \n\n\n//SEQ ID NO: 695\n\n\n\n\n\n\n121\n\n\n-------\n\n\n\n\n\n\n \n\n\nAAGGACGATTC\n\n\n \n\n\n//SEQ ID NO: 697\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S  C\n\n\n—\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 6\n\n\nFc-L-KTX1 Bacterial Expression\n\n\nBacterial expression of Fc-L-KTX1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-KTX1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGGTGTTGAAATCAA\n\n\nSEQ ID NO: 698\n\n\n\n\n\n\nCGTTAAATGCT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCGGTTCCCCGCAGTGCCTGAAACCGTGCAAAGACG\n\n\nSEQ ID NO: 699\n\n\n\n\n\n\nCTGGTATGCGTTTCGGTAAATGCATGAACCGTAAAT\n\n\n\n\n\n\nGCCACTGCACCCCGAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTATTTCGGGGTGCAGTGGCATTTACGGTTCATGC\n\n\nSEQ ID NO: 700\n\n\n\n\n\n\nATTTACCGAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGCATACCAGCGTCTTTGCACGGTTTCAGGCACTGC\n\n\nSEQ ID NO: 701\n\n\n\n\n\n\nGGGGAACCGGAGCATTTAACGTTGATTTCAACACCG\n\n\n\n\n\n\nGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligo duplex formed is shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGGTGTTGAAATCAACGTTAAATGCTCCGGTTCCCCGCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCCACAACTTTAGTTGCAATTTACGAGGCCAAGGGGCGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  G  V  E  I  N  V  K  C  S  G  S  P  Q\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nGTGCCTGAAACCGTGCAAAGACGCTGGTATGCGTTTCGGTAAATGCATGAACCGTAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nCACGGACTTTGGCACGTTTCTGCGACCATACGCAAAGCCATTTACGTACTTGGCATTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  L  K  P  C  K  D  A  G  M  R  F  G  K  C  M  N  R  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCACTGCACCCCGAAA\n\n\n \n\n\n//SEQ ID NO: 702\n\n\n\n\n\n\n121\n\n\n---------+------\n\n\n\n\n\n\n \n\n\nGGTGACGTGGGGCTTTATTC\n\n\n \n\n\n//SEQ ID NO: 704\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n H  C  T  P  K\n\n\n—\n\n\n//SEQ ID NO: 703\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nPurification and refolding of Fc-L-KTX1 expressed in bacteria. Frozen, \nE. coli \npaste (28 g) was combined with 210 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 ml water using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet (4.8 g) was then dissolved in 48 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The dissolved pellet was then reduced by adding 30 μl 1 M dithiothreitol to 3 ml of the solution and incubating at 37° C. for 30 minutes. The reduced pellet solution was then centrifuged at 14,000 g for 5 min at room temperature, and then 2.5 ml of the supernatant was transferred to 250 ml of the refolding buffer (2 M urea, 50 mM tris, 160 mM arginine HCl, 5 mM EDTA, 1 mM cystamine HCl, 4 mM cysteine, pH 8.5) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 2 days at 4° C. The refolding solution was then filtered through a 0.22 μm cellulose acetate filter and stored at 4° C. for 3 days.\n\n\nThe stored refold was then diluted with 1 L of water and the pH was adjusted to 7.5 using 1 M H\n3\nPO\n4\n. The pH adjusted material was then loaded on to a 10 ml Amersham SP-HP HiTrap column at 10 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.3) at 7° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.3) followed by a step to 100% S-Buffer B at 5 ml/\nmin\n 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data (45 ml). The pool was then loaded on to a 1 ml Amersham rProtein A HiTrap column in PBS at 2 ml/\nmin\n 7° C. Then column was then washed with several column volumes of PBS and eluted with 100 mM glycine pH 3.0. To the elution peak (2.5 ml), 62.5 μl 2 M tris base was added, and then the pH adjusted material was filtered though a Pall Life Sciences Acrodisc with a 0.22 μm, 25 mm Mustang E membrane at 2 ml/min room temperature.\n\n\nA spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 28C\n). The concentration of the filtered material was determined to be 2.49 mg/ml using a calculated molecular mass of 30,504 g/mol and extinction coefficient of 35,410 M\n−1\ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 28A\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 50-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 45 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 28B\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 28D\n) and these studies confirmed the integrity of the purified peptibody, within experimental error. The product was then stored at −80° C.\n\n\nPurified Fc-L-KTX1 blocked the human Kv1.3 current in a dose-dependent fashion (\nFIG. 32A\n and \nFIG. 32B\n) by electrophysiology (method was as described in Example 36).\n\n\nExample 7\n\n\nFc-L-HsTx1 Bacterial Expression\n\n\nBacterial expression of Fc-L-HsT1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-HsTx1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGCTTCCTGCCGTAC\n\n\nSEQ ID NO: 705\n\n\n\n\n\n\nCCCGAAAGAC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTGCGCTGACCCGTGCCGTAAAGAAACCGGTTGCCCG\n\n\nSEQ ID NO: 706\n\n\n\n\n\n\nTACGGTAAATGCATGAACCGTAAATGCAAATGCAAC\n\n\n\n\n\n\nCGTTGC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGCAACGGTTGCATTTGCATTTACGGTTCATGC\n\n\nSEQ ID NO: 707\n\n\n\n\n\n\nATTTACCGTACG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGGCAACCGGTTTCTTTACGGCACGGGTCAGCGCAGT\n\n\nSEQ ID NO: 708\n\n\n\n\n\n\nCTTTCGGGGTACGGCAGGAAGCGGAACCACCACCA\n\n\n\n\n\n\nCCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe duplex formed by the oligos above is shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGCTTCCTGCCGTACCCCGAAAGACTGCGCTGACCCGTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCGAAGGACGGCATGGGGCTTTCTGACGCGACTGGGCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  A  S  C  R  T  P  K  D  C  A  D  P  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTAAAGAAACCGGTTGCCCGTACGGTAAATGCATGAACCGTAAATGCAAATGCAACCG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGGCATTTCTTTGGCCAACGGGCATGCCATTTACGTACTTGGCATTTACGTTTACGTTGGC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  K  E  T  G  C  P  Y  G  K  C  M  N  R  K  C  K  C  N  R\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTGC\n\n\n \n\n\nSEQ ID ND: 709\n\n\n\n\n\n\n121\n\n\n----\n\n\n124\n\n\n\n\n\n\n \n\n\nAACGATTC\n\n\n \n\n\nSEQ ID NO: 711\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C\n\n\n—\n\n\nSEQ ID NO: 710\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 8\n\n\nFc-L-MgTx Bacterial Expression\n\n\nBacterial expression of Fc-L-MgTx. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-MgTx.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCACCATCATCAACGT\n\n\nSEQ ID NO: 712\n\n\n\n\n\n\nTAAATGCACCTC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCCGAAACAGTGCCTGCCGCCGTGCAAAGCTCAGTT\n\n\nSEQ ID NO: 713\n\n\n\n\n\n\nCGGTCAGTCCGCTGGTGCTAAATGCATGAACGGTAA\n\n\n\n\n\n\nATGCAAATGCTACCCGCAC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGTGCGGGTAGCATTTGCATTTACCGTTCATGC\n\n\nSEQ ID NO: 714\n\n\n\n\n\n\nATTTAGCACCAG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGGACTGACCGAACTGAGCTTTGCACGGCGGCAGGC\n\n\nSEQ ID NO: 715\n\n\n\n\n\n\nACTGTTTCGGGGAGGTGCATTTAACGTTGATGATG\n\n\n\n\n\n\nGTGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCACCATCATCAACGTTAAATGCACCTCCCCGAAACAGTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGTGGTAGTAGTTGCAATTTACCTCGAGGGGCTTTGTCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  T  I  I  N  V  K  C  T  S  P  K  Q  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCTGCCGCCGTGCAAAGCTCAGTTCGGTCAGTCCGCTGGTGCTAAATGCATGAACGGTAA\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGGACGGCGGCACGTTTCGAGTCAAGCCAGTCAGGCGACCACGATTTACGTACTTGCCATT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n L  P  P  C  K  A  Q  F  G  Q  S  A  G  A  K  C  M  N  G  K\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nATGCAAATGCTACCCGCAC\n\n\n \n\n\nSEQ ID NO: 716\n\n\n\n\n\n\n121\n\n\n---------+---------\n\n\n\n\n\n\n \n\n\nTACGTTTACGATGGGCGTGATTC\n\n\n \n\n\nSEQ ID NO: 718\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  K  C  Y  P  H\n\n\n—\n\n\nSEQ ID NO: 717\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 9\n\n\nFc-L-AgTx2 Bacterial Expression\n\n\nBacterial expression of Fc-L-AgTx2. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-AgTx2.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGGTGTTCCGATCAA\n\n\nSEQ ID NO: 719\n\n\n\n\n\n\nCGTTTCCTGCACCGGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCCCCGCAGTGCATCAAACCGTGCAAAGACGCTGGT\n\n\nSEQ ID NO: 720\n\n\n\n\n\n\nATGCGTTTCGGTAAATGCATGAACCGTAAATGCCAC\n\n\n\n\n\n\nTGCACCCCGAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTATTTCGGGGTGCAGTGGCATTTACGGTTCATGC\n\n\nSEQ ID NO: 721\n\n\n\n\n\n\nATTTACCGAAACGCATA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCAGCGTCTTTGCACGGTTTGATGCACTGCGGGGAA\n\n\nSEQ ID NO: 722\n\n\n\n\n\n\nCCGGTGCAGGAAACGTTGATCGGAACACCGGAACCA\n\n\n\n\n\n\nCCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos listed above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGGTGTTCCGATCAACGTTTCCTGCACCGGTTCCCCGCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCCACAAGGCTAGTTGCAAAGGACGTGGCCAAGGGGCGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  G  V  P  I  N  V  S  C  T  G  S  P  Q\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nGTGCATCAAACCGTGCAAAGACGCTGGTATGCGTTTCGGTAAATGCATGAACCGTAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nCACGTAGTTTGGCACGTTTCTGCGACCATACGCAAAGCCATTTACGTACTTGGCATTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  I  K  P  C  K  D  A  G  M  R  F  G  K  C  M  N  R  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCACTGCACCCCGAAA_\n\n\n \n\n\nSEQ ID NO: 723\n\n\n\n\n\n\n121\n\n\n---------+------\n\n\n\n\n\n\n \n\n\nGGTGACGTGGGGCTTTATTC\n\n\n \n\n\nSEQ ID NO: 725\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n H  C  T  P  K\n\n\n—\n\n\nSEQ ID NO: 724\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nRefolding and purification of Fc-L-AgTx2 expressed in bacteria. Frozen, \nE. coli \npaste (15 g) was combined with 120 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 ml water using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet (4.6 g) was then dissolved in 46 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The dissolved pellet was then reduced by adding 30 μl 1 M dithiothreitol to 3 ml of the solution and incubating at 37° C. for 30 minutes. The reduced pellet solution was then centrifuged at 14,000 g for 5 min at room temperature, and then 2.5 ml of the supernatant was transferred to 250 ml of the refolding buffer (2 M urea, 50 mM tris, 160 mM arginine HCl, 5 mM EDTA, 1 mM cystamine HCl, 4 mM cysteine, pH 9.5) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 2 days at 4° C. The refolding solution was then filtered through a 0.22 μm cellulose acetate filter and stored at −70° C.\n\n\nThe stored refold was defrosted and then diluted with 1 L of water and the pH was adjusted to 7.5 using 1 M H\n3\nPO\n4\n. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 10 ml Amersham SP-HP HiTrap column at 10 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.3) at 7° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.3) followed by a step to 100% S-Buffer B at 5 ml/\nmin\n 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data (15 ml). The pool was then loaded on to a 1 ml Amersham rProtein A HiTrap column in PBS at 2 ml/\nmin\n 7° C. Then column was then washed with several column volumes of 20 mM NaH\n2\nPO\n4 \npH 6.5, 1 M NaCl and eluted with 100 mM glycine pH 3.0. To the elution peak (1.5 ml), 70 μl 1 M tris HCl pH 8.5 was added, and then the pH-adjusted material was filtered though a 0.22 μm cellulose acetate filter.\n\n\nA spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 29C\n). The concentration of the filtered material was determined to be 1.65 mg/ml using a calculated molecular mass of 30,446 g/mol and extinction coefficient of 35,410 M\n−1\ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 29A\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 33-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <4 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 20 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 29D\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μL of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 29E\n) and these studies confirmed the integrity of the purified peptibody, within experimental error. The product was then stored at −80° C.\n\n\nExample 10\n\n\nFc-L-OSK1 Bacterial Expression\n\n\nBacterial expression of Fc-L-OSK1. The methods used to clone and express the peptibody in bacteria were as described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-OSK1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGGTGTTATCATCAA\n\n\nSEQ ID NO: 726\n\n\n\n\n\n\nCGTTAAATGCAAAATCTCCCGTCAGTGCCTGGAACC\n\n\n\n\n\n\nGTGCAAAAAAG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTGGTATGCGTTTCGGTAAATGCATGAACGGTAAAT\n\n\nSEQ ID NO: 727\n\n\n\n\n\n\nGCCACTGCACCCCGAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTATTTCGGGGTGCAGTGGCATTTACCGTTCATGC\n\n\nSEQ ID NO: 728\n\n\n\n\n\n\nATTTACCGAAACGCATACCAGCTTTTTTGCACGGT\n\n\n\n\n\n\nTCCAGGCACTGA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGGGAGATTTTGCATTTAACGTTGATGATAACACCG\n\n\nSEQ ID NO: 729\n\n\n\n\n\n\nGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGGTGTTATCATCAACGTTAAATGCAAAATCTCCCGTCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCCACAATAGTAGTTGCAATTTACGTTTTAGAGGGCAGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  G  V  I  I  N  V  K  C  K  I  S  R  Q\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nGTGCCTGGAACCGTGCAAAAAAGCTGGTATGCGTTTCGGTAAATGCATGAACGGTAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nCACGGACCTTGGCACGTTTTTTCGACCATACGCAAAGCCATTTACGTACTTGCCATTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  L  E  P  C  K  K  A  G  M  R  F  G  K  C  M  N  G  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCACTGCACCCCGAAA\n\n\n \n\n\nSEQ ID NO: 730\n\n\n\n\n\n\n121\n\n\n---------+------\n\n\n\n\n\n\n \n\n\nGGTGACGTGGGGCTTTATTC\n\n\n \n\n\nSEQ ID NO: 732\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n H  C  T  P  K\n\n\n—\n\n\nSEQ ID NO: 731\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen for later use. Purification of Fc-L10-OSK1 from \nE. coli \npaste is described in Example 40 herein below.\n\n\nExample 11\n\n\nFc-L-OSK1(E16K, K20D) Bacterial Expression\n\n\nBacterial expression of Fc-L-OSK1(E16K, K20D). The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-OSK1(E16K, K20D).\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGGTGTTATCATCAA\n\n\nSEQ ID NO: 733\n\n\n\n\n\n\nCGTTAAATGCAAAATCTCCCGTCAGTGCCTGAAAC\n\n\n\n\n\n\nCGTGCAAAGACG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTGGTATGCGTTTCGGTAAATGCATGAACGGTAAAT\n\n\nSEQ ID NO: 734\n\n\n\n\n\n\nGCCACTGCACCCCGAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTATTTCGGGGTGCAGTGGCATTTACCGTTCATGC\n\n\nSEQ ID NO: 735\n\n\n\n\n\n\nATTTACCGAAACGCATACCAGCGTCTTTGCACGGTT\n\n\n\n\n\n\nTCAGGCACTGA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGGGAGATTTTGCATTTAACGTTGATGATAACACCG\n\n\nSEQ ID NO: 736\n\n\n\n\n\n\nGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTCCTTCCCCTGTTATCATCAACCTTAAATCCAAAATCTCCCGTCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCCACAATAGTAGTTGCAATTTACGTTTTAGAGGGCAGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  G  V  I  I  N  V  K  C  K  I  S  R  Q\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nGTGCCTGAAACCGTGCAAAGACGCTGGTATGCGTTTCGGTAAATGCATGAACGGTAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nCACGGACTTTGGCACGTTTCTGCGACCATACGCAAAGCCATTTACGTACTTGCCATTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  L  K  P  C  K  D  A  G  M  R  F  G  K  C  M  N  G  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCACTGCACCCCGAAA\n\n\n \n\n\nSEQ ID NO: 737\n\n\n\n\n\n\n121\n\n\n---------+------\n\n\n\n\n\n\n \n\n\nGGTGACGTGGGGCTTTATTC\n\n\n \n\n\nSEQ ID NO: 739\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n H  C  T  P  K\n\n\n—\n\n\nSEQ ID NO: 738\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen for later use.\n\n\nExample 12\n\n\nFc-L-Anuroctoxin Bacterial Expression\n\n\nBacterial expression of Fc-L-Anuroctoxin. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-Anuroctoxin.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCAAAGAATGCACCGG\n\n\nSEQ ID NO: 740\n\n\n\n\n\n\nTCCGCAGCACTGCACCAACTTCTGCCGTAAAAACAA\n\n\n\n\n\n\nATGCACCCACG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGTAAATGCATGAACCGTAAATGCAAATGCTTCAACT\n\n\nSEQ ID NO: 741\n\n\n\n\n\n\nGCAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTATTTGCAGTTGAAGCATTTGCATTTACGGTTCA\n\n\nSEQ ID NO: 742\n\n\n\n\n\n\nTGCATTTACCGTGGGTGCATTTGTTTTTACGGCAG\n\n\n\n\n\n\nAAGTTGGTGCAG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTGCTGCGGACCGGTGCATTCTTTGGAACCACCACCA\n\n\nSEQ ID NO: 743\n\n\n\n\n\n\nCCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTCCTGGTTCCAAAGAATGCACCGGTCCGCAGCACTGCACCAACTTCTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGTTTCTTACGTGGCCAGGCGTCGTGACGTGGTTGAAGAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  K  E  C  T  G  P  Q  H  C  T  N  F  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTAAAAACAAATGCACCCACGGTAAATGCATGAACCGTAAATGCAAATGCTTCAACTG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGGCATTTTTGTTTACGTGGGTGCCATTTACGTACTTGGCATTTACGTTTACGAAGTTGAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  K  N  K  C  T  H  G  K  C  M  N  R  K  C  K  C  F  N  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCAAA\n\n\n \n\n\nSEQ ID NO: 744\n\n\n\n\n\n\n121\n\n\n----\n\n\n\n\n\n\n \n\n\nGTTTATTC\n\n\n \n\n\nSEQ ID NO: 746\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n K\n\n\n—\n\n\nSEQ ID NO: 745\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 13\n\n\nFc-L-Noxiustoxin Bacterial Expression\n\n\nBacterial expression of Fc-L-Noxiustoxin or Fc-L-NTX. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-NTX.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCACCATCATCAACGT\n\n\nSEQ ID NO: 747\n\n\n\n\n\n\nTAAATGCACCTCCCCGAAACAGTGCTCCAAACCGT\n\n\n\n\n\n\nGCAAAGAACTGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nACGGTTCCTCCGCTGGTGCTAAATGCATGAACGGTA\n\n\nSEQ ID NO: 748\n\n\n\n\n\n\nAATGCAAATGCTACAACAAC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGTTGTTGTAGCATTTGCATTTACCGTTCATGC\n\n\nSEQ ID NO: 749\n\n\n\n\n\n\nATTTAGCACCAGCGGAGGAACCGTACAGTTCTTTG\n\n\n\n\n\n\nCACGGTTTGGAG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCACTGTTTCGGGGAGGTGCATTTAACGTTGATGATG\n\n\nSEQ ID NO: 750\n\n\n\n\n\n\nGTGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCACCATCATCAACGTTAAATGCACCTCCCCGAAACAGTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGTGGTAGTAGTTGCAATTTACGTGGAGGGGCTTTGTCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  T  I  I  N  V  K  C  T  S  P  K  Q  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTCCAAACCGTGCAAAGAACTGTACGGTTCCTCCGCTGGTGCTAAATGCATGAACGGTAA\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGAGGTTTGGCACGTTTCTTGACATGCCAAGGAGGCGACCACGATTTACGTACTTGCCATT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S  K  P  C  K  E  L  Y  G  S  S  A  G  A  K  C  M  N  G  K\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nATGCAAATGCTACAACAAC\n\n\n \n\n\nSEQ ID NO: 751\n\n\n\n\n\n\n121\n\n\n---------+---------\n\n\n\n\n\n\n \n\n\nTACGTTTACGATGTTGTTGATTC\n\n\n \n\n\nSEQ ID NO: 753\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  K  C  Y  N  N\n\n\n—\n\n\nSEQ ID NO: 752\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 14\n\n\nFc-L-Pi2 Bacterial Expression\n\n\nBacterial expression of Fc-L-Pi2. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-Pi2.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCACCATCTCCTGCAC\n\n\nSEQ ID NO: 754\n\n\n\n\n\n\nCAACCCG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nAAACAGTGCTACCCGCACTGCAAAAAAGAAACCGGT\n\n\nSEQ ID NO: 755\n\n\n\n\n\n\nTACCCGAACGCTAAATGCATGAACCGTAAATGCA\n\n\n\n\n\n\nAATGCTTCGGTCGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAACGACCGAAGCATTTGCATTTACGGTTCATGC\n\n\nSEQ ID NO: 756\n\n\n\n\n\n\nATTTAGCG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTCGGGTAACCGGTTTCTTTTTTGCAGTGCGGGTAG\n\n\nSEQ ID NO: 757\n\n\n\n\n\n\nCACTGTTTCGGGTTGGTGCAGGAGATGGTGGAACC\n\n\n\n\n\n\nACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCACCATCTCCTGCACCAACCCGAAACAGTGCTACCCGCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGTGGTAGAGGACGTGGTTGGGCTTTGTCACGATGGGCGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  T  I  S  C  T  N  P  K  Q  C  Y  P  H\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTGCAAAAAAGAAACCGGTTACCCGAACGCTAAATGCATGAACCGTAAATGCAAATGCTT\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGACGTTTTTTCTTTGGCCAATGGGCTTGCGATTTACGTACTTGGCATTTACGTTTACGAA\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C  K  K  E  T  G  Y  P  N  A  K  C  M  N  R  K  C  K  C  F\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGGTCGT\n\n\n \n\n\nSEQ ID NO: 758\n\n\n\n\n\n\n121\n\n\n-------\n\n\n\n\n\n\n \n\n\nGCCAGCAATTC\n\n\n \n\n\nSEQ ID NO: 760\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  R\n\n\n—\n\n\nSEQ ID NO: 759\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 15\n\n\nShK[1-35]-L-Fc Bacterial Expression\n\n\nBacterial expression of ShK[1-35]-L-Fc. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Pep-Fc and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of ShK[1-35]-L-Fc.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTATGCGTTCTTGTATTGATACTATTCCAAAA\n\n\nSEQ ID NO: 761\n\n\n\n\n\n\n \n\n\nTCTCGTTGTACTGCTTTTCAATGTAAACATT\n\n\n\n\n\n\n \n\n\nCTATGAAATATCGTCTTTCTT//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTTTGTCGTAAAACTTGTGGTACTTGTTCTGG\n\n\nSEQ ID NO: 762\n\n\n\n\n\n\n \n\n\nTGGTGGTGGTTCT//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCACCAGAACCACCACCACCAGAACAAGTAC\n\n\nSEQ ID NO: 763\n\n\n\n\n\n\n \n\n\nCACAAGTTTTACGACAAAAAGAAAGACGATA\n\n\n\n\n\n\n \n\n\nTTTCATAGAATGTTTACATTGA//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nAAAGCAGTACAACGAGATTTTGGAATAGTAT\n\n\nSEQ ID NO: 764\n\n\n\n\n\n\n \n\n\nCAATACAAGAACG//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTATGCGTTCTTGTATTGATACTATTCCAAAATCTCGTTGTACTGCTTTTCAATGTAAACA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    GCAAGAACATAACTATGATAAGGTTTTAGAGCAACATGACGAAAAGTTACATTTGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n M  R  S  C  I  D  T  I  P  K  S  R  C  T  A  F  Q  C  K  H\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTCTATGAAATATCGTCTTTCTTTTTGTCGTAAAACTTGTGGTACTTGTTCTGGTGGTGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nAAGATACTTTATAGCAGAAAGAAAAACAGCATTTTGAACACCATGAACAAGACCACCACC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S  M  K  Y  R  L  S  F  C  R  K  T  C  G  T  C  S  G  G  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTGGTTCT\n\n\n \n\n\nSEQ ID MO: 765\n\n\n\n\n\n\n121\n\n\n-------\n\n\n127\n\n\n\n\n\n\n \n\n\nACCAAGACCAC\n\n\n \n\n\nSEQ ID NO: 767\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S\n\n\n—\n\n\nSEQ ID NO: 766\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen. Purification of met-ShK[1-35]-Fc was as described in Example 51 herein below.\n\n\nExample 16\n\n\nShK[2-35]-L-Fc Bacterial Expression\n\n\nBacterial expression of ShK[2-35]-L-Fc. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Pep-Fc and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of ShK[2-35]-L-Fc.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTATGTCTTGTATTGATACTATTCCAAAATCTC\n\n\nSEQ ID NO: 768\n\n\n\n\n\n\nGTTGTACTGCTTTTCAATGTAAACATTCTATG\n\n\n\n\n\n\nAAATATCGTCTTTCTT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTTGTCGTAAAACTTGTGGTACTTGTTCTGG\n\n\nSEQ ID NO: 769\n\n\n\n\n\n\nTGGTGGTGGTTCT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCACCAGAACCACCACCACCAGAACAAGTACCA\n\n\nSEQ ID NO: 770\n\n\n\n\n\n\nCAAGTTTTACGACAAAAAGAAAGACGATATTT\n\n\n\n\n\n\nCATAGAATGTTTACATTGA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nAAAGCAGTACAACGAGATTTTGGAATAGTATC\n\n\nSEQ ID NO: 771\n\n\n\n\n\n\nAATACAAGA;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTATGTCTTGTATTGATACTATTCCAAAATCTCGTTGTACTGCTTTTCAATGTAAACATTC\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGAACATAACTATGATAAGGTTTTAGAGCAACATGACGAAAAGTTACATTTGTAAG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n M  S  C  I  D  T  I  P  K  S  R  C  T  A  F  Q  C  K  H  S\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTATGAAATATCGTCTTTCTTTTTGTCGTAAAACTTGTGGTACTTGTTCTGGTGGTGGTGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nATACTTTATAGCAGAAAGAAAAACAGCATTTTGAACACCATGAACAAGACCACCACCACC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n M  K  Y  R  L  S  F  C  R  K  T  C  G  T  C  S  G  G  G  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTCT\n\n\n \n\n\nSEQ ID NO: 772\n\n\n\n\n\n\n121\n\n\n----\n\n\n\n\n\n\n \n\n\nAAGACCAC\n\n\n \n\n\nSEQ ID NO: 774\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S\n\n\n—\n\n\nSEQ ID NO: 773\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen. Purification of the ShK[2-35]-Fc was as described in Example 50 herein below.\n\n\nExample 17\n\n\nFc-L-ChTx Bacterial Expression\n\n\nBacterial expression of Fc-L-ChTx. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ChTx.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACC\n\n\nSEQ ID NO: 775\n\n\n\n\n\n\nAACGTT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCCTGCACCACCTCCAAAGAATGCTGGTCC\n\n\nSEQ ID NO: 776\n\n\n\n\n\n\nGTTTGCCAGCGTCTGCACAACACCTCCCGT\n\n\n\n\n\n\nGGTAAATGCATGAACAAAAAATGCCGTTGC\n\n\n\n\n\n\nTACTCC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGGAGTAGCAACGGCATTTTTTGTTCATG\n\n\nSEQ ID NO: 777\n\n\n\n\n\n\nCATTTA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCACGGGAGGTGTTGTGCAGACGCTGGCAA\n\n\nSEQ ID NO: 778\n\n\n\n\n\n\nACGGACCAGCATTCTTTGGAGGTGGTGCAGG\n\n\n\n\n\n\nAAACGTTGGTGAACTGGGAACCACCACCA\n\n\n\n\n\n\nCCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACCAACGTTTCCTGCACCACCTCCAAAGAATG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGGTCAAGTGGTTGCAAAGGACGTGGTGGAGGTTTCTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  Q  F  T  N  V  S  C  T  T  S  K  E  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTGGPCCGTTTGCCAGCGTCTGCACAACACCTCCCGTGGTAAATGCATGAACAAAAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGACCAGGCAAACGGTCGCAGACGTGTTGTGGAGGGCACCATTTACGTACTTGTTTTTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n W  S  V  C  Q  R  L  H  N  T  S  R  G  K  C  M  N  K  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTTGCTACTCC\n\n\n \n\n\nSEQ ID NO: 779\n\n\n\n\n\n\n121\n\n\n---------+---\n\n\n\n\n\n\n \n\n\nGGCAACGATGAGGATTC\n\n\n \n\n\nSEQ ID NO: 781\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  C  Y  S\n\n\n—\n\n\nSEQ ID NO: 780\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 18\n\n\nFc-L-MTX Bacterial Expression\n\n\nBacterial expression of Fc-L-MTX. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-MTX.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGTTTCCTGCA\n\n\nSEQ ID NO: 782\n\n\n\n\n\n\nCCGGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTCCAAAGACTGCTACGCTCCGTGCCGTAAAC\n\n\nSEQ ID NO: 783\n\n\n\n\n\n\nAGACCGGTTGCCCGAACGCTAAATGCATCAA\n\n\n\n\n\n\nCAAATCCTGCAAATGCTACGGTTGC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGCAACCGTAGCATTTGCAGGATTTGTTG\n\n\nSEQ ID NO: 784\n\n\n\n\n\n\nATGCAT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTAGCGTTCGGGCAACCGGTCTGTTTACGG\n\n\nSEQ ID NO: 785\n\n\n\n\n\n\nCACGGAGCGTAGCAGTCTTTGGAACCGGTG\n\n\n\n\n\n\nCAGGAAACGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGTTTCCTGCACCGGTTCCAAAGACTGCTACGCTCCGTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCAAAGGACGTGGCCAAGGTTTCTGACGATGCGAGGCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  V  S  C  T  G  S  K  D  C  Y  A  P  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTAAACAGACCGGTTGCCCGAACGCTAAATGCATCAACAAATCCTGCAAATGCTACGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGGCATTTGTCTGGCCAACGGGCTTGCGATTTACGTAGTTGTTTAGGACGTTTACGATGCC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  K  Q  T  G  C  P  N  A  K  C  I  N  K  S  C  K  C  Y  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTGC\n\n\n \n\n\nSEQ ID NO: 786\n\n\n\n\n\n\n121\n\n\n----\n\n\n\n\n\n\n \n\n\nAACGATTC\n\n\n \n\n\nSEQ ID NO: 788\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n C\n\n\n—\n\n\nSEQ ID NO: 787\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 19\n\n\nFc-L-ChTx (K32E) Bacterial Expression\n\n\nBacterial expression of Fc-L-ChTx (K32E). The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ChTx (K32E).\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACCA\n\n\nSEQ ID NO: 789\n\n\n\n\n\n\nACGTTTCCTG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCACCACCTCCAAAGAATGCTGGTCCGTTTGCC\n\n\nSEQ ID NO: 790\n\n\n\n\n\n\nAGCGTCTGCACAACACCTCCCGTGGTAAATGC\n\n\n\n\n\n\nATGAACAAAGAATGCCGTTGCTACTCC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGGAGTAGCAACGGCATTCTTTGTTCATG\n\n\nSEQ ID NO: 791\n\n\n\n\n\n\nCATTTACCACG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGGAGGTGTTGTGCAGACGCTGGCAAACGGAC\n\n\nSEQ ID NO: 792\n\n\n\n\n\n\nCAGCATTCTTTGGAGGTGGTGCAGGAAACGTT\n\n\n\n\n\n\nGGTGAACTGGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACCAACGTTTCCTGCACCACCTCCAAAGAATG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGGTCAAGTGGTTGCAAAGGACGTGGTGGAGGTTTCTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  Q  F  T  N  V  S  C  T  T  S  K  E  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTGGTCCGTTTGCCAGCGTCTGCACAACACCTCCCGTGGTAAATGCATGAACAAAGAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGACCAGGCAAACGGTCGCAGACGTGTTGTGGAGGGCACCATTTACGTACTTGTTTCTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n W  S  V  C  Q  R  L  H  N  T  S  R  G  K  C  M  N  K  E  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTTGCTACTCC\n\n\n \n\n\nSEQ ID NO: 793\n\n\n\n\n\n\n121\n\n\n---------+---\n\n\n\n\n\n\n \n\n\nGGCAACGATGAGGATTC\n\n\n \n\n\nSEQ ID NO: 795\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  C  Y  S\n\n\n—\n\n\nSEQ ID NO: 794\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 20\n\n\nFc-L-Apamin Bacterial Expression\n\n\nBacterial expression of Fc-L-Apamin. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-Apamin.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCTGCAACTGCA\n\n\nSEQ ID NO: 796\n\n\n\n\n\n\nAAGCTCCGGAAACCGCTCTGTGCGCTCGTCG\n\n\n\n\n\n\nTTGCCAGCAGCACGGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAACCGTGCTGCTGGCAACGACGAGCGCA\n\n\nSEQ ID NO: 797\n\n\n\n\n\n\nCAGAGCGGTTTCCGGAGCTTTGCAGTTGCAGG\n\n\n\n\n\n\nAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCTGCAACTGCAAAGCTCCGGAAACCGCTCTGTGCGCTCG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n 1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGACGTTGACGTTTCGAGGCCTTTGGCGAGACACGCGAGC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  C  N  C  K  A  P  E  T  A  L  C  A  R\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTCGTTGCCAGCAGCACGGT\n\n\n \n\n\nSEQ ID NO: 798\n\n\n\n\n\n\n61\n\n\n---------+---------\n\n\n\n\n\n\n \n\n\nAGCAACGGTCGTCGTGCCAATTC\n\n\n \n\n\nSEQ ID NO: 800\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  C  Q  Q  H  G\n\n\n—\n\n\nSEQ ID NO: 799\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 21\n\n\nFc-L-Scyllatoxin Bacterial Expression\n\n\nBacterial expression of Fc-L-Scyllatoxin or Fc-L-ScyTx. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ScyTx.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGCTTTCTGC\n\n\nSEQ ID NO: 801\n\n\n\n\n\n\nAACCTGCG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTATGTGCCAGCTGTCCTGCCGTTCCCTGGGTC\n\n\nSEQ ID NO: 802\n\n\n\n\n\n\nTGCTGGGTAAATGCATCGGTGACAAATGCGAA\n\n\n\n\n\n\nTGCGTTAAACAC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGTGTTTAACGCATTCGCATTTGTCACCG\n\n\nSEQ ID NO: 803\n\n\n\n\n\n\nATGCATTT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nACCCAGCAGACCCAGGGAACGGCAGGACA\n\n\nSEQ ID NO: 804\n\n\n\n\n\n\nGCTGGCACATACGCAGGTTGCAGAAAGCGG\n\n\n\n\n\n\nAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGCTTTCTGCAACCTGCGTATGTGCCAGCTGTCCTGCCG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n 1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCGAAAGACGTTGGACGCATACACGGTCGACAGGACGGC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  A  F  C  N  L  R  M  C  Q  L  S  C  R\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTCCCTGGGTCTGCTGGGTAAATGCATCGGTGACAAATGCGAATGCGTTAAACAC\n\n\n \n\n\nSEQ ID NO: 805\n\n\n\n\n\n\n61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n\n\n\n\n \n\n\nAAGGGACCCAGACGACCCATTTACGTAGCCACTGTTTACGCTTACGCAATTTGTGATTC\n\n\n \n\n\nSEQ ID NO: 807\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S  L  G  L  L  G  K  C  I  G  D  K  C  E  C  V  K  H\n\n\n—\n\n\nSEQ ID NO: 806\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 22\n\n\nFc-L-IbTx Bacterial Expression\n\n\nBacterial expression of Fc-L-lbTx. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-lbTx.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACC\n\n\nSEQ ID NO: 808\n\n\n\n\n\n\nGACGTTGACTGCTCCGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTCCAAAGAATGCTGGTCCGTTTGCAAAGACC\n\n\nSEQ ID NO: 809\n\n\n\n\n\n\nTGTTCGGTGTTGACCGTGGTAAATGCATGGGT\n\n\n\n\n\n\nAAAAAATGCCGTTGCTACCAG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTACTGGTAGCAACGGCATTTTTTACCCATG\n\n\nSEQ ID NO: 810\n\n\n\n\n\n\nCATTTACCACGGTCAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCACCGAACAGGTCTTTGCAAACGGACCAGCA\n\n\nSEQ ID NO: 811\n\n\n\n\n\n\nTTCTTTGGAAACGGAGCAGTCAACGTCGGTGA\n\n\n\n\n\n\nACTGGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCAGTTCACCGACGTTGACTGCTCCGTTTCCAAAGAATG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCGAGGAGCACCAAGGGTCAAGTGGCTGCAACTGACGAGGCAAAGGTTTCTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  Q  F  T  D  V  D  C  S  V  S  K  E  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTGGTCCGTTTGCAAAGACCTGTTCGGTGTTGACCGTGGTAAATGCATGGGTAAAAAATG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGACCAGGCAAACGTTTCTGGACAAGCCACAACTGGCACCATTTACGTACCCATTTTTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n W  S  V  C  K  D  L  F  G  V  D  R  G  K  C  M  G  K  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCGTTGCTACCAG\n\n\n \n\n\nSEQ ID NO: 812\n\n\n\n\n\n\n121\n\n\n---------+---\n\n\n\n\n\n\n \n\n\nGGCAACGATGGTCATTC\n\n\n \n\n\nSEQ ID NO: 814\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  C  Y  Q\n\n\n—\n\n\nSEQ ID NO: 813\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 23\n\n\nFc-L-HaTx1 Bacterial Expression\n\n\nBacterial expression of Fc-L-HaTx1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-HaTx1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGAATGCCGT\n\n\nSEQ ID NO: 815\n\n\n\n\n\n\nTACCTGTTCGGTGGTTG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCAAAACCACCTCCGACTGCTGCAAACACCTGG\n\n\nSEQ ID NO: 816\n\n\n\n\n\n\nGTTGCAAATTCCGTGACAAATACTGCGCTTGG\n\n\n\n\n\n\nGACTTCACCTTCTCC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGGAGAAGGTGAAGTCCCAAGCGCAGTA\n\n\nSEQ ID NO: 817\n\n\n\n\n\n\nTTTGTCACGGAATTTGC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nAACCCAGGTGTTTGCAGCAGTCGGAGGTGGT\n\n\nSEQ ID NO: 818\n\n\n\n\n\n\nTTTGCAACCACCGAACAGGTAACGGCATTCG\n\n\n\n\n\n\nGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGAATGCCGTTACCTGTTCGGTGGTTGCAAAACCACCTC\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCTTACGGCAATGGACAAGCCACCAACGTTTTGGTGGAG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  E  C  R  Y  L  F  G  G  C  K  T  T  S\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGACTGCTGCAAACACCTGGGTTGCAAATTCCGTGACAAATACTGCGCTTGGGACTTCAC\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGCTGACGACGTTTGTGGACCCAACGTTTAAGGCACTGTTTATGACGCGAACCCTGAAGTG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n D  C  C  K  H  L  G  C  K  F  R  D  K  Y  C  A  W  D  F  T\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTTCTCC\n\n\n \n\n\nSEQ ID NO: 819\n\n\n\n\n\n\n121\n\n\n-------\n\n\n\n\n\n\n \n\n\nGAAGAGGATTC\n\n\n \n\n\nSEQ ID NO: 821\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n F  S\n\n\n—\n\n\nSEQ ID NO: 820\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nRefolding and purification of Fc-L-HaTx1 expressed in bacteria. Frozen, \nE. coli \npaste (13 g) was combined with 100 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet was then resuspended in 200 ml water using a tissue grinder and then centrifuged at 22,000 g for 20 min at 4° C. The pellet (2.6 g) was then dissolved in 26 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The dissolved pellet was then reduced by adding 30 μl 1 M dithiothreitol to 3 ml of the solution and incubating at 37° C. for 30 minutes. The reduced pellet solution was then centrifuged at 14,000 g for 5 min at room temperature, and then 2.5 ml of the supernatant was transferred to 250 ml of the refolding buffer (2 M urea, 50 mM tris, 160 mM arginine HCl, 5 mM EDTA, 1 mM cystamine HCl, 4 mM cysteine, pH 8.5) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 2 days at 4° C. The refolding solution was then filtered through a 0.22 μm cellulose acetate filter and stored at −70° C.\n\n\nThe stored refold was defrosted and then diluted with 1 L of water and the pH was adjusted to 7.5 using 1 M H\n3\nPO\n4\n. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 10 ml Amersham SP-HP HiTrap column at 10 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.3) at 7° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.3) followed by a step to 100% S-Buffer B at 5 ml/\nmin\n 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data (15 ml). The pool was then loaded on to a 1 ml Amersham rProtein A HiTrap column in PBS at 2 ml/\nmin\n 7° C. Then column was then washed with several column volumes of 20 mM NaH\n2\nPO\n4 \npH 6.5, 1 M NaCl and eluted with 100 mM glycine pH 3.0. To the elution peak (1.4 ml), 70 μl 1 M tris HCl pH 8.5 was added, and then the pH adjusted material was filtered though a 0.22 μm cellulose acetate filter.\n\n\nA spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 29F\n). The concentration of the filtered material was determined to be 1.44 mg/ml using a calculated molecular mass of 30,469 g/mol and extinction coefficient of 43,890 M\n−1 \ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 29B\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 33-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <4 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 20 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 29G\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). The resultant solution (1 μl) was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 29H\n) and these studies confirmed the integrity of the purified peptibody, within experimental error. The product was then stored at −80° C.\n\n\nExample 24\n\n\nFc-L-PaTx2 Bacterial Expression\n\n\nBacterial expression of Fc-L-PaTx2. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-PaTx2.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCTACTGCCAGA\n\n\nSEQ ID NO: 822\n\n\n\n\n\n\nAATGGA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTGTGGACCTGCGACGAAGAACGTAAATGCTG\n\n\nSEQ ID NO: 823\n\n\n\n\n\n\nCGAAGGTCTGGTTTGCCGTCTGTGGTGCAAAC\n\n\n\n\n\n\nGTATCATCAACATG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTACATGTTGATGATACGTTTGCACCACAGA\n\n\nSEQ ID NO: 824\n\n\n\n\n\n\nCGGCAAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCAGACCTTCGCAGCATTTACGTTCTTCGTCG\n\n\nSEQ ID NO: 825\n\n\n\n\n\n\nCAGGTCCACATCCATTTCTGGCAGTAGGAACC\n\n\n\n\n\n\nACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCTACTGCCAGAAATGGATGTGGACCTGCGACGAAGAACG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n 1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGATGACGGTCTTTACCTACACCTGGACGCTGCTTCTTGC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  Y  C  Q  K  W  M  W  T  C  D  E  E  R\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTAAATGCTGCGAAGGTCTGGTTTGCCGTCTGTGGTGCAAACGTATCATCAACATG\n\n\n \n\n\nSEQ ID NO: 826\n\n\n\n\n\n\n61\n\n\n---------+---------+---------+---------+---------+-----\n\n\n\n\n\n\n \n\n\nATTTACGACGCTTCCAGACCAAACGGCAGACACCACGTTTGCATAGTAGTTGTACATTC\n\n\n \n\n\nSEQ ID NO: 828\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n K  C  C  E  G  L  V  C  R  L  W  C  K  R  I  I  N  M\n\n\n—\n\n\nSEQ ID NO: 827\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 25\n\n\nFc-L-wGVIA Bacterial Expression\n\n\nBacterial expression of Fc-L-wGVIA. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-wGVIA.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCTGCAAATCCC\n\n\nSEQ ID NO: 829\n\n\n\n\n\n\nCGGGTT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCCTCCTGCTCCCCGACCTCCTACAACTGCTGC\n\n\nSEQ ID NO: 830\n\n\n\n\n\n\nCGTTCCTGCAACCCGTACACCAAACGTTGCTA\n\n\n\n\n\n\nCGGT;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAACCGTAGCAACGTTTGGTGTACGGGTTG\n\n\nSEQ ID NO: 831\n\n\n\n\n\n\nCAGGAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGGCAGCAGTTGTAGGAGGTCGGGGAGCAGGA\n\n\nSEQ ID NO: 832\n\n\n\n\n\n\nGGAACCCGGGGATTTGCAGGAACCACCACCAC\n\n\n\n\n\n\nCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCTGCAAATCCCCGGGTTCCTCCTGCTCCCCGACCTCCTA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n 1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGACGTTTAGGGGCCCAAGGAGGACGAGGGGCTGGAGGAT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  C  K  S  P  G  S  S  C  S  P  T  S  Y\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCAACTGCTGCCGTTCCTGCAACCCGTACACCAAACGTTGCTACGGT\n\n\n \n\n\nSEQ ID NO: 833\n\n\n\n\n\n\n61\n\n\n---------+---------+---------+---------+------\n\n\n\n\n\n\n \n\n\nGTTGACGACGGCAAGGACGTTGGGCATGTGGTTTGCAACGATGCCAATTC\n\n\n \n\n\nSEQ ID NO: 835\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n N  C  C  R  S  C  N  P  Y  T  K  R  C  Y  G\n\n\n \n\n\nSEQ ID NO: 834\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 26\n\n\nFc-L-ωMVIIA Bacterial Expression\n\n\nBacterial expression of Fc-L-ωMVIIA. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ωMVIIA.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCTGCAAAGGTA\n\n\nSEQ ID NO: 836\n\n\n\n\n\n\nAA//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGGTGCTAAATGCTCCCGTCTGATGTACGACTG\n\n\nSEQ ID NO: 837\n\n\n\n\n\n\nCTGCACCGGTTCCTGCCGTTCCGGTAAATGCG\n\n\n\n\n\n\nGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAACCGCATTTACCGGAACGGCAGGAACCG\n\n\nSEQ ID NO: 838\n\n\n\n\n\n\nGT//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCAGCAGTCGTACATCAGACGGGAGCATTTAG\n\n\nSEQ ID NO: 839\n\n\n\n\n\n\nCACCTTTACCTTTGCAGGAACCACCACCACCG\n\n\n\n\n\n\nGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCTGCAAAGGTAAAGGTGCTAAATGCTCCCGTCTGATGTA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGACGTTTCCATTTCCACGATTTACGAGGGCAGACTACAT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  C  K  G  K  G  A  K  C  S  R  L  M  Y\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGACTGCTGCACCGGTTCCTGCCGTTCCGGTAAATGCGGT\n\n\n \n\n\nSEQ ID NO: 840\n\n\n\n\n\n\n61\n\n\n---------+---------+---------+---------+\n\n\n\n\n\n\n \n\n\nGCTGACGACGTGGCCAAGGACGGCAAGGCCATTTACGCCAATTC\n\n\n \n\n\nSEQ ID NO: 842\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n D  C  C  T  G  S  C  R  S  G  K  C  G\n\n\n—\n\n\nSEQ ID NO: 841\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 27\n\n\nFc-L-PtuI Bacterial Expression\n\n\nBacterial expression of Fc-L-Ptu1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-Ptu1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCGCTGAAAAAG\n\n\nSEQ ID NO: 843\n\n\n\n\n\n\nACTGCATC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nGCTCCGGGTGCTCCGTGCTTCGGTACCGACA\n\n\nSEQ ID NO: 844\n\n\n\n\n\n\nAACCGTGCTGCAACCCGCGTGCTTGGTGCTCC\n\n\n\n\n\n\nTCCTACGCTAACAAATGCCTG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTACAGGCATTTGTTAGCGTAGGAGGAGCAC\n\n\nSEQ ID NO: 845\n\n\n\n\n\n\nCAAGCACG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCGGGTTGCAGCACGGTTTGTCGGTACCGAAGC\n\n\nSEQ ID NO: 846\n\n\n\n\n\n\nACGGAGCACCCGGAGCGATGCAGTCTTTTTCA\n\n\n\n\n\n\nGCGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGCTGAAAAAGACTGCATCGCTCCGGGTGCTCCGTGCTT\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCGACTTTTTCTGACGTAGCGAGGCCCACGAGGCACGAA\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  A  E  K  D  C  I  A  P  G  A  P  C  F\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n \nCGGTACCGACAAACCGTGCTGCAACCCGCGTGCTTGGTGCTCCTCCTACGCTAACAAATG\n \n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGCCATGGCTGTTTGGCACGACGTTGGGCGCACGAACCACGAGGAGGATGCGATTGTTTAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  T  D  K  P  C  C  N  P  R  A  W  C  S  S  Y  A  N  K  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCTG\n\n\n \n\n\nSEQ ID NO: 847\n\n\n\n\n\n\n121\n\n\n----\n\n\n\n\n\n\n \n\n\nGGACATTC\n\n\n \n\n\nSEQ ID NO: 849\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n L\n\n\n—\n\n\nSEQ ID NO: 648\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 28\n\n\nFc-L-ProTx1 Bacterial Expression\n\n\nBacterial expression of Fc-L-ProTx1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-ProTx1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTGGTTCCGGTGGTGGTGGTTCCGAATGCCGT\n\n\nSEQ ID NO: 850\n\n\n\n\n\n\n \n\n\nTACTGGCTGG//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGTGGTTGCTCCGCTGGTCAGACCTGCTGCAA\n\n\nSEQ ID NO: 851\n\n\n\n\n\n\n \n\n\nACACCTGGTTTGCTCCCGTCGTCACGGTTGG\n\n\n\n\n\n\n \n\n\nTGCGTTTGGGACGGTACCTTCTCC//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCTTAGGAGAAGGTACCGTCCCAAACGCACC\n\n\nSEQ ID NO: 852\n\n\n\n\n\n\n \n\n\nAACCGTGACGA//;\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nCGGGAGCAAACCAGGTGTTTGCAGCAGGTCT\n\n\nSEQ ID NO: 853\n\n\n\n\n\n\n \n\n\nGACCAGCGGAGCAACCACCCAGCCAGTAAC\n\n\n\n\n\n\n \n\n\nGGCATTCGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCGAATGCCGTTACTGGCTGGGTGGTTGCTCCGCTGGTCA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGCTTACGGCAATGACCGAGCCACCAACGAGGCGAGCAGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  E  C  R  Y  W  L  G  G  C  S  A  G  Q\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nGACCTGCTGCAAACACCTGGTTTGCTCCCGTCGTCACGGTTGGTGCGTTTGGGACGGTAC\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nCTGGACGACGTTTGTGGACCAAACGAGGGCAGCAGTGCCAACCACGCAAACCCTGCCATG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n T  C  C  K  H  L  V  C  S  R  R  H  G  W  C  V  W  D  G  T\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTTCTCC\n\n\n \n\n\nSEQ ID NO: 854\n\n\n\n\n\n\n121\n\n\n------->\n\n\n\n\n\n\n \n\n\nGAAGAGGATTC\n\n\n \n\n\nSEQ ID NO: 856\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n F  S\n\n\n—\n\n\nSEQ ID NO: 855\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 29\n\n\nFc-L-BeKM1 Bacterial Expression\n\n\nBacterial expression of Fc-L-BeKM1. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-BeKM1.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nTGGTTCCGGTGGTGGTGGTTCCCGTCCGACCG\n\n\nSEQ ID NO: 857\n\n\n\n\n\n\nACATCAAATG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTCCGAATCCTACCAGTGCTTCCCGGTTTGCA\n\n\nSEQ ID NO: 858\n\n\n\n\n\n\nAATCCCGTTTCGGTAAAACCAACGGTCGTTGC\n\n\n\n\n\n\nGTTAACGGTTTCTGCGACTGCTTC//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nCTTAGAAGCAGTCGCAGAAACCGTTAACGCA\n\n\nSEQ ID NO: 859\n\n\n\n\n\n\nACGACCGTTGG//;\n\n\n\n\n\n\n \n\n\n\n\n\n\nTTTTACCGAAACGGGATTTGCAAACCGGGAAG\n\n\nSEQ ID NO: 860\n\n\n\n\n\n\nCACTGGTAGGATTCGGAGCATTTGATGTCGGT\n\n\n\n\n\n\nCGGACGGGAACCACCACCACCGGA//;\n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCCGTCCGACCGACATCAAATGCTCCGAATCCTACCAGTG\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGGCAGGCTGGCTGTAGTTTACGAGGCTTAGGATGGTCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  R  P  T  D  I  K  C  S  E  S  Y  Q  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTTCCCGGTTTGCAAATCCCGTTTCGGTAAAACCAACGGTCGTTGCGTTAACGGTTTCTG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nGAAGGGCCAAACGTTTAGGGCAAAGCCATTTTGGTTGCCAGCAACGCAATTGCCAAAGAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n F  P  V  C  K  S  R  F  G  K  T  N  G  R  C  V  N  G  F  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCGACTGCTTC\n\n\n \n\n\nSEQ ID NO: 861\n\n\n\n\n\n\n121\n\n\n---------+\n\n\n\n\n\n\n \n\n\nGCTGACGAAGATTC\n\n\n \n\n\nSEQ ID NO: 863\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n D  C  F\n\n\n—\n\n\nSEQ ID NO: 862\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 30\n\n\nFc-L-CTX Bacterial Expression\n\n\nBacterial expression of Fc-L-CTX. The methods to clone and express the peptibody in bacteria are described in Example 3. The vector used was pAMG21ampR-Fc-Pep and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Fc-L-CTX.\n\n\nOligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTGGTTCCGGTGGTGGTGGTTCCATG\n\n\nSEQ ID NO: 864\n\n\n\n\n\n\n \n\n\nTGCATGCCGTGCTTCAC//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCACCGACCACCAGATGGCTCGTAAATGCG\n\n\nSEQ ID NO: 865\n\n\n\n\n\n\n \n\n\nACGACTGCTGCGGTGGTAAAGG\n\n\n \n\n\n\n\n\n\n \n\n\nTCGTGGTAAATGCTACGGTCCG\n\n\n \n\n\n\n\n\n\n \n\n\nCAGTGCCTGTGCCGT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTTAACGGCACAGGCACTGCGGACCG\n\n\nSEQ ID NO: 866\n\n\n\n\n\n\n \n\n\nTAGCATTTACCACGAC//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCTTTACCACCGCAGCAGTCGTCGCATTTA\n\n\nSEQ ID NO: 867\n\n\n\n\n\n\n \n\n\nCGAGCCATCTGGTGGTCGGTGG\n\n\n \n\n\n\n\n\n\n \n\n\nTGAAGCACGGCATGCACATGGA\n\n\n \n\n\n\n\n\n\n \n\n\nACCACCACCACCGGA//;\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos above were used to form the duplex below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nTGGTTCCGGTGGTGGTGGTTCCATGTGCATGCCGTGCTTCACCACCGACCACCAGATGGC\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    AGGCCACCACCACCAAGGTACACGTACGGCACGAAGTGGTGGCTGGTGGTCTACCG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G  G  G  G  S  M  C  M  P  C  F  T  T  D  H  Q  M  A\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTCGTAAATGCGACGACTGCTGCGGTGGTAAAGGTCGTGGTAAATGCTACCGTCCGCAGTG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nAGCATTTACGCTGCTGACGACGCCACCATTTCCAGCACCATTTACGATGCCAGGCGTCAC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n R  K  C  D  D  C  C  G  G  K  G  R  G  K  C  Y  G  P  Q  C\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nCCTGTGCCGT\n\n\n \n\n\nSEQ ID NO: 868\n\n\n\n\n\n\n121\n\n\n---------+\n\n\n\n\n\n\n \n\n\nGGACACGGCACCAC\n\n\n \n\n\nSEQ ID NO: 870\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n L  C  R\n\n\n—\n\n\nSEQ ID NO: 869\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 31\n\n\nN-Terminally PEGylated-Des-Arg1-ShK\n\n\nPeptide Synthesis of reduced Des-Arq1-ShK. Des-Arg1-ShK, having the sequence\n\n\nSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC  (\nPeptide\n 1, SEQ ID NO: 92)\n\n\nwas synthesized in a stepwise manner on a Symphony™ multi-peptide synthesizer by solid-phase peptide synthesis (SPPS) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-methyl morpholine (NMM)/N,N-dimethyl-formamide (DMF) coupling chemistry at 0.1 mmol equivalent resin scale on Tentagel™-S PHB Fmoc-Cys(Trt)-resin. N-alpha-(9-fluorenylmethyloxycarbonyl)- and side-chain protected amino acids were purchased from Midwest Biotech Incorporated. Fmoc-Cys(Trt)-Tentagel™ resin was purchased from Fluka. The following side-chain protection strategy was employed: Asp(O\nt\nBu), Arg(Pbf), Cys(Trt), Gln(Trt), His(Trt), Lys(N\nε\n-Boc), Ser(O\nt\nBu), Thr(O\nt\nBu) and Tyr(O\nt\nBu). Two Oxazolidine dipeptides, Fmoc-Gly-Thr(\nψMe,Me\nPro)-OH and Fmoc-Leu-Ser(\nψMe,Me\nPro)-OH, were used in the chain assembly and were obtained from NovaBiochem and used in the synthesis of the sequence. The protected amino acid derivatives (20 mmol) were dissolved in 100 \nml\n 20% dimethyl sulfoxide (DMSO) in DMF (v/v). Protected amino acids were activated with 20 mM HBTU, 400 mM NMM in 20% DMSO in DMF, and coupling were carried out using two treatments with 0.5 mmol protected amino acid, 0.5 mmol HBTU, 1 mmol NMM in 20% DMF/DMSO for 25 minutes and then 40 minutes. Fmoc deprotection reactions were carried out with two treatments using a 20% piperidine in DMF (v/v) solution for 10 minutes and then 15 minutes. Following synthesis, the resin was then drained, and washed with DCM, DMF, DCM, and then dried in vacuo. The peptide-resin was deprotected and released from the resin by treatment with a TFA/EDT/TIS/H\n2\nO (92.5:2.5:2.5:2.5 (v/v)) solution at room temperature for 1 hour. The volatiles were then removed with a stream of nitrogen gas, the crude peptide precipitated twice with cold diethyl ether and collected by centrifugation. The crude peptide was then analyzed on a Waters 2795 analytical RP-HPLC system using a linear gradient (0-60% buffer B in 12 minutes, A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile) on a \nJupiter\n 4 \nμm Proteo™\n 90 Å column. A PE-Sciex™ API Electro-spray mass spectrometer was used to confirm correct peptide product mass. Crude peptide was obtained in 143 mg yield at approximately 70% pure based as estimated by analytical RP-HPLC analysis. Reduced Des-Arg1-ShK (Peptide 1) Retention time (Rt)=5.31 minutes, calculated molecular weight=3904.6917 Da (average); Experimental observed molecular weight 3907.0 Da.\n\n\n\nFolding of Des-Arq1-ShK (Disulphide bond formation). Following TFA cleavage and peptide precipitation, reduced Des-Arg1-ShK was then air-oxidized to give the folded peptide. The crude cleaved peptide was extracted using 20% AcOH in water (v/v) and then diluted with water to a concentration of approximately 0.15 mg reduced Des-Arg1-ShK per mL, the pH adjusted to about 8.0 using NH\n4\nOH (28-30%), and gently stirred at room temperature for 36 hours. Folding process was monitored by LC-MS analysis. Following this, folded Des-Arg1-ShK peptide was purified using reversed phase HPLC using a 1″ \nLuna\n 5 \nμm C18\n 100 Å Proteo™ column with a linear gradient 0-40% buffer B in 120 min (A=0.1% TFA in water, B=0.1% TFA in acetonitrile). Folded Des-Arg1-ShK crude peptide eluted earlier (when compared to the elution time in its reduced form) at approximately 25% buffer B. Folded Des-Arg1-ShK (Peptide 2) was obtained in 23.2 mg yield in >97% purity as estimated by analytical RP-HPLC analysis (\nFIG. 20A\n). Calculated molecular weight=3895.7693 Da (monoisotopic), experimental observed molecular weight=3896.5 Da(analyzed on a Waters LCT Premier Micromass MS Technologies). (\nFIG. 20B\n). Des-Arg1-ShK disulfide connectivity was C1-C6, C2-C4, C3-C5.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nN-terminal PEGylation of Folded Des-Arq1-ShK. Folded Des-Arg1-ShK, (Peptide 2) was dissolved in water at 1 mg/ml concentration. A 2 M MeO-PEG-Aldehyde, CH\n3\nO—[CH\n2\nCH\n2\nO]n-CH\n2\nCH\n2\nCHO (average \nmolecular weight\n 20 kDa), solution in 50 mM NaOAc, pH 4.5, and a separate 1 \nM\n solution of NaCNBH\n3 \nwere freshly prepared. The peptide solution was then added to the MeO-PEG-Aldehyde containing solution and was followed by the addition of the NaCNBH\n3 \nsolution. The reaction stoichiometry was peptide:PEG:NaCNBH3 (1:2:0.02), respectively. The reaction was left for 48 hours, and was analyzed on an Agilent 1100 RP-HPLC system using Zorbax™ 300SB-\nC8\n 5 μm column at 40° C. with a linear gradient (6-60% B in 16 minutes, A: 0.1% TFA in water, B: 0.1% TFA/90% ACN in water). Mono-pegylated folded Des-Arg1-ShK constituted approximately 58% of the crude product by analytical RP-HPLC. Mono Pegylated Des-Arg1-ShK was then isolated using a \nHiTrap™\n 5 ml SP HP cation exchange column on AKTA FPLC system at 4° C. at 1 mL/min using a gradient of 0-50% B in 25 column volumes (Buffers: A=20 m\nM\n sodium acetate pH 4.0, B=1 \nM\n NaCl, 20 m\nM\n sodium acetate, pH 4.0). The fractions were analyzed using a 4-20 tris-Gly SDS-PAGE gel and RP-HPLC (as described for the crude). SDS-PAGE gels were run for 1.5 hours at 125 V, 35 mA, 5 W. Pooled product was then dialyzed at 4° C. in 3 changes of 1 L of A4S buffer (10 m\nM\n NaOAc, 5% sorbitol, pH 4.0). The dialyzed product was then concentrated in 10 K microcentrifuge filter to 2 mL volume and sterile-filtered using 0.2 μM syringe filter to give the final product. N-Terminally PEGylated-Des-Arg1-ShK (Peptide 3) was isolated in 1.7 mg yield with 85% purity as estimated by analytical RP-HPLC analysis (\nFIG. 23\n).\n\n\nThe N-Terminally PEGylated-Des-Arg1-ShK, also referred to as “PEG-ShK[2-35]”, was active in blocking human Kv1.3 (\nFIG. 38A\n and \nFIG. 38B\n) as determined by patch clamp electrophysiology (Example 36).\n\n\nExample 32\n\n\nN-Terminally PEGylated ShK\n\n\nThe experimental procedures of this working example correspond to the results shown in \nFIG. 17\n.\n\n\nPeptide Synthesis of reduced ShK. ShK, having the amino acid sequence\n\n\n \n \n \n \n \nRSCIDTIPKSRCTAFQCKHSMKY\n \n(\nPeptide\n 4, SEQ ID NO: 5)\n \n \n \nRLSFCRKTCGTC\n \n \n \n \n \n \n \n\nwas synthesized in a stepwise manner on a Symphony™ multi-peptide synthesizer by solid-phase peptide synthesis (SPPS) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-methyl morpholine (NMM)/N,N-dimethyl-formamide (DMF) coupling chemistry at 0.1 mmol equivalent resin scale on Tentagel™-S PHB Fmoc-Cys(Trt)-resin. N-alpha-9-fluorenylmethyloxycarbonyl) and side-chain protected amino acids were purchased from Midwest Biotech Incorporated. Fmoc-Cys(Trt)-Tentagel™ resin was purchased from Fluka. The following side-chain protection strategy was employed: Asp(O\nt\nBu), Arg(Pbf), Cys(Trt), Gln(Trt), His(Trt), Lys(N\nε\n-Boc), Ser(O\nt\nBu), Thr(O\nt\nBu) and Tyr(O\nt\nBu). Two Oxazolidine dipeptides, Fmoc-Gly-Thr(\nψMe,Me\nPro)-OH and Fmoc-Leu-Ser(\nψMe,Me\nPro)-OH, were used in the chain assembly and were obtained from NovaBiochem and used in the synthesis of the sequence. The protected amino acid derivatives (20 mmol) were dissolved in 100 \nml\n 20% dimethyl sulfoxide (DMSO) in DMF (v/v). Protected amino acids were activated with 200 mM HBTU, 400 mM NMM in 20% DMSO in DMF, and coupling were carried out using two treatments with 0.5 mmol protected amino acid, 0.5 mmol HBTU, 1 mmol NMM in 20% DMF/DMSO for 25 minutes and then 40 minutes. Fmoc deprotections were carried out with two treatments using a 20% piperidine in DMF (v/v) solution for 10 minutes and then 15 minutes. Following synthesis, the resin was then drained, and washed with DCM, DMF, DCM, and then dried in vacuo. The peptide-resin was deprotected and released from the resin by treatment with a TFA/EDT/TIS/H\n2\nO (92.5:2.5:2.5:2.5 (v/v)) solution at room temperature for 1 hour. The volatiles were then removed with a stream of nitrogen gas, the crude peptide precipitated twice with cold diethyl ether and collected by centrifugation. The crude peptide was then analyzed on a Waters 2795 analytical RP-HPLC system using a linear gradient (0-60% buffer B in 12 minutes, A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile) on a \nJupiter\n 4 \nμm Proteo™\n 90 Å column. A PE-Sciex API Electro-spray mass spectrometer was used to confirm correct peptide product mass. Crude peptide was approximately was obtained 170 mg yield at about 45% purity as estimated by analytical RP-HPLC analysis. Reduced ShK (Peptide 4) Retention time (Rt)=5.054 minutes, calculated molecular weight=4060.8793 Da (average); experimental observed molecular weight=4063.0 Da.\n\n\n\nFolding of ShK (Disulphide bond formation). Following TFA cleavage and peptide precipitation, reduced ShK was then air oxidized to give the folded peptide. The crude cleaved peptide was extracted using 20% AcOH in water (v/v) and then diluted with water to a concentration of approximately 0.15 mg reduced ShK per mL, the pH adjusted to about 8.0 using NH\n4\nOH (28-30%), and gently stirred at room temperature for 36 hours. Folding process was monitored by LC-MS analysis. Following this, folded ShK peptide was purified by reversed phase HPLC using a 1″ \nLuna\n 5 \nμm C18\n 100 Å Proteo™ column with a linear gradient 0-40% buffer B in 120 min (A=0.1% TFA in water, B=0.1% TFA in acetonitrile). Folded ShK crude peptide eluted earlier (when compared to the elution time in its reduced form) at approximately 25% buffer B. Folded ShK (Peptide 5) was obtained in 25.5 mg yield in >97% purity as estimated by analytical RP-HPLC analysis. See \nFIG. 60\n. Calculated molecular weight=4051.8764 Da (monoisotopic); experimental observed molecular weight=4052.5 Da (analyzed on Waters LCT Premier Micromass MS Technologies). ShK disulfide connectivity was C1-C6, C2-C4, and C3-C5.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nN-terminal PEGylation of Folded ShK. Folded ShK, having the amino acid sequence\n\n\n \n \n \n \n \nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n \n(SEQ ID NO: 5)\n \n \n \n \n \n\ncan be dissolved in water at 1 mg/ml concentration. A 2 M MeO-PEG-Aldehyde, CH\n3\nO—CH\n2\nCH\n2\nO]n-CH\n2\nCH\n2\nCHO (average \nmolecular weight\n 20 kDa), solution in 50 mM NaOAc, pH 4.5 and a separate 1 M solution of NaCNBH\n3 \ncan be freshly prepared. The peptide solution can be then added to the MeO-PEG-Aldehyde containing solution and can be followed by the addition of the NaCNBH\n3 \nsolution. The reaction stoichiometry can be peptide:PEG:NaCNBH3 (1:2:0.02), respectively. The reaction can be left for 48 hours, and can be analyzed on an Agilent™ 1100 RP-HPLC system using Zorbax™ 300SB-\nC8\n 5 μm column at 40° C. with a linear gradient (6-60% B in 16 minutes, A: 0.1% TFA in water, B: 0.1% TFA/90% ACN in water). Mono-pegylated Shk (Peptide 6) can be then isolated using a \nHiTrap™\n 5 mL SP HP cation exchange column on AKTA FPLC system at 4° C. at 1 mL/min using a gradient of 0-50% B in 25 column volumes (Buffers: A=20 mM sodium acetate pH 4.0, B=1 M NaCl, 20 mM sodium acetate, pH 4.0). The fractions can be analyzed using a 4-20 tris-Gly SDS-PAGE gel and RP-HPLC. SDS-PAGE gels can be run for 1.5 hours at 125 V, 35 mA, 5 W. Pooled product can be then dialyzed at 4° C. in 3 changes of 1 L of A4S buffer (10 m\nM\n sodium acetate, 5% sorbitol, pH 4.0). The dialyzed product can be then concentrated in 10 K microcentrifuge filter to 2 mL volume and sterile-filtered using 0.2 μM syringe filter to give the final product.\n\n\n\nExample 33\n\n\nN-Terminally PEGylated ShK by Oxime Formation\n\n\nPeptide Synthesis of reduced ShK. ShK, having the sequence\n\n\n \n \n \n \n \nRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC\n \n(SEQ ID NO: 5)\n \n \n \n \n \n\ncan be synthesized in a stepwise manner on a Symphony™ multi-peptide synthesizer by solid-phase peptide synthesis (SPPS) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-methyl morpholine (NMM)/N,N-dimethyl-formamide (DMF) coupling chemistry at 0.1 mmol equivalent resin scale on Tentagel™-S PHB Fmoc-Cys(Trt)-resin. N-alpha-(9-fluorenylmethyloxycarbonyl)- and side-chain protected amino acids can be purchased from Midwest Biotech Incorporated. Fmoc-Cys(Trt)-Tentagel™ resin can be purchased from Fluka. The following side-chain protection strategy can be employed: Asp(O\nt\nBu), Arg(Pbf), Cys(Trt), Gln(Trt), His(Trt), Lys(N\nε\n-Boc), Ser(O\nt\nBu), Thr(O\nt\nBu) and Tyr(O\nt\nBu). Two Oxazolidine dipeptides, Fmoc-Gly-Thr(Ψ\nMe,Me\nPro)-OH and Fmoc-Leu-Ser(ψ\nMe,Me\nPro)-OH, can be used in the chain assembly and can be obtained from NovaBiochem and used in the synthesis of the sequence. The protected amino acid derivatives (20 mmol) can be dissolved in 100 \nml\n 20% dimethyl sulfoxide (DMSO) in DMF (v/v). Protected amino acids can be activated with 200 mM HBTU, 400 mM NMM in 20% DMSO in DMF, and coupling can be carried out using two treatments with 0.5 mmol protected amino acid, 0.5 mmol HBTU, 1 mmol NMM in 20% DMF/DMSO for 25 minutes and then 40 minutes. Fmoc deprotection reactions can be carried out with two treatments using a 20% piperidine in DMF (v/v) solution for 10 minutes and then 15 minutes. Following the chain-assembly of the Shk peptide, Boc-amionooxyacetic acid (1.2 equiv) can be coupled at the N-terminus using 0.5 \nM\n HBTU in DMF with 4 equiv collidine for 5 minutes. Following synthesis, the resin can be then drained, and washed with DCM, DMF, DCM, and then dried in vacuo. The peptide-resin can be deprotected and released from the resin by treatment with a TFA/amionooxyacetic acid/TIS/EDT/H2O (90:2.5:2.5:2.5:2.5) solution at room temperature for 1 hour. The volatiles can be then removed with a stream of nitrogen gas, the crude peptide precipitated twice with cold diethyl ether and collected by centrifugation. The aminooxy-Shk peptide (Peptide 7) can be then analyzed on a Waters 2795 analytical RP-HPLC system using a linear gradient (0-60% buffer B in 12 minutes, A: 0.1% TFA in water also containing 0.1% aminooxyacetic acid, B: 0.1% TFA in acetonitrile) on a \nJupiter\n 4 \nμm Proteo™\n 90 Å column.\n\n\n\nReversed-Phase HPLC Purification. Preparative Reversed-phase high-performance liquid chromatography can be performed on C18, 5 μm, 2.2 cm×25 cm) column. Chromatographic separations can be achieved using linear gradients of buffer B in A (A=0.1% aqueous TFA; B=90% aq. ACN containing 0.09% TFA and 0.1% aminooxyacetic acid), typically 5-95% over 90 minutes at 15 mL/min. Preparative HPLC fractions can be characterized by ESMS and photodiode array (PDA) HPLC, combined and lyophilized.\n\n\nN-Terminal PEGylation of Shk by Oxime Formation. Lyophilized aminooxy-Shk (Peptide 7) can be dissolved in 50% HPLC buffer A/B (5 mg/mL) and added to a two-fold molar excess of MeO-PEG-Aldehyde, CH\n3\nO—[CH\n2\nCH\n2\nO]\nn\n—CH\n2\nCH\n2\nCHO (average \nmolecular weight\n 20 kDa). The reaction can be left for 24 hours, and can be analyzed on an Agilent™ 1100 RP-HPLC system using Zorbax™ 300SB-\nC8\n 5 μm column at 40° C. with a linear gradient (6-60% B in 16 minutes, A: 0.1% TFA in water, B: 0.1% TFA/90% ACN in water). Mono-pegylated reduced Shk constituted approximately 58% of the crude product by analytical RP-HPLC. Mono PEGylated (oximated) Shk (Peptide 8) can be then isolated using a \nHiTrap™\n 5 mL SP HP cation exchange column on AKTA FPLC system at 4° C. at 1 mL/min using a gradient of 0-50% B in 25 column volumes (Buffers: A 20 mM sodium acetate pH 4.0, B=1 M NaCl, 20 mM sodium acetate, pH 4.0). The fractions can be analyzed using a 4-20 tris-Gly SDS-PAGE gel and RP-HPLC. SDS-PAGE gels can be run for 1.5 hours at 125 V, 35 mA, 5 W. Pooled product can be then dialyzed at 4° C. in 3 changes of 1 L of A4S buffer (10 mM NaOAc, 5% sorbitol, pH 4.0). The dialyzed product can be then concentrated in 10 K microcentrifuge filter to 2 mL volume and sterile-filtered using 0.2 μM syringe filter to give the final product.\n\n\nFolding of ShK (Disulphide bond formation). The mono-PEGylated (oximated) Shk can be dissolved in 20% AcOH in water (v/v) and can be then diluted with water to a concentration of approximately 0.15 mg peptide mL, the pH adjusted to about 8.0 using NH\n4\nOH (28-30%), and gently stirred at room temperature for 36 hours. Folding process can be monitored by LC-MS analysis. Following this, folded mono-PEGylated (oximated) Shk (Peptide 9) can be purified using by reversed phase HPLC using a 1″ \nLuna\n 5 \nμm C18\n 100 Å Proteo™ column with a linear gradient 0-40% buffer B in 120 min (A=0.1% TFA in water, B=0.1% TFA in acetonitrile). Mono-PEGylated (oximated) ShK disulfide connectivity can be C1-C6, C2-C4, and C3-C5.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nExample 34\n\n\nN-Terminally PEGylated ShK (Amidation)\n\n\nThe experimental procedures of this working example correspond to the results shown in \nFIG. 18\n.\n\n\nN-Terminal PEGylation of Shk by Amide Formation. A 10 mg/mL solution of folded Shk (Peptide 5), in 100 m\nM\n Bicine pH 8.0, can be added to solid succinimidyl ester of 20 kDa PEG propionic acid (mPEG-SPA; CH\n3\nO—[CH\n2\nCH\n2\nO]n-CH\n2\nCH\n2\nCO—NHS) at room temperature using a 1.5 molar excess of the mPEG-SPA to Shk. After one hour with gentle stirring, the mixture can be diluted to 2 mg/mL with water, and the pH can be adjusted to 4.0 with dilute HCl. The extent of mono-pegylated Shk (Peptide 10), some di-PEGylated Shk or tri-PEGylated Shk, unmodified Shk and succinimidyl ester hydrolysis can be determined by SEC HPLC using a \nSuperdex™\n 75 \nHR\n 10/30 column (Amersham) eluted with 0.05 \nM\n NaH\n2\nPO\n4\n, 0.05 \nM\n Na\n2\nHPO\n4\n, 0.15 \nM\n NaCl, 0.01 \nM\n NaN\n3\n, pH 6.8, at 1 mL/min. The fractions can be analyzed using a 4-20 tris-Gly SDS-PAGE gel and RP-HPLC. SDS-PAGE gels can be run for 1.5 hours at 125 V, 35 mA, 5 W. Pooled product can be then dialyzed at 4° C. in 3 changes of 1 L of A4S buffer (10 m\nM\n NaOAc, 5% sorbitol, pH 4.0). The dialyzed N-terminally PEGylated (amidated) ShK (Peptide 10) can be then concentrated in 10 K microcentrifuge filter to 2 mL volume and sterile-filtered using 0.2 μ\nM\n syringe filter to give the final product.\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\nExample 35\n\n\nFc-L-SmIIIA\n\n\nFc-SmIIIA expression vector. A 104 bp BamHI-NotI fragment containing partial linker sequence and SmIIIA peptide encoded with human high frequency codons was assembled by PCR with overlapping primers 3654-50 and 3654-51 and cloned into to the 7.1 kb NotI-BamHI back bone to generate pcDNA3.1(+) CMVi-hFc-SmIIIA as described in Example 1.\n\n\n \n \n \n \n \n \n \n \n \n  \nBamHI\n \n \n \n \n \n \n5′\nGGATCC\nGGAGGAGGAGGAAGCTGCTGCAACGGC\n \nSEQ ID NO: 872\n \n \n \nCGCCGCGGCTGCAGCAGCCGCTGG\n \n \n \n \n \n                       C  C  N  G  R\n \nSEQ ID NO: 873\n \n \n \nR  G  C  S  S  R  W\n \n \n \n \n \n \n \n \n \nTGCCGCGACCACAGCCGC\n \n \n \n \n \nC  R  D  H  S  R  C\n \n \n \n \n \nTGCTGCTGA\nGCGGCCGC3\n′//\n \n \n \n \n \n \nC     NotI\n \n \n \n \n \n \n \n \n \n \nForward\n \n \n \n 5′-3′:\n \n \n \n \n \nGGAGGAGGATCCGGAGGAGGAGGAAGCTGCTG\n \nSEQ ID NO: 874\n \n \n \nCAACGGCCGCCGCGGCTGCAGCAGC CGC\n//\n \n \n \n \n \n \n \n \n \n \nReverse\n \n \n \n 5′-3′:\n \n \n \n \n \nATTATTGCGGCCGCTCAGCAGCAGCGGCTGTG\n \nSEQ ID NO: 875\n \n \n \nGTCGCGGCACCAGCGGCTGCTGCAG CCGC\n \n \n \n \n \n \n \n\nThe sequences of the BamHI to NotI fragments in the final constructs were verified by sequencing.\n\n\n\nTransient expression of Fc-L-SmIIIa. 7.5 ug of the toxin peptide Fc fusion construct pcDNA3.1(+) CMVi-hFc-SmIIIA were transfected into 293-T cells in 10 cm tissue culture plate with \nFuGENE\n 6 as transfection reagent. Culture medium was replaced with serum-free medium at 24 hours post-transfection and the conditioned medium was harvested at \nday\n 5 post-transfection. Transient expression of Fc-SmIIIA from 293-T cells was analyzed by Western blot probed with anti-hFc antibody (\nFIG. 25A\n and \nFIG. 25B\n). Single band of expressed protein with estimated MW was shown in both reduced and non-reduced samples. Transient expression level of Fc-SmIIIA was further determined to be 73.4 μg/ml according to ELISA.\n\n\nExample 36\n\n\nElectrophysiology Experiments\n\n\nCell Culture. Stable cell line expressing human Kv1.3 channel was licensed from Biofocus. Cells were kept at 37° C. in 5% CO\n2 \nenvironment. Culture medium contains DMEM with GlutaMax™ (Invitrogen), 1× non-essential amino acid, 10% fetal bovine serum and 500 μg/mL geneticin. Cells were plated and grown at low confluence on 35 mm culture dishes for at least 24 hours prior to electrophysiology experiments.\n\n\nElectrophysiology Recording by Patch Clamping. Whole-cell currents were recorded from single cells by using tight seal configuration of the patch-clamp technique. A 35 mm culture dish was transferred to the recording stage after rinsing and replacing the culture medium with recording buffer containing 135 m\nM\n NaCl, 5 mM KCl, 1.8 mM CaCl\n2\n, 10 mM HEPES, and 5 mM Glucose. pH was adjusted to 7.4 with NaOH and the osmolarity was set at 300 mOsm. Cells were perfused continuously with the recording buffer via one of the glass capillaries arranged in parallel and attached to a motorized rod, which places the glass capillary directly on top of the cell being recorded. Recording pipette solution contained 90 m\nM\n K-gluconate, 20 m\nM\n KF, 10 m\nM\n NaCl, 1 m\nM\n MgCl\n2\n-6H\n2\nO, 10 m\nM\n EGTA, 5 mM K2-ATP, and 10 mM HEPES. The pH for the internal solution was adjusted to 7.4 with KOH and the osmolarity was set at 280 mOsm. Experiments were performed at room temperature (20-22° C.) and recorded using Multiclamp™ 700 A amplifier (Molecular Devices Inc.). Pipette resistances were typically 2-3 MΩ.\n\n\nProtein toxin potency determination on Kv1.3 current: HEK293 cells stably expressing human Kv1.3 channel were voltage clamped at −80 mV holding potential. Outward Kv1.3 currents were activated by giving 200 msec long depolarizing steps to +30 mV from the holding potential of −80 mV and filtered at 3 kHz. Each depolarizing step was separated from the subsequent one with a 10 s interval. Analogue signals were digitized by Digidata™ 1322A digitizer (Molecular Devices) and subsequently stored on computer disk for offline analyses using Clampfit™ 9 (Molecular Devices Inc.). In all studies, stable baseline K\nV\n1.3 current amplitudes were established for 4 minutes before starting the perfusion of the protein toxin at incremental concentrations. A steady state block was always achieved before starting the perfusion of the subsequent concentration of the protein toxin.\n\n\nData analysis. Percent of control (POC) is calculated based on the following equation: (K\nV\n1.3 current after protein toxin addition/K\nV\n1.3 current in control)*100. At least 5 concentrations of the protein toxin (e.g. 0.003, 0.01, 0.03, 0.1, 0.3, 100 n\nM\n) were used to calculate the IC\n50 \nvalue. IC\n50 \nvalues and curve fits were estimated using the four parameter logistic fit of XLfit software (Microsoft Corp.). IC\n50 \nvalues are presented as mean value±s.e.m. (standard error of the mean).\n\n\nDrug preparations. Protein toxins (typically 10-100 μM) were dissolved in distilled water and kept frozen at −80° C. Serial dilutions of the stock protein toxins were mixed into the recording buffer containing 0.1% bovine serum albumin (BSA) and subsequently transferred to glass perfusion reservoirs. Electronic pinch valves controlled the flow of the protein toxin from the reservoirs onto the cell being recorded.\n\n\nExample 37\n\n\nImmunobiology and Channel Binding\n\n\nInhibition of T cell cytokine Production following PMA and anti-CD3 antibody stimulation of PBMCs. PBMC's were previously isolated from normal human donor Leukophoresis packs, purified by density gradient centrifugation (Ficoll Hypaque), cryopreserved in CPZ Cryopreservation Medium Complete (INCELL, MCPZF-100 plus 10% DMSO final). PBMC's were thawed (95% viability), washed, and seeded at 2×10\n5 \ncells per well in culture medium (RPMI medium 1640; GIBCO) supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/\nml streptomycin\n 2 mM L-glutamine, 100 uM non-essential amino acids, and 20 uM 2-ME) in 96-well flat-bottom tissue culture plates. Cells were pre-incubated with serially diluted (100 nM-0.001 nM final) ShK[1-35], Fc-L10-ShK[1-35] or fc control for 90 min before stimulating for 48 hr with PMA/anti-CD3 (1 ng/ml and 50 ng/ml, respectively) in a final assay volume of 200 ul. Analysis of the assay samples was performed using the Meso Scale Discovery (MSD) SECTOR™ Imager 6000 (Meso Scale Discovery, Gaithersbury, Md.) to measure the IL-2 and IFNg protein levels by utilizing electrochemiluminescence (ECL). The conditioned medium (50 ul) was added to the MSD Multi-spot 96-well plates (each well containing three capture antibodies; IL-2, TNF, IFNγ). The plates were sealed, wrapped in tin foil, and incubated at room temperature on a plate shaker for 2 hr. The wells were washed 1× with 200 ul PBST (BIOTEK, Elx405 Auto Plate Washer). For each well, 20 ul of Ruthenium-labeled detection antibodies (1 μg/ml final in Antibody Dilution Buffer; IL-1, TNF, IFNγ) and 130 ul of 2×MSD Read Buffer added, \nfinal volume\n 150 ul. The plates were sealed, wrapped in tin foil, and incubated at room temperature on a plate shaker for 1 hr. The plates were then read on the \nSECTOR™ Imager\n 6000. \nFIGS. 35A & 35B\n shows the CHO-derived Fc-L10-ShK[1-35] peptibody potently inhibits IL-2 and IFNg production from T cells in a dose-dependent manner. Compared to native ShK[1-35] peptide, the peptibody produces a greater extent of inhibition (POC=Percent Of Control of response in the absence of inhibitor).\n\n\nInhibition of T cell cytokine production following anti-CD3 and anti-CD28 antibody stimulation of PBMCs. PBMCs were previously isolated from normal human donor Leukopheresis packs, purified by density gradient centrifugation (Ficoll Hypaque), and cryopreserved using INCELL Freezing Medium. PBMCs were thawed (95% viability), washed, and seeded (in RPMI complete medium containing serum replacement, PSG) at 2×10\n5 \ncells per well into 96-well flat bottom plates. Cells were pre-incubated with serially diluted (100 nM-0.003 nM final) ShK[1-35], Fc-L10-ShK[1-35], or Fc control for 1 hour before the addition of aCD3 and aCD28 (2.5 ng/mL and 100 ng/mL respectively) in a final assay volume of 200 mL. Supernatants were collected after 48 hours, and analyzed using the Meso Scale Discovery (MSD) SECTOR™ Imager 6000 (Meso Scale Discovery, Gaithersbury, Md.) to measure the IL-2 and IFNg protein levels by utilizing electrochemiluminescence (ECL). 20 mL of supernatant was added to the MSD multi-spot 96-well plates (each well containing IL-2, TNFa, and IFNg capture antibodies). The plates were sealed and incubated at room temperature on a plate shaker for 1 hour. Then 20 mL of Ruthenium-labeled detection antibodies (1 μg/ml final of IL-2, TNFα, and IFNγ in Antibody Dilution Buffer) and 110 mL of 2×MSD Read Buffer were added. The plates were sealed, covered with tin foil, and incubated at room temperature on a plate shaker for 1 hour. The plates were then read on the \nSECTOR™ Imager\n 6000. \nFIGS. 37A & 37B\n shows the CHO-derived Fc-L10-ShK[1-35] peptibody potently inhibits IL-2 and IFNg production from T cells in a dose-dependent manner. Compared to native ShK[1-35] peptide which shows only partial inhibition, the peptibody produces nearly complete inhibition of the inflammatory cytokine response. (POC=Percent Of Control of response in the absence of inhibitor).\n\n\nInhibition of T cell proliferation following anti-CD3 and anti-CD28 antibody stimulation of PBMCs. PBMC's were previously isolated from normal human donor Leukophoresis packs, purified by density gradient centrifugation (Ficoll Hypaque), cryopreserved in CPZ Cryopreservation Medium Complete (INCELL, MCPZF-100 plus 10% DMSO final). PBMC's were thawed (95% viability), washed, and seeded at 2×10\n5 \ncells per well in culture medium (RPMI medium 1640; GIBCO) supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 100 μM non-essential amino acids, and 20 μM 2-ME) in 96-well flat-bottom tissue culture plates. Cells were pre-incubated with either anti-human CD32 (FcyRII) blocking antibody (per manufacturers instructions EASY SEP Human Biotin Selection Kit #18553, StemCell Technologies Vancouver, BC) or Fc-L10-ShK (100 nM-0.001 nM final) for 45 min. Fc-L10-ShK (100 nM-0.001 nM final) was then added to the cells containing anti-human CD32 blocking antibody while medium was added to the cells containing Fc-L10-ShK. Both sets were incubated for an additional 45 min before stimulating for 48 hr with aCD3/aCD28 (0.2 ng/ml and 100 ng/ml, respectively). Final assay volume was 200 ul. [3H]TdR (1 uCi per well) was added and the plates were incubated for an additional 16 hrs. Cells were then harvested onto glass fiber filters and radioactivity was measured in a B-scintillation counter. \nFIGS. 36A & 36B\n shows the CHO-derived Fc-L10-ShK[1-35] peptibody potently inhibits proliferation of T cells in a dose-dependent manner. Pre-blocking with the anti-CD32 (FcR) blocking antibody has little effect on the peptibodies ability to inhibit T cell proliferation suggesting Kv1.3 inhibition and not FcR binding is the mechanism for the inhibition observed (POC=Percent Of Control of response in the absence of inhibitor).\n\n\nImmunohistochemistry analysis of Fc-L10-ShK[1-35] binding to \nHEK\n 293 cells overexpressing human Kv1.3. \nHEK\n 293 cells overexpressing human Kv1.3 (HEK Kv1.3) were obtained from BioFocus plc (Cambridge, UK) and maintained per manufacturer's recommendation. The \nparental HEK\n 293 cell line was used as a control. Cells were plated on Poly-D-\nLysine\n 24 well plates (#35-4414; Becton-Dickinson, Bedford, Mass.) and allowed to grow to approximately 70% confluence. HEK KV1.3 were plated at 0.5×10e5 cells/well in 1 ml/well of medium. \nHEK\n 293 cells were plated at a density of 1.5×10e5 cells/well in 1 ml/well of medium. Before staining, cells were fixed with formalin (Sigma HT50-1-1 Formalin solution, diluted 1:1 with PBS/0.5% BSA before use) by removing cell growth medium, adding 0.2 ml/well formalin solution and incubating at room temperature for ten minutes. Cells were stained by incubating with 0.2 ml/well of 5 μg/ml Fc-L10-ShK[1-35] in PBS/BSA for 30′ at room temperature. Fc-L10-ShK[1-35] was aspirated and then the cells were washed one time with PBS/0.5% BSA. Detection antibody (Goat F(ab)2 anti-human IgG-phycoerythrin; Southern Biotech Associates, Birmingham, Ala.) was added to the wells at 5 μg/ml in PBS/0.5% BSA and incubated for 30′ at room temperature. Wash cells once with PBS/0.5% BSA and examine using confocal microscopy (LSM 510 Meta Confocal Microscope; Carl Zeiss AG, Germany). \nFIG. 33B\n shows the Fc-L10-ShK[1-35] peptibody retains binds to Kv1.3 \noverexpressing HEK\n 293 cells but shows little binding to untransfected cells (\nFIG. 33A\n) indicating the Fc-L10-ShK[1-35] peptibody can be used as a reagent to detect cells overexpressing the Kv1.3 channel. In disease settings where activated T effector memory cells have been reported to overproduce Kv1.3, this reagent can find utility in both targeting these cells and in their detection.\n\n\nAn ELISA assay demonstrating Fc-L10-ShK[1-35] binding to \nfixed HEK\n 293 cells overexpressing Kv1.3. \nFIG. 34A\n shows a dose-dependent increase in the peptibody binding to fixed cells that overexpress Kv1.3, demonstrating that the peptibody shows high affinity binding to its target and the utility of the Fc-L10-ShK[1-35] molecule in detection of cells expressing the channel. Antigen specific T cells that cause disease in patients with multiple sclerosis have been shown to overexpress Kv1.3 by whole cell patch clamp electrophysiology,—a laborius approach. Our peptibody reagent can be a useful and convenient tool for monitoring Kv1.3 channel expression in patients and have utility in diagnostic applications. The procedure shown in \nFIG. 34A\n and \nFIG. 34B\n follows.\n\n\n \nFIG. 34A\n. A whole cell immunoassay was performed to show binding of intact Fc-L10-ShK[1-35] to Kv1.3 transfected \nHEK\n 293 cells (BioFocus plc, Cambridge, UK). \nParent HEK\n 293 cells or HEK Kv1.3 cells were plated at 3×10e4 cells/well in poly-D-Lysine coated ninety-six well plates (#35-4461; Becton-Dickinson, Bedford, Mass.). Cells were fixed with formalin (Sigma HT50-1-1 Formalin solution, diluted 1:1 with PBS/0.5% BSA before use) by removing cell growth medium, adding 0.2 ml/well formalin solution and incubating at room temperature for 25 minutes and then washing one time with 100 μl/well of PBS/0.5% BSA. Wells were blocked by addition of 0.3 ml/well of BSA blocker (50-61-00; \nKPL\n 10% BSA Diluent/Blocking Solution, diluted 1:1 with PBS; KPL, Gaithersburg, Md.) followed by incubation at room temperature, with shaking, for 3 hr. Plates were washed 2 times with 1×KP Wash Buffer (50-63-00; KPL). Samples were diluted in Dilution Buffer (PBS/0.5% Tween-20) or Dilution Buffer with 1% Male Lewis Rat Serum (RATSRM-M; Bioreclamation Inc., Hicksville, N.Y.) and 0.1 ml/well was added to blocked plates, incubating for 1 hr at room temperature with shaking. Plates were washed 3 times with 1×KP Wash Buffer and then incubated with HRP-Goat anti-human IgG Fc (#31416; Pierce, Rockford, Ill.) diluted 1:5000 in PBS/0.1% Tween-20 for 1 hr at room temperature, with shaking. Plates were washed \nplates\n 3 times with 1×KP Wash Buffer, and then 0.1 ml/well TMB substrate (52-00-01; KPL) was added. The reactions were stopped by addition of 0.1 ml/well 2 N Sulfuric Acid. Absorbance was read at 450 nm on a Molecular Devices SpectroMax 340 (Sunnyvale, Calif.).\n\n\n \nFIG. 34B\n. Whole cell immunoassay was performed as above with the following modifications. \nHEK\n 293 cells were plated at 1×10e5 cells/well and HEK Kv1.3 cells were plated at 6×10e4 cells/well in poly-D-Lysine coated 96 well plates. Fc Control was added at 500 ng/ml in a volume of 0.05 ml/well. HRP-Goat anti-human IgG Fc (#31416; Pierce, Rockford, Ill.) was diluted 1:10,000 in PBS/0.1% Tween-20. ABTS (50-66-00, KPL) was used as the substrate. Absorbances were read at 405 nm after stopping reactions by addition of 0.1 ml/well of 1% SDS.\n\n\nExample 38\n\n\nPurification of Fc-L10-ShK(1-35)\n\n\nExpression of Fc-L10-ShK[1-35] was as described in Example 3 herein above. Frozen, \nE. coli \npaste (18 g) was combined with 200 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 22,000 g for 15 min at 4° C. The pellet was then resuspended in 200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 22,000 g for 15 min at 4° C. The pellet was then resuspended in 200 ml water using a tissue grinder and then centrifuged at 22,000 g for 15 min at 4° C. The pellet (3.2 g) was then dissolved in 32 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The pellet solution was then centrifuged at 27,000 g for 15 min at room temperature, and then 5 ml of the supernatant was transferred to 500 ml of the refolding buffer (3 M urea, 20% glycerol, 50 mM tris, 160 mM arginine HCl, 5 mM EDTA, 1 mM cystamine HCl, 4 mM cysteine, pH 9.5) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 2 days at 4° C. The refolding solution was then stored at −70° C.\n\n\nThe stored refold was defrosted and then diluted with 2 L of water and the pH was adjusted to 7.3 using 1 M H\n3\nPO\n4\n. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 60 ml Amersham SP-FF (2.6 cm I.D.) column at 20 ml/min in S-Buffer A (20 mM NaH2PO4, pH 7.3) at 7° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (20 mM NaH2PO4, 1 M NaCl, pH 7.3) followed by a step to 100% S-Buffer B at 10 ml/\nmin\n 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pool was then loaded on to a 1 ml Amersham rProtein A HiTrap column in PBS at 1 ml/\nmin\n 7° C. Then column was then washed with several column volumes of 20 mM NaH\n2\nPO\n4 \npH 6.5, 1 M NaCl and eluted with 100 mM glycine pH 3.0. To the elution peak, 0.0125 volumes (25 ml) of 3 M sodium acetate was added.\n\n\nA spectral scan was then conducted on 50 μl of the combined pool diluted in 700 μl water using a Hewlett Packard 8453 spectrophotometer (\nFIG. 46A\n). The concentration of the filtered material was determined to be 2.56 mg/ml using a calculated molecular mass of 30,410 g/mol and extinction coefficient of 36,900 M−1 cm−1. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 46B\n). The macromolecular state of the product was then determined using size exclusion chromatography on 20 μg of the product injected on to a Phenomenex BioSep \nSEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 46C\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). One milliliter of the resultant solution was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses. The product was then stored at −80° C.\n\n\nThe IC\n50 \nfor blockade of human Kv1.3 by purified \nE. coli\n-derived Fc-L10-ShK[1-35], also referred to as “Fc-L-ShK[1-35]”, is shown in Table 35 (in Example 50 herein below).\n\n\nExample 39\n\n\nPurification of Bacterially Expressed Fc-L10-ShK(2-35)\n\n\nExpression of Fc-L10-ShK[2-35] was as described in Example 4 herein above. Frozen, \nE. coli \npaste (16.5 g) was combined with 200 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 22,000 g for 15 min at 4° C. The pellet was then resuspended in 200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 22,000 g for 15 min at 4° C. The pellet was then resuspended in 200 ml water using a tissue grinder and then centrifuged at 22,000 g for 15 min at 4° C. The pellet (3.9 g) was then dissolved in 39 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The pellet solution was then centrifuged at 27,000 g for 15 min at room temperature, and then 5 ml of the supernatant was transferred to 500 ml of the refolding buffer (3 M urea, 20% glycerol, 50 mM tris, 160 mM arginine HCl, 5 mM EDTA, 1 mM cystamine HCl, 4 mM cysteine, pH 9.5) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 2 days at 4° C. The refolding solution was then stored at −70° C.\n\n\nThe stored refold was defrosted and then diluted with 2 L of water and the pH was adjusted to 7.3 using 1 M H\n3\nPO\n4\n. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 60 ml Amersham SP-FF (2.6 cm I.D.) column at 20 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.3) at 7° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (20 mM NaH2PO4, 1 M NaCl, pH 7.3) followed by a step to 100% S-Buffer B at 10 ml/\nmin\n 7° C. The fractions containing the desired product were pooled and filtered through a 0.22 μm cellulose acetate filter. The pool was then loaded on to a 1 ml Amersham rProtein A HiTrap column in PBS at 2 ml/\nmin\n 7° C. Then column was then washed with several column volumes of 20 mM NaH\n2\nPO\n4 \npH 6.5, 1 M NaCl and eluted with 100 mM glycine pH 3.0. To the elution peak, 0.0125 volumes (18 ml) of 3 M sodium acetate was added, and the sample was filtered through a 0.22 μm cellulose acetate filter.\n\n\nA spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl water using a Hewlett Packard 8453 spectrophotometer (\nFIG. 40A\n). The concentration of the filtered material was determined to be 3.20 mg/ml using a calculated molecular mass of 29,282 g/mol and extinction coefficient of 36,900 M\n−1 \ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 40B\n). The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a Phenomenex BioSep \nSEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 40C\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). One milliliter of the resultant solution was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses (\nFIG. 40D\n). The product was then stored at −80° C.\n\n\nThe IC\n50 \nfor blockade of human Kv1.3 by purified \nE. coli\n-derived Fc-L10-ShK[2-35], also referred to as “Fc-L-ShK[2-35]”, is shown in Table 35 (in Example 50 herein below).\n\n\nExample 40\n\n\nPurification of Bacterially Expressed Fc-L10-OsK1\n\n\nFrozen, \nE. coli \npaste (129 g; see Example 10) was combined with 1290 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 7.8 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 17,700 g for 15 min at 4° C. The pellet was then resuspended in 1290 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 17,700 g for 15 min at 4° C. The pellet was then resuspended in 1290 ml water using a tissue grinder and then centrifuged at 17,700 g for 15 min at 4° C. 8 g of the pellet (16.3 g total) was then dissolved in 160 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. 100 ml of the pellet solution was then incubated with 1 ml of 1 M DTT for 60 min at 37° C. The reduced material was transferred to 5000 ml of the refolding buffer (1 M urea, 50 mM tris, 160 mM arginine HCl, 2.5 mM EDTA, 1.2 mM cystamine HCl, 4 mM cysteine, pH 10.5) at 2 ml/min, 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 3 days at 4° C.\n\n\nThe pH of the refold was adjusted to 8.0 using acetic acid. The pH adjusted material was then filtered through a 0.22 μm cellulose acetate filter and loaded on to a 50 ml Amersham Q Sepharose-FF (2.6 cm I.D.) column at 10 ml/min in Q-Buffer A (20 mM Tris, pH 8.5) at 8° C. with an inline 50 Amersham Protein A column (2.6 cm I.D.). After loading, the Q Sepharose column was removed from the circuit, and the remaining chromatography was carried out on the protein A column. The column was washed with several column volumes of Q-Buffer A, followed by elution using a step to 100 mM glycine pH 3.0. The fractions containing the desired product were pooled and immediately loaded on to a 50 ml Amersham SP-Sepharose HP column (2.6 cm I.D.) at 20 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 8° C. The column was then washed with several column volumes of S-Buffer A followed by a linear gradient from 5% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) followed by a step to 100% S-Buffer B. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE. The fractions containing the bulk of the desired product were pooled and then applied to a 75 ml MEP Hypercel column (2.6 cm I.D.) at 5 ml/min in MEP Buffer A (20 mM tris, 200 mM NaCl, pH 8.0) at 8° C. Column was eluted with a linear gradient from 5% to 50% MEP Buffer B (50 mM sodium citrate pH 4.0) followed by a step to 100% MEP Buffer B. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the bulk of the desired product were pooled.\n\n\nThe MEP pool was then concentrated to about 20 ml using a Pall Jumbo-Sep with a 10 kDa membrane followed by buffer exchange with Formulation Buffer (20 mM NaH\n2\nPO\n4\n, 200 mM NaCl, pH 7.0) using the same membrane. A spectral scan was then conducted on 50 μl of the combined pool diluted in 700 μl Formulation Buffer using a Hewlett Packard 8453 spectrophotometer (\nFIG. 41A\n). The concentration of the material was determined to be 4.12 mg/ml using a calculated molecular mass of 30,558 g/mol and extinction coefficient of 35,720 M\n−1 \ncm\n−1\n. The purity of the material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 41B\n). The macromolecular state of the product was then determined using size exclusion chromatography on 123 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 41C\n). The product was then subject to mass spectral analysis by chromatographing approximately 4 μg of the sample through a RP-HPLC column (Vydac C\n4\n, 1×150 mm). Solvent A was 0.1% trifluoroacetic acid in water and solvent B was 0.1% trifluoroacetic acid in 90% acetonitrile, 10% water. The column was pre-equilibrated in 10% solvent B at a flow rate of 80 μl per min. The protein was eluted using a linear gradient of 10% to 90% solvent B over 30 min. Part of the effluent was directed into a LCQ ion trap mass spectrometer. The mass spectrum was deconvoluted using the Bioworks software provided by the mass spectrometer manufacturer. (\nFIG. 41D\n). The product was filtered through a 0.22 μm cellulose acetate filter and then stored at −80° C.\n\n\nThe yield for the \nE. coli\n-expressed Fc-L10-OSK1 prep was 81 mg from 40 g of cell paste (129 g×(8 g/16.3 g)×(100 ml/160 ml)=39.6 g which was rounded to 40 g), the purity was greater than 80% judging by SDS-PAGE, it is running as the expected dimer judging by SEC-HPLC, and the mass was within the expected molecular weight range judging by MS.\n\n\nThe IC\n50 \nfor blockade of human Kv1.3 by purified \nE. coli\n-derived Fc-L10-OSK1, also referred to as “Fc-L-OSK1”, is shown in Table 35 (in Example 50 herein below).\n\n\nExample 41\n\n\nFc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1 [K7S,E16K,K20D] Expressed by Mammalian Cells\n\n\nFc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1 [K7S,E16K,K20D], inhibitors of Kv1.3, were expressed in mammalian cells. A DNA sequence coding for the Fc region of human IgG1 fused in-frame to a linker sequence and a monomer of the Kv1.3 inhibitor peptide OSK1, OSK1[K7S], OSK1[E16K,K20D], or OSK1[K7S,E16K,K20D] was constructed as described below. Methods for expressing and purifying the peptibody from mammalian cells (\nHEK\n 293 and Chinese Hamster Ovary cells) are disclosed herein.\n\n\nFor construction of Fc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] expression vectors, a PCR strategy was employed to generate the full length genes, OSK1, OSK1[K7S], OSK1[E16K,K20D], and OSK1[K7S,E16K,K20D], each linked to a four glycine and one serine amino acid linker with two stop codons and flanked by BamHI and NotI restriction sites as shown below.\n\n\nTwo oligos for each of OSK1, OSK1[K7S], OSK1[E16K,K20D], and [K7S,E16K,K20D]OSK1 with the sequence as depicted below were used in a PCR reaction with PfuTurbo HotStart DNA polymerase (Stratagene) at 95° C.-30 sec, 55° C.-30 sec, 75° C.-45 sec for 35 cycles; BamHI (ggatcc) and NotI (gcggccgc) restriction sites are underlined.\n\n\n\n\n\n\n\n\n\n\n\n\nOSK1:\n\n\n \n\n\n \n\n\n\n\n\n\nForward primer: cat \ngga tcc\n gga gga gga gga agc\n\n\n(SEQ ID NO: 876)\n\n\n\n\n\n\nggc gtg atc atc aac gtg aag tgc aag atc agc cgc\n\n\n \n\n\n\n\n\n\ncag tgc ctg gag ccc tgc aag aag gcc g;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nReverse primer: cat \ngcg gcc gc\nt tac tac ttg ggg gtg\n\n\n(SEQ ID NO: 877)\n\n\n\n\n\n\ncag tgg cac ttg ccg ttc atg cac ttg ccg aag cgc\n\n\n \n\n\n\n\n\n\natg ccg gcc ttc ttg cag ggc tcc a;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1[K7S]:\n\n\n \n\n\n\n\n\n\nForward primer: cat \ngga tcc\n gga gga gga gga agc\n\n\n(SEQ ID NO: 878)\n\n\n\n\n\n\nggc gtg atc atc aac gtg agc tgc aag atc agc cgc\n\n\n \n\n\n\n\n\n\ncag tgc ctg gag ccc tgc aag aag gcc g;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nReverse primer: cat \ngcg gcc gc\nt tac tac ttg ggg gtg\n\n\n(SEQ ID NO: 879)\n\n\n\n\n\n\ncag tgg cac ttg ccg ttc atg cac ttg ccg aag cgc\n\n\n \n\n\n\n\n\n\natg ccg gcc ttc ttg cag ggc tcc a;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1[E16K, K20D]:\n\n\n \n\n\n\n\n\n\nForward primer: cat \ngga tcc\n gga gga gga gga agc\n\n\n(SEQ ID NO: 880)\n\n\n\n\n\n\nggc gtg atc atc aac gtg aag tgc aag atc agc cgc\n\n\n \n\n\n\n\n\n\ncag tgc ctg aag ccc tgc aag gac gcc g;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nReverse primer: cat \ngcg gcc gc\nt tac tac ttg ggg gtg\n\n\n(SEQ ID NO: 881)\n\n\n\n\n\n\ncag tgg cac ttg ccg ttc atg cac ttg ccg aag cgc\n\n\n \n\n\n\n\n\n\natg ccg gcg tcc ttg cag ggc ttc a;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1[K7S, E16K, K20D]:\n\n\n \n\n\n\n\n\n\nForward primer: cat \ngga tcc\n gga gga gga gga agc\n\n\n(SEQ ID NO: 882)\n\n\n\n\n\n\nggc gtg atc atc aac gtg agc tgc aag atc agc cgc\n\n\n \n\n\n\n\n\n\ncag tgc ctg aag ccc tgc aag gac gcc g;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nReverse primer: cat \ngcg gcc gc\nt tac tac ttg ggg gtg\n\n\n(SEQ ID NO: 883)\n\n\n\n\n\n\ncag tgg cac ttg ccg ttc atg cac ttg ccg aag cgc\n\n\n \n\n\n\n\n\n\natg ccg gcg tcc ttg cag ggc ttc a.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe resulting PCR products were resolved as the 155 bp bands on a four percent agarose gel. The 155 bp PCR product was purified using PCR Purification Kit (Qiagen), then digested with BamHI and NotI (Roche) restriction enzymes, and agarose gel was purified by Gel Extraction Kit (Qiagen). At the same time, the pcDNA3.1(+) CMVi-hFc-Shk[2-35] vector was digested with BamHI and NotI restriction enzymes and the large fragment was purified by Gel Extraction Kit. The gel purified PCR fragment was ligated to the purified large fragment and transformed into One Shot® Top10F′ (Invitrogen). DNAs from transformed bacterial colonies were isolated and digested with BamHI and NotI restriction enzymes and resolved on a two percent agarose gel. DNAs resulting in an expected pattern were submitted for sequencing. Although, analysis of several sequences of clones yielded a 100% percent match with the above sequences, only one clone from each gene was selected for large scaled plasmid purification. The DNA of Fc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] in pCMVi vector was resequenced to confirm the Fc and linker regions and the sequence was 100% identical to the above sequences. The sequences and pictorial representations of Fc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] are depicted in \nFIG. 42A-B\n, \nFIG. 43A-B\n, \nFIG. 44A-B\n and \nFIG. 45A-B\n, respectively.\n\n\nHEK-293 cells used in transient transfection expression of Fc-L110-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] in pCMVi protein were cultured in growth medium containing DMEM High Glucose (Gibco), 10% fetal bovine serum (FBS from Gibco), 1× non-essential amino acid (NEAA from Gibco) and 1× Penicillin/Streptomycine/Glutamine (Pen/Strep/Glu from Gibco). 5.6 μg each of Fc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] in pCMVi plasmid that had been phenol/chloroform extracted was transfected into HEK-293 cells using FuGENE 6 (Roche). The cells were recovered for 24 hours, and then placed in DMEM High Glucose, 1×NEAA and 1× Pen/Strep/Glu medium for 48 hours. Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] were purified from medium conditioned by these transfected HEK-293 cells using a protocol described in Example 50 herein below.\n\n\nFifteen μl of conditioned medium was mixed with an in-\nhouse\n 4× Loading Buffer (without β-mercaptoethanol) and electrophoresed on a Novex 4-20% tris-glycine gel using a Novex Xcell II apparatus at 101V/46 mA for 2 hours in a 1× Gel Running solution (25 mM Tris Base, 192 mM Glycine, 3.5 mM SDS) along with 20 μl of BenchMark Pre-Stained Protein ladder (Invitrogen). The gel was then soaked in Electroblot buffer (25 mM Tris base, 192 mM glycine, 20% methanol,) for 5 minutes. -A nitrocellulose membrane from Invitrogen (Cat. No. LC200, 0.2 μm pores size) was soaked in Electroblot buffer. The pre-soaked gel was blotted to the nitrocellulose membrane using the Mini Trans-Blot Cell module according to the manufacturer instructions (Bio-Rad Laboratories) at 300 mA for 2 hours. The blot was rinsed in Tris buffered saline solution pH7.5 with 0.1% Tween20 (TBST). Then, the blot was first soaked in a 5% milk (Camation) in TBST for 1 hour at room temperature, followed by washing three times in TBST for 10 minutes per wash. Then, incubated with 1:1000 dilution of the HRP-conjugated Goat anti-human IgG, (Fcγ) antibody (Pierece Biotechnology Cat. no. 31413) in TBST with 5% milk buffer for 1 hour with shaking at room temperature. The blot was then washed three times in TBST for 15 minutes per wash at room temperature. The primary antibody was detected using Amersham Pharmacia Biotech's ECL western blotting detection reagents according to manufacturers instructions. Upon ECL detection, the western blot analysis displayed the expected size of 66 kDa under non-reducing gel conditions (\nFIG. 46\n).\n\n\nPlasmids containing the Fc-L10-OSK1, Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K,K20D], and Fc-L10-OSK1[K7S,E16K,K20D] inserts in pCMVi vector were digested with XbaI and NotI (Roche) restriction enzymes and gel purified. The inserts were individually ligated into SpeI and NotI (Roche) digested pDSRα24 (Amgen Proprietary) expression vector. Integrity of the resulting constructs were confirmed by DNA sequencing. Although, analysis of several sequences of clones yielded a 100% percent match with the above sequence, only one clone was selected for large scaled plasmid purification.\n\n\nAM1 CHOd- (Amgen Proprietary) cells used in the stable expression of Fc-L10-OSK1 protein were cultured in AM1 CHOd- growth medium containing DMEM High Glucose, 10% fetal bovine serum, 1× hypoxantine/thymidine (HT from Gibco), 1×NEAA and 1× Pen/Strep/Glu. 5.6 μg of pDSRα-24-Fc-L10-OSK1 plasmid was transfected into AM1 CHOd- \ncells using FuGene\n 6. Twenty-four hours post transfection, the cells were split 1:11 into DHFR selection medium (DMEM High Glucose plus 10% Dialyzed Fetal Bovine Serum (dFBS), 1×NEAA and 1× Pen/Strep/Glu) at 1:50 dilution for colony selection. The cells were selected in DHFR selection medium for thirteen days. The ten 10-cm\n2 \npools of the resulting colonies were expanded to ten T-175 flasks, then were scaled up ten roller bottles and cultured under AM1 CHOd- production medium (DMEM/F12 (1:1), 1×NEAA, 1× Sodium Pyruvate (Na Pyruvate), 1× Pen/Strep/Glu and 1.5% DMSO). The conditioned medium was harvested and replaced at one-week intervals. The resulting six liters of conditioned medium were filtered through a 0.45 μm cellulose acetate filter (Corning, Acton, Mass.), and characterized by SDS-PAGE analysis as shown in \nFIG. 47\n. Then, transferred to Protein Chemistry for purification.\n\n\nTwelve colonies were selected after 13 days on DHFR selection medium and picked into one 24-well plate. The plate was allowed to grow up for one week, and then was transferred to AM1 CHOd- production medium for 48-72 hours and the conditioned medium was harvested. The expression levels were evaluated by Western blotting similar to the transient Western blot analysis with detection by the same HRP-conjugated Goat anti-human IgG, (Fcγ) antibody to screen 5 μl of conditioned medium. All 12 stable clones exhibited expression at the expected size of 66 kDa. Two clones, A3 and C2 were selected and expanded to T175 flask for freezing with A3 as a backup to the primary clone C2 (\nFIG. 48\n).\n\n\nThe C2 clone was scaled up into fifty roller bottles (Corning) using selection medium and grown to confluency. Then, the medium was exchanged with a production medium, and let incubate for one week. The conditioned medium was harvested and replaced at the one-week interval. The resulting fifty liters of conditioned medium were filtered through a 0.45 μm cellulose acetate filter (Corning, Acton, Mass.), and characterized by SDS-PAGE analysis (data not shown). Further purification was accomplished as described in Example 42 herein below.\n\n\nExample 42\n\n\nPurification of Fc-L10-OSK1, Fc-L10-OSK1(K7S), Fc-L10-OSK1(E16K,K20D), and Fc-L10-OSK1(K7S,E16K,K20D) Expressed by Mammalian Cells\n\n\nPurification of Fc-L10-OSK1. Approximately 6 L of CHO (AM1 CHOd-) cell-conditioned medium (see, Example 41 above) was loaded on to a 35 ml MAb Select column (GE Healthcare) at 10 ml/\nmin\n 7° C., and the column was washed with several column volumes of Dulbecco's phosphate buffered saline without divalent cations (PBS) and sample was eluted with a step to 100 mM glycine pH 3.0. The MAb Select elution was directly loaded on to an inline 65 ml SP-HP column (GE Healthcare) in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 10 ml/\nmin\n 7° C. After disconnecting the MAb select column, the SP-HP column was then washed with several column volumes S-Buffer A, and then developed using a linear gradient from 5% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) at 10 ml/min followed by a step to 100% S-Buffer B at 7° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pooled material was then concentrated to about 20 ml using a Pall Life Sciences Jumbosep 10K Omega centrifugal ultra-filtration device. The concentrated material was then buffer exchanged by diluting with 20 ml of 20 mM NaH\n2\nPO\n4\n, pH 7.0 and reconcentrated to 20 ml using the Jumbosep 10K Omega filter. The material was then diluted with 20 \nml\n 20 mM NaH\n2\nPO\n4\n, 200 mM NaCl, pH 7.0 and then reconcentrated to 22 ml. The buffer exchanged material was then filtered though a Pall Life Sciences Acrodisc with a 0.22 μm, 25 mm Mustang E membrane at 1 ml/min room temperature. A spectral scan was then conducted on 50 μl of the filtered material diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 49A\n, black trace). The concentration of the filtered material was determined to be 4.96 mg/ml using a calculated molecular mass of 30,371 g/mol and extinction coefficient of 35,410 M\n−1 \ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 49B\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 30-fold dilution of the sample in Charles Rivers Laboratories Endotoxin Specific Buffer yielding a result of 1.8 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 149 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 49C\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). One milliliter of the resultant solution was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from about 200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses. (\nFIG. 49D\n). The product was then stored at −80° C.\n\n\nThe yield for the mammalian Fc-L10-OSK1 prep was 115 mg from 6 L, the purity was >90% judging by SDS-PAGE; Fc-L10-OSK1 ran as the expected dimer judging by SEC-HPLC, and the mass is with the expected range judging by MS.\n\n\nThe activity of purified Fc-L10-OSK1 in blocking human Kv1.3 and human Kv1.1 is described in Example 43 herein below.\n\n\nPurification of Fc-L10-OSK1(K7S). Fc-L10-OSK1(E16K,K20D), and Fc-L10-OSK1(K7S,E16K,K20D). Approximately 500 mL of medium conditioned by transfected HEK-293 (see, Example 41 above) was combined with a 65% slurry of MAb Select resin (1.5 ml) (GE Healthcare) and 500 \nμl\n 20% NaN\n3\n. The slurry was then gently agitated for 3 days at 4° C. followed by centrifugation at 1000 g for 5 minutes at 4° C. using no brake. The majority of the supernatant was then aspirated and the remaining slurry in the pellet was transferred to a 14 ml conical tube and combined with 12 ml of Dulbecco's phosphate buffered saline without divalent cations (PBS). The slurry was centrifuged at 2000 g for 1 minute at 4° C. using a low brake and the supernatant was aspirated. The PBS wash cycle was repeated an additional 3 times. The bound protein was then eluted by adding 1 ml of 100 mM glycine pH 3.0 and gently agitating for 5 min at room temperature. The slurry was then centrifuged at 2000 g for 1 minute at 4° C. using a low brake and the supernatant was aspirated as the first elution. The elution cycle was repeated 2 more times, and all 3 supernatants were combined into a single pool. Sodium acetate (37.5 μl of a 3 M solution) was added to the elution pool to raise the pH, which was then dialyzed against 10 mM acetic acid, 5% sorbitol, pH 5.0 for 2 hours at room temperature using a 10 kDa SlideAlyzer (Pierce). The dialysis buffer was changed, and the dialysis continued over night at 4° C. The dialyzed material was then filtered through a 0.22 μm cellulose acetate filter syringe filter. Then concentration of the filtered material was determined to be 1.27 mg/ml using a calculated molecular mass of 30,330 and extinction coefficient of 35,410 M\n−1 \ncm\n−1 \n(\nFIG. 50A\n). The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 50B\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 25-fold dilution of the sample in Charles Rivers Laboratories Endotoxin Specific Buffer yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 50C\n). The product was then subject to mass spectral analysis by diluting 1 μl of the sample into 10 μl of sinapinic acid (10 mg per ml in 0.05% trifluoroacetic acid, 50% acetonitrile). One milliter of the resultant solution was spotted onto a MALDI sample plate. The sample was allowed to dry before being analyzed using a Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse). The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots. External mass calibration was accomplished using purified proteins of known molecular masses. (\nFIG. 50D\n). The product was then stored at −80° C.\n\n\n \nFIGS. 51A-D\n show results from the purification and analysis for Fc-L10-OsK1(E16K, K20D), which was conducted using the same protocol as that for the Fc-L110-OsK1 (K7S) molecule (described above) with the following exceptions: the concentration was found to be 1.59 mg/ml using a calculated molecular mass of 30,357 g/mol and a calculated extinction coefficient of 35,410; the pyrogen level was found to be <1 EU/mg using a 32-fold dilution.\n\n\n \nFIGS. 52A-D\n show results from the purification and analysis for Fc-L10-OsK1(K7S,E16K, K20D), which was conducted using the same protocol as that for the Fc-L10-OsK1(K7S) molecule (described above) with the following exceptions: the concentration was found to be 0.81 mg/ml using a calculated molecular mass of 30,316 g/mol and a calculated extinction coefficient of 35,410; the pyrogen level was found to be <1 EU/mg using a 16-fold dilution.\n\n\nThe activity of purified Fc-L10-OSK1[K7S], Fc-L10-OSK1[E16K, K20D] and Fc-L10-OSK1[K7S, E16K, K20D] in blocking human Kv1.3 and human Kv1.1 is described in Example 43 herein below.\n\n\nExample 43\n\n\nElectrophysiology of OSK1 and OSK1 Peptibody Analogs\n\n\nA 38-residue peptide toxin of the Asian scorpion \nOrthochirus scrobiculosus \nvenom (OSK1) was synthesized (see, Examples 41) to evaluate its impact on the human Kv1.1 and Kv1.3 channels, subtypes of the potassium channel family. The potency and selectivity of synthetic OSK1 in inhibiting the human Kv1.1 and Kv1.3 channels was evaluated by the use of HEK293 cell expression system and electrophysiology (\nFIG. 53\n). Whole cell patch clamp recording of stably expressed Kv1.3 channels revealed that the synthetic OSK1 peptide is more potent in inhibiting human Kv1.3 when compared to Kv1.1 (Table 33).\n\n\nFusion of OSK1 peptide toxin to antibody to generate OSK1 peptibody. To improve plasma half-life and prevent OSK1 peptide toxin from penetrating the CNS, the OSK1 peptide toxin was fused to the Fc-fragment of a human antibody IgG1 via a linker chain length of 10 amino acid residues (Fc-L10-OSK1), as described in Example 41 herein. This fusion resulted in a decrease in the potency of Kv1.3 by 5-fold when compared to the synthetic OSK1 peptide. However, it significantly improved the selectivity of OSK1 against Kv1.1 by 210-fold when compared to that of the synthetic peptide alone (4-fold; Table 33 and \nFIG. 54\n).\n\n\nModification of OSK1-peptibody (Fc-L10-OSK1). OSK1 shares 60 to 80% sequence homology to other members of scorpion toxins, which are collectively termed α-KTx3. Sequence alignment of OSK1 and other members of α-KTx3 family revealed 4 distinct structural differences at \n \n \n \npositions\n \n \n \n 12, 16, 20, and 36. These structural differences of OSK1 have been postulated to play an important role in its wide range of activities against other potassium channels, which is not observed with other members of α-KTx3 family. Hence, two amino acid residues at \n \nposition\n \n 16 and 20 were restored to the more conserved amino acid residues within the OSK1 sequence in order to evaluate their impact on selectivity against other potassium channels such as Kv1.1, which is predominantly found in the CNS as a heterotetromer with Kv1.2. By substituting for glutamic acid at \nposition\n 16, and for lysine at \nposition\n 20, the conserved lysine and aspartic acid residues, respectively (i.e., Fc-L10-OSK1[E16K, K20D]), we did not observe a significant change in potency when compared to that of Fc-L10-OSK1 (1.3-fold difference; \nFIG. 56\n and Table 33). However, this double mutation removed the blocking activity against Kv1.1. The selectivity ratio of Kv1.1/Kv1.3 was 403-fold, which was a significant improvement over the selectivity ratio for Fc-L10-OSK1 (210-fold). A single amino acid mutation at \nposition\n 7 from lysine to serine (Fc-L10-OSK1[K7S]) produced a slight change in potency and selectivity by 2- and 1.3-fold, respectively, when compared to those of Fc-L10-OSK1 (\nFIG. 55\n and Table 33). There was a significant decrease in potency as well as selectivity when all three residues were mutated to generate Fc-L10-OSK1[K7S, E16K, K20D] (\nFIG. 57\n and Table 33).\n\n\nAs demonstrated by the results in Table 33, we dramatically improved selectivity against Kv1.1 by fusing the OSK1 peptide toxin to the Fc-fragment of the human antibody IgG1, but reduced target potency against Kv1.3. The selectivity against Kv1.1 was further improved when 2 residues at two key positions were restored to the conserved residues found in other members of the α-KTx3 family.\n\n\nTable 33shows a summary of IC50 values for OSK1 analogs against hKv1.3 and hKv1.1 channels. All analogues are ranked based on their potency against hKv1.3. Also shown in the table is the selectivity ratio of hKv1.1/hKv1.3 for all OSK1 analogs.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nhKv1.3: IC\n50\n \n\n\nhKv1.1: IC\n50\n \n\n\nhKv1.1/\n\n\n\n\n\n\nCompound\n\n\n[pM]\n\n\n[pM]\n\n\nhKv1.3\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \nSynthetic OSK1\n \n\n\n39\n\n\n160\n\n\n4\n\n\n\n\n\n\nFc-L10-OSK1\n\n\n198\n\n\n41600\n\n\n210\n\n\n\n\n\n\nFc-L10-OSK1[E16K, K20D]\n\n\n248\n\n\n100000\n\n\n403\n\n\n\n\n\n\nFc-L10-OSK1[K7S]\n\n\n372\n\n\n100000\n\n\n269\n\n\n\n\n\n\nFc-L10-OSK1[K7S, E16K, K20D]\n\n\n812\n\n\n10000\n\n\n12\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExample 44\n\n\nPharmacokinetic Study of PEG-ShK[1-35] Molecule in Rats\n\n\nThe intravenous (IV) pharmacokinetic profile was determined of a about 24-\nkDa\n 20K PEG-ShK[1-35] molecule and the about 4-kDa small native ShK peptide was determined in Spraque Dawley rats. The IV dose for the native ShK peptide and our novel 20K PEG-ShK[1-35] molecule was 1 mg/kg. This dose represented equal molar amounts of these two molecules. The average weight of the rats was about 0.3 kg and two rats were used for each dose & molecule. At various times following IV injection, blood was drawn and about 0.1 ml of serum was collected. Serum samples were stored frozen at −80° C. until analysis.\n\n\nAssay Plate preparation for electrophysiology. Rat serum samples containing the 20K PEG-ShK[1-35] molecule or the native ShK peptide from pharmacokinetic studies were received frozen. Before experiments, each sample was thawed at room temperature and an aliquot (70 to 80 μl) was transferred to a well in a 96-well polypropylene plate. In order to prepare the Assay Plate, several dilutions were made from the pharmacokinetic serum samples to give rise to Test Solutions. Dilutions of serum samples from the pharmacokinetic study were into 10% Phosphate Buffered Saline (PBS, with Ca\n2+\n and Mg\n2+\n). For determination of the amount of our novel 20K PEG-ShK[1-35] molecule in serum samples from the pharmacokinetic study, the final serum concentrations in the Test Solutions were 90%, 30%, 10%, 3.3% and 1.1%. \nPurified\n 20K PEG-Shk[1-35] Standard inhibition curves were also prepared in the Assay Plate. To do this, 8-point serial dilutions of the purified 20K PEG-ShK[1-35] molecule (Standard) were prepared in either 90%, 30%, 10%, 3.3% or 1.1% rat serum and the final concentration of standard was 50, 16.7, 5.5, 1.85, 0.62, 0.21, 0.068 and 0.023 nM.\n\n\nCell preparation for electrophysiology. CHO cells stably expressing the voltage-activated K\n+\n channel, K\nV\n1.3 were plated in T-175 tissue culture flasks (at a density of 5×10\n6\n) 2 days before experimentation and allowed to grow to around 95% confluence. Immediately prior to the experiment, the cells were washed with PBS and then detached with a 2 ml mixture (1:1 volume ratio) of trypsin (0.25%) and versene (1:5000) at 37° C. (for 3 minutes). Subsequently, the cells were re-suspended in the flask in 10 ml of tissue culture medium (HAM's F-12 with Glutamax, Invitrogen, Cat#31765) with 10% FBS, 1×NEAA and 750 μg/ml of G418) and centrifuged at about 1000 rpm for 1½ minutes. The resultant cell pellet was re-suspended in PBS at 3-5×10\n6 \ncells/ml.\n\n\nIonWorks electrophysiology and data analysis. The ability of Test solutions or Standards in serum to inhibit K\n+\n currents in the CHO-K\nv\n1.3 cells was investigated using the automated electrophysiology system, IonWorks Quattro. Re-suspended cells, the Assay Plate, a Population Patch Clamp (PPC) PatchPlate as well as appropriate intracellular (90 mMK-Gluconate, 20 mMKF, 2 mM NaCl, 1 mM MgCl2, 10 mM EGTA, 10 mM HEPES, pH 7.35) and extracellular (PBS, with Ca\n2+\n and Mg\n2+\n) buffers were positioned on IonWorks Quattro. Electrophysiology recordings were made from the CHO-K\nv\n1.3 cells using an amphotericin-based perforated patch-clamp method. Using the voltage-clamp circuitry of the IonWorks Quattro, cells were held at a membrane potential of −80 mV and voltage-activated K\n+\n currents were evoked by stepping the membrane potential to +30 mV for 400 ms. K\n+\n currents were evoked under control conditions i.e., in the absence of inhibitor at the beginning of the experiment and after 10-minute incubation in the presence of the Test Solution or Standard. The mean K\n+\n current amplitude was measured between 430 and 440 ms and the data were exported to a Microsoft Excel spreadsheet. The amplitude of the K\n+\n current in the presence of each concentration of the Test Solution or Standard was expressed as a percentage of the K\n+\n current in control conditions in the same well.\n\n\nStandard inhibition curves were generated for each standard in various levels of rat serum and expressed as current percent of control (POC) versus log of nM concentration. Percent of control (POC) is inversely related to inhibition, where 100 POC is no inhibition and 0 POC is 100% inhibition. Linear regression over a selected region of the curve was used to derive an equation to enable calculation of drug concentrations within Test solutions. Only current values within the linear portion of the Standard curve were used to calculate the concentration of drug in Test solutions. The corresponding Standard curve in a given level of serum, was always compared to the same level of serum of Test solution when calculating drug level. The Standard curves for ShK and 20K PEG-ShK[1-35] are shown in \nFIG. 58A\n and \nFIG. 58B\n, respectively, and each figure contains linear regression equations for each Standard at a given percentage of serum. For the 20K PEG-ShK[1-35] standard curve the linear portion of the Standard curve was from 20 POC to 70 POC and only current values derived from the Test solution which fell within this range were used to calculate drug concentration within the Test solution.\n\n\nThe pharmacokinetic profile of our novel 20K PEG ShK[1-35] molecule after IV injection is shown in \nFIG. 59\n. The terminal half-life (t\n1/2 \nb) of this molecule is estimated from this curve to be between 6 to 12 hours long. Beyond 48 hours, the level of drug falls outside the linear range of the Standard curve and is not calculated. The calculated 6 to 12 hour half-life of our novel 20K PEG-ShK[1-35] molecule was substantially longer than the approximately 0.33 hour (or 20 min) half-life of the native ShK molecule reported earlier by C. Beeton et al. [C. Beeton et al. (2001) Proc. Natl. Acad. Sci. 98, 13942-13947], and is a desirable feature of a therapeutic molecule. A comparison of the relative levels of Kv1.3 inhibitor after an equal molar IV injection of ShK versus 20K PEG-ShK[1-35] is shown in \nFIG. 60\n. As can be seen from this figure examining 5% serum Test solutions, the 20K PEG-ShK[1-35] molecule showed significant suppression of Kv1.3 current (<70 POC) for more than 24 hours, whereas the native ShK peptide only showed a significant level of inhibition of Kv1.3 current for the first hour and beyond 1 hour showed no significant blockade. These data again demonstrate a desirable feature of the 20K PEG ShK[1-35] molecule as a therapeutic for treatment of autoimmune disease.\n\n\nExample 45\n\n\nPEGylated Toxin Peptide Suppressed Severe Autoimmune Encephalomyelitis in Animal Model\n\n\nThe 20KPEG-ShK inhibitor of Kv1.3 shows improved efficacy in suppressing severe autoimmune encephalomyelitis in rats. Using an adoptive transfer experimental autoimmune encephalomyelitis (AT-EAE) model of multiple sclerosis described earlier [C. Beeton et al. (2001) J. Immunol. 166, 936], we examined the activity in vivo of our novel 20KPEG-ShK molecule and compared its efficacy to that of the ShK toxin peptide alone. The study design is illustrated in \nFIG. 61\n. The results from this in vivo study are provided in \nFIG. 62\n and \nFIG. 63\n. The 20KPEG-ShK molecule delivered subcutaneously (SC) at 10 μg/kg daily from day −1 to \nday\n 3 significantly reduced disease severity and increased survival, whereas animals treated with an equal molar dose (10 μg/kg) of the small ShK peptide developed severe disease and died.\n\n\nThe 35-amino acid toxin peptide ShK (\nStichodactyla helianthus \nneurotoxin) was purchased from Bachem Bioscience Inc and confirmed by electrophysiology to potently block Kv1.3 (see Example 36 herein). The synthesis, PEGylation and purification of the 20KPEG ShK molecule was as described herein above. The encephalomyelogenic CD4+ rat T cell line, PAS, specific for myelin-basic protein (MBP) originated from Dr. Evelyne Beraud. The maintenance of these cells in vitro and their use in the AT-EAE model has been described earlier [C. Beeton et al. (2001) \nPNAS\n 98, 13942]. PAS T cells were maintained in vitro by alternating rounds of antigen stimulation or activation with MBP and irradiated thymocytes (2 days), and propagation with T cell growth factors (5 days). Activation of PAS T cells (3×10\n5\n/ml) involved incubating the cells for 2 days with 10 μg/ml MBP and 15×10\n6\n/ml syngeneic irradiated (3500 rad) thymocytes. On \nday\n 2 after in vitro activation, 10-15×10\n6 \nviable PAS T cells were injected into 6-12 week old female Lewis rats (Charles River Laboratories) by tail IV. Daily subcutaneous injections of vehicle (2% Lewis rat serum in PBS), 20KPEG-ShK or ShK were given from days −1 to 3 (\nFIG. 61\n), where day −1 represent 1 day prior to injection of PAS T cells (day 0). In vehicle treated rats, acute EAE developed 4 to 5 days after injection of PAS T cells (\nFIG. 62\n). Serum was collected by retro-orbital bleeding at \nday\n 4 and by cardiac puncture at day 8 (end of the study) for analysis of levels of inhibitor. Rats were weighed on days −1, 4, 6, and 8. Animals were scored blinded once a day from the day of cell transfer (day 0) to \nday\n 3, and twice a day from \nday\n 4 to \nday\n 8. Clinical signs were evaluated as the total score of the degree of paresis of each limb and tail. Clinical scoring: 0=No signs, 0.5=distal limp tail, 1.0=limp tail, 2.0=mild paraparesis, ataxia, 3.0=moderate paraparesis, 3.5=one hind leg paralysis, 4.0=complete hind leg paralysis, 5.0=complete hind leg paralysis and incontinence, 5.5=tetraplegia, 6.0=moribund state or death. Rats reaching a score of 5.5 were euthanized.\n\n\nTreatment of rats with the Kv1.3 blocker PEG-ShK prior to the onset of EAE caused a lag in the onset of disease, inhibited the progression of disease, and prevented death in a dose-dependent manner (\nFIG. 62\n). Onset of disease in rats that were treated with the vehicle alone, 10 μg/kg ShK or 1 μg/kg of PEG-ShK was observed on \nday\n 4, compared to day 4.5 in rats treated with 10 μg/kg PEG-ShK or 100 μg/kg PEG-ShK. In addition, rats treated with vehicle alone, 10 μg/kg ShK or 1 μg/kg of PEG-ShK all developed severe disease by the end of the study with an EAE score of 5.5 or above. In contrast, rats treated with 10 μg/kg PEG-ShK or 100 μg/kg PEG-ShK, reached a peak clinical severity score average of <2, and all but one rat survived to the end of the study. Furthermore, we found that rat body weight correlated with disease severity (\nFIG. 63\n). Rats treated with vehicle alone, 10 μg/kg ShK or 1 μg/kg of PEG-ShK all lost an average of 31 g, 30 g, and 30 g, respectively, while rats treated with 10 μg/kg PEG-ShK or 100 μg/kg PEG-ShK lost 18 g and 11 g, respectively. Rats in the latter two groups also appeared to be gaining weight by the end of the study, a sign of recovery. It should be noted that rats treated with 10 μg/kg ShK and 10 μg/kg PEG-ShK received molar equivalents of the ShK peptide. The significantly greater efficacy of the PEG-ShK molecule relative to unconjugated ShK, is likely due to the PEG-ShK molecule's greater stability and prolonged half-life in vivo (see, Example 44).\n\n\nExample 46\n\n\nCompositions Including Kv1.3 Antagonist Peptides Block Inflammation in Human Whole Blood\n\n\nEx vivo assay to examine impact of Kv1.3 inhibitors on secretion of IL-2 and IFN-g. Human whole blood was obtained from healthy, non-medicated donors in a heparin vacutainer. DMEM complete media was Iscoves DMEM (with L-glutamine and 25 mM Hepes buffer) containing 0.1% human albumin (Bayer #68471), 55 μM 2-mercaptoethanol (Gibco), and 1× Pen-Strep-Gln (PSG, Gibco, Cat#10378-016). Thapsigargin was obtained from Alomone Labs (Israel). A 10 mM stock solution of thapsigargin in 100% DMSO was diluted with DMEM complete media to a 40 μM, 4× solution to provide the 4× thapsigargin stimulus for calcium mobilization. The Kv1.3 inhibitor peptide ShK (\nStichodacytla helianthus \ntoxin, Cat# H2358) and the BKCa1 inhibitor peptide IbTx (Iberiotoxin, Cat# H9940) were purchased from Bachem Biosciences, whereas the Kv1.1 inhibitor peptide DTX-k (Dendrotoxin-K) was from Alomone Labs (Israel). The CHO-derived Fc-L10-ShK[2-35] peptibody inhibitor of Kv1.3 was obtained as described herein at Example 4 and Example 39. The calcineurin inhibitor cyclosporin A was obtained from the Amgen sample bank, but is also available commercially from a variety of vendors. Ten 3-fold serial dilutions of inhibitors were prepared in DMEM complete media at 4× final concentration and 50 μl of each were added to wells of a 96-well Falcon 3075 flat-bottom microtiter plate. Whereas columns 1-5 and 7-11 of the microtiter plate contained inhibitors (each row with a separate inhibitor dilution series), 50 μl of DMEM complete media alone was added to the 8 wells in \n \ncolumn\n \n 6 and 100 μl of DMEM complete media alone was added to the 8 wells in \ncolumn\n 12. To initiate the experiment, 100 μl of whole blood was added to each well of the microtiter plate. The plate was then incubated at 37° C., 5% CO\n2 \nfor one hour. After one hour, the plate was removed and 50 μl of the 4× thapsigargin stimulus (40 μM) was added to all wells of the plate, except the 8 wells in \ncolumn\n 12. The plates were placed back at 37° C., 5% CO\n2 \nfor 48 hours. To determine the amount of IL-2 and IFN-g secreted in whole blood, 100 μl of the supernatant (conditioned media) from each well of the 96-well plate was transferred to a storage plate. For MSD electrochemilluminesence analysis of cytokine production, 20 μl of the supernatants (conditioned media) were added to MSD Multi-Spot Custom Coated plates (meso-scale.com). The working electrodes on these plates were coated with four Capture Antibodies (hIL-5, hIL-2, hIFNg and hIL-4) in advance. After addition of 20 μl of conditioned media to the MSD plate, 150 μl of a cocktail of Detection Antibodies and P4 Buffer were added to each well. The 150 μl cocktail contained 20 ul of four Detection Antibodies (hIL-5, hIL-2, hIFNg and hIL-4) at 1 μg/ml each and 130 ul of 2×P4 Buffer. The plates were covered and placed on a shaking platform overnight (in the dark). The next morning the plates were read on the MSD Sector Imager. Since the 8 wells in \ncolumn\n 6 of each plate received only the thapsigargin stimulus and no inhibitor, the average MSD response here was used to calculate the “High” value for a plate. The calculate “Low” value for the plate was derived from the average MSD response from the 8 wells in \ncolumn\n 12 which contained no thapsigargin stimulus and no inhibitor. Percent of control (POC) is a measure of the response relative to the unstimulated versus stimulated controls, where 100 POC is equivalent to the average response of thapsigargin stimulus alone or the “High” value. Therefore, 100 POC represents 0% inhibition of the response. In contrast, 0 POC represents 100% inhibition of the response and would be equivalent to the response where no stimulus is given or the “Low” value. To calculate percent of control (POC), the following formula is used: [(MSD response of well)−(“Low”)]/[(“High”)−(“Low”)]×100. The potency of the molecules in whole blood was calculated after curve fitting from the inhibition curve (IC) and IC50 was derived using standard curve fitting software. Although we describe here measurement of cytokine production using a high throughput MSD electrochemillumenescence assay, one of skill in the art can readily envision lower throughput ELISA assays are equally applicable for measuring cytokine production.\n\n\nEx vivo assay demonstrating Kv1.3 inhibitors block cell surface activation of CD40L & IL-2R. Human whole blood was obtained from healthy, non-medicated donors in a heparin vacutainer. DMEM complete media was Iscoves DMEM (with L-glutamine and 25 mM Hepes buffer) containing 0.1% human albumin (Bayer #68471), 55 μM 2-mercaptoethanol (Gibco), and 1× Pen-Strep-Gln (PSG, Gibco, Cat#10378-016). Thapsigargin was obtained from Alomone Labs (Israel). A 10 mM stock solution of thapsigargin in 100% DMSO was diluted with DMEM complete media to a 40 μM, 4× solution to provide the 4× thapsigargin stimulus for calcium mobilization. The Kv1.3 inhibitor peptide ShK (\nStichodacytla helianthus \ntoxin, Cat# H2358) and the BKCa1 inhibitor peptide IbTx (Iberiotoxin, Cat# H9940) were purchased from Bachem Biosciences, whereas the Kv1.1 inhibitor peptide DTX-k (Dendrotoxin-K) was from Alomone Labs (Israel). The CHO-derived Fc-L110-ShK[2-35] peptibody inhibitor of Kv1.3 was obtained as described in Example 4 and Example 39. The calcineurin inhibitor cyclosporin A was obtained from the Amgen sample bank, but is also available commercially from a variety of vendors. The ion channel inhibitors ShK, IbTx or DTK-k were diluted into DMEM complete media to 4× of the final concentration desired (final=50 or 100 nM). The calcineurin inhibitor cyclosporin A was also diluted into DMEM complete media to 4× final concentration (final=10 μM). To appropriate wells of a 96-well Falcon 3075 flat-bottom microtiter plate, 50 μl of either DMEM complete media or the 4× inhibitor solutions were added. Then, 100 μl of human whole blood was added and the plate was incubated for 1 hour at 37° C., 5% CO\n2\n. After one hour, the plate was removed and 50 μl of the 4× thapsigargin stimulus (40 μM) was added to all wells of the plate containing inhibitor. To some wells containing no inhibitor but just DMEM complete media, thapsigargin was also added whereas others wells with just DMEM complete media had an additional 50 μl of DMEM complete media added. The wells with no inhibitor and no thapsigargin stimulus represented the untreated “Low” control. The wells with no inhibitor but which received thapsigargin stimulus represented the control for maximum stimulation or “High” control. Plates were placed back at 37° C., 5% CO\n2 \nfor 24 hours. After 24 hours, plates were removed and wells were process for FACS analysis. Cells were removed from the wells and washed in staining buffer (phosphate buffered saline containing 2% heat-inactivated fetal calf serum). Red blood cells were lysed using BD FACS Lysing Solution containing 1.5% formaldehyde (BD Biosciences) as directed by the manufacturer. Cells were distributed at a concentration of 1 million cells per 100 microliters of staining buffer per tube. Cells were first stained with 1 microliter of biotin-labeled anti-human CD4, washed, then stained simultaneously 1 microliter each of streptavidin-APC, FITC-labeled anti-human CD45RA, and phycoerythrin (PE)-labeled anti-human CD25 (IL-2Ra) or PE-labeled anti-human CD40L. Cells were washed with staining buffer between antibody addition steps. All antibodies were obtained from BD Biosciences (San Diego, Calif.). Twenty to fifty thousand live events were collected for each sample on a Becton Dickinson FACSCaliber (Mountain View, Calif.) flow cytometer and analyzed using FlowJo software (Tree Star Inc., San Carlos, Calif.). Dead cells, monocytes, and granulocytes were excluded from the analysis on the basis of forward and side scatter properties.\n\n\n \nFIG. 64\n and \nFIG. 67\n demonstrate that Kv1.3 inhibitors ShK and Fc-L10-ShK[2-35] potently blocked IL-2 secretion in human whole blood, in addition to suppressing activation of the IL-2R on CD4+ T cells. The Kv1.3 inhibitor Fc-L10-ShK[2-35] was more than 200 times more potent in blocking IL-2 production in human whole blood than cyclosporine A (\nFIG. 64\n) as reflected by the IC50. \nFIG. 65\n shows that Kv1.3 inhibitors also potently blocked secretion of IFNg in human whole blood, and \nFIG. 66\n demonstrates that upregulation of CD40L on T cells was additionally blocked. The data in \nFIGS. 64-67\n show that the Fc-L10-ShK[2-35] molecule was stable in whole blood at 37° C. for up to 48 hours, providing potent blockade of inflammatory responses. Toxin peptide therapeutic agents that target Kv1.3 and have prolonged half-life, are sought to provide sustained blockade of these responses in vivo over time. In contrast, despite the fact the Kv1.3 inhibitor peptide ShK also showed potent blockade in whole blood, the ShK peptide has a short (˜20 min) half-life in vivo (C. Beeton et al. (2001) Proc. Natl. Acad. Sci. 98, 13942), and cannot, therefore, provide prolonged blockade. Whole blood represents a physiologically relevant assay to predict the response in animals. The whole blood assays described here can also be used as a pharmacodynamic (PD) assay to measure target coverage and drug exposure following dosing of patients. These human whole blood data support the therapeutic usefulness of the compositions of the present invention for treatment of a variety immune disorders, such as multiple sclerosis, \ntype\n 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus.\n\n\nExample 47\n\n\nPEGylated Peptibodies\n\n\nBy way of example, PEGylated peptibodies of the present invention were made by the following method. CHO-expressed FcL10-OsK1 (19.2 mg; MW 30,371 Da, 0.63 micromole) in 19.2 ml A5S, 20 mM NaBH\n3\nCN, \npH\n 5, was treated with 38 mg PEG aldehyde (\nMW\n 20 kDa; 3×, Lot 104086). The sealed reaction mixture was stirred in a cold room overnight. The extent of the protein modification during the course of the reaction was monitored by SEC HPLC using a \nSuperose\n 6 \nHR\n 10/30 column (Amersham Pharmacia Biotech) eluted with a 0.05 M phosphate buffer, 0.5 M NaCl, pH 7.0 at 0.4 ml/min. The reaction mixture was dialyzed with A5S, \npH\n 5 overnight. The dialyzed material was then loaded onto an SP HP FPLC column (16/10) in \nA5S pH\n 5 and eluted with a 1 M NaCl gradient. The collected fractions were analyzed by SEC HPLC, pooled into 3 pools, exchanged into DPBS, concentrated and submitted for functional testing (Table 34).\n\n\nIn another example, FcL10-ShK1 (16.5 mg; MW 30,065 Da, 0.55 micro mole) in 16.5 ml A5S, 20 mM NaBH\n3\nCN, \npH\n 5 was treated with 44 mg PEG aldehyde (\nMW\n 20 kDa; 4×, Lot 104086). The sealed reaction mixture was stirred in a cold room overnight. The extent of the protein modification during the course of the reaction was monitored by SEC HPLC using a \nSuperose\n 6 \nHR\n 10/30 column (Amersham Pharmacia Biotech) eluted with a 0.05 M phosphate buffer, 0.5 M NaCl, pH 7.0 at 0.4 ml/min. The reaction mixture was dialyzed with A5S, \npH\n 5 overnight. The dialyzed material was loaded onto an SP HP FPLC column (16/10) in \nA5S pH\n 5 and was eluted with a 1 M NaCl gradient. The collected fractions were analyzed by SEC HPLC, pooled into 3 pools, exchanged into DPBS, concentrated and submitted for functional testing (Table 34).\n\n\nThe data in Table 34 demonstrate potency of the PEGylated peptibody molecules as Kv1.3 inhibitors.\n\n\nTable 34 shows determinations of IC50 made by whole cell patch clamp electrophysiology with \nHEK\n 293 as described in Example 36 herein above. The sustained IC50 was derived from the current 400 msecs after voltage ramp from −80 mV to +30 mV. \nPool #\n \n \n \n2\n samples comprised di-PEGylated peptibodies and \nPool #\n \n \n \n3\n samples comprised mono-PEGylated peptibodies.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nPEGylated Peptibody\n\n\nPool #\n\n\nIC50 Sustained (nM)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\nPEG-Fc-L10-SHK(2-35)\n\n\n3\n\n\n0.175(n = 4)\n\n\n\n\n\n\n \n\n\nPEG-Fc-L10-SHK(2-35)\n\n\n2\n\n\n0.158(n = 4)\n\n\n\n\n\n\n \n\n\nPEG-Fc-L10-\nOSK1\n \n\n\n3\n\n\n0.256(n = 3)\n\n\n\n\n\n\n \n\n\nPEG-Fc-L10-\nOSK1\n \n\n\n2\n\n\n0.332(n = 3)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nExample 48\n\n\nPEGylated Toxin Peptides\n\n\nShk and Osk-1 PEGylation, purification and analysis. Synthetic Shk or OSK1-1 toxin peptides were selectively PEGylated by reductive alkylation at their N-termini. Conjugation was achieved, with either Shk or OSK-1 toxin peptides, at 2 mg/ml in 50 mM NaH\n2\nPO\n4\n, pH 4.5 reaction buffer containing 20 mM sodium cyanoborohydride and a 2 molar excess of 20 kDa monomethoxy-PEG-aldehyde (Nektar Therapeutics, Huntsville, Ala.). Conjugation reactions were stirred overnight at room temperature, and their progress was monitored by RP-HPLC. Completed reactions were quenched by 4-fold dilution with 20 mM NaOAc, \npH\n 4, adjusted to pH 3.5 and chilled to 4° C. The PEG-peptides were then purified chromatographically at 4° C.; using SP Sepharose HP columns (GE Healthcare, Piscataway, N.J.) eluted with linear 0-1M NaCl gradients in 20 mM NaOAc, pH 4.0. (\nFIG. 68A\n and \nFIG. 68B\n) Eluted peak fractions were analyzed by SDS-PAGE and RP-HPLC and pooling determined by purity >97%. Principle contaminants observed were di-PEGylated toxin peptide and unmodified toxin peptide. Selected pools were concentrated to 2-5 mg/ml by centrifugal filtration against 3 kDa MWCO membranes and dialyzed into 10 mM NaOAc, \npH\n 4 with 5% sorbitol. Dialyzed pools were then sterile filtered through 0.2 micron filters and purity determined to be >97% by SDS-PAGE and RP-HPLC (\nFIG. 69A\n and \nFIG. 69B\n). Reverse-phase HPLC was performed on an Agilent 1100 model HPLC running a \nZorbax\n 5 μm 300SB-C8 4.6×50 mm column (Phenomenex) in 0.1% TFA/\nH\n \n \n \n2\n0 at 1 ml/min and column temperature maintained at 40° C. Samples of PEG-peptide (20 μg) were injected and eluted in a linear 6-60% gradient while monitoring wavelengths 215 nm and 280 nm.\n\n\nElectrophysiology performed by patch clamp on whole cells (see, Example 36) yielded a peak IC50 of 1.285 nM for PEG-OSK1 and 0.169 nM for PEG-ShK[1-35] (\nFIG. 74\n), in a concentration dependent block of the outward potassium current recorded from HEK293 cells stably expressing human Kv1.3 channel. The purified PEG-ShK[1-35] molecule, also referred to as “20K PEG-ShK[1-35]” and “PEG-ShK”, had a much longer half-life in vivo than the small ShK peptide (\nFIG. 59\n and \nFIG. 60\n). PEG-ShK[1-35] suppressed severe autoimmune encephalomyelitis in rats (Example 45, \nFIGS. 61-63\n) and showed greater efficacy than the small native ShK peptide.\n\n\nPEG conjugates of OSK1 peptide analogs were also generated and tested for activity in blocking T cell inflammation in the human whole blood assay (Example 46). As shown in Table 43, OSK1[Ala12], OSK1[Ala29], OSK1[1Nal11] and OSK1[Ala29, 1Nal34] analogs containing an N-\nterminal\n 20K PEG conjugate, all provided potent blockade of the whole blood cytokine response in this assay. The 20K PEG-ShK was also highly active (Table 43).\n\n\nExample 49\n\n\nFc Loop Insertions of ShK and OSK1 Toxin Peptides\n\n\nAs exemplified in \nFIG. 70\n, \nFIG. 71\n, \nFIG. 72\n, and \nFIG. 73\n, disulphide-constrained toxin peptides were inserted into the human IgG1 Fc-loop domain, defined as the sequence D\n137\nE\n138\nL\n139\nT\n140\nK\n141\n, according to the method published in Example 1 in Gegg et al., Modified Fc molecules, WO 2006/036834 A2 [PCT/US2005/034273]). Exemplary FcLoop-L2-OsK1-L2, FcLoop-L2-ShK-L2, FcLoop-L2-ShK-L4, and FcLoop-L4-OsK1-L2 were made having three linked domains. These were collected, purified and submitted for functional testing.\n\n\nThe peptide insertion for these examples was between Fc residues Leu\n139 \nand Thr\n140 \nand included 2-4 Gly residues as linkers flanking either side of the inserted peptide. However, alternate insertion sites for the human IgG1 Fc sequence, or different linkers, are also useful in the practice of the present invention, as is known in the art, e.g., as described in Example 13 of Gegg et al., Modified Fc molecules, WO 2006/036834 A2 [PCT/US2005/034273]).\n\n\nPurified FcLoop OSK1 and FcLoop ShK1 molecules were tested in the whole blood assay of inflammation (see, Example 46). FcLoop-L2-OsK1-L2, FcLoop-L4-OsK1-L4 and FcLoop-L2-ShK-L2 toxin conjugates all provided potent blockade of the whole blood cytokine response in this assay, with IC50 values in the pM range (Table 43).\n\n\nExample 50\n\n\nPurification of ShK(2-35)-L-Fc from \nE. coli \n \n\n\nFrozen, \nE. coli \npaste (117 g), obtained as described in Example 16 herein above, was combined with 1200 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 7.5 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 17,700 g for 30 min at 4° C. The pellet was then resuspended in 1200 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 17,700 g for 30 min at 4° C. The pellet was then resuspended in 1200 ml water using a tissue grinder and then centrifuged at 17,700 g for 30 min at 4° C. 6.4 g of the pellet (total 14.2 g) was then dissolved in 128 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. 120 ml of the pellet solution was then incubated with 0.67 ml of 1 M DTT for 60 min at 37° C. The reduced material was transferred to 5500 ml of the refolding buffer (3 M urea, 50 mM tris, 160 mM arginine HCl, 2.5 mM EDTA, 2.5 mM cystamine HCl, 4 mM cysteine, pH 9.5) at 2 ml/min, 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 3 days at 4° C.\n\n\nThe refold was diluted with 5.5 L of water, and the pH was adjusted to 8.0 using acetic acid, then the solution was filtered through a 0.22 μm cellulose acetate filter and loaded on to a 35 ml Amersham Q Sepharose-FF (2.6 cm I.D.) column at 10 ml/min in Q-Buffer A (20 mM Tris, pH 8.5) at 8° C. with an inline 35 ml Amersham Mab Select column (2.6 cm I.D.). After loading, the Q Sepharose column was removed from the circuit, and the remaining chromatography was carried out on the Mab Select column. The column was washed with several column volumes of Q-Buffer A, followed by elution using a step to 100 mM glycine pH 3.0. The fractions containing the desired product immediately loaded on to a 5.0 ml Amersham SP-Sepharose HP column at 5.0 ml/min in S-Buffer A (10 mM NaH\n2\nPO\n4\n, pH 7.0) at 8° C. The column was then washed with several column volumes of S-Buffer A followed by a linear gradient from 5% to 60% S-Buffer B (10 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) followed by a step to 100% S-Buffer B. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE. The fractions containing the bulk of the desired product were pooled and then applied to a 50 ml MEP Hypercel column (2.6 cm I.D.) at 10 ml/min in MEP Buffer A (20 mM tris, 200 mM NaCl, pH 8.0) at 8° C. Column was eluted with a linear gradient from 5% to 50% MEP Buffer B (50 mM sodium citrate pH 4.0) followed by a step to 100% MEP Buffer B. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the bulk of the desired product were pooled.\n\n\nThe MEP-pool was then concentrated to about 10 ml using a Pall Jumbo-Sep with a 10 kDa membrane. A spectral scan was then conducted on 50 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 76A\n). Then concentration of the material was determined to be 3.7 mg/ml using a calculated molecular mass of 30,253 and extinction coefficient of 36,900 M\n−1 \ncm\n−1\n. The purity of the material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 76B\n). The macromolecular state of the product was then determined using size exclusion chromatography on 70 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 76C\n). The product was then subject to mass spectral analysis by chromatographing approximately 4 μg of the sample through a RP-HPLC column (Vydac C\n4\n, 1×150 mm). Solvent A was 0.1% trifluoroacetic acid in water and solvent B was 0.1% trifluoroacetic acid in 90% acetonitrile, 10% water. The column was pre-equilibrated in 10% solvent B at a flow rate of 80 μl per min. The protein was eluted using a linear gradient of 10% to 90% solvent B over 30 min. Part of the effluent was directed into a LCQ ion trap mass spectrometer. The mass spectrum was deconvoluted using the Bioworks software provided by the mass spectrometer manufacturer. (\nFIG. 76D\n). The product was filtered through a 0.22 μm cellulose acetate filter and then stored at −80° C.\n\n\nIn Table 35, IC50 data for the purified \nE. coli\n-derived ShK[2-35]-L-Fc are compared to some other embodiments of the inventive composition of matter.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 35\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nE. coli\n-derived recombinant Fc-L-ShK[1-35], Fc-L-ShK[2-35],\n\n\n\n\n\n\nFc-L-OSK1, Shk[1-35]-L-Fc and ShK[2-35]-L-Fc peptibodies\n\n\n\n\n\n\ncontaining Fc at either the N-terminus or C-termmus show\n\n\n\n\n\n\npotent blockade of human Kv1.3.\n\n\n\n\n\n\n\n\n\n\n \n\n\nKv1.3 IC\n50\n \n\n\nKv1.3 IC\n50\n \n\n\n\n\n\n\nMolecule\n\n\nby WCVC (nM)\n\n\nby IWQ (nM)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \nE. coli\n-derived Fc-L-ShK[1-35]\n\n\n1.4\n\n\n \n\n\n\n\n\n\n \nE. coli\n-derived Fc-L-ShK[2-35]\n\n\n1.3\n\n\n2.8\n\n\n\n\n\n\n \nE. coli\n-derived Fc-L-\nOSK\n 1\n\n\n3.2\n\n\n\n\n\n\n \nE. coli\n-derived Shk[1-35]-L-Fc\n\n\n \n\n\n2.4\n\n\n\n\n\n\n \nE. coli\n-derived ShK[2-35]-L-Fc\n\n\n \n\n\n4.9\n\n\n\n\n\n\nCHO-derived Fc-L10-ShK[1-35]\n\n\n \n\n\n2.2\n\n\n\n\n\n\nR1Q\n\n\n\n\n\n\n \n\n\n\n\n\n\nThe activity of the CHO-derived Fc-L10-ShK[1-35] R1Q mutant is also shown. Whole cell patch clamp electrophysiology (WCVC), by methods described in Example 36, was performed using HEK293/Kv1.3 cells and the IC50 shown is the average from dose-response curves from 3 or more cells. IonWorks ™ (IWQ) planar patch clamp electrophysiology by methods described in Example 44 was on CHO/Kv1.3 cells and the average IC50 is shown. The inventive molecules were obtained by methods as described in the indicated Example: \nE. coli\n-derived Fc-L-ShK[1-35] (Example 3 and Example 38), \nE. coli\n-derived Fc-L-ShK[2- 35] (Example 4 and Example 39), \nE. coli \nFc-L-OSK1 (Example 10 and Example 40), ShK[1-35]-L-Fc (Example 15 and Example 51), and ShK[2-35]-L-Fc (Example 16 and this Example 50). CHO-derived Fc-L10-ShK[1-35] R1Q molecule was generated using methods similar to those described for CHO-derived Fc-L10-ShK[1-35].\n\n\n\n\n\n\n\n\n\n\n\n\nExample 51\n\n\nPurification of Met-ShK(1-35)-Fc from \nE. coli \n \n\n\nFrozen, \nE. coli \npaste (65 g), obtained as described in Example 15 herein above was combined with 660 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 7.5 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 17,700 g for 30 min at 4° C. The pellet was then resuspended in 660 \nml\n 1% deoxycholic acid using a tissue grinder and then centrifuged at 17,700 g for 30 min at 4° C. The pellet was then resuspended in 660 ml water using a tissue grinder and then centrifuged at 17,700 g for 30 min at 4° C. 13 g of the pellet was then dissolved in 130 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. 10 ml of the pellet solution was then incubated with 0.1 ml of 1 M DTT for 60 min at 37° C. The reduced material was transferred to 1000 ml of the refolding buffer (2 M urea, 50 mM tris, 160 mM arginine HCl, 2.5 mM EDTA, 1.2 mM cystamine HCl, 4 mM cysteine, pH 8.5) at 2 ml/min, 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for 3 days at 4° C.\n\n\nThe refold was diluted with 1 L of water, and filtered through a 0.22 μm cellulose acetate filter then loaded on to a 35 ml Amersham Q Sepharose-FF (2.6 cm I.D.) column at 10 ml/min in Q-Buffer A (20 mM Tris, pH 8.5) at 8° C. with an inline 35 ml Amersham Mab Select column (2.6 cm I.D.). After loading, the Q Sepharose column was removed from the circuit, and the remaining chromatography was carried out on the Mab Select column. The column was washed with several column volumes of Q-Buffer A, followed by elution using a step to 100 mM glycine pH 3.0. The fractions containing the desired product immediately loaded on to a 5.0 ml Amersham SP-Sepharose HP column at 5.0 ml/min in S-Buffer A (20 mM NaH\n2\nPO\n4\n, pH 7.0) at 8° C. The column was then washed with several column volumes of S-Buffer A followed by a linear gradient from 5% to 60% S-Buffer B (20 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.0) followed by a step to 100% S-Buffer B. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE. The fractions containing the bulk of the desired product were pooled.\n\n\nThe S-pool was then concentrated to about 10 ml using a Pall Jumbo-Sep with a 10 kDa membrane. A spectral scan was then conducted on 20 μl of the combined pool diluted in 700 μl PBS using a Hewlett Packard 8453 spectrophotometer (\nFIG. 77A\n). Then concentration of the material was determined to be 3.1 mg/ml using a calculated molecular mass of 30,409 and extinction coefficient of 36,900 M\n−1 \ncm\n−1\n. The purity of the material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 77B\n). The macromolecular state of the product was then determined using size exclusion chromatography on 93 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 77C\n). The product was then subject to mass spectral analysis by MALDI mass spectrometry.\n\n\nAn aliquot of the sample was spotted with the MALDI matrix sinapinic acid on sample plate. A Voyager DE-RP time-of-flight mass spectrometer equipped with a nitrogen laser (337 nm, 3 ns pulse) was used to collect spectra. The positive ion/linear mode was used, with an accelerating voltage of 25 kV. Each spectrum was produced by accumulating data from ˜200 laser shots (\nFIG. 77D\n). External mass calibration was accomplished using purified proteins of known molecular masses.\n\n\nThe IC\n50 \nfor blockade of human Kv1.3 by purified \nE. coli\n-derived Met-ShK(1-35)-Fc, also referred to as “ShK[1-35]-L-Fc”, is shown in Table 35 herein above.\n\n\nExample 52\n\n\nBacterial Expression of OsK1-L-Fc Inhibitor of Kv1.3\n\n\nThe methods to clone and express the peptibody in bacteria were as described in Example 3. The vector used was pAMG21amgR-pep-Fc and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of OsK1-L-Fc. Oligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nGGGTGTTATCATCAACGTTAAATGCAAAAT\n\n\nSEQ ID NO: 1347\n\n\n\n\n\n\nCTCCCGTCAGTGCCTGGAACCGTGCA\n\n\n \n\n\n\n\n\n\nAAAAAGCTGGTATGCGT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nTTCGGTAAATGCATGAACGGTAAATGCCA\n\n\nSEQ ID NO: 1348\n\n\n\n\n\n\nCTGCACCCCGAAATCTGGTGG\n\n\n \n\n\n\n\n\n\nTGGTGGTTCT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nCACCAGAACCACCACCACCACCAGATTTCG\n\n\nSEQ ID NO: 1349\n\n\n\n\n\n\nGGGTGCAGTGGCATTTACCGTTCA\n\n\n \n\n\n\n\n\n\nTGCATTTACCGAAACGCAT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nACCAGCTTTTTTGCACGGTTCCAGGCACT\n\n\nSEQ ID NO: 1310\n\n\n\n\n\n\nGACGGGAGATTTTGCATTTAA\n\n\n \n\n\n\n\n\n\nCGTTGATGATAAC//;\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nGGGTGTTATCATCAACGTTAAATGCAAAATCTCCCGTCAGTGCCTGGAACCGTGCAAAAA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    CAATAGTAGTTGCAATTTACGTTTTAGAGGGCAGTCACGGACCTTGGCACGTTTTT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  V  I  I  N  V  K  C  K  I  S  R  Q  C  L  E  P  C  K  K\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nAGCTGGTATGCGTTTCGGTAAATGCATGAACGGTAAATGCCACTGCACCCCGAAATCTGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nTCGACCATACGCAAAGCCATTTACGTACTTGCCATTTACGGTGACGTGGGGCTTTAGACC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n A  G  M  R  F  G  K  C  M  N  G  K  C  H  C  T  P  K  S  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTGGTGGTGGTTCT\n\n\n \n\n\n//SEQ ID NO: 1350\n\n\n\n\n\n\n121\n\n\n---------+-------\n\n\n137\n\n\n\n\n\n\n \n\n\nACCACCACCAAGACCAC\n\n\n \n\n\n//SEQ ID NO: 1352\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  G  G  S  G\n\n\n—\n\n\n//SEQ ID NO: 1351\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 53\n\n\nBacterial Expression of Gly-ShK(1-35)-L-Fc Inhibitor of Kv1.3\n\n\nThe methods to clone and express the peptibody in bacteria were as described in Example 3. The vector used was pAMG21amgR-pep-Fc and the oligos listed below were used to generate a duplex (see below) for cloning and expression in bacteria of Gly-ShK(1-35)-L-Fc. Oligos used to form duplex are shown below:\n\n\n\n\n\n\n\n\n\n\n\n\nGGGTCGTTCTTGTATTGATACTATTCCA\n\n\nSEQ ID NO: 1313\n\n\n\n\n\n\nAAATCTCGTTGTACTGCTTTTCA\n\n\n \n\n\n\n\n\n\nATGTAAACATTCTATGAAATAT\n\n\n \n\n\n\n\n\n\nCGTCTTTCTT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nTTTGTCGTAAAACTTGTGGTACTTGTTCTG\n\n\nSEQ ID NO: 1314\n\n\n\n\n\n\nGTGGTGGTGGTTCT//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nCACCAGAACCACCACCACCAGAACAAG\n\n\nSEQ ID NO: 1353\n\n\n\n\n\n\nTACCACAAGTTTTACGACAAA\n\n\n \n\n\n\n\n\n\nAAGAAAGACGATATTTCATAGA\n\n\n \n\n\n\n\n\n\nATGTTTACATTGA//;\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nAAAGCAGTACAACGAGATTTTGGAATA\n\n\nSEQ ID NO: 1354\n\n\n\n\n\n\nGTATCAATACAAGAACG//\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe oligos shown above were used to form the duplex shown below:\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n \nGGGTCGTTCTTGTATTGATACTATTCCAAAATCTCGTTGTACTGCTTTTCAATGTAAACA\n \n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\n  1\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n 60\n\n\n\n\n\n\n \n\n\n    GCAAGAACATAACTATGATAAGGTTTTAGAGCAACATGACGAAAAGTTACATTTGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  R  S  C  I  D  T  I  P  K  S  R  C  T  A  F  Q  C  K  H\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTTCTATGAAATATCGTCTTTCTTTTTGTCGTAAAACTTGTGCTACTTGTTCTGGTGGTGG\n\n\n\n\n\n\n 61\n\n\n---------+---------+---------+---------+---------+---------+\n\n\n120\n\n\n\n\n\n\n \n\n\nAAGATACTTTATAGCAGAAAGAAAAACAGCATTTTGAACACCATGAACAAGACCACCACC\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n S  M  K  Y  R  L  S  F  C  R  K  T  C  G  T  C  S  G  G  G\n\n\n—\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nTGGTTCT\n\n\n \n\n\n//SEQ ID NO: 1355\n\n\n\n\n\n\n121\n\n\n---------+-\n\n\n131\n\n\n\n\n\n\n \n\n\nACCAAGACCAC\n\n\n \n\n\n//SEQ ID NO: 1357\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n G  S  G\n\n\n—\n\n\n//SEQ ID NO: 1356\n\n\n\n\n\n\n\n\n\n\n\n\nBacterial expression of the peptibody was as described in Example 3 and paste was stored frozen.\n\n\nExample 54\n\n\nBacterial Expression of CH2-OSK1 Inhibitor of Kv1.3\n\n\nThe methods to clone and express the fusion of a CH2 domain of an Fc with OSK1 in bacteria were generally as described in Example 3. The vector used was pAMG21.G2.H6.G3.CH2.(G4S)2.OSK. Briefly, the pAMG21 vector was modified to remove the multi-cloning site's BamHI. This allowed the BamHI in front of the OSK as a site to swap out different sequences for fusion with the OSK. The sequence upstream of the OSK1 coding sequence was ligated between the NdeI and BamHI sites.\n\n\nThe sequence of the entire vector, including the insert was the following:\n\n\n\n\n\n\n\n\n\n\n\n\nSEQ ID NO: 4914\n\n\n\n\n\n\ngtcgtcaacgaccccccattcaagaacagcaagcagcattgagaactttg\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaatccagtccctcttccacctgctgaccggatcagcagtccccggaaca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcgtagctgacgccttcgcgttgctcagttgtccaaccccggaaacggga\n\n\n\n\n\n\n \n\n\n\n\n\n\naaaagcaagttttccccgctcccggcgtttcaataactgaaaaccatact\n\n\n\n\n\n\n \n\n\n\n\n\n\natttcacagtttaaatcacattaaacgacagtaatccccgttgatttgtg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgccaacacagatcttcgtcacaattctcaagtcgctgatttcaaaaaac\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtagtatcctctgcgaaacgatccctgtttgagtattgaggaggcgaga\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtcgcagacagaaaatgcagtgacttcctcattgagtcaaaagcggttt\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcgcagaggtaagcctatgactgactctgagaaacaaatggccgttgt\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgcaagaaaacgtcttacacacaaagagataaaagtttttgtcaaaaatc\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctgaaggatctcatggttgagtactgcgagagagaggggataacacag\n\n\n\n\n\n\n \n\n\n\n\n\n\ngctcagttcgttgagaaaatcatcaaagatgaactgcaaagactggatat\n\n\n\n\n\n\n \n\n\n\n\n\n\nactaaagtaaagactttactttgtggcgtagcatgctagattactgatcg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttaaggaattttgtggctggccacgccgtaaggtggcaaggaactggtt\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgatgtggatttacaggagccagaaaagcaaaaaccccgataatcttct\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcaacttttgcgagtacgaaaagattaccggggcccacttaaaccgtata\n\n\n\n\n\n\n \n\n\n\n\n\n\ngccaacaattcagctatgcggggagtatagttatatgcccggaaaagttc\n\n\n\n\n\n\n \n\n\n\n\n\n\naagacttctttctgtgctcgctccttctgcgcattgtaagtgcaggatgg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtgactgatcttcaccaaacgtattaccgccaggtaaagaacccgaatc\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggtgtttacaccccgtgaaggtgcaggaacgctgaagttctgcgaaaaa\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgatggaaaaggcggtgggcttcacttcccgttttgatttcgccattca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtggcgcacgcccgttcgcgtgatctgcgtcgccgtatgccaccagtgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgcgtcgtcgggctattgatgcgctcttgcaggggctgtgtttccactat\n\n\n\n\n\n\n \n\n\n\n\n\n\ngacccgctggccaaccgcgtccagtgctccatcaccacgctggccattga\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcggactggcgacggagtctgctgccggaaaactctccatcacccgtg\n\n\n\n\n\n\n \n\n\n\n\n\n\nccacccgtgccctgacgttcctgtcagagctgggactgattacctaccag\n\n\n\n\n\n\n \n\n\n\n\n\n\nacggaatatgacccgcttatcgggtgctacattccgaccgatatcacgtt\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacatctgcactgtttgctgccctcgatgtatcagaggaggcagtggccg\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgcgcgccgcagccgtgtggtatgggaaaacaaacaacgcaaaaagcag\n\n\n\n\n\n\n \n\n\n\n\n\n\ngggctggataccctgggcatggatgaactgatagcgaaagcctggcgttt\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgttcgtgagcgttttcgcagttatcagacagagcttaagtcccgtggaa\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaaagcgtgcccgtgcgcgtcgtgatgcggacagggaacgtcaggatatt\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcaccctggtgaaacggcagctgacgcgcgaaatcgcggaagggcgctt\n\n\n\n\n\n\n \n\n\n\n\n\n\ncactgccaatcgtgaggcggtaaaacgcgaagttgagcgtcgtgtgaagg\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcgcatgattctgtcacgtaaccgtaattacagccggctggccacagct\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccccctgaaagtgacctcctctgaataatccggcctgcgccggaggctt\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgcacgtctgaagcccgacagcgcacaaaaaatcagcaccacatacaaa\n\n\n\n\n\n\n \n\n\n\n\n\n\naaacaacctcatcatccagcttctggtgcatccggccccccctgttttcg\n\n\n\n\n\n\n \n\n\n\n\n\n\natacaaaacacgcctcacagacggggaattttgcttatccacattaaact\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcaagggacttccccataaggttacaaccgttcatgtcataaagcgccat\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgccagcgttacagggtgcaatgtatcttttaaacacctgtttatatct\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctttaaactacttaattacattcatttaaaaagaaaacctattcactgc\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgtccttggacagacagatatgcacctcccaccgcaagcggcgggcccc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccggagccgctttagttacaacactcagacacaaccaccagaaaaacc\n\n\n\n\n\n\n \n\n\n\n\n\n\nccggtccagcgcagaactgaaaccacaaagcccctccctcataactgaaa\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcggccccgccccggtccgaagggccggaacagagtcgcttttaattat\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaatgttgtaactacttcatcatcgctgtcagtcttctcgctggaagttc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcagtacacgctcgtaagcggccctgacggcccgctaacgcggagatacg\n\n\n\n\n\n\n \n\n\n\n\n\n\nccccgacttcgggtaaaccctcgtcgggaccactccgaccgcgcacagaa\n\n\n\n\n\n\n \n\n\n\n\n\n\ngctctctcatggctgaaagcgggtatggtctggcagggctggggatgggt\n\n\n\n\n\n\n \n\n\n\n\n\n\naaggtgaaatctatcaatcagtaccggcttacgccgggcttcggcggttt\n\n\n\n\n\n\n \n\n\n\n\n\n\ntactcctgtttcatatatgaaacaacaggtcaccgccttccatgccgctg\n\n\n\n\n\n\n \n\n\n\n\n\n\natgcggcatatcctggtaacgatatctgaattgttatacatgtgtatata\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtggtaatgacaaaaataggacaagttaaaaatttacaggcgatgcaat\n\n\n\n\n\n\n \n\n\n\n\n\n\ngattcaaacacgtaatcaatatcgggggtgggcgaagaactccagcatga\n\n\n\n\n\n\n \n\n\n\n\n\n\ngatccccgcgctggaggatcatccagccggcgtcccggaaaacgattccg\n\n\n\n\n\n\n \n\n\n\n\n\n\naagcccaacctttcatagaaggcggcggtggaatcgaaatctcgtgatgg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggttgggcgtcgcttggtcggtcatttcgaaccccagagtcccgctca\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggag\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggcgataccgtaaagcacgaggaagcggtcagcccattcgccgccaagc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcttcagcaatatcacgggtagccaacgctatgtcctgatagcggtccgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ncacacccagccggccacagtcgatgaatccagaaaagcggccattttcca\n\n\n\n\n\n\n \n\n\n\n\n\n\nccatgatattcggcaagcaggcatcgccatgagtcacgacgagatcctcg\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgtcgggcatgcgcgccttgagcctggcgaacagttcggctggcgcgag\n\n\n\n\n\n\n \n\n\n\n\n\n\ncccctgatgctcttcgtccagatcatcctgatcgacaagaccggcttcca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntccgagtacgtgctcgctcgatgcgatgtttcgcttggtggtcgaatggg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggtagccggatcaagcgtatgcagccgccgcattgcatcagccatgat\n\n\n\n\n\n\n \n\n\n\n\n\n\nggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccg\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcacttcgcccaatagcagccagtcccttcccgcttcagtgacaacgtcg\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcacagctgcgcaaggaacgcccgtcgtggccagccacgatagccgcgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgcctcgtcctgcaattcattcaggacaccggacaggtcggtcttgacaa\n\n\n\n\n\n\n \n\n\n\n\n\n\naaagaaccgggcgcccctgcgctgacagccggaacacggcggcatcagag\n\n\n\n\n\n\n \n\n\n\n\n\n\ncagccgattgtctgttgtgcccagtcatagccgaatagcctctccaccca\n\n\n\n\n\n\n \n\n\n\n\n\n\nagcggccggagaacctgcgtgcaatccatcttgttcaatcatgcgaaacg\n\n\n\n\n\n\n \n\n\n\n\n\n\natcctcatcctgtctcttgatctgatcttgatcccctgcgccatcagatc\n\n\n\n\n\n\n \n\n\n\n\n\n\ncttggcggcaagaaagccatccagtttactttgcagggcttcccaacctt\n\n\n\n\n\n\n \n\n\n\n\n\n\naccagagggcgccccagctggcaattccggttcgcttgctgtccataaaa\n\n\n\n\n\n\n \n\n\n\n\n\n\nccgcccagtctagctatcgccatgtaagcccactgcaagctacctgcttt\n\n\n\n\n\n\n \n\n\n\n\n\n\nctctttgcgcttgcgttttcccttgtccagatagcccagtagctgacatt\n\n\n\n\n\n\n \n\n\n\n\n\n\ncatccggggtcagcaccgtttctgcggactggctttctacgtgttccgct\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcctttagcagcccttgcgccctgagtgcttgcggcagcgtgaagctaca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntatatgtgatccgggcaaatcgctgaatattccttttgtctccgaccatc\n\n\n\n\n\n\n \n\n\n\n\n\n\naggcacctgagtcgctgtctttttcgtgacattcagttcgctgcgctcac\n\n\n\n\n\n\n \n\n\n\n\n\n\nggctctggcagtgaatgggggtaaatggcactacaggcgccttttatgga\n\n\n\n\n\n\n \n\n\n\n\n\n\nttcatgcaaggaaactacccataatacaagaaaagcccgtcacgggcttc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcagggcgttttatggcgggtctgctatgtggtgctatctgactttttgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgttcagcagttcctgccctctgattttccagtctgaccacttcggatta\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcccgtgacaggtcattcagactggctaatgcacccagtaaggcagcggt\n\n\n\n\n\n\n \n\n\n\n\n\n\natcatcaacaggcttacccgtcttactgtcgaagacgtgcgtaacgtatg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncatggtctccccatgcgagagtagggaactgccaggcatcaaataaaacg\n\n\n\n\n\n\n \n\n\n\n\n\n\naaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcgg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgaacgctctcctgagtaggacaaatccgccgggagcggatttgaacgtt\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcgaagcaacggcccggagggtggcgggcaggacgcccgccataaactgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggcatcaaattaagcagaaggccatcctgacggatggcctttttgcgt\n\n\n\n\n\n\n \n\n\n\n\n\n\nttctacaaactcttttgtttatttttctaaatacattcaaatatggacgt\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtacttaacttttaaagtatgggcaatcaattgctcctgttaaaattgc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttagaaatactttggcagcggtttgttgtattgagtttcatttgcgcat\n\n\n\n\n\n\n \n\n\n\n\n\n\ntggttaaatggaaagtgaccgtgcgcttactacagcctaatatttttgaa\n\n\n\n\n\n\n \n\n\n\n\n\n\natatcccaagagctttttccttcgcatgcccacgctaaacattctttttc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcttttggttaaatcgttgtttgatttattatttgctatatttatttttc\n\n\n\n\n\n\n \n\n\n\n\n\n\ngataattatcaactagagaaggaacaattaatggtatgttcatacacgca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgtaaaaataaactatctatatagttgtctttctctgaatgtgcaaaact\n\n\n\n\n\n\n \n\n\n\n\n\n\naagcattccgaagccattattagcagtatgaatagggaaactaaacccag\n\n\n\n\n\n\n \n\n\n\n\n\n\ntgataagacctgatgatttcgcttctttaattacatttggagatttttta\n\n\n\n\n\n\n \n\n\n\n\n\n\ntttacagcattgttttcaaatatattccaattaatcggtgaatgattgga\n\n\n\n\n\n\n \n\n\n\n\n\n\ngttagaataatctactataggatcatattttattaaattagcgtcatcat\n\n\n\n\n\n\n \n\n\n\n\n\n\naatattgcctccattttttagggtaattatccagaattgaaatatcagat\n\n\n\n\n\n\n \n\n\n\n\n\n\nttaaccatagaatgaggataaatgatcgcgagtaaataatattcacaatg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaccattttagtcatatcagataagcattgattaatatcattattgcttc\n\n\n\n\n\n\n \n\n\n\n\n\n\ntacaggctttaattttattaattattctgtaagtgtcgtcggcatttatg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntctttcatacccatctctttatccttacctattgtttgtcgcaagttttg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtgttatatatcattaaaacggtaatagattgacatttgattctaataa\n\n\n\n\n\n\n \n\n\n\n\n\n\nattggatttttgtcacactattatatcgcttgaaatacaattgtttaaca\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaagtacctgtaggatcgtacaggtttacgcaagaaaatggtttgttata\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcgattaatcgatttgattctagatttgttttaactaattaaaggagga\n\n\n\n\n\n\n \n\n\n\n\n\n\nataacatatgggcggccatcatcatcatcatcatggcgggggaccgtcag\n\n\n\n\n\n\n \n\n\n\n\n\n\nttttcctcttccccccaaaacccaaggacaccctcatgatctcccggacc\n\n\n\n\n\n\n \n\n\n\n\n\n\ncctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggt\n\n\n\n\n\n\n \n\n\n\n\n\n\ncaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaa\n\n\n\n\n\n\n \n\n\n\n\n\n\nagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctc\n\n\n\n\n\n\n \n\n\n\n\n\n\naccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt\n\n\n\n\n\n\n \n\n\n\n\n\n\nctccaacaaagccctcccagcccccatcgagaaaaccatctccggcggcg\n\n\n\n\n\n\n \n\n\n\n\n\n\ngcggcagcggcggcggcggatccggtgttatcatcaacgttaaatgcaaa\n\n\n\n\n\n\n \n\n\n\n\n\n\natctcccgtcagtgcctggaaccgtgcaaaaaagctggtatgcgtttcgg\n\n\n\n\n\n\n \n\n\n\n\n\n\ntaaatgcatgaacggtaaatgccactgcaccccgaaataatgaattcgag\n\n\n\n\n\n\n \n\n\n\n\n\n\nctcactagtgtcgacctgcagggtaccatggaagcttactcgaagatccg\n\n\n\n\n\n\n \n\n\n\n\n\n\ncggaaagaagaagaagaagaagaaagcccgaaaggaagctgagttggctg\n\n\n\n\n\n\n \n\n\n\n\n\n\nctgccaccgctgagcaataactagcataaccccttggggcctctaaacgg\n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcttgaggggttttttgctgaaaggaggaaccgctcttcacgctcttca\n\n\n\n\n\n\n \n\n\n\n\n\n\ncgcggataaataagtaacgatccggtccagtaatgacctcagaactccat\n\n\n\n\n\n\n \n\n\n\n\n\n\nctggatttgttcagaacgctcggttgccgccgggcgttttttattggtga\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaatcgcagcaacttgtcgcgccaatcgagccatgtc//.\n\n\n\n\n\n\n\n\n\n\n\n\nThe insert DNA sequence was the following:\n\n\n\n\n\n\n\n\n\n\n\n\natgggcggccatcatcatcatcatcatggcgggg\n\n\nSEQ ID NO: 4915\n\n\n\n\n\n\n \n\n\n\n\n\n\ngaccgtcagttttcctcttccccccaaaacccaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggacaccctcatgatctcccgga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncccctgaggtcacatgcgtggtggtggacgtgag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nccacgaagaccctgaggtcaagttcaactggtac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggacggcgtggaggtgcat\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naatgccaagacaaagccgcgggaggagcagt\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nacaacagcacgtaccgtgtggtcagcgtcctcac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtcctgcaccaggactggctg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naatggcaaggagtacaagtgcaaggtctccaac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naaagccctcccagcccccatcgagaaaaccatc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntccggcggcggcggcagcgg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncggcggcggatccggtgttatcatcaacgttaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\natgcaaaatctcccgtcagtgcctggaaccgtgc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naaaaaagctggtatgcgtttcggt\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naaatgcatgaacggtaaatgccactgcaccccg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naaa//.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe amino acid sequence of the CH2-OSK1 fusion protein product was the following:\n\n\n\n\n\n\n\n\n\n\n\n\nMGGHHHHHHGGGPSVFLFPPKPKDTLMIS\n\n\nSEQ ID NO: 4917\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTPEVTCVVVDVSHEDPEVKFNWYVDGV\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nEVHNAKTKPREEQYNSTYRVVSVLTVLHQD\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nWLNGKEYKCKVSNKALPAPIEKTISGGGGSG\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nGGGSGVIINVKCKISRQCLEPCKKAGMRFGK\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nCMNGKCHCTPK//.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nSEQ ID NO: 4917 includes the OSK1 sequence\n\n\n\n\n\n\n\n\n\n\n\n\nGVIINVKCKISRQCLEPCKKAGMRFGKCMNG\n\n\n(SEQ ID NO: 25)\n\n\n\n\n\n\nKCHCTPK.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nPurification and refolding of CH2-OSK1 expressed in bacteria. Frozen, \nE. coli \npaste (13.8 g) was combined with 180 ml of \nroom temperature\n 50 mM tris HCl, 5 mM EDTA, pH 8.0 and was brought to about 0.1 mg/ml hen egg white lysozyme. The suspended paste was passed through a chilled microfluidizer twice at 12,000 PSI. The cell lysate was then centrifuged at 17,700 g for 50 min at 4° C. The pellet was then resuspended in 90 \nml\n 1% deoxycholate using a tissue grinder and then centrifuged at 15,300 g for 40 min at 4° C. The pellet was then resuspended in 90 ml water using a tissue grinder and then centrifuged at 15,300 g for 40 min at 4° C. The pellet (3.2 g) was then dissolved in 64 ml 8 M guanidine HCl, 50 mM tris HCl, pH 8.0. The suspension was then incubated at room temperature (about 23° C.) for 30 min with gentle agitation followed by centrifugation at 15,300 g for 30 min at 4° C. The supernatant (22 ml) was then reduced by adding 220 μl 1 M dithiothreitol and incubating at 37° C. for 30 minutes. The reduced suspension (20 ml) was transferred to 2000 ml of the refolding buffer (1 M urea, 50 mM ethanolamine, 160 mM arginine HCl, 0.02% NaN\n3\n, 1.2 mM cystamine HCl, 4 mM cysteine, pH 9.8) at 4° C. with vigorous stirring. The stirring rate was then slowed and the incubation was continued for approximately 2.5 days at 4° C.\n\n\nTen milliliters of 500 mM imidazole was added to the refolding solution and the pH was adjusted to pH to 8.0 with 5 M acetic acid. The refold was then filtered through a 0.45 μm cellulose acetate filter with two pre-filters. This material was then loaded on to a 50 ml Qiagen Ni-NTA Superflow column (2.6 cm ID) in Ni-Buffer A (50 mM NaH\n2\nPO\n4\n, 300 mM NaCl, pH 7.5) at 15 ml/min 13° C. The column was then washed with 10 column volumes of Ni-Buffer A followed by 8% Ni-Buffer B (250 mM imidazole, 50 mM NaH\n2\nPO\n4\n, 300 mM NaCl, pH 7.5) at 25 ml/min. The column was then eluted with 60% Ni-Buffer B followed by 100% Ni-Buffer B at 10 ml/min. The peak fractions were collected and dialyzed against S-Buffer A (10 mM NaH\n2\nPO\n4\n, pH 7.1)\n\n\nThe dialyzed sample was then loaded on to a 5 ml Amersham SP-HP HiTrap column at 5 ml/min in S-Buffer A at 13° C. The column was then washed with several column volumes of S-Buffer A, followed by elution with a linear gradient from 0% to 60% S-Buffer B (10 mM NaH\n2\nPO\n4\n, 1 M NaCl, pH 7.1) followed by a step to 100% S-Buffer B at 1.5 ml/min 13° C. Fractions were then analyzed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE, and the fractions containing the desired product were pooled based on these data. The pool was then concentrated to about 1.6 ml using a Pall Macrosep with a 10 kDa membrane at 4° C. The concentrated sample was then filtered through a 0.22 μm cellulose acetate centrifugal filter.\n\n\nA spectral scan was then conducted on 10 μl of the combined pool diluted in 150 μl water using a Hewlett Packard 8453 spectrophotometer (\nFIG. 78\n). The concentration of the filtered material was determined to be 3.35 mg/ml using a calculated molecular mass of 17,373 g/mol and extinction coefficient of 17,460 M\n−1 \ncm\n−1\n. The purity of the filtered material was then assessed using a Coomassie brilliant blue stained tris-glycine 4-20% SDS-PAGE (\nFIG. 79\n). The endotoxin level was then determined using a Charles River Laboratories Endosafe-PTS system (0.05-5 EU/ml sensitivity) using a 67-fold dilution of the sample in Charles Rivers Endotoxin Specific Buffer BG120 yielding a result of <1 EU/mg protein. The macromolecular state of the product was then determined using size exclusion chromatography on 50 μg of the product injected on to a \nPhenomenex BioSep SEC\n 3000 column (7.8×300 mm) in 50 mM NaH\n2\nPO\n4\n, 250 mM NaCl, pH 6.9 at 1 ml/min observing the absorbance at 280 nm (\nFIG. 80\n). The product was then subject to mass spectral analysis by chromatographing approximately 4 μg of the sample through a RP-HPLC column (Vydac C\n4\n, 1×150 mm). Solvent A was 0.1% trifluoroacetic acid in water and solvent B was 0.1% trifluoroacetic acid in 90% acetonitrile, 10% water. The column was pre-equilibrated in 10% solvent B at a flow rate of 80 μl per min. The protein was eluted using a linear gradient of 10% to 90% solvent B over 30 min. Part of the effluent was directed into a LCQ ion trap mass spectrometer. The mass spectrum was deconvoluted using the Bioworks software provided by the mass spectrometer manufacturer. (\nFIG. 81\n). The product was then stored at −80° C.\n\n\nPEGylation of CH2-OSK1. The CH2-OSK1 fusion protein was diluted to 2 mg/ml in 50 mM sodium acetate, 10 mM sodium cyanoborohydride, pH 4.8 with a 4-fold molar excess of 20 kD methoxy-PEG-aldehyde (Nektar Therapeutics, Huntsville, Ala.). The reaction was allowed to proceed overnight (˜18 hrs) at 4° C. Upon completion, reaction was quenched with 4 volumes of 10 mM sodium acetate, 50 mM NaCl, \npH\n 5, then loaded at 0.7 mg protein/ml resin to an SP Sepharose HP column (GE Healthcare, Piscataway, N.J.) equilibrated in 10 mM sodium acetate, 50 mM NaCl, \npH\n 5. The mono-PEGylated CH2-Osk fusion was eluted with a linear 50 mM-1 M NaCl gradient (\nFIG. 82\n). Peak fractions were evaluated by SDS-PAGE and the mono-PEG-CH2-OSK1 fractions pooled, concentrated and dialyzed into Dulbecco's Phosphate Buffered Saline. The final product was analyzed by SDS-PAGE (\nFIG. 83\n).\n\n\nAs shown in Table 43, the purified CH2-OSK1 (“L2-6H-L3-CH2-L10-OsK1(1-38)”) and PEGylated CH2-OSK1 (“20 k PEG-L2-6H-L3-CH2-L10-OSK1(1-38)”) molecules were active in blocking inflammation in the human whole blood assay (See, Example 46).\n\n\nExample 55\n\n\nBioactivity of OSK1 Peptide Analogs\n\n\nThe activity of OSK1 peptide analogs in blocking human Kv1.3 versus human Kv1.1 current is shown in \nFIGS. 84 through 86\n and Tables 37-41. Three electrophysiology techniques were used (See, e.g., Example 36 and Example 44). Whole cell patch clamp (\nFIGS. 84 & 85\n and Table 41) represents a low throughput technique which is well established in the field and has been available for many years. We also used two new planar patch clamp techniques, PatchXpress and IonWorks Quattro, with improved throughput which facilitate assessment of potency and selectivity of novel OSK1 analogs described in this application. The PatchXpress technique is of moderate throughput and the novel OSK1[Ala-12] analog (SEQ ID No:1410) had similar Kv1.3 potency and selectivity over Kv1.1 to that observed by whole cell patch clamp (\nFIG. 84\n and Table 41). IonWorks Quattro represents a 384-well planar patch clamp electrophysiology system of high throughput. Using this IonWorks system, the novel OSK1[Ala-29] analog (SEQ ID No:1424) showed potent inhibition of the Kv1.3 current and improved selectivity over Kv1.1 (\nFIG. 86\n). The OSK1[Ala-29] analog (SEQ ID No:1424) showed similar Kv1.3 activity and selectivity over Kv1.1 by whole cell patch clamp electrophysiology (\nFIG. 85\n) to that observed by IonWorks (\nFIG. 86\n). The Kv1.3 and Kv1.1 activities of Alanine, Arginine, Glutamic acid and 1-Naphthylalanine analogs of OSK1 were determined by IonWorks electrophysiology and is reported in Tables 37-40. OSK1 peptide analogs identified by IonWorks to have good potency or Kv1.3 selectivity, were tested further in whole cell patch clamp studies (see, Table 41). The Kv1.3 IC50 of the His34Ala analog of OSK1 (SEQ ID No:1428) was 797 fold lower than its IC50 against Kv1.1 (Table 41), demonstrating that this analog is a highly selective Kv1.3 inhibitor. In this same assay, native OSK1 (SEQ ID NO: 25) showed only slight Kv1.3 selectivity, with the Kv1.1 IC50 being only 5 fold higher than Kv1.3.\n\n\nThe novel OSK1 peptide analogs described in this application which inhibit Kv1.3 are useful in the treatment of autoimmune disease and inflammation. Kv1.3 is expressed on T cells and Kv1.3 inhibitors suppress inflammation by these cells. As one measure of inflammation mediated by T cells, we examined the impact of OSK1 analogs on IL-2 and IFN-g production in human whole blood following addition of a pro-inflammatory stimulus (Tables 36-40 and Table 42). “WB/IL-2” in these tables refers to the assay measuring IL-2 response of whole blood (see, Example 46), whereas “WB/IFNg” refers to the assay measuring IFNg response of whole blood (see, Example 46). The IC50 values listed in Tables 36-40 and 42, represent the average IC50 value determined from experiments done with two or more blood donors. The whole blood assay (see Example 46) allows for a combined measurement of the potency of the analogs in blocking inflammation and Kv1.3, as well as an assessment of the stability of the molecules in a complex biological fluid. Using this assay, several OSK1 analogs were examined and found to potently suppress inflammation (\nFIGS. 90C & 90D\n, Tables 36-40). Some of these analogs showed reduced activity in this whole blood assay, which may indicate that these residues play an important role in binding Kv1.3. Relative to the immunosuppressive agent cyclosporin A, Kv1.3 peptide inhibitors ShK-Ala22, OSK1-Ala29, and OSK1-Ala12 were several orders of magnitude more potent in blocking the cytokine response in human whole blood (\nFIG. 90\n).\n\n\nThe solution NMR structure of OSK1 has been solved and is provided as pdb accession number “1SCO” in Entrez's Molecular Modeling Database (MMDB) [J. Chen et al. (2003) Nucleic Acids Res. 31, 474-7]. \nFIG. 89\n shows space filling (\nFIG. 89A\n, \n89\nB, \n89\nD) and worm (\nFIG. 89C\n) Cn3D rendering of the OSK1 structure. Light colored OSK1 amino acid residues Phe25, Gly26, Lys27, Met29 and Asn30 are shown in \nFIG. 89B\n. Some analogs of these residues were found to significantly reduce Kv1.3 activity (Tables 37-40), implying that these residues may make important contacts with the Kv1.3 channel. The molecular structure shown in \nFIG. 89A\n indicates these amino acids reside on a common surface of the OSK1 three-dimensional (3D) structure. \nFIG. 89D\n shows OSK1 residues (light shading) Ser11, Met29 and His34. These residues when converted to some amino acid analogs, provide improved Kv1.3 selectivity over Kv1.1 (Table 41). Although about 23 amino acids are between residues Ser11 and His34 in the contiguous polypeptide chain, the structure shown in \nFIG. 89D\n illustrates that in the 3D structure of the folded molecule these residues are relatively close to one another. Upon comparing \nFIGS. 89D and 89B\n, one can see that residues His34 and Ser11 (\nFIG. 89D\n) are on the left and right side, respectively, and adjacent to the major Kv1.3 contact surface displayed in \nFIG. 89B\n. It is envisioned that molecular modeling can be used to identify OSK1 analogs with improved Kv1.3 activity and selectivity, upon considering the Kv1.3 and Kv1.1 bioactivity information provided in Tables 37 through 42 and the solution NMR structure of OSK1 described above. \nFIG. 89C\n shows a worm rendering of the OSK1 structure with secondary structure elements (beta strands and alpha helices) depicted. The primary amino acid sequence of OSK1 is provided in \nFIG. 89E\n and amino acid residues comprising the beta strands & alpha helix are underlined. Wiggly lines in \nFIG. 89C\n indicate amino acid residues between or beyond these secondary structure elements, whereas straight lines depict the three disulfide bridges in OSK1. The first beta strand (β1) shown in \nFIGS. 89C and 89E\n contains no disulfide bridges to link it covalently to other secondary structure elements of the OSK1 molecule, unlike beta strand 3 (β3) that has two disulfide bridges with the alpha helix (α1). As shown in Table 42, OSK1 analogs without beta strand 1 (labeled “des 1-7”) still retain activity in blocking inflammation (see SEQ ID No: 4989 of Table 42) suggesting that this region of OSK1 is not essential for the molecules Kv1.3 bioactivity.\n\n\nOSK1 analogs containing multiple amino acid changes were generated and their activity in the human whole blood assay of inflammation is provided in Table 42. Several analogs retain high potency in this assay despite as many as 12 amino acid changes. Based on the improved Kv1.3 selectivity of analogs with single amino acid changes, anologs with multiple amino acid changes may result in additional improvements in selectivity. It is also envisioned that analogs with multiple amino acid changes may have improved activity or stability in vivo, alone or in the context of a peptide conjugate to a half-life prolonging moiety.\n\n\nKv1.3 peptide toxins conjugated to half-life prolonging moieties are provided within this application. The bioactivity of several toxin conjugates is described in Table 43. OSK1 analogs with a N-terminal half-life prolonging 20K PEG moiety (see Example 48) were found to provide potent suppression of the whole blood IL-2 (“WB/IL-2”) and IFNg (“WB/IFNg”) response (Table 43). The 20K PEG-ShK conjugate, shown earlier to have prolonged half-life in vivo (see Examples 44 and 48), was also highly active in this whole blood assay. The FcLoop-OSK1 conjugates (see Example 49) were highly active in blocking inflammation (Table 43), and the CH2-OSK1 or PEG-CH2-OSK1 conjugates (see Example 54) provided modest blockade of the whole blood cytokine response (Table 43). The IL-2 and IFNg cytokine response measured in this whole blood assay results from T cell activation. Since this cytokine response is Kv1.3 dependent and potently blocked by the Kv1.3 peptide and peptide-conjugate inhibitors described herein, these whole blood studies illustrate the therapeutic utility of these molecules in treatment of immune disorders.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 36\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nActivity of OSK1 analogs in blocking thapsigargin-induced IL-2 and IFNg\n\n\n\n\n\n\nproduction in 50% human whole blood as described in Example 46.\n\n\n\n\n\n\n\n\n\n\n \n\n\nThapsigargin Induced IL-2 & IFNg in\n\n\n\n\n\n\n \n\n\nHuman Whole Blood\n\n\n\n\n\n\n\n\n\n\n \n\n\nAverage\n\n\nStd Dev\n\n\nAverage\n\n\nStd Dev\n\n\nAnalog IC\n50 \nDivided\n\n\n\n\n\n\n \n\n\nIC50 (nM)\n\n\nIC50 (nM)\n\n\nIC50 (nM)\n\n\nIC50 (nM)\n\n\nby Ala-1 IC\n50\n \n\n\n\n\n\n\n\n\n\n\nOSK1 Analog\n\n\nIL-2\n\n\nIL-2\n\n\nIFNg\n\n\nIFNg\n\n\nIL2\n\n\nIFNg\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAla-1 (SEQ ID No: 1400)\n\n\n0.1220\n\n\n0.0791\n\n\n0.1194\n\n\n0.0802\n\n\n1.00\n\n\n1.00\n\n\n\n\n\n\nAla-2 (SEQ ID No: 1401)\n\n\n0.0884\n\n\n0.0733\n\n\n0.1035\n\n\n0.0776\n\n\n0.72\n\n\n0.87\n\n\n\n\n\n\nAla-3 (SEQ ID No: 1402)\n\n\n0.0883\n\n\n0.0558\n\n\n0.0992\n\n\n0.1007\n\n\n0.72\n\n\n0.83\n\n\n\n\n\n\nAla-4 (SEQ ID No: 1403)\n\n\n0.1109\n\n\n0.1098\n\n\n0.0873\n\n\n0.0993\n\n\n0.91\n\n\n0.73\n\n\n\n\n\n\nAla-5 (SEQ ID No: 1404)\n\n\n0.0679\n\n\n0.0566\n\n\n0.0670\n\n\n0.0446\n\n\n0.56\n\n\n0.56\n\n\n\n\n\n\nAla-6 (SEQ ID No: 1405)\n\n\n0.0733\n\n\n0.0477\n\n\n0.0805\n\n\n0.0696\n\n\n0.60\n\n\n0.67\n\n\n\n\n\n\nAla-7 (SEQ ID No: 1406)\n\n\n0.0675\n\n\n0.0383\n\n\n0.0591\n\n\n0.0260\n\n\n0.55\n\n\n0.49\n\n\n\n\n\n\nAla-9 (SEQ ID No: 1407)\n\n\n0.0796\n\n\n0.0761\n\n\n0.0711\n\n\n0.0627\n\n\n0.65\n\n\n0.60\n\n\n\n\n\n\nAla-10 (SEQ ID No: 1408)\n\n\n0.0500\n\n\n0.0425\n\n\n0.0296\n\n\n0.0084\n\n\n0.41\n\n\n0.25\n\n\n\n\n\n\nAla-12 (SEQ ID No: 1410)\n\n\n0.1235\n\n\n0.0823\n\n\n0.1551\n\n\n0.0666\n\n\n1.01\n\n\n1.30\n\n\n\n\n\n\nAla-13 (SEQ ID No: 1411)\n\n\n0.1481\n\n\n0.0040\n\n\n0.1328\n\n\n0.0153\n\n\n1.21\n\n\n1.11\n\n\n\n\n\n\nAla-15 (SEQ ID No: 1412)\n\n\n0.1075\n\n\n \n\n\n0.1075\n\n\n \n\n\n0.88\n\n\n0.90\n\n\n\n\n\n\nAla-16 (SEQ ID No: 1413)\n\n\n0.1009\n\n\n \n\n\n0.1009\n\n\n \n\n\n0.83\n\n\n0.84\n\n\n\n\n\n\nAla-17 (SEQ ID No: 1414)\n\n\n0.1730\n\n\n \n\n\n0.1730\n\n\n \n\n\n1.42\n\n\n1.45\n\n\n\n\n\n\nAla-19 (SEQ ID No: 1415)\n\n\n0.1625\n\n\n \n\n\n0.1625\n\n\n \n\n\n1.33\n\n\n1.36\n\n\n\n\n\n\nAla-20 (SEQ ID No: 1416)\n\n\n0.3790\n\n\n \n\n\n0.3790\n\n\n \n\n\n3.11\n\n\n3.17\n\n\n\n\n\n\nAla-22 (SEQ ID No: 1418)\n\n\n7.0860\n\n\n \n\n\n7.0860\n\n\n \n\n\n58.07\n\n\n59.33\n\n\n\n\n\n\nAla-23 (SEQ ID No: 1419)\n\n\n0.2747\n\n\n \n\n\n0.2747\n\n\n \n\n\n2.25\n\n\n2.30\n\n\n\n\n\n\nAla-25 (SEQ ID No: 1421)\n\n\n3.0800\n\n\n \n\n\n3.0800\n\n\n \n\n\n25.24\n\n\n25.79\n\n\n\n\n\n\nAla-27 (SEQ ID No: 1423)\n\n\n3.4510\n\n\n2.5781\n\n\n1.5792\n\n\n1.9217\n\n\n28.28\n\n\n13.22\n\n\n\n\n\n\nAla-29 (SEQ ID No: 1424)\n\n\n0.4469\n\n\n0.1727\n\n\n0.2919\n\n\n0.2422\n\n\n3.66\n\n\n2.44\n\n\n\n\n\n\nAla-3O (SEQ ID No: 1425)\n\n\n0.9710\n\n\n0.7538\n\n\n0.6370\n\n\n0.2674\n\n\n7.96\n\n\n5.33\n\n\n\n\n\n\nAla-34 (SEQ ID No: 1428)\n\n\n0.0725\n\n\n0.0275\n\n\n0.0573\n\n\n0.0341\n\n\n0.59\n\n\n0.48\n\n\n\n\n\n\nPro-12, Lys-16, Asp-20, Ile-\n\n\n0.5138\n\n\n0.4064\n\n\n0.5127\n\n\n0.1597\n\n\n4.21\n\n\n4.29\n\n\n\n\n\n\n23, Ile-29, Ala-34 (SEQ ID\n\n\n\n\n\n\nNo: 1393)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 37\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Alanine Analogs.\n\n\n\n\n\n\n\n\n\n\nSEQ ID\n\n\n \n\n\nAnalogue Activity (IC50, pM)\n\n\n\n\n\n\n\n\n\n\nNO:\n\n\nAnalogue\n\n\nKv1.3\n\n\nKv1.1\n\n\nWB/IL-2\n\n\nWB/\nIFNg\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1400\n\n\nG1A\n\n\n41.11\n\n\n13.89\n\n\n122.035\n\n\n119.425\n\n\n\n\n\n\n1401\n\n\nV2A\n\n\n81.78\n\n\n9.94\n\n\n88.395\n\n\n103.515\n\n\n\n\n\n\n1402\n\n\nI3A\n\n\n96.59\n\n\n10.64\n\n\n88.255\n\n\n99.16\n\n\n\n\n\n\n1403\n\n\nI4A\n\n\n195.30\n\n\n16.92\n\n\n110.865\n\n\n87.255\n\n\n\n\n\n\n1404\n\n\nN5A\n\n\n159.98\n\n\n14.01\n\n\n67.91\n\n\n66.985\n\n\n\n\n\n\n1405\n\n\nV6A\n\n\n173.75\n\n\n12.84\n\n\n73.26\n\n\n80.465\n\n\n\n\n\n\n1406\n\n\nK7A\n\n\n181.04\n\n\n21.88\n\n\n67.5\n\n\n59.075\n\n\n\n\n\n\n1407\n\n\nK9A\n\n\n166.27\n\n\n40.59\n\n\n79.58\n\n\n71.065\n\n\n\n\n\n\n1408\n\n\nI10A\n\n\n91.23\n\n\n4.46\n\n\n49.97\n\n\n29.63\n\n\n\n\n\n\n1409\n\n\nS11A\n\n\n40.79\n\n\n113.15\n\n\n90\n\n\n110\n\n\n\n\n\n\n1410\n\n\nR12A\n\n\n389.90\n\n\n55.89\n\n\n123.49\n\n\n155.1\n\n\n\n\n\n\n1411\n\n\nQ13A\n\n\n249.45\n\n\n21.65\n\n\n148.05\n\n\n132.75\n\n\n\n\n\n\n1412\n\n\nL15A\n\n\n43.07\n\n\n15.04\n\n\n107.5\n\n\n107.5\n\n\n\n\n\n\n1413\n\n\nE16A\n\n\n21.55\n\n\n6.87\n\n\n100.9\n\n\n100.9\n\n\n\n\n\n\n1414\n\n\nP17A\n\n\n33.89\n\n\n9.08\n\n\n173\n\n\n173\n\n\n\n\n\n\n1415\n\n\nK19A\n\n\n210.48\n\n\n16.85\n\n\n162.5\n\n\n162.5\n\n\n\n\n\n\n1416\n\n\nK20A\n\n\n1036.08\n\n\n185.01\n\n\n379\n\n\n379\n\n\n\n\n\n\n1417\n\n\n\n\n\n\n1418\n\n\nG22A\n\n\n>3000\n\n\n>3000\n\n\n7086\n\n\n7086\n\n\n\n\n\n\n1419\n\n\nM23A\n\n\n71.39\n\n\n38.63\n\n\n274.7\n\n\n274.7\n\n\n\n\n\n\n1420\n\n\nR24A\n\n\n>3000\n\n\n1890.78\n\n\n\n\n\n\n1421\n\n\nF25A\n\n\n1486.97\n\n\n47.30\n\n\n3080\n\n\n3080\n\n\n\n\n\n\n1422\n\n\nG26A\n\n\n710.98\n\n\n733.36\n\n\n12075\n\n\n10730\n\n\n\n\n\n\n1423\n\n\nK27A\n\n\n232.44\n\n\n>3000\n\n\n1232\n\n\n1579.15\n\n\n\n\n\n\n1424\n\n\nM29A\n\n\n59.47\n\n\n>3333\n\n\n446.9\n\n\n291.85\n\n\n\n\n\n\n1425\n\n\nN30A\n\n\n692.54\n\n\n>3000\n\n\n971\n\n\n637\n\n\n\n\n\n\n1426\n\n\nG31A\n\n\n70.17\n\n\n61.78\n\n\n\n\n\n\n1427\n\n\nK32A\n\n\n \n\n\n \n\n\n41.3\n\n\n34\n\n\n\n\n\n\n1428\n\n\nH34A\n\n\n19.36\n\n\n368.41\n\n\n72.54\n\n\n57.29\n\n\n\n\n\n\n1429\n\n\nT36A\n\n\n \n\n\n \n\n\n728.4\n\n\n723.5\n\n\n\n\n\n\n1430\n\n\nP37A\n\n\n \n\n\n \n\n\n956\n\n\n849.7\n\n\n\n\n\n\n1431\n\n\nK38A\n\n\n \n\n\n \n\n\n221\n\n\n343\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 38\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Arginine Analogs.\n\n\n\n\n\n\n\n\n\n\nSEQ ID\n\n\n \n\n\nAnalogue Activity (IC50, pM)\n\n\n\n\n\n\n\n\n\n\nNO:\n\n\nAnalogue\n\n\nKv1.3\n\n\nKv1.1\n\n\nWB/IL-2\n\n\nWB/IFNg\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1432\n\n\nG1R\n\n\n68.75\n\n\n9.91\n\n\n554\n\n\n991\n\n\n\n\n\n\n1433\n\n\nV2R\n\n\n133.34\n\n\n25.79\n\n\n775\n\n\n986\n\n\n\n\n\n\n1434\n\n\nI3R\n\n\n19.90\n\n\n2.47\n\n\n148\n\n\n180\n\n\n\n\n\n\n1435\n\n\nI4R\n\n\n10.41\n\n\n1.92\n\n\n168\n\n\n175\n\n\n\n\n\n\n1436\n\n\nN5R\n\n\n13.62\n\n\n2.15\n\n\n95\n\n\n120\n\n\n\n\n\n\n1437\n\n\nV6R\n\n\n8.65\n\n\n2.40\n\n\n84\n\n\n115\n\n\n\n\n\n\n1438\n\n\nK7R\n\n\n13.17\n\n\n<1.52401\n\n\n78\n\n\n71\n\n\n\n\n\n\n1439\n\n\nK9R\n\n\n11.99\n\n\n2.01\n\n\n107\n\n\n77\n\n\n\n\n\n\n1440\n\n\nI10R\n\n\n11.68\n\n\n1.73\n\n\n307\n\n\n474\n\n\n\n\n\n\n1441\n\n\nS11R\n\n\n16.72\n\n\n210.05\n\n\n2118\n\n\n4070\n\n\n\n\n\n\n1442\n\n\nQ13R\n\n\n15.34\n\n\n<1.52401\n\n\n160\n\n\n172\n\n\n\n\n\n\n1443\n\n\nL15R\n\n\n13.73\n\n\n2.16\n\n\n93\n\n\n116\n\n\n\n\n\n\n1444\n\n\nE16R\n\n\n10.36\n\n\n<1.52401\n\n\n556\n\n\n454\n\n\n\n\n\n\n1445\n\n\nP17R\n\n\n10.42\n\n\n<1.52401\n\n\n202\n\n\n355\n\n\n\n\n\n\n1446\n\n\nK19R\n\n\n12.57\n\n\n2.41\n\n\n44\n\n\n62\n\n\n\n\n\n\n1447\n\n\nK20R\n\n\n9.85\n\n\n<1.52401\n\n\n67\n\n\n83\n\n\n\n\n\n\n1448\n\n\nA21R\n\n\n14.92\n\n\n2.61\n\n\n90\n\n\n149\n\n\n\n\n\n\n1449\n\n\nG22R\n\n\n23.74\n\n\n3.49\n\n\n292\n\n\n349\n\n\n\n\n\n\n1450\n\n\nM23R\n\n\n12.34\n\n\n2.01\n\n\n182\n\n\n148\n\n\n\n\n\n\n1451\n\n\nF25R\n\n\n>3333\n\n\n817.42\n\n\n25027\n\n\n30963\n\n\n\n\n\n\n1452\n\n\nG26R\n\n\n>3333\n\n\n>3333\n\n\n100000\n\n\n100000\n\n\n\n\n\n\n1453\n\n\nK27R\n\n\n1492.94\n\n\n>3333\n\n\n15088\n\n\n10659\n\n\n\n\n\n\n1454\n\n\nM29R\n\n\n200.39\n\n\n1872.11\n\n\n11680\n\n\n7677\n\n\n\n\n\n\n1455\n\n\nN30R\n\n\n18.90\n\n\n45.71\n\n\n405\n\n\n445\n\n\n\n\n\n\n1456\n\n\nG31R\n\n\n22.16\n\n\n1.59\n\n\n314\n\n\n343\n\n\n\n\n\n\n1457\n\n\nK32R\n\n\n30.83\n\n\n7.24\n\n\n28\n\n\n34\n\n\n\n\n\n\n1458\n\n\nH34R\n\n\n13.57\n\n\n4.49\n\n\n92\n\n\n108\n\n\n\n\n\n\n1459\n\n\nT36R\n\n\n1308.07\n\n\n26.55\n\n\n9697\n\n\n10050\n\n\n\n\n\n\n1460\n\n\nP37R\n\n\n13.32\n\n\n2.01\n\n\n229\n\n\n253\n\n\n\n\n\n\n1461\n\n\nK38R\n\n\n14.99\n\n\n1.84\n\n\n39\n\n\n40\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 39\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Glutamic Acid Analogs.\n\n\n\n\n\n\n\n\n\n\nSEQ ID\n\n\n \n\n\nAnalogue Activity (IC50, pM)\n\n\n\n\n\n\n\n\n\n\nNO:\n\n\nAnalogue\n\n\nKv1.3\n\n\nKv1.1\n\n\nWB/IL-2\n\n\nWB/IFNg\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1462\n\n\nG1E\n\n\n185.78\n\n\n50.97\n\n\n1217\n\n\n1252\n\n\n\n\n\n\n1463\n\n\nV2E\n\n\n36.23\n\n\n35.01\n\n\n97\n\n\n184\n\n\n\n\n\n\n1464\n\n\nI3E\n\n\n22.00\n\n\n42.99\n\n\n120\n\n\n160\n\n\n\n\n\n\n1465\n\n\nI4E\n\n\n15.65\n\n\n3.19\n\n\n218\n\n\n191\n\n\n\n\n\n\n1466\n\n\nN5E\n\n\n23.38\n\n\n4.44\n\n\n100\n\n\n65\n\n\n\n\n\n\n1467\n\n\nV6E\n\n\n17.73\n\n\n2.43\n\n\n48\n\n\n68\n\n\n\n\n\n\n1468\n\n\nK7E\n\n\n14.16\n\n\n<1.52401\n\n\n58\n\n\n68\n\n\n\n\n\n\n1469\n\n\nK9E\n\n\n31.76\n\n\n110.67\n\n\n179\n\n\n171\n\n\n\n\n\n\n1470\n\n\nI10E\n\n\n120.35\n\n\n33.50\n\n\n2573\n\n\n2736\n\n\n\n\n\n\n1471\n\n\nS11E\n\n\n>3333\n\n\n>3333\n\n\n39878\n\n\n16927\n\n\n\n\n\n\n1472\n\n\nR12E\n\n\n89.71\n\n\n193.25\n\n\n1787\n\n\n2001\n\n\n\n\n\n\n1473\n\n\nQ13E\n\n\n45.87\n\n\n6.28\n\n\n1063\n\n\n799\n\n\n\n\n\n\n1474\n\n\nL15E\n\n\n47.48\n\n\n436.05\n\n\n785\n\n\n1059\n\n\n\n\n\n\n1475\n\n\nP17E\n\n\n14.47\n\n\n1.81\n\n\n520\n\n\n947\n\n\n\n\n\n\n1476\n\n\nK19E\n\n\n23.51\n\n\n13.71\n\n\n\n\n\n\n1477\n\n\nK20E\n\n\n25.45\n\n\n5.76\n\n\n\n\n\n\n1478\n\n\nA21E\n\n\n7.37\n\n\n<1.52401\n\n\n117\n\n\n138\n\n\n\n\n\n\n1479\n\n\nG22E\n\n\n13.88\n\n\n2.56\n\n\n109\n\n\n164\n\n\n\n\n\n\n1480\n\n\nM23E\n\n\n24.28\n\n\n10.44\n\n\n606\n\n\n666\n\n\n\n\n\n\n1481\n\n\nR24E\n\n\n \n\n\n \n\n\n7161\n\n\n9543\n\n\n\n\n\n\n1482\n\n\nF25E\n\n\n>3333\n\n\n>3333\n\n\n100000\n\n\n100000\n\n\n\n\n\n\n1483\n\n\nG26E\n\n\n>3333\n\n\n>3333\n\n\n100000\n\n\n100000\n\n\n\n\n\n\n1484\n\n\nK27E\n\n\n>3333\n\n\n548.55\n\n\n5548\n\n\n7144\n\n\n\n\n\n\n1485\n\n\nM29E\n\n\n>3333\n\n\n>3333\n\n\n27099\n\n\n24646\n\n\n\n\n\n\n1486\n\n\nN30E\n\n\n \n\n\n \n\n\n14024\n\n\n24372\n\n\n\n\n\n\n1487\n\n\nG31E\n\n\n12.01\n\n\n2.37\n\n\n95\n\n\n111\n\n\n\n\n\n\n1488\n\n\nK32E\n\n\n15.56\n\n\n17.31\n\n\n62\n\n\n63\n\n\n\n\n\n\n1489\n\n\nH34E\n\n\n330.15\n\n\n1689.82\n\n\n1618\n\n\n2378\n\n\n\n\n\n\n1490\n\n\nT36E\n\n\n161.06\n\n\n>3333\n\n\n1742\n\n\n2420\n\n\n\n\n\n\n1491\n\n\nP37E\n\n\n62.67\n\n\n622.18\n\n\n239\n\n\n1604\n\n\n\n\n\n\n1492\n\n\nK38E\n\n\n25.76\n\n\n34.33\n\n\n526\n\n\n713\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 40\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Naphthylalanine Analogs.\n\n\n\n\n\n\n\n\n\n\nSEQ ID\n\n\n \n\n\nAnalogue Activity (IC50, pM)\n\n\n\n\n\n\n\n\n\n\nNO:\n\n\nAnalogue\n\n\nKv1.3\n\n\nKv1.1\n\n\nWB/IL-2\n\n\nWB/IFNg\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1493\n\n\nG1Nal\n\n\n20.66\n\n\n33.93\n\n\n2793\n\n\n2565\n\n\n\n\n\n\n1494\n\n\nV2Nal\n\n\n11.55\n\n\n2.46\n\n\n750\n\n\n524\n\n\n\n\n\n\n1495\n\n\nI3Nal\n\n\n10.31\n\n\n2.34\n\n\n907\n\n\n739\n\n\n\n\n\n\n1496\n\n\nI4Nal\n\n\n15.03\n\n\n<1.52401\n\n\n1094\n\n\n1014\n\n\n\n\n\n\n1497\n\n\nN5Nal\n\n\n21.78\n\n\n<1.52401\n\n\n760\n\n\n431\n\n\n\n\n\n\n1498\n\n\nV6Nal\n\n\n20.97\n\n\n<1.52401\n\n\n1776\n\n\n2465\n\n\n\n\n\n\n1499\n\n\nK7Nal\n\n\n23.61\n\n\n<1.52401\n\n\n222\n\n\n246\n\n\n\n\n\n\n1500\n\n\nK9Nal\n\n\n65.82\n\n\n2.92\n\n\n1070\n\n\n1217\n\n\n\n\n\n\n1501\n\n\nI10Nal\n\n\n45.44\n\n\n<1.52401\n\n\n184\n\n\n257\n\n\n\n\n\n\n1502\n\n\nS11Nal\n\n\n95.87\n\n\n>3333\n\n\n23915\n\n\n17939\n\n\n\n\n\n\n1503\n\n\nR12Nal\n\n\n37.66\n\n\n24.99\n\n\n460\n\n\n387\n\n\n\n\n\n\n1504\n\n\nQ13Nal\n\n\n13.44\n\n\n<1.52401\n\n\n140\n\n\n198\n\n\n\n\n\n\n1505\n\n\nL15Nal\n\n\n17.84\n\n\n<1.52401\n\n\n358\n\n\n370\n\n\n\n\n\n\n1506\n\n\nE16Nal\n\n\n9.58\n\n\n<1.52401\n\n\n1025\n\n\n1511\n\n\n\n\n\n\n1507\n\n\nP17Nal\n\n\n16.19\n\n\n<1.52401\n\n\n193\n\n\n357\n\n\n\n\n\n\n1508\n\n\nK19Nal\n\n\n17.22\n\n\n<1.52401\n\n\n58\n\n\n99\n\n\n\n\n\n\n1509\n\n\nK20Nal\n\n\n13.53\n\n\n<1.52401\n\n\n74\n\n\n12\n\n\n\n\n\n\n1510\n\n\nA21Nal\n\n\n26.10\n\n\n<1.52401\n\n\n315\n\n\n434\n\n\n\n\n\n\n1511\n\n\nG22Nal\n\n\n>3333\n\n\n426.27\n\n\n10328\n\n\n10627\n\n\n\n\n\n\n1512\n\n\nH23Nal\n\n\n35.96\n\n\n64.37\n\n\n581\n\n\n1113\n\n\n\n\n\n\n1513\n\n\nR24Nal\n\n\n45.26\n\n\n2.85\n\n\n293\n\n\n818\n\n\n\n\n\n\n1514\n\n\nF25Nal\n\n\n28.63\n\n\n51.75\n\n\n1733\n\n\n1686\n\n\n\n\n\n\n1515\n\n\nG26Nal\n\n\n>3333\n\n\n1573.75\n\n\n9898\n\n\n10651\n\n\n\n\n\n\n1516\n\n\nK27Nal\n\n\n>3333\n\n\n1042.84\n\n\n14971\n\n\n27025\n\n\n\n\n\n\n1517\n\n\nM29Nal\n\n\n93.46\n\n\n46.88\n\n\n100000\n\n\n100000\n\n\n\n\n\n\n1518\n\n\nN30Nal\n\n\n>3333\n\n\n1283.88\n\n\n100000\n\n\n37043\n\n\n\n\n\n\n1519\n\n\nG31Nal\n\n\n33.76\n\n\n<1.52401\n\n\n331\n\n\n467\n\n\n\n\n\n\n1520\n\n\nK32Nal\n\n\n26.13\n\n\n1.91\n\n\n134\n\n\n196\n\n\n\n\n\n\n1521\n\n\nH34Nal\n\n\n60.31\n\n\n>3333\n\n\n3323\n\n\n6186\n\n\n\n\n\n\n1522\n\n\nT36Nal\n\n\n \n\n\n \n\n\n100000\n\n\n37811\n\n\n\n\n\n\n1523\n\n\nP37Nal\n\n\n70.80\n\n\n6.74\n\n\n1762\n\n\n3037\n\n\n\n\n\n\n1524\n\n\nK38Nal\n\n\n \n\n\n \n\n\n308\n\n\n409\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 41\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Analogues with Improved Selectivity at Kv1.3\n\n\n\n\n\n\nover Kv1.1 (whole cell patch clamp ePhys).\n\n\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\nKv1.3\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\nSelectivity\n\n\n\n\n\n\nSEQ\n\n\n \n\n\nKv1.3\n\n\nKv1.1\n\n\n(=Kv1.1/Kv.3\n\n\n\n\n\n\nID NO:\n\n\nAnalogue\n\n\n(IC50, pM)\n\n\n(IC50, pM)\n\n\nIC50)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n25\n\n\nwild-\ntype\n \n\n\n39\n\n\n 202\n\n\n5\n\n\n\n\n\n\n1441\n\n\n \nS11R\n \n\n\n40\n\n\n 9130\n\n\n228\n\n\n\n\n\n\n1502\n\n\nS11Nal\n\n\n1490\n\n\n85324\n\n\n57\n\n\n\n\n\n\n1410\n\n\n \nR12A\n \n\n\n25\n\n\n 440\n\n\n17\n\n\n\n\n\n\n1474\n\n\n \nL15E\n \n\n\n190\n\n\n65014\n\n\n342\n\n\n\n\n\n\n1423\n\n\nK27A\n\n\n289\n\n\n 10085*\n\n\n35\n\n\n\n\n\n\n1424\n\n\n \nM29A\n \n\n\n33\n\n\n 3472\n\n\n105\n\n\n\n\n\n\n1454\n\n\nM29R\n\n\n760\n\n\n23028\n\n\n30\n\n\n\n\n\n\n1425\n\n\nN30A\n\n\n766\n\n\n10168\n\n\n14\n\n\n\n\n\n\n1428\n\n\n \nK34A\n \n\n\n16\n\n\n12754\n\n\n797\n\n\n\n\n\n\n1521\n\n\nH34Nal\n\n\n215\n\n\n29178\n\n\n136\n\n\n\n\n\n\n1489\n\n\nH34E\n\n\n1322\n\n\n39352\n\n\n30\n\n\n\n\n\n\n1490\n\n\nT36E\n\n\n1921\n\n\n83914\n\n\n44\n\n\n\n\n\n\n1491\n\n\n \nP37E\n \n\n\n241\n\n\n15699\n\n\n65\n\n\n\n\n\n\n \n\n\n\n\n\n\n*PatchXpress data\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 42\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nOSK1 Analogues with Multiple Amino Acid Substitutions.\n\n\n\n\n\n\n\n\n\n\nSEQ\n\n\n# Amino\n\n\n \n\n\nWB/IL-2\n\n\nWB/IFNg\n\n\n\n\n\n\nID\n\n\nAcid\n\n\nAmino Acid\n\n\n(IC50,\n\n\n(IC50,\n\n\n\n\n\n\nNO:\n\n\nChanges\n\n\nChanges\n\n\nnM)\n\n\nnM)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n4988\n\n\n2\n\n\nM29A, H34Nal\n\n\n0.087\n\n\n0.102\n\n\n\n\n\n\n296\n\n\n2\n\n\nE16K, K20D\n\n\n1.579\n\n\n1.32\n\n\n\n\n\n\n4986\n\n\n2\n\n\nI4K(Gly), H34A\n\n\n0.470\n\n\n0.451\n\n\n\n\n\n\n4987\n\n\n2\n\n\nH34A, K38K(Gly)\n\n\n1.249\n\n\n2.380\n\n\n\n\n\n\n4985\n\n\n2\n\n\nK19K(Gly), H34A\n\n\n1.514\n\n\n1.633\n\n\n\n\n\n\n1392\n\n\n3\n\n\nR12A, E16K, K20D\n\n\n0.041\n\n\n0.092\n\n\n\n\n\n\n4990\n\n\n3\n\n\nE16K, K20D, H34A\n\n\n65.462\n\n\n26.629\n\n\n\n\n\n\n298\n\n\n3\n\n\nE16K, K20D, T36Y\n\n\n0.639\n\n\n0.923\n\n\n\n\n\n\n4991\n\n\n4\n\n\nS11Nal, R12A, M29A,\n\n\n12.665\n\n\n14.151\n\n\n\n\n\n\n \n\n\n \n\n\nH34Nal\n\n\n\n\n\n\n1396\n\n\n5\n\n\nE16K, K20D,\n\n\n3.941\n\n\n6.988\n\n\n\n\n\n\n \n\n\n \n\n\ndes36-38\n\n\n\n\n\n\n1395\n\n\n5\n\n\nGGGGS-Osk1\n\n\n1.357\n\n\n2.204\n\n\n\n\n\n\n1274\n\n\n5\n\n\nE16K, K20D, T36G,\n\n\n2.636\n\n\n3.639\n\n\n\n\n\n\n \n\n\n \n\n\nP37G, K38G\n\n\n\n\n\n\n4992\n\n\n5\n\n\nS11Nal, R12A, M29A,\n\n\n3.511\n\n\n5.728\n\n\n\n\n\n\n \n\n\n \n\n\nH34Nal, P37E\n\n\n\n\n\n\n4994\n\n\n5\n\n\nS11Nal, R12A, M23F,\n\n\n8.136\n\n\n22.727\n\n\n\n\n\n\n \n\n\n \n\n\nM29A H34Nal\n\n\n\n\n\n\n1398\n\n\n5\n\n\nR12P, E16K, K20D,\n\n\n0.527\n\n\n0.736\n\n\n\n\n\n\n \n\n\n \n\n\nT37Y, K38Ne\n\n\n\n\n\n\n1397\n\n\n5\n\n\nR12P, E16Om, K20E,\n\n\n6.611\n\n\n18.454\n\n\n\n\n\n\n \n\n\n \n\n\nT37Y, K38Ne\n\n\n\n\n\n\n4995\n\n\n6\n\n\nS11Nal, R12A, M23Ne,\n\n\n14.32\n\n\n68.158\n\n\n\n\n\n\n \n\n\n \n\n\nM29A, H34Nal, P37E\n\n\n\n\n\n\n4916\n\n\n7\n\n\ndes1, V2G, R12A, E16K,\n\n\n1.499\n\n\n2.244\n\n\n\n\n\n\n \n\n\n \n\n\nK19R, K20D, H34A\n\n\n\n\n\n\n4993\n\n\n7\n\n\nS11Nal, R12A, L15E,\n\n\n>100\n\n\n>100\n\n\n\n\n\n\n \n\n\n \n\n\nM29A H34Nal, T36E, P37E\n\n\n\n\n\n\n4989\n\n\n12\n\n\ndes1-7, E16K, K20D,\n\n\n8.179\n\n\n8.341\n\n\n\n\n\n\n \n\n\n \n\n\ndes36-38\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 43\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nBioactivity of OSK1 and OSK1 peptide analog conjugates\n\n\n\n\n\n\nwith half-life-extending moieties as indicated.\n\n\n\n\n\n\n\n\n\n\nF\n1 \n(and\n\n\n \n\n\n \n\n\n \n\n\n\n\n\n\nF\n2 \nif\n\n\n \n\n\nWB/IL-2\n\n\nWB/IFNg\n\n\n\n\n\n\npresent)\n\n\nShort-hand Designation\n\n\n(IC50, nM)\n\n\n(IC50, nM)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nPEG\n\n\n20k PEG-OSK1[Ala12]\n\n\n0.270\n\n\n0.137\n\n\n\n\n\n\nPEG\n\n\n20k PEG-OSK1[Ala29]\n\n\n5.756\n\n\n5.577\n\n\n\n\n\n\nPEG\n\n\n20k PEG-OSK1[Ala29, 1Nal34]\n\n\n0.049\n\n\n0.081\n\n\n\n\n\n\nPEG\n\n\n20k PEG-OSK1[1Nal11]\n\n\n0.019\n\n\n0.027\n\n\n\n\n\n\nPEG\n\n\n20k PEG-ShK\n\n\n0.046\n\n\n0.065\n\n\n\n\n\n\nFcLoop\n\n\nFcLoop-G2-OSK-G2\n\n\n0.028\n\n\n0.056\n\n\n\n\n\n\nFcLoop\n\n\nFcLoop-G4-OSK-G2\n\n\n0.150\n\n\n0.195\n\n\n\n\n\n\nFcLoop\n\n\nFcLoop-G2-ShK-G2\n\n\n0.109\n\n\n0.119\n\n\n\n\n\n\nPEG-CH2\n\n\n20k PEG-L2-6H-L3-CH2-\n\n\n8.325\n\n\n50.144\n\n\n\n\n\n\n \n\n\nL10-OsK1(1-38)\n\n\n\n\n\n\nCH2\n\n\nL2-6H-L3-CH2-L10-\n\n\n38.491\n\n\n55.162\n\n\n\n\n\n\n \n\n\nOsK1(1-38)\n\n\n\n\n\n\n \n\n\n\n\n\n\nFcloop structures G2-OSK1-G2 (SEQ ID N0: 976), G4-OSK1-G2 (SEQ ID NO: 979), and G2-SHK-G2 (SEQ ID N0: 977) are described in Example 49, and CH2-L10-OSK1(1-38) SEQ ID NO: 4917 is described in Example 54.\n\n\n\n\n\n\n\n\n\n\n\n\nExample 56\n\n\nDesign and Expression of Monovalent Fc-Fusion Molecules\n\n\nThere may be pharmacokinetic or other reasons, in some cases, to prefer a monovalent dimeric Fc-toxin peptide fusion (as represented schematically in \nFIG. 2B\n) to a (“bivalent”) dimer (as represented schematically in \nFIG. 2C\n). However, conventional Fc fusion constructs typically result in a mixture containing predominantly dimeric molecules, both monovalent and bivalent. Monovalent dimeric Fc-toxin peptide fusions (or “peptibodies”), including monovalent dimeric Fc-OSK1 peptide analog fusions and Fc-ShK peptide analog fusions, can be isolated from conditioned media which also contains bivalent dimeric Fc-toxin peptide, and dimeric Fc lacking the toxin peptide fusion. Separation of all three species can be accomplished using ion exchange chromatography, for example, as described in Examples 1, 2, and 41 herein.\n\n\nA number of other exemplary ways that a monovalent dimeric Fc-toxin peptide fusion can be produced with greater efficiency are provided here, including for the production of monovalent dimeric Fc-OSK1 peptide analog fusions:\n\n\n(1) Co-expressing equal amounts of Fc and Fc-toxin peptide in the same cells (e.g. mammalian cells). With the appropriate design, a mixture of bivalent dimeric Fc-toxin peptide fusion, monovalent dimeric Fc-toxin peptide fusion and dimeric Fc will be produced and released into the conditioned media. The monovalent dimeric Fc-toxin peptide can be purified from the mixture using conventional purification methods, for example, methods described in Examples 1, 2, and 41 herein.\n\n\n(2) Engineering and recombinantly expressing in mammalian cells a single polypeptide construct represented by the following schematic:\n\n\nSignal peptide-Fc-furin cleavage site-linker-furin cleavage site-Fc-toxin peptide\n\n\nFurin cleavage occurs as the molecule travels through the endoplasmic reticulum and the intra-molecular Fc pairing (resulting in monovalent dimeric Fc-toxin peptide fusion) can occur preferentially to intermolecular Fc pairing (resulting in dimeric Fc-toxin peptide being expressed into conditioned medium; \nFIG. 87A-B\n).\n\n\n\nBy way of example of method (2) above, a DNA construct was produced for recombinant expression in mammalian cells of the following schematic polypeptide construct:\n\n\nSignal peptide-Fc-furin cleavage site-linker-furin cleavage site-Fc-ShK(2-35)\n\n\n\nThe DNA construct had the following nucleotide coding sequence:\n\n\n\n\n\n\n\n\n\n\n\n\natggaatggagctgggtctttctcttcttcctg\n\n\nSEQ ID NO: 5007\n\n\n\n\n\n\n \n\n\n\n\n\n\ntcagtaacgactggtgtccactccgacaaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nactcacacatgcccaccgtgcc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncagcacctgaactcctggggggaccgtca\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcttcctcttccccccaaaacccaaggac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naccctcatgatctcccggacccc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntgaggtcacatgcgtggtggtggacgtga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngccacgaagaccctgaggtcaagttca\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nactggtacgtggacggcgtggaggt\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngcataatgccaagacaaagccgcggga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggagcagtacaacagcacgtaccgtgt\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggtcagcgtcctcaccgtcctgcac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncaggactggctgaatggcaaggagtacaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngtgcaaggtctccaacaaagccctccca\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngcccccatcgagaaaaccatct\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nccaaagccaaagggcagccccgagaac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncacaggtgtacaccctgcccccatcccgg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngatgagctgaccaagaaccag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngtcagcctgacctgcctggtcaaaggcttcta\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntcccagcgacatcgccgtggagtgggaga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngcaatgggcagccggagaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncaactacaagaccacgcctcccgtgctgga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nctccgacggctccttcttcctctacagcaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngctcaccgtggacaagagcag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngtggcagcaggggaacgtcttctcatgctc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncgtgatgcatgaggctctgcacaaccac\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntacacgcagaagagcctctccctg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntctccgggtaaacgaggcaagagggctg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntggggggcggtgggagcggcggcggg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggctcaggtggcgggggaagtgg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncgggggagggagtggagggggaggg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagtggaggcgggggatccggcggggg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngggtagcaagcgtcgcgagaagcg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggataagacccatacctgccccccctgt\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncccgcgcccgagttgctcgggggcccc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagcgtgtttttgtttcctcccaagcctaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagatacattgatgattagtagaacaccc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngaagtgacctgtgtcgtcgtcgatgtctc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntcatgaggatcccgaagtgaaattcaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nttggtatgtcgatggggtcgaagtccaca\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nacgctaaaaccaaacccagagaaga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nacagtataattctacctatagggtcgtg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntctgtgttgacagtgctccatcaagattgg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nctcaacgggaaagaatacaaatgtaa\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nagtgagtaataaggctttgcccgctcct\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nattgaaaagacaattagtaaggctaagg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngccaacctagggagccccaagtctat\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nacactccctcccagtagagacgagct\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngaccaagaaccaggtcagcctgacct\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngcctggtcaaaggcttctatcccagcga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncatcgccgtggagtgggagagcaatg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggcagccggagaacaactacaaga\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nccacgcctcccgtgctggactccgacg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngctccttcttcctctacagcaagctcaccg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntggacaagagcaggtggcagcaggg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngaacgtcttctcatgctccgtgatgcatg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naggctctgcacaaccactacacgcag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naagagcctctccctgtctccgggtaaag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngaggaggaggatccggaggaggag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngaagcagctgcatcgacaccatcccc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naagagccgctgcaccgccttccagtgc\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\naagcacagcatgaagtaccgcctgag\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ncttctgccgcaagacctgcggcacctg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nctaa//.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nThe resulting expressed polypeptide (from vector pTT5-Fc-Fc-L10-Shk(2-35)) had the following amino acid sequence before furin cleavage (the first 19 residues are a signal peptide sequence; furin cleavage sites are underlined):\n\n\n\n\n\n\n\n\n\n\n\n\nmewswvflfflsvttgvhsdkthtcppcpape\n\n\nSEQ ID NO: 5008\n\n\n\n\n\n\n \n\n\n\n\n\n\nllggpsvflfppkpkdtlmisrtpevtcvvv\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ndvshedpevkfnwyvdgvevhna\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nktkpreeqynstyrvvsvltvlhqdwlngkey\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nkckvsnkalpapiektiskakgqprepqvytlpp\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nsrdeltknqvsltclvkgfypsdiavewesngqp\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nennykttppvldsdgsfflyskltvdksrwqqgn\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nvfscsvmhealhnhytqkslslspgk\nrgkr\navgg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nggsggggsggggsggggsggggsggggsggg\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ngs\nkrrekr\ndkthtcppcpapellggpsvflfp\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\npkpkdtlmisrtpevtcvvvdvshedpevkfnwy\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nvdgvevhnaktkpreeqynstyrvvsvltvlhqd\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nwlngkeykckvsnkalpapiektiskakgqpre\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\npqvytlppsrdeltknqvsltclvkgfypsdia\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nvewesngqpennykttppvldsdgsfflys\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nkltvdksrwqqgnvfscsvmhealhnhy\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\ntqkslslspgkggggsggggsscidtipks\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nrctafqckhsmkyrlsfcrktcgtc//.\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nFIG. 87A-B\n demonstrates recombinant expression of a monovalent dimeric Fc-L-ShK(2-35) molecule product expressed by and released into the conditioned media from transiently transfected mammalian cells. \nFIG. 88\n shows results from a pharmacokinetic study on the monovalent dimeric Fc-ShK(1-35) in SD rats. Serum samples were added to microtiter plates coated with an anti-human Fc antibody to enable affinity capture. Plates were then washed, captured samples were released by SDS and run on a polyacrylamide gel. Samples were then visualized by western blot using an anti-human Fc-specific antibody and secondary-HRP conjugate. The MW of bands from serum samples is roughly identical to the original purified material, suggesting little, if any, degradation of the protein occurred in vivo over a pro-longed half-life, in spite of the presence of Arg at \nposition\n 1 of the ShK(1-35) sequence.\n\n\n(3) Similar to (2) above, a Fc-toxin peptide fusion monomer can be conjugated with an immunoglobulin light chain and heavy chain resulting in a monovalent chimeric immunoglobulin-Fc-toxin peptide molecule. We have termed an immunoglobulin (light chain+heavy chain)-Fc construct a “hemibody”; such “hemibodies” containing a dimeric Fc portion can provide the long half-life typical of a dimeric antibody. The schematic representation in \nFIG. 92A-C\n illustrates an embodiment of a hemibody-toxin peptide fusion protein and its recombinant expression by mammalian cells.\n\n\nIf the antibody chosen is a target specific antibody (e.g., an anti-Kv1.3 or anti-IKCa1 antibody), the chimeric molecule may also enhance the targeting efficiency of the toxin peptide. \nFIG. 91A-B\n demonstrates that such chimeric molecules, in this example Fc-L10-ShK(2-35) dimerized with human IgG1 or human IgG2 light and heavy chains, can be expressed and released into the conditioned media from transfected mammalian cells.\n\n\nExample 57\n\n\nOsk1 PEGylated at \nResidue\n 4 by Oxime Formation\n\n\n[Dpr\n(AOA)-PEG)\n4]Osk1 Peptide Synthesis of reduced [Dpr\n(AOA)\n4]Osk1. [Dpr\n(AOA)\n4]Osk1, having the sequence:\n\n\n \n \n \n \n \n(SEQ ID NO: 5009)\n \n \n \nGVI\n[Dpr(AOA)]\nNVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK\n \n \n \n \n \n\ncan be synthesized in a stepwise manner on a Symphony™ multi-peptide synthesizer by solid-phase peptide synthesis (SPPS) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N-methyl morpholine (NMM)/N,N-dimethyl-formamide (DMF) coupling chemistry at 0.1 mmol equivalent resin scale on Fmoc-Lys(Boc)-Wang resin (Novabiochem). N-alpha-(9-fluorenylmethyloxycarbonyl)- and side-chain protected amino acids can be purchased from Novabiochem. The following side-chain protection strategy can be employed: Asp(O\nt\nBu), Arg(Pbf), Cys(Trt), Gln(Trt), His(Trt), Lys(N\nε\n-Boc), Ser(O\nt\nBu), Thr(O\nt\nBu) and Tyr(O\nt\nBu). Dpr(AOA), i.e., N-α-Fmoc-N-b-(N-t.-Boc-amino-oxyacetyl)-L-diaminopropionic acid, can be purchased from Novabiochem (Cat. No. 04-12-1185). The protected amino acid derivatives (20 mmol) can be dissolved in 100 \nml\n 20% dimethyl sulfoxide (DMSO) in DMF (v/v). Protected amino acids can be activated with 200 mM HBTU, 400 mM NMM in 20% DMSO in DMF, and coupling can be carried out using two treatments with 0.5 mmol protected amino acid, 0.5 mmol HBTU, 1 mmol NMM in 20% DMF/DMSO for 25 minutes and then 40 minutes. Fmoc deprotection reactions can be carried out with two treatments using a 20% piperidine in DMF (v/v) solution for 10 minutes then 15 minutes. Following synthesis and removal of the N-terminal Fmoc group, the resin can be then drained, and washed with DCM, DMF, DCM, and then dried in vacuo. The peptide-resin can be deprotected and released from the resin by treatment with a TFA/amionooxyacetic acid/TIS/EDT/H2O (90:2.5:2.5:2.5:2.5) solution at room temperature for 1 hour. The volatiles can be then removed with a stream of nitrogen gas, the crude peptide precipitated twice with cold diethyl ether and collected by centrifugation. The [Dpr\n(AOA)\n4]Osk1 peptide can be then analyzed on a Waters 2795 analytical RP-HPLC system using a linear gradient (0-60% buffer B in 12 minutes, A: 0.1% TFA in water also containing 0.1% aminooxyacetic acid, B: 0.1% TFA in acetonitrile) on a \nJupiter\n 4 \nμm Proteo™\n 90 Å column.\n\n\n\nReversed-Phase HPLC Purification. Preparative Reversed-phase high-performance liquid chromatography can be performed on C18, 5 μm, 2.2 cm×25 cm) column. The [Dpr\n(AOA)\n4]Osk1 peptide is dissolved in 50% aqueous acetronitrile containing acetic acid and amionooxyacetic acid and loaded onto a preparative HPLC column. Chromatographic separations can be achieved using linear gradients of buffer B in A (A=0.1% aqueous TFA; B=90% aq. ACN containing 0.09% TFA), typically 5-95% over 90 minutes at 15 mL/min. Preparative HPLC fractions can be characterized by ESMS and photodiode array (PDA) HPLC, combined and lyophilized.\n\n\nOsk1 peptide analog PEGylated at \nresidue\n 4 by oxime formation: [Dpr\n(AOA)-PEG)\n4]Osk1 (i.e., GVI[Dpr\n(AOA-PEG)\n]NVKCKISRQCLEPCKKAGMRFGKCMNGKCHCTPK//SEQ ID NO:5010) can be made as follows. Lyophilized [Dpr\n(AOA)\n4]Osk1 peptide can be dissolved in 50% HPLC buffer A/B (5 mg/mL) and added to a two-fold molar excess of MeO-PEG-aldehyde, CH\n3\nO—[CH\n2\nCH\n2\nO]\nn\n—CH\n2\nCH\n2\nCHO (average \nmolecular weight\n 20 kDa). The aminoxyacetyl group within the peptide at \nresidue\n 4 reacts with the aldehyde group of the PEG to form a covalent oxime linkage. The reaction can be left for 24 hours, and can be analyzed on an Agilent™ 1100 RP-HPLC system using Zorbax™ 300SB-\nC8\n 5 μm column at 40° C. with a linear gradient (6-60% B in 16 minutes, A: 0.1% TFA in water, B: 0.1% TFA/90% ACN in water). Mono PEGylated [Dpr\n(AOA)-PEG)\n4]Osk1 peptide can be then isolated using a \nHiTrap™\n 5 mL SP HP cation exchange column on AKTA FPLC system at 4° C. at 1 mL/min using a gradient of 0-50% B in 25 column volumes (Buffers: A=20 mM sodium acetate pH 4.0, B=1 M NaCl, 20 mM sodium acetate, pH 4.0). The fractions can be analyzed using a 4-20 tris-Gly SDS-PAGE gel and RP-HPLC. SDS-PAGE gels can be run for 1.5 hours at 125 V, 35 mA, 5 W. Pooled product, mono-PEGylated [Dpr\n(AOA)-PEG)\n4]Osk1 peptide, can be then dialyzed at 4° C. in 3 changes of 1 L of A4S buffer (10 mM NaOAc, 5% sorbitol, pH 4.0). The dialyzed product can be then concentrated in 10 K microcentrifuge filter to 2 mL volume and sterile-filtered using 0.2 μM syringe filter to give the final product.\n\n\nFolding of [Dpr\n(AOA)-PEG)\n4]Osk1 (Disulphide bond formation). The mono-PEGylated [Dpr\n(AOA)-PEG)\n4]Osk1 peptide can be dissolved in 20% AcOH in water (v/v) and can be then diluted with water to a concentration of approximately 0.15 mg peptide mL, the pH adjusted to about 8.0 using NH\n4\nOH (28-30%), and gently stirred at room temperature for 36 hours. Folding process can be monitored by LC-MS analysis. Following this, folded mono-PEGylated [Dpr\n(AOA)-PEG)\n4]Osk1 can be purified using by reversed phase HPLC using a 1″ \nLuna\n 5 \nμm C18\n 100 Å Proteo™ column with a linear gradient 0-40% buffer B in 120 min (A=0.1% TFA in water, B=0.1% TFA in acetonitrile). Mono-PEGylated (oximated) [Dpr\n(AOA)-PEG)\n4]Osk1 peptide disulfide connectivity can be C1-C4, C2-C5, and C3-C6.\n\n\nABBREVIATIONS\n\n\nAbbreviations used throughout this specification are as defined below, unless otherwise defined in specific circumstances.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\nAc\n\n\nacetyl (used to refer to acetylated residues)\n\n\n\n\n\n\n \n\n\nAcBpa\n\n\nacetylated p-benzoyl-L-phenylalanine\n\n\n\n\n\n\n \n\n\nADCC\n\n\nantibody-dependent cellular cytotoxicity\n\n\n\n\n\n\n \n\n\nAib\n\n\naminoisobutyric acid\n\n\n\n\n\n\n \n\n\nbA\n\n\nbeta-alanine\n\n\n\n\n\n\n \n\n\nBpa\n\n\np-benzoyl-L-phenylalanine\n\n\n\n\n\n\n \n\n\nBrAc\n\n\nbromoacetyl (BrCH\n2\nC(O)\n\n\n\n\n\n\n \n\n\nBSA\n\n\nBovine serum albumin\n\n\n\n\n\n\n \n\n\nBzl\n\n\nBenzyl\n\n\n\n\n\n\n \n\n\nCap\n\n\nCaproic acid\n\n\n\n\n\n\n \n\n\nCOPD\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n \n\n\nCTL\n\n\nCytotoxic T lymphocytes\n\n\n\n\n\n\n \n\n\nDCC\n\n\nDicylcohexylcarbodiimide\n\n\n\n\n\n\n \n\n\nDde\n\n\n1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)ethyl\n\n\n\n\n\n\n \n\n\nESI-MS\n\n\nElectron spray ionization mass spectrometry\n\n\n\n\n\n\n \n\n\nFmoc\n\n\nfluorenylmethoxycarbonyl\n\n\n\n\n\n\n \n\n\nHOBt\n\n\n1-Hydroxybenzotriazole\n\n\n\n\n\n\n \n\n\nHPLC\n\n\nhigh performance liquid chromatography\n\n\n\n\n\n\n \n\n\nHSL\n\n\nhomoserine lactone\n\n\n\n\n\n\n \n\n\nIB\n\n\ninclusion bodies\n\n\n\n\n\n\n \n\n\nKCa\n\n\ncalcium-activated potassium channel \n\n\n\n\n\n\n \n\n\n \n\n\n(including IKCa, BKCa, SKCa)\n\n\n\n\n\n\n \n\n\nKv\n\n\nvoltage-gated potassium channel\n\n\n\n\n\n\n \n\n\nLau\n\n\nLauric acid\n\n\n\n\n\n\n \n\n\nLPS\n\n\nlipopolysaccharide\n\n\n\n\n\n\n \n\n\nLYMPH\n\n\nlymphocytes\n\n\n\n\n\n\n \n\n\nMALDI-MS\n\n\nMatrix-assisted laser desorption ionization mass \n\n\n\n\n\n\n \n\n\n \n\n\nspectrometry\n\n\n\n\n\n\n \n\n\nMe\n\n\nmethyl\n\n\n\n\n\n\n \n\n\nMeO\n\n\nmethoxy\n\n\n\n\n\n\n \n\n\nMHC\n\n\nmajor histocompatibility complex\n\n\n\n\n\n\n \n\n\nMMP\n\n\nmatrix metalloproteinase\n\n\n\n\n\n\n \n\n\n1-Nap\n\n\n1-napthylalanine\n\n\n\n\n\n\n \n\n\nNEUT\n\n\nneutrophils\n\n\n\n\n\n\n \n\n\nNle\n\n\nnorleucine\n\n\n\n\n\n\n \n\n\nNMP\n\n\nN-methyl-2-pyrrolidinone\n\n\n\n\n\n\n \n\n\nPAGE\n\n\npolyacrylamide gel electrophoresis\n\n\n\n\n\n\n \n\n\nPBMC\n\n\nperipheral blood mononuclear cell\n\n\n\n\n\n\n \n\n\nPBS\n\n\nPhosphate-buffered saline\n\n\n\n\n\n\n \n\n\nPbf\n\n\n2,2,4,6,7-pendamethyldihydrobenzofuran-5-sulfonyl\n\n\n\n\n\n\n \n\n\nPCR\n\n\npolymerase chain reaction\n\n\n\n\n\n\n \n\n\nPec\n\n\npipecolic acid\n\n\n\n\n\n\n \n\n\nPEG\n\n\nPoly(ethylene glycol)\n\n\n\n\n\n\n \n\n\npGlu\n\n\npyroglutamic acid\n\n\n\n\n\n\n \n\n\nPic\n\n\npicolinic acid\n\n\n\n\n\n\n \n\n\npY\n\n\nphosphotyrosine\n\n\n\n\n\n\n \n\n\nRBS\n\n\nribosome binding site\n\n\n\n\n\n\n \n\n\nRT\n\n\nroom temperature (25° C.)\n\n\n\n\n\n\n \n\n\nSar\n\n\nsarcosine\n\n\n\n\n\n\n \n\n\nSDS\n\n\nsodium dodecyl sulfate\n\n\n\n\n\n\n \n\n\nSTK\n\n\nserine-threonine kinases\n\n\n\n\n\n\n \n\n\nt-Boc\n\n\ntert-Butoxycarbonyl\n\n\n\n\n\n\n \n\n\ntBu\n\n\ntert-Butyl\n\n\n\n\n\n\n \n\n\nTHF\n\n\nthymic humoral factor\n\n\n\n\n\n\n \n\n\nTrt\n\n\ntrityl"
  },
  {
    "id": "EP2292301A2",
    "text": "Anti-interferon-alpha antibodies AbstractThe present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). Claims (\n13\n)\n\n\n\n\n \n\n\nAn antibody comprising a light chain variable domain of SEQ ID N0:3 and a heavy chain variable domain of SEQ ID NO:5.\n\n\n\n\n \n \n\n\nThe antibody of claim 1 which comprises\n\n(i) the light chain variable domain amino acid sequence, or the entire chimeric light chain amino acid sequence, encoded by the VLV30-IgG2 vector having the ATCC accession no. PTA-2882, and\n\n\n(ii) the heavy chain variable domain amino acid sequence, or the entire chimeric heavy chain amino acid sequence, encoded by the VHV30-IgG2 vector having the ATCC accession no. PTA-2881.\n \n\n\n\n\n \n \n\n\nAn isolated nucleic acid molecule encoding an antibody of claim 1 or claim 2.\n\n\n\n\n \n \n\n\nA vector comprising a nucleic acid molecule according to claim 3.\n\n\n\n\n \n \n\n\nA host cell transformed with a nucleic acid molecule according to claim 3 or a vector according to claim 4.\n\n\n\n\n \n \n\n\nA method of producing the antibody of claim 1 or claim 2 comprising culturing a host cell according to claim 5 under conditions wherein the nucleic acid sequence is expressed to produce the antibody.\n\n\n\n\n \n \n\n\nA cell line comprising a nucleic acid molecule according to claim 4.\n\n\n\n\n \n \n\n\nAn antibody produced by the cell line of claim 7.\n\n\n\n\n \n \n\n\nA pharmaceutical composition comprising an effective amount of the antibody of claim 1, claim 2 or claim 8 in admixture with a pharmaceutically acceptable carrier.\n\n\n\n\n \n \n\n\nA method for diagnosing an immune mediated or autoimmune condition associated with the expression of IFN-α comprising contacting an isolated cell with an anti-IFN-α antibody of claim 1, claim 2 or claim 8, and detecting the presence of IFN-α.\n\n\n\n\n \n \n\n\nAn anti-IFN-α antibody according to any one of claim 1, claim 2 or claim 8, for use in a method of treating an immune mediated or autoimmune disease or condition associated with the expression of IFN-α in a patient.\n\n\n\n\n \n \n\n\nAn anti-IFN-α antibody of claim 11 for use in a method according to claim 11, wherein said disease is selected from the group consisting of insulin-dependent diabetes mellitus (IDDM); systemic lupus erythematosus (SLE); and autoimmune thyroiditis.\n\n\n\n\n \n \n\n\nA method of detecting or determining IFN-α in an isolated biological sample comprising admixing the sample with an anti- IFN-α antibody according to claim 1, claim 2 or claim 8, allowing the antibody to form antibody/ IFN-α complex with any IFN-α subtype present in the mixture, and detecting any antibody/IFN-α complex present in the mixture. Description\n\n\n\n\n\n\nBackground of the Invention\n\n\n\n\n\n\nField of the Invention\n\n\n\n\n \n \n \nThe present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).\n\n\n \n\n\nDescription of the Related Art\n\n\n\n\n\n\nInterferon-α (IFN-α)\n\n\n\n\n \n \n \nAlthough interferons were initially discovered for their anti-viral activities, subsequent research has unraveled a plethora of regulatory activities associated with these powerful cytokines. Type I interferons form an ancient family of cytokines that includes IFN-α, IFN-β, IFN-δ, IFN-ω and IFN-τ (\nRoberts et al., J. Interferon Cytokine Res. 18: 805-816 [1998\n]). They are coded by intronless genes and are widely distributed amongst vertebrates. Whereas IFN-β is coded by a single gene in primates and rodents, more than 10 and 15 different subtypes of IFN-α have been found in mice and man respectively. Other interferons of type I are more restricted, e.g. IFN-δ in the pig, IFN-τ in cattle and sheep, and IFN-ω in cattle and humans. Thus, human type I interferons comprise multiple members of the IFN-α family, and single members of the IFN-β and IFN-ω families. All type I IFNs appear to bind to a single receptor that is comprised of at least two membrane spanning proteins. Type II interferons on the other hand are represented by a single member, IFN-γ, and bind to a distinct receptor.\n\n\n \n \n \n \nAlthough all type I IFNs, including IFN-α, exhibit anti-viral and anti-proliferative activities and thereby help to control viral infections and tumors (\nLefevre et al., Biochimie 80: 779-788 [1998\n];\n Horton et al., Cancer Res. 59: 4064-4068 [1999\n]; \nAlexenko et al., J. Interferon Cytokine Res. 17: 769-779 [1997\n]; \nGresser, J. Leukoc. Biol. 61: 567-574 [1997\n]), there are also several autoimmune diseases that are associated with increased expression of IFNα, most notably insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).\n\n\n \n \n \n \nType I diabetes, also known as autoimmune diabetes or insulin-dependent diabetes mellitus (IDDM), is an autoimmune disease characterized by the selective destruction of pancreatic β cells by autoreactive T lymphocytes (\nBach, Endocr. Rev. 15: 516-542 [1994\n]; \nCastano and Eisenbarth, Annu. Rev. Immunol. 8: 647-679 [1990\n]; \nShehadeh and Lafferty, Diabetes Rev. 1: 141-151 [1993\n]). The pathology of IDDM is very complex involving an interaction between an epigenetic event (possibly a viral infection), the pancreatic β cells and the immune system in a genetically susceptible host. A number of cytokines, including IFN-α and IFN-γ, have been implicated in the pathogenesis of IDDM in humans and in animal models of the disease (\nCampbell et al., J. Clin. Invest. 87: 739-742 [1991\n]; \nHuang et al., Diabetes 44: 658-664 [1995\n]; \nRhodes and Taylor, Diabetologia 27: 601-603 [1984\n]. For example, pancreatic \nIfn\n-α mRNA expression and the presence of immunoreactive IFN-α in β cells of patients with IDDM have been reported (\nFoulis et al., Lancet 2: 1423-1427 [1987\n]; Huang \net al.,\n [1995] \nsupra\n; \nSomoza et al., J. Immunol. 153: 1360-1377 [1994\n]). IFN-α expression has been associated with hyperexpression of major histocompatibility complex (MHC) class I\nA\n antigens in human islets (Foulis \net al.,\n [1987] \nsupra\n; Somoza \net al.,\n [1994] \nsupra\n). In two rodent models of autoimmune diabetes, the diabetes-prone DP-BB rat and streptozotocin-treated mice, \nIfn-\nα mRNA expression in islets precedes insulitis and diabetes (\nHuang et al., Immunity 1: 469-478 [1994\n]). Furthermore, transgenic mice harboring a hybrid human insulin promoter-\nIfn-α\n construct develop hypoinsulinemic diabetes accompanied by insulitis (\nStewart et al., Science 260: 1942-1946 [1993\n]).\n\n\n \n \n \n \nIt appears that local expression of IFN-α by pancreatic islet cells in response to potential diabetogenic stimuli such as viruses may trigger the insulitic process. Consistent with its role as an initiating agent, IFN-α has been shown to induce intercellular adhesion molecule-1 (ICAM-1) and HLA class I\nA\n on endothelial cells from human islets, which may contribute to leukocyte infiltration during insulitis (\nChakrabarti et al., J. Immunol. 157: 522-528 [1996\n]). Furthermore, IFN-α facilitates T cell stimulation by the induction of the co-stimulatory molecules ICAM-1 and B7.2 on antigen-presenting cells in islets (\nChakrabarti et al., Diabetes 45: 1336-1343 [1996\n]). These studies collectively indicate that early IFN-α expression by β cells may be a critical event in the initiation of autoimmune diabetes. Although there are a number of reports implicating IFN-γ in the development of IDDM in rodent models, there is a poor correlation between the expression of this cytokine and human IDDM. Thus, cells expressing IFN-γ can be found in the islets of a subset of human patients selected for significant lymphocytic infiltration into the islets. In a group of patients that were not selected by this criterion there was no obvious association between IFN-γ expression and human IDDM.\n\n\n \n \n \n \nBased on the increased level of IFN-α expression in patients with systemic lupus erythematosus (SLE), IFN-α has also been implicated in the pathogenesis of SLE (\nYtterberg and Schnitzer, Arthritis Rheum. 25: 401-406 [1982\n]; \nShi et al., Br. J. Dermatol. 117: 155-159 [1987\n]). It is interesting to note that IFN-α is currently used for the treatment of cancer as well as viral infection such as chronic hepatitis due to hepatitis B or hepatitis C virus infection. Consistent with the observations of increased levels of IFN-α triggering autoimmunity, significant increase in the appearance of autoimmune disorders such as IDDM, SLE and autoimmune thyroiditis has been reported in the patients undergoing IFN-α therapy. For example, prolonged use of IFN-α as an anti-viral therapy has been shown to induce IDDM (\nWaguri et al., Diabetes Res. Clin. Pract. 23: 33-36 [1994\n]; \nFabris et al., J. Hepatol. 28: 514-517 [1998\n]) or SLE (\nGarcia-Porrua et al., Clin. Exp. Rheumatol. 16: 107-108 [1998\n]). The treatment of coxsackievirus B (CBV) infection with IFN-α therapy is also associated with the induction of IDDM (\nChehadeh et al., J. Infect. Dis. 181: 1929-1939 [2000\n]). Similarly, there are multiple case reports documenting IDDM or SLE in IFN-α treated cancer patients (\nRonnblom et al., J. Intern. Med. 227: 207-210 [1990\n]).\n\n\n \n\n\n\n\nAntibody therapy\n\n\n\n\n\n\n \n \n \nThe use of monoclonal antibodies as therapeutics has gained increased acceptance with several monoclonal antibodies (mAbs) either approved for human use or in late stage clinical trials. The first mAb approved by the US Food and Drug Administration (FDA) for the treatment of allograft rejection was anti-CD3 (OKT3) in 1986. Since then the pace of progress in the field of mAbs has been considerably accelerated, particularly from 1994 onwards which led to approval of additional seven mAbs for human treatment. These include ReoPro\n®\n for the management of complications of coronary angioplasty in 1994, Zenapax\n®\n (anti-CD25) for the prevention of allograft rejection in 1997, Rituxan\n®\n (anti-CD20) for the treatment of B cell non-Hodgkin's lymphoma in 1997, Infliximab\n®\n (anti-TNF-α) initially for the treatment of Crohn's disease in 1998 and subsequently for the treatment of rheumatoid arthritis in 1999, Simulect\n®\n (anti-CD25) for the prevention of allograft rejection in 1998, Synagis\n®\n (anti-F protein of respiratory syncitial virus) for the treatment of respiratory infections in 1998, and Herceptin\n®\n (anti-HER2/neu) for the treatment of HER2 overexpressing metastatic breast tumors in 1998 (\nGlennie and Johnson, Immunol. Today 21: 403-410 [2000\n]).\n\n\n \n\n\n \nAnti-IFN\n-α \nAntibodies\n \n\n\n\n\n \n \n \nDisease states that are amenable to intervention with mAbs include all those in which there is a pathological level of a target antigen. For example, an antibody that neutralizes IFN-α present in the sera of patients with SLE, and expressed by the pancreatic islets in IDDM, is a potential candidate for therapeutic intervention in these diseases. It could also be used for therapeutic intervention in other autoimmune diseases with underlying increase in and causative role of IFN-α expression. In both human IDDM (\nFoulis, et al., Lancet 2: 1423-1427 [1987\n]; \nHuang, et al., Diabetes 44: 658-664 [1995\n]; \nSomoza, et al., J. Immunol. 153: 1360-1377 [1994\n]) and human SLE (\nHooks, et al., Arthritis & Rheumatism 25: 396-400 [1982\n]; \nKim, et al., Clin. Exp. Immunol. 70: 562-569 [1987\n]; \nLacki, et al., J. Med. 28: 99-107 [1997\n]; \nRobak, et al., Archivum Immunologiae et Therapiae Experimentalis 46: 375-380 [1998\n]; \nShiozawa, et al., Arthritis & Rheumatism 35: 417-422 [1992\n]; \nvon Wussow, et al., Rheumatology International 8: 225-230 [1988\n]) there appears to be correlation between disease and IFN-α but not with either IFN-β or IFN-γ. Thus, anti-interferon mAb intervention in IDDM or SLE would require specific neutralization of most, if not all, of the IFN-α subtypes, without any significant neutralization of IFN-β or IFN-γ. Leaving the activity of these last two interferons intact may also have an advantage in allowing the retention of significant anti-viral activity.\n\n\n \n \n \n \nWhile a few mAbs that show reactivity with a range of recombinant human IFN-α subtypes have been described, these were found to neutralize only a limited subset of the recombinant IFN-α subtypes analyzed or were not capable of neutralizing the mixture of IFN-α subtypes that are produced by stimulated peripheral blood leukocytes (\nTsukui et al., Microbiol. Immunol. 30: 1129-1139 [1986\n]; \nBerg, J. Interferon Res. 4: 481-491 [1984\n]; \nMeager and Berg, J. Interferon Res. 6: 729-736 [1986\n]; \n \nUS Patent No. 4,902,618\n \n; and \n \nEP publication No. 0,139,676 B1\n \n).\n\nAccordingly, there is a great need for anti-IFN-α antibodies that not only bind to most, preferably all, subtypes of IFN-α but also neutralize such subtypes while do not interfere with the biological function of other interferons.\n\n\n \n\n\nSummary of the Invention\n\n\n\n\n \n \n \nThe present invention is based on the development of a monoclonal antibody that was experimentally found to neutralize all seven of different recombinant human IFN-α subtypes tested and two independent pools of natural human IFN-α subtypes.\n\n\n \n \n \n \nIn one aspect, the invention provides an anti-human IFN-α monoclonal antibody which binds to and neutralizes a biological activity of at least human IFN-α subtypes IFN-αl, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21. In a further aspect, the invention provides an anti-human IFN-α monoclonal antibody which binds to and neutralizes a biological activity of all human IFN-α subtypes. The antibody of the invention can significantly reduce or eliminate a biological activity of the human IFN-α in question. In one embodiment, the antibody of the invention is capable of neutralizing at least 60%, or at least 70%, preferably at least 75%, more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, still more preferably at least 95%, most preferably at least 99% of a biological activity of the subject human IFN-α. In another embodiment, the human IFN-α biological activity-neutralizing monoclonal antibody does not neutralize the corresponding biological activity of human IFN-∃.\n\n\n \n \n \n \nThe biological activity of the subject human IFN-α's may be IFNAR2-binding activity. In a particular embodiment, the invention provides an anti-human IFN-∀ monoclonal antibody is capable of binding to and blocking at least 60%, or at least 70%, preferably at least 75%, more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, still more preferably at least 95%, most preferably at least 99% of the IFNAR2-binding activity of all, or substantially all human IFN-α subtypes. In another embodiment, the invention provides an anti-human IFN-∀ monoclonal antibody that is capable of binding to and blocking at least 60%, or at least 70%, preferably at least 75%, more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, still more preferably at least 95%, most preferably at least 99% of the IFNAR2-binding activity of each of human IFN-∀ \n \n \n \n \n \n \nsubtypes\n \n \n \n \n \n \n 1, 2, 4, 5, 8, 10 and 21. In another embodiment, the anti-human IFN-∀ monoclonal antibody does not cross-react with human IFN-∃.\n\n\n \n \n \n \nThe biological activity of the subject human TFN-α's may be an antiviral activity. In one embodiment, the anti-human IFN-∀ monoclonal antibody is capable of binding to and neutralizing the antiviral activity of all, or substantially all human IFN-α subtypes. In another embodiment, the anti-human IFN-∀ monoclonal antibody is capable of binding to and neutralizing the antiviral activity of each of human IFN-∀ \n \n \n \n \n \n \nsubtypes\n \n \n \n \n \n \n 1, 2, 4, 5, 8, 10 and 21. In a particular embodiment, the invention provides an anti-human IFN-∀ monoclonal antibody that is capable of binding to and neutralizing at least 60%, or at least 70%, preferably at least 75%, more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, still more preferably at least 95%, most preferably at least 99% of the antiviral activity of all, or substantially all human IFN-α subtypes. In yet another embodiment, the invention provides an anti-human IFN-∀ monoclonal antibody which binds to and neutralizes at least 60%, or at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99% of the antiviral activity of each of human IFN-∀ \n \n \n \n \n \n \nsubtypes\n \n \n \n \n \n \n 1, 2, 4, 5, 8, 10 and 21. In still another embodiment, the human IFN-α antiviral activity-neutralizing monoclonal antibody does not neutralize the antiviral activity of human IFN-∃.\n\n\n \n \n \n \nThe antibody may be a murine, humanized or human antibody. The antibody may be the murine anti-human IFN-α monoclonal antibody 9F3 or a humanized version of it such as version 13 (V13) or chimeric form thereof. The scope of the invention also covers an antibody that binds essentially the same IFN-α epitope as murine anti-human IFN-α monoclonal antibody 9F3 or a humanized or chimeric form thereof. For example, a reference antibody for this purpose is an anti-IFN-α antibody produced by the murine hybridoma cell line 9F3.18.5 deposited with ATCC on January 18, 2001 and having accession No. PTA-2917. In another embodiment, the invention provides a murine or murine/human chimeric anti-human IFN-α monoclonal antibody comprising the murine light chain variable domain amino acid sequence shown in \nFig. 5A\n (SEQ ID NO:1) and/or the murine heavy chain variable domain amino acid sequence shown in \nFig. 5B\n (SEQ ID NO:2). In yet another embodiment, the invention provides a humanized anti-human IFN-α monoclonal antibody comprising the humanized light chain variable domain amino acid sequence shown in \nFig. 5A\n (SEQ ID NO:3) and/or the humanized heavy chain variable domain amino acid sequence shown in \nFig. 5B\n (SEQ ID NO.:5).\n\n\n \n \n \n \nAdditionally provided is an anti-human IFN-α monoclonal antibody that binds essentially the same epitopes on human IFN-\n \n \n \n \n \n \nα subtypes\n \n \n \n \n \n \n 1, 2, 4, 5, 8, 10 and 21 that are bound by murine anti-human IFN-α monoclonal antibody 9F3 or a humanized or chimeric form thereof. Further provided herein is an anti-human IFN-α monoclonal antibody that competes with murine anti-human IFN-α monoclonal antibody 9F3 for binding to each of human IFN-\n \n \n \n \n \n \nα subtypes\n \n \n \n \n \n \n 1, 2, 4, 5, 8, 10 and 21.\n\n\n \n \n \n \nAlso provided is an isolated nucleic acid molecule encoding any of the antibodies described herein, a vector comprising the isolated nucleic acid molecule, a host cell transformed with the nucleic acid molecule, and a method of producing the antibody comprising culturing the host cell under conditions wherein the nucleic acid molecule is expressed to produce the antibody and optionally recovering the antibody from the host cell. The antibody may be of the IgG class and isotypes such as IgG\n1\n, IgG\n2\n, IgG\n3\n, or IgG\n4\n. The scope of the invention also covers antibody fragments such as Fv, scFv, Fab, F(ab')\n2\n, and Fab' fragments.\n\n\n \n \n \n \nIn another aspect, the present invention provides an anti-human IFN-α monoclonal antibody light chain or a fragment thereof, comprising the following CDR's (as defined by \nKabat, et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD [1991], vols. 1-3\n): (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7); (b) L2 of the formula YASNLES (SEQ ID NO: 8); and (c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9). The scope of the invention also covers the light chain variable domain of such anti-human IFN-α monoclonal antibody light chain fragment. The scope of the invention further includes an anti-human IFN-α monoclonal antibody light chain polypeptide comprising the mouse/human chimeric light chain variable domain amino acid sequence, or the entire chimeric light chain polypeptide amino acid sequence, encoded by the XAIFN-ChLpDRl vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2880. The scope of the invention additionally includes an anti-human IFN-α monoclonal antibody light chain polypeptide comprising the humanized light chain variable domain amino acid sequence, or the entire humanized light chain polypeptide amino acid sequence, encoded by the VLV30-IgG vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2882.\n\n\n \n \n \n \nIn yet another aspect, the invention provides an anti-human IFN-α monoclonal antibody heavy chain or a fragment thereof, comprising the following CDR's: (a) H1 of the formula GYTFT EYIIH (SEQ ID NO: 10); (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and (c) H3 of the formula WISDFFDY (SEQ ID NO: 12). The scope of the invention also covers the heavy chain variable domain of such anti-human IFN-α monoclonal antibody heavy chain fragment. The scope of the invention further includes an anti-human IFN-α monoclonal antibody heavy chain polypeptide comprising the mouse/human chimeric heavy chain variable domain amino acid sequence, or the entire chimeric heavy chain polypeptide amino acid sequence, encoded by the XAIFN-ChHpDR2 vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2883. Additionally included is an anti-human IFN-α monoclonal antibody heavy chain polypeptide comprising the humanized heavy chain variable domain amino acid sequence, or the entire humanized heavy chain polypeptide amino acid sequence, encoded by the vector VHV30-IgG2 deposited with the ATCC on January 9, 2001 and having accession No. PTA-2881.\n\n\n \n \n \n \nIn a further aspect, the invention provides an anti-human IFN-α monoclonal antibody comprising (A) at least one light chain or a fragment thereof, comprising the following CDR's: (a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7); (b) L2 of the formula YASNLES (SEQ ID NO: 8); and (c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9); and (B) at least one heavy chain or a fragment thereof, comprising the following CDR's: (a) H1 of the formula GYTFTEYIIH (SEQ ID NO: 10); (b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and (c) H3 of the formula WISDFFDY (SEQ ID NO: 12). The antibody may be a homo-tetrameric structure composed of two disulfide-bonded antibody heavy chain-light chain pairs. The scope of the invention specifically includes a linear antibody, a murine antibody, a chimeric antibody, a humanized antibody, or a human antibody. Further provided is a chimeric antibody comprising (1) the mouse/human chimeric light chain variable domain amino acid sequence, or the entire chimeric light chain polypeptide amino acid sequence, encoded by the XAIFN-ChLpDRl vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2880; and (2) the mouse/human chimeric heavy chain variable domain amino acid sequence, or the entire chimeric heavy chain polypeptide amino acid sequence, encoded by the XAIFN-ChHpDR2 vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2883. Additionally provided herein is a humanized antibody comprising (1) the humanized light chain variable domain amino acid sequence, or the entire humanized light chain polypeptide amino acid sequence, encoded by the VLV30-IgG vector deposited with the ATCC on January 9, 2001 and having accession No. PTA-2882; and (2) the humanized heavy chain variable domain amino acid sequence, or the entire humanized heavy chain polypeptide amino acid sequence, encoded by the vector VHV30-IgG2 deposited with the ATCC on January 9, 2001 and having accession No. PTA-2881.\n\n\n \n \n \n \nIn yet another aspect, the invention provides a pharmaceutical composition comprising an effective amount of the antibody of the invention in admixture with a pharmaceutically acceptable carrier.\n\n\n \n \n \n \nIn a different aspect, the invention provides a method for diagnosing a condition associated with the expression of IFN-α in a cell, comprising contacting the cell with an anti-IFN-α antibody, and detecting the presence of IFN-α.\n\n\n \n \n \n \nIn yet another aspect, the invention provides a method for the treatment of a disease or condition associated with the expression of IFN-α in a patient, comprising administering to the patient an effective amount of an anti-IFN-α antibody. The patient is a mammalian patient, preferably a human patient. The disease is an autoimmune disease, such as insulin-dependent diabetes mellitus (IDDM); systemic lupus erythematosus (SLE); or autoimmune thyroiditis.\n\n\n \n\n\nBrief Description of the Drawings\n\n\n\n\n \n \n \n\n\n \n \n\n\n \nFig. 1\n shows a schematic diagram of the strategy used for the development of the anti-human IFN-α monoclonal antibodies.\n\n\n \nFig. 2\n shows that a murine anti-human IFN-α mAb (9F3) is able to neutralize a spectrum of recombinant IFN-α subtypes but not recombinant IFN-β. The indicated IFN's were assayed for inhibition of encephalomyocarditis (EMC) viral growth in A549 cells in the presence of increasing concentrations of the mAb 9F3. Data are presented as the percentage of the viral growth inhibition activity obtained with the indicated IFN in the absence of mAb 9F3.\n\n\n \nFigs. 3A-3B\n show the neutralization of leukocyte interferon (Sigma) (\nFig. 3A\n) and lymphoblastoid interferon (NIH reference Ga23-901-532) (\nFig. 3B\n). In \nFig. 3A\n, 20,000 IU/ml (filled bars) or 5,000 IU/ml (open bars) of leukocyte interferon (Sigma Product No. I-2396) were incubated with blank control (buffer only) (denoted as \"-\"), 10 :g/ml control mouse IgG (denoted as \"mIgG\"), or 10 :g/ml mAb 9F3 (denoted as \"9F3\"). Dilutions were assayed and the amount of remaining activity shown. The results shown are means of duplicate determinations. In \nFig. 3B\n, lymphoblastoid interferon (NIH reference Ga23-901-532) was assayed at 10 (filled columns) or 3 (open columns) IU/ml in the presence or absence of the indicated concentrations of mAb 9F3. A higher cytopathic effect is indicative of a decrease in interferon activity. The results shown are the means of duplicate determinations.\n\n\n \nFig. 4\n depicts results of an electrophoretic mobility shift assay (EMSA) showing the induction of an ISGF3/ISRE complex by IFN-α and the ability of 9F3 mAb to prevent the formation of the complex. EMSA was performed in the presence or absence of either human IFN-α2 (denoted as \"α2\") or IFN-∃ (denoted as \"3\") at a concentration of 25 ng/ml with 9F3 mAb (denoted as \"9F3\") or murine IgG control antibody (denoted as \"IgG\") at a concentration of 10 :g/ml.\n\n\n \nFig. 5A\n shows the alignment of light chain variable domain amino acid sequences of murine 9F3 (murine, SEQ ID NO: 1), humanized 9F3 version 13 (V13, SEQ ID NO: 3), and the consensus human variable domain light κ subgroup I (huKI, SEQ ID NO: 4). The CDRs (L1, SEQ ID NO: 7; L2, SEQ ID NO: 8; and L3, SEQ ID NO: 9) are highlighted by underlining. The residue numbering is according to Kabat \net al.,\n (1991) \nsupra.\n The differences between the murine 9F3 and V13 sequences and the differences between 9F3 and hukI sequences are indicated by asterisks.\n\n\n \nFig. 5B\n shows the alignment of heavy chain variable domain amino acid sequences of murine 9F3 (murine, SEQ ID NO: 2), humanized 9F3 version 13 (V13, SEQ ID NO: 5), and the consensus human variable domain heavy subgroup III (huIII, SEQ ID NO: 6). The CDRs (H1, SEQ ID NO: 10; H2, SEQ ID NO: 11; and H3, SEQ ID NO: 12) are highlighted by underlining. The residue numbering is according to Kabat \net al.\n (1991) \nsupra.\n The differences between the murine 9F3 and V13 sequences and the differences between 9F3 and huIII sequences are indicated by asterisks.\n\n\n \nFig. 6\n shows neutralization activity of the starting mAb 9F3 (left panel) and the chimeric protein CH8-2 (right panel) toward the viral growth inhibition exhibited by recombinant IFN-α subtypes in A549 cells challenged with encephalomyocarditis (EMC) virus.\n\n\n \nFig. 7\n depicts a model of humanized 9F3 version 13. Backbone of VL and VH domains is shown as a ribbon. CDRs are shown in white and are labeled (L1, L2, L3, H1, H2, H3). Framework side chains altered from human to murine are shown in white and are labeled by residue number.\n\n\n\n\n\n\nDetailed Description of the Preferred Embodiment\n\n\n\n\nA. \nDefinitions\n \n\n\n \n \n \nUnless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. See, e.g. \nSingleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994\n); \nSambrook et al., Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, NY 1989\n). For purposes of the present invention, the following terms are defined below.\n\n\n \n \n \n \nAs used herein, the term \"type I interferon\" is defined to include all subtypes of native sequence type I interferons of any mammalian species, including interferon-α, interferon-β, interferon-δ, interferon-ω and interferon-τ. Similarly, the term \"human type I interferon\" is defined to include all subtypes of native sequence type I human interferons, including human interferon-α, interferon-β and interferon-ω classes and which bind to a common cellular receptor.\n\n\n \n \n \n \nUnless otherwise expressly provided, the terms \"interferon-α,\" \"IFN-α,\" and \"human interferon-α\", \"human IFN-α\" and \"hIFN-∀\" are used herein to refer to all species of native sequence human alpha interferons, including all subtypes of native sequence human interferons-α. Natural (native sequence) human interferon-α comprises 23 or more closely related proteins encoded by distinct genes with a high degree of structural homology (\nWeissmann and Weber, Prog. Nucl. Acid. Res. Mol. Biol., 33: 251 [1986\n]; \nJ. Interferon Res., 13: 443-444 [1993\n]; \nRoberts et al., J. Interferon Cytokine Res. 18: 805-816 [1998\n]). The human IFN-α locus comprises two subfamilies. The first subfamily consists of at least 14 functional, non-allelic genes, including genes encoding IFN-αA (IFN-α2), IFN-αB (IFN-α8), IFN-αC (IFN-α10), IFN-αD (IFN-α1), IFN-αE (IFN-α22), IFN-αF (IFN-α21), IFN-αG (IFN-α5), and IFN-αH (IFN-α14), and pseudogenes having at least 80% homology. The second subfamily, α\n11\n or T, contains at least 5 pseudogenes and one functional gene (denoted herein as \"IFN-\nα\n \n \n \n11\n1\" or \"IFN-T\") which exhibits 70% homology with the IFN-α genes (Weissmann and Weber [1986] \nsupra\n).\n\n\n \n \n \n \nAs used herein, the terms \"first human interferon-∀ (hIFN-∀) receptor\", \"IFN-∀R\", \"hIFNAR1\", \"IFNAR1\", and \"Uze chain\" are defined as the 557 amino acid receptor protein cloned by \nUze et al., Cell, 60: 225-234 (1990\n), including an extracellular domain of 409 residues, a transmembrane domain of 21 residues, and an intracellular domain of 100 residues, as shown in \nFig. 5\n on page 229 of Uze \net al.\n Also encompassed by the foregoing terms are fragments of IFNAR1 that contain the extracellular domain (ECD) (or fragments of the ECD) of IFNAR1.\n\n\n \n \n \n \nAs used herein, the terms \"second human interferon-∀ (hIFN-∀) receptor\", \"IFN-∀∃R\", \"hIFNAR2\", \"IFNAR2\", and \"Novick chain\" are defined as the 515 amino acid receptor protein cloned by \nDomanski et al., J. Biol. Chem., 37: 21606-21611 (1995\n), including an extracellular domain of 217 residues, a transmembrane domain of 21 residues, and an intracellular domain of 250 residues, as shown in \nFig. 1\n on page 21608 of Domanski \net al.\n Also encompassed by the foregoing terms are fragments of TFNAR2 that contain the extracellular domain (ECD) (or fragments of the ECD) of IFNAR2, and soluble forms of IFNAR2, such as IFNAR2 ECD fused to an immunoglobulin sequence, e.g. IFNAR2 ECD-IgG Fc as described below.\n\n\n \n \n \n \nThe term \"native sequence\" in connection with type I interferon, IFN-α or any other polypeptide refers to a polypeptide that has the same amino acid sequence as a corresponding polypeptide derived from nature, regardless of its mode of preparation. Such native sequence polypeptide can be isolated from nature or can be produced by recombinant and/or synthetic means or any combinations thereof. The term \"native sequence\" specifically encompasses naturally-occurring truncated or secreted forms (\ne.g\n., an extracellular domain sequence), naturally-occurring variant forms (\ne.g\n., alternatively spliced forms) and naturally-occurring allelic variants of the full length polypeptides. \"Polymerase chain reaction\" or \"PCR\" refers to a procedure or technique in which minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in \n \nU.S. Patent No. 4,683,195 issued 28 July 1987\n \n. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers can coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally \nMullis et al., Cold Spring Harbor Symp. Quant. Biol. 51:263 (1987\n); \nErlich, ed., PCR Technology (Stockton Press, NY, 1989\n). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.\n\n\n \n \n \n \n\"Antibodies\" (Abs) and \"immunoglobulins\" (Igs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.\n\n\n \n \n \n \n\"Native antibodies and immunoglobulins\" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains (\nChothia et al., J. Mol. Biol. 186:651 [1985\n]; \nNovotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 [1985\n]; \nChothia et al., Nature 342: 877-883 [1989\n]).\n\n\n \n \n \n \nThe term \"variable\" refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat \net al.\n (1991) \nsupra\n). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.\n\n\n \n \n \n \nPapain digestion of antibodies produces two identical antigen-binding fragments, called \"Fab\" fragments, each with a single antigen-binding site, and a residual \"Fc\" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')\n2\n fragment that has two antigen-combining sites and is still capable of cross-linking antigen.\n\n\n \n \n \n \n\"Fv\" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. In a two-chain Fv species, this region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. In a single-chain Fv species, one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a \"dimeric\" structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.\n\n\n \n \n \n \nThe Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')\n2\n antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.\n\n\n \n \n \n \nThe \"light chains\" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called κ and λ, based on the amino acid sequences of their constant domains.\n\n\n \n \n \n \nDepending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG\n1\n, IgG\n2\n, IgG\n3\n, IgG\n4\n, IgA\n1\n, and IgA\n2\n. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and µ respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.\n\n\n \n \n \n \nThe term \"antibody\" includes all classes and subclasses of intact immunoglobulins. The term \"antibody\" also covers antibody fragments. The term \"antibody\" specifically covers monoclonal antibodies, including antibody fragment clones.\n\n\n \n \n \n \n\"Antibody fragments\" comprise a portion of an intact antibody that contains the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')\n2\n, and Fv fragments; diabodies; single-chain antibody molecules, including single-chain Fv (scFv) molecules; and multispecific antibodies formed from antibody fragments.\n\n\n \n \n \n \nThe term \"monoclonal antibody\" as used herein refers to an antibody (or antibody fragment) obtained from a population of substantially homogeneous antibodies, \ni.e\n., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, and are not contaminated by other immunoglobulins. The modifier \"monoclonal\" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by \nKohler et al., Nature, 256:495 (1975\n), or may be made by recombinant DNA methods (see, \ne.g.,\n \n \nU.S. Patent No. 4,816,567\n \n). The \"monoclonal antibodies\" also include clones of antigen-recognition and binding-site containing antibody fragments (Fv clones) isolated from phage antibody libraries using the techniques described in \nClackson et al., Nature, 352:624-628 (1991)\n and \nMarks et al., J. Mol. Biol., 222:581-597 (1991)\n, for example.\n\n\n \n \n \n \nThe monoclonal antibodies herein specifically include \"chimeric\" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (\n \nU.S. Patent No. 4,816,567 to Cabilly et al\n \n.; \nMorrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 [1984\n]).\n\n\n \n \n \n \n\"Humanized\" forms of non-human (\ne.g.,\n murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')\n2\n or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from part or all of a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see \nJones et al., Nature, 321:522-525 (1986\n); \nReichmann et al., Nature, 332:323-329 (1988\n); \nPresta, Curr. Op. Struct. Biol., 2:593-596 (1992\n); and \nClark, Immunol. Today 21: 397-402 (2000\n). The humanized antibody includes a Primatized™ antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.\n\n\n \n \n \n \n\"Single-chain Fv\" or \"scFv\" antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. For a review of scFv see \nPluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994\n), \nDall'Acqua and Carter, Curr. Opin. Struct. Biol. 8: 443-450 (1998\n), and\n Hudson, Curr. Opin. Immunol. 11: 548-557 (1999\n).\n\n\n \n \n \n \nThe term \"diabodies\" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH - VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, \n \nEP 404,097\n \n; \n \nWO 93/11161\n \n; and \nHollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993\n).\n\n\n \n \n \n \nAn \"isolated\" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody \nin situ\n within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.\n\n\n \n \n \n \nBy \"neutralizing antibody\" is meant an antibody molecule which is able to eliminate or significantly reduce an effector function of a target antigen to which it binds. Accordingly, a \"neutralizing\" anti-IFN-α antibody is capable of eliminating or significantly reducing an effector function, such as receptor binding and/or elicitation of a cellular response, of IFN-α.\n\n\n \n \n \n \nFor the purpose of the present invention, the ability of an anti-IFN-α antibody to neutralize the receptor activation activity of IFN-α can be monitored, for example, in a Kinase Receptor Activation (KIRA) Assay as described in \n \nWO 95/14930, published June 1, 1995\n \n, by measuring the ability of a candidate antibody to reduce tyrosine phosphorylation (resulting from ligand binding) of the 1FNAR1/R2 receptor complex.\n\n\n \n \n \n \nFor the purpose of the present invention, the ability of the anti-IFN-α antibodies to neutralize the elicitation of a cellular response by IFN-α is preferably tested by monitoring the neutralization of the antiviral activity of IFN-α, as described by \nKawade, J. Interferon Res. 1:61-70 (1980\n), or \nKawade and Watanabe, J. Interferon Res. 4:571-584 (1984\n), or \nYousefi, et al., Am. J. Clin. Pathol. 83: 735-740 (1985\n), or by testing the ability of an anti-IFN-α antibody to neutralize the ability of IFN-α to activate the binding of the signaling molecule, interferon-stimulated factor 3 (ISGF3), to an oligonucleotide derived from the interferon-stimulated response element (ISRE), in an electrophoretic mobility shift assay, as described by \nKurabayashi et al., Mol. Cell Biol., 15: 6386 (1995\n).\n\n\n \n \n \n \n\"Significant\" reduction means at least about 60%, or at least about 70%, preferably at least about 75%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, still more preferably at least about 95%, most preferably at least about 99% reduction of an effector function of the target antigen (e.g. IFN-α), such as receptor (e.g. IFNAR2) binding and/or elicitation of a cellular response. Preferably, the \"neutralizing\" antibodies as defined herein will be capable of neutralizing at least about 60%, or at least about 70%, preferably at least about 75%, more preferably at least about 80%, even more preferably at least about 85%, still more preferably at least about 90%, still more preferably at least about 95%, most preferably at least about 99% of the anti-viral activity of IFN-α, as determined by the anti-viral assay of Kawade (1980), \nsupra,\n or Yousefi (1985), \nsupra.\n In another preferred embodiment, the \"neutralizing\" antibodies herein will be capable of reducing tyrosine phosphorylation, due to IFN-α binding, of the IFNAR1/IFNAR2 receptor complex, by at least about 60%, or at least about 70%, preferably at least about 75%, more preferably at least about 80%; even more preferably at least about 85%, still more preferably at least about 90%, still more preferably at least about 95%, most preferably at least about 99%, as determined in the KIRA assay referenced above. In a particularly preferred embodiment, the neutralizing anti-IFN-α antibodies herein will be able to neutralize all, or substantially all, subtypes of IFN-α and will not be able to neutralize IFN-∃. In this context, the term \"substantially all\" means that the neutralizing anti-IFN-α antibody will neutralize at least IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21.\n\n\n \n \n \n \nFor the purpose of the present invention, the ability of an anti-IFN-α antibody to block the binding of an IFN-α to receptor is defined as the property or capacity of a certain concentration of the antibody to reduce or eliminate the binding of IFN-α to IFNAR2 in a competition binding assay, as compared to the effect of an equivalent concentration of irrelevant control antibody on IFN-α binding to IFNAR2 in the assay. Preferably, the blocking anti-IFN-α antibody reduces the binding of IFN-α to IFNAR2 by at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99%, as compared to the irrelevant control antibody.\n\n\n \n \n \n \nFor the purpose of the present invention, the ability of an anti-IFN-α antibody to block the binding of IFN-α to IFNAR2 can be determined by a routine competition assay such as that described in \nAntibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988\n). For example, the IFN-α-binding ELISA assay described in Example 2 below could be modified to employ competition binding between an anti-IFN-α antibody and a soluble IFNAR2. Such an assay could be performed by layering the IFN-α on microtiter plates, incubating the layered plates with serial dilutions of unlabeled anti-IFN-α antibody or unlabeled control antibody admixed with a selected concentration of labeled IFNAR2 ECD-human IgG Fc fusion protein, detecting and measuring the signal in each incubation mixture, and then comparing the signal measurements exhibited by the various dilutions of antibody.\n\n\n \n \n \n \nIn a particularly preferred embodiment, the blocking anti-IFN-α antibodies herein will be able to block the IFNAR2-binding of all, or substantially all, subtypes of IFN-α and will not cross-react with IFN-β. In this context, the term \"substantially all\" means that the blocking anti-IFN-α antibody will block the IFNAR2-binding of at least IFN-α1, IFN-α2, IFN-α4, IFN-α5, IFN-α8, IFN-α10, and IFN-α21. In a particularly preferred embodiment, the blocking anti-IFN-α antibodies of the present invention will block the IFNAR2-binding of all known subtypes of IFN-α.\n\n\n \n \n \n \nThe term \"epitope\" is used to refer to binding sites for (monoclonal or polyclonal) antibodies on protein antigens.\n\n\n \n \n \n \nAntibodies which bind to a particular epitope can be identified by \"epitope mapping.\" There are many methods known in the art for mapping and characterizing the location of epitopes on proteins, including solving the crystal structure of an antibody-antigen complex, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described, for example, in \nChapter 11 of Harlow and Lane, Using Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1999\n. Competition assays are discussed above and below. According to the gene fragment expression assays, the open reading frame encoding the protein is fragmented either randomly or by specific genetic constructions and the reactivity of the expressed fragments of the protein with the antibody to be tested is determined. The gene fragments may, for example, be produced by PCR and then transcribed and translated into protein \nin vitro,\n in the presence of radioactive amino acids. The binding of the antibody to the radioactively labeled protein fragments is then determined by immunoprecipitation and gel electrophoresis. Certain epitopes can also be identified by using large libraries of random peptide sequences displayed on the surface of phage particles (phage libraries). Alternatively, a defined library of overlapping peptide fragments can be tested for binding to the test antibody in simple binding assays. The latter approach is suitable to define linear epitopes of about 5 to 15 amino acids.\n\n\n \n \n \n \nAn antibody binds \"essentially the same epitope\" as a reference antibody, when the two antibodies recognize identical or sterically overlapping epitopes. The most widely used and rapid methods for determining whether two epitopes bind to identical or sterically overlapping epitopes are competition assays, which can be configured in all number of different formats, using either labeled antigen or labeled antibody. Usually, the antigen is immobilized on a 96-well plate, and the ability of unlabeled antibodies to block the binding of labeled antibodies is measured using radioactive or enzyme labels.\n\n\n \n \n \n \nThe term amino acid or amino acid residue, as used herein, refers to naturally occurring L amino acids or to D amino acids as described further below with respect to variants. The commonly used one- and three-letter abbreviations for amino acids are used herein (\nBruce Alberts et al., Molecular Biology of the Cell, Garland Publishing, Inc., New York (3d ed. 1994\n)).\n\n\n \n \n \n \n\"Percent (%) amino acid sequence identity\" with respect to the polypeptide sequences referred to herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and its source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California, and the source code for the ALIGN-2 program and instructions for its use are disclosed in International Application Publication No. \n \nWO2000/39297 published July 6, 2000\n \n. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.\n\n\n \n \n \n \nFor purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:\n\n \n \n \n100 times the fraction X/Y\n \n\nwhere X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (\nAltschul et al., Nucleic Acids Res. 25:3389-3402 (1997\n)). The NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.\n    \n \n \n \nIn situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:\n\n \n \n \n100 times the fraction X/Y\n \n\nwhere X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.\n    \n \n \n \nNucleic acid is \"operably linked\" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, \"operably linked\" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.\n\n\n \n \n \n \nThe term \"disease state\" refers to a physiological state of a cell or of a whole mammal in which an interruption, cessation, or disorder of cellular or body functions, systems, or organs has occurred.\n\n\n \n \n \n \nThe term \"effective amount\" refers to an amount of a drug effective to treat (including prevention) of a disease, disorder or unwanted physiological conditions in a mammal. In the present invention, an \"effective amount\" of an anti-IFN-α antibody may reduce, slow down or delay an autoimmune disorder such as IDDM or SLE; reduce, prevent or inhibit (\ni.e\n., slow to some extent and preferably stop) the development of an autoimmune disorder such as IDDM or SLE; and/or relieve to some extent one or more of the symptoms associated with autoimmune disorders such as IDDM or SLE.\n\n\n \n \n \n \nIn the methods of the present invention, the term \"control\" and grammatical variants thereof, are used to refer to the prevention, partial or complete inhibition, reduction, delay or slowing down of an unwanted event, e.g. physiological condition, such as the generation of autoreactive T cells and development of autoimmunity.\n\n\n \n \n \n \n\"Treatment\" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. \"Treatment\" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.\n\n\n \n \n \n \n\"Pharmaceutically acceptable\" carriers, excipients, or stabilizers are ones which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween™, polyethylene glycol (PEG), and Pluronics™.\n\n\n \n \n \n \n\"Mammal\" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, \netc.\n Preferably, the mammal is human.\n\n\n \nB. \nMethods for carrying out the \ninvention\n \n \n\n\n1. Generation of Antibodies\n\n\n\n\n(i) Polyclonal antibodies\n\n\n\n\n \n \n \nMethods of preparing polyclonal antibodies are known in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized, such as serum albumin, or soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM.\n\n\n \n \n \n \nIn another preferred embodiment, animals are immunized with a mixture of various, preferably all, IFN-α subtypes in order to generate anti-IFN-α antibodies with broad reactivity against IFN-α subtypes. In another preferred embodiment, animals are immunized with the mixture of human IFN-α subtypes that is present in the human lymphoblastoid interferons secreted by Burkitt lymphoma cells (Namalva cells) induced with Sendai virus, as described in Example 1 below. A suitable preparation of such human lymphoblastoid interferons can be obtained commercially (Product No. I-9887) from Sigma Chemical Company, St. Louis, MO.\n\n\n \n\n\n(ii) Monoclonal antibodies\n\n\n\n\n \n \n \nMonoclonal antibodies may be made using the hybridoma method first described by \nKohler et al., Nature 256: 495 (1975\n), or may be made by recombinant DNA methods (\n \nU.S. Patent No. 4,816,567\n \n).\n\n\n \n \n \n \nIn the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized \nin vitro.\n Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (\nGoding, Monoclonal Antibodies: Principles and Practice, pp.59-103, [Academic Press, 1996\n]).\n\n\n \n \n \n \nThe hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.\n\n\n \n \n \n \nPreferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP-21 and MC.-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (\nKozbor, J. Immunol. 133: 3001 (1984\n); \nBrodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63, Marcel Dekker, Inc., New York, [1987\n]).\n\n\n \n \n \n \nCulture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an \nin vitro\n binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).\n\n\n \n \n \n \nThe binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of \nMunson et al., Anal. Biochem. 107: 220 (1980\n).\n\n\n \n \n \n \nAfter hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the cells may be subcloned by limiting dilution procedures and grown by standard methods (\nGoding, Monoclonal Antibodies: Principles and Practice, pp.59-103, Academic Press, 1996\n). Suitable culture media for this purpose include, for example, DMEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown \nin vivo\n as ascites tumors in an animal.\n\n\n \n \n \n \nThe monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.\n\n\n \n \n \n \nDNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (\ne.g\n., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as \nE. coli\n cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (\nMorrison, et al., Proc. Nat. Acad. Sci. 81: 6851 [1984\n]), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, \"chimeric\" or \"hybrid\" antibodies are prepared that have the binding specificity of an anti-IFN-α monoclonal antibody herein.\n\n\n \n \n \n \nTypically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an IFN-α and another antigen-combining site having specificity for a different antigen.\n\n\n \n \n \n \nChimeric or hybrid antibodies also may be prepared \nin vitro\n using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.\n\n\n \n \n \n \nRecombinant production of antibodies will be described in more detail below.\n\n\n \n\n\n(iii) Humanized antibodies\n\n\n\n\n \n \n \nGenerally, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as \"import\" residues, which are typically taken from an \"import\" variable domain. Humanization can be essentially performed following the method of Winter and co-workers by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody (\nJones et al., Nature 321: 522-525 [1986\n]; \nRiechmann et al., Nature 332: 323-327 [1988\n]; \nVerhoeyen et al., Science 239: 1534-1536 [1988\n)]; reviewed in \nClark, Immunol. Today 21: 397-402 [2000\n]).\n\n\n \n \n \n \nAccordingly, such \"humanized\" antibodies are chimeric antibodies (Cabilly, \nsupra\n), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.\n\n\n \n \n \n \nIt is important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e. the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding. For further details, see \n \nU.S. patent No. 5,821,337\n \n.\n\n\n \n\n\n(iv) Human antibodies\n\n\n\n\n \n \n \nAttempts to use the same technology for generating human mAbs have been hampered by the lack of a suitable human myeloma cell line. The best results were obtained using heteromyelomas (mouse x human hybrid myelomas) as fusion partners (\nKozbor, J. Immunol. 133: 3001 (1984\n); \nBrodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63, Marcel Dekker, Inc., New York, 1987\n). Alternatively, human antibody-secreting cells can be immortalized by infection with the Epstein-Barr virus (EBV). However, EBV-infected cells are difficult to clone and usually produce only relatively low yields of immunoglobulin (\nJames and Bell, J. Immunol. Methods 100: 5-40 [1987\n]). In future, the immortalization of human B cells might possibly be achieved by introducing a defined combination of transforming genes. Such a possibility is highlighted by a recent demonstration that the expression of the telomerase catalytic subunit together with the SV40 large T oncoprotein and an oncogenic allele of H-\nras\n resulted in the tumorigenic conversion of normal human epithelial and fibroblast cells (\nHahn et al., Nature 400: 464-468 [1999\n]).\n\n\n \n \n \n \nIt is now possible to produce transgenic animals (e.g. mice) that are capable, upon immunization, of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production (\nJakobovits et al., Nature 362: 255-258 [1993\n]; \nLonberg and Huszar, Int. Rev. Immunol. 13: 65-93 [1995\n]; \nFishwild et al., Nat. Biotechnol. 14: 845-851 [1996\n];\n Mendez et al., Nat. Genet. 15: 146-156 [1997\n]; \nGreen, J. Immunol. Methods 231: 11-23 [1999\n];\n Tomizuka et al., Proc. Natl. Acad. Sci. USA 97: 722-727 [2000\n]; reviewed in \nLittle et al., Immunol. Today 21: 364-370 [2000\n]). For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (J\nH\n) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production (\nJakobovits et al., Proc. Natl. Acad. Sci. USA 90: 2551-2555 [1993\n]). Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice results in the production of human antibodies upon antigen challenge (\nJakobovits et al., Nature 362: 255-258 [1993\n]).\n\n\n \n \n \n \n \nMendez et al. (Nature Genetics 15: 146-156 [1997\n]) have generated a line of transgenic mice designated as \"XenoMouse\n®\n II\" that, when challenged with an antigen, generates high affinity fully human antibodies. This was achieved by germ-line integration of megabase human heavy chain and light chain loci into mice with deletion into endogenous J\nH\n segment as described above. The XenoMouse\n®\n II harbors 1,020 kb of human heavy chain locus containing approximately 66 V\nH\n genes, complete D\nH\n and J\nH\n regions and three different constant regions (µ, δ and γ), and also harbors 800 kb of human κ locus containing 32 Vκ genes, Jκ segments and Cκ genes. The antibodies produced in these mice closely resemble that seen in humans in all respects, including gene rearrangement, assembly, and repertoire. The human antibodies are preferentially expressed over endogenous antibodies due to deletion in endogenous J\nH\n segment that prevents gene rearrangement in the murine locus.\n\n\n \n \n \n \n \nTomizuka et al. (Proc. Natl. Acad. Sci. USA 97: 722-727 [2000\n]) have recently described generation of a double trans-chromosomic (Tc) mice by introducing two individual human chromosome fragments (hCFs), one containing the entire Ig heavy chain locus (\nIgH,\n ∼1.5 Mb) and the other the entire κ light chain locus (\nIg\nκ, ∼2 Mb) into a mouse strain whose endogenous IgH and \nIgκ\n loci were inactivated. These mice mounted antigen-specific human antibody response in the absence of mouse antibodies. The Tc technology may allow for the humanization of over megabase-sized, complex loci or gene clusters (such as those encoding T-cell receptors, major histocompatibility complex, P450 cluster etc) in mice or other animals. Another advantage of the method is the elimination of a need of cloning the large loci. This is a significant advantage since the cloning of over megabase-sized DNA fragments encompassing whole Ig loci remains difficult even with the use of yeast artificial chromosomes (\nPeterson et al., Trends Genet. 13: 61-66 [1997\n]; \nJacobovits, Curr. Biol. 4: 761-763 [1994\n]). Moreover, the constant region of the human \nIgH\n locus is known to contain sequences difficult to clone (\nKang and Cox, Genomics 35: 189-195 [1996\n]).\n\n\n \n \n \n \nAlternatively, the phage display technology can be used to produce human antibodies and antibody fragments \nin vitro,\n from immunoglobulin variable (V) domain gene repertoires from unimmunized donors (\nMcCafferty et al., Nature 348: 552-553 [1990\n]; reviewed in \nKipriyanov and Little, Mol. Biotechnol. 12: 173-201 [1999\n]; \nHoogenboom and Chames, Immunol. Today 21: 371-378 [2000\n]). According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats (reviewed in \nJohnson and Chiswell, Current Opinion in Structural Biology 3: 564-571 [1993\n)]; \nWinter et al., Annu. Rev. Immunol. 12: 433-455 [1994\n]; \nDall'Acqua and Carter, Curr. Opin. Struct. Biol. 8: 443-450 [1998\n]; \nHoogenboom and Chames, Immunol. Today 21: 371-378 [2000\n]). Several sources of V-gene segments can be used for phage display. \nClackson et al., (Nature 352: 624-628 [1991\n]) isolated a diverse array of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from unimmunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by \nMarks et al., J. Mol. Biol. 222: 581-597 (1991\n), or \nGriffiths et al., EMBO J. 12: 725-734 (1993\n). In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by employing the technique known as \"chain shuffling\" (\nMarks et al., Bio/Technol. 10: 779-783 [1992\n]). In this method, the affinity of \"primary\" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from unimmunized donors. This technique allows the production of antibodies and antibody fragments with affinities in the nM range. A strategy for making very large phage antibody repertoires (also known as \"the mother-of-all libraries\") has been described by \nWaterhouse et al., Nucl. Acids Res. 21: 2265-2266 (1993\n), and the isolation of a high affinity human antibody directly from such large phage library is reported by \nGriffiths et al., EMBO J. 13: 3245-3260 (1994\n). Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as \"epitope imprinting\", the heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigen-binding site, i.e. the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is obtained (see \n \nPCT patent application WO 93/06213, published 1 April 1993\n \n). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.\n\n\n \n\n\n(v) Bispecific antibodies\n\n\n\n\n \n \n \nBispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an IFN-α to provide a neutralizing antibody, the other one is for any other antigen.\n\n\n \n \n \n \nMethods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (\nMillstein and Cuello, Nature 305: 537-539 [1983\n]). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in \n \nPCT application publication No. WO 93/08829 (published 13 May 1993\n \n), and in \nTraunecker et al., EMBO J. 10: 3655-3659 (1991\n).\n\n\n \n \n \n \nAccording to a different and more preferred approach, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy chain constant domain, comprising at least part of the hinge, CH2 and CH3 regions. It is preferred to have the first heavy chain constant region (CH1) containing the site necessary for light chain binding, present in at least one of the fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum yields. It is, however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance. In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It was found that this asymmetric structure facilitates the separation of the desired bispecific compound from unwanted immunoglobulin chain combinations, as the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides for a facile way of separation.\n\n\n \n \n \n \nFor further details of generating bispecific antibodies see, for example, \nSuresh et al., Methods in Enzymology 121, 210 (1986\n).\n\n\n \n\n\n(vi) Heteroconjugate antibodies\n\n\n\n\n \n \n \nHeteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (\n \nU.S. Patent No. 4,676,980\n \n), and for treatment of HIV infection (\n \nPCT application publication Nos. WO 91/00360\n \n and \n \nWO 92/200373\n \n; \n \nEP 03089\n \n). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in \n \nU.S. Patent No. 4,676,980\n \n, along with a number of cross-linking techniques.\n\n\n \n\n\n(vii) Antibody fragments\n\n\n\n\n \n \n \nIn certain embodiments, the neutralizing anti-IFN-α antibody (including murine, human and humanized antibodies, and antibody variants) is an antibody fragment. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, \ne.g\n., \nMorimoto et al., J. Biochem. Biophys. Methods 24:107-117 [1992\n] and \nBrennan et al., Science 229:81 [1985\n]). However, these fragments can now be produced directly by recombinant host cells (reviewed in\n Hudson, Curr. Opin. Immunol. 11: 548-557 [1999\n]; \nLittle et al., Immunol. Today 21: 364-370 [2000\n]). For example, Fab'-SH fragments can be directly recovered from \nE. coli\n and chemically coupled to form F(ab')\n2\n fragments (\nCarter et al., Bio/Technology 10:163-167 [1992\n]). In another embodiment, the F(ab')\n2\n is formed using the leucine zipper GCN4 to promote assembly of the F(ab')\n2\n molecule. According to another approach, Fv, Fab or F(ab')\n2\n fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.\n\n\n \n\n\n(viii) Amino acid sequence variants of antibodies\n\n\n\n\n \n \n \nAmino acid sequence modification(s) of the anti-IFN-α antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the anti-IFN-α antibodies are prepared by introducing appropriate nucleotide changes into the nucleic acid encoding the anti-IFN-α antibody chains, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-IFN-α antibody. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the anti-IFN-α antibody, such as changing the number or position of glycosylation sites.\n\n\n \n \n \n \nA useful method for identification of certain residues or regions of the neutralizing anti-IFN-α antibody that are preferred locations for mutagenesis is called \"alanine scanning mutagenesis,\" as described by \nCunningham and Wells Science, 244:1081-1085 (1989\n). Here, a residue or group of target residues are identified (\ne.g\n., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation \nper se\n need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed anti-IFN-α antibody variants are screened for the desired activity.\n\n\n \n \n \n \nAmino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intra-sequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an anti-IFN-α neutralizing antibody with an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants of the anti-IFN-α antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme or a polypeptide which increases the serum half-life of the antibody.\n\n\n \n \n \n \nAnother type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the neutralizing anti-IFN-α antibody molecule removed and a different residue inserted in its place. The sites of greatest interest for substitution mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 1 under the heading of \"preferred substitutions\". If such substitutions result in a change in biological activity, then more substantial changes, denominated \"exemplary substitutions\" in Table 1, or as further described below in reference to amino acid classes, may be introduced and the products screened.\n\n \n \n \nTable 1\n \n \n \n \n \n \nOriginal Residue\n \n \n \nExemplary Substitutions\n \n \n \nPreferred Substitutions\n \n \n \n \n \nAla (A)\n \nval; leu; ile\n \nval\n \n \n \nArg (R)\n \nlys; gln; asn\n \nlys\n \n \n \nAsn (N)\n \ngln; his; asp, lys; arg\n \ngln\n \n \n \nAsp (D)\n \nglu; asn\n \nglu\n \n \n \nCys (C)\n \nser; ala\n \nser\n \n \n \nGln (Q)\n \nasn; glu\n \nasn\n \n \n \nGlu (E)\n \nasp; gln\n \nasp\n \n \n \nGly (G)\n \nala\n \nala\n \n \n \nHis (H)\n \nasn; gln; lys; arg\n \narg\n \n \n \nIle (I)\n \nleu; val; met; ala; phe; norleucine\n \nleu\n \n \n \nLeu (L)\n \nnorleucine; ile; val; met; ala; phe\n \nile\n \n \n \nLys (K)\n \narg; gin; asn\n \narg\n \n \n \nMet (M)\n \nleu; phe; ile\n \nleu\n \n \n \nPhe (F)\n \nleu; val; ile; ala; tyr\n \ntyr\n \n \n \nPro (P)\n \nala\n \nala\n \n \n \nSer (S)\n \nthr\n \nthr\n \n \n \nThr (T)\n \nser\n \nser\n \n \n \nTrp (W)\n \ntyr; phe\n \ntyr\n \n \n \nTyr (Y)\n \ntrp; phe; thr; ser\n \nphe\n \n \n \nVal (V)\n \nile; leu; met; phe; ala; norleucine\n \nleu\n \n \n \n \n \n\n\n \n \n \n \nSubstantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:\n\n \n \n \n(1) hydrophobic: norleucine, met, ala, val, leu, ile;\n \n(2) neutral hydrophilic: cys, ser, thr;\n \n(3) acidic: asp, glu;\n \n(4) basic: asn, gln, his, lys, arg;\n \n(5) residues that influence chain orientation: gly, pro; and\n \n(6) aromatic: trp, tyr, phe.\n \n\n\n \n \n \nNon-conservative substitutions will entail exchanging a member of one of these classes for another class.\n\n\n \n \n \n \nAny cysteine residue not involved in maintaining the proper conformation of the neutralizing anti-IFN-α antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as a Fv fragment).\n\n\n \n \n \n \nA particularly preferred type of substitution variant involves substituting one or more hypervariable region residues of a parent antibody (\ne.g\n. a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitution variants is affinity maturation using phage display. Briefly, several hypervariable region sites (\ne.g\n. 6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (\ne.g\n. antagonist activity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and IFN-α. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.\n\n\n \n\n\n(ix) Glycosylation Variants\n\n\n\n\n \n \n \nAntibodies are glycosylated at conserved positions in their constant regions (\nJefferis and Lund, Chem. Immunol. 65:111-128 [1997\n]; \nWright and Morrison, Trends Biotechnol. 15:26-32 [1997\n]). The oligosaccharide side chains of the immunoglobulins affect the protein's function (\nBoyd et al., Mol. Immunol. 32:1311-1318 [1996\n]; \nWittwe and Howard, Biochem. 29:4175-4180 [1990\n]), and the intramolecular interaction between portions of the glycoprotein which can affect the conformation and presented three-dimensional surface of the glycoprotein (Jefferis and Lund, \nsupra\n; \nWyss and Wagner, Current Opin. Biotech. 7:409-416 [1996\n]). Oligosaccharides may also serve to target a given glycoprotein to certain molecules based upon specific recognition structures. For example, it has been reported that in agalactosylated IgG, the oligosaccharide moiety 'flips' out of the inter-CH2 space and terminal N-acetylglucosamine residues become available to bind mannose binding protein (\nMalhotra et al., Nature Med. 1:237-243 [1995\n]). Removal by glycopeptidase of the oligosaccharides from CAMPATH-1H (a recombinant humanized murine monoclonal IgG1 antibody which recognizes the CDw52 antigen of human lymphocytes) produced in Chinese Hamster Ovary (CHO) cells resulted in a complete reduction in complement mediated lysis (CMCL) (\nBoyd et al., Mol. Immunol. 32:1311-1318 [1996\n]), while selective removal of sialic acid residues using neuraminidase resulted in no loss of DMCL. Glycosylation of antibodies has also been reported to affect antibody-dependent cellular cytotoxicity (ADCC). In particular, CHO cells with tetracycline-regulated expression of β(1,4)-N-acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase catalyzing formation of bisecting GlcNAc, was reported to have improved ADCC activity (\nUmana et al., Mature Biotech. 17:176-180 [1999\n]).\n\n\n \n \n \n \nGlycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.\n\n\n \n \n \n \nGlycosylation variants of antibodies are variants in which the glycosylation pattern of an antibody is altered. By altering is meant deleting one or more carbohydrate moieties found in the antibody, adding one or more carbohydrate moieties to the antibody, changing the composition of glycosylation (glycosylation pattern), the extent of glycosylation, etc.\n\n\n \n \n \n \nAddition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). Similarly, removal of glycosylation sites can be accomplished by amino acid alteration within the native glycosylation sites of the antibody.\n\n\n \n \n \n \nThe amino acid sequence is usually altered by altering the underlying nucleic acid sequence. Nucleic acid molecules encoding amino acid sequence variants of the anti-IFN-α antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the anti-IFN-α antibody.\n\n\n \n \n \n \nThe glycosylation (including glycosylation pattern) of antibodies may also be altered without altering the amino acid sequence or the underlying nucleotide sequence. Glycosylation largely depends on the host cell used to express the antibody. Since the cell type used for expression of recombinant glycoproteins, e.g. antibodies, as potential therapeutics is rarely the native cell, significant variations in the glycosylation pattern of the antibodies can be expected (see, e.g. \nHse et al., J. Biol. Chem. 272:9062-9070 [1997\n]). In addition to the choice of host cells, factors which affect glycosylation during recombinant production of antibodies include growth mode, media formulation, culture density, oxygenation, pH, purification schemes and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host organism including introducing or overexpressing certain enzymes involved in oligosaccharide production (\n \nU. S. Patent Nos. 5,047,335\n \n; \n \n5,510,261\n \n and \n \n5.278,299\n \n). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example using endoglycosidase H (Endo H). In addition, the recombinant host cell can be genetically engineered, e.g. make defective in processing certain types of polysaccharides. These and similar techniques are well known in the art.\n\n\n \n \n \n \nThe glycosylation structure of antibodies can be readily analyzed by conventional techniques of carbohydrate analysis, including lectin chromatography, NMR, Mass spectrometry, HPLC, GPC, monosaccharide compositional analysis, sequential enzymatic digestion, and HPAEC-PAD, which uses high pH anion exchange chromatography to separate oligosaccharides based on charge. Methods for releasing oligosaccharides for analytical purposes are also known, and include, without limitation, enzymatic treatment (commonly performed using peptide-N-glycosidase F/endo-β-galactosidase), elimination using harsh alkaline environment to release mainly O-linked structures, and chemical methods using anhydrous hydrazine to release both N- and O-linked oligosaccharides.\n\n\n \n\n\n(x) Other modifications of antibodies\n\n\n\n\n \n \n \nThe neutralizing anti-IFN-α antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in \nEpstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985\n); \nHwang et al., Proc. Natl Acad. Sci. USA 77:4030 (1980\n); and \n \nU.S. Pat. Nos. 4,485,045\n \n and \n \n4,544,545\n \n. Liposomes with enhanced circulation time are disclosed in \n \nU.S. Patent No. 5,013,556\n \n.\n\n\n \n \n \n \nParticularly useful liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in \nMartin et al., J. Biol. Chem. 257:286-288 (1982\n) via a disulfide interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See \nGabizon et al., J. National Cancer Inst.81(19):1484 (1989\n).\n\n\n \n \n \n \nThe antibody of the present invention may also be used in ADEPT by conjugating the antibody to a prodrug-activating enzyme which converts a prodrug (\ne.g\n., a peptidyl chemotherapeutic agent, see \n \nWO81/01145\n \n) to an active drug. See, for example, \n \nWO 88/07378\n \n and \n \nU.S. Patent No. 4,975,278\n \n.\n\n\n \n \n \n \nThe enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active form exhibiting the desired biological properties.\n\n\n \n \n \n \nEnzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as β-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; β-lactamase useful for converting drugs derivatized with 3-lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as \"abzymes\", can be used to convert the prodrugs of the invention into free active drugs (see, \ne.g.,\n \nMassey, Nature 328:457-458 (1987\n)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a desired cell population.\n\n\n \n \n \n \nThe enzymes can be covalently bound to the neutralizing anti-IFN-α antibodies by techniques well known in the art such as the use of the heterobifunctional crosslinking reagents discussed above. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, \ne.g.,\n \nNeuberger et al., Nature 312:604-608 [1984\n]).\n\n\n \n \n \n \nIn certain embodiments of the invention, it may be desirable to use an antibody fragment, rather than an intact antibody. In this case, it may be desirable to modify the antibody fragment in order to increase its serum half-life. This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody fragment (\ne.g\n., by mutation of the appropriate region in the antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at either end or in the middle, \ne.g\n., by DNA or peptide synthesis). See \n \nWO96/32478 published October 17, 1996\n \n.\n\n\n \n \n \n \nThe salvage receptor binding epitope generally constitutes a region wherein any one or more amino acid residues from one or two loops of a Fc domain are transferred to an analogous position of the antibody fragment. Even more preferably, three or more residues from one or two loops of the Fc domain are transferred. Still more preferred, the epitope is taken from the CH2 domain of the Fc region (\ne.g.,\n of an IgG) and transferred to the CH1, CH3, or V\nH\n region, or more than one such region, of the antibody. Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the C\nL\n region or V\nL\n region, or both, of the antibody fragment.\n\n\n \n \n \n \nCovalent modifications of the neutralizing anti-IFN-α antibodies are also included within the scope of this invention. They may be made by chemical synthesis or by enzymatic or chemical cleavage of the antibody, if applicable. Other types of covalent modifications of the antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Exemplary covalent modifications of polypeptides are described in \n \nUS Patent 5,534,615\n \n, specifically incorporated herein by reference. A preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of nonproteinaceous polymers, \ne.g\n., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in \n \nU.S. Patent Nos. 4,640,835\n \n; \n \n4,496,689\n \n; \n \n4,301,144\n \n; \n \n4,670,417\n \n; \n \n4,791,192\n \n or \n \n4,179,337\n \n.\n\n\n \n2. Screening for antibodies with the desired properties\n\n\n \n \n \nTechniques for generating antibodies have been described above. Anti-IFN-α antibodies with the desired, broad range neutralizing properties can then be identified by methods known in the art.\n\n\n \n\n\n(i) Binding Assays\n\n\n\n\n \n \n \nThus, for example, the neutralizing anti-IFN-α antibodies of the present invention can be identified in IFN-α binding assays, by incubating a candidate antibody with one or more individual IFN-α subtypes, or an array or mixture of various IFN-α subtypes, and monitoring binding and neutralization of a biological activity of IFN-α. The binding assay may be performed with purified IFN-α polypeptide(s). In one embodiment, the binding assay is a competitive binding assay, where the ability of a candidate antibody to compete with a known anti-IFN-α antibody for IFN-α binding is evaluated. The assay may be performed in various formats, including the ELISA format, also illustrated in the Examples below. IFN-α binding of a candidate antibody may also be monitored in a BIAcore\n™\n Biosensor assay, as described below.\n\n\n \n \n \n \nAny suitable competition binding assay known in the art can be used to characterize the ability of a candidate anti-IFN-α monoclonal antibody to compete with murine anti-human IFN-α monoclonal antibody 9F3 for binding to a particular IFN-α species. A routine competition assay is described in \nAntibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988\n). In another embodiment, the IFN-α-binding ELISA assay described in Example 2 below could be modified to employ IFN-α binding competition between a candidate antibody and the 9F3 antibody. Such an assay could be performed by layering the IFN-α on microtiter plates, incubating the layered plates with serial dilutions of unlabeled anti-IFN-α antibody or unlabeled control antibody admixed with a selected concentration of labeled 9F3 antibody, detecting and measuring the signal from the 9F3 antibody label, and then comparing the signal measurements exhibited by the various dilutions of antibody.\n\n\n \n\n\n(ii) Antiviral Assays\n\n\n\n\n \n \n \nThe ability of a candidate antibody to neutralize a biological activity of IFN-α can, for example, be carried out by monitoring the neutralization of the antiviral activity of IFN-α as described by \nKawade, J. Interferon Res. 1:61-70 (1980\n), or \nKawade and Watanabe, J. Interferon Res. 4:571-584 (1984\n). Briefly, a fixed concentration of IFN-α premixed with various dilutions of a candidate antibody is added to human amnion-derived FL cells, and the ability of the candidate antibody to neutralize the antiviral activity of IFN-α is determined, using an appropriate virus, e.g. Sindbis virus. The titers are expressed in international units (IU), as determined with the international reference human IFN-α (NIH Ga23-901-527).\n\n\n \n \n \n \nThe candidate anti-IFN-α antibody is considered able to inhibit the anti-viral activity of a selected IFN-α subtype if a certain concentration of the antibody inhibits more anti-viral activity than the baseline level of anti-viral activity inhibition measured in the presence of an equivalent concentration of control antibody. Optionally, the certain concentration of the candidate anti-IFN-α antibody will inhibit at least or about 60%, or at least or about 70%, preferably at least or about 75%, or more preferably at least or about 80%, or even more preferably at least or about 85%, or still more preferably at least or about 90%, or still more preferably at least or about 95%, or most preferably at least or about 99% of the anti-viral activity of the selected IFN-α subtype in the anti-viral activity assay as compared to baseline activity measured in the presence of an equivalent concentration of control antibody. The candidate anti-IFN-α antibody is considered unable to inhibit the anti-viral activity of a selected IFN-α subtype if there is no concentration of the antibody that exhibits more anti-viral activity inhibition than the baseline level of anti-viral activity inhibition measured in the presence of an equivalent concentration of control antibody.\n\n\n \n \n \n \nIn a preferred embodiment, each interferon species used in the viral infectivity assay is titrated to a concentration that provides the same level of inhibition of viral growth as that induced by a preselected number of units of an IFN-α standard. This concentration serves to provide the normalized units of the subject interferon species. In order to assess the ability of an anti-IFN-α antibody to inhibit the anti-viral activity of various IFN-α subtypes, the effective concentration (EC50) of anti-IFN-α antibody for inhibiting 50% of a particular IFN-α subtype's anti-viral activity (at the concentration titrated to provide the normalized units of activity) is determined for each IFN-α subtype to be tested.\n\n\n \n \n \n \nIn one embodiment, the antiviral activity neutralization assay is performed as described in Example 1 below. Briefly, A549 cells are grown to a density of 5x10\n5\n A549 cells/well on 96-well microtiter plates. Serial dilutions of candidate anti-IFN-α antibody are incubated with 0.2 units/:1 of a selected IFN-α subtype (normalized to 0.2 units/:l of NIH reference standard recombinant human IFN-α2) in a total volume of 100 :1 at 37EC for one hour. Each 100 :1 volume of antibody/interferon incubation mixture is then added to 5x10\n5\n A549 cells and 100 :1 of culture medium in an individual well on the microtiter plate, yielding a final IFN-α concentration of 100 units/ml in each well. The resulting cell culture mixtures are incubated for 24 hours at 37EC. Cells are then challenged with 2x10\n5\n pfu of encephalomyocarditis (EMC) virus and incubated for an additional 24 hours at 37EC. At the end of the incubation, cell viability is determined by visual microscopic examination or crystal violet staining. The effective concentration (EC50) of a candidate IFN-α antibody for inhibiting 50% of a particular IFN-α subtype's anti-viral activity in the assay is determined for each IFN-α subtype to be tested.\n\n\n \n \n \n \nIn one aspect of the invention, the anti-IFN-α antibody that exhibits anti-viral activity neutralization against the subject IFN-α subtypes will exhibit an EC50 of up to or about 20 :g/ml, or up to or about 10 :g/ml, or up to or about 5 :g/ml, or up to or about 4 :g/ml, or up to or about 3 :g/ml, or up to or about 2 :g/ml, or up to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that exhibits anti-viral activity neutralization against the subject IFN-α subtypes will exhibit an EC50 from or about 0.1 :g/ml to or about 20 :g/ml, from or about 0.1 :g/ml to or about 10 :g/ml, from or about 0.1 :g/ml to or about 5: g/ml, or from or about 0.1 :g/ml to or about 4 :g/ml, from or about 0.1 :g/ml to or about 3 :g/ml, from or about 0.1 :g/ml to or about 2 :g/ml, or from or about 0.1 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that anti-viral activity neutralization against the subject IFN-α subtypes will exhibit an EC50 from or about 0.2 :g/ml to or about 20 :g/ml, from or about 0.2 :g/ml to or about 10 :g/ml, from or about 0.2 :g/ml to or about 5 :g/ml, or from or about 0.2 :g/ml to or about 4 :g/ml, from or about 0.2 :g/ml to or about 3 :g/ml, from or about 0.2 :g/ml to or about 2 :g/ml, or from or about 0.2 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.3 :g/ml to or about 20 :g/ml, from or about 0.3 :g/ml to or about 10 :g/ml, from or about 0.3 :g/ml to or about 5 :g/ml, or from or about 0.3 :g/ml to or about 4 :g/ml, from or about 0.3 :g/ml to or about 3 :g/ml, from or about 0.3 :g/ml to or about 2 :g/ml, or from or about 0.3 :g/ml to or about 1 :glml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.4 :g/ml to or about 20 :g/ml, from or about 0.4 :g/ml to or about 10 :g/ml, from or about 0.4 :g/ml to or about 5 :g/ml, or from or about 0.4 :g/ml to or about 4 :g/ml, from or about 0.4 :g/ml to or about 3 :g/ml, from or about 0.4 :g/ml to or about 2 :g/ml, or from or about 0.4 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-WN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.5 :g/ml to or about 20 :g/ml, from or about 0.5 :g/ml to or about 10 :g/ml, from or about 0.5 :g/ml to or about 5 :g/ml, or from or about 0.5 :g/ml to or about 4 :g/ml, from or about 0.5 :g/ml to or about 3 :g/ml, from or about 0.5 :g/ml to or about 2 :g/ml, or from or about 0.5 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.6 :g/ml to or about 20 :g/ml, from or about 0.6 :g/ml to or about 10 :g/ml, from or about 0.6 :g/ml to or about 5 :g/ml, or from or about 0.6 :g/ml to or about 4 :g/ml, from or about 0.6 :g/ml to or about 3 :g/ml, from or about 0.6 :g/ml to or about 2 :g/ml, or from or about 0.6 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.7 :g/ml to or about 20 :g/ml, from or about 0.7 :g/ml to or about 10 :g/ml, from or about 0.7 :g/ml to or about 5 g/ml; or from or about 0.7 :g/ml to or about 4 :g/ml, from or about 0.7 :g/ml to or about 3 :g/ml, from or about 0.7 :g/ml to or about 2 :g/ml, or from or about 0.7 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.8 :g/ml to or about 20 :g/ml, from or about 0.8 :g/ml to or about 10 :g/ml, from or about 0.8 :g/ml to or about 5 :g/ml, or from or about 0.8 :g/ml to or about 4 :g/ml, from or about 0.8 :g/ml to or about 3 :g/ml, from or about 0.8 :g/ml to or about 2 :g/ml, or from or about 0.8 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 0.9 :g/ml to or about 20 :g/ml, from or about 0.9 :g/ml to or about 10 :g/ml, from or about 0.9 :g/ml to or about 5 :g/ml, or from or about 0.9 :g/ml to or about 4 :g/ml, from or about 0.9 :g/ml to or about 3 :g/ml, from or about 0.9 :g/ml to or about 2 :g/ml, or from or about 0.9 :g/ml to or about 1 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n \n \n \nIn another aspect of the invention, the anti-IFN-α antibody that neutralizes the anti-viral activity of the subject IFN-α subtypes will exhibit an EC50 from or about 1 :g/ml to or about 20 :g/ml, from or about 1 :g/ml to or about 10 :g/ml, from or about 1 :g/ml to or about 5 :g/ml, or from or about 1 :g/ml to or about 4 :g/ml, from or about 1 :g/ml to or about 3 :g/ml, or from or about 1 :g/ml to or about 2 :g/ml with respect to each of the subject IFN-α subtypes in the A549 cell EMC viral inhibition assay described above.\n\n\n \n\n\n(iii) Cross-blocking Assays\n\n\n\n\n \n \n \nTo screen for antibodies which bind to an epitope on IFN-α bound by an antibody of interest, a routine cross-blocking assay such as that described in \nAntibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988\n), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the IFN-α epitope bound by a monoclonal antibody of the present invention can be determined by competitive binding analysis as described in \nFendly et al. Cancer Research 50:1550 -1558 (1990\n). In another example, cross-blocking studies can be done with direct fluorescence on microtiter plates. In this method, the monoclonal antibody of interest is conjugated with fluorescein isothiocyanate (FITC), using established procedures (\nWofsy et al. Selected Methods in Cellular Immunology, p. 287, Mishel and Schiigi (eds.) San Francisco: W.J. Freeman Co. (1980\n)). The selected IFN-α is layered onto the wells of microtiter plates, the layered wells are incubated with mixtures of (1) FITC-labeled monoclonal antibody of interest and (2) unlabeled test monoclonal antibody, and the fluorescence in each well is quantitated to determine the level of cross-blocking exhibited by the antibodies. Monoclonal antibodies are considered to share an epitope if each blocks binding of the other by 50% or greater in comparison to an irrelevant monoclonal antibody control.\n\n\n \n \n \n \nThe results obtained in the cell-based biological assays can then be followed by testing in animal, e.g. murine, models, and human clinical trials. If desired, murine monoclonal antibodies identified as having the desired properties can be converted into chimeric antibodies, or humanized by techniques well known in the art, including the \"gene conversion mutagenesis\" strategy, as described in \n \nU.S. Patent No. 5,821,337\n \n, the entire disclosure of which is hereby expressly incorporated by reference. Humanization of a particular anti-IFN-α antibody herein is also described in the Examples below.\n\n\n \n\n\n(iv) Phage Display Method\n\n\n\n\n \n \n \nAnti-IFN-α antibodies of the invention can be identified by using combinatorial libraries to screen for synthetic antibody clones with the desired activity or activities. In principle, synthetic antibody clones are selected by screening phage libraries containing phage that display various fragments (e.g. Fab, F(ab')\n2\n, etc.) of antibody variable region (Fv) fused to phage coat protein. Such phage libraries are panned by affinity chromatography against the desired antigen. Clones expressing Fv fragments capable of binding to the desired antigen are adsorbed to the antigen and thus separated from the non-binding clones in the library. The binding clones are then eluted from the antigen, and can be further enriched by additional cycles of antigen adsorption/elution. Any of the anti-IFN-α antibodies of the invention can be obtained by designing a suitable antigen screening procedure to select for the phage clone of interest followed by construction of a full length anti-TFN-α antibody clone using the Fv sequences from the phage clone of interest and suitable constant region (Fc) sequences described in Kabat \net al.\n (1991), \nsupra.\n \n\n\n \n\n\nConstruction of phage display libraries\n\n\n\n\n \n \n \nThe antigen-binding domain of an antibody is formed from two variable (V) regions of about 110 amino acids each, from the light (VL) and heavy (VH) chains, that both present three hypervariable loops or complementarity-determining regions (CDRs). Variable domains can be displayed functionally on phage, either as single-chain Fv (scFv) fragments, in which VH and VL are covalently linked through a short, flexible peptide, or as or D(ab')\n2\n fragments, in which they are each fused to a constant domain and interact non-covalently, as described in \nWinter et al., Ann. Rev. Immunol., 12: 433-455 (1994\n). As used herein, scFv encoding phage clones and Fab or F(ab')\n2\n encoding phage clones are collectively referred to as \"Fv phage clones\" or \"Fv clones\".\n\n\n \n \n \n \nThe naive repertoire of an animal (the repertoire before antigen challenge) provides it with antibodies that can bind with moderate affinity (K\nd\n \n-1\n of about 10\n6\n to 10\n7\n M\n-1\n) to essentially any non-self molecule. The sequence diversity of antibody binding sites is not encoded directly in the germline but is assembled in a combinatorial manner from V gene segments. In human heavy chains, the first two hypervariable loops (H1 and H2) are drawn from less than 50 VH gene segments, which are combined with D segments and JH segments to create the third hypervariable loop (H3). In human light chains, the first two hypervariable loops (L1 and L2) and much of the third (L3) are drawn from less than approximately 30 V8 and less than approximately 30 V6 segments to complete the third hypervariable loop (L3).\n\n\n \n \n \n \nEach combinatorial rearrangement of V-gene segments in stem cells gives rise to a B cell that expresses a single VH-VL combination. Immunizations triggers any B cells making a combination that binds the immunogen to proliferate (clonal expansion) and to secrete the corresponding antibody. These naive antibodies are then matured to high affinity (K\nd\n \n-1\n of 10\n9\n-10\n10\n M\n-1\n) by a process of mutagenesis and selection known as affinity maturation. It is after this point that cells are normally removed to prepare hybridomas and generate high-affinity monoclonal antibodies.\n\n\n \n \n \n \nAt three stages of this process, repertoires of VH and VL genes can be separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be searched for antigen-binding clones as described in \nWinter et al., Ann. Rev. Immunol., 12: 433-455 (1994\n). Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned to provide a single source of human antibodies to a wide range of non-self and also self antigens without any immunization as described by \nGriffiths et al., EMBO J, 12: 725-734 (1993\n). Finally, naive libraries can also be made synthetically by cloning the unrearranged V- or VIII-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro as described by \nHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992\n).\n\n\n \n \n \n \nPhage display mimics the B cell. Filamentous phage is used to display antibody fragments by fusion to the minor coat protein pIII. The antibody fragments can be displayed as single chain Fv fragments, in which VH and VL domains are connected on the same polypeptide chain by a flexible polypeptide spacer, e.g. as described by \nMarks et al., J. Mol. Biol., 222: 581-597 (1991\n), or as Fab (including F(ab')\n2\n) fragments, in which one chain is fused to pIII and the other is secreted into the bacterial host cell periplasm where assembly of a Fab-coat protein structure which becomes displayed on the phage surface by displacing some of the wild type coat proteins, e.g. as described in \nHoogenboom et al., Nucl. Acids Res., 19: 4133-4137 (1991\n). When antibody fragments are fused to the N-terminus of pIII, the phage is infective. However, if the N-terminal domain of pIII is excised and fusions made to the second domain, the phage is not infective, and wild type pIII must be provided by helper phage.\n\n\n \n \n \n \nThe pIII fusion and other proteins of the phage can be encoded entirely within the same phage replicon, or on different replicons. When two replicons are used, the pIII fusion is encoded on a phagemid, a plasmid containing a phage origin of replication. Phagemids can be packaged into phage particles by \"rescue\" with a helper phage such as M13K07 that provides all the phage proteins, including pIII, but due to a defective origin is itself poorly packaged in competitions with the phagemids as described in \nVieira and Messing, Meth. Enzymol., 153: 3-11 (1987\n). In a preferred method, the phage display system is designed such that the recombinant phage can be grown in host cells under conditions permitting no more than a minor amount of phage particles to display more than one copy of the Fv-coat protein fusion on the surface of the particle as described in\n Bass et al., Proteins, 8: 309-314 (1990\n) and in \n \nWO 92/09690\n \n (\n \nPCT/US91/09133 published June 11, 1992\n \n).\n\n\n \n \n \n \nIn general, nucleic acids encoding antibody gene fragments are obtained from immune cells harvested from humans or animals. If a library biased in favor of anti-IFN-α clones is desired, the subject is immunized with IFN-α to generate an antibody response, and spleen cells and/or circulating B cells other peripheral blood lymphocytes (PBLs) are recovered for library construction. In a preferred embodiment, a human antibody gene fragment library biased in favor of anti-human IFN-α clones is obtained by generating an anti-human IFN-α antibody response in transgenic mice carrying a functional human immunoglobulin gene array (and lacking a functional endogenous antibody production system) such that IFN-α immunization gives rise to B cells producing human-sequence antibodies against IFN-α.\n\n\n \n \n \n \nIn another preferred embodiment, animals are immunized with a mixture of various, preferably all, IFN-α subtypes in order to generate an antibody response that includes B cells producing anti-IFN-α antibodies with broad reactivity against IFN-α subtypes. In another preferred embodiment, animals are immunized with the mixture of human IFN-α subtypes that is present in the human lymphoblastoid interferons secreted by Burkitt lymphoma cells (Namalva cells) induced with Sendai virus, as described in Example 1 below. A suitable preparation of such human lymphoblastoid interferons can be obtained commercially (Product No. 1-9887) from Sigma Chemical Company, St. Louis, MO.\n\n\n \n \n \n \nAdditional enrichment for anti-IFN-α reactive cell populations can be obtained by using a suitable screening procedure to isolate B cells expressing IFN-α-specific membrane bound antibody, e.g., by cell separation with IFN-α affinity chromatography or adsorption of cells to fluorochrome-labeled IFN-α followed by fluorescence-activated cell sorting (FACS).\n\n\n \n \n \n \nAlternatively, the use of spleen cells and/or B cells or other PBLs from an unimmunized donor provides a better representation of the possible antibody repertoire, and also permits the construction of an antibody library using any animal (human or non-human) species in which IFN-α is not antigenic. For libraries incorporating \nin vitro\n antibody gene construction, stem cells are harvested from the subject to provide nucleic acids encoding unrearranged antibody gene segments. The immune cells of interest can be obtained from a variety of animal species, such as human, mouse, rat, lagomorpha, luprine, canine, feline, porcine, bovine, equine, and avian species, etc.\n\n\n \n \n \n \nNucleic acid encoding antibody variable gene segments (including VH and VL segments) are recovered from the cells of interest and amplified. In the case of rearranged VH and VL gene libraries, the desired DNA can be obtained by isolating genomic DNA or mRNA from lymphocytes followed by polymerase chain reaction (PCR) with primers matching the 5' and 3' ends of rearranged VH and VL genes as described in \nOrlandi et al., Proc. Nati. Acad. Sci. (USA), 86: 3833-3837 (1989\n), thereby making diverse V gene repertoires for expression. The V genes can be amplified from cDNA and genomic DNA, with back primers at the 5' end of the exon encoding the mature V-domain and forward primers based within the J-segment as described in Orlandi \net al.\n (1989) and in \nWard et al., Nature, 341: 544-546 (1989\n). However, for amplifying from cDNA, back primers can also be based in the leader exon as described in \nJones et al., Biotechnol., 9: 88-89 (1991\n), and forward primers within the constant region as described in \nSastry et al., Proc. Natl. Acad. Sci. (USA), 86: 5728-5732 (1989\n). To maximize complementarity, degeneracy can be incorporated in the primers as described in Orlandi \net al.\n (1989) or Sastry \net al.\n (1989). Preferably, the library diversity is maximized by using PCR primers targeted to each V-gene family in order to amplify all available VH and VL arrangements present in the immune cell nucleic acid sample, e.g. as described in the method of \nMarks et al., J. Mol. Biol., 222: 581-597 (1991\n) or as described in the method of \nOrum et al., Nucleic Acids Res., 21: 4491-4498 (1993\n). For cloning of the amplified DNA into expression vectors, rare restriction sites can be introduced within the PCR primer as a tag at one end as described in Orlandi \net al.\n (1989), or by further PCR amplification with a tagged primer as described in \nClackson et al., Nature, 352: 624-628 (1991\n).\n\n\n \n \n \n \nRepertoires of synthetically rearranged V genes can be derived in vitro from V gene segments. Most of the human VH-gene segments have been cloned and sequenced (reported in \nTomlinson et al., J. Mol. Biol., 227: 776-798 (1992\n)), and mapped (reported in \nMatsuda et al., Nature Genet., 3: 88-94 (1993\n); these cloned segments (including all the major conformations of the H1 and H2 loop) can be used to generate diverse VH gene repertoires with PCR primers encoding H3 loops of diverse sequence and length as described in \nHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992\n). VH repertoires can also be made with all the sequence diversity focussed in a long H3 loop of a single length as described in \nBarbas et al., Proc. Natl. Acad. Sci. USA, 89: 4457-4461 (1992\n). Human V6 and V8 segments have been cloned and sequenced (reported in \nWilliams and Winter, Eur. J. Immunol., 23: 1456-1461 (1993\n)) and can be used to make synthetic light chain repertoires. Synthetic V gene repertoires, based on a range of VH and VL folds, and L3 and H3 lengths, will encode antibodies of considerable structural diversity. Following amplification of V-gene encoding DNAs, germline V-gene segments can be rearranged \nin vitro\n according to the methods of \nHoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992\n).\n\n\n \n \n \n \nRepertoires of antibody fragments can be constructed by combining VH and VL gene repertoires together in several ways. Each repertoire can be created in different vectors, and the vectors recombined \nin vitro,\n e.g., as described in \nHogrefe et al., Gene, 128: 119-126 (1993\n), or \nin vivo\n by combinatorial infection, e.g., the loxP system described in \nWaterhouse et al., Nucl. Acids Res., 21: 2265-2266 (1993\n). The \nin vivo\n recombination approach exploits the two-chain nature of Fab fragments to overcome the limit on library size imposed by \nE. coli\n transformation efficiency. Naive VH and VL repertoires are cloned separately, one into a phagemid and the other into a phage vector. The two libraries are then combined by phage infection of phagemid-containing bacteria so that each cell contains a different combination and the library size is limited only by the number of cells present (about 10\n12\n clones). Both vectors contain \nin vivo\n recombination signals so that the VH and VL genes are recombined onto a single replicon and are co-packaged into phage virions. These huge libraries provide large numbers of diverse antibodies of good affinity (K\nd\n \n-1\n of about 10\n-8\n M).\n\n\n \n \n \n \nAlternatively, the repertoires may be cloned sequentially into the same vector, e.g. as described in \nBarbas et al., Proc. Natl. Acad. Sci. USA, 88: 7978-7982 (1991\n), or assembled together by PCR and then cloned, e.g. as described in \nClackson et al., Nature, 352: 624-628 (1991\n). PCR assembly can also be used to join VH and VL DNAs with DNA encoding a flexible peptide spacer to form single chain Fv (scFv) repertoires. In yet another technique, \"in cell PCR assembly\" is used to combine VH and VL genes within lymphocytes by PCR and then clone repertoires of linked genes as described in \nEmbleton et al., Nucl. Acids Res., 20: 3831-3837 (1992\n).\n\n\n \n \n \n \nThe antibodies produced by naive libraries (either natural or synthetic) can be of moderate affinity (K\nd\n \n-1\n of about 10\n6\n to 10\n7\n M\n-1\n), but affinity maturation can also be mimicked \nin vitro\n by constructing and reselecting from secondary libraries as described in Winter \net al.\n (1994), \nsupra.\n For example, mutation can be introduced at random in vitro by using error-prone polymerase (reported in \nLeung et al., Technique, 1: 11-15 (1989\n)) in the method of \nHawkins et al., J. Mol. Biol., 226: 889-896 (1992\n) or in the method of \nGram et al., Proc. Natl. Acad. Sci USA, 89: 3576-3580 (1992\n). Additionally, affinity maturation can be performed by randomly mutating one or more CDRs, e.g. using PCR with primers carrying random sequence spanning the CDR of interest, in selected individual Fv clones and screening for higher affinity clones. \n \nWO 9607754 (published 14 March 1996\n \n) described a method for inducing mutagenesis in a complementarity determining region of an immunoglobulin light chain to create a library of light chain genes. Another effective approach is to recombine the VH or VL domains selected by phage display with repertoires of naturally occurring V domain variants obtained from unimmunized donors and screen for higher affinity in several rounds of chain reshuffling as described in \nMarks et al., Biotechnol., 10: 779-783 (1992\n). This technique allows the production of antibodies and antibody fragments with affinities in the 10\n-9\n M range.\n\n\n \n\n\nPanning Phage Display Libraries for Anti-IFN-α Clones\n\n\n\n\na. Synthesis of IFN-α\n\n\n \n \n \nNucleic acid sequence encoding the IFN-α subtypes used herein can be designed using published amino acid and nucleic acid sequences of interferons, e.g. see the \nJ. Interferon Res., 13: 443-444 (1993\n) compilation of references containing genomic and cDNA sequences for various type I interferons, and the references cited therein. For the IFN-αA (IFN-α2), IFN-αB (IFN-α8), IFN-αC (IFN-α10), IFN-αD (IFN-α1), IFN-αE (IFN-α22), IFN-αF (IFN-α21), IFN-αG (IFN-α5), and IFN-αH (EFN-α14) amino acid sequences or cDNA sequences, see \nFigs. 3\n and \n4\n on pages 23-24 of \nGoeddel et al., Nature, 290: 20-26 (1981\n). For cDNA encoding the amino acid sequence of IFN-α7 (IFN-αJ), see \nCohen et al., Dev. Biol. Standard, 60: 111-122 (1985\n). DNAs encoding the interferons of interest can be prepared by a variety of methods known in the art. These methods include, but are not limited to, chemical synthesis by any of the methods described in \nEngels et al., Agnew. Chem. Int. Ed. Engl., 28: 716-734 (1989\n), such as the triester, phosphite, phosphoramidite and H-phosphonate methods. In one embodiment, codons preferred by the expression host cell are used in the design of the interferon-encoding DNA. Alternatively, DNA encoding the interferon can be isolated from a genomic or cDNA library.\n\n\n \n \n \n \nFollowing construction of the DNA molecule encoding the interferon of interest, the DNA molecule is operably linked to an expression control sequence in an expression vector, such as a plasmid, wherein the control sequence is recognized by a host cell transformed with the vector. In general, plasmid vectors contain replication and control sequences which are derived from species compatible with the host cell. The vector ordinarily carries a replication site, as well as sequences which encode proteins that are capable of providing phenotypic selection in transformed cells.\n\n\n \n \n \n \nFor expression in prokaryotic hosts, suitable vectors include pBR322 (ATCC No. 37,017), phGH107 (ATCC No. 40,011), pBO475, pS0132, pRIT5, any vector in the pRIT20 or pRIT30 series (\nNilsson and Abrahmsen, Meth. Enzymol., 185: 144-161 (1990\n)), pRIT2T, pKK233-2, pDR540 and pPL-lambda. Prokaryotic host cells containing the expression vectors suitable for use herein include \nE. coli\n K12 strain 294 (ATCC NO. \n31446), E coli\n strain JM101 (\nMessing et al., Nucl.Acid Res., 9: 309 (1981\n)), \nE. coli\n strain B, \nE. coli\n strain II1776 (ATCC No. 31537), \nE. coli\n c600 (Appleyard, \nGenetics,\n 39: 440 (1954)), \nE. coli\n W3110 (F-, gamma-, prototrophic, ATCC No. 27325), \nE. coli\n strain 27C7 (W3110, \ntonA, phoA E15, (argF-lac)169, ptr3, degP41, ompT, kan\n \nr\n) (\n \nU.S. Patent No. 5,288,931\n \n, ATCC No. 55,244), \nBacillus subtilis, Salmonella typhimurium, Serratia marcesans,\n and \nPseudomonas\n species.\n\n\n \n \n \n \nIn addition to prokaryotes, eukaryotic organisms, such as yeasts, or cells derived from multicellular organisms can be used as host cells. For expression in yeast host cells, such as common baker's yeast or \nSaccharomyces cerevisiae,\n suitable vectors include episomally replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors. For expression in insect host cells, such as Sf9 cells, suitable vectors include baculoviral vectors. For expression in plant host cells, particularly dicotyledonous plant hosts, such as tobacco, suitable expression vectors include vectors derived from the Ti plasmid of \nAgrobacterium tumefaciens.\n \n\n\n \n \n \n \nHowever, interest has been greatest in vertebrate host cells. Examples of useful mammalian host cells include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, \nGraham et al., J. Gen Virol., 36: 59 (1977\n)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, \nUrlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980\n)); mouse sertoli cells (\nTM4, Mather, Biol. Reprod., 23: 243-251 (1980\n)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (\nMather et al., Annals N.Y. Acad. Sci., 383: 44-68 (1982\n)); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2). For expression in mammalian host cells, useful vectors include vectors derived from SV40, vectors derived from cytomegalovirus such as the pRK vectors, including pRK5 and pRK7 (\nSuva et al., Science, 237: 893-896 (1987\n), \n \nEP 307,247 (3/15/89\n \n), \n \nEP 278,776 (8/17/88\n \n)) vectors derived from vaccinia viruses or other pox viruses, and retroviral vectors such as vectors derived from Moloney's murine leukemia virus (MoMLV).\n\n\n \n \n \n \nOptionally, the DNA encoding the interferon of interest is operably linked to a secretory leader sequence resulting in secretion of the expression product by the host cell into the culture medium. Examples of secretory leader sequences include stII, ecotin, lamB, herpes GD, Ipp, alkaline phosphatase, invertase, and alpha factor. Also suitable for use herein is the 36 amino acid leader sequence of protein A (\nAbrahmsen et al., EMBO J., 4: 3901 (1985\n)).\n\n\n \n \n \n \nHost cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.\n\n\n \n \n \n \nTransfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO\n4\n precipitation and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.\n\n\n \n \n \n \nTransformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of \nSambrook et al., Molecular Cloning (2nd ed.), Cold Spring Harbor Laboratory, NY (1989\n), is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with \nAgrobacterium tumefaciens\n is used for transformation of certain plant cells, as described by \nShaw et al., Gene, 23: 315 (1983\n) and \n \nWO 89/05859 published 29 June 1989\n \n. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.30-16.37 of Sambrook \net al., supra,\n is preferred. General aspects of mammalian cell host system transformations have been described by \n \nAxel in U.S. 4,399,216 issued 16 August 1983\n \n. Transformations into yeast are typically carried out according to the method of \nVan Solingen et al., J. Bact., 130: 946 (1977\n) and \nHsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829 (1979\n). However, other methods for introducing DNA into cells such as by nuclear injection, electroporation, or by protoplast fusion may also be used.\n\n\n \n \n \n \nProkaryotic host cells used to produce the interferon of interest can be cultured as described generally in Sambrook \net al., supra.\n \n\n\n \n \n \n \nThe mammalian host cells used to produce the interferon of interest can be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in \nHam and Wallace, Meth. Enz., 58: 44 (1979\n), \nBarnes and Sato, Anal. Biochem., 102: 255 (1980\n), \n \nU.S. 4,767,704\n \n; \n \n4,657,866\n \n; \n \n4,927,762\n \n; or \n \n4,560,655\n \n; \n \nWO 90/03430\n \n; \n \nWO 87/00195\n \n; \n \nU.S. Pat. Re. 30,985\n \n; or \n \nU.S. 5,122,469\n \n, the disclosures of all of which are incorporated herein by reference, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin\n™\n drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.\n\n\n \n \n \n \nThe host cells referred to in this disclosure encompass cells in \nin vitro\n culture as well as cells that are within a host animal.\n\n\n \n \n \n \nIn an intracellular expression system or periplasmic space secretion system, the recombinantly expressed interferon protein can be recovered from the culture cells by disrupting the host cell membrane/cell wall (e.g. by osmotic shock or solubilizing the host cell membrane in detergent). Alternatively, in an extracellular secretion system, the recombinant protein can be recovered from the culture medium. As a first step, the culture medium or lysate is centrifuged to remove any particulate cell debris. The membrane and soluble protein fractions are then separated. Usually, the interferon is purified from the soluble protein fraction. If the IFN-α is expressed as a membrane bound species, the membrane bound peptide can be recovered from the membrane fraction by solubilization with detergents. The crude peptide extract can then be further purified by suitable procedures such as fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; hydrophobic affinity resins and ligand affinity using interferon receptor immobilized on a matrix.\n\n\n \n \n \n \nMany of the human IFN-α used herein can be obtained from commercial sources, e.g. from Sigma (St. Louis, MO), Calbiochem-Novabiochem Corporation (San Diego, CA) or ACCURATE Chemical & Scientific Corporation (Westbury, NY).\n\n\n \n \n \n \nStandard cloning procedures described in \nManiatis et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989\n) are used to construct plasmids that direct the translocation of the various species of hIFN-α into the periplasmic space of \nE. coli.\n PCR reactions are performed on cDNA clones of the various subspecies of hIFN-α disclosed in \nGoeddel et al., Nature 290: 20-26 (1981\n) with Nsil and Styl restriction sites added to the primers. These PCR products are then subcloned into the corresponding sites of the expression vector pB0720 described in \nCunningham et al., Science 243:1330-1336 (1989\n). The resulting plasmids place production of the hIFN-α subtypes under control of the \nE. coli pho\nA promoter and the heat-stable enterotoxin II signal peptide as described in \nChang et al., Gene 55: 189-196 (1987\n). The correct DNA sequence of each gene is confirmed using the United States Biochemical Sequenase Kit version 2.0. Each plasmid is transformed into the \nE. coli\n strain 27C7 (ATCC # 55244) and grown in 10 liter fermentors as described in \nCarter et al.,Bio/Technology 10: 163-167 (1992\n). Human hIFNs are purified from \nE. coli\n paste containing each IFN-α by affinity chromatography. Bacterial cells are lysed, and the lysate is centrifuged at 10,000 x g to remove debris. The supernatant is applied to an immunoaffinity column containing a mouse anti-hIFN-αB antibody (LI-1) that is obtained as described in \nStaehelin et al., Proc. Natl. Acad. Sci. 78:1848-1852 (1981\n). LI-1 is immobilized on controlled pore glass by a modification of the method of \nRoy et al., Journal of Chromatography, 303: 225-228 (1984\n). The bound interferon is eluted from the column with 0.1 M citrate, pH 3.0, containing 20% (w/v) glycerol. The purified IFN is analyzed by SDS-PAGE and immunoblotting, and is assayed for bioactivity by the hIFN-induced anti-viral assay as described herein.\n\n\n \n \n \n \nHuman IFN-α2/1 hybrid molecule (IFN-α2\n1-62\n/α\n64-166\n) was obtained as described in \nRehberg et al., J. Biol. Chem., 257: 11497-11502 (1992\n) or \nHorisberger and Marco, Pharmac. Ther., 66: 507-534 (1995\n).\n\n\n \nb. Immobilization of IFN-α\n\n\n \n \n \nThe purified IFN-α can be attached to a suitable matrix such as agarose beads, acrylamide beads, glass beads, cellulose, various acrylic copolymers, hydroxyl methacrylate gels, polyacrylic and polymethacrylic copolymers, nylon, neutral and ionic carriers, and the like, for use in the affinity chromatographic separation of phage display clones. Attachment of the IFN-α protein to the matrix can be accomplished by the methods described in \nMethods in Enzymology, vol. 44 (1976\n). A commonly employed technique for attaching protein ligands to polysaccharide matrices, e.g. agarose, dextran or cellulose, involves activation of the carrier with cyanogen halides and subsequent coupling of the peptide ligand's primary aliphatic or aromatic amines to the activated matrix.\n\n\n \n \n \n \nAlternatively, IFN-α can be used to coat the wells of adsorption plates, expressed on host cells affixed to adsorption plates or used in cell sorting, or conjugated to biotin for capture with streptavidin-coated beads, or used in any other art-known method for panning phage display libraries.\n\n\n \nc. Panning Procedures\n\n\n \n \n \nThe phage library samples are contacted with immobilized IFN-α under conditions suitable for binding of at least a portion of the phage particles with the adsorbent. Normally, the conditions, including pH, ionic strength, temperature and the like are selected to mimic physiological conditions. The phage bound to the solid phase are washed and then eluted by acid, e.g. as described in \nBarbas et al., Proc. Natl. Acad. Sci USA, 88: 7978-7982 (1991\n), or by alkali, e.g. as described in \nMarks et al., J. Mol. Biol., 222: 581-597 (1991\n), or by IFN-α antigen, e.g. in a procedure similar to the antigen competition method of \nClackson et al., Nature, 352: 624-628 (1991\n). Phage can be enriched 20-1,000-fold in a single round of selection. Moreover, the enriched phage can be grown in bacterial culture and subjected to further rounds of selection.\n\n\n \n \n \n \nIn a preferred embodiment, phage are serially incubated with various IFN-α subtypes immobilized in order to identify and further characterize phage clones that exhibit appreciable binding to a majority, preferably all, of IFN-α subtypes. In this method, phage are first incubated with one specific IFN-α subtype. The phage bound to this subtype are eluted and subjected to selection with another IFN-α subtype. The process of binding and elution is thus repeated with all IFN-α subtypes. At the end, the procedure yields a population of phage displaying antibodies with broad reactivity against all IFN-α subtypes. These phage can then be tested against other IFN species, i.e. other than IFN-α, in order to select those clones which do not show appreciable binding to other species of IFNs. Finally, the selected phage clones can be examined for their ability to neutralize biological activity, e.g. anti-viral activity, of various IFN-α subtypes, and clones representing antibodies with broad neutralization activity against a majority, preferably all, of IFN-α subtypes are finally selected.\n\n\n \n \n \n \nThe efficiency of selection depends on many factors, including the kinetics of dissociation during washing, and whether multiple antibody fragments on a single phage can simultaneously engage with antigen. Antibodies with fast dissociation kinetics (and weak binding affinities) can be retained by use of short washes, multivalent phage display and high coating density of antigen in solid phase. The high density not only stabilizes the phage through multivalent interactions, but favors rebinding of phage that has dissociated. The selection of antibodies with slow dissociation kinetics (and good binding affinities) can be promoted by use of long washes and monovalent phage display as described in \nBass et al., Proteins, 8: 309-314 (1990\n) and in \n \nWO 92/09690\n \n, and a low coating density of antigen as described in \nMarks et al., Biotechnol., 10: 779-783 (1992\n).\n\n\n \n \n \n \nIt is possible to select between phage antibodies of different affinities, even with affinities that differ slightly, for IFN-α. However, random mutation of a selected antibody (e.g. as performed in some of the affinity maturation techniques described above) is likely to give rise to many mutants, most binding to antigen, and a few with higher affinity. With limiting IFN-α, rare high affinity phage could be competed out. To retain all the higher affinity mutants, phage can be incubated with excess biotinylated IFN-α, but with the biotinylated IFN-α at a concentration of lower molarity than the target molar affinity constant for IFN-α. The high affinity-binding phage can then be captured by streptavidin-coated paramagnetic beads. Such \"equilibrium capture\" allows the antibodies to be selected according to their affinities of binding, with sensitivity that permits isolation of mutant clones with as little as two-fold higher affinity from a great excess of phage with lower affinity. Conditions used in washing phage bound to a solid phase can also be manipulated to discriminate on the basis of dissociation kinetics.\n\n\n \n \n \n \nIn one embodiment, phage are serially incubated with various IFN-α subtypes immobilized on a solid support, such as chromatographic polymer matrix beads described above. In this method, the phage are first incubated with one specific IFN-α subtype. The phage bound to this subtype are eluted from solid phase with a suitable eluent, such as any salt or acid buffer capable of releasing the bound phage into solution. Next, the eluted phage clones are subjected to selection with another IFN-α subtype. In order to enrich the population for clones that compete with soluble IFNAR2 for binding to IFN-α, the phage clones recovered from the series of IFN-α subtype chromatographic separations are incubated with a complex of immobilized IFNAR2 preadsorbed to IFN-α, and the non-adsorbed phage clones are recovered from the incubation reaction mixture.\n\n\n \n \n \n \nThe selection procedures can be designed to utilize any suitable batch chromatographic technique. In one embodiment, the phage clones are adsorbed to IFN-α-derivatized polymer matrix beads in suspension, the adsorbed beads are recovered by centrifugation, the recovered beads are resuspended and incubated in a suitable elution buffer, such as any salt or acid buffer capable of releasing the bound phage into solution, the elution mixture is centrifuged, the eluted phage clones are recovered from the supernatant, and then the adsorption/elution procedure is repeated for every additional IFN-α subtype. In order to enrich the population for clones that compete with soluble IFNAR2 for binding to IFN-α, the phage clones recovered from the IFN-α subtype chromatographic separations are incubated with a suspension of IFNAR2-derivatized polymer matrix beads preadsorbed to IFN-α, the incubation mixture is centrifuged, and the non-adsorbed phage clones are recovered from the supernatant.\n\n\n \n \n \n \nIn another embodiment, the selection procedure is designed to enrich the phage population for the property of inhibiting IFN-α binding to IFNAR2 during each of the affinity chromatographic separations. In this method, the phage are serially incubated with each of the specific IFN-α subtypes immobilized on a solid support and then eluted from solid phase with an eluent comprising an excess of soluble IFNAR2, such as IFNAR2 ECD-IgG Fc, under conditions wherein soluble IFNAR2 is capable of displacing any phage clone that competes with IFNAR2 for binding to the immobilized IFN-α. The process of binding and elution is thus repeated with each of the specific IFN-α subtypes.\n\n\n \n \n \n \nIn another embodiment, the phage clones are adsorbed to IFN-α-derivatized polymer matrix beads in suspension, the adsorbed beads are recovered by centrifugation, the recovered beads are resuspended and incubated in a suitable elution buffer comprising an excess of soluble IFNAR2 (such as IFNAR2 ECD-IgG Fc) under conditions wherein the soluble IFNAR2 is capable of displacing any phage clone that competes with IFNAR2 for binding to the immobilized IFN-α and releasing the bound phage into solution, the elution mixture is centrifuged, the eluted phage clones are recovered from the supernatant, and then the adsorption/elution procedure is repeated for every additional IFN-α subtype.\n\n\n \n \n \n \nAt the end, the procedure yields a population of phage displaying antibodies with IFNAR2-binding inhibition activity against a broad range of IFN-α subtypes. These phage can then be tested against other IFN species (other than IFN-α species), such as IFN-∃, in order to select those clones which do not show appreciable binding to other species of IFN. Finally, the selected phage clones can be examined for their ability to neutralize biological activity, e.g. anti-viral activity, of various IFN-α subtypes, and clones representing antibodies with broad neutralization activity against a majority, preferably all, of IFN-α subtypes are finally selected.\n\n\n \n\n\n \nActivity Selection of Anti-IFN-\nα \nClones\n \n\n\n\n\n \n \n \nIn one embodiment, the invention provides anti-IFN-α antibodies that bind to as well as neutralize the activity of a majority, preferably all, of IFN-α subtypes, but do not significantly bind to or neutralize the activity of any other interferon species. For example, the ability of various phage clones to neutralize the anti-viral activities of various IFN-α subtypes can be tested, essentially in the same manner as described earlier for the antibodies.\n\n\n \n4. Preparation of soluble IFNAR2-IgG\n\n\n \n \n \nA cDNA encoding the human immunoglobulin fusion proteins (immunoadhesins) based on the extracellular domain (ECD) of the hIFNAR2 (pRK5 hIFNAR2-IgG clone) can be generated using methods similar to those described by \nHaak-Frendscho et al., Immunology 79: 594-599 (1993\n) for the construction of a murine IFN-( receptor immunoadhesin. Briefly, the plasmid pRKCD4\n2\nFc\n1\n is constructed as described in Example 4 of \n \nWO 89/02922\n \n (\n \nPCTfUS88/03414 published April 6, 1989\n \n). The cDNA coding sequence for the first 216 residues of the mature hIFNAR2 ECD is obtained from the published sequence (\nNovick et al., Cell, 77: 391-400 [1994\n]). The CD4 coding sequence in the pRKCD4\n2\nFc\n1\n is replaced with the hIFNAR2 ECD encoding cDNA to form the pRK5hIFNAR2-IgG clone. hIFNAR2-IgG is expressed in human embryonic kidney 293 cells by transient transfection using a calcium phosphate precipitation technique. The immunoadhesin is purified from serum-free cell culture supernatants in a single step by affinity chromatography on a protein A-sepharose column as described in Haak-Frendscho \net al.\n (1993), \nsupra.\n Bound hIFNAR2-IgG is eluted with 0.1 M citrate buffer, pH 3.0, containing 20% (w/v) glycerol. The hIFNAR2-IgG purified is over 95% pure, as judged by SDS-PAGE.\n\n\n \n5. Diagnostic uses of anti-IFN-α antibodies\n\n\n \n \n \nThe anti-IFN-α antibodies of the invention are unique research reagents in diagnostic assays for IFN-α expression. As discussed earlier, IFN-α expression is increased in certain autoimmune diseases such as IDDM, SLE, and autoimmune thyroiditis. Increased expression of various IFN-α subtypes in such disorders can be detected and quantitated using anti-IFN-α antibodies of the instant invention with broad reactivity against a majority of IFN-α subtypes. Anti-IFN-α, antibodies are also useful for the affinity purification of various IFN-α subtypes from recombinant cell culture or natural sources.\n\n\n \n \n \n \nAnti-IFN-α antibodies can be used for the detection of IFN-α in any one of a number of well known diagnostic assay methods. For example, a biological sample may be assayed for IFN-α by obtaining the sample from a desired source, admixing the sample with anti-IFN-α antibody to allow the antibody to form antibody/IFN-α complex with any IFN-α subtype present in the mixture, and detecting any antibody/IFN-α complex present in the mixture. The biological sample may be prepared for assay by methods known in the art which are suitable for the particular sample. The methods of admixing the sample with antibodies and the methods of detecting antibody/IFN-α complex are chosen according to the type of assay used. Such assays include competitive and sandwich assays, and steric inhibition assays. Competitive and sandwich methods employ a phase-separation step as an integral part of the method while steric inhibition assays are conducted in a single reaction mixture.\n\n\n \n \n \n \nAnalytical methods for IFN-α all use one or more of the following reagents: labeled IFN-α analogue, immobilized IFN-α analogue, labeled anti-IFN-α antibody, immobilized anti-IFN-α antibody and steric conjugates. The labeled reagents also are known as \"tracers.\"\n\n\n \n \n \n \nThe label used is any detectable functionality that does not interfere with the binding of IFN-α and anti-IFN-α antibody. Numerous labels are known for use in immunoassay, examples including moieties that may be detected directly, such as fluorochrome, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized to be detected. Examples of such labels include the radioisotopes \n32\nP, \n14\nC, \n125\nI, \n3\nH, and\n131\nI, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (\n \nU.S. Pat. No. 4,737,456\n \n), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.\n\n\n \n \n \n \nConventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, \n \nU.S. Pat. Nos. 3,940,475\n \n (fluorimetry) and \n \n3,645,090\n \n (enzymes); \nHunter et al., Nature, 144: 945 (1962\n); \nDavid et al., Biochemistry, 13: 1014-1021 (1974\n); \nPain et al., J. Immunol. Methods, 40: 219-230 (1981\n); and \nNygren, J. Histochem. and Cytochem., 30: 407-412 (1982\n). Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.\n\n\n \n \n \n \nThe conjugation of such label, including the enzymes, to the antibody is a standard manipulative procedure for one of ordinary skill in immunoassay techniques. See, for example, \nO'Sullivan et al., \"\nMethods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay,\n\" in Methods in Enzymology, ed. J.J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, New York, 1981), pp. 147-166\n.\n\n\n \n \n \n \nImmobilization of reagents is required for certain assay methods. Immobilization entails separating the anti-IFN-α antibody from any IFN-α that remains free in solution. This conventionally is accomplished by either insolubilizing the anti-IFN-α antibody or IFN-α analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (\n \nBennich et al.., U.S. 3,720,760\n \n), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the anti-IFN-α antibody or IFN-α analogue afterward, e.g., by immunoprecipitation.\n\n\n \n \n \n \nOther assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry.\n\n\n \n \n \n \nCompetitive assays rely on the ability of a tracer IFN-α analogue to compete with the test sample IFN-α for a limited number of anti-IFN-α antibody antigen-binding sites. The anti-IFN-α antibody generally is insolubilized before or after the competition and then the tracer and IFN-α bound to the anti-IFN-α antibody are separated from the unbound tracer and IFN-α. This separation is accomplished by decanting (where the binding partner was pre-insolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction). The amount of test sample IFN-α is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of IFN-α are prepared and compared with the test results to quantitatively determine the amount of IFN-α present in the test sample. These assays are called ELISA systems when enzymes are used as the detectable markers.\n\n\n \n \n \n \nAnother species of competitive assay, called a \"homogeneous\" assay, does not require a phase separation. Here, a conjugate of an enzyme with the IFN-α is prepared and used such that when anti-IFN-α antibody binds to the IFN-α the presence of the anti-IFN-α antibody modifies the enzyme activity. In this case, the IFN-α or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugates are selected for use with anti-IFN-α antibody so that binding of the anti-IFN-α antibody inhibits or potentiates the enzyme activity of the label. This method \nper se\n is widely practiced under the name of EMIT.\n\n\n \n \n \n \nSteric conjugates are used in steric hindrance methods for homogeneous assay. These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small IFN-α fragment so that antibody to hapten is substantially unable to bind the conjugate at the same time as anti-IFN-α antibody. Under this assay procedure the IFN-α present in the test sample will bind anti-IFN-α antibody, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore.\n\n\n \n \n \n \nSandwich assays particularly are useful for the determination of IFN-α or anti-IFN-α antibodies. In sequential sandwich assays an immobilized anti-IFN-α antibody is used to adsorb test sample IFN-α, the test sample is removed as by washing, the bound IFN-α is used to adsorb a second, labeled anti-IFN-α antibody and bound material is then separated from residual tracer. The amount of bound tracer is directly proportional to test sample IFN-α. In \"simultaneous\" sandwich assays the test sample is not separated before adding the labeled anti-IFN-α. A sequential sandwich assay using an anti-IFN-α monoclonal antibody as one antibody and a polyclonal anti-IFN-α antibody as the other is useful in testing samples for IFN-α.\n\n\n \n \n \n \nThe foregoing are merely exemplary diagnostic assays for IFN-α. Other methods now or hereafter developed that use anti-IFN-α antibody for the determination of IFN-α are included within the scope hereof, including the bioassays described above.\n\n\n \n6. Therapeutic compositions and administration of anti-IFN-α antibodies\n\n\n \n \n \nTherapeutic formulations of the anti-IFN-α antibodies of the invention are prepared for storage by mixing antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (\nRemington: The Science and Practice of Pharmacy, 19th Edition, Alfonso, R., ed, Mack Publishing Co. (Easton, PA: 1995\n)), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG).\n\n\n \n \n \n \nThe anti-IFN-α antibody to be used for \nin vivo\n administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The anti-IFN-α antibody ordinarily will be stored in lyophilized form or in solution.\n\n\n \n \n \n \nTherapeutic anti-IFN-α antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.\n\n\n \n \n \n \nThe route of anti-IFN-α antibody administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, subcutaneous, intramuscular, intraocular, intraarterial, intracerebrospinal, or intralesional routes, or by sustained release systems as noted below. Preferably the antibody is given systemically.\n\n\n \n \n \n \nSuitable examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (\n \nU.S. 3,773,919\n \n, \n \nEP 58,481\n \n), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (\nSidman et al., Biopolymers, 22: 547-556 (1983\n)), poly (2-hydroxyethyl-methacrylate) (\nLanger et al., J. Biomed. Mater. Res., 15: 167-277 (1981\n) and \nLanger, Chem. Tech., 12: 98-105 (1982\n)), ethylene vinyl acetate (Langer \net al., supra\n) or poly-D-(-)-3-hydroxybutyric acid (\n \nEP 133,988\n \n). Sustained-release anti-IFNAR2 antibody compositions also include liposomally entrapped antibody. Liposomes containing antibody are prepared by methods known \nper se\n: \n \nDE 3,218,121\n \n;\n Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985\n);\n Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030-4034 (1980\n); \n \nEP 52,322\n \n; \n \nEP 36,676\n \n; \n \nEP 88,046\n \n; \n \nEP 143,949\n \n; \n \nEP 142,641\n \n; Japanese patent application \n \n83-118008\n \n; \n \nU.S. 4,485,045\n \n and \n \n4,544,545\n \n; and \n \nEP 102,324\n \n. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamelar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal antibody therapy.\n\n\n \n \n \n \nAnti-IFN-α antibody can also be administered by inhalation. Commercially available nebulizers for liquid formulations, including jet nebulizers and ultrasonic nebulizers are useful for administration. Liquid formulations can be directly nebulized and lyophilized powder can be nebulized after reconstitution. Alternatively, anti-IFN-α antibody can be aerosolized using a fluorocarbon formulation and a metered dose inhaler, or inhaled as a lyophilized and milled powder.\n\n\n \n \n \n \nAn \"effective amount\" of anti-IFN-α antibody to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, the type of anti-IFN-α antibody employed, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. Typically, the clinician will administer the anti-IFN-α antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.\n\n\n \n \n \n \nThe patients to be treated with the anti-IFN-α antibody of the invention include preclinical patients or those with recent onset of immune-mediated disorders, and particularly autoimmune disorders. Patients are candidates for therapy in accord with this invention until such point as no healthy tissue remains to be protected from immune-mediated destruction. For example, a patient suffering from insulin-dependent diabetes mellitus (IDDM) can benefit from therapy with an anti-IFN-α antibody of the invention until the patient's pancreatic islet cells are no longer viable. It is desirable to administer an anti-IFN-α antibody as early as possible in the development of the immune-mediated or autoimmune disorder, and to continue treatment for as long as is necessary for the protection of healthy tissue from destruction by the patient's immune system. For example, the IDDM patient is treated until insulin monitoring demonstrates adequate islet response and other indicia of islet necrosis diminish (e.g. reduction in anti-islet antibody titers), after which the patient can be withdrawn from anti-IFN-α antibody treatment for a trial period during which insulin response and the level of anti-islet antibodies are monitored for relapse.\n\n\n \n \n \n \nIn the treatment and prevention of an immune-mediated or autoimmune disorder by an anti-IFN-α antibody, the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the antibody, the particular type of antibody, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The \"therapeutically effective amount\" of antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat the disorder, including treating chronic autoimmune conditions and immunosuppression maintenance in transplant recipients. Such amount is preferably below the amount that is toxic to the host or renders the host significantly more susceptible to infections.\n\n\n \n \n \n \nAs a general proposition, the initial pharmaceutically effective amount of the antibody administered parenterally will be in the range of about 0.1 to 50 mg/kg of patient body weight per day, with the typical initial range of antibody used being 0.3 to 20 mg/kg/day, more preferably 0.3 to 15 mg/kg/day. The desired dosage can be delivered by a single bolus administration, by multiple bolus administrations, or by continuous infusion administration of antibody, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve.\n\n\n \n \n \n \nAs noted above, however, these suggested amounts of antibody are subject to a great deal of therapeutic discretion. The key factor in selecting an appropriate dose and scheduling is the result obtained, as indicated above.\n\n\n \n \n \n \nThe antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the immune-mediated or autoimmune disorder in question. For example, in rheumatoid arthritis, the antibody may be given in conjunction with a glucocorticosteroid. The effective amount of such other agents depends on the amount of anti-IFN-α antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.\n\n\n \n \n \n \nFurther details of the invention can be found in the following example, which further defines the scope of the invention. All references cited throughout the specification, and the references cited therein, are hereby expressly incorporated by reference in their entirety.\n\n\n \nEXAMPLES\n\n\n \n \n \nThe following examples are offered by way of illustration and not by way of limitation. The examples are provided so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the compounds, compositions, and methods of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to insure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in degrees C, and pressure is at or near atmospheric. The disclosures of all citations in the specification are expressly incorporated herein by reference.\n\n\n \nExample 1. \nGeneration and characterization of a broad reactive mouse anti-IFN-α monoclonal antibody\n \n\n\n\n\nMaterials and Methods\n\n\n\n\n \nA murine monoclonal antibody with broad reactivity against IFN-\nα \nsubtypes\n \n\n\n \n \n \nA pan-IFN-α neutralizing antibody was developed by sequentially immunizing mice with the mixture of human IFN-α subtypes, generating a large number of candidate mAbs, and then screening for binding and activity. In particular, Balb/c mice were immunized into each hind footpad 9 times (at two week intervals) with 2.5 :g of lymphoblastoid hIFN-∀ (Product No. I-9887 of Sigma, St. Louis, MO) resuspended in MPL-TDM (Ribi Immunochemical Research, Inc., Hamilton, MT). Three days after the final boost, popliteal lymph node cells were fused with murine myeloma cells P3X63Ag8.U.1 (ATCC CRL1597), using 35% polyethylene glycol. Hybridomas were selected in HAT medium. Ten days after the fusion, hybridoma culture supernatants were first screened for mAbs binding to the various species of hIFN-α in an ELISA. The selected hybridoma culture supernatants were then tested for their ability to inhibit the anti-viral cytophathic effect of IFN on human lung carcinoma cell line A549 cells as described below. As indicated in \nFig. 1\n, three mAbs obtained from 1794 fusion wells were able to neutralize a diverse set of IFN-α subtypes. These three mAbs were subcloned and re-analyzed.\n\n\n \n \nNeutralization of antiviral activity of IFN-\nα\n\n\n \n \n \nThe ability of a candidate antibody to neutralize the antiviral activity of IFN-α was assayed as described by \nYousefi, S., et al., Am. J. Clin. Pathol., 83: 735-740 (1985\n). Briefly, the assay was performed using human lung carcinoma A549 cells challenged with encephalomyocarditis (EMC) virus. Serial dilutions of mAbs were incubated with various units of type I interferons for one hour at 37EC in a total volume of 100 :1. These mixtures were then incubated with 5x10\n5\n A549 cells in 100 :1 of cell culture medium for 24 hours. Cells were then challenged with 2x10\n5\n pfu of EMC virus for an additional 24 hours. At the end of the incubation, cell viability was determined by visual microscopic examination or crystal violet staining. The neutralizing antibody titer (EC50) was defined as the concentration of antibody which neutralizes 50% of the anti-viral cytopathic effect by 100 units/ml of type I IFNs. The units of type I IFNs used in this study were determined using NIH reference recombinant human IFN-∀2 as a standard. The specific activities of the various type I IFNs tested were as follows: IFN-∀2/-∀1 (IFN-∀2 residues 1-62/∀1 residues 64-166) (2x10\n7\n IU/mg), IFN-∀1 (3x10\n7\n IU/mg), IFN-∀2 (2x10\n7\n IU/mg), IFN-∀5 (8x10\n7\n IU/mg), IFN-∀8 (19x10\n7\n IU/mg), and IFN-∀10 (1.5x10\n5\n IU/mg). The leukocyte IFN tested was Sigma Product No. I-2396. The lymphoblastoid IFN tested was NIH reference standard Ga23-901-532. The data shown in \nFig. 3B\n was obtained using the above-described assay format in experiments performed by Access Biomedical (San Diego, CA) at the behest of applicant.\n\n\n \n\n\nElectrophoretic mobility shift assay\n\n\n\n\n \n \n \nMost of the immediate actions of IFN have been linked to activation of latent cytoplasmic signal transducers and activators of transcription (STAT) proteins to produce a multiprotein complex, interferon-stimulated gene factor-3 (ISGF3), which induces transcription from target promoter interferon-stimulated response element (ISRE). ISGF3 is composed of three protein subunits: STAT1, STAT2 and p48/ISGF3γ. The p48 protein belongs to the interferon regulatory factor (IRF) family, and is a DNA-binding protein that directly interacts with ISRE. Thus, monitoring ISRE specific cellular DNA-binding complex in response to IFN treatment provides a simple, rapid and convenient method to assess the effect of IFN on target cells. One of the convenient formats to carry out such an analysis is electrophoretic mobility shift assay (EMSA), wherein the induction of an ISRE-binding activity by IFN treatment results in the shift in the electrophoretic mobility of a radiolabeled double-stranded oligonucleotide probe corresponding to the consensus sequence of ISRE.\n\n\n \n \n \n \nThe assay was carried out essentially as described by \nKurabayashi et al., Mol. Cell Biol., 15: 6386 (1995\n). Briefly, 5 ng of a specific IFN-α subtype plus various concentrations (5-100 µg/ml) of anti-IFN-α mAbs were incubated with 5x10\n5\n HeLa cells in 200 µl of DMEM for 30 minutes at 37°C. Cells were preincubated with antibody for 15 minutes at 4°C before the addition of the hIFN-∀. Cells were washed in PBS and resuspended in 125 µl buffer A (10 mM HEPES, pH 7.9, 10 mM KCI, 0.1 mM ETDA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin). After a 15 minute incubation on ice, cells were lysed by the addition of 0.025% NP40. The nuclear pellet was obtained by centrifugation and was resuspended in 50 µl buffer B (20 mM HEPES, pH 7.9, 400 mM NaCl, 0.1 mM EDTA, I mM DTT, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin) and kept on ice for 30 min. The nuclear fraction was cleared by centrifugation and the supernatant stored at - 70°C until use. Double-stranded probes were prepared from single-stranded oligonucleotides (ISG15 top : 5'-GATCGGGAAAGGGAAACCGAAACTGAAGCC-3' [SEQ ID NO. 13], ISG15 bottom: 5'-GATCGGCTTCAGTTTCGGTTTCCCTTTC CC-3' [SEQ ID NO. 14]) utilizing a DNA polymerase I Klenow filling reaction with \n32\nP- dATP (3,000 Ci/mM, Amersham). Labeled oligonucleotides were purified from unincorporated radioactive nucleotides using BIO-Spin 30 columns (Bio-Rad). Binding reactions containing 5 µl nuclear extract, 25,000 cpm of labeled probe and 2 µg of non-specific competitor poly (dI-dC)-poly (dI-dC) in 15 µl binding buffer (10 mM Tris-HCL, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride and 15% glycerol) were incubated at RT for 30 minutes. DNA-protein complexes were resolved in 6% non-denaturing polyacrylamide gels and analyzed by autoradiograph. The specificity of the assay was determined by the addition of 350 ng of unlabeled ISG15 probe in separate reaction mixtures. Formation of an ISGF3 specific complex was confirmed by a super shift assay with anti-STAT1 antibody.\n\n\n \n \nCloning of a gene encoding 9F3 anti-IFN-\nα \nmonoclonal antibody\n \n\n\n \n \n \nThe murine anti-human IFN-α mAb 9F3 was generated, cloned and sequenced. The plasmid pEMX1 used for expression and mutagenesis of F(ab)s in \nE. coli\n has been described previously (\nWerther et al., J. Immunol. 157: 4986-4995 [1996\n]). Briefly, the plasmid contains a DNA fragment encoding a consensus \nhuman κ subgroup\n 1 light chain (VLκ1-CL) and a consensus human subgroup III heavy chain (VHIII-CH1) and an alkaline phosphatase promoter. The use of the consensus sequences for VL and VH has been described previously (\nCarter et al., Proc. Natl. Acad. Sci. USA 89: 4285-4289 [1992\n]).\n\n\n \n\n\nResults\n\n\n\n\n \n \n \nWe have previously shown that there is a wide spectrum of IFN-α subtypes expressed by the islets of patients with IDDM (\nHuang et al., Diabetes 44: 658-664 [1995\n]). We also demonstrated that there is no obvious association between IDDM and the expression of either IFN-β or IFN-γ (Huang \net al.,\n [1995] \nsupra\n). While the specific IFN-α subtypes expressed as part of the SLE pathology have not been defined, as with IDDM, the association is with IFN-α and not with either of IFN-β or IFN-γ (\nHooks, et al., Arthritis & Rheumatism 25: 396-400 [1982\n]; \nKim, et al., Clin. Exp. Immunol. 70: 562-569 [1987\n]; \nLacki, et al., J. Med. 28: 99-107 [1997\n]; \nRobak, et al., Archivum Immunologiae et Therapiae Experimentalis 46: 375-380 [1998\n]; \nShiozawa, et al., Arthritis & Rheumatism 35: 417-422 [1992\n]; \nvon Wussow, et al., Rheumatology International 8: 225-230 [1988\n]). These observations led us to propose that a candidate antibody for therapeutic intervention in IDDM or SLE would need to neutralize a majority of the IFN-α subtypes while leaving intact the activities of other interferons (β, γ and ω) and interleukins that may be required for host defense.\n\n\n \n \n \n \nOne of them (9F3) was able to neutralize a wide spectrum of recombinant interferon α subtypes and was further characterized. As shown in \nFig. 2A\n, 9F3 was able to neutralize the anti-viral activity of seven recombinant interferons, IFN-α - 2, 4, 5, 8 and 10 (\nFig. 2\n) and IFN-\nα\n 1 and 21 (Table 2 and \nFig. 6\n). These IFN-α subtypes cover the full spectrum of sequences as projected in a type I interferon sequence dendrogram. More importantly, the 9F3 mAb that neutralized the IFN-α subtypes was unable to neutralize IFN-β (\nFig. 2\n, Table 2) or IFN-(. The small increase in activity shown in \nFig. 2\n for IFN-β was not reproducible in other assays and appears to be the result of assay variation.\n\n\n \n \n \n \nOther mAbs that are neutralizing toward IFN-α have been developed (\nTsukui et al., Microbiol. Immunol. 30: 1129-1139 [1986\n]; \nBerg, J. Interferon Res. 4: 481-491 [1984\n]; \nMeager and Berg, J Interferon Res. 6:729-736 [1986\n]; \n \nUS Patent No. 4,902,618\n \n; and \n \nEP publication No. 0,139,676 B1\n \n). However, these antibodies neutralize only a limited number of recombinant IFN-α subtypes and are unable to neutralize a wide spectrum of IFN-α subtypes such as those produced by activated leukocytes. In contrast, 9F3 Mab was able to neutralize at least 95% of the anti-viral activity in the heterogeneous collection of IFN-α subtypes produced by activated leukocytes (\nFig. 3A\n). Similarly, 9F3 mAb was also able to block the anti-viral activity of an independent preparation of lymphoblastoid IFN (NIH reference standard) as determined in an independent experiment (\nFig. 3B\n).\n\n\n \n \n \n \nThe ability of 9F3 mAb to neutralize IFN-α was also tested using an alternative bioassay. The assay was based on the ability of IFN-α to activate the binding of the signaling molecule, interferon-stimulated gene factor 3 (ISGF3), to an oligonucleotide derived from the interferon-stimulated response element (ISRE) in a DNA binding assay known as electrophoretic mobility shift assay (\nHorvath et al., Genes Dev. 9: 984-994 [1995\n]). The transduction of type I interferon signals to the nucleus relies on activation of a protein complex, ISGF3, involving two signal transducers and activators of transcription (STAT) proteins, STAT1 and STAT2, and the interferon regulatory factor (IRF) protein, p48/ISGF3γ (\nWathelet et al., Mol. Cell 1: 507-518 [1998\n]). The latter is a DNA sequence recognition subunit of ISGF3 and directly interacts with ISRE (\nMcKendry et al., Proc. Natl. Acad. Sci. USA 88: 11455-11459 [1991\n]; \nJohn et al., Mol. Cell. Biol. 11: 4189-4195 [1991\n]). The treatment of COS cells with either IFN-α or IFN-β led to the appearance of a complex corresponding to the binding of ISGF3 to the ISRE derived probe. The appearance of the IFN-α-induced but not the IFN-β-induced complex was blocked by 9F3 mAb (\nFig. 4\n). Furthermore, 9F3 mAb was able to neutralize the activity of six recombinant IFN-α subtypes that were tested in this assay (Table 2).\n\n \n \nTable 2\n \n \n \n \nInhibition of ISGF3 formation induced by type I IFNs by mAb 9F3\n \n \n \n \nmAb\n \nIFN-α2/1\n \nIFN-α1\n \nIFN-α2\n \nIFN-α5\n \nIFN-α8\n \nIFN-α21\n \nIFN-β\n \n \n \n9F3.18.5\n \n+++\n \n+++\n \n+++\n \n+\n \n+++\n \n+++\n \n-\n \n \n \nIgG1\n \n-\n \n-\n \n-\n \n-\n \n-\n \n-\n \n-\n \n \n \n \n\nThe extent of inhibition of the IFN induced complex by 9F3 is indicated where - indicates that the induced band was not altered; + indicates that the band was partially lost and +++ indicates that the induced band was largely abolished. mAb was used at 10 µg/ml; IFN-α was used at 25 ng/ml\n\n\n \n \n \n \nHaving established that 9F3 was able to neutralize both a wide variety of recombinant IFN-α subtypes and the mixture of IFN-α subtypes produced by activated leukocytes, we cloned and sequenced the cDNAs encoding both the heavy and light chains of 9F3 mAb. The heavy and light chains were purified and the N terminal amino acid sequences derived were used to design degenerate 5' primers corresponding to the N terminus, and the 3' primers were designed corresponding to the constant domain of mouse κ light chain and IgG2 heavy chain. The corresponding cDNAs were cloned using conventional PCR technique and the nucleotide sequence of the inserts was determined. \nFigure 5\n shows sequence alignment of VL (5A) and VH (5B) domains of a murine 9F3 monoclonal antibody, a humanized version (V13) and consensus sequence of the human heavy chain subgroup ill and the human κ light chain subgroup III. In order to ensure that the cDNAs that were cloned encoded the correct Mab reflecting the specificity and characteristics of 9F3 mAb, recombinant chimeric proteins were generated that utilized the mouse cDNA sequences shown in \nFig. 5\n and a human CH1 domain. The resultant chimera (CH8-2) was able to fully neutralize various recombinant IFN-α subtypes (\nFig. 6\n). The amino acid sequences for the heavy and light chains were then used to generate a humanized antibody.\n\n\n \nExample 2. \nHumanization of 9F3 pan-IFN-α neutralizing monoclonal antibody\n \n\n\n\n\nMaterials and Methods\n\n\n\n\n\n\nConstruction of Humanized F(ab)s\n\n\n\n\n \n \n \nTo construct the first F(ab) variant of humanized 9F3, site-directed mutagenesis (\nKunkel, Proc. Natl. Acad. Sci. USA 82: 488-492 [1985\n]) was performed on a deoxyuridine-containing template of pEMX1. The six CDRs were changed to the murine 9F3 sequence (\nFig. 5\n); the residues included in each CDR were from the sequence-based CDR definitions (Kabat \net al.,\n (1991) \nsupra\n). F-1 therefore consisted of a complete human framework (\nVL κ subgroup\n 1 and VH subgroup III) with the six complete murine CDR sequences. Plasmids for all other F(ab) variants were constructed from the plasmid template of F-1. Plasmids were transformed into \nE. coli\n strain XL-1 Blue (Stratagene, San Diego, CA) for preparation of double- and single-stranded DNA using commercial kits (Qiagen, Valencia, CA). For each variant, DNA coding for light and heavy chains was completely sequenced using the dideoxynucleotide chain termination method (Sequenase, U.S. Biochemical Corp., Cleveland, OH). Plasmids were transformed into \nE. coli\n strain 16C9, a derivative of MM294, plated onto Luria broth plates containing 50 µg/ml carbenicillin, and a single colony selected for protein expression. The single colony was grown in 5 ml Luria broth-100 µg/ml carbenicillin for 5-8 h at 37°C. The 5 ml culture was added to 500 ml AP5 medium containing 50 µg/ml carbenicillin and allowed to grow for 20 h in a 4 L baffled shake flask at 30°C. AP5 medium consists of: 1.5 g glucose, 11.0 g Hycase SF, 0.6 g yeast extract (certified), 0.19 g MgSO\n4\n (anhydrous), 1.07 g NH\n4\nCl, 3.73 g KCI, 1.2 g NaCl, 120 ml 1 M triethanolamine, pH 7.4, to 1 L water and then sterile filtered through 0.1 µm Sealkeen filter. Cells were harvested by centrifugation in a 1 L centrifuge bottle at 3000xg and the supernatant removed. After freezing for 1 h, the pellet was resuspended in 25 ml cold 10 mM Tris-1 mM EDTA-20% sucrose, pH 7.5, 250 µl of 0.1 M benzamidine (Sigma, St. Louis, MO) was added to inhibit proteolysis. After gentle stirring on ice for 3 h, the sample was centrifuged at 40,000xg for 15 min. The supernatant was then applied to a Protein G-Sepharose CL-4B (Pharmacia, Uppsala, Sweden) column (0.5 ml bed volume) equilibrated with 10 mM Tris-1 mM EDTA, pH 7.5. The column was washed with 10 ml of 10 mM Tris-1 mM EDTA, pH 7.5, and eluted with 3 ml 0.3 M glycine, pH 3.0, into 1.25 ml 1 M Tris, pH 8.0. The F(ab) was then buffer exchanged into PBS using a Centricon-30 (Amicon, Beverly, MA) and concentrated to a final volume of 0.5 ml. SDS-PAGE gels of all F(ab)s were run to ascertain purity and the molecular weight of each variant was verified by electrospray mass spectrometry. F(ab) concentrations were determined using quantitative amino acid analysis.\n\n\n \n\n\nConstruction of Chimeric and Humanized 1gG\n\n\n\n\n \n \n \nFor generation of human IgG2 versions of chimeric and humanized 9F3, the appropriate murine or humanized VL and VH (F-13, Table 3) domains were subcloned into separate previously described pRK vectors (\nEaton et al., Biochemistry 25: 8343-8347 [1986\n]) that contained DNA coding for human IgG2 CH1-Fc or human light chain CL domain. The DNA coding for the entire light and the entire heavy chain of each variant was verified by dideoxynucleotide sequencing. The chimeric IgG consists of the entire murine 9F3 VH domain fused to a human CH1 domain at amino acid SerH113 and the entire murine 9F3 VL domain fused to a human CL domain at amino acid LysL 107.\n\n\n \n \n \n \nHeavy and light chain plasmids were co-transfected into an adenovirus-transformed human embryonic kidney cell line, 293 (\nGraham et al., J. Gen. Virol. 36: 59-74 [1977\n]), using a high efficiency procedure (\nGorman et al., DNA Prot. Eng. Tech. 2: 3-10 [1990\n]). Media was changed to serum-free and harvested daily for up to five days. Antibodies were purified from the pooled supernatants using Protein A-Sepharose CL-4B (Pharmacia). The eluted antibody was buffer exchanged into PBS using a Centricon-30 (Amicon), concentrated to 0.5 ml, sterile filtered using a Millex-GV (Millipore, Bedford, MA) and stored at 4°C. IgG2 concentrations were determined using quantitative amino acid analysis.\n\n\n \n \nIFN-\nα \nBinding Assay\n \n\n\n \n \n \nIn the ELISA, 96 well microtiter plates (Nunc) were coated by adding 50 µl of 0.1 µg/ml IFN-α in PBS to each well and incubated at 4°C overnight. The plates were then washed three times with wash buffer (PBS plus 0.05% Tween 20). The wells in microtiter plates were then blocked with 200 µl of SuperBlock (Pierce) and incubated at room temperature for 1 hour. The plates were then washed again three times with wash buffer. After washing step, 100 µl of serial dilutions of humanized mAb starting at 10 µg/ml were added to designated wells. The plates were incubated at room temperature for 1 hour on a shaker apparatus and then washed three times with wash buffer. Next, 100 µl of horseradish peroxidase (HRP)-conjugated goat anti-human Fab specific (Cappel), diluted at 1:1000 in assay buffer (0.5% bovine serum albumin, 0.05\n% Tween\n 20 in PBS), was added to each well. The plates were incubated at room temperature on a shaker apparatus and then washed three times with wash buffer, followed by addition of 100 µl of substrate (TMB, 3,3',5,5'-tetramethylbenzidine; Kirkegaard & Perry) to each well and incubated at room temperature for 10 minutes. The reaction was stopped by adding 100 µl of stop solution (from Kirkegaard & Perry) to each well, and absorbance at 450 nm was read in an automated microtiter plate reader.\n\n\n \n \nBIAcore\n™ \nBiosensor Assay\n \n\n\n \n \n \nIFN-α binding of the humanized F(ab)s, chimeric and humanized IgG2 antibodies were measured using a BIACore™ biosensor (\nKarlsson et al., Methods: A. companion to Methods in Enzymology 6: 97-108 [1994\n]). The IFN-α was immobilized on the sensor chip at 60 µg/ml in 50 mM MES buffer, pH 6.3. Antibodies were exposed to the chip at 75 µg/ml (500 nM) in phosphate-buffered saline/1% Tween-20. The antibody on-rate (k\non\n) was measured.\n\n\n \n\n\nComputer Graphics Modes of Murine and Humanized F(ab)s\n\n\n\n\n \n \n \nSequences of the VL and VH domains (\nFig. 5A\n and \nB\n) were used to construct a computer graphics model of the murine 9F3 VL-VH domains (\nFig. 7\n). This model was used to determine which framework residues should be incorporated into the humanized antibody. A model of the humanized F(ab) was also constructed to verify correct selection of murine framework residues. Construction of models was performed as described previously (Carter \net al.,\n [1992] \nsupra\n; Werther \net al.,\n [1996] \nsupra\n).\n\n\n \n\n\nResults\n\n\n\n\n \n \n \nThe consensus sequence for the human heavy chain subgroup III and the light chain subgroup I were used as the framework for the humanization as shown in \nFig. 5\n (Kabat \net al.,\n (1991), \nsupra\n). This framework has been successfully used in the humanization of other murine antibodies (\nCarter et al., Proc. Natl. Acad. Sci. USA 89: 4285-4289 [1992\n]; \nPresta et al., J. Immunol. 151: 2623-2632 [1993\n]; \nEigenbrot et al., Proteins 18: 49-62 [1994\n]; \nWerther et al., J. Immunol. 157: 4986-4995 [1996\n]). All humanized variants were initially made and screened for binding as F(ab)s expressed in \nE. coli.\n Typical yields from 500 ml shake flasks were 0.1-0.4 mg F(ab).\n\n\n \n \n \n \nThe complementarity determining region (CDR) residues have been defined either based on sequence hypervariability (Kabat \net al.,\n (1991) \nsupra\n) or crystal structure of F(ab)-antigen complexes (\nChothia et al., Nature 342: 877-883 [1989\n]). Although the sequence-based CDRs are larger than the structure-based CDRs, the two definitions are generally in agreement except for CDR-H1. According to the sequence-based definition, CDR-H1 includes residues H31-H35, whereas the structure-based system defines residues H26-H32 as CDR-H1 (light chain residue numbers are prefixed with L; heavy chain residue numbers are prefixed with H). For the present study, CDR-H1 was defined as a combination of the two, i.e. including residues H26-H35. The other CDRs were defined using the sequence-based definition (Kabat \net al.,\n (1991) \nsupra\n).\n\n\n \n \n \n \nIn the initial variant, F-1, the CDR residues were transferred from the murine antibody to the human framework. In addition, F(ab)s which consisted of the chimeric heavy chain with F-1 light chain (Ch-1) and F-1 heavy chain with chimeric light chain (Ch-2) were generated and tested for binding. F-1 bound IFN-α poorly (Table 3). Comparing the binding affinities of Ch-1 and Ch-2 (Table 3) suggested that framework residues in the F-1 VH domain needed to be altered in order to increase binding.\n\n \n \nTable 3\n \n \n \n \nHumanized Anti-IFN-α Versions\n \n \n \n \n \n \n \n \n \nOD\n450nm\n at 10 µg/ml\n \n \n \nVersion\n \nTemplate\n \nChanges\na\n \n \nMean\n \nSD\n \nN\n \n \n \n \nCh-1\n \nF-1 VL/ Murine VH\n \n \n \n1.45\n \n0.11\n \n3\n \n \n \nCh-2\n \nMurine VL/ F-2 VH\n \n \n \n.024\n \n0.04\n \n3\n \n \n \nF-1\n \nHuman FR/ CDR swap\n \n \n \n0.06\n \n0.00\n \n3\n \n \n \nF-2\n \nF-1\n \nArgH71\nLeu\n;\n \n0.08\n \n0.01\n \n3\n \n \n \n \n \n \n \nAsnH73\nLys\n \n \n \n \n \n \n \n \n \n \nF-3\n \nF-2\n \nPheH67\nAla\n;\n \n0.14\n \n0.02\n \n3\n \n \n \n \n \n \n \nIleH69\nLeu\n;\n \n \n \n \n \n \n \n \n \n \n \n \n \nLeuH78\nAla\n \n \n \n \n \n \n \n \n \n \nF-4\n \nF-3\n \nArgH94\nSer\n \n \n0.495\n \n0.02\n \n3\n \n \n \nF-5\n \nF-4\n \nAlaH24\nThr\n \n \n0.545\n \n0.03\n \n3\n \n \n \nF-6\n \nF-5\n \nValH48\nIle\n;\n \n0.527\n \n0.02\n \n2\n \n \n \n \n \n \n \nAlaH49\nGly\n \n \n \n \n \n \n \n \n \n \n \nF-7\n \n \n \nF-5\n \n \n \n \nAla\nH78Leu\n \n \n0.259\n \n0.02\n \n2\n \n \n \n \nF-8\n \n \n \nF-5\n \n \n \n \nLeu\nH69Ile\n \n \n0.523\n \n0.05\n \n3\n \n \n \n \nF-9\n \n \n \nF-5\n \n \n \n \nAla\nH67Phe\n \n \n0.675\n \n0.09\n \n3\n \n \n \n \nF-10\n \n \n \nF-9\n \n \n \n \nLeu\nH69Ile\n \n \n0.690\n \n0.03\n \n3\n \n \n \nF-11\n \nF-10\n \nLysH75\nSer\n \n \n0.642\n \n0.06\n \n3\n \n \n \nF-12\n \nF-10\n \nAsnH76\nArg\n \n \n0.912\n \n0.05\n \n3\n \n \n \nF-13\n \nF-12\n \nLeuL46\nVal\n \n \n1.050\n \n0.16\n \n3\n \n \n \n \n \n \n \nTyrL49Ser\n \n \n \n \n \n \n \n \n \n \nF-14\n \n \n \nF-13\n \n \n \n \nLeu\nH71Arg\n \n \n0.472\n \n0.06\n \n3\n \n \n \n \nF-15\n \n \n \nF-13\n \n \n \n \nLys\nH73Asn\n \n \n0.868\n \n0.32\n \n3\n \n \n \n \n \n \na\nMurine residues are in bold; residue numbers are according to Kabat et al. (1991). Standard text indicates a change from a human framework residue to mouse. Italic text indicates a change from a mouse framework residue to human. Fab binding to IFN-α was assayed by ELISA and results are provided as OD\n450 nm\n at 10 µg/ml. SD, standard deviation; n, number of experimental replicates.\n \n \n \n \n \n\n\n \n \n \n \nPrevious humanizations (\nXiang et al., J. Mol. Biol. 253: 385-390 [1995\n]; Werther \net al.,\n [1996] \nsupra\n) as well as studies of F(ab)-antigen crystal structures (Chothia \net al.,\n [1989] \nsupra\n; \nTramontano et al., J. Mol. Biol. 215: 175-182 [1990\n]) have shown that residues H71 and H73 can have a profound effect on binding, possibly by influencing the conformations of CDR-H1 and CDR-H2. Changing the human residues at positions H71 and H73 to their murine counterparts improved binding only slightly (version F-2, Table 3). Further simultaneous changes at positions H67, H69 and H78 (version F-3) followed by changes ArgH94Ser (version F-4) and AlaH24Thr (version F-5) significantly improved binding (Table 3). Since positions H67, H69 and H78 had been changed simultaneously, each was individually altered back to the human consensus framework residue; versions F-7, F-8, F-9, and F-10 show that the human residue is preferred at position H67, position H69 does not show any preference for the human or murine residue, and the murine residue is preferred at position H78.\n\n\n \n \n \n \nWe have found during previous humanizations that residues in a framework loop, FR-3 (Kabat \net al.,\n (1991) \nsupra\n), adjacent to CDR-H1 and CDR-H2 can affect binding (Eigenbrot \net al.,\n (1994) \nsupra\n). Accordingly, two residues in this loop were changed to their murine counterparts: LysH75 to murine Ser (version F-11) and AsnH76 to murine Arg (version F-12). Only the AsnH76Arg change effected an improvement in binding (Table 3).\n\n\n \n \n \n \nInspection of the models of the murine and humanized F(ab)s suggested that residue L46, buried at the VL-VH interface and interacting with CDR-H3, might also play a role either in determining the conformation of CDR-H3 and/or affecting the interactions between the VL and VH domains. Similarly, L49 position which is adjacent to CDR-L2 differs between the human consensus (Tyr) and the 9F3 (Ser) sequence. Therefore, LeuL46Val and TyrL49Ser residues were simultaneously substituted, which resulted in a variant (F-13) with further improvement in the binding (Table 3). Based on its best binding among all the variants generated, F-13 was chosen as the final humanized version.\n\n\n \n \n \n \nA humanized recombinant anti-IFN-α monoclonal antibody (V13IgG2) was generated by fusing VH and VL domains derived from F-13 to human IgG2 CH1-Fc and human CL domains respectively. The C\nON\n rates and K\nD\n values of V13IgG2 were then compared with a chimeric IgG2 or murine 9F3. BIACore™ measurement of V13IgG2 and chimeric IgG2 binding to immobilized IFN-α showed that their C\nON\n rates were similar (Table 4). Affinity measurement using Kinexa™ technology showed that the affinity of V13IgG2 for IFNα was reduced by 2-fold compared to the parental murine 9F3 antibody (Table 4).\n\n \n \nTable 4\n \n \n \n \nBIACore™ and Kinexa™ Data for Anti-IFNα Antibodies\n \n \n \nAntibody\na\n \n \nK\non\n(µM/sec)\n \nKd (nM)\nb\n \n \nMethod\n \n \n \n \n \n \n \n \n0.14\n \nBIACore™\n \n \n \nChIgG2\n \n3.9\n \n \n \nBIACore™\n \n \n \nV13IgG2\n \n3.3\n \n \n \nBIACore™\n \n \n \nV13Fab\n \n \n \n4.1\n \nBIACore™\n \n \n \n \n \n \n \n \n \n \n \n \n \nAntibody\na\n \n \nK\nD\n(pM)\n \n \n \n \n \n \n \nmurine 9F3\n \n1.5\n \n \n \nKinexa™\n \n \n \nV13Fab\n \n3.4\n \n \n \nKinexa™\n \n \n \n \n \n \na\nV13IgG2 is F-13 VH domain joined to human IgG2 CH1-Fc and F-13 VL domain joined to a human CL domain; ChIgG2 is mouse 9F3 VH domain joined to human IgG2 CH1-Fc and mouse 9F3 VL domain joined to human CL domain. \nb\nICoff/Kon.\n \n \n \n \n \n\n\n \n\n\nDeposit of Material\n\n\n\n\n \n \n \nThe following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC):\n\n \n \n \n \n \nMaterial\n \nATCC Dep. No.\n \n \nDeposit Date\n \n \n \n \n \n1. A hybridoma cell line secreting 9F3 murine anti-IFN-α monoclonal antibodies (Id. Ref.: 9F3.18.5)\n \nPTA-2917\n \nJanuary 18,2001\n \n \n \n2. pRK-based vector for the expression of heavy chain of chimeric CH8-2 full-length IgG (Id. Ref.: XAIFN-ChHpDR2)\n \nPTA-2883\n \nJanuary 9, 2001\n \n \n \n3. pRK-based vector for the expression of light chain of chimeric CH8-2 full-length IgG (Id. Ref.: XAIFN-ChLpDRI)\n \nPTA-2880\n \nJanuary 9, 2001\n \n \n \n4. pRK-based vector for the expression of heavy chain of humanized V13 full-length IgG\n2\n (Id. Ref.: VHV30-IgG2)\n \nPTA-2881\n \nJanuary 9, 2001\n \n \n \n5. pRK-based vector for the expression of light chain of humanized V13 full-length IgG\n2\n (Id. Ref.: VLV30-IgG)\n \nPTA-2882\n \nJanuary 9, 2001\n \n \n \n \n \n\n\n \n \n \n \nThis deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 U.S.C. § 122 and the Commissioner's rules pursuant thereto (including 37 C.F.R. § 1.14 with particular reference to 886 OG 638).\n\n\n \n \n \n \nThe assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.\n\n\n \n \n \n \nThe foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.\n\n\n \n \n \n \nSome additional embodiments of the invention are described in the following numbered clauses:\n\n \n \n \n1. An anti-IFN-a monoclonal antibody which binds to and neutralizes a biological activity of at least IFN-a subtypes, IFN-α1, IFN- α2, IFN- α4, IFN- α5, IFN- α8, IFN- α10, and IFN- α21.\n \n2. The antibody of \nclause\n 1 which is a murine antibody.\n \n3. The antibody of \nclause\n 1 which is a humanized antibody.\n \n4. The antibody of \nclause\n 1 which is a human antibody.\n \n5. The antibody of \nclause\n 1 wherein said biological activity is antiviral activity.\n \n6. The antibody of \nclause\n 5 wherein said antibody is capable of neutralizing at least 70% of the antiviral activity of said IFN-α \ns\nubtypes.\n \n7. The antibody of \nclause\n 5 wherein said antibody is capable of neutralizing at least 80% of the antiviral activity of said IFN-α subtypes.\n \n8. The antibody of \nclause\n 5 wherein said antibody is capable of neutralizing at least 90% of the antiviral activity of said IFN-α subtypes.\n \n9. The antibody of \nclause\n 5 wherein said antibody is capable of neutralizing at least 99% of the antiviral activity of said IFN-α subtypes.\n \n10. The antibody of \nclause\n 1 which binds essentially the same IFN-α epitope as murine anti-human IFN-α monoclonal antibody 9F3 or a humanized or chimeric form thereof.\n \n11. The antibody of \nclause\n 1 which is murine anti-human IFN-α monoclonal antibody 9F3 or a humanized or chimeric form thereof.\n \n12. The antibody of clause 11 which is humanized anti-human IFN-α monoclonal antibody 9F3 version 13 (V13).\n \n13. The antibody of \nclause\n 1 which binds essentially the same IFN-α epitope as the anti-IFN-α antibody produced by the hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.\n \n14. The antibody of \nclause\n 1 which is of the IgG class.\n \n15. The antibody of clause 14 which has an IgG\n1\n, IgG\n2\n, IgG\n3\n, or IgG\n4\n isotype.\n \n16. The antibody of \nclause\n 1 which is an antibody fragment.\n \n17. The antibody of clause 16 which is a Fab fragment.\n \n18. The antibody of clause 16 which is a F(ab')\n2\n fragment.\n \n19. The antibody of clause 16 which is a Fab' fragment.\n \n20. An anti-IFN-α antibody light chain or a fragment thereof, comprising the following CDR's:\n\n \n(a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);\n \n(b) L2 of the formula YASNLES (SEQ ID NO: 8); and\n \n(c) L3 of the formula QHSWGIPRTF (SEQ ID NO: 9).\n \n \n \n21. The anti-IFN-a antibody light chain fragment of \nclause\n 20 which is the light chain variable domain.\n \n22. An anti-IFN-α antibody heavy chain or a fragment thereof, comprising the following CDR's:\n\n \n(a) H1 of the formula GYTFTEYIIH (SEQ ID NO: 10);\n \n(b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and\n \n(c) H3 of the formula WISDFFDY (SEQ ID NO: 12).\n \n \n \n23. The anti-IFN-a antibody heavy chain fragment of clause 22 which is the heavy chain variable domain.\n \n24. An anti-IFN-α antibody comprising\n\n \n(A) at least one light chain or a fragment thereof, comprising the following CDR's:\n\n \n(a) L1 of the formula RASQSVSTSSYSYMH (SEQ ID NO: 7);\n \n(b) L2 of the formula YASNLES (SEQ ID NO: 8); and\n \n(c) L3 of the formula QHSWGIPRTF (SEQ ID NO; 9); and\n \n \n \n(B) at least one heavy chain or a fragment thereof, comprising the following CDR's:\n\n \n(a) H1 of the formula GYTFTEYIIH (SEQ ID NO: 10);\n \n(b) H2 of the formula SINPDYDITNYNQRFKG (SEQ ID NO: 11); and\n \n(c) H3 of the formula WISDFFDY (SEQ ID NO: 12).\n \n \n \n \n \n25. The antibody of \nclause\n 24 having a homo-tetrameric structure composed of two disulfide-bonded antibody heavy chain-light chain pairs.\n \n26. The antibody of \nclause\n 24 which is a linear antibody.\n \n27. The antibody of \nclause\n 24 which is a murine antibody.\n \n28. The antibody of \nclause\n 24 which is a chimeric antibody.\n \n29. The antibody of \nclause\n 24 which is a humanized antibody.\n \n30. The antibody of \nclause\n 24 which is a human antibody.\n \n31. An isolated nucleic acid molecule encoding an antibody of \nclause\n 1.\n \n32. An isolated nucleic acid molecule encoding an antibody of clause 11.\n \n33. An isolated nucleic acid molecule encoding an antibody of \nclause\n 12.\n \n34. An isolated nucleic acid molecule encoding an antibody of \nclause\n 24.\n \n35. An isolated nucleic acid molecule encoding an antibody light chain or light chain fragment of \nclause\n 20.\n \n36. An isolated nucleic acid molecule encoding an antibody heavy chain or heavy chain fragment of clause 22.\n \n37. An isolated nucleic acid molecule comprising the light chain polypeptide - encoding nucleic acid sequence of the vector deposited with ATCC on January 9,2001 and having accession No. PTA-2882.\n \n38. An isolated nucleic acid molecule comprising the heavy chain polypeptide-encoding nucleic acid sequence of the vector deposited with ATCC on January 9,2001 and having accession No. PTA-2881.\n \n39. A vector comprising a nucleic acid molecule according to anyone of clauses 31 to 38.\n \n40. A host cell transformed with a nucleic acid molecule according to anyone of clauses 31 to 38.\n \n41. A method of producing the antibody of anyone of \n \n \nclauses\n \n \n 1, 11, 12 and 24 comprising culturing a host cell comprising a nucleic acid sequence encoding the antibody under conditions wherein the nucleic acid sequence is expressed to produce the antibody.\n \n42. A hybridoma cell line comprising a nucleic acid molecule according to any one of clauses 31 to 38.\n \n43. A hybridoma cell line deposited with ATCC on January 18, 2001 and having accession No. PTA-2917.\n \n44. An antibody produced by the hybridoma cell line of clause 42.\n \n45. A pharmaceutical composition comprising an effective amount of the antibody of \nclause\n 1 in admixture with a pharmaceutically acceptable carrier.\n \n46. A pharmaceutical composition comprising an effective amount of the antibody of clause 11 in admixture with a pharmaceutically acceptable carrier.\n \n47. A pharmaceutical composition comprising an effective amount of the antibody of \nclause\n 12 in admixture with a pharmaceutically acceptable carrier.\n \n48. A pharmaceutical composition comprising an effective amount of the antibody of \nclause\n 24 in admixture with a pharmaceutically acceptable carrier.\n \n49. A method for diagnosing a condition associated with the expression of IFNα in a cell, comprising contacting said cell with an anti-IFN-α antibody of \nclause\n 1, and detecting the presence of IFN-α.\n \n50. A method for the treatment of a disease or condition associated with the expression of IFN-α in a patient, comprising administering to said patient an effective amount of an anti-IFN-α antibody of \nclause\n 1.\n \n51. The method of \nclause\n 50 wherein said patient is a mammalian patient.\n \n52. The method of clause 51 wherein said patient is human.\n \n53. The method of clause 52 wherein said disease is an autoimmune disease.\n \n54. The method of clause 53 wherein said disease is selected from the group consisting of insulin-dependent diabetes mellitus (IDDM); systemic lupus erythematosus (SLE); and autoimmune thyroiditis."
  }
]